https://evidence-hub.com/study/2-legionella-and-legionellosis2026-10-20 https://evidence-hub.com/study/3-levofloxacin-in-veterinary-medicine-a-literature-review2026-10-08 https://evidence-hub.com/study/5-levofloxacin-in-children2026-10-20 https://evidence-hub.com/study/6-delirium-induced-by-levofloxacin2026-10-08 https://evidence-hub.com/study/7-levofloxacin-a-review-of-its-antibacterial-activity-pharmacokinetics2026-10-20 https://evidence-hub.com/study/8-the-clinical-pharmacokinetics-of-levofloxacin2026-10-13 https://evidence-hub.com/study/9-a-case-of-levofloxacin-induced-hepatotoxicity2026-10-08 https://evidence-hub.com/study/10-pharmacokinetic-pharmacodynamic-based-optimization-of-levofloxacin2026-10-08 https://evidence-hub.com/study/11-absence-of-a-pharmacokinetic-interaction-between-digoxin-and2026-10-08 https://evidence-hub.com/study/12-levofloxacin-versus-ceftriaxone-for-the-treatment-of-acute2026-10-20 https://evidence-hub.com/study/13-cardiac-risks-associated-with-antibiotics-azithromycin-and2026-10-08 https://evidence-hub.com/study/14-levofloxacin-associated-encephalopathy-with-severe-hyperventilation2026-10-08 https://evidence-hub.com/study/15-levofloxacin-an-updated-review-of-its-use-in-the-treatment-of2026-10-20 https://evidence-hub.com/study/16-bactericidal-activity-and-inhibition-of-levofloxacin-induced2026-10-08 https://evidence-hub.com/study/17-efficacy-and-safety-of-levofloxacin-as-a-treatment-for-complicated2026-10-20 https://evidence-hub.com/study/18-levofloxacin-and-other-fluoroquinolones-in-therapy-of-respiratory2026-10-08 https://evidence-hub.com/study/19-comparison-of-side-effects-of-levofloxacin-versus-other2026-10-08 https://evidence-hub.com/study/20-levofloxacin-for-the-treatment-of-community-acquired-pneumonia2026-10-08 https://evidence-hub.com/study/21-levofloxacin-in-the-treatment-of-community-acquired-pneumonia2026-10-20 https://evidence-hub.com/study/22-activity-of-delafloxacin-versus-that-of-levofloxacin-against2026-10-08 https://evidence-hub.com/study/23-effect-of-ciprofloxacin-vs-levofloxacin-on-qtc-interval-and2026-10-08 https://evidence-hub.com/study/24-a-shigella-sonnei-outbreak-in-nagasaki2026-10-08 https://evidence-hub.com/study/25-study-of-pharmacokinetics-pharmacodynamics-of-levofloxacin2026-10-20 https://evidence-hub.com/study/26-population-pharmacokinetics-and-pharmacodynamics-modeling-of-oral2026-10-20 https://evidence-hub.com/study/27-levofloxacin-induced-acute-rhabdomyolysis-a-case-report2026-10-08 https://evidence-hub.com/study/28-hemodialysis-for-treatment-of-levofloxacin-induced-neurotoxicity2026-10-08 https://evidence-hub.com/study/29-latest-industry-information-on-the-safety-profile-of-levofloxacin-in2026-10-08 https://evidence-hub.com/study/30-evaluation-of-ciprofloxacin-and-levofloxacin-disk-diffusion-and-etest2026-10-08 https://evidence-hub.com/study/31-clinical-applications-of-levofloxacin-for-severe-infections2026-10-19 https://evidence-hub.com/study/32-pyrvinium-pamoate-potentiates-levofloxacin-against-levofloxacin2026-10-08 https://evidence-hub.com/study/33-easy-assessment-of-levofloxacin-and-minocycline-in-relevant2026-10-08 https://evidence-hub.com/study/34-management-of-chronic-pseudomonas-aeruginosa-infection-with-inhaled2026-10-08 https://evidence-hub.com/study/35-a-case-report-of-anticoagulation-management-in-acquired-hemophilia2026-10-08 https://evidence-hub.com/study/36-levofloxacin-for-the-treatment-of-pyelonephritis2026-10-19 https://evidence-hub.com/study/37-gold-nanoparticles-conjugated-levofloxacin-for-improved-antibacterial2026-10-08 https://evidence-hub.com/study/38-rates-of-torsades-de-pointes-associated-with-ciprofloxacin-ofloxacin2026-10-05 https://evidence-hub.com/study/39-synergistic-antibacterial-effect-of-graphene-coated-titanium-loaded2026-10-08 https://evidence-hub.com/study/40-levofloxacin-induced-severe-thrombocytopenia2026-10-08 https://evidence-hub.com/study/41-prevalences-of-levofloxacin-resistance-and-pnca-mutation-in-isoniazid2026-10-08 https://evidence-hub.com/study/42-characteristics-of-levofloxacin-and-its-clinical-application-review2026-10-08 https://evidence-hub.com/study/43-levofloxacin-induced-myopathy-of-the-iliac-and-gluteal-muscles2026-10-08 https://evidence-hub.com/study/44-levofloxacin-a-review-of-its-use-in-the-treatment-of-bacterial2026-10-20 https://evidence-hub.com/study/45-activity-of-delafloxacin-and-levofloxacin-against-stenotrophomonas2026-10-08 https://evidence-hub.com/study/46-current-and-future-perspectives-for-levofloxacin-in-severe2026-10-08 https://evidence-hub.com/study/47-population-pharmacokinetics-and-dose-optimization-of-levofloxacin-in2026-10-08 https://evidence-hub.com/study/48-retrospective-analysis-of-risk-factors-for-levofloxacin-induced-liver2026-10-08 https://evidence-hub.com/study/49-infections-in-cystic-fibrosis-up-to-date2026-10-08 https://evidence-hub.com/study/50-the-effect-of-levofloxacin-on-the-lung-microbiota-of-laboratory-rats2026-10-08 https://evidence-hub.com/study/51-advances-in-development-of-tuberculosis-vaccines-and-preventive-drug2026-10-08 https://evidence-hub.com/study/52-antibiotic-resistance-landscape-and-genomic-characterization-of2026-10-08 https://evidence-hub.com/study/53-antimicrobial-susceptibility-profiles-multidrug-resistance-patterns2026-10-08 https://evidence-hub.com/study/54-single-molecule-nanopore-sequencing-reveals-spatial-coordination-of2026-10-08 https://evidence-hub.com/study/55-comparison-of-clinical-characteristics-species-composition-and2026-10-08 https://evidence-hub.com/study/56-isolation-identification-and-antibiogram-assay-of-escherichia-coli2026-10-08 https://evidence-hub.com/study/57-culture-free-rapid-phenotypic-antimicrobial-susceptibility-testing2026-10-08 https://evidence-hub.com/study/58-development-and-validation-of-an-hplc-uv-method-for-the-determination2026-10-08 https://evidence-hub.com/study/59-molecularly-imprinted-polymers-based-on-cyclodextrin-derivatives-and2026-10-08 https://evidence-hub.com/study/60-development-of-low-cost-robust-and-reproducible-biofilm-static-and2026-10-08 https://evidence-hub.com/study/61-severe-multisite-methicillin-susceptible-staphylococcus-aureus2026-10-08 https://evidence-hub.com/study/62-porous-europium-metal-organic-frameworks-as-highly-sensitive-bi2026-10-08 https://evidence-hub.com/study/63-pneumococcal-disease-burden-and-pediatric-invasive-pneumococcal2026-10-08 https://evidence-hub.com/study/64-antimicrobial-resistance-patterns-in-uropathogens-isolated-from-type2026-10-08 https://evidence-hub.com/study/65-high-level-ciprofloxacin-resistance-in-pseudomonas-aeruginosa-is2026-10-08 https://evidence-hub.com/study/66-increased-prevalence-of-multidrug-resistant-escherichia-coli-as-an2026-10-20 https://evidence-hub.com/study/67-identification-and-antibiogram-assay-of-escherichia-coli-isolated2026-10-08 https://evidence-hub.com/study/68-risk-factors-and-antimicrobial-resistance-of-esbl-positive2026-10-08 https://evidence-hub.com/study/69-effects-of-levofloxacin-eye-drops-on-ocular-surface-bacterial2026-10-08 https://evidence-hub.com/study/70-antimicrobial-susceptibility-profiles-and-associated-clinical-risk2026-10-08 https://evidence-hub.com/study/71-staphylococcus-aureus-mnh1-cation-proton-antiporter-promotes2026-10-08 https://evidence-hub.com/study/72-fluoroquinolone-triggered-prophage-induction-in-streptococcus2026-10-08 https://evidence-hub.com/study/73-effect-of-cranberry-plant-extract-on-gene-expression-in-antibiotic2026-10-08 https://evidence-hub.com/study/74-microbial-etiology-antibiotic-susceptibility-profiles-and-multidrug2026-10-20 https://evidence-hub.com/study/75-bacterial-profile-and-antimicrobial-susceptibility-patterns-among2026-10-08 https://evidence-hub.com/study/76-comparative-analysis-of-antimicrobial-resistance-patterns-among2026-10-20 https://evidence-hub.com/study/77-levofloxacin-based-concomitant-versus-sequential-therapy-for2026-10-08 https://evidence-hub.com/study/78-real-world-practices-of-fluoroquinolone-prophylaxis-in-spontaneous2026-10-08 https://evidence-hub.com/study/79-lytic-bacteriophages-against-salmonella-typhi-as-a-potential2026-10-08 https://evidence-hub.com/study/80-diagnostic-performance-of-fluorescence-based-rapid-on-site-specimen2026-10-08 https://evidence-hub.com/study/81-synergistic-effect-of-zinc-oxide-nanoparticles-with-antibiotics2026-10-08 https://evidence-hub.com/study/82-levofloxacin-associated-tendon-disorders-sex-age-and-route-specific2026-10-08 https://evidence-hub.com/study/83-comparative-efficacies-of-current-second-and-third-generation2026-10-08 https://evidence-hub.com/study/84-exploring-the-evolution-of-multidrug-resistance-patterns-in-eskapee2026-10-08 https://evidence-hub.com/study/85-evaluation-of-antibiotic-resistance-rates-in-s-aureus-infections-by2026-10-08 https://evidence-hub.com/study/86-disseminated-tuberculosis-in-adolescent-systemic-lupus-erythematosus2026-10-08 https://evidence-hub.com/study/87-prediction-of-antimicrobial-resistance-of-klebsiella-pneumoniae2026-10-08 https://evidence-hub.com/study/88-the-impact-of-long-term-levofloxacin-on-the-bacterial-gut-microbiome2026-10-08 https://evidence-hub.com/study/89-ferrocene-functionalized-nh2-uio-66-moo3-ratiometric-electrochemical2026-10-08 https://evidence-hub.com/study/90-comparative-effectiveness-of-levofloxacin-versus-third-generation2026-10-08 https://evidence-hub.com/study/91-comparative-effectiveness-of-genotype-guided-and-empirical-bismuth2026-10-20 https://evidence-hub.com/study/92-emergence-of-serotype-23f-among-levofloxacin-resistant-invasive2026-10-08 https://evidence-hub.com/study/93-levofloxacin-hemihydrate-adorned-floating-drug-delivery-system-to2026-10-08 https://evidence-hub.com/study/94-heatmap-based-and-regression-analysis-of-antibiotic-co-resistance2026-10-08 https://evidence-hub.com/study/95-spondylodiscitis-due-to-stenotrophomonas-maltophilia-after-endoscopic2026-10-08 https://evidence-hub.com/study/96-revealing-the-disease-spectrum-of-acute-q-fever-in-china-s-coastal2026-10-08 https://evidence-hub.com/study/97-genetic-characteristics-and-antimicrobial-resistance-profile-of-non2026-10-08 https://evidence-hub.com/study/98-a-case-report-of-complex-co-infection-with-talaromyces-marneffei-and2026-10-08 https://evidence-hub.com/study/99-case-report-dynamic-susceptibility-informed-therapy-for-bile-leak2026-10-08 https://evidence-hub.com/study/100-double-blind-placebo-controlled-study-of-three-month-treatment-with2026-10-08 https://evidence-hub.com/study/101-a-multicenter-double-blind-study-to-compare-the-safety-and-efficacy2026-10-08 https://evidence-hub.com/study/102-evaluation-of-the-performance-of-maf-1217-on-surgery-induced-ded-when2026-10-04 https://evidence-hub.com/study/103-an-interventional-open-label-non-randomized-phase-ia-safety-and2026-09-26 https://evidence-hub.com/study/104-a-randomized-control-trial-of-high-dose-isoniazid-adjuvant-therapy2026-10-08 https://evidence-hub.com/study/105-a-prospective-randomized-trial-of-levofloxacin-amoxicillin-triple2026-09-26 https://evidence-hub.com/study/106-a-phase-3-randomized-double-blind-double-dummy-multicenter2026-10-20 https://evidence-hub.com/study/107-an-open-label-randomized-multiple-dose-study-to-evaluate-levofloxacin2026-10-05 https://evidence-hub.com/study/108-a-study-of-sodium-carboxymethylcellulose-for-post-cataract-surgery2026-10-08 https://evidence-hub.com/study/109-population-pharmacokinetics-of-levofloxacin-in-intensive-care2026-10-08 https://evidence-hub.com/study/110-antibiotyping-and-prevalence-of-virulent-genotypes-among-helicobacter2026-10-05 https://evidence-hub.com/study/111-bioequivalence-study-of-levomerc-levofloxacin-500-mg-tablet-with2026-10-05 https://evidence-hub.com/study/112-comparative-controlled-trial-of-treatment-of-minor-unexpected-uterine2026-10-08 https://evidence-hub.com/study/113-a-phase-iv-comparative-study-of-the-safety-and-efficacy-of-cefdinir2026-10-08 https://evidence-hub.com/study/114-a-multi-center-randomized-double-blind-parallel-comparative-phase-iii2026-10-20 https://evidence-hub.com/study/115-refining-multidrug-tuberculosis-treatment-with-the-ultra-short-all2026-10-04 https://evidence-hub.com/study/116-phase-i-ii-randomized-open-label-trial-to-evaluate-the-pk-safety-and2026-10-08 https://evidence-hub.com/study/117-a-double-blind-randomized-controlled-pilot-study-comparing-the-safety2026-10-08 https://evidence-hub.com/study/118-antibiotic-treatment-for-7-days-versus-14-days-in-patients-with-acute2026-10-20 https://evidence-hub.com/study/119-phase-i-single-and-multi-dose-placebo-controlled-randomized-dose2026-10-04 https://evidence-hub.com/study/120-evaluation-of-corneal-hysteresis-and-corneal-resistance-factor-after2026-10-05 https://evidence-hub.com/study/121-swiss-pack-cxl-photoactivated-chromophore-for-infectious-keratitis2026-10-04 https://evidence-hub.com/study/122-a-multicenter-double-blind-randomized-study-to-compare-the-safety-and2026-10-20 https://evidence-hub.com/study/123-personalized-treatment-for-refractory-h-pylori-infection2026-10-05 https://evidence-hub.com/study/124-the-clinical-trial-of-methylene-blue-application-combined-with2026-10-20 https://evidence-hub.com/study/125-an-open-label-study-of-levofloxacin-to-evaluate-bacteriologic-outcome2026-09-26 https://evidence-hub.com/study/126-a-phase-3-randomized-multicenter-double-blind-study-to-evaluate-the2026-10-20 https://evidence-hub.com/study/127-treatment-of-acute-uncomplicated-pyelonephritis-with-short-course2026-10-08 https://evidence-hub.com/study/128-an-open-label-multi-center-non-comparative-sinus-puncture-study-of2026-10-08 https://evidence-hub.com/study/129-a-randomized-prospective-double-blind-placebo-controlled-trial-of2026-10-04 https://evidence-hub.com/study/130-a-randomized-double-blind-comparative-multi-center-study-of-the2026-10-20 https://evidence-hub.com/study/131-a-randomized-double-masked-parallel-group-study-of-de-108-ophthalmic2026-09-29 https://evidence-hub.com/study/132-assessment-of-hematological-effect-of-h-pylori-and-h-pylori2026-10-05 https://evidence-hub.com/study/133-evaluation-of-two-strategies-of-antibiotic-treatment-with2026-09-29 https://evidence-hub.com/study/134-comparative-study-of-the-levofloxacin-based-and-clarithromycin-based2026-10-20 https://evidence-hub.com/study/135-phase-4-study-of-azitromicin-in-the-treatment-of-pid2026-10-04 https://evidence-hub.com/study/136-a-multicenter-active-controlled-randomized-study-to-evaluate-the2026-10-08 https://evidence-hub.com/study/137-an-open-label-randomized-3-way-crossover-study-to-evaluate-the2026-09-26 https://evidence-hub.com/study/138-a-phase-ii-multi-center-randomized-parallel-controlled-study-to2026-10-08 https://evidence-hub.com/study/139-aqueous-humour-concentrations-after-topical-application-of-combined2026-10-08 https://evidence-hub.com/study/140-efficacies-of-antimicrobial-susceptibility-guided-versus-empirical2026-10-05 https://evidence-hub.com/study/141-prospective-randomized-study-to-compare-clinical-outcomes-in-patients2026-10-08 https://evidence-hub.com/study/142-phase-i-clinical-trial-to-evaluate-the-safety-and-tolerability-of-the2026-10-08 https://evidence-hub.com/study/143-efficacies-of-two-bismuth-quadruple-therapies-in-the-second-line2026-09-26 https://evidence-hub.com/study/144-a-single-centre-randomised-study-of-the-clinical-and-microbiological2026-10-04 https://evidence-hub.com/study/145-comparing-the-efficacy-of-14-day-therapy-doxycycline-with-bismuth2026-10-05 https://evidence-hub.com/study/146-assessment-of-the-effects-and-tolerability-of-rd03-2016-levofloxacin2026-10-08 https://evidence-hub.com/study/147-a-phase-3-randomized-double-blind-double-dummy-multicenter2026-10-20 https://evidence-hub.com/study/148-a-randomized-observer-masked-parallel-group-multicenter-trial2026-10-05 https://evidence-hub.com/study/149-randomized-controled-multicentric-trial-of-non-inferiority-comparing2026-10-20 https://evidence-hub.com/study/150-pharmacodynamics-of-levofloxacin-a-new-paradigm-for-early-clinical2026-10-20 https://evidence-hub.com/study/151-levofloxacin-to-prevent-bacterial-infection-in-patients-with-cancer2026-10-08 https://evidence-hub.com/study/152-resistance-to-levofloxacin-and-failure-of-treatment-of-pneumococcal2026-10-08 https://evidence-hub.com/study/153-ciprofloxacin-and-levofloxacin-attenuate-microglia-inflammatory2026-10-08 https://evidence-hub.com/study/154-levofloxacin-a-review-of-its-use-as-a-high-dose-short-course2026-10-20 https://evidence-hub.com/study/157-high-dose-short-course-levofloxacin-for-community-acquired-pneumonia2026-10-08 https://evidence-hub.com/study/158-levofloxacin-its-use-in-infections-of-the-respiratory-tract-skin-soft2026-10-20 https://evidence-hub.com/study/159-systematic-review-and-meta-analysis-levofloxacin-based-rescue2026-10-08 https://evidence-hub.com/study/161-adsorption-behavior-of-the-antibiotic-levofloxacin-on-microplastics2026-10-08 https://evidence-hub.com/study/162-levofloxacin-a-therapeutic-review2026-10-20 https://evidence-hub.com/study/167-in-vitro-and-in-vivo-antibacterial-activities-of-levofloxacin-l2026-10-20 https://evidence-hub.com/study/168-levofloxacin-a-second-generation-fluoroquinolone2026-10-20 https://evidence-hub.com/study/169-a-multicenter-randomized-study-comparing-the-efficacy-and-safety-of2026-10-20 https://evidence-hub.com/study/170-pharmacodynamics-of-levofloxacin-and-ciprofloxacin-against2026-10-20 https://evidence-hub.com/study/172-risk-factors-for-acquisition-of-levofloxacin-resistant-streptococcus2026-10-08 https://evidence-hub.com/study/173-population-pharmacokinetics-of-levofloxacin-gatifloxacin-and2026-10-08 https://evidence-hub.com/study/174-pharmacokinetic-profile-of-levofloxacin-following-once-daily-5002026-10-08 https://evidence-hub.com/study/176-bacteremia-due-to-viridans-group-streptococci-with-diminished2026-10-08 https://evidence-hub.com/study/178-early-and-extended-early-bactericidal-activity-of-levofloxacin2026-10-03 https://evidence-hub.com/study/179-levofloxacin-based-triple-therapy-versus-bismuth-based-quadruple2026-10-13 https://evidence-hub.com/study/180-ceftolozane-tazobactam-compared-with-levofloxacin-in-the-treatment-of2026-10-20 https://evidence-hub.com/study/181-antimicrobial-chemotherapy-for-legionnaires-disease-levofloxacin2026-10-08 https://evidence-hub.com/study/182-pharmacodynamic-comparisons-of-levofloxacin-ciprofloxacin-and2026-10-08 https://evidence-hub.com/study/183-effect-of-levofloxacin-prophylaxis-on-bacteremia-in-children-with2026-10-08 https://evidence-hub.com/study/184-outcomes-of-patients-with-multidrug-resistant-pulmonary-tuberculosis2026-10-08 https://evidence-hub.com/study/187-azithromycin-and-levofloxacin-use-and-increased-risk-of-cardiac2026-10-08 https://evidence-hub.com/study/189-fluoroquinolone-resistant-streptococcus-pneumoniae-associated-with2026-10-08 https://evidence-hub.com/study/190-inhibitors-of-efflux-pumps-in-pseudomonas-a-eruginosa-potentiate-the2026-10-03 https://evidence-hub.com/study/193-in-vitro-and-in-vivo-activities-of-levofloxacin-against-biofilm2026-10-20 https://evidence-hub.com/study/194-multifunctional-ph-sensitive-3d-scaffolds-for-treatment-and2026-10-08 https://evidence-hub.com/study/195-3d-scaffold-with-effective-multidrug-sequential-release-against2026-10-08 https://evidence-hub.com/study/196-effective-reduction-of-biofilm-through-photothermal-therapy-by-gold2026-10-08 https://evidence-hub.com/study/197-a-versatile-multicomponent-mesoporous-silica-nanosystem-with-dual2026-10-08 https://evidence-hub.com/study/198-concanavalin-a-targeted-mesoporous-silica-nanoparticles-for-infection2026-10-08 https://evidence-hub.com/study/199-a-novel-semi-supervised-algorithm-for-rare-prescription-side-effect2026-10-08 https://evidence-hub.com/study/200-multifunctional-antibiotic-and-zinc-containing-mesoporous-bioactive2026-10-08 https://evidence-hub.com/study/201-impact-of-the-antibiotic-cargo-from-msns-on-gram-positive-and-gram2026-10-08 https://evidence-hub.com/study/202-molecular-gates-in-mesoporous-bioactive-glasses-for-the-treatment-of2026-10-08 https://evidence-hub.com/study/203-mesoporous-silica-nanoparticles-decorated-with-polycationic2026-10-08 https://evidence-hub.com/study/204-prevalence-of-antibiotic-resistance-in-helicobacter-pylori-a2026-10-13 https://evidence-hub.com/study/205-drug-associated-adverse-events-in-the-treatment-of-multidrug2026-10-08 https://evidence-hub.com/study/206-efficacy-of-treatment-options-for-complicated-urinary-tract2026-10-20 https://evidence-hub.com/study/207-global-primary-antibiotic-resistance-rate-of-helicobacter-pylori-in2026-10-08 https://evidence-hub.com/study/208-global-prevalence-of-helicobacter-pylori-antibiotic-resistance-among2026-10-13 https://evidence-hub.com/study/209-identifying-the-best-initial-oral-antibiotics-for-adults-with2026-10-08 https://evidence-hub.com/study/210-primary-antibiotic-resistance-of-helicobacter-pylori-in-the-asia2026-10-08 https://evidence-hub.com/study/211-efficacy-of-doxycycline-for-mild-to-moderate-community-acquired2026-10-20 https://evidence-hub.com/study/212-respiratory-fluoroquinolone-monotherapy-versus-lactam-plus-macrolide2026-10-20 https://evidence-hub.com/study/213-treatment-of-helicobacter-pylori-infection-in-korea-a-systematic2026-10-08 https://evidence-hub.com/study/214-a-systematic-review-and-meta-analysis-of-levofloxacin-and2026-10-20 https://evidence-hub.com/study/215-meta-analysis-on-effectiveness-and-safety-of-moxifloxacin-in2026-10-08 https://evidence-hub.com/study/216-a-meta-analysis-of-levofloxacin-for-contacts-of-multidrug-resistant2026-10-08 https://evidence-hub.com/study/217-fluoroquinolones-in-the-management-of-tuberculous-meningitis2026-10-08 https://evidence-hub.com/study/218-safety-of-quinolones-in-children-a-systematic-review-and-meta-analysis2026-10-08 https://evidence-hub.com/study/219-meta-analysis-of-fluoroquinolones-versus-macrolides-for-treatment-of2026-10-20 https://evidence-hub.com/study/220-the-prevalence-of-antibiotic-resistant-clostridium-species-in-iran-a2026-10-08 https://evidence-hub.com/study/221-fluoroquinolones-for-treating-tuberculosis2026-10-08 https://evidence-hub.com/study/222-fluoroquinolones-for-treating-tuberculosis2026-10-08 https://evidence-hub.com/study/223-antibiotic-resistance-of-helicobacter-pylori-in-mainland-china-a2026-10-08 https://evidence-hub.com/study/224-fluoroquinolones-increase-the-risk-of-serious-arrhythmias-a2026-10-08 https://evidence-hub.com/study/225-a-meta-analytic-perspective-on-arcobacter-spp-antibiotic-resistance2026-10-08 https://evidence-hub.com/study/226-fluoroquinolones-and-the-risk-of-tendon-injury-a-systematic-review2026-10-08 https://evidence-hub.com/study/227-the-effect-of-antibiotic-resistance-on-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/228-drug-treatment-of-scrub-typhus-a-systematic-review-and-meta-analysis2026-10-08 https://evidence-hub.com/study/229-the-effects-of-adding-quinolones-to-beta-lactam-antibiotics-for-sepsis2026-10-08 https://evidence-hub.com/study/230-systematic-review-and-meta-analysis-of-antimicrobial-treatment-effect2026-10-20 https://evidence-hub.com/study/231-prevalence-of-antibiotic-heteroresistance-associated-with2026-10-08 https://evidence-hub.com/study/232-antibiotics-for-community-acquired-pneumonia-in-children2026-10-08 https://evidence-hub.com/study/233-antibiotic-resistance-of-helicobacter-pylori-in-turkey-a-systematic2026-10-08 https://evidence-hub.com/study/234-a-systematic-review-and-meta-analysis-of-comparative-clinical-studies2026-10-08 https://evidence-hub.com/study/235-pharmacokinetics-and-optimal-dosing-of-levofloxacin-in-children-for2026-10-08 https://evidence-hub.com/study/236-the-increasing-antimicrobial-resistance-of-helicobacter-pylori-in2026-10-08 https://evidence-hub.com/study/237-helicobacter-pylori-antibiotic-resistance-in-portugal-systematic2026-10-08 https://evidence-hub.com/study/238-efficacy-of-levofloxacin-as-an-antibacterial-prophylaxis-for-acute2026-10-08 https://evidence-hub.com/study/239-molecular-characterization-of-invasive-streptococcus-dysgalactiae2026-10-08 https://evidence-hub.com/study/240-whole-genome-sequencing-predicting-phenotypic-antitubercular-drug2026-10-08 https://evidence-hub.com/study/241-trends-of-fluoroquinolones-resistance-in-mycoplasma-and-ureaplasma2026-10-08 https://evidence-hub.com/study/242-helicobacter-pylori-eradication-in-older-individuals-a-systematic2026-10-08 https://evidence-hub.com/study/243-efficacy-of-second-line-regimens-for-helicobacter-pylori-eradication2026-10-08 https://evidence-hub.com/study/244-an-updated-systematic-review-and-meta-analysis-on-the-helicobacter2026-10-08 https://evidence-hub.com/study/245-efficacy-and-safety-of-drug-therapies-for-treating-tuberculous2026-10-08 https://evidence-hub.com/study/246-comparison-of-pathogen-eradication-rate-and-safety-of-anti-bacterial2026-10-20 https://evidence-hub.com/study/247-changes-in-treatment-for-multidrug-resistant-tuberculosis-according2026-10-08 https://evidence-hub.com/study/248-prevalence-of-antibiotic-resistant-cutibacterium-acnes-formerly2026-10-08 https://evidence-hub.com/study/249-efficacy-of-bismuth-for-antibiotic-resistant-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/250-high-dose-rifampicin-for-the-treatment-of-tuberculous-meningitis-a2026-10-08 https://evidence-hub.com/study/251-comparison-of-fosfomycin-against-fluoroquinolones-for-transrectal2026-10-20 https://evidence-hub.com/study/252-effectiveness-and-safety-of-levofloxacin-in-the-treatment-of2026-10-20 https://evidence-hub.com/study/253-efficacy-of-fluoroquinolone-prophylaxis-in-high-risk-neutropenic2026-10-08 https://evidence-hub.com/study/254-mutation-driven-mechanisms-underlying-antibiotic-resistance-of2026-10-08 https://evidence-hub.com/study/255-global-prevalence-of-fluoroquinolone-resistance-in-escherichia-coli2026-10-20 https://evidence-hub.com/study/256-antimicrobial-resistance-patterns-and-microbial-epidemiology-of-oral2026-10-08 https://evidence-hub.com/study/257-efficacy-of-fluoroquinolone-prophylaxis-during-induction-phase-in2026-10-12 https://evidence-hub.com/study/258-association-of-oral-vancomycin-prophylaxis-with-clostridium-difficile2026-10-20 https://evidence-hub.com/study/259-open-access-genomic-drug-resistance-prediction-tools-for2026-10-08 https://evidence-hub.com/study/260-tailored-screening-and-eradication-of-helicobacter-pylori-at-a2026-10-08 https://evidence-hub.com/study/261-treatment-shortening-and-relapse-control-in-drug-susceptible2026-10-08 https://evidence-hub.com/study/262-systematic-evaluation-and-meta-analysis-of-prevalence-and-trends-for2026-10-08 https://evidence-hub.com/study/263-global-prevalence-and-antimicrobial-resistance-of-staphylococcus2026-10-08 https://evidence-hub.com/study/264-clinical-efficacy-of-yinhua-miyanling-tablet-in-the-treatment-of2026-10-13 https://evidence-hub.com/study/265-a-systematic-review-and-meta-analysis-of-the-global-prevalence-of2026-10-13 https://evidence-hub.com/study/266-local-versus-systemic-antibiotics-for-diabetic-foot-infection-a2026-10-08 https://evidence-hub.com/study/267-antibiotic-combinations-in-bismuth-containing-quadruple-therapy-for2026-10-08 https://evidence-hub.com/study/268-global-antibiotic-resistance-trends-in-enterococcus-faecalis-from2026-10-08 https://evidence-hub.com/study/269-network-meta-analysis-of-the-prevalence-and-antimicrobial-resistance2026-10-08 https://evidence-hub.com/study/270-the-efficacy-of-different-treatment-options-in-cutaneous-sarcoidosis2026-10-08 https://evidence-hub.com/study/271-effectiveness-and-safety-of-bedaquiline-containing-modified-shorter2026-10-08 https://evidence-hub.com/study/272-distribution-and-antibiotic-resistance-of-pathogens-in-post2026-10-08 https://evidence-hub.com/study/273-effect-of-a-topical-antibiotic-and-povidone-iodine-vs-povidone-iodine2026-10-08 https://evidence-hub.com/study/274-resistance-profile-and-influence-factors-of-carbapenem-resistant2026-10-13 https://evidence-hub.com/study/275-a-comprehensive-meta-analysis-on-antimicrobial-resistance-patterns-of2026-10-08 https://evidence-hub.com/study/276-prophylactic-fluoroquinolones-in-hematopoietic-stem-cell-transplant2026-10-13 https://evidence-hub.com/study/277-comparative-efficacy-safety-and-compliance-with-dual-triple-and2026-10-16 https://evidence-hub.com/study/278-recent-advances-in-electrochemical-detection-of-antibiotics-on2026-10-08 https://evidence-hub.com/study/279-burden-of-helicobacter-pylori-infection-in-children-and-adults-in2026-10-08 https://evidence-hub.com/study/280-meta-analysis-of-fluoroquinolone-antibiotics-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/281-prevalence-of-antimicrobial-resistance-in-equine-associated2026-10-08 https://evidence-hub.com/study/282-effectiveness-of-amoxicillin-and-amoxicillin-clavulanate-for-the2026-10-08 https://evidence-hub.com/study/283-macrolides-usage-as-anti-inflammatory-agents-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/284-should-metronidazole-be-included-in-second-line-treatment-after2026-10-08 https://evidence-hub.com/study/285-soothing-the-liver-and-activating-blood-circulation-for-the-treatment2026-10-08 https://evidence-hub.com/study/286-comparison-of-ceftolozane-tazobactam-and-ceftazidime-avibactam-in-the2026-10-13 https://evidence-hub.com/study/287-antimicrobial-resistance-in-bordetella-pertussis-a-systematic-review2026-10-08 https://evidence-hub.com/study/288-expression-of-multidrug-efflux-pump-gene-acrab-in-escherichia-coli-a2026-10-13 https://evidence-hub.com/study/289-antimicrobial-resistance-in-bloodstream-infections-in-west-africa-a2026-10-13 https://evidence-hub.com/study/290-efficacy-and-safety-of-quadruple-therapy-with-semisynthetic2026-10-08 https://evidence-hub.com/study/291-optimal-duration-of-perioperative-antibiotics-in-radical-cystectomy2026-10-13 https://evidence-hub.com/study/292-colistin-based-combination-therapy-versus-monotherapy-for-carbapenem2026-10-13 https://evidence-hub.com/study/293-prevalence-of-sight-threatening-ocular-abnormalities-identified-by2026-10-08 https://evidence-hub.com/study/294-effect-of-antibiotic-therapy-versus-no-antibiotics-on-nonoperative2026-10-08 https://evidence-hub.com/study/295-the-effectiveness-of-isoniazid-preventive-treatment-among-contacts-of2026-10-08 https://evidence-hub.com/study/296-susceptibility-guided-versus-empirical-first-line-therapy-of2026-10-08 https://evidence-hub.com/study/297-high-antibiotic-resistance-rates-in-helicobacter-pylori-strains-in2026-10-08 https://evidence-hub.com/study/298-guideline-for-antibacterial-prophylaxis-administration-in-pediatric2026-10-13 https://evidence-hub.com/study/299-a-systematic-review-of-the-drug-drug-interaction-between-statins-and2026-10-13 https://evidence-hub.com/study/300-antibiotic-resistance-of-legionella-pneumophila-in-clinical-and-water2026-10-08 https://evidence-hub.com/study/301-an-update-on-legionella2026-10-08 https://evidence-hub.com/study/302-clinical-pharmacokinetics-of-potassium-competitive-acid-blockers-a2026-10-20 https://evidence-hub.com/study/303-a-systematic-review-of-randomised-clinical-trials-for-oral-antibiotic2026-10-13 https://evidence-hub.com/study/304-antimicrobial-treatment-of-stenotrophomonas-maltophilia-invasive2026-10-08 https://evidence-hub.com/study/305-efficacy-and-side-effects-of-antibiotics-in-the-treatment-of-acute2026-10-08 https://evidence-hub.com/study/306-mrsa-treating-people-with-infection2026-10-08 https://evidence-hub.com/study/307-worldwide-and-regional-efficacy-estimates-of-first-line-helicobacter2026-10-08 https://evidence-hub.com/study/308-effectiveness-and-safety-of-levofloxacin-containing-regimen-in-the2026-10-08 https://evidence-hub.com/study/309-third-line-and-rescue-therapy-for-refractory-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/310-global-patterns-of-antibiotic-resistance-in-group-b-streptococcus-a2026-10-08 https://evidence-hub.com/study/311-effects-of-fluroquinolones-in-newly-diagnosed-sputum-positive2026-10-08 https://evidence-hub.com/study/312-the-treatment-effect-of-levofloxacin-moxifloxacin-and-gatifloxacin2026-10-08 https://evidence-hub.com/study/313-v-spanish-consensus-conference-on-helicobacter-pylori-infection2026-10-08 https://evidence-hub.com/study/314-efficacy-and-safety-of-short-course-antibiotic-therapy-for-community2026-10-20 https://evidence-hub.com/study/315-population-pharmacokinetics-of-levofloxacin-a-systematic-review2026-10-08 https://evidence-hub.com/study/316-the-clinical-and-epidemiological-landscape-of-mycobacterium2026-10-08 https://evidence-hub.com/study/317-efficacy-and-safety-of-antibiotic-regimens-for-helicobacter-pylori2026-10-16 https://evidence-hub.com/study/318-fluoroquinolones-and-the-risk-of-panic-attacks-a-systematic-review2026-10-13 https://evidence-hub.com/study/319-spontaneous-bacterial-peritonitis-due-to-brucella-species-versus2026-10-13 https://evidence-hub.com/study/320-kluyvera-infections-in-humans-a-systematic-review2026-10-13 https://evidence-hub.com/study/321-effectiveness-and-safety-of-maxing-shigan-decoction-for-community2026-10-08 https://evidence-hub.com/study/322-edwardsiella-tarda-infections-in-humans-a-systematic-review-of2026-10-13 https://evidence-hub.com/study/323-antibiotic-resistance-rates-in-cutibacterium-acnes-isolated-from2026-10-08 https://evidence-hub.com/study/324-chronic-laparoscopic-port-site-infection-a-systematic-review2026-10-08 https://evidence-hub.com/study/325-effects-of-fluoroquinolones-on-aortic-aneurysm-or-dissection2026-10-13 https://evidence-hub.com/study/326-global-trends-and-research-profile-of-antibiotic-heteroresistance-a2026-10-08 https://evidence-hub.com/study/327-comparing-potassium-competitive-acid-blocker-based-therapies-for2026-10-20 https://evidence-hub.com/study/328-effectiveness-of-classic-triple-therapy-compared-with-alternative2026-10-08 https://evidence-hub.com/study/329-moraxella-peritoneal-dialysis-related-infections-a-systematic-review2026-10-08 https://evidence-hub.com/study/330-performance-of-next-generation-sequencing-technologies-for-detecting2026-10-08 https://evidence-hub.com/study/331-wound-infection-caused-by-non-decarboxylated-leclercia-case-report2026-10-08 https://evidence-hub.com/study/332-use-of-antibiotics-for-prevention-and-treatment-of-sinus-lift2026-10-08 https://evidence-hub.com/study/333-etiology-and-management-of-cholangitis-in-pediatric-liver-transplant2026-10-13 https://evidence-hub.com/study/334-relationship-between-small-intestinal-bacterial-overgrowth-and2026-10-08 https://evidence-hub.com/study/335-antibiotic-resistance-in-odontogenic-infections-a-systematic-review2026-10-08 https://evidence-hub.com/study/336-leveraging-artificial-intelligence-for-analysis-of-the-gut-microbiome2026-10-08 https://evidence-hub.com/study/337-drug-clearance-and-dosing-during-cytosorb-hemoadsorption-a-systematic2026-10-08 https://evidence-hub.com/study/338-value-of-emerging-and-existing-pre-prophylaxis-and-therapeutic2026-10-08 https://evidence-hub.com/study/339-gastric-cancer-prevention-by-h-pylori-eradication-in-china-a-meta2026-10-08 https://evidence-hub.com/study/340-antibiotic-therapy-for-uncomplicated-acute-appendicitis-ten-year2026-10-08 https://evidence-hub.com/study/341-antibiotic-therapy-vs-appendectomy-for-treatment-of-uncomplicated2026-10-08 https://evidence-hub.com/study/342-levofloxacin-preventive-treatment-in-children-exposed-to-mdr2026-10-08 https://evidence-hub.com/study/343-a-pragmatic-trial-of-a-6-month-strategy-for-rifampicin-resistant2026-10-08 https://evidence-hub.com/study/344-levofloxacin-for-the-prevention-of-multidrug-resistant-tuberculosis2026-10-08 https://evidence-hub.com/study/345-five-year-follow-up-of-antibiotic-therapy-for-uncomplicated-acute2026-10-08 https://evidence-hub.com/study/346-three-year-outcomes-of-oral-antibiotics-vs-intravenous-and-oral2026-10-08 https://evidence-hub.com/study/347-doxycycline-versus-levofloxacin-combined-with-tinidazole-for-treating2026-10-08 https://evidence-hub.com/study/348-a-multicentre-randomised-double-blind-double-dummy-parallel2026-10-20 https://evidence-hub.com/study/349-nine-months-of-bedaquiline-linezolid-levofloxacin-clofazimine-and2026-10-08 https://evidence-hub.com/study/350-fourteen-day-vonoprazan-based-bismuth-quadruple-therapy-for-h-pylori2026-10-08 https://evidence-hub.com/study/351-a-randomized-controlled-trial-volunteer-study-of-sitafloxacin2026-10-08 https://evidence-hub.com/study/352-safety-and-efficacy-of-additional-levofloxacin-in-tuberculous2026-10-08 https://evidence-hub.com/study/354-a-randomised-comparison-of-management-strategies-for-drug-induced2026-10-08 https://evidence-hub.com/study/355-efficacy-and-safety-of-higher-doses-of-levofloxacin-for-multidrug2026-10-08 https://evidence-hub.com/study/356-an-optimized-background-regimen-design-to-evaluate-the-contribution2026-10-08 https://evidence-hub.com/study/357-safety-and-efficacy-of-levofloxacin-versus-rifampicin-in-tuberculous2026-10-08 https://evidence-hub.com/study/358-efficacy-of-antibiotic-prophylaxis-in-patients-undergoing-cystoscopy2026-10-13 https://evidence-hub.com/study/359-effect-of-levofloxacin-on-neutrophilic-airway-inflammation-in-stable2026-10-08 https://evidence-hub.com/study/360-prulifloxacin-vs-levofloxacin-for-exacerbation-of-copd-after-failure2026-10-06 https://evidence-hub.com/study/361-a-double-blind-randomized-controlled-pilot-study-comparing-the-safety2026-10-08 https://evidence-hub.com/study/362-treatment-of-complicated-urinary-tract-infection-and-acute2026-10-20 https://evidence-hub.com/study/363-precision-therapy-guided-by-genotypic-antibiotic-resistance-for2026-10-13 https://evidence-hub.com/study/364-clinical-and-microbiological-effects-of-levofloxacin-in-the-treatment2026-10-08 https://evidence-hub.com/study/365-a-randomized-controlled-clinical-trial-of-levofloxacin-750-mg-versus2026-10-08 https://evidence-hub.com/study/366-treatment-with-levofloxacin-does-not-resolve-asymptomatic2026-10-08 https://evidence-hub.com/study/367-pharmacokinetics-and-pharmacodynamics-of-intensive-antituberculosis2026-10-08 https://evidence-hub.com/study/368-a-randomized-trial-regarding-antimicrobial-prophylaxis-amp-in2026-10-13 https://evidence-hub.com/study/369-efficacy-of-levofloxacin-in-the-treatment-of-bk-viremia-a-multicenter2026-10-08 https://evidence-hub.com/study/370-tetracycline-levofloxacin-versus-amoxicillin-levofloxacin-quadruple2026-10-08 https://evidence-hub.com/study/371-effectiveness-of-prophylactic-antimicrobial-levofloxacin-against2026-10-13 https://evidence-hub.com/study/372-pharmacokinetics-of-levofloxacin-after-single-intravenous-and-repeat2026-10-19 https://evidence-hub.com/study/373-antituberculosis-effect-of-levofloxacin2026-10-08 https://evidence-hub.com/study/374-a-randomized-active-controlled-multicentre-clinical-trial-to-evaluate2026-10-20 https://evidence-hub.com/study/375-safety-and-efficacy-of-oral-nemonoxacin-versus-levofloxacin-in2026-10-20 https://evidence-hub.com/study/376-levofloxacin-for-the-prevention-of-febrile-episodes-in-non-hodgkin2026-10-20 https://evidence-hub.com/study/377-efficacy-and-safety-of-cefuroxime-tetracycline-containing-bismuth2026-10-16 https://evidence-hub.com/study/378-early-bactericidal-activity-of-sitafloxacin-against-pulmonary2026-10-08 https://evidence-hub.com/study/379-tailored-therapy-guided-by-antibiotic-genotypic-resistances-and2026-10-08 https://evidence-hub.com/study/380-effectiveness-and-tolerability-of-short-course-co-trimoxazole2026-10-20 https://evidence-hub.com/study/381-tigecycline-versus-levofloxacin-for-the-treatment-of-community2026-10-20 https://evidence-hub.com/study/382-efficacy-of-1-day-prophylaxis-medication-with-fluoroquinolone-for2026-10-08 https://evidence-hub.com/study/383-comparison-of-topical-gatifloxacin-and-levofloxacin-at-different2026-10-08 https://evidence-hub.com/study/384-factors-associated-with-screening-failure-and-study-withdrawal-in2026-10-08 https://evidence-hub.com/study/385-a-multi-center-randomized-controlled-double-blind-and-double-dummy2026-10-08 https://evidence-hub.com/study/386-effectiveness-of-1-25-povidone-iodine-combined-with-topical2026-10-08 https://evidence-hub.com/study/387-complex-therapy-of-chronic-bacterial-prostatitis-using-the2026-10-08 https://evidence-hub.com/study/388-helicobacter-pylori-eradication-in-the-era-of-rising-antibiotic2026-10-08 https://evidence-hub.com/study/389-susceptibility-guided-versus-empirical-therapy-for-helicobacter2026-10-08 https://evidence-hub.com/study/390-efficacy-and-safety-of-yinhua-miyanling-tablets-for-uncomplicated2026-10-20 https://evidence-hub.com/study/391-on-hierarchical-composite-endpoints-in-pediatric-cancer-supportive2026-10-08 https://evidence-hub.com/study/392-levofloxacin-versus-moxifloxacin-in-nitazoxanide-based-quadruple2026-10-08 https://evidence-hub.com/study/393-efficacy-and-safety-of-levofloxacin-versus-moxifloxacin-based2026-10-08 https://evidence-hub.com/study/394-14-day-vonoprazan-minocycline-dual-therapy-versus-bismuth-containing2026-10-08 https://evidence-hub.com/study/395-analysis-of-the-efficacy-of-fosfomycin-trometamol-in-preventing2026-10-20 https://evidence-hub.com/study/396-comparison-of-the-efficacy-and-safety-of-levofloxacin-eye-drops-and2026-10-08 https://evidence-hub.com/study/397-effect-of-a-modified-soft-contact-lens-combined-with-a-noncontact2026-10-08 https://evidence-hub.com/study/398-vonoprazan-based-dual-therapy-with-amoxicillin-or-doxycycline-versus2026-10-13 https://evidence-hub.com/study/399-clinical-efficacy-of-abdominal-moxibustion-at-the-zhongji-cv3-in2026-10-20 https://evidence-hub.com/study/400-efficacy-of-fourteen-day-once-daily-vonoprazan-based-quadruple2026-10-13 https://evidence-hub.com/study/401-antimicrobial-photodynamic-therapy-in-the-treatment-of-diabetic-foot2026-10-08 https://evidence-hub.com/study/402-a-6-to-9-months-oral-regimen-for-rifampicin-resistant-tuberculosis-a2026-10-08 https://evidence-hub.com/study/403-cost-effectiveness-of-oral-levofloxacin-versus-amoxicillin2026-10-08 https://evidence-hub.com/study/404-the-efficacy-of-combined-bandage-contact-lens-and-nasal-margin-suture2026-10-08 https://evidence-hub.com/study/405-vonoprazan-amoxicillin-dual-therapy-combined-with-probiotics-for2026-10-13 https://evidence-hub.com/study/406-innovating-shorter-all-oral-precise-individualized-treatment-regimen2026-10-08 https://evidence-hub.com/study/407-the-effect-of-povidone-iodine-10-plus-levofloxacin-0-5-before2026-10-08 https://evidence-hub.com/study/408-eradication-of-helicobacter-pylori-that-contributes-to-hepatogenic2026-10-08 https://evidence-hub.com/study/409-the-effect-of-psychological-intervention-combined-with-standard2026-10-08 https://evidence-hub.com/study/410-four-week-vs-six-week-antibiotic-therapy-in-the-management-of2026-10-13 https://evidence-hub.com/study/411-rebamipide-for-managing-dyspeptic-symptoms-during-proton-pump2026-10-08 https://evidence-hub.com/study/412-comparison-of-preoperative-5-povidone-iodine-plus-moxifloxacin-versus2026-10-08 https://evidence-hub.com/study/413-randomized-controlled-diagnostic-trial-to-assess-drast-time-to-result2026-10-13 https://evidence-hub.com/study/414-clinical-observation-of-early-postoperative-wear-of-balafilcon-a-and2026-10-08 https://evidence-hub.com/study/415-14-day-empirical-therapy-compared-with-7-day-tailored-therapy-for2026-10-08 https://evidence-hub.com/study/416-comparison-of-the-effectiveness-of-single-dose-levofloxacin-with2026-10-20 https://evidence-hub.com/study/417-effect-of-hiv-on-bedaquiline-and-delamanid-pharmacokinetics-in2026-10-08 https://evidence-hub.com/study/418-comparison-of-the-prophylactic-effect-of-cefazolin-injection-versus2026-10-13 https://evidence-hub.com/study/419-effects-of-huang-e-capsules-on-type-iiia-prostatitis-and-inflammatory2026-10-08 https://evidence-hub.com/study/420-enteral-versus-intravenous-antibiotics-for-critically-ill-patients-a2026-10-13 https://evidence-hub.com/study/421-comparison-of-cefuroxime-based-dual-therapy-with-quadruple-therapy-in2026-10-08 https://evidence-hub.com/study/422-a-study-on-the-efficacy-and-safety-of-fecal-microbiota2026-10-08 https://evidence-hub.com/study/423-comparison-of-levofloxacin-and-garenoxacin-for-antibacterial2026-10-06 https://evidence-hub.com/study/424-safety-and-effectiveness-of-vonoprazan-based-rescue-therapy-for2026-10-08 https://evidence-hub.com/study/425-pharmacokinetics-and-optimized-dosing-of-dispersible-and-non2026-10-08 https://evidence-hub.com/study/426-assessment-of-helicobacter-pylori-eradication-rate-of-triple2026-10-08 https://evidence-hub.com/study/427-pharmacokinetics-of-levofloxacin-in-comparison-to-the-racemic-mixture2026-10-06 https://evidence-hub.com/study/428-aqueous-and-vitreous-penetration-of-levofloxacin-after-topical-and-or2026-10-08 https://evidence-hub.com/study/429-evaluation-of-analgesic-activity-of-levofloxacin-in-human2026-10-08 https://evidence-hub.com/study/430-levofloxacin-pharmacokinetics-in-children2026-10-08 https://evidence-hub.com/study/431-levofloxacin-amoxicillin-clavulanate-rabeprazole-versus-a-standard2026-10-08 https://evidence-hub.com/study/432-antibiotic-prophylaxis-in-transarterial-chemoembolization-of2026-10-08 https://evidence-hub.com/study/433-comparison-of-10-day-levofloxacin-bismuth-based-quadruple-therapy-and2026-10-06 https://evidence-hub.com/study/434-empirical-levofloxacin-containing-versus-clarithromycin-containing2026-10-08 https://evidence-hub.com/study/435-levofloxacin-in-the-treatment-of-acute-and-bacteriologically2026-10-08 https://evidence-hub.com/study/436-aqueous-and-vitreous-penetration-of-linezolid-and-levofloxacin-after2026-10-06 https://evidence-hub.com/study/437-intrapulmonary-concentration-of-levofloxacin-in-patients-with2026-10-08 https://evidence-hub.com/study/438-pharmacokinetics-of-multiple-intravenous-instillation-of-levofloxacin2026-10-06 https://evidence-hub.com/study/439-the-clinical-and-bacteriological-factors-for-optimal-levofloxacin2026-10-08 https://evidence-hub.com/study/440-comparing-the-efficacy-of-sequential-and-standard-quadruple-therapy2026-10-06 https://evidence-hub.com/study/441-levofloxacin-treatment-in-patients-with-rheumatoid-arthritis2026-10-08 https://evidence-hub.com/study/442-clinical-trial-clarithromycin-vs-levofloxacin-in-first-line-triple2026-10-08 https://evidence-hub.com/study/443-phase-ii-clinical-trial-for-prevention-of-delayed-diarrhea-with2026-10-08 https://evidence-hub.com/study/444-assessment-of-musculoskeletal-toxicity-5-years-after-therapy-with2026-10-08 https://evidence-hub.com/study/445-the-effects-of-levofloxacin-on-ecg-parameters-and-late-potentials2026-10-08 https://evidence-hub.com/study/446-levofloxacin-prophylaxis-to-prevent-bacterial-infection-in2026-10-08 https://evidence-hub.com/study/447-pharmacokinetics-and-safety-of-mp-376-levofloxacin-inhalation2026-10-08 https://evidence-hub.com/study/448-cefadroxil-as-oral-transitional-therapy-for-gram-positive-bacteremia2026-10-13 https://evidence-hub.com/study/449-administration-of-levofloxacin-combined-with-metronidazole2026-10-08 https://evidence-hub.com/study/450-population-based-study-of-pharmacogenetics-and-pharmacokinetics-in2026-10-08 https://evidence-hub.com/study/451-bismuth-based-quintuple-therapy-a-step-beyond-quadruple-regimens-in-h2026-10-08 https://evidence-hub.com/study/452-direct-stimulation-of-acupuncture-at-extraocular-muscle-attachment2026-10-08 https://evidence-hub.com/study/453-hypoalbuminemia-and-reduced-sputum-microbiome-diversity-associated2026-10-08 https://evidence-hub.com/study/454-the-use-of-step-down-oral-antibiotic-therapy-for-uncomplicated-gram2026-10-08 https://evidence-hub.com/study/455-protecting-households-on-exposure-to-newly-diagnosed-index-multidrug2026-10-13 https://evidence-hub.com/study/456-intensified-treatment-of-tuberculous-meningitis-in-adults-a2026-10-08 https://evidence-hub.com/study/457-effectiveness-of-doxycycline-in-combination-with-other-antibiotics2026-10-08 https://evidence-hub.com/study/458-lascufloxacin-switch-therapy-versus-ampicillin-sulbactam-for-older2026-10-20 https://evidence-hub.com/study/459-vonoprazan-amoxicillin-dual-therapy-with-or-without-saccharomyces2026-10-08 https://evidence-hub.com/study/460-evaluation-of-an-oral-bedaquiline-regimen-for-treating-multidrug2026-10-08 https://evidence-hub.com/study/461-a-prospective-cohort-study-on-the-usage-safety-and-efficacy-of2026-10-08 https://evidence-hub.com/study/462-a-non-randomized-pragmatic-historically-controlled-trial-evaluating2026-10-08 https://evidence-hub.com/study/463-safety-of-liposomal-daunorubicin-cytarabine-cpx-351-in-secondary-aml2026-10-08 https://evidence-hub.com/study/464-pharmacokinetics-bactericidal-activity-and-toxicity-of-short-oral2026-10-08 https://evidence-hub.com/study/465-effectiveness-and-safety-of-shortened-intensive-treatment-for2026-10-08 https://evidence-hub.com/study/466-study-protocol-for-a-duration-randomized-clinical-trial-to-determine2026-10-08 https://evidence-hub.com/study/467-tildrakizumab-for-the-prophylaxis-of-graft-versus-host-disease-after2026-10-08 https://evidence-hub.com/study/468-efficacy-of-susceptibility-guided-quadruple-therapy-with-antibiotic2026-10-08 https://evidence-hub.com/study/469-efficacy-of-1-5-levofloxacin-otic-solution-in-treating-acute-otitis2026-10-08 https://evidence-hub.com/study/470-application-of-directional-customized-corneal-relaxing-incision-in2026-10-08 https://evidence-hub.com/study/471-impact-of-drug-resistance-diagnosis-based-on-whole-genome-sequencing2026-10-08 https://evidence-hub.com/study/472-venetoclax-in-combination-with-cytarabine-with-or-without-idarubicin2026-10-08 https://evidence-hub.com/study/473-prime-editing-for-p47phox-deficient-chronic-granulomatous-disease2026-10-08 https://evidence-hub.com/study/474-comparison-of-remimazolam-versus-propofol-under-deep-sedation-for2026-10-08 https://evidence-hub.com/study/475-study-protocol-for-a-multicenter-multinational-prospective-randomized2026-10-08 https://evidence-hub.com/study/476-ciprofloxacin-versus-levofloxacin-prophylaxis-in-hematopoietic-stem2026-10-19 https://evidence-hub.com/study/477-infections-in-patients-receiving-daratumumab-for-newly-diagnosed2026-10-13 https://evidence-hub.com/study/478-belantamab-mafodotin-lenalidomide-and-dexamethasone-for-intermediate2026-10-08 https://evidence-hub.com/study/479-pharmacokinetics-and-safety-of-clofazimine-in-children-with2026-10-08 https://evidence-hub.com/study/480-base-curves-of-bandage-contact-lenses-and-their-effects-on-post-trans2026-10-08 https://evidence-hub.com/study/481-efficacy-and-in-vitro-activity-of-gepotidacin-against-bacterial2026-10-13 https://evidence-hub.com/study/482-rifasutenizol-based-triple-therapy-versus-bismuth-plus-clarithromycin2026-10-08 https://evidence-hub.com/study/483-efficacy-of-adding-levofloxacin-to-gemcitabine-and-nanoparticle2026-10-08 https://evidence-hub.com/study/484-clinical-utility-of-oral-nemonoxacin-500-mg-once-daily-for-the2026-10-13 https://evidence-hub.com/study/485-a-randomized-observer-blinded-active-controlled-phase-iiib-study-to2026-10-08 https://evidence-hub.com/study/486-the-efficacy-and-safety-of-minocycline-containing-quadruple-therapies2026-10-08 https://evidence-hub.com/study/488-assessment-of-nationally-recommended-antibiotics-for-treatment-of-uti2026-10-20 https://evidence-hub.com/study/489-levofloxacin-treatment-of-active-tuberculosis-and-the-risk-of-adverse2026-10-08 https://evidence-hub.com/study/490-treatment-outcomes-of-isoniazid-resistant-rifampicin-susceptible2026-10-08 https://evidence-hub.com/study/491-levofloxacin-for-treatment-of-ventilator-associated-pneumonia-a2026-10-08 https://evidence-hub.com/study/492-high-levels-of-treatment-success-and-zero-relapse-in-multidrug2026-10-08 https://evidence-hub.com/study/493-comparison-of-the-effects-of-levofloxacin-on-qt-qtc-interval-assessed2026-10-08 https://evidence-hub.com/study/494-comparative-efficacy-and-safety-of-moxifloxacin-and-levofloxacin-in-a2026-10-08 https://evidence-hub.com/study/495-moxifloxacin-and-glucose-homeostasis-a-pooled-analysis-of-the2026-10-08 https://evidence-hub.com/study/496-sonication-versus-the-conventional-method-for-evaluation-of-the2026-10-08 https://evidence-hub.com/study/497-changes-of-resistance-rates-in-pseudomonas-aeruginosa-strains-are2026-10-08 https://evidence-hub.com/study/498-efficacy-of-ceftolozane-tazobactam-versus-levofloxacin-in-the2026-10-20 https://evidence-hub.com/study/499-effects-of-three-fluoroquinolones-on-qt-analysis-after-standard2026-10-08 https://evidence-hub.com/study/500-levofloxacin-for-the-treatment-of-pneumonia-caused-by-streptococcus2026-10-20 https://evidence-hub.com/study/501-efficacy-of-ceftolozane-tazobactam-against-urinary-tract-and-intra2026-10-13 https://evidence-hub.com/study/502-cardiac-events-after-macrolides-or-fluoroquinolones-in-patients2026-10-08 https://evidence-hub.com/study/503-regional-difference-of-antibiotic-resistance-of-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/504-quality-of-life-and-patient-satisfaction-at-7-year-follow-up-of2026-10-08 https://evidence-hub.com/study/505-identification-and-pretherapy-susceptibility-of-pathogens-in-patients2026-10-20 https://evidence-hub.com/study/506-global-population-structure-virulence-factors-and-antibiotic2026-10-08 https://evidence-hub.com/study/507-fluoroquinolones-versus-trimethoprim-sulfamethoxazole-for-the2026-10-08 https://evidence-hub.com/study/508-association-of-levofloxacin-resistance-with-mortality-in-adult2026-10-08 https://evidence-hub.com/study/509-helicobacter-pylori-antibiotic-resistance-in-russia-a-systematic2026-10-08 https://evidence-hub.com/study/510-fluoroquinolone-prophylaxis-in-patients-with-neutropenia-a-meta2026-10-08 https://evidence-hub.com/study/511-qt-prolongation-risk-factors-and-a-monitoring-strategy-in-rifampicin2026-10-08 https://evidence-hub.com/study/512-analysis-of-patients-with-diabetes-and-complicated-intra-abdominal2026-10-20 https://evidence-hub.com/study/513-levofloxacin-750-mg-qd-for-five-days-versus-amoxicillin-clavulanate2026-10-08 https://evidence-hub.com/study/514-qt-prolongation-risk-factors-and-a-monitoring-strategy-in-rifampicin2026-10-08 https://evidence-hub.com/study/515-ceftolozane-tazobactam-for-complex-and-resistant-infections2026-10-20 https://evidence-hub.com/study/516-dietary-intake-analyses-for-the-pharmacometrics-to-advance-novel2026-10-08 https://evidence-hub.com/study/517-a-multifunctional-bioactive-nanoscale-coating-deposited-by2026-10-13 https://evidence-hub.com/study/518-bacteriological-spectrum-and-antibiotic-utilization-in-community2026-10-08 https://evidence-hub.com/study/519-antimicrobial-resistance-trends-among-dominant-pathogens-in-six2026-10-08 https://evidence-hub.com/study/520-prevalence-of-primary-helicobacter-pylori-antibiotic-resistance-in2026-10-13 https://evidence-hub.com/study/521-levofloxacin-induced-cutaneous-adverse-reactions-characteristics-and2026-10-20 https://evidence-hub.com/study/522-epidemiological-characteristics-and-antimicrobial-resistance-of2026-10-08 https://evidence-hub.com/study/523-screening-and-tuberculosis-preventive-treatment-among-household2026-10-08 https://evidence-hub.com/study/524-economic-evaluation-of-empirical-and-tailored-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/525-benzoxaborole-based-inhibitors-block-lexa-autocleavage-and-suppress2026-10-08 https://evidence-hub.com/study/526-prophylactic-azithromycin-for-chronic-lung-allograft-dysfunction2026-10-08 https://evidence-hub.com/study/527-case-report-pulmonary-nocardiosis-three-case-reports-and-literature2026-10-08 https://evidence-hub.com/study/528-limited-role-of-mycoplasma-genitalium-chlamydia-trachomatis-and2026-10-08 https://evidence-hub.com/study/529-a-silent-saboteur-of-immunotherapy-antibiotic-use-and-its-impact-on2026-10-08 https://evidence-hub.com/study/530-analysis-of-the-impact-of-national-centralized-volume-based2026-10-13 https://evidence-hub.com/study/531-factors-predictive-of-early-discontinuation-of-preventive-treatment2026-10-08 https://evidence-hub.com/study/532-clinical-response-to-clozapine-in-black-people-with-psychosis-a2026-10-08 https://evidence-hub.com/study/533-deriving-dosages-for-levofloxacin-tuberculosis-preventive-treatment2026-10-08 https://evidence-hub.com/study/534-qt-prolongation-in-participants-receiving-bedaquiline-containing2026-10-08 https://evidence-hub.com/study/535-wohlfahrtiimonas-chitiniclastica-a-potential-disruptor-of-wound2026-10-08 https://evidence-hub.com/study/536-antimicrobial-resistance-patterns-and-cumulative-antibiogram-of2026-10-13 https://evidence-hub.com/study/537-clinical-impact-of-high-dose-esomeprazole-amoxicillin-dual-therapy-as2026-10-08 https://evidence-hub.com/study/538-tuberculosis-prevention-in-pregnant-women-living-with-hiv-a-review-of2026-10-08 https://evidence-hub.com/study/539-prevalence-and-risk-factors-of-fluoroquinolone-resistance-in-major2026-10-13 https://evidence-hub.com/study/540-emergence-of-amoxicillin-resistance-in-refractory-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/541-preheating-colistimethate-sodium-enhances-its-efficacy-against-multi2026-10-08 https://evidence-hub.com/study/542-indian-society-of-critical-care-medicine-guidelines-on-evidence-based2026-10-08 https://evidence-hub.com/study/543-an-injectable-self-healing-hydrogel-based-on-g-quadruplexes2026-10-08 https://evidence-hub.com/study/544-the-resistance-landscape-of-uropathogens-in-a-romanian-tertiary2026-10-20 https://evidence-hub.com/study/545-qt-prolongation-ventricular-arrhythmia-and-cardiac-arrest-signals2026-10-08 https://evidence-hub.com/study/546-radiologically-measured-renal-pelvis-urine-density-is-associated-with2026-10-13 https://evidence-hub.com/study/547-antimicrobial-susceptibility-determination-of-less-frequently2026-10-08 https://evidence-hub.com/study/548-tildrakizumab-in-the-treatment-of-complex-and-severe-psoriasis-a-case2026-10-08 https://evidence-hub.com/study/549-concomitant-versus-tailored-therapy-based-on-antibiotic-resistance2026-10-08 https://evidence-hub.com/study/550-enhanced-biofilm-disruption-in-methicillin-resistant-staphylococcus2026-10-08 https://evidence-hub.com/study/551-fluoroquinolone-use-and-risk-of-pneumothorax-in-adults-hospitalized2026-10-08 https://evidence-hub.com/study/552-renal-allograft-malakoplakia-mimicking-malignancy-the-value-of2026-10-13 https://evidence-hub.com/study/553-diagnostic-accuracy-of-the-passive-mast-cell-activation-test-in2026-10-08 https://evidence-hub.com/study/554-comparative-effectiveness-of-single-dose-vs-multi-dose-prophylactic2026-10-08 https://evidence-hub.com/study/555-burn-wound-infections-with-staphylococcus-aureus-clinical2026-10-08 https://evidence-hub.com/study/556-colonization-with-fluoroquinolone-resistant-enterobacterales2026-10-08 https://evidence-hub.com/study/557-trimethoprim-sulfamethoxazole-versus-levofloxacin-for-the-treatment2026-10-08 https://evidence-hub.com/study/558-sequential-changes-of-antibiotic-resistances-of-helicobacter-pylori2026-10-06 https://evidence-hub.com/study/559-safety-and-efficacy-of-prophylactic-levofloxacin-in-pediatric-and2026-10-08 https://evidence-hub.com/study/560-a-treatment-method-for-chronic-suppurative-lacrimal-canaliculitis2026-10-08 https://evidence-hub.com/study/561-perioperative-antibiotic-prophylaxis-in-radical-prostatectomy-single2026-10-19 https://evidence-hub.com/study/562-best-treatment-options-for-severe-helicobacter-pylori-infections2026-10-06 https://evidence-hub.com/study/563-helicobacter-pylori-infection-frequency-of-first-line-treatment2026-10-08 https://evidence-hub.com/study/564-analysis-of-drug-resistance-and-treatment-efficacy-of-helicobacter2026-10-08 https://evidence-hub.com/study/565-clinical-experience-of-using-a-combination-of-dexamethasone-and2026-10-06 https://evidence-hub.com/study/566-frequency-of-and-risk-factors-for-carbapenem-resistant2026-10-08 https://evidence-hub.com/study/567-predictors-of-therapeutic-exposure-and-pharmacokinetic-variability-of2026-10-06 https://evidence-hub.com/study/568-systematic-evaluation-of-helicobacter-pylori-susceptibility-to2026-10-08 https://evidence-hub.com/study/569-levofloxacin-susceptibility-of-staphylococci-from-conjunctiva-in2026-10-08 https://evidence-hub.com/study/570-a-priori-optimization-of-levofloxacin-dose-regimen-based-on-a2026-10-08 https://evidence-hub.com/study/571-retrospective-review-of-ceftriaxone-versus-levofloxacin-for-treatment2026-10-20 https://evidence-hub.com/study/572-appraisal-of-the-cardiovascular-risks-of-azithromycin-an2026-10-08 https://evidence-hub.com/study/573-brucellar-reproductive-system-injury-a-retrospective-study-of-222026-10-06 https://evidence-hub.com/study/574-safety-of-prolonged-high-dose-levofloxacin-therapy-for-bone-infections2026-10-08 https://evidence-hub.com/study/575-analysis-of-acenocoumarol-and-levofloxacin-interaction-in-elderly2026-10-08 https://evidence-hub.com/study/576-efficacy-and-safety-of-levofloxacin-in-patients-with-nursing-and2026-10-20 https://evidence-hub.com/study/577-in-vitro-activity-of-delafloxacin-against-clinical-levofloxacin2026-10-20 https://evidence-hub.com/study/578-helicobacter-pylori-antimicrobial-resistance-in-a-pediatric-population2026-10-08 https://evidence-hub.com/study/579-evaluation-of-empiric-antibiotic-de-escalation-in-febrile-neutropenia2026-10-08 https://evidence-hub.com/study/580-efficacy-of-two-week-therapy-with-doxycycline-based-quadruple-regimen2026-10-13 https://evidence-hub.com/study/581-levofloxacin-prophylaxis-in-neutropenic-patients2026-10-08 https://evidence-hub.com/study/582-long-term-cardiovascular-adverse-events-induced-by-fluoroquinolones-a2026-10-08 https://evidence-hub.com/study/583-pk-pd-profile-and-post-marketing-surveillance-of-levofloxacin2026-10-08 https://evidence-hub.com/study/584-molecular-mechanisms-of-quinolone-resistance-in-non-typhoidal2026-10-06 https://evidence-hub.com/study/585-increased-risk-of-pigmentary-degeneration-of-the-iris-and-pigmentary2026-10-08 https://evidence-hub.com/study/586-risk-factors-and-outcome-of-levofloxacin-resistant-elizabethkingia2026-10-08 https://evidence-hub.com/study/587-oral-levofloxacin-versus-intravenous-ceftriaxone-and-amoxicillin2026-10-08 https://evidence-hub.com/study/588-effects-of-the-pharmaceutical-formulation-of-topical-medications-on2026-10-08 https://evidence-hub.com/study/589-frequency-and-severity-of-myasthenia-gravis-exacerbations-associated2026-10-05 https://evidence-hub.com/study/590-doxycycline-vs-levofloxacin-for-macrolide-unresponsive-mycoplasma2026-10-20 https://evidence-hub.com/study/591-speed-of-recovery-in-adult-patients-with-community-acquired-pneumonia2026-10-08 https://evidence-hub.com/study/592-low-level-primary-clarithromycin-resistance-of-helicobacter-pylori-in2026-10-06 https://evidence-hub.com/study/593-mrsa-incidence-and-antibiotic-trends-in-urban-hand-infections-a-102026-10-08 https://evidence-hub.com/study/594-efficacy-of-levofloxacin-based-third-line-therapy-for-the-eradication2026-10-06 https://evidence-hub.com/study/595-is-ema-warning-on-quinolones-and-fluoroquinolones-really-assessed-an2026-10-06 https://evidence-hub.com/study/596-evaluation-of-the-effect-of-gentamicin-in-surgical-perfusion-solution2026-10-08 https://evidence-hub.com/study/597-genomic-determinants-of-antibiotic-resistance-for-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/598-characteristics-of-infectious-keratitis-in-bandage-contact-lens-wear2026-10-08 https://evidence-hub.com/study/599-management-of-isoniazid-monoresistant-tuberculosis-hr-tb-in2026-10-08 https://evidence-hub.com/study/600-treatment-of-stenotrophomonas-malthophilia-bloodstream-infections2026-10-08 https://evidence-hub.com/study/601-analysis-of-clinical-characteristics-and-automatic-monitoring-of-drug2026-10-06 https://evidence-hub.com/study/602-fluoroquinolone-related-neuropsychiatric-events-in-hospitalized2026-10-08 https://evidence-hub.com/study/603-drug-induced-stevens-johnson-syndrome-and-toxic-epidermal-necrolysis2026-10-08 https://evidence-hub.com/study/604-prophylactic-use-of-levofloxacin-during-induction-of-acute2026-10-08 https://evidence-hub.com/study/605-comparison-of-antimicrobial-susceptibility-interpretation-among2026-10-06 https://evidence-hub.com/study/606-microbial-profile-and-antimicrobial-susceptibility-of-bacteria-found2026-10-06 https://evidence-hub.com/study/607-efficacy-of-moxifloxacin-combined-with-levofloxacin-in-the-treatment2026-10-06 https://evidence-hub.com/study/608-macrolide-resistance-of-mycoplasma-pneumoniae-in-several-regions-of2026-10-08 https://evidence-hub.com/study/609-primary-and-secondary-antibiotic-resistance-of-helicobacter-pylori-in2026-10-06 https://evidence-hub.com/study/610-secondary-antibiotic-resistance-of-helicobacter-pylori-isolates-in2026-10-06 https://evidence-hub.com/study/611-are-prophylactic-systemic-antibiotics-required-in-patients-with2026-10-08 https://evidence-hub.com/study/612-clinical-features-of-proteus-mirabilis-pneumonia2026-10-19 https://evidence-hub.com/study/613-evaluating-culture-free-targeted-next-generation-sequencing-for2026-10-08 https://evidence-hub.com/study/614-phenotypic-and-genotypic-detection-of-carbapenemase-producing2026-10-08 https://evidence-hub.com/study/615-treatment-regimens-used-in-the-management-of-helicobacter-pylori-in2026-10-08 https://evidence-hub.com/study/616-antimicrobial-resistance-of-neisseria-gonorrhoeae-in-jakarta2026-10-08 https://evidence-hub.com/study/617-urinary-tract-infections-in-internal-medicine2026-10-19 https://evidence-hub.com/study/618-conjunctival-bacterial-flora-and-antimicrobial-susceptibility-in2026-10-08 https://evidence-hub.com/study/619-antimicrobial-resistance-of-helicobacter-pylori-in-west-flanders2026-10-08 https://evidence-hub.com/study/620-attitudes-and-practice-related-to-helicobacter-pylori-infection-among2026-10-08 https://evidence-hub.com/study/621-saliva-point-of-care-testing-for-suboptimal-levofloxacin-and2026-10-08 https://evidence-hub.com/study/622-prevalence-of-primary-resistance-of-helicobacter-pylori-to2026-10-08 https://evidence-hub.com/study/623-analysis-of-qtc-interval-during-levofloxacin-prescription-in-cardiac2026-10-08 https://evidence-hub.com/study/624-antibiotic-resistance-of-helicobacter-pylori-in-patients-with-peptic2026-10-08 https://evidence-hub.com/study/625-survey-of-antituberculosis-drug-administration-and-adverse-effects-in2026-10-08 https://evidence-hub.com/study/626-non-diarrhoeic-pigs-as-source-of-highly-virulent-and-multidrug2026-10-08 https://evidence-hub.com/study/627-antibiogram-of-esbl-and-mbl-producing-pseudomonas-aeruginosa-among2026-10-06 https://evidence-hub.com/study/628-the-percentage-of-antibiotic-resistance-in-uncomplicated-community2026-10-20 https://evidence-hub.com/study/629-antimicrobial-resistance-of-helicobacter-pylori-isolated-from-latin2026-10-08 https://evidence-hub.com/study/630-clostridium-difficile-in-retail-baskets-trolleys-conveyor-belts-and2026-10-08 https://evidence-hub.com/study/631-pre-banking-microbial-contamination-of-donor-conjunctiva-and-storage2026-10-08 https://evidence-hub.com/study/632-prevalence-of-pseudomonas-aeruginosa-and-its-antibiotic-resistance-in2026-10-13 https://evidence-hub.com/study/633-incidence-of-blood-culture-related-sepsis-in-neonates-and-antibiotics2026-10-08 https://evidence-hub.com/study/634-prevalence-and-molecular-characterization-of-staphylococcus-aureus2026-10-08 https://evidence-hub.com/study/635-availability-of-access-watch-and-reserve-aware-group-of-antibiotics2026-10-08 https://evidence-hub.com/study/636-clinical-evaluation-of-a-commercial-culture-free-targeted-next2026-10-08 https://evidence-hub.com/study/637-a-comprehensive-study-of-helicobacter-pylori-infection-molecular2026-10-06 https://evidence-hub.com/study/638-molecular-detection-of-blaimp-genes-in-metallo-beta-lactamase2026-10-08 https://evidence-hub.com/study/639-epidemiology-of-streptococcus-group-a-in-school-aged-children-in-pemba2026-10-08 https://evidence-hub.com/study/640-prevalence-of-multidrug-resistant-pseudomonas-aeruginosa-isolated2026-10-08 https://evidence-hub.com/study/641-pathogenic-role-and-antibiotic-resistance-of-methicillin-resistant2026-10-08 https://evidence-hub.com/study/642-ampc-beta-lactamases-in-klebsiella-pneumoniae-an-emerging-threat-to2026-10-08 https://evidence-hub.com/study/643-a-cross-sectional-survey-of-snake-oral-bacterial-flora-from-hong-kong2026-10-08 https://evidence-hub.com/study/644-high-metronidazole-and-clarithromycin-resistance-of-helicobacter2026-10-06 https://evidence-hub.com/study/645-multidrug-resistance-bacteremia-in-neonates-and-its-association-with2026-10-08 https://evidence-hub.com/study/646-identification-of-bacterial-isolates-in-neonatal-sepsis-and-their2026-10-08 https://evidence-hub.com/study/647-distribution-and-antimicrobial-resistance-patterns-of-urinary2026-10-13 https://evidence-hub.com/study/648-extensively-drug-resistant-enteric-fever-in-children-surging-threats2026-10-06 https://evidence-hub.com/study/649-burden-of-fluoroquinolone-resistance-in-clinical-isolates-of2026-10-08 https://evidence-hub.com/study/650-antibiotic-use-and-consumption-among-medical-patients-of-two2026-10-06 https://evidence-hub.com/study/651-clinical-retrospective-analysis-of-218-cases-of-infectious2026-10-08 https://evidence-hub.com/study/652-community-acquired-bacterial-pneumonia-aetiology-laboratory-detection2026-10-08 https://evidence-hub.com/study/653-prevalence-and-genetic-profiles-of-isoniazid-resistance-in2026-10-06 https://evidence-hub.com/study/654-the-price-may-not-be-right-the-value-of-comparison-shopping-for2026-10-08 https://evidence-hub.com/study/655-prevalence-of-helicobacter-pylori-resistance-to-certain-antibiotics2026-10-08 https://evidence-hub.com/study/656-availability-price-and-affordability-of-anti-tuberculosis-drugs-in2026-10-08 https://evidence-hub.com/study/657-assessment-of-antibacterial-drug-utilization-patterns-and-antibiogram2026-10-08 https://evidence-hub.com/study/658-antibiotics-use-in-a-tertiary-care-hospital-using-point-prevalence2026-10-08 https://evidence-hub.com/study/659-the-change-in-antimicrobial-resistance-during-the-covid-19-pandemic2026-10-08 https://evidence-hub.com/study/660-prevalence-and-antimicrobial-resistance-profile-of-staphylococcus2026-10-08 https://evidence-hub.com/study/661-antibiotic-resistance-of-escherichia-coli-urinary-tract-infections-at2026-10-13 https://evidence-hub.com/study/662-tularemia-antimicrobial-treatment-and-prophylaxis-cdc-recommendations2026-10-13 https://evidence-hub.com/study/663-increasing-incidence-of-contact-lens-related-acanthamoeba-keratitis2026-10-08 https://evidence-hub.com/study/664-aerococcus-urinae-urinary-tract-infections-a-case-series2026-10-19 https://evidence-hub.com/study/665-clinical-features-of-streptococcus-intermedius-infection-in-children2026-10-08 https://evidence-hub.com/study/666-therapeutic-options-for-stenotrophomonas-maltophilia-infections2026-10-13 https://evidence-hub.com/study/667-scleritis-following-intravitreal-brolucizumab-injection-a-case-series2026-10-08 https://evidence-hub.com/study/668-febrile-urinary-tract-infections-pyelonephritis-and-urosepsis2026-10-20 https://evidence-hub.com/study/669-severe-infectious-complications-of-intravesical-bacillus-calmette2026-10-08 https://evidence-hub.com/study/670-case-series-of-patients-with-coronavirus-disease-2019-pneumonia2026-10-18 https://evidence-hub.com/study/671-clinical-course-and-management-of-sars-in-health-care-workers-in2026-10-08 https://evidence-hub.com/study/672-endogenous-endophthalmitis-caused-by-group-b-streptococcus-case2026-10-13 https://evidence-hub.com/study/673-an-overview-of-case-reports-and-case-series-of-pulmonary2026-10-13 https://evidence-hub.com/study/674-interactions-between-warfarin-and-three-commonly-prescribed2026-10-08 https://evidence-hub.com/study/675-disease-patterns-of-microbial-keratitis-in-singapore-a-retrospective2026-10-08 https://evidence-hub.com/study/676-how-safe-are-fluoroquinolones-for-diabetic-patients-a-systematic2026-10-08 https://evidence-hub.com/study/677-clinical-profile-and-outcome-of-neonates-with-elizabethkingia-sepsis2026-10-08 https://evidence-hub.com/study/678-levofloxacin-induced-arthralgia-in-multidrug-resistant-tuberculosis2026-10-08 https://evidence-hub.com/study/679-retrospective-analysis-of-clinical-features-of-liver-injury-induced2026-10-08 https://evidence-hub.com/study/680-levofloxacin-use-in-the-neonate-a-case-series2026-10-08 https://evidence-hub.com/study/681-posttraumatic-bacillus-cereus-endophthalmitis-clinical2026-10-08 https://evidence-hub.com/study/682-a-case-series-of-acute-kidney-injury-during-anti-tuberculosis2026-10-08 https://evidence-hub.com/study/683-clinico-microbiological-profile-of-burkholderia-cepacia-keratitis-a2026-10-08 https://evidence-hub.com/study/684-clinical-analysis-of-hospital-acquired-mycoplasma-pneumoniae2026-10-08 https://evidence-hub.com/study/685-mycobacterium-simiae-pulmonary-infection-a-case-series-and-literature2026-10-08 https://evidence-hub.com/study/686-clinical-characteristics-and-serogroup-analysis-of-16-pediatric-cases2026-10-08 https://evidence-hub.com/study/687-endophthalmitis-caused-by-streptococcus-clinical-outcomes-and2026-10-08 https://evidence-hub.com/study/688-effectiveness-of-oral-antibiotics-for-treating-pyelonephritis-caused2026-10-13 https://evidence-hub.com/study/689-long-term-effects-of-cataract-surgery-with-topical-levofloxacin-on2026-10-08 https://evidence-hub.com/study/690-endophthalmitis-isolates-and-antibiotic-susceptibilities-a-10-year2026-10-08 https://evidence-hub.com/study/691-unusual-recurrence-of-antituberculosis-drug-induced-hepatotoxicity-in2026-10-13 https://evidence-hub.com/study/692-probable-interaction-between-acenocoumarol-and-levofloxacin-a-case2026-10-08 https://evidence-hub.com/study/693-global-prevalence-and-distribution-of-antibiotic-resistance-among2026-10-08 https://evidence-hub.com/study/694-burden-of-enteral-supplement-interactions-with-common-antimicrobial2026-10-08 https://evidence-hub.com/study/695-brain-abscess-caused-by-streptococcus-anginosus-group-three-case2026-10-08 https://evidence-hub.com/study/696-demographics-and-microbiology-of-otorrhea-through-patent-tubes2026-10-08 https://evidence-hub.com/study/697-analysis-of-epidemiological-characteristics-and-risk-factors-of2026-10-13 https://evidence-hub.com/study/698-the-spectrum-of-legionnaires-disease-a-case-series-illustrating2026-10-20 https://evidence-hub.com/study/699-stenotrophomonas-maltophilia-infections-in-haematological2026-10-08 https://evidence-hub.com/study/700-infections-after-anterior-cruciate-ligament-reconstruction-which2026-10-08 https://evidence-hub.com/study/701-a-case-series-of-bacillus-cereus-septicemia-in-patients-with2026-10-08 https://evidence-hub.com/study/702-mycoplasma-hominis-infections-in-solid-organ-transplant-recipients2026-10-08 https://evidence-hub.com/study/703-microsporidial-keratoconjunctivitis-first-outbreak-in-japan2026-10-08 https://evidence-hub.com/study/704-dolosigranulum-pigrum-keratitis-a-three-case-series2026-10-08 https://evidence-hub.com/study/705-endophthalmitis-after-clear-corneal-cataract-surgery-outcomes-over2026-10-08 https://evidence-hub.com/study/706-clinical-characteristics-and-antibiotic-susceptibility-patterns-of2026-10-08 https://evidence-hub.com/study/707-management-of-de-novo-mycobacterial-infection-after-lung2026-10-08 https://evidence-hub.com/study/708-outbreak-of-microsporidial-keratoconjunctivitis-associated-with-water2026-10-08 https://evidence-hub.com/study/709-scorten-in-contrast-two-cases-of-sjs-ten-overlap-with-divergent2026-10-13 https://evidence-hub.com/study/710-real-life-application-of-the-penicillin-allergy-decision-rule-pen2026-10-08 https://evidence-hub.com/study/711-efficacy-safety-and-in-vitro-sensitivity-of-omadacycline-in-the2026-10-20 https://evidence-hub.com/study/712-awake-prone-positioning-in-moderate-ards-a-case-report2026-10-20 https://evidence-hub.com/study/713-a-complex-case-of-piperacillin-tazobactam-resistant-elizabethkingia2026-10-20 https://evidence-hub.com/study/714-local-injections-of-fluorouracil-for-eyelid-hordeolum2026-10-08 https://evidence-hub.com/study/715-intra-abdominal-infections-caused-by-achromobacter-xylosoxidans-a2026-10-08 https://evidence-hub.com/study/716-acute-klebsiella-pneumoniae-infection-of-the-knee-joint-following2026-10-20 https://evidence-hub.com/study/717-dvia-technique-for-acute-periprosthetic-joint-infection-a-surgical2026-10-08 https://evidence-hub.com/study/718-application-of-balf-combined-with-tngs-for-detecting-chlamydia2026-10-08 https://evidence-hub.com/study/719-campylobacter-beyond-the-gut-a-case-series-of-campylobacter-jejuni2026-10-13 https://evidence-hub.com/study/720-lung-infection-due-to-species-infrequently-isolated-in-the-community2026-10-19 https://evidence-hub.com/study/721-clinical-characteristics-and-outcomes-of-severe-legionella2026-10-20 https://evidence-hub.com/study/722-recurrent-refractory-multidrug-and-pre-multidrug-resistant2026-10-08 https://evidence-hub.com/study/723-fulminant-klebsiella-pneumoniae-endogenous-endophthalmitis-with-globe2026-10-08 https://evidence-hub.com/study/724-malakoplakia-in-immunocompromised-hosts-a-case-series-and-literature2026-10-08 https://evidence-hub.com/study/725-from-traumatic-necrotizing-fasciitis-to-central-nervous-system2026-10-08 https://evidence-hub.com/study/726-bacteremic-group-a-streptococcal-co-infection-in-two-adults-with-h3n22026-10-08 https://evidence-hub.com/study/727-clinical-features-misdiagnosis-and-treatment-of-clinically-diagnosed2026-10-08 https://evidence-hub.com/study/728-cystitis-caused-by-citrobacter-amalonaticus-in-an-older-outpatient-in2026-10-20 https://evidence-hub.com/study/729-extragenital-mycoplasma-hominis-infection-following-obinutuzumab2026-10-20 https://evidence-hub.com/study/730-adult-empyema-caused-by-refractory-methicillin-resistant2026-10-08 https://evidence-hub.com/study/731-dexamethasone-iontophoresis-for-musculoskeletal-tendinopathies-a-case2026-10-08 https://evidence-hub.com/study/732-beyond-the-bladder-case-series-of-mycobacterium-bovis-bacillus2026-10-13 https://evidence-hub.com/study/733-periprosthetic-fractures-around-chronically-infected-total-hip2026-10-08 https://evidence-hub.com/study/734-incomplete-lemierre-s-syndrome-a-case-report2026-10-13 https://evidence-hub.com/study/735-immune-related-cystitis-following-immune-checkpoint-inhibitor-therapy2026-10-20 https://evidence-hub.com/study/736-successful-sequential-therapy-for-stenotrophomonas-maltophilia2026-10-19 https://evidence-hub.com/study/737-host-susceptibility-spectrum-and-diagnostic-challenges-in-pediatric2026-10-08 https://evidence-hub.com/study/738-suspected-ruptured-medulla-oblongata-abscess-treated-conservatively2026-10-08 https://evidence-hub.com/study/739-two-rare-cases-of-neonatal-meningitis-caused-by-globicatella2026-10-13 https://evidence-hub.com/study/740-clinical-approach-to-drug-resistant-tuberculosis-of-the-brain-and2026-10-08 https://evidence-hub.com/study/741-keratoconjunctivitis-caused-by-dieffenbachia-plant-sap-a-case-series2026-10-08 https://evidence-hub.com/study/742-disproportionality-and-case-based-evidence-for-a-possible-association2026-10-13 https://evidence-hub.com/study/743-case-series-of-primary-esophageal-tuberculosis2026-10-08 https://evidence-hub.com/study/744-high-prevalence-of-blandm-gene-among-a-series-of-carbapenem-resistant2026-10-08 https://evidence-hub.com/study/745-combination-therapy-with-cefiderocol-and-minocycline-for2026-10-20 https://evidence-hub.com/study/746-interaction-between-warfarin-and-levofloxacin-case-series2026-10-08 https://evidence-hub.com/study/747-managing-nasal-ischemia-and-necrosis-post-triamcinolone-injection-a2026-10-08 https://evidence-hub.com/study/748-successful-use-of-bacteriophage-therapy-for-a-staphylococcus-aureus2026-10-13 https://evidence-hub.com/study/749-development-of-pseudomonas-aeruginosa-drug-resistant-due-to-prolonged2026-10-08 https://evidence-hub.com/study/750-role-of-vonoprazan-amoxicillin-dual-therapy-in-pediatric-refractory2026-10-13 https://evidence-hub.com/study/751-intraoperative-oct-guided-pneumodescemetopexy-and-corneal-compression2026-10-08 https://evidence-hub.com/study/752-elizabethkingia-miricola-mediastinitis-and-bacteraemia2026-10-13 https://evidence-hub.com/study/753-scrotal-abscess-and-fournier-gangrene-caused-by-klebsiella-pneumoniae2026-10-13 https://evidence-hub.com/study/754-subconjunctival-eyelash-removal-with-a-27-gauge-needle-a-novel2026-10-08 https://evidence-hub.com/study/755-levofloxacin-induced-fixed-drug-eruption2026-10-08 https://evidence-hub.com/study/756-levofloxacin-induced-delirium2026-10-08 https://evidence-hub.com/study/757-levofloxacin-induced-dyskinesia-in-an-elderly-patient-with2026-10-08 https://evidence-hub.com/study/758-levofloxacin-induced-toxic-epidermal-necrolysis2026-10-08 https://evidence-hub.com/study/759-neonatal-gonococcal-conjunctivitis-caused-by-fluoroquinolone2026-10-06 https://evidence-hub.com/study/760-infected-clitoral-smegmatic-pseudocysts2026-10-08 https://evidence-hub.com/study/761-recognizing-emphysematous-gastritis2026-10-08 https://evidence-hub.com/study/762-burkholderia-gladioli-sinonasal-infection2026-10-08 https://evidence-hub.com/study/763-multidrug-induced-erythema-multiforme2026-10-20 https://evidence-hub.com/study/764-timely-bespoke-phage-antibiotic-combination-to-treat-refractory2026-10-08 https://evidence-hub.com/study/765-seizures-associated-with-fluoroquinolones2026-10-08 https://evidence-hub.com/study/766-nebulized-levofloxacin-for-chronic-burkholderia-cenocepacia-pulmonary2026-10-08 https://evidence-hub.com/study/767-stenotrophomonas-maltophilia-an-emerging-pathogen-of-the-respiratory2026-10-08 https://evidence-hub.com/study/768-a-super-infection-in-the-cornea-caused-by-stemphylium-acremonium-and2026-10-06 https://evidence-hub.com/study/769-drug-induced-thrombotic-microangiopathy-caused-by-levofloxacin2026-10-08 https://evidence-hub.com/study/770-possible-case-of-levofloxacin-induced-thrombocytopenia2026-10-08 https://evidence-hub.com/study/771-treatment-of-listeria-monocytogenes-bacteremia-with-oral-levofloxacin2026-10-08 https://evidence-hub.com/study/772-g-csf-induced-aortitis-mimicking-tipic-syndrome2026-10-06 https://evidence-hub.com/study/773-pulmonary-mycobacterium-kyorinense-disease-a-case-report-and-review2026-10-06 https://evidence-hub.com/study/774-rare-presentation-of-an-old-bug2026-10-08 https://evidence-hub.com/study/775-levofloxacin-induced-desquamation-a-possible-and-rare-case-report2026-10-08 https://evidence-hub.com/study/776-levofloxacin-induced-rhabdomyolysis-a-case-report2026-10-08 https://evidence-hub.com/study/777-treatment-of-tularemia-with-fluoroquinolones-two-cases-and-review2026-10-08 https://evidence-hub.com/study/778-cd30-lymphomatoid-drug-reactions2026-10-08 https://evidence-hub.com/study/779-levofloxacin-induced-generalized-fixed-drug-eruption2026-10-08 https://evidence-hub.com/study/780-legionella-indianapolisensis-sp-nov-isolated-from-a-patient-with2026-10-08 https://evidence-hub.com/study/781-legionella-micdadei-aquaticum-infection-a-case-report-and-literature2026-10-08 https://evidence-hub.com/study/782-levofloxacin-induced-bullous-fixed-drug-eruption-a-rare-case-report2026-10-08 https://evidence-hub.com/study/783-levofloxacin-associated-transient-mixed-sensorimotor-lacunar-syndrome2026-10-08 https://evidence-hub.com/study/784-luteibacter-jiangsuensis-blood-stream-infection-a-first-case-report2026-10-08 https://evidence-hub.com/study/785-fluoroquinolone-resistance-in-streptococcus-pyogenes2026-10-08 https://evidence-hub.com/study/786-fluoroquinolone-induced-tendon-diseases2026-10-08 https://evidence-hub.com/study/787-levofloxacin-induced-acute-anxiety-and-insomnia2026-10-08 https://evidence-hub.com/study/788-levofloxacin-induced-tendinopathy-of-the-hip2026-10-08 https://evidence-hub.com/study/789-a-case-of-drug-induced-lung-injury-caused-by-levofloxacin-eye-drops2026-10-06 https://evidence-hub.com/study/790-acute-fibrinous-and-organising-pneumonia2026-10-08 https://evidence-hub.com/study/791-fluoroquinolone-associated-tendinopathy-of-the-hand-and-wrist-a2026-10-08 https://evidence-hub.com/study/792-lactational-mastitis-caused-by-streptococcus-lactarius2026-10-08 https://evidence-hub.com/study/793-one-case-report-of-epilepsy-and-rapidly-progressive-cognitive2026-10-08 https://evidence-hub.com/study/794-levofloxacin-induced-acute-immune-mediated-thrombocytopenia-of-rapid2026-10-08 https://evidence-hub.com/study/795-a-case-of-meningitis-caused-by-ralstonia-insidiosa-a-rare2026-10-06 https://evidence-hub.com/study/796-fluoroquinolone-mediated-achilles-rupture-a-case-report-and-review-of2026-10-06 https://evidence-hub.com/study/797-community-acquired-pseudomonas-aeruginosa-osteomyelitis-caused-by-an2026-10-08 https://evidence-hub.com/study/798-inhaled-levofloxacin-in-a-combination-regimen-for-stenotrophomonas2026-10-08 https://evidence-hub.com/study/799-oromandibular-dyskinesia-associated-with-levofloxacin-and-responsive2026-10-08 https://evidence-hub.com/study/800-bk-virus-associated-haemorrhagic-cystitis-following-allogeneic2026-10-20 https://evidence-hub.com/study/801-peritoneal-dialysis-related-peritonitis-caused-by-mycobacterium2026-10-08 https://evidence-hub.com/study/802-musculoskeletal-adverse-effects-associated-with-inhaled-levofloxacin2026-10-08 https://evidence-hub.com/study/803-brain-abscess-formation-following-cerebral-infarction-during2026-10-08 https://evidence-hub.com/study/804-late-onset-sepsis-and-meningitis-caused-by-elizabethkingia2026-10-20 https://evidence-hub.com/study/805-staged-reconstruction-of-an-extensive-oncologic-scalp-defect-using2026-10-08 https://evidence-hub.com/study/806-genomic-characterization-of-a-multidrug-resistant-serratia-marcescens2026-10-08 https://evidence-hub.com/study/807-therapeutic-drug-monitoring-guided-linezolid-salvage-therapy-for2026-10-08 https://evidence-hub.com/study/808-severe-pneumonic-tularemia-following-inhalational-exposure-with-acute2026-10-08 https://evidence-hub.com/study/809-chronic-prosthetic-joint-infection-caused-by-coxiella-burnetii2026-10-08 https://evidence-hub.com/study/810-campylobacter-jejuni-associated-lumbar-vertebral-osteomyelitis-with2026-10-08 https://evidence-hub.com/study/811-reversible-acute-on-chronic-kidney-injury-complicating-antibiotic2026-10-08 https://evidence-hub.com/study/812-recognizing-subtle-neurological-adverse-effects-of-fluoroquinolones-a2026-10-08 https://evidence-hub.com/study/813-aztreonam-avibactam-successfully-treated-severe-stenotrophomonas2026-10-20 https://evidence-hub.com/study/814-levofloxacin-associated-leukocytoclastic-vasculitis-with-bullous2026-10-08 https://evidence-hub.com/study/815-diagnostic-challenge-of-mixed-lens-induced-glaucoma-after-chronic2026-10-08 https://evidence-hub.com/study/816-first-reported-survival-of-anthrax-meningoencephalitis-in-a-low2026-10-08 https://evidence-hub.com/study/817-severe-nonhepatic-hyperammonemia-associated-with-ureaplasma-parvum2026-10-20 https://evidence-hub.com/study/818-clindamycin-demonstrates-clinical-effectiveness-for-bacteremic2026-10-08 https://evidence-hub.com/study/819-a-case-of-pyogenic-spondylitis-caused-by-mesh-infection-after2026-10-08 https://evidence-hub.com/study/820-stevens-johnson-syndrome-induced-by-fluoroquinolones-in-a-patient2026-10-13 https://evidence-hub.com/study/821-challenges-in-causality-assessment-of-renal-dysfunction-during2026-10-08 https://evidence-hub.com/study/822-bordetella-hinzii-antenatal-sepsis-in-a-pregnant-woman-with-sickle2026-10-20 https://evidence-hub.com/study/823-right-knee-ureaplasma-septic-arthritis-in-an-immunocompromised-host2026-10-08 https://evidence-hub.com/study/824-analysis-of-antimicrobial-resistance-and-infection-characteristics-of2026-10-20 https://evidence-hub.com/study/825-acupuncture-related-digital-joint-infection-managed-with-staged2026-10-08 https://evidence-hub.com/study/826-prolonged-suppression-of-bacterial-growth-in-urine-culture-following2026-10-20 https://evidence-hub.com/study/827-pharmacist-driven-optimization-of-presumptive-psittacosis-management2026-10-08 https://evidence-hub.com/study/828-management-of-mycobacterium-bovis-meningitis-the-case-for-adjunctive2026-10-08 https://evidence-hub.com/study/829-headache-in-a-case-of-tuberculosis-think-beyond-meningitis-a-case2026-10-13 https://evidence-hub.com/study/830-fatal-elizabethkingia-anophelis-bacteremia-complicated-by-meningitis2026-10-13 https://evidence-hub.com/study/831-community-acquired-carbapenem-resistant-acinetobacter-baumannii2026-10-08 https://evidence-hub.com/study/832-a-case-of-miliary-tuberculosis-after-prophylactic-therapy-for-latent2026-10-08 https://evidence-hub.com/study/833-nasopharyngeal-13-virus-pcr-panel-for-the-rapid-diagnosis-of2026-10-20 https://evidence-hub.com/study/834-aeromonas-hydrophila-necrotizing-soft-tissue-infection-with-acute-on2026-10-08 https://evidence-hub.com/study/835-presumably-recurrent-ureaplasma-parvum-infection-in-a-female2026-10-08 https://evidence-hub.com/study/836-linezolid-as-a-potential-alternative-to-glycopeptide-in-treating2026-10-20 https://evidence-hub.com/study/837-disseminated-mpox-with-suspected-immune-reconstitution-inflammatory2026-10-08 https://evidence-hub.com/study/838-acg-clinical-guideline-treatment-of-helicobacter-pylori-infection2026-10-19 https://evidence-hub.com/study/839-acg-clinical-guideline-treatment-of-helicobacter-pylori-infection2026-10-08 https://evidence-hub.com/study/840-the-2024-european-guideline-on-the-management-of-epididymo-orchitis2026-10-08 https://evidence-hub.com/study/841-antimicrobial-treatment-guidelines-for-acute-bacterial-rhinosinusitis2026-10-20 https://evidence-hub.com/study/842-update-of-separ-guideline-diagnosis-and-treatment-of-drug-resistant2026-10-08 https://evidence-hub.com/study/843-uncomplicated-bacterial-community-acquired-urinary-tract-infection-in2026-10-20 https://evidence-hub.com/study/844-american-college-of-gastroenterology-guideline-on-the-management-of2026-10-08 https://evidence-hub.com/study/845-treatment-of-uncomplicated-pelvic-inflammatory-disease-cngof-and2026-10-08 https://evidence-hub.com/study/846-guidelines-for-the-management-of-helicobacter-pylori-infection-in2026-10-08 https://evidence-hub.com/study/847-second-asia-pacific-consensus-guidelines-for-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/848-position-statement-of-the-spanish-society-of-paediatric-infectious2026-10-08 https://evidence-hub.com/study/849-united-kingdom-british-association-for-sexual-health-and-hiv-national2026-10-13 https://evidence-hub.com/study/850-executive-summary-clinical-practice-guidelines-on-the-management-of2026-10-08 https://evidence-hub.com/study/851-clinical-practice-guideline-for-the-evaluation-treatment-and-follow2026-10-08 https://evidence-hub.com/study/852-the-fifth-mexican-consensus-on-the-diagnosis-and-treatment-of2026-10-08 https://evidence-hub.com/study/853-minimum-inhibitory-concentration-quality-control-guidelines-for2026-10-08 https://evidence-hub.com/study/854-guideline-for-the-treatment-of-leprosy-by-new-quinolones2026-10-08 https://evidence-hub.com/study/855-chinese-guideline-for-the-chemotherapy-of-multidrug-resistant2026-10-08 https://evidence-hub.com/study/856-evidence-based-guidelines-for-the-diagnosis-and-treatment-of2026-10-20 https://evidence-hub.com/study/857-recommendations-for-antibacterial-prophylaxis-in-children-receiving2026-10-13 https://evidence-hub.com/study/858-guideline-for-antimicrobial-treatment-of-multidrug-resistant-gram2026-10-13 https://evidence-hub.com/study/859-guidelines-for-the-management-of-helicobacter-pylori-infection-in2026-10-08 https://evidence-hub.com/study/860-management-of-adult-bronchiectasis-consensus-based-guidelines-of-the2026-10-08 https://evidence-hub.com/study/861-european-stroke-organisation-guideline-on-stroke-associated-pneumonia2026-10-13 https://evidence-hub.com/study/862-on-the-german-s3-guideline-on-perioperative-and-periinterventional2026-10-08 https://evidence-hub.com/study/863-dutch-guideline-for-the-prevention-and-control-of-multidrug-resistant2026-10-08 https://evidence-hub.com/study/864-first-regional-consensus-on-the-management-of-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/865-treatment-of-mdr-pre-xdr-xdr-and-rifampicin-resistant-tuberculosis-or2026-10-08 https://evidence-hub.com/study/866-a-clinical-practice-guideline-for-tuberculous-meningitis2026-10-08 https://evidence-hub.com/study/867-essential-japanese-guidelines-for-the-prevention-of-perioperative2026-10-13 https://evidence-hub.com/study/868-key-summary-of-german-national-guideline-for-adult-patients-with2026-10-08 https://evidence-hub.com/study/869-australasian-hidradenitis-suppurativa-management-guidelines2026-10-08 https://evidence-hub.com/study/870-antibiotic-treatment-of-acute-and-recurrent-otitis-media-in-children2026-10-08 https://evidence-hub.com/study/871-blood-culture-negative-endocarditis-a-scientific-statement-from-the2026-10-08 https://evidence-hub.com/study/872-s3-guideline-on-sepsis-prevention-diagnosis-therapy-and-follow-up2026-10-08 https://evidence-hub.com/study/873-2022-chinese-national-clinical-practice-guideline-on-helicobacter2026-10-08 https://evidence-hub.com/study/874-rhinosinusitis-evidence-and-experience-20242026-10-13 https://evidence-hub.com/study/875-updates-on-the-treatment-of-drug-susceptible-and-drug-resistant2026-10-08 https://evidence-hub.com/study/876-evidence-based-guidelines-for-the-treatment-of-helicobacter-pylori2026-10-13 https://evidence-hub.com/study/877-antimicrobial-treatment-and-prophylaxis-of-plague-recommendations-for2026-10-08 https://evidence-hub.com/study/878-pneumococcal-vaccine-for-adults-aged-19-years-recommendations-of-the2026-10-13 https://evidence-hub.com/study/879-2023-korean-sexually-transmitted-infections-guidelines-for-non2026-10-08 https://evidence-hub.com/study/880-guideline-for-the-treatment-of-no-light-perception-eyes-induced-by2026-10-08 https://evidence-hub.com/study/881-primary-prophylaxis-of-bacterial-infections-and-pneumocystis2026-10-13 https://evidence-hub.com/study/882-transarterial-chemoembolization-for-hepatocellular-carcinoma-20232026-10-08 https://evidence-hub.com/study/883-best-practice-considerations-by-the-american-society-of-transplant2026-10-13 https://evidence-hub.com/study/884-covid-19-and-acute-lymphoblastic-leukemias-of-children-and2026-10-08 https://evidence-hub.com/study/885-guideline-for-the-management-of-fever-and-neutropenia-in-pediatric2026-10-13 https://evidence-hub.com/study/886-integrated-care-protocol-chronic-complications-of-diabetes-mellitus-22026-10-08 https://evidence-hub.com/study/887-evidence-based-clinical-practice-guidelines-for-peptic-ulcer-disease2026-10-13 https://evidence-hub.com/study/888-covid19-and-acute-lymphoblastic-leukemias-of-children-and-adolescents2026-10-08 https://evidence-hub.com/study/889-sexually-transmitted-infections-treatment-guidelines-20212026-10-13 https://evidence-hub.com/study/890-severe-legionnaires-disease2026-10-08 https://evidence-hub.com/study/891-comparative-in-vitro-susceptibilities-of-human-mycoplasmas-and2026-10-20 https://evidence-hub.com/study/892-epididymitis-an-overview2026-10-08 https://evidence-hub.com/study/893-legionnaires-disease-update-on-diagnosis-and-treatment2026-10-08 https://evidence-hub.com/study/894-the-treatment-of-tuberculosis2026-10-08 https://evidence-hub.com/study/895-review-of-rifaximin-as-treatment-for-sibo-and-ibs2026-10-08 https://evidence-hub.com/study/896-the-toronto-consensus-for-the-treatment-of-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/897-fluoroquinolone-antibiotics-occurrence-mode-of-action-resistance2026-10-08 https://evidence-hub.com/study/898-legionnaires-disease2026-10-08 https://evidence-hub.com/study/899-helicobacter-pylori-related-diseases2026-10-08 https://evidence-hub.com/study/900-fluoroquinolone-induced-renal-failure2026-10-08 https://evidence-hub.com/study/901-fluoroquinolones-and-tuberculosis2026-10-08 https://evidence-hub.com/study/902-the-newer-fluoroquinolones2026-10-08 https://evidence-hub.com/study/903-quinolone-induced-psychosis-an-updated-review2026-10-13 https://evidence-hub.com/study/904-helicobacter-pylori-treatment-strategies-in-singapore2026-10-08 https://evidence-hub.com/study/906-eradication-of-helicobacter-pylori-infection2026-10-08 https://evidence-hub.com/study/907-arrhythmias-associated-with-fluoroquinolone-therapy2026-10-08 https://evidence-hub.com/study/909-eravacycline-a-newly-approved-fluorocycline2026-10-13 https://evidence-hub.com/study/910-antimycobacterial-drugs2026-10-08 https://evidence-hub.com/study/911-review-article-the-global-emergence-of-helicobacter-pylori-antibiotic2026-10-08 https://evidence-hub.com/study/912-primary-antibiotic-resistance-of-helicobacter-pylori-in-china2026-10-08 https://evidence-hub.com/study/913-helicobacter-pylori-eradication-therapy2026-10-08 https://evidence-hub.com/study/914-multidrug-resistance-in-helicobacter-pylori-infection2026-10-08 https://evidence-hub.com/study/915-pharmacodynamics-and-pharmacokinetics-of-levofloxacin2026-10-08 https://evidence-hub.com/study/916-listeria-infections-of-the-eye2026-10-08 https://evidence-hub.com/study/917-fluoroquinolone-associated-movement-disorder-a-literature-review2026-10-08 https://evidence-hub.com/study/918-drug-resistance-in-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/919-levofloxacin-insights-into-antibiotic-resistance-and-product-quality2026-10-08 https://evidence-hub.com/study/920-evolution-of-helicobacter-pylori-resistance-to-antibiotics-a-topic-of2026-10-06 https://evidence-hub.com/study/921-pharmacokinetics-and-pharmacodynamics-of-fluoroquinolones2026-10-08 https://evidence-hub.com/study/922-safety-and-tolerability-of-fluoroquinolones2026-10-08 https://evidence-hub.com/study/923-novel-and-effective-therapeutic-regimens-for-helicobacter-pylori-in2026-10-06 https://evidence-hub.com/study/924-stenotrophomonas-maltophilia-in-the-antimicrobial-resistance-era2026-10-20 https://evidence-hub.com/study/925-a-review-of-heterogeneous-peroxymonosulfate-activation-for2026-10-08 https://evidence-hub.com/study/926-antimicrobial-resistance-mechanisms-treatment-challenges-and-emerging2026-10-20 https://evidence-hub.com/study/927-mechanism-matched-helicobacter-pylori-treatment-in-the-potassium2026-10-08 https://evidence-hub.com/study/928-the-efficacy-and-safety-of-helicobacter-pylori-eradication-regimens2026-10-08 https://evidence-hub.com/study/929-helicobacter-pylori-eradication-a-narrative-review2026-10-08 https://evidence-hub.com/study/930-some-newer-antibiotics-active-against-helicobacter-pylori-and2026-10-20 https://evidence-hub.com/study/931-antibacterial-prophylaxis-and-antimicrobial-stewardship-in-the-era-of2026-10-08 https://evidence-hub.com/study/932-delafloxacin-what-does-a-new-fluoroquinolone-offer2026-10-20 https://evidence-hub.com/study/933-phenotypic-trends-and-molecular-mechanisms-of-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/934-global-and-regional-patterns-of-drug-resistance-and-treatment2026-10-08 https://evidence-hub.com/study/936-candida-albicans-as-marker-of-the-impact-of-antibiotics-on-gut2026-10-08 https://evidence-hub.com/study/937-implementing-shorter-all-oral-treatment-durations-for-multidrug2026-10-08 https://evidence-hub.com/study/938-broadly-defined-antibiotic-adjuvants-for-pseudomonas-aeruginosa2026-10-20 https://evidence-hub.com/study/939-prevalence-of-extensively-drug-resistant-tuberculosis-and-drug2026-10-08 https://evidence-hub.com/study/940-helicobacter-pylori-eradication-in-the-era-of-antibiotic-resistance2026-10-08 https://evidence-hub.com/study/941-levofloxacin-induced-eosinophilic-pneumonia-with-systemic2026-10-08 https://evidence-hub.com/study/942-role-of-reactive-oxygen-species-in-chronic-rhinosinusitis-a-narrative2026-10-08 https://evidence-hub.com/study/943-acquired-hemophilia-a-caused-by-complicated-urinary-tract-infection2026-10-20 https://evidence-hub.com/study/944-ignavigranum-ruoffiae-isolated-from-a-scrotal-abscess-a-case-report2026-10-08 https://evidence-hub.com/study/945-repositioning-of-fluoroquinolones-a-new-approach-in-antitumor-therapy2026-10-08 https://evidence-hub.com/study/946-a-review-on-the-progress-and-strategies-of-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/947-stenotrophomonas-maltophilia-infections-current-status-on-first-line2026-10-08 https://evidence-hub.com/study/948-microalgal-and-nanotechnology-based-strategies-for-sustainable2026-10-08 https://evidence-hub.com/study/949-current-recommendations-antibiotic-resistance-and-emerging-treatments2026-10-08 https://evidence-hub.com/study/950-cerebral-venous-sinus-thrombosis-secondary-to-nasopharyngeal-abscess2026-10-08 https://evidence-hub.com/study/951-progress-in-immunotherapy-for-helicobacter-pylori-infections2026-10-08 https://evidence-hub.com/study/952-global-epidemiology-of-carbapenem-resistant-pseudomonas-aeruginosa2026-10-20 https://evidence-hub.com/study/953-a-scoping-review-of-interventions-in-childhood-tuberculosis2026-10-08 https://evidence-hub.com/study/954-qt-prolonging-medications-prevalence-of-use-and-associated-risks-in2026-10-13 https://evidence-hub.com/study/955-treatment-of-helicobacter-pylori-infection-in-korea-an-evidence-based2026-10-20 https://evidence-hub.com/study/956-delftia-spp-as-opportunistic-pathogens-a-narrative-review2026-10-13 https://evidence-hub.com/study/957-systematic-review-with-meta-analysis-the-efficacy-of-levofloxacin2026-10-08 https://evidence-hub.com/study/958-is-levofloxacin-based-triple-therapy-an-alternative-for-first-line2026-10-08 https://evidence-hub.com/study/959-levofloxacin-based-therapy-as-an-efficient-alternative-for2026-10-13 https://evidence-hub.com/study/960-levofloxacin-based-first-line-therapy-versus-standard-first-line2026-10-08 https://evidence-hub.com/study/961-the-efficacy-and-safety-of-nemonoxacin-compared-with-levofloxacin-in2026-10-20 https://evidence-hub.com/study/962-treatment-correlates-of-successful-outcomes-in-pulmonary-multidrug2026-10-08 https://evidence-hub.com/study/963-comparison-of-high-dose-short-course-levofloxacin-treatment-vs2026-10-13 https://evidence-hub.com/study/964-resistance-pattern-of-escherichia-coli-to-levofloxacin-in-iran-a2026-10-13 https://evidence-hub.com/study/965-comparative-effectiveness-and-tolerance-of-treatments-for2026-10-08 https://evidence-hub.com/study/966-safety-and-efficacy-of-nemonoxacin-vs-levofloxacin-in-patients-with2026-10-20 https://evidence-hub.com/study/968-primary-antibiotic-resistance-in-helicobacter-pylori-in-the-asia2026-10-08 https://evidence-hub.com/study/969-helicobacter-pylori-antibiotic-resistance-in-the-united-states2026-10-08 https://evidence-hub.com/study/970-diagnosis-and-treatment-of-helicobacter-pylori-infection2026-10-08 https://evidence-hub.com/study/971-comparison-of-the-effectiveness-of-the-antibiotics-fosfomycin-and2026-10-13 https://evidence-hub.com/study/972-comparative-efficacy-and-safety-of-combination-therapy-with-high-dose2026-10-13 https://evidence-hub.com/study/973-primary-antibiotic-resistance-of-helicobacter-pylori-in-different2026-10-08 https://evidence-hub.com/study/974-modified-sequential-therapy-regimens-for-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/976-correction-safety-and-efficacy-of-nemonoxacin-vs-levofloxacin-in2026-10-20 https://evidence-hub.com/study/977-prevalence-of-primary-antimicrobial-resistance-of-h-pylori-in-turkey2026-10-08 https://evidence-hub.com/study/978-respiratory-fluoroquinolones-for-the-treatment-of-community-acquired2026-10-08 https://evidence-hub.com/study/979-pharmacological-regimens-for-eradication-of-helicobacter-pylori-an2026-10-08 https://evidence-hub.com/study/981-efficacy-of-antibiotic-prophylaxis-in-patients-with-cancer-and2026-10-08 https://evidence-hub.com/study/982-maternal-colonization-with-group-b-streptococcus-and-antibiotic2026-10-08 https://evidence-hub.com/study/984-clinical-relevance-of-the-caga-and-vaca-s1m1-status-and-antibiotic2026-10-08 https://evidence-hub.com/study/986-repurposing-of-antibiotics-for-clinical-management-of-covid-19-a2026-10-08 https://evidence-hub.com/study/987-comparison-of-inhaled-antibiotics-for-the-treatment-of-chronic2026-10-08 https://evidence-hub.com/study/988-sensing-levofloxacin-with-an-rna-aptamer-as-a-bioreceptor2026-10-08 https://evidence-hub.com/study/989-levofloxacin-for-the-treatment-of-respiratory-tract-infections2026-10-08 https://evidence-hub.com/study/990-revealing-the-molecular-mechanisms-of-levofloxacin-induced-cognitive2026-10-08 https://evidence-hub.com/study/991-fluoroquinolone-resistance-in-streptococcus-pneumoniae-isolates-in2026-10-08 https://evidence-hub.com/study/992-levofloxacin-efflux-and-smed-in-clinical-isolates-of-stenotrophomonas2026-10-06 https://evidence-hub.com/study/993-levofloxacin-inhalation-solution-superior-efficacy-and-minimized2026-10-08 https://evidence-hub.com/study/994-cost-effective-reconstruction-of-long-standing-lateral-orbital-rim2026-10-08 https://evidence-hub.com/study/995-brucellar-spondylitis-occurring-in-the-cervical-vertebra-a-rare-case2026-10-08 https://evidence-hub.com/study/996-extended-susceptibility-testing-for-refractory-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/997-case-report-guillain-barre-syndrome-temporally-associated-with2026-10-13 https://evidence-hub.com/study/998-intraocular-micro-led-epiretinal-projection-for-anterior-segment2026-10-08 https://evidence-hub.com/study/999-liquid-bodied-antibiofilm-robot-with-switchable-viscoelastic-response2026-10-08 https://evidence-hub.com/study/1000-therapeutic-potential-of-probiotics-in-the-modulation-of-antibiotic2026-10-08 https://evidence-hub.com/study/1001-antimicrobial-resistance-of-serratia-marcescens-recovered-from2026-10-13 https://evidence-hub.com/study/1002-beyond-urease-new-potential-enzymatic-targets-in-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/1003-case-report-gallbladder-perforation-after-endoscopic-retrograde2026-10-08 https://evidence-hub.com/study/1004-clinical-management-of-severe-cupriavidus-gilardii-superinfection2026-10-20 https://evidence-hub.com/study/1005-staged-approach-to-chronic-mesh-infection-following-hernia-repair-a2026-10-08 https://evidence-hub.com/study/1006-pulmonary-tularemia-with-antineutrophil-cytoplasmic-antibody-negative2026-10-08 https://evidence-hub.com/study/1007-a-20-1-kg-adrenal-cavernous-haemangioma-presenting-as-a-giant2026-10-08 https://evidence-hub.com/study/1008-tailored-levofloxacin-incorporated-extracellular-matrix-nanoparticles2026-10-08 https://evidence-hub.com/study/1009-quantitative-gonioscopic-assessment-of-anterior-chamber-angle2026-10-08 https://evidence-hub.com/study/1010-multiple-pyogenic-arthritis-caused-by-edwardsiella-tarda-bacteremia-a2026-10-13 https://evidence-hub.com/study/1011-b-bronchiseptica-empyema-necessitans-a-case-report2026-10-08 https://evidence-hub.com/study/1012-analytical-performance-evaluation-of-the-helibac-rapid-urease-test2026-10-08 https://evidence-hub.com/study/1013-effectiveness-of-implementing-hospital-wastewater-treatment-systems2026-10-08 https://evidence-hub.com/study/1014-case-report-thymoma-associated-stiff-person-syndrome-and-myasthenia2026-10-08 https://evidence-hub.com/study/1015-genomic-and-phenotypic-characterization-of-klebsiella-pneumoniae2026-10-13 https://evidence-hub.com/study/1016-comparison-of-vonoprazan-triple-therapy-bismuth-quadruple-therapy-and2026-10-08 https://evidence-hub.com/study/1017-in-silico-assessment-of-neuromuscular-blocking-agents-and2026-10-08 https://evidence-hub.com/study/1018-inhaled-antibiotic-and-biologic-formulations-targeting-pseudomonas2026-10-08 https://evidence-hub.com/study/1019-novel-ag-ni-bimetallic-loaded-sawdust-derived-biochar-as-a-periodate2026-10-08 https://evidence-hub.com/study/1020-retrospective-comparative-study-on-efficacy-and-safety-of-different2026-10-13 https://evidence-hub.com/study/1021-prevalence-of-antimicrobial-resistance-in-klebsiella-pneumoniae-in2026-10-13 https://evidence-hub.com/study/1022-brucellosis-associated-hemophagocytic-lymphohistiocytosis-a-case2026-10-08 https://evidence-hub.com/study/1023-challenges-in-antimicrobial-treatment-and-antimicrobial-stewardship2026-10-13 https://evidence-hub.com/study/1024-fatal-cerebral-myiasis-secondary-to-squamous-cell-carcinoma-case2026-10-08 https://evidence-hub.com/study/1025-eradication-of-helicobacter-pylori-in-the-primary-prevention-of2026-10-08 https://evidence-hub.com/study/1026-is-there-evidence-for-changes-in-antibiotic-resistance-of2026-10-08 https://evidence-hub.com/study/1027-incidence-of-qt-interval-prolongation-in-patients-receiving2026-10-08 https://evidence-hub.com/study/1028-generation-of-novel-natural-products-by-disrupting-azaphilone2026-10-08 https://evidence-hub.com/study/1029-aeromonas-infections-in-humans-antibiotic-resistance-and-treatment2026-10-08 https://evidence-hub.com/study/1030-investigation-and-control-of-two-consecutive-serratia-marcescens2026-10-13 https://evidence-hub.com/study/1031-ciprofloxacin-resistance-in-community-and-hospital-acquired-urinary2026-10-13 https://evidence-hub.com/study/1032-novel-lytic-phages-improve-the-antibiofilm-activity-of-dalbavancin2026-10-08 https://evidence-hub.com/study/1033-isolation-characterization-and-genomic-analysis-of-a-novel-lytic2026-10-13 https://evidence-hub.com/study/1034-a-comparative-study-of-levofloxacin-and-ceftriaxone-in-the-treatment2026-10-20 https://evidence-hub.com/study/1035-levofloxacin-failure-in-a-patient-with-pneumococcal-pneumonia2026-10-08 https://evidence-hub.com/study/1036-clinical-outcomes-for-hospitalized-patients-with-legionella-pneumonia2026-10-08 https://evidence-hub.com/study/1037-levofloxacin-prophylaxis-in-patients-with-newly-diagnosed-myeloma2026-10-13 https://evidence-hub.com/study/1038-levofloxacin-inhalation-solution-mp-376-in-patients-with-cystic2026-10-08 https://evidence-hub.com/study/1039-risk-of-severe-dysglycemia-among-diabetic-patients-receiving2026-10-08 https://evidence-hub.com/study/1040-bacteremic-pneumonia-due-to-multidrug-resistant-pneumococci-in-32026-10-08 https://evidence-hub.com/study/1041-levofloxacin-treatment-failure-in-a-patient-with-fluoroquinolone2026-10-08 https://evidence-hub.com/study/1042-single-dose-levofloxacin-prophylaxis-for-prostate-biopsy-in-patients2026-10-13 https://evidence-hub.com/study/1043-a-10-day-levofloxacin-based-triple-therapy-in-patients-who-have2026-10-08 https://evidence-hub.com/study/1044-a-retrospective-comparative-evaluation-of-dysglycemias-in2026-10-08 https://evidence-hub.com/study/1045-levofloxacin-population-pharmacokinetics-and-creation-of-a2026-10-13 https://evidence-hub.com/study/1046-pharmacokinetics-of-levofloxacin-and-ciprofloxacin-during-continuous2026-10-08 https://evidence-hub.com/study/1048-comparison-of-levofloxacin-and-cefotaxime-combined-with-ofloxacin-for2026-10-20 https://evidence-hub.com/study/1049-a-10-day-levofloxacin-based-therapy-in-patients-with-resistant2026-10-08 https://evidence-hub.com/study/1050-levofloxacin-disposition-in-cerebrospinal-fluid-in-patients-with2026-10-08 https://evidence-hub.com/study/1051-pharmacokinetics-and-safety-of-levofloxacin-in-patients-with-human2026-10-08 https://evidence-hub.com/study/1052-levofloxacin-compared-with-imipenem-cilastatin-followed-by2026-10-20 https://evidence-hub.com/study/1053-a-randomized-trial-comparing-the-cardiac-rhythm-safety-of2026-10-08 https://evidence-hub.com/study/1054-relevance-of-soft-tissue-penetration-by-levofloxacin-for-target-site2026-10-08 https://evidence-hub.com/study/1055-identification-of-a-novel-coronavirus-in-patients-with-severe-acute2026-10-03 https://evidence-hub.com/study/1056-pharmacokinetics-and-pharmacodynamics-of-intravenous-levofloxacin-in2026-10-20 https://evidence-hub.com/study/1057-second-line-rescue-therapy-with-levofloxacin-after-h-pylori-treatment2026-10-08 https://evidence-hub.com/study/1058-susceptibility-to-levofloxacin-of-mycobacterium-tuberculosis-isolates2026-10-08 https://evidence-hub.com/study/1059-pharmacokinetics-and-intrapulmonary-diffusion-of-levofloxacin-in2026-10-08 https://evidence-hub.com/study/1060-helicobacter-pylori-first-line-treatment-and-rescue-option-containing2026-10-08 https://evidence-hub.com/study/1061-standards-for-the-diagnosis-and-treatment-of-patients-with-copd-a2026-10-03 https://evidence-hub.com/study/1062-epidemiology-of-bloodstream-infections-in-patients-with-acute-myeloid2026-10-08 https://evidence-hub.com/study/1063-levofloxacin-pharmacokinetics-and-pharmacodynamics-in-patients-with2026-10-08 https://evidence-hub.com/study/1064-7-day-triple-therapy-of-helicobacter-pylori-infection-with2026-10-08 https://evidence-hub.com/study/1066-pharmacokinetics-of-moxifloxacin-and-levofloxacin-in-intensive-care2026-10-05 https://evidence-hub.com/study/1067-levofloxacin-induced-toxic-epidermal-necrolysis-in-an-elderly-patient2026-10-08 https://evidence-hub.com/study/1068-levofloxacin-in-the-empirical-treatment-of-patients-with-suspected2026-10-08 https://evidence-hub.com/study/1069-tuberculosis-prophylaxis-with-levofloxacin-in-liver-transplant2026-10-08 https://evidence-hub.com/study/1070-concentrations-of-levofloxacin-hr-355-in-the-respiratory-tract2026-10-03 https://evidence-hub.com/study/1071-cerebrospinal-fluid-penetration-of-levofloxacin-in-patients-with2026-10-08 https://evidence-hub.com/study/1072-cavitary-penetration-of-levofloxacin-among-patients-with-multidrug2026-10-08 https://evidence-hub.com/study/1073-skin-inspired-and-self-regulated-hydrophobic-hydrogel-for-diabetic2026-10-08 https://evidence-hub.com/study/1074-engineering-of-a-mantis-forelimb-inspired-bioabsorbable-lens-like2026-10-08 https://evidence-hub.com/study/1075-treating-anthrax-induced-meningitis-in-rabbits2026-10-08 https://evidence-hub.com/study/1076-pharmacokinetic-and-tissue-analyses-of-levofloxacin-in-sheep-ovis2026-10-08 https://evidence-hub.com/study/1077-pharmacokinetics-of-levofloxacin-after-single-intravenous-oral-and2026-10-08 https://evidence-hub.com/study/1078-pharmacokinetics-of-rectally-and-orally-administered-levofloxacin-in2026-10-06 https://evidence-hub.com/study/1079-role-of-interleukin-6-in-the-pathogenesis-of-an-avian-model-of2026-10-08 https://evidence-hub.com/study/1080-efficacy-of-cefiderocol-and-levofloxacin-against-stenotrophomonas2026-10-20 https://evidence-hub.com/study/1081-analysis-of-virulence-genes-drug-resistance-detection-and2026-10-06 https://evidence-hub.com/study/1082-mechanisms-of-cellular-retention-of-melanin-bound-drugs-experiments2026-10-08 https://evidence-hub.com/study/1083-a-synergistic-bactericidal-effect-of-low-frequency-and-low-intensity2026-10-08 https://evidence-hub.com/study/1084-comparison-of-efficacies-of-oral-levofloxacin-and-oral-ciprofloxacin2026-10-08 https://evidence-hub.com/study/1085-pharmacological-effects-and-mechanism-of-maxing-shigan-decoction-in2026-10-08 https://evidence-hub.com/study/1086-levofloxacin-hemihydrate-in-situ-gelling-ophthalmic-solution2026-10-08 https://evidence-hub.com/study/1087-pharmacokinetic-profiles-of-levofloxacin-after-intravenous2026-10-08 https://evidence-hub.com/study/1088-formulation-and-evaluation-of-simvastatin-polymeric-nanoparticles2026-10-08 https://evidence-hub.com/study/1089-effect-of-topical-fluoroquinolones-on-the-expression-of-matrix2026-10-08 https://evidence-hub.com/study/1090-mechanism-of-histamine-release-induced-by-levofloxacin-a2026-10-08 https://evidence-hub.com/study/1091-nanoniosome-encapsulated-levoflaxicin-as-an-antibacterial-agent2026-10-08 https://evidence-hub.com/study/1092-two-different-concentrations-of-topical-levofloxacin-for-the2026-10-06 https://evidence-hub.com/study/1093-levofloxacin-effect-on-erlotinib-absorption-evaluation-of-the2026-10-08 https://evidence-hub.com/study/1094-hyaluronic-acid-based-levofloxacin-nanomicelles-for-nitric-oxide2026-10-18 https://evidence-hub.com/study/1095-study-effect-and-mechanism-of-levofloxacin-on-the-neurotoxicity-of2026-10-06 https://evidence-hub.com/study/1096-comparative-study-on-characteristics-and-mechanism-of-levofloxacin2026-10-08 https://evidence-hub.com/study/1097-implementation-of-a-post-exposure-tularemia-treatment-model-for2026-10-08 https://evidence-hub.com/study/1098-fabrication-of-levofloxacin-loaded-porcine-acellular-dermal-matrix2026-10-20 https://evidence-hub.com/study/1099-effects-of-antibiotics-ceftriaxone-and-levofloxacin-on-the-growth-of2026-10-03 https://evidence-hub.com/study/1100-developmental-stage-and-infection-status-may-affect-drug-distribution2026-10-06 https://evidence-hub.com/study/1101-therapeutic-effect-of-the-quinolone-levofloxacin-on-inflammatory2026-10-08 https://evidence-hub.com/study/1102-levofloxacin-pharmacokinetics-and-tissue-residue-concentrations-after2026-10-08 https://evidence-hub.com/study/1103-ameliorative-effects-of-moringa-oleifera-leaf-extract-on-levofloxacin2026-10-08 https://evidence-hub.com/study/1104-assessment-the-efficacy-of-some-various-treatment-methods-in-vitro2026-10-06 https://evidence-hub.com/study/1105-dietary-nobiletin-regulated-cefuroxime-and-levofloxacin-associated2026-10-06 https://evidence-hub.com/study/1106-number-of-bacteria-and-time-of-coincubation-with-bacteria-required2026-10-06 https://evidence-hub.com/study/1107-uplc-q-tof-ms-based-metabolomics-and-molecular-docking-analysis-of2026-10-08 https://evidence-hub.com/study/1108-deciphering-the-complexation-process-of-a-fluoroquinolone-antibiotic2026-10-06 https://evidence-hub.com/study/1109-nephroprotective-effect-of-vitamin-d-against-levofloxacin-induced2026-10-06 https://evidence-hub.com/study/1110-effects-of-ciprofloxacin-and-levofloxacin-on-initial-colonization-of2026-10-06 https://evidence-hub.com/study/1111-enhanced-antibacterial-activity-of-levofloxacin-hydroxypropyl2026-10-08 https://evidence-hub.com/study/1112-investigation-of-the-effects-of-three-different-generations-of2026-10-08 https://evidence-hub.com/study/1113-pharmacokinetics-of-levofloxacin-mesylate-in-healthy-adult-giant2026-10-08 https://evidence-hub.com/study/1114-compare-two-methods-of-measuring-dna-damage-induced-by2026-10-08 https://evidence-hub.com/study/1115-pharmacokinetics-of-levofloxacin-after-single-intravenous-and-oral2026-10-06 https://evidence-hub.com/study/1116-general-pharmacology-of-the-new-quinolone-antibacterial-agent2026-10-08 https://evidence-hub.com/study/1117-sustained-release-of-levofloxacin-from-thermosensitive-chitosan-based2026-10-08 https://evidence-hub.com/study/1119-antimicrobial-effects-of-minocycline-tigecycline-ciprofloxacin-and2026-10-08 https://evidence-hub.com/study/1120-pseudomonas-aeruginosa-infections-animal-modeling-and-therapeutics2026-10-13 https://evidence-hub.com/study/1121-role-of-rifampin-against-propionibacterium-acnes-biofilm-in-vitro-and2026-10-08 https://evidence-hub.com/study/1122-levofloxacin-cures-experimental-pneumonic-plague-in-african-green2026-10-08 https://evidence-hub.com/study/1123-cerebrospinal-fluid-penetration-and-pharmacokinetics-of-levofloxacin2026-10-13 https://evidence-hub.com/study/1124-pharmacokinetics-and-pharmacodynamics-of-fluoroquinolones2026-10-08 https://evidence-hub.com/study/1125-impact-of-bacterial-biofilm-formation-on-in-vitro-and-in-vivo2026-10-08 https://evidence-hub.com/study/1126-comparative-assessment-of-prurifloxacin-sparfloxacin-gatifloxacin-and2026-10-08 https://evidence-hub.com/study/1127-pharmacodynamics-of-levofloxacin-and-ciprofloxacin-in-a-murine2026-10-20 https://evidence-hub.com/study/1129-efficacy-of-antimicrobial-polymer-coatings-in-an-animal-model-of2026-10-08 https://evidence-hub.com/study/1130-establishing-a-murine-model-of-the-hematopoietic-syndrome-of-the2026-10-08 https://evidence-hub.com/study/1131-activity-of-ciprofloxacin-and-levofloxacin-in-experimental-pneumonia2026-10-20 https://evidence-hub.com/study/1132-physiologically-based-pharmacokinetic-pbpk-modeling-and-simulation2026-10-03 https://evidence-hub.com/study/1133-francisella-tularensis-susceptibility-to-antibiotics-a-comprehensive2026-10-08 https://evidence-hub.com/study/1134-in-vitro-activity-of-levofloxacin-against-clinical-isolates-of2026-10-08 https://evidence-hub.com/study/1135-a-systematic-review-of-animal-models-for-staphylococcus-aureus2026-10-13 https://evidence-hub.com/study/1136-levofloxacin-prophylaxis-during-induction-therapy-for-pediatric-acute2026-10-08 https://evidence-hub.com/study/1137-laboratory-animal-models-for-brucellosis-research2026-10-13 https://evidence-hub.com/study/1138-mutant-selection-window-in-levofloxacin-and-moxifloxacin-treatments2026-10-08 https://evidence-hub.com/study/1139-development-and-characterization-of-mwcnts-from-activated-carbon-as2026-10-08 https://evidence-hub.com/study/1140-levofloxacin-proliposomes-opportunities-for-use-in-lung-tuberculosis2026-10-08 https://evidence-hub.com/study/1141-protection-afforded-by-fluoroquinolones-in-animal-models-of2026-10-08 https://evidence-hub.com/study/1142-streptococcus-pneumoniae-response-to-repeated-moxifloxacin-or2026-10-08 https://evidence-hub.com/study/1143-novel-murine-model-of-pneumococcal-pneumonia-use-of-temperature-as-a2026-10-20 https://evidence-hub.com/study/1145-the-mutant-selection-window-in-rabbits-infected-with-staphylococcus2026-10-08 https://evidence-hub.com/study/1146-pharmacokinetics-of-levofloxacin-following-oral-administration-of-a2026-10-08 https://evidence-hub.com/study/1148-effective-antimicrobial-regimens-for-use-in-humans-for-therapy-of2026-10-08 https://evidence-hub.com/study/1149-levofloxacin-versus-tetracycline-antibiotics-for-the-treatment-of2026-10-08 https://evidence-hub.com/study/1150-reply-to-efficacy-and-pharmacodynamics-of-simulated-human-like2026-10-20 https://evidence-hub.com/study/1151-animal-models-of-bacterial-keratitis2026-10-08 https://evidence-hub.com/study/1152-phase-i-study-of-levofloxacin-s-ofloxacin2026-10-08 https://evidence-hub.com/study/1153-pharmacodynamics-of-levofloxacin-in-a-murine-pneumonia-model-of2026-10-08 https://evidence-hub.com/study/1154-pharmacodynamics-of-once-or-twice-daily-levofloxacin-versus2026-10-08 https://evidence-hub.com/study/1155-review-of-third-and-fourth-generation-fluoroquinolones-in2026-10-08 https://evidence-hub.com/study/1156-evaluation-of-drug-induced-liver-toxicity-of-trovafloxacin-and2026-10-08 https://evidence-hub.com/study/1158-bioavailability-and-efficacy-of-levofloxacin-against-francisella2026-10-08 https://evidence-hub.com/study/1159-comparison-of-levofloxacin-alatrofloxacin-and-vancomycin-for2026-10-08 https://evidence-hub.com/study/1160-efficacy-and-pharmacodynamics-of-simulated-human-like-treatment-with2026-10-20 https://evidence-hub.com/study/1161-impact-of-resistance-selection-and-mutant-growth-fitness-on-the2026-10-08 https://evidence-hub.com/study/1162-diphenhydramine-and-levofloxacin-combination-therapy-against2026-10-08 https://evidence-hub.com/study/1163-in-vitro-activity-of-delafloxacin-against-highly-levofloxacin2026-10-08 https://evidence-hub.com/study/1164-in-vitro-activity-of-ceragenins-against-burkholderia-cepacia-complex2026-10-08 https://evidence-hub.com/study/1165-in-vitro-combination-of-tigecycline-with-other-antibiotics-in2026-10-08 https://evidence-hub.com/study/1166-in-vitro-effects-of-ciprofloxacin-levofloxacin-and-moxifloxacin-on2026-10-08 https://evidence-hub.com/study/1167-in-vitro-evaluation-of-antibiotic-synergy-for-carbapenem-resistant2026-10-08 https://evidence-hub.com/study/1168-conjugates-of-ciprofloxacin-and-levofloxacin-with-cell-penetrating2026-10-08 https://evidence-hub.com/study/1169-comparison-of-garenoxacin-with-levofloxacin-as-antimicrobial2026-10-08 https://evidence-hub.com/study/1170-in-vitro-activity-of-delafloxacin-and-finafloxacin-against-mycoplasma2026-10-06 https://evidence-hub.com/study/1171-insights-on-the-properties-of-levofloxacin-adsorbed-sr-and-mg-doped2026-10-06 https://evidence-hub.com/study/1172-in-vitro-activity-of-a-novel-quinolone-ub-8902-against-ofloxacin2026-10-08 https://evidence-hub.com/study/1173-the-combination-of-salmonella-phage-st-3-and-antibiotics-to-prevent2026-10-06 https://evidence-hub.com/study/1174-combination-therapy-with-levofloxacin-and-the-probiotic-clostridium2026-10-08 https://evidence-hub.com/study/1175-in-vitro-efficacy-of-various-antibiotic-combinations-against2026-10-08 https://evidence-hub.com/study/1176-evaluating-the-in-vitro-efficacy-of-gatifloxacin-levofloxacin-and2026-10-08 https://evidence-hub.com/study/1177-in-vitro-and-in-vivo-activities-of-sparfloxacin-against-mycoplasma2026-10-08 https://evidence-hub.com/study/1178-development-of-levofloxacin-loaded-plga-microspheres-of-suitable2026-10-08 https://evidence-hub.com/study/1179-immunomodulatory-action-of-levofloxacin-on-cytokine-production-by2026-10-08 https://evidence-hub.com/study/1180-in-vitro-activity-of-solithromycin-against-anaerobic-bacteria-from2026-10-08 https://evidence-hub.com/study/1181-in-vitro-activity-of-moxifloxacin-levofloxacin-gatifloxacin-and2026-10-08 https://evidence-hub.com/study/1182-inhibiting-tirap-mediated-inflammatory-signaling-a-promising2026-10-08 https://evidence-hub.com/study/1183-in-vitro-antibacterial-activity-of-azd0914-against-human-mycoplasmas2026-10-08 https://evidence-hub.com/study/1184-in-vitro-activity-of-new-fluoroquinolones-and-linezolid-against-non2026-10-08 https://evidence-hub.com/study/1185-bioequivalence-and-in-vitro-antimicrobial-activity-between-generic2026-10-08 https://evidence-hub.com/study/1186-in-vitro-activity-of-ciprofloxacin-ofloxacin-and-levofloxacin-against2026-10-08 https://evidence-hub.com/study/1187-synergistic-effects-of-baicalin-and-levofloxacin-against2026-10-08 https://evidence-hub.com/study/1188-in-vitro-activities-of-n-acetyl-cysteine-and-levofloxacin-as-a2026-10-06 https://evidence-hub.com/study/1189-the-mechanisms-of-insulin-secretion-and-calcium-signaling-in2026-10-06 https://evidence-hub.com/study/1190-conversion-of-antibacterial-quinolone-drug-levofloxacin-to-potent2026-10-06 https://evidence-hub.com/study/1191-hydrophilic-and-degradable-polyesters-based-on-l-aspartic-acid-with2026-10-06 https://evidence-hub.com/study/1192-in-vitro-activity-of-omadacycline-against-chlamydia-pneumoniae2026-10-08 https://evidence-hub.com/study/1193-development-and-characterization-of-levofloxacin-loaded-vitamin-a2026-10-05 https://evidence-hub.com/study/1194-antimicrobial-susceptibilities-of-40-isolates-of-bacillus-anthracis2026-10-06 https://evidence-hub.com/study/1195-levofloxacin-exerts-broad-spectrum-anticancer-activity-via-regulation2026-10-06 https://evidence-hub.com/study/1196-fluoroquinolones-and-propionic-acid-derivatives-induce-inflammatory2026-10-08 https://evidence-hub.com/study/1197-synthesis-and-biological-evaluation-of-novel-n-n-diarylurea2026-10-08 https://evidence-hub.com/study/1198-in-vitro-susceptibility-of-a-penicillin-resistant-and-tolerable2026-10-06 https://evidence-hub.com/study/1199-in-vitro-synergy-of-colistin-combinations-against-extensively-drug2026-10-08 https://evidence-hub.com/study/1200-preparation-oral-levofloxacin-colon-specific-microspheres-delivery-in2026-10-08 https://evidence-hub.com/study/1201-comparative-in-vitro-antibacterial-activity-of-ozenoxacin-against2026-10-08 https://evidence-hub.com/study/1202-in-vitro-induction-and-selection-of-fluoroquinolone-resistant-mutants2026-10-06 https://evidence-hub.com/study/1203-comparative-in-vitro-activity-of-telithromycin-hmr-3647-three2026-10-06 https://evidence-hub.com/study/1204-enhancing-the-antimicrobial-efficacy-of-polyester-hernia-meshes-via2026-10-08 https://evidence-hub.com/study/1205-the-impact-of-surfactants-in-tailoring-nanostructured-lipid-carriers2026-10-20 https://evidence-hub.com/study/1206-development-and-validation-of-spectrophotometric-method-for2026-10-08 https://evidence-hub.com/study/1207-surgical-site-infection-due-to-mycobacterium-wolinskyi-after-inguinal2026-10-08 https://evidence-hub.com/study/1208-structure-of-chloramphenicol-bound-mexb-reveals-residues-in-the2026-10-08 https://evidence-hub.com/study/1209-electrospun-zn-cobimetinib-levofloxacin-pva-pvp-nanofibers-for-skin2026-10-08 https://evidence-hub.com/study/1210-characterization-of-blandm-1-and-blaoxa-23-type-carbapenemases-in2026-10-13 https://evidence-hub.com/study/1211-fusobacterium-necrophorum-brain-abscess-with-concurrent2026-10-08 https://evidence-hub.com/study/1212-macroheterocycle-functionalized-pvdf-meshes-with-hybrid-nanocomposite2026-10-08 https://evidence-hub.com/study/1213-synchronous-gastric-signet-ring-cell-adenocarcinoma-and-mucosa2026-10-08 https://evidence-hub.com/study/1214-persistent-pathogens-following-minimally-invasive-surgery-is-it-time2026-10-08 https://evidence-hub.com/study/1215-nanoencapsulation-of-anise-oil-and-evaluation-of-its-antimicrobial2026-10-08 https://evidence-hub.com/study/1216-design-and-production-of-respirable-effervescent-microparticles-to2026-10-08 https://evidence-hub.com/study/1217-3d-printing-for-pelvic-organ-prolapse-management-a-narrative-review2026-10-08 https://evidence-hub.com/study/1218-applications-and-challenges-of-3d-printing-in-female-reproductive2026-10-13 https://evidence-hub.com/study/1219-from-pelvis-to-groin-non-communicating-rudimentary-uterine-horn-and2026-10-13 https://evidence-hub.com/study/1220-antimicrobial-research-productivity-in-lebanon-a-pubmed-based2026-10-13 https://evidence-hub.com/study/1221-the-covid-19-pandemic-an-underlying-factor-for-increased2026-10-13 https://evidence-hub.com/study/1222-levofloxacin-loaded-surfactant-nanocarriers-a-computational-study2026-10-08 https://evidence-hub.com/study/1223-global-profile-of-drug-resistance-related-to-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/1224-formulation-and-clinical-translation-of-inhalable-nanomedicines-for2026-10-08 https://evidence-hub.com/study/1225-rheological-modulation-and-drug-delivery-efficiency-of-carbon2026-10-08 https://evidence-hub.com/study/1226-recurrent-giant-neurofibroma-of-the-posterior-neck-and-upper-back2026-10-08 https://evidence-hub.com/study/1227-efficacy-and-safety-of-minocycline-containing-bismuth-quadruple2026-10-08 https://evidence-hub.com/study/1228-txa11114-discovery-of-an-in-vivo-efficacious-efflux-pump-inhibitor2026-10-08 https://evidence-hub.com/study/1229-mannose-modified-mir-223-nanoparticles-remodel-pathological2026-10-08 https://evidence-hub.com/study/1230-precision-bacterial-immunotherapy-an-integrated-mechanistic-taxonomy2026-10-13 https://evidence-hub.com/study/1232-spanlastic-laden-in-situ-gel-as-a-promising-approach-for-ocular2026-10-08 https://evidence-hub.com/study/1233-activity-of-levofloxacin-in-combination-with-colistin-against2026-10-08 https://evidence-hub.com/study/1234-formulation-optimization-in-vitro-and-in-vivo-evaluation-of2026-10-08 https://evidence-hub.com/study/1235-levofloxacin-in-vitro-activity-and-time-kill-evaluation-of2026-10-08 https://evidence-hub.com/study/1236-in-vitro-cytotoxicity-synergistic-antibacterial-activity-and2026-10-08 https://evidence-hub.com/study/1237-levofloxacin-in-vitro-activity-results-from-an-international2026-10-08 https://evidence-hub.com/study/1238-evaluation-of-the-efficacy-of-doxycycline-ciprofloxacin-levofloxacin2026-10-08 https://evidence-hub.com/study/1239-levofloxacin-in-vitro-activity-against-bacteremic-isolates-of2026-10-08 https://evidence-hub.com/study/1240-development-of-a-dual-delivery-of-levofloxacin-and-prednisolone2026-10-08 https://evidence-hub.com/study/1241-synergistic-effect-of-chlorogenic-acid-and-levofloxacin-against2026-10-13 https://evidence-hub.com/study/1242-assessment-of-the-in-vitro-activity-of-azithromycin-niosomes-alone2026-10-08 https://evidence-hub.com/study/1243-bovine-lactoferrin-enhances-the-efficacy-of-levofloxacin-based-triple2026-10-08 https://evidence-hub.com/study/1244-preparation-of-levofloxacin-loaded-in-situ-gel-for-sustained-ocular2026-10-08 https://evidence-hub.com/study/1246-improvement-of-ocular-efficacy-of-levofloxacin-by-bioadhesive2026-10-08 https://evidence-hub.com/study/1250-combined-effect-of-levofloxacin-and-n-acetylcysteine-against2026-10-08 https://evidence-hub.com/study/1251-in-vitro-and-in-vivo-combined-antibacterial-effect-of-levofloxacin2026-10-08 https://evidence-hub.com/study/1252-potent-synergistic-combination-of-rosuvastatin-and-levofloxacin2026-10-08 https://evidence-hub.com/study/1253-design-and-characterization-of-nanocarriers-loaded-with-levofloxacin2026-10-08 https://evidence-hub.com/study/1256-efficacy-of-levofloxacin-against-biofilms-of-pseudomonas-aeruginosa2026-10-08 https://evidence-hub.com/study/1258-comparative-in-vitro-activity-of-ciprofloxacin-and-levofloxacin2026-10-13 https://evidence-hub.com/study/1261-increased-in-vitro-antimicrobial-resistance-of-mycoplasma-pneumoniae2026-10-08 https://evidence-hub.com/study/1263-levofloxacin-formulation-and-in-vitro-evaluation-of-alginate-and2026-10-08 https://evidence-hub.com/study/1265-comparative-in-vitro-activity-of-delafloxacin-and-other2026-10-08 https://evidence-hub.com/study/1268-cannabidiol-demonstrates-remarkable-efficacy-in-treating-multidrug2026-10-08 https://evidence-hub.com/study/1269-potential-effectiveness-of-parenteral-nemonoxacin-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/1270-in-vitro-evaluation-of-tigecycline-synergy-testing-with-nine2026-10-08 https://evidence-hub.com/study/1271-formulation-and-in-vitro-evaluation-of-size-expanding-gastro2026-10-08 https://evidence-hub.com/study/1272-comparison-of-toxicities-of-moxifloxacin-cefuroxime-and-levofloxacin2026-10-08 https://evidence-hub.com/study/1273-inhibitory-effects-of-the-quinolone-antibiotics-trovafloxacin2026-10-08 https://evidence-hub.com/study/1274-in-vitro-and-in-vivo-activities-of-levofloxacin-against-mycobacterium2026-10-08 https://evidence-hub.com/study/1275-comparative-in-vitro-activity-of-gatifloxacin-grepafloxacin2026-10-08 https://evidence-hub.com/study/1276-biopharmaceutical-characterization-of-oral-immediate-release-drug2026-10-08 https://evidence-hub.com/study/1277-effects-of-nora-inhibitors-on-in-vitro-antibacterial-activities-and2026-10-01 https://evidence-hub.com/study/1278-inhibitory-and-bactericidal-activities-of-levofloxacin-against2026-10-08 https://evidence-hub.com/study/1279-pharmacodynamics-of-levofloxacin-ofloxacin-and-ciprofloxacin-alone2026-10-08 https://evidence-hub.com/study/1281-in-vitro-pharmacodynamics-of-levofloxacin-and-other-aerosolized2026-10-08 https://evidence-hub.com/study/1283-pharmacodynamics-of-moxifloxacin-and-levofloxacin-against2026-10-08 https://evidence-hub.com/study/1284-phenotypic-resistance-of-staphylococcus-aureus-selected2026-10-01 https://evidence-hub.com/study/1285-in-vitro-activities-of-ciprofloxacin-levofloxacin-lomefloxacin2026-10-04 https://evidence-hub.com/study/1286-activities-of-mutant-prevention-concentration-targeted-moxifloxacin2026-10-08 https://evidence-hub.com/study/1287-topical-levofloxacin-1-5-overcomes-in-vitro-resistance-in-rabbit2026-10-08 https://evidence-hub.com/study/1288-in-vitro-activity-of-linezolid-in-combination-with-doxycycline2026-10-08 https://evidence-hub.com/study/1291-in-vitro-activity-of-ofloxacin-levofloxacin-and-d-ofloxacin-against2026-10-08 https://evidence-hub.com/study/1292-comparative-bactericidal-activities-of-ciprofloxacin-clinafloxacin2026-10-01 https://evidence-hub.com/study/1293-levofloxacin-and-ciprofloxacin-in-vitro-activities-against-4-0032026-10-08 https://evidence-hub.com/study/1295-in-vitro-activities-of-levofloxacin-used-alone-and-in-combination2026-10-01 https://evidence-hub.com/study/1296-comparative-in-vitro-activities-of-linezolid-telithromycin2026-10-05 https://evidence-hub.com/study/1297-in-vitro-activity-of-levofloxacin-against-gram-positive-bacteria2026-10-08 https://evidence-hub.com/study/1300-in-vitro-activity-of-levofloxacin-against-contemporary-clinical2026-10-04 https://evidence-hub.com/study/1301-the-effects-of-levofloxacin-on-rabbit-fibroblast-like-synoviocytes-in2026-10-08 https://evidence-hub.com/study/1302-in-silico-evaluation-of-who-endorsed-molecular-methods-to-detect-drug2026-10-08 https://evidence-hub.com/study/1303-levofloxacin-in-bone-and-joint-infections-development-of-an2026-10-08 https://evidence-hub.com/study/1304-integrative-analysis-of-levofloxacin-induced-liver-injury-insights2026-10-08 https://evidence-hub.com/study/1305-antibacterial-potential-of-novel-acetamide-derivatives-of-22026-10-08 https://evidence-hub.com/study/1306-molecular-detection-of-h-pylori-antibiotic-resistant-genes-and2026-10-08 https://evidence-hub.com/study/1307-population-pharmacokinetics-and-dose-optimization-of-intravenous2026-10-20 https://evidence-hub.com/study/1308-isolation-and-characterization-of-werneria-chromene-and2026-10-08 https://evidence-hub.com/study/1309-synthesis-and-molecular-docking-study-of-some-3-4-dihydrothieno-2-3-d2026-10-08 https://evidence-hub.com/study/1310-an-experimental-in-silico-study-on-covid-19-response-of-neutrophil2026-10-08 https://evidence-hub.com/study/1311-parallel-slipped-electron-donor-acceptor-in-adsorption-process2026-10-08 https://evidence-hub.com/study/1312-prediction-of-antimicrobial-resistance-in-gram-negative-bacteria-from2026-10-08 https://evidence-hub.com/study/1313-an-association-study-of-hla-with-levofloxacin-induced-severe2026-10-08 https://evidence-hub.com/study/1314-population-pharmacokinetics-of-oral-levofloxacin-in-healthy2026-10-08 https://evidence-hub.com/study/1315-analytical-profiling-of-mutations-in-quinolone-resistance-determining2026-10-13 https://evidence-hub.com/study/1316-molecular-epidemiology-and-antibiotic-resistance-profiling-of2026-10-08 https://evidence-hub.com/study/1317-ab-initio-molecular-dynamics-simulations-and-experimental-speciation2026-10-08 https://evidence-hub.com/study/1318-drug-repurposing-based-on-protozoan-proteome-in-vitro-evaluation-of2026-10-13 https://evidence-hub.com/study/1319-could-respiratory-fluoroquinolones-levofloxacin-and-moxifloxacin2026-10-08 https://evidence-hub.com/study/1320-interaction-of-levofloxacin-with-lung-surfactant-at-the-air-water2026-10-08 https://evidence-hub.com/study/1321-identification-and-antibiotic-profiling-of-wohlfahrtiimonas2026-10-08 https://evidence-hub.com/study/1322-identifying-24-h-variation-in-the-pharmacokinetics-of-levofloxacin-a2026-10-08 https://evidence-hub.com/study/1323-study-of-andrographolide-bioactivity-against-pseudomonas-aeruginosa2026-10-05 https://evidence-hub.com/study/1324-homology-modeling-molecular-dynamics-and-virtual-screening-of-nora2026-10-08 https://evidence-hub.com/study/1325-in-silico-and-in-vitro-genotoxicity-evaluation-of-descarboxyl2026-10-08 https://evidence-hub.com/study/1326-estimation-of-country-specific-tuberculosis-resistance-antibiograms2026-10-05 https://evidence-hub.com/study/1327-phylogenic-analysis-of-coronavirus-genome-and-molecular-studies-on2026-10-08 https://evidence-hub.com/study/1328-design-synthesis-molecular-docking-anti-proteus-mirabilis-and-urease2026-10-08 https://evidence-hub.com/study/1329-levofloxacin-alleviates-blood-brain-barrier-disruption-following2026-10-08 https://evidence-hub.com/study/1330-mechanistic-study-of-the-electrochemical-oxidation-of2026-10-08 https://evidence-hub.com/study/1331-characteristics-of-a-carbapenem-resistant-acinetobacter-baumannii2026-10-08 https://evidence-hub.com/study/1332-in-silico-screening-and-in-vitro-assessment-of-natural-products-with2026-10-13 https://evidence-hub.com/study/1333-molecular-determinants-of-the-bacterial-resistance-to2026-10-08 https://evidence-hub.com/study/1334-vivo-complexes-with-antibacterial-quinolone-ligands-and-their2026-10-08 https://evidence-hub.com/study/1335-genomic-features-comparative-genomics-and-antimicrobial2026-10-08 https://evidence-hub.com/study/1336-in-silico-discovery-of-druggable-targets-in-citrobacter-koseri-using2026-10-13 https://evidence-hub.com/study/1337-molecular-interactions-of-fluoroquinolone-antibiotics-with-lipid2026-10-04 https://evidence-hub.com/study/1338-antimicrobial-resistance-in-clinical-ureaplasma-spp-and-mycoplasma2026-10-08 https://evidence-hub.com/study/1339-comparative-molecular-profiling-of-multidrug-resistant-pseudomonas2026-10-08 https://evidence-hub.com/study/1340-therapeutic-potential-activity-of-quercetin-complexes-against2026-10-08 https://evidence-hub.com/study/1341-genomic-and-epidemiological-characterization-of-a-blactx-m-272026-10-08 https://evidence-hub.com/study/1342-synthesis-antibacterial-evaluation-and-dna-gyrase-inhibition-profile2026-10-08 https://evidence-hub.com/study/1343-molecular-diversity-and-evolutionary-dynamics-of-phage-receptor2026-10-08 https://evidence-hub.com/study/1344-exploration-of-pyrazole-based-pyridine-4-carbohydrazide-derivatives2026-10-08 https://evidence-hub.com/study/1345-r5-and-r7-positions-on-fluoroquinolone-scaffolds-drive-f-actin2026-10-08 https://evidence-hub.com/study/1346-design-synthesis-and-anti-biofilm-activity-of-c-28-modified-betulinic2026-10-13 https://evidence-hub.com/study/1347-multimodal-computational-discovery-of-mvfr-inhibitors-targeting2026-10-08 https://evidence-hub.com/study/1348-discovery-of-novel-uridine-based-chitin-synthase-inhibitors-design2026-10-08 https://evidence-hub.com/study/1349-natural-inhibitors-of-salmonella-mdr-efflux-pumps-acrab-and-acrd-an2026-10-13 https://evidence-hub.com/study/1350-bioinformatics-analysis-of-the-anti-inflammatory-mechanism-and2026-10-13 https://evidence-hub.com/study/1351-synergistic-effects-of-pyrrosia-lingua-caffeoylquinic-acid-compounds2026-10-13 https://evidence-hub.com/study/1352-structural-characterization-derivatization-and-bioactivities-of2026-10-08 https://evidence-hub.com/study/1353-synthesis-characterization-and-bio-evaluation-of-novel-series-of2026-10-08 https://evidence-hub.com/study/1354-montelukast-treats-streptococcus-pneumoniae-induced-sepsis-via2026-10-08 https://evidence-hub.com/study/1355-novel-fluoroquinolones-with-possible-antibacterial-activity-in-gram2026-10-08 https://evidence-hub.com/study/1356-in-silico-molecular-docking-synthesis-and-preliminary-evaluation-of2026-10-13 https://evidence-hub.com/study/1357-in-silico-activity-prediction-and-docking-studies-of-the-binding2026-10-13 https://evidence-hub.com/study/1358-levofloxacin-and-sulfa-drugs-linked-via-schiff-bases-exploring-their2026-10-08 https://evidence-hub.com/study/1359-in-silico-evaluation-of-doxorubicin-and-levofloxacin-as-multi-isoform2026-10-08 https://evidence-hub.com/study/1360-the-application-of-in-silico-experimental-model-in-the-assessment-of2026-10-13 https://evidence-hub.com/study/1361-the-effects-of-p-glycoprotein-modulators-on-the-transition-of2026-10-08 https://evidence-hub.com/study/1362-microwave-assisted-synthesis-and-in-vitro-and-in-silico-studies-of2026-10-08 https://evidence-hub.com/study/1363-prediction-and-mechanism-of-combined-toxicity-of-surfactants-and2026-10-08 https://evidence-hub.com/study/1364-tio2-modified-activated-carbon-for-pharmaceutical-contaminant-removal2026-10-08 https://evidence-hub.com/study/1365-exploring-the-potential-role-of-gyra-inhibiting-quinoline-analog-an2026-10-08 https://evidence-hub.com/study/1366-in-silico-trials-using-monte-carlo-simulation-to-evaluate2026-10-08 https://evidence-hub.com/study/1367-exploring-novel-tetrahydropyrimidine-and-fused-pyrimidine-based2026-10-08 https://evidence-hub.com/study/1368-in-silico-analysis-to-search-for-an-alternative-inhibitor-of-biofilm2026-10-08 https://evidence-hub.com/study/1369-doxycycline-post-exposure-prophylaxis-could-theoretically-select-for2026-10-13 https://evidence-hub.com/study/1370-antiurease-activity-of-antibiotics-in-vitro-in-silico-structure2026-10-13 https://evidence-hub.com/study/1371-in-silico-prediction-of-antibiotics-biodegradation-by-ganoderma2026-10-08 https://evidence-hub.com/study/1372-activity-of-fluoroquinolones-and-proton-pump-inhibitors-against2026-10-13 https://evidence-hub.com/study/1373-growth-inhibition-of-p-aeruginosa-by-methanol-extract-of-bridelia2026-10-13 https://evidence-hub.com/study/1374-design-synthesis-characterization-pharmacological-evaluation-and-in2026-10-20 https://evidence-hub.com/study/1375-studi-in-silico-senyawa-fitokimia-daun-ketepeng-cina-cassia-alata2026-10-08 https://evidence-hub.com/study/1377-in-silico-docking-resistance-modulation-and-biofilm-gene-expression2026-10-08 https://evidence-hub.com/study/1378-in-silico-and-in-vitro-genotoxicity-evaluation-of-levofloxacin-n2026-10-08 https://evidence-hub.com/study/1379-design-synthesis-in-vitro-and-in-silico-bioactivity-profiles-of-new2026-10-08 https://evidence-hub.com/study/1380-in-vitro-and-in-silico-interactions-of-antiulcer-glucocorticoids-and2026-10-08 https://evidence-hub.com/study/1381-chromanone-oxime-analogs-of-quinolone-drugs-as-cytotoxic-agents-in2026-10-08 https://evidence-hub.com/study/1382-origin-of-macromolecular-crowding-analysis-of-recognition-mechanism2026-10-08 https://evidence-hub.com/study/1383-exploring-the-phototransformation-and-assessing-the-in-vitro-and-in2026-10-08 https://evidence-hub.com/study/1384-the-search-of-potential-inhibitors-of-the-acrab-tolc-system-of2026-10-08 https://evidence-hub.com/study/1385-in-silico-and-in-vitro-evaluation-of-some-synthesized-quinoline2026-10-08 https://evidence-hub.com/study/1386-in-silico-drug-design-and-molecular-docking-studies-of-some-quinolone2026-10-08 https://evidence-hub.com/study/1387-cox-2-enzyme-inhibitors-study-and-efficacy-pharmacokinetic-by2026-10-08 https://evidence-hub.com/study/1388-structure-based-in-silico-analysis-of-quinolone-resistance-in2026-10-08 https://evidence-hub.com/study/1389-detection-of-oxa-1-lactamase-gene-of-klebsiella-pneumoniae-from-blood2026-10-13 https://evidence-hub.com/study/1390-comparing-efficacies-of-moxifloxacin-levofloxacin-and-gatifloxacin-in2026-10-08 https://evidence-hub.com/study/1391-synthesis-of-novel-hydrazones-of-levofloxacin-related-molecule-and2026-10-08 https://evidence-hub.com/study/1392-development-of-novel-in-silico-model-to-predict-corneal-permeability2026-10-08 https://evidence-hub.com/study/1393-physicochemical-properties-of-lomefloxacin-levofloxacin-and2026-10-08 https://evidence-hub.com/study/1394-introduction-pages-notulae-scientia-biologicae-17-1-20252026-10-08 https://evidence-hub.com/study/1395-genomic-insights-into-virulence-biofilm-formation-and-antimicrobial2026-10-08 https://evidence-hub.com/study/1396-sequence-variation-and-structural-insights-into-porin-genes-ompf-ompc2026-10-08 https://evidence-hub.com/study/1397-molecular-docking-analysis-of-coumarin-and-indole-derivatives2026-10-08 https://evidence-hub.com/study/1398-network-based-in-silico-drug-efficacy-screening2026-10-08 https://evidence-hub.com/study/1399-identification-of-natural-compound-inhibitors-for-multidrug-efflux2026-10-01 https://evidence-hub.com/study/1400-development-and-evaluation-of-a-generic-physiologically-based2026-10-08 https://evidence-hub.com/study/1401-the-trends-and-future-prospective-of-in-silico-models-from-the2026-10-01 https://evidence-hub.com/study/1402-identification-and-characterization-of-potential-therapeutic2026-10-01 https://evidence-hub.com/study/1403-ciprofloxacin-and-moxifloxacin-could-interact-with-sars-cov-22026-10-13 https://evidence-hub.com/study/1404-the-degradation-of-levofloxacin-in-infusions-exposed-to-daylight-with2026-10-13 https://evidence-hub.com/study/1405-pediatric-tuberculous-meningitis-model-based-approach-to-determining2026-10-08 https://evidence-hub.com/study/1406-drug-induced-shortening-of-the-electromechanical-window-is-an2026-10-01 https://evidence-hub.com/study/1409-the-sos-response-master-regulator-lexa-is-associated-with-sporulation2026-10-08 https://evidence-hub.com/study/1411-synthesis-characterization-and-in-vitro-antibacterial-activity-of2026-10-01 https://evidence-hub.com/study/1412-electrochemical-degradation-of-levofloxacin-in-synthetic-hospital2026-10-08 https://evidence-hub.com/study/1413-in-silico-identification-of-two-peptides-with-antibacterial-activity2026-10-01 https://evidence-hub.com/study/1414-levofloxacin-is-phytotoxic-and-modifies-the-protein-profile-of-lupin2026-10-13 https://evidence-hub.com/study/1415-moxifloxacin-plus-rifampin-as-an-alternative-for-levofloxacin-plus2026-10-08 https://evidence-hub.com/study/1416-synthesis-and-potential-antitumor-activity-of-7-4-substituted2026-10-01 https://evidence-hub.com/study/1417-isolation-characterization-anti-mrsa-evaluation-and-in-silico-multi2026-10-08 https://evidence-hub.com/study/1418-exploring-anti-malarial-potential-of-fda-approved-drugs-an-in-silico2026-10-01 https://evidence-hub.com/study/1419-multiple-drug-transporters-contribute-to-the-brain-transfer-of2026-10-08 https://evidence-hub.com/study/1420-rapid-determination-of-anti-tuberculosis-drug-resistance-from-whole2026-10-01 https://evidence-hub.com/study/1421-importance-of-gastric-secretion-and-the-rapid-gastric-emptying-of2026-10-08 https://evidence-hub.com/study/1423-mutation-of-smerv-renders-stenotrophomonas-maltophilia-resistant-to2026-10-08 https://evidence-hub.com/study/1424-design-synthesis-spectroscopic-characterization-in-vitro2026-10-08 https://evidence-hub.com/study/1425-the-role-of-fluoroquinolones-in-the-treatment-of-tuberculosis-in-20192026-10-08 https://evidence-hub.com/study/1426-pharmacokinetics-and-pharmacodynamics-of-levofloxacin-in-critically2026-10-08 https://evidence-hub.com/study/1427-mechanochemically-induced-solid-state-transformations-of-levofloxacin2026-10-05 https://evidence-hub.com/study/1428-probability-of-target-attainment-of-oral-antimicrobials-for2026-10-08 https://evidence-hub.com/study/1429-pharmacokinetics-of-levofloxacin-in-multidrug-and-extensively-drug2026-10-08 https://evidence-hub.com/study/1430-levofloxacin-pharmacokinetics-pharmacodynamics-dosing-susceptibility2026-10-08 https://evidence-hub.com/study/1431-population-pharmacokinetics-and-pharmacodynamics-of-levofloxacin-in2026-10-08 https://evidence-hub.com/study/1432-pharmacodynamics-of-moxifloxacin-and-levofloxacin-simulating-human2026-10-08 https://evidence-hub.com/study/1433-intrapulmonary-pharmacokinetics-and-pharmacodynamics-of-high-dose2026-10-08 https://evidence-hub.com/study/1434-antibiotic-dosing-in-continuous-renal-replacement-therapy2026-10-08 https://evidence-hub.com/study/1435-in-vivo-pharmacodynamics-of-lascufloxacin-and-levofloxacin-against2026-10-20 https://evidence-hub.com/study/1436-fluoroquinolones-in-the-management-of-community-acquired-pneumonia-in2026-10-20 https://evidence-hub.com/study/1437-optimization-of-anti-pseudomonal-antibiotics-for-cystic-fibrosis2026-10-06 https://evidence-hub.com/study/1438-culture-based-antimicrobial-susceptibility-testing-for-helicobacter2026-10-06 https://evidence-hub.com/study/1439-pharmacodynamics-of-moxifloxacin-and-levofloxacin-at-simulated2026-10-19 https://evidence-hub.com/study/1440-oral-levofloxacin-population-pharmacokinetics-model-and2026-10-03 https://evidence-hub.com/study/1441-levofloxacin-inhalation-solution-for-the-treatment-of-chronic2026-10-06 https://evidence-hub.com/study/1442-differential-antimicrobial-susceptibilities-of-granulicatella2026-10-06 https://evidence-hub.com/study/1443-pharmacokinetics-and-pharmacodynamics-of-levofloxacin-in-bronchial2026-10-08 https://evidence-hub.com/study/1444-nemonoxacin-pharmacokinetics-pharmacodynamics-against-escherichia2026-10-20 https://evidence-hub.com/study/1445-three-fluoroquinolones-with-different-epithelial-lining-fluid2026-10-20 https://evidence-hub.com/study/1446-a-ten-year-trend-of-antimicrobial-resistance-in-pseudomonas2026-10-08 https://evidence-hub.com/study/1447-characterization-of-gepotidacin-activity-including-in-vitro-kill2026-10-20 https://evidence-hub.com/study/1448-determinants-of-levofloxacin-prophylaxis-failure-in-high-risk2026-10-20 https://evidence-hub.com/study/1449-pharmacokinetics-and-pharmacodynamics-of-levofloxacin-injection-in2026-10-13 https://evidence-hub.com/study/1450-targeted-prostatic-delivery-of-levofloxacin-via-a-novel-vas-deferens2026-10-06 https://evidence-hub.com/study/1451-determination-of-frequency-of-spontaneous-resistance-for-gepotidacin2026-10-13 https://evidence-hub.com/study/1452-effect-of-quinolone-prophylaxis-discontinuation-during-pre2026-10-06 https://evidence-hub.com/study/1453-population-pharmacokinetics-and-exposure-response-analysis-of2026-10-20 https://evidence-hub.com/study/1454-wild-type-mic-distribution-and-evaluation-of-epidemiological-cut-offs2026-10-06 https://evidence-hub.com/study/1455-antibacterial-therapy-in-central-nervous-system-infections2026-10-08 https://evidence-hub.com/study/1456-hemodialysis-central-venous-catheter-associated-bloodstream-infection2026-10-08 https://evidence-hub.com/study/1457-prevalence-of-polypharmacy-and-drug-interactions-in-geriatric2026-10-06 https://evidence-hub.com/study/1458-in-vitro-antimicrobial-activity-of-ceftobiprole-and-comparator-agents2026-10-20 https://evidence-hub.com/study/1459-the-potential-role-of-verapamil-against-fluconazole-induced-torsade2026-10-06 https://evidence-hub.com/study/1460-do-aminopenicillins-have-a-role-in-treating-ampicillin-resistant2026-10-06 https://evidence-hub.com/study/1461-a-study-of-antibiotic-tolerance-to-levofloxacin-and-rifampin-in2026-10-06 https://evidence-hub.com/study/1462-understanding-the-role-of-macrocycle-size-and-amide-linkage-in2026-10-06 https://evidence-hub.com/study/1463-pharmacodynamics-of-levofloxacin-against-characterized-ciprofloxacin2026-10-19 https://evidence-hub.com/study/1464-eskape-pathogens-emerging-isolates-in-odontogenic-orofacial-infections2026-10-06 https://evidence-hub.com/study/1465-antimicrobial-and-synergistic-activity-of-metformin-against2026-10-06 https://evidence-hub.com/study/1466-recurrence-of-postneurosurgical-central-nervous-system-infection2026-10-06 https://evidence-hub.com/study/1467-efflux-pump-overexpression-in-fluoroquinolone-multidrug-resistance2026-10-20 https://evidence-hub.com/study/1468-trip-score-a-three-pillar-risk-stratification-model-proposal-for2026-10-06 https://evidence-hub.com/study/1469-association-between-antimicrobial-regimens-and-28-day-mortality-in2026-10-20 https://evidence-hub.com/study/1470-pharmacodynamics-of-levofloxacin-in-patients-with-acute-exacerbation2026-10-08 https://evidence-hub.com/study/1471-evaluation-of-antibiotic-use-in-patients-admitted-to-a-hungarian2026-10-06 https://evidence-hub.com/study/1472-anti-shigella-activity-and-killing-kinetics-of-compounds-from-mmv2026-10-06 https://evidence-hub.com/study/1473-pharmacokinetics-and-pharmacodynamics-of-levofloxacin-in-intensive2026-10-08 https://evidence-hub.com/study/1474-managing-infections-in-burn-patients-strategies-and-considerations2026-10-06 https://evidence-hub.com/study/1475-an-antimicrobial-susceptibility-study-to-compare-the-in-vitro2026-10-20 https://evidence-hub.com/study/1476-evaluation-of-lung-epithelial-lining-fluid-concentrations-of2026-10-08 https://evidence-hub.com/study/1477-cefiderocol-in-children-with-hematologic-malignancies-the-multicenter2026-10-08 https://evidence-hub.com/study/1478-genomic-phylogeny-taxonomic-classification-genetic-landscape-and2026-10-06 https://evidence-hub.com/study/1479-the-pharmacokinetics-pk-pharmacodynamics-pd-of-pretomanid-delamanid2026-10-06 https://evidence-hub.com/study/1480-effects-of-acute-renal-failure-and-ganciclovir-on-the2026-10-01 https://evidence-hub.com/study/1481-comparison-between-the-antimicrobial-activity-of-colistin-and2026-10-06 https://evidence-hub.com/study/1482-urinary-bactericidal-activity-of-4-doses-of-levofloxacin-250-500-7502026-10-05 https://evidence-hub.com/study/1483-population-pharmacokinetics-and-pharmacodynamics-modeling-to-optimize2026-10-08 https://evidence-hub.com/study/1484-prospective-randomized-blinded-phase-ii-pharmacokinetic2026-10-20 https://evidence-hub.com/study/1485-pharmacodynamic-of-ceftaroline-and-levofloxacin-against-pathogens2026-10-08 https://evidence-hub.com/study/1486-a-placebo-and-active-comparator-controlled-multiple-dose-study-to2026-10-08 https://evidence-hub.com/study/1487-randomized-open-label-multiple-dose-phase-i-study-of-the-early2026-10-08 https://evidence-hub.com/study/1488-evaluation-of-efficacy-and-safety-parameters-of-different-antibiotics2026-10-05 https://evidence-hub.com/study/1489-pharmacokinetics-and-pharmacodynamics-of-levofloxacin-against2026-10-01 https://evidence-hub.com/study/1490-pharmacodynamics-of-levofloxacin-and-ofloxacin-against-streptococcus2026-09-26 https://evidence-hub.com/study/1491-pharmacodynamics-of-moxifloxacin-levofloxacin-and-sparfloxacin2026-09-29 https://evidence-hub.com/study/1493-pharmacodynamically-guided-levofloxacin-dosing-for-pediatric2026-10-08 https://evidence-hub.com/study/1494-comparative-pharmacodynamic-interaction-analysis-between2026-10-01 https://evidence-hub.com/study/1495-pharmacodynamic-modeling-of-the-evolution-of-levofloxacin-resistance2026-09-26 https://evidence-hub.com/study/1496-pharmacodynamics-of-levofloxacin-against-pseudomonas-aeruginosa-with2026-10-01 https://evidence-hub.com/study/1497-pharmacodynamics-of-750-mg-and-500-mg-doses-of-levofloxacin-against2026-09-29 https://evidence-hub.com/study/1498-pharmacodynamics-of-trovafloxacin-and-levofloxacin-against2026-10-08 https://evidence-hub.com/study/1499-mutant-prevention-concentration-based-pharmacokinetic-pharmacodynamic2026-09-26 https://evidence-hub.com/study/1500-pharmacokinetics-and-pharmacodynamics-of-intravenous-levofloxacin-at2026-10-01 https://evidence-hub.com/study/1501-worldwide-antimicrobial-susceptibility-patterns-and-pharmacodynamic2026-09-26 https://evidence-hub.com/study/1502-abt492-and-levofloxacin-comparison-of-their-pharmacodynamics-and2026-09-26 https://evidence-hub.com/study/1503-pharmacodynamic-analysis-of-ceftriaxone-gatifloxacin-and-levofloxacin2026-10-08 https://evidence-hub.com/study/1504-pharmacodynamic-profiling-of-levofloxacin-and-gatifloxacin-using2026-09-30 https://evidence-hub.com/study/1505-pharmacodynamics-of-moxifloxacin-and-levofloxacin-against2026-10-08 https://evidence-hub.com/study/1506-application-of-fluoroquinolone-pharmacodynamics2026-09-26 https://evidence-hub.com/study/1507-levofloxacin-pharmacokinetics-pharmacodynamics-and-outcome-in2026-10-08 https://evidence-hub.com/study/1508-fluoroquinolones-for-treating-tuberculosis-presumed-drug-sensitive2026-10-08 https://evidence-hub.com/study/1509-rapid-assays-for-fluoroquinolone-resistance-in-mycobacterium2026-10-08 https://evidence-hub.com/study/1510-primary-antibiotic-resistance-in-helicobacter-pylori-in-china-a2026-10-08 https://evidence-hub.com/study/1511-antimicrobial-therapy-for-chronic-bacterial-prostatitis2026-10-13 https://evidence-hub.com/study/1512-efficacy-and-safety-of-quinolone-containing-rescue-therapies-after2026-10-08 https://evidence-hub.com/study/1513-levofloxacin-amoxicillin-based-schemes-vs-quadruple-therapy-for2026-10-08 https://evidence-hub.com/study/1514-assessment-of-the-risk-of-musculoskeletal-adverse-events-associated2026-10-13 https://evidence-hub.com/study/1515-levofloxacin-adverse-effects-data-from-clinical-trials-and2026-10-08 https://evidence-hub.com/study/1516-a-comparison-of-different-antibiotic-regimens-for-the-treatment-of2026-10-08 https://evidence-hub.com/study/1517-treatment-of-community-acquired-pneumonia-with-levofloxacin-500-mg2026-10-16 https://evidence-hub.com/study/1518-advantages-of-moxifloxacin-and-levofloxacin-based-triple-therapy-for2026-10-08 https://evidence-hub.com/study/1519-primary-antibiotic-resistance-of-helicobacter-pylori-in-india-over2026-10-08 https://evidence-hub.com/study/1520-a-comparison-of-different-antibiotic-regimens-for-the-treatment-of2026-10-13 https://evidence-hub.com/study/1521-globally-vibrio-cholera-antibiotics-resistance-to-rna-and-dna2026-10-08 https://evidence-hub.com/study/1522-effectiveness-and-safety-of-tuberculosis-preventive-treatment-for2026-10-08 https://evidence-hub.com/study/1523-postexposure-prophylaxis-and-treatment-of-bacillus-anthracis2026-10-08 https://evidence-hub.com/study/1524-continuous-versus-intermittent-infusion-of-lactams-in-patients-with2026-10-08 https://evidence-hub.com/study/1525-efficacy-and-safety-of-early-antibiotic-de-escalation-in-febrile2026-10-08 https://evidence-hub.com/study/1526-minocycline-in-the-eradication-of-helicobacter-pylori-infection-a2026-10-06 https://evidence-hub.com/study/1527-first-line-eradication-of-helicobacter-pylori-infection-with-high2026-10-13 https://evidence-hub.com/study/1528-meta-analysis-of-drug-delivery-approaches-for-treating-intracellular2026-10-13 https://evidence-hub.com/study/1529-efficacy-and-safety-of-novel-glycopeptides-versus-vancomycin-for-the2026-10-08 https://evidence-hub.com/study/1530-global-estimates-and-determinants-of-antituberculosis-drug2026-10-06 https://evidence-hub.com/study/1531-antibiotics-for-ventilator-associated-pneumonia2026-10-13 https://evidence-hub.com/study/1532-systematic-review-and-meta-analyses-of-the-effect-of-chemotherapy-on2026-10-06 https://evidence-hub.com/study/1533-a-comparison-of-fluoroquinolones-versus-other-antibiotics-for2026-10-06 https://evidence-hub.com/study/1534-preclinical-models-to-optimize-treatment-of-tuberculous-meningitis-a2026-10-08 https://evidence-hub.com/study/1535-fluoroquinolone-related-adverse-events-resulting-in-health-service2026-10-08 https://evidence-hub.com/study/1536-emerging-infections-in-vulnerable-hosts-stenotrophomonas-maltophilia2026-10-08 https://evidence-hub.com/study/1537-antibiotics-for-community-acquired-pneumonia-in-adult-outpatients2026-10-19 https://evidence-hub.com/study/1538-intrapulmonary-pharmacokinetics-of-antibiotics-used-to-treat2026-10-08 https://evidence-hub.com/study/1539-prescribing-cascades-an-umbrella-review-and-updated-systematic-review2026-10-20 https://evidence-hub.com/study/1540-systematic-review-of-ceftaroline-fosamil-in-the-management-of2026-10-08 https://evidence-hub.com/study/1541-updated-antimicrobial-dosing-recommendations-for-obese-patients2026-10-08 https://evidence-hub.com/study/1542-intensified-antituberculosis-therapy-regimen-containing-higher-dose2026-10-06 https://evidence-hub.com/study/1543-a-systematic-review-on-maternal-to-infant-transfer-of-drugs-through2026-10-06 https://evidence-hub.com/study/1544-a-systematic-review-of-studies-reporting-antibiotic-pharmacokinetic2026-10-06 https://evidence-hub.com/study/1545-dose-recommendations-for-common-drugs-in-patients-with-liver2026-10-06 https://evidence-hub.com/study/1546-antimicrobial-stewardship-implementation-before-and-during-the-covid2026-10-06 https://evidence-hub.com/study/1547-improving-antibacterial-prescribing-safety-in-the-management-of-copd2026-10-06 https://evidence-hub.com/study/1548-pharmacokinetics-of-antiretroviral-and-tuberculosis-drugs-in-children2026-10-06 https://evidence-hub.com/study/1549-evaluation-of-evidence-for-pharmacokinetics-pharmacodynamics-based2026-10-06 https://evidence-hub.com/study/1550-managing-community-acquired-pneumonia-in-the-elderly-the-next2026-10-06 https://evidence-hub.com/study/1551-d-cycloserine-pharmacokinetics-pharmacodynamics-susceptibility-and2026-10-06 https://evidence-hub.com/study/1552-analysis-of-the-assessment-of-antimicrobial-susceptibility-non2026-10-06 https://evidence-hub.com/study/1553-gaps-in-drug-dosing-for-obese-children-a-systematic-review-of2026-10-06 https://evidence-hub.com/study/1554-real-world-use-of-ceftolozane-tazobactam-a-systematic-literature2026-10-13 https://evidence-hub.com/study/1555-sars-cov-2-neutralising-monoclonal-antibodies-for-treatment-of-covid2026-10-06 https://evidence-hub.com/study/1556-six-months-therapy-for-tuberculous-meningitis2026-10-06 https://evidence-hub.com/study/1557-oral-regimens-for-rifampin-resistant-fluoroquinolone-susceptible2026-10-05 https://evidence-hub.com/study/1558-randomized-clinical-trial-of-high-dose-rifampicin-with-or-without2026-10-08 https://evidence-hub.com/study/1559-effect-of-meropenem-vaborbactam-vs-piperacillin-tazobactam-on2026-10-20 https://evidence-hub.com/study/1560-efficacy-and-safety-of-8-week-regimens-for-the-treatment-of2026-10-06 https://evidence-hub.com/study/1561-evaluation-of-efficacy-and-safety-of-lacticaseibacillus-rhamnosus2026-10-08 https://evidence-hub.com/study/1562-analysis-of-the-drug-therapy-of-gatifloxacin-and-levofloxacin-in-the2026-10-08 https://evidence-hub.com/study/1563-analysis-of-efficacy-and-safety-of-linezolid-based-chemotherapeutic2026-10-06 https://evidence-hub.com/study/1564-quadruple-sequential-and-concomitant-first-line-therapies-for-h2026-10-08 https://evidence-hub.com/study/1565-different-doses-of-ilaprazole-for-dual-therapy-versus-bismuth2026-10-08 https://evidence-hub.com/study/1566-towards-pharmacokinetic-boosting-of-phenoxymethylpenicillin2026-10-08 https://evidence-hub.com/study/1567-immediate-or-high-dose-antituberculosis-therapy-for-hiv-related2026-10-06 https://evidence-hub.com/study/1568-pharmacokinetics-of-levofloxacin-in-non-lactating-goats-and2026-10-08 https://evidence-hub.com/study/1569-keverprazan-a-novel-potassium-competitive-acid-blocker-multiple-oral2026-10-16 https://evidence-hub.com/study/1570-efficacy-and-safety-of-pl-5-peceleganan-spray-for-wound-infections-a2026-10-06 https://evidence-hub.com/study/1571-aqueous-humour-concentrations-after-topical-application-of-combined2026-10-08 https://evidence-hub.com/study/1572-optimized-dual-therapy-for-treatment-naive-patients-of-helicobacter2026-10-06 https://evidence-hub.com/study/1573-comparison-the-cost-efficacy-of-furazolidone-based-versus2026-10-06 https://evidence-hub.com/study/1574-bwc0977-a-broad-spectrum-antibacterial-clinical-candidate-to-treat2026-10-13 https://evidence-hub.com/study/1575-clinical-and-microbiological-outcomes-by-causative-pathogen-in-the2026-10-13 https://evidence-hub.com/study/1576-brief-report-pharmacodynamics-safety-and-clinical-efficacy-of-amg-8112026-10-08 https://evidence-hub.com/study/1577-the-prognostic-impact-of-dose-attenuated-r-chop-therapy-for-elderly2026-10-06 https://evidence-hub.com/study/1578-pharmacokinetics-and-pharmacodynamics-of-multiple-dose-intravenous2026-10-08 https://evidence-hub.com/study/1579-population-pharmacokinetics-and-pharmacodynamics-of-ofloxacin-in2026-10-06 https://evidence-hub.com/study/1580-pharmacometrics-based-dose-selection-of-levofloxacin-as-a-treatment2026-10-08 https://evidence-hub.com/study/1581-a-randomized-study-of-the-single-dose-safety-pharmacokinetics-and2026-10-08 https://evidence-hub.com/study/1582-clinical-outcomes-of-extended-versus-intermittent-administration-of2026-10-13 https://evidence-hub.com/study/1583-evaluation-of-daptomycin-exposure-and-efficacy-and-safety-endpoints2026-10-06 https://evidence-hub.com/study/1584-randomized-pharmacokinetic-and-pharmacodynamic-comparison-of2026-10-01 https://evidence-hub.com/study/1585-thorough-qt-study-of-the-effect-of-oral-moxifloxacin-on-qtc-interval2026-10-06 https://evidence-hub.com/study/1586-pharmacokinetics-pharmacodynamics-of-tigecycline-in-patients-with2026-10-06 https://evidence-hub.com/study/1587-tigecycline-population-pharmacokinetics-in-patients-with-community-or2026-10-08 https://evidence-hub.com/study/1588-pharmacodynamics-of-fluoroquinolones-against-streptococcus-pneumoniae2026-10-19 https://evidence-hub.com/study/1589-absence-of-an-effect-of-levofloxacin-on-warfarin-pharmacokinetics-and2026-10-06 https://evidence-hub.com/study/1590-multiple-dose-safety-and-pharmacokinetics-of-oral-garenoxacin-in2026-10-06 https://evidence-hub.com/study/1591-application-of-visual-gene-clip-based-tailored-therapy-for-the2026-10-06 https://evidence-hub.com/study/1592-testing-novel-strategies-for-patients-hospitalised-with-hiv2026-10-08 https://evidence-hub.com/study/1593-pharmacokinetics-and-pharmacodynamics-of-oral-pradofloxacin2026-10-06 https://evidence-hub.com/study/1594-safety-and-pharmacokinetics-pharmacodynamics-of-a-shorter2026-10-06 https://evidence-hub.com/study/1595-intensified-tuberculosis-treatment-to-reduce-the-mortality-of-hiv2026-10-06 https://evidence-hub.com/study/1596-population-pharmacokinetic-model-and-limited-sampling-strategies-for2026-10-08 https://evidence-hub.com/study/1597-early-oral-stepdown-antibiotic-therapy-versus-continuing-intravenous2026-10-13 https://evidence-hub.com/study/1598-plasma-concentrations-of-second-line-antituberculosis-drugs-in2026-10-06 https://evidence-hub.com/study/1599-phase-i-study-of-selinexor-a-selective-inhibitor-of-nuclear-export-in2026-10-06 https://evidence-hub.com/study/1600-pharmacokinetics-safety-and-tolerability-of-single-dose-intravenous2026-10-13 https://evidence-hub.com/study/1601-influence-of-borderline-cefepime-mic-on-the-outcome-of-cefepime2026-10-13 https://evidence-hub.com/study/1602-oral-candida-in-patients-with-fixed-orthodontic-appliance-in-vitro2026-10-06 https://evidence-hub.com/study/1603-a-phase-1-2-study-of-carfilzomib-in-japanese-patients-with-relapsed2026-10-13 https://evidence-hub.com/study/1604-responding-to-the-challenge-of-untreatable-gonorrhea-etx0914-a-first2026-10-13 https://evidence-hub.com/study/1605-optimal-dose-finding-of-garenoxacin-based-on-population2026-10-01 https://evidence-hub.com/study/1606-comparison-of-the-pharmacodynamics-of-biapenem-in-bronchial2026-10-06 https://evidence-hub.com/study/1607-dose-findings-of-antofloxacin-hydrochloride-for-treating-bacterial2026-10-06 https://evidence-hub.com/study/1608-effect-of-age-on-the-pharmacokinetics-of-busulfan-in-patients2026-10-06 https://evidence-hub.com/study/1609-penetration-of-meropenem-into-epithelial-lining-fluid-of-patients2026-10-06 https://evidence-hub.com/study/1610-levofloxacin-pharmacokinetics-in-adult-cystic-fibrosis2026-10-08 https://evidence-hub.com/study/1611-evaluation-of-tigecycline-penetration-into-colon-wall-tissue-and2026-10-06 https://evidence-hub.com/study/1612-drug-interactions-with-clinafloxacin2026-10-06 https://evidence-hub.com/study/1613-pharmacokinetics-and-pharmacodynamics-of-gatifloxacin-against2026-10-06 https://evidence-hub.com/study/1614-open-label-crossover-study-to-determine-pharmacokinetics-and2026-10-06 https://evidence-hub.com/study/1615-efficacy-and-safety-of-levofloxacin-in-the-context-of-other2026-10-20 https://evidence-hub.com/study/1616-efficacy-of-ultra-short-course-chemotherapy-for-new-smear-positive2026-10-08 https://evidence-hub.com/study/1617-clinical-validation-of-antimicrobial-dosing-regimens-for-continuous2026-10-06 https://evidence-hub.com/study/1618-bronchopulmonary-pharmacokinetic-and-pharmacodynamic-profiles-of2026-10-06 https://evidence-hub.com/study/1620-colistin-versus-meropenem-in-the-empirical-treatment-of-ventilator2026-10-19 https://evidence-hub.com/study/1621-maximizing-pharmacodynamics-with-high-dose-levofloxacin2026-10-08 https://evidence-hub.com/study/1622-levofloxacin-induced-qtc-prolongation-depends-on-the-time-of-drug2026-10-08 https://evidence-hub.com/study/1625-effectiveness-of-levofloxacin-eye-drops-a-microbiological-perspective2026-10-08 https://evidence-hub.com/study/1627-levofloxacin-and-warfarin-interaction2026-10-08 https://evidence-hub.com/study/1628-plazomicin-a-new-aminoglycoside-in-the-fight-against-antimicrobial2026-10-13 https://evidence-hub.com/study/1629-fluoroquinolone-efficacy-against-tuberculosis-is-driven-by2026-10-08 https://evidence-hub.com/study/1630-pharmacokinetic-pharmacodynamic-determinants-of-clinical-outcomes-for2026-10-06 https://evidence-hub.com/study/1631-cancer-drug-repurposing-pathophysiology-therapeutic-targeting-and2026-10-05 https://evidence-hub.com/study/1632-the-combination-of-meropenem-and-levofloxacin-is-synergistic-with2026-10-01 https://evidence-hub.com/study/1633-ceftolozane-tazobactam-a-new-generation-cephalosporin2026-10-20 https://evidence-hub.com/study/1634-iris-study-a-phase-ii-study-of-the-steroid-sulfatase-inhibitor2026-10-06 https://evidence-hub.com/study/1635-together-or-apart-revealing-the-impact-of-dietary-interventions-on2026-10-13 https://evidence-hub.com/study/1636-clinical-perspectives-on-new-antimicrobials-focus-on-fluoroquinolones2026-10-19 https://evidence-hub.com/study/1637-clinical-applications-of-azithromycin-microspheres-in-respiratory2026-10-06 https://evidence-hub.com/study/1638-ceftolozane-tazobactam-a-new-cephalosporin-and-lactamase-inhibitor2026-10-19 https://evidence-hub.com/study/1643-fluoroquinolone-antibiotic-prophylaxis-to-prevent-post-traumatic2026-10-06 https://evidence-hub.com/study/1644-doripenem-monohydrate-a-broad-spectrum-carbapenem-antibiotic2026-10-19 https://evidence-hub.com/study/1645-guide-to-selection-of-fluoroquinolones-in-patients-with-lower2026-10-13 https://evidence-hub.com/study/1646-ciprofloxacin-dosage-and-emergence-of-resistance-in-human-commensal2026-10-08 https://evidence-hub.com/study/1648-in-vitro-activity-of-delafloxacin-and-microbiological-response2026-10-06 https://evidence-hub.com/study/1649-the-use-of-in-vitro-pharmacodynamic-models-of-infection-to-optimize2026-10-01 https://evidence-hub.com/study/1650-therapeutic-drug-monitoring-the-need-for-practical-guidance2026-10-06 https://evidence-hub.com/study/1651-serious-adverse-drug-reactions-associated-with-off-label-and2026-10-06 https://evidence-hub.com/study/1652-role-of-cefiderocol-in-the-treatment-of-carbapenem-resistant2026-10-13 https://evidence-hub.com/study/1653-eravacycline-from-broad-spectrum-coverage-to-novel-clinical2026-10-13 https://evidence-hub.com/study/1654-comparative-in-vitro-antibacterial-activity-of-nemonoxacin-and-other2026-10-08 https://evidence-hub.com/study/1655-metallo-lactamase-producing-pseudomonas-aeruginosa-epidemiology2026-10-13 https://evidence-hub.com/study/1656-cardiovascular-adverse-effects-of-common-non-oncologic-medications2026-10-06 https://evidence-hub.com/study/1657-comparative-analysis-of-treatment-outcomes-and-risk-factors2026-10-08 https://evidence-hub.com/study/1658-bk-polyomavirus-infection-in-kidney-transplantation-a-comprehensive2026-10-13 https://evidence-hub.com/study/1659-challenges-and-opportunities-in-the-management-of-severe-pneumonia2026-10-13 https://evidence-hub.com/study/1660-antimicrobial-laden-perossal-beads-display-in-vitro-inhibition-and2026-10-13 https://evidence-hub.com/study/1661-overview-of-changes-in-the-clinical-and-laboratory-standards2026-10-13 https://evidence-hub.com/study/1662-optimizing-treatment-for-carbapenem-resistant-acinetobacter-baumannii2026-10-13 https://evidence-hub.com/study/1663-nosocomial-pneumonia-current-etiology-and-impact-on-antimicrobial2026-10-08 https://evidence-hub.com/study/1664-third-generation-tetracyclines-current-knowledge-and-therapeutic2026-10-13 https://evidence-hub.com/study/1665-cefiderocol-for-the-treatment-of-multidrug-resistant-gram-negative2026-10-08 https://evidence-hub.com/study/1666-overview-of-side-effects-of-antibacterial-fluoroquinolones-new-drugs2026-10-05 https://evidence-hub.com/study/1667-impact-of-guideline-adherence-on-outcomes-in-patients-hospitalized2026-10-06 https://evidence-hub.com/study/1668-clinical-evaluation-of-meropenem-vaborbactam-combination-for-the2026-10-13 https://evidence-hub.com/study/1669-therapeutic-drug-monitoring-of-glycopeptide-antimicrobials-an2026-10-08 https://evidence-hub.com/study/1670-diagnostic-accuracy-of-a-liquid-chromatography-tandem-mass2026-10-06 https://evidence-hub.com/study/1671-clinical-pharmacology-of-antibiotics2026-10-06 https://evidence-hub.com/study/1672-therapeutic-approaches-for-chronic-obstructive-pulmonary-disease-copd2026-10-06 https://evidence-hub.com/study/1673-cefiderocol-a-new-siderophore-cephalosporin-for-the-treatment-of2026-10-01 https://evidence-hub.com/study/1674-an-update-on-the-clinical-management-of-hiv-and-tuberculosis-co2026-10-06 https://evidence-hub.com/study/1675-chirality-of-new-drug-approvals-2013-2022-trends-and-perspectives2026-10-13 https://evidence-hub.com/study/1676-pharmacoeconomics-of-medicines-used-for-geriatric-individuals-in-a2026-10-06 https://evidence-hub.com/study/1677-practical-considerations-for-the-daratumumab-management-in-portuguese2026-10-06 https://evidence-hub.com/study/1678-bacterial-and-fungal-coinfection-in-individuals-with-coronavirus-a2026-10-01 https://evidence-hub.com/study/1679-using-medicare-data-to-assess-the-proarrhythmic-risk-of-non-cardiac2026-10-06 https://evidence-hub.com/study/1680-delafloxacin-place-in-therapy-and-review-of-microbiologic-clinical2026-10-06 https://evidence-hub.com/study/1681-focus-on-jnj-q2-a-novel-fluoroquinolone-for-the-management-of2026-10-06 https://evidence-hub.com/study/1682-drug-drug-interactions-of-direct-oral-anticoagulants-doacs-from2026-10-06 https://evidence-hub.com/study/1683-guidelines-for-antibiotics-prescription-in-critically-ill-patients2026-10-08 https://evidence-hub.com/study/1684-the-role-of-dexlansoprazole-modified-release-in-the-management-of2026-10-20 https://evidence-hub.com/study/1685-sex-and-gender-based-pharmacological-response-to-drugs2026-10-06 https://evidence-hub.com/study/1686-new-lactam-lactamase-inhibitor-combinations2026-10-06 https://evidence-hub.com/study/1687-treatment-of-pulmonary-disease-of-cystic-fibrosis-a-comprehensive2026-10-06 https://evidence-hub.com/study/1688-anti-infective-associated-aki-a-narrative-review-of-the-epidemiology2026-10-13 https://evidence-hub.com/study/1689-potential-impact-of-outpatient-stewardship-interventions-on2026-10-06 https://evidence-hub.com/study/1690-once-daily-high-dose-tigecycline-is-optimal-tigecycline-pk-pd2026-10-06 https://evidence-hub.com/study/1691-individualization-of-irinotecan-treatment-a-review-of2026-10-01 https://evidence-hub.com/study/1692-applications-of-the-microphysiology-systems-database-for-experimental2026-10-06 https://evidence-hub.com/study/1693-cumulative-clinical-experience-from-over-a-decade-of-use-of2026-10-20 https://evidence-hub.com/study/1694-effectiveness-of-helicobacter-pylori-treatments-according-to2026-10-05 https://evidence-hub.com/study/1695-levofloxacin-or-gonadotropin-releasing-hormone-agonist-treatment2026-10-06 https://evidence-hub.com/study/1696-antimicrobial-resistance-of-nosocomial-strains-of-staphylococcus2026-10-06 https://evidence-hub.com/study/1697-clinical-predictors-of-aminoglycoside-induced-ototoxicity-in-drug2026-10-06 https://evidence-hub.com/study/1698-prospective-evaluation-of-thin-layer-agar-colour-test-in-routine2026-10-06 https://evidence-hub.com/study/1699-microbial-spectrum-of-intra-abdominal-abscesses-in-perforating-crohn2026-10-06 https://evidence-hub.com/study/1700-literature-review-on-the-distribution-characteristics-and2026-10-08 https://evidence-hub.com/study/1703-clinical-impact-of-the-revised-2019-clsi-levofloxacin-breakpoints-in2026-10-08 https://evidence-hub.com/study/1705-odoribacter-splanchnicus-bacteremia-a-rare-condition-associated-with2026-10-06 https://evidence-hub.com/study/1706-use-of-cystic-fibrosis-inhaled-medication-before-and-after2026-10-06 https://evidence-hub.com/study/1707-susceptibility-patterns-of-multidrug-resistant-acinetobacter-baumannii2026-10-06 https://evidence-hub.com/study/1708-fluoroquinolones-and-the-risk-for-incidental-seizures-a-comparative2026-10-06 https://evidence-hub.com/study/1709-fluoroquinolone-susceptibility-and-comparative-outcomes-of-gram2026-10-06 https://evidence-hub.com/study/1710-bacteriological-profile-and-antimicrobial-resistance-patterns-of2026-10-06 https://evidence-hub.com/study/1711-low-penicillin-susceptibility-in-streptococcus-mitis-oralis-from2026-10-06 https://evidence-hub.com/study/1712-clinical-characteristics-and-antimicrobial-susceptibility-of-bacillus2026-10-06 https://evidence-hub.com/study/1713-prevalence-and-antimicrobial-susceptibility-of-ureaplasma-urealyticum2026-10-06 https://evidence-hub.com/study/1714-susceptibility-profile-of-aeromonas-spp-from-clinical-strains2026-10-06 https://evidence-hub.com/study/1715-major-aspects-of-burkholderia-gladioli-and-burkholderia-cepacia2026-10-06 https://evidence-hub.com/study/1716-how-does-gender-affect-ureaplasma-and-mycoplasma-growth-and2026-10-19 https://evidence-hub.com/study/1717-distribution-and-drug-resistance-of-common-pathogens-causing-lower2026-10-08 https://evidence-hub.com/study/1718-no-outbreak-of-vancomycin-and-linezolid-resistance-in-staphylococcal2026-10-06 https://evidence-hub.com/study/1719-aetiology-and-antimicrobial-susceptibility-pattern-of-bacterial2026-10-08 https://evidence-hub.com/study/1720-virulence-genes-distributed-among-staphylococcus-aureus-causing-wound2026-10-08 https://evidence-hub.com/study/1721-molecular-detection-of-the-virulent-exou-genotype-of-pseudomonas2026-10-08 https://evidence-hub.com/study/1722-survey-of-helicobacter-pylori-levofloxacin-and-clarithromycin2026-10-08 https://evidence-hub.com/study/1723-antibiotic-resistant-cutibacterium-acnes-among-acne-patients-in2026-10-08 https://evidence-hub.com/study/1724-prevalence-of-nasal-carriers-of-methicillin-resistant-staphylococcus2026-10-08 https://evidence-hub.com/study/1725-prevalence-of-antibiotic-resistance-pattern-in-shigella-isolates2026-10-08 https://evidence-hub.com/study/1726-sociodemographic-and-clinical-factors-influencing-typhoid-fever2026-10-06 https://evidence-hub.com/study/1727-antimicrobial-resistance-of-helicobacter-pylori-among-low-resource2026-10-08 https://evidence-hub.com/study/1728-incidence-of-biofilms-among-the-multidrug-resistant-e-coli-isolated2026-10-13 https://evidence-hub.com/study/1729-an-evaluation-of-multidrug-resistant-escherichia-coli-isolates-in2026-10-13 https://evidence-hub.com/study/1730-tuberculosis-treatment-without-rifampin-in-kidney-kidney-pancreas2026-10-08 https://evidence-hub.com/study/1731-non-tuberculous-mycobacterial-surgical-site-infections-after2026-10-08 https://evidence-hub.com/study/1732-effect-of-triple-antimicrobial-therapy-on-electrocardiography2026-10-08 https://evidence-hub.com/study/1733-adverse-events-associated-with-pyrazinamide-and-levofloxacin-in-the2026-10-08 https://evidence-hub.com/study/1734-ocular-flora-and-their-antibiotic-susceptibility-in-patients-having2026-10-08 https://evidence-hub.com/study/1735-breast-abscess-bacteriologic-features-in-the-era-of-community2026-10-08 https://evidence-hub.com/study/1736-unmasking-the-uncommon-a-case-series-of-multi-drug-resistant2026-10-08 https://evidence-hub.com/study/1737-clinical-and-histopathologic-features-of-fluoroquinolone-induced2026-10-08 https://evidence-hub.com/study/1738-an-analysis-of-a-community-acquired-pathogen-in-a-kentucky-community2026-10-08 https://evidence-hub.com/study/1739-microbial-keratitis-in-los-angeles-the-doheny-eye-institute-and-the2026-10-08 https://evidence-hub.com/study/1740-infantile-acute-conjunctivitis-induced-by-lactamase-positive2026-10-08 https://evidence-hub.com/study/1741-oral-therapy-for-infective-endocarditis-where-do-we-stand2026-10-06 https://evidence-hub.com/study/1742-ceftazidime-avibactam-for-the-treatment-of-multidrug-resistant-or2026-10-13 https://evidence-hub.com/study/1743-when-culture-results-don-t-tell-the-whole-story-a-practical-review-of2026-10-13 https://evidence-hub.com/study/1744-experience-in-ceftazidime-avibactam-for-treatment-of-mdr-bgn2026-10-13 https://evidence-hub.com/study/1745-therapeutic-challenges-and-emerging-strategies-against-carbapenem2026-10-13 https://evidence-hub.com/study/1746-navigating-tuberculosis-in-pregnancy-and-lactation-a-review-of2026-10-06 https://evidence-hub.com/study/1747-phage-therapy-for-bone-and-joint-infections-towards-clinical2026-10-06 https://evidence-hub.com/study/1748-antimicrobial-management-of-severe-chlamydia-psittaci-pneumonia-in2026-10-08 https://evidence-hub.com/study/1749-colistin-resistance-from-laboratory-research-to-modern-clinical2026-10-06 https://evidence-hub.com/study/1750-the-role-of-the-lymphocyte-transformation-test-in-immune-related2026-10-06 https://evidence-hub.com/study/1751-treating-extensively-drug-resistant-acinetobacter-baumannii2026-10-13 https://evidence-hub.com/study/1752-pharmacokinetics-and-safety-of-group-a-and-b-anti-tuberculosis-drugs2026-10-06 https://evidence-hub.com/study/1753-newer-antibiotics-for-drug-resistant-gram-negative-infections-in2026-10-08 https://evidence-hub.com/study/1754-a-narrative-review-on-antimicrobial-dosing-in-adult-critically-ill2026-10-05 https://evidence-hub.com/study/1755-a-scoping-review-about-smoking-smoking-cessation-and-their-effects-on2026-10-06 https://evidence-hub.com/study/1756-tailored-therapy-vs-empirical-therapy-for-helicobacter-pylori2026-10-06 https://evidence-hub.com/study/1757-sulbactam-for-carbapenem-resistant-acinetobacter-baumannii-infections2026-10-08 https://evidence-hub.com/study/1758-fluoroquinolone-resistant-latent-tuberculosis-infection-a-literature2026-10-06 https://evidence-hub.com/study/1759-crossing-the-barrier-eikenella-corrodens-bacteremia-following-cns2026-10-06 https://evidence-hub.com/study/1760-exploring-the-opportunity-for-therapeutic-drug-monitoring-tdm-and2026-10-06 https://evidence-hub.com/study/1761-genetic-polymorphisms-and-adverse-reactions-to-antituberculosis2026-10-06 https://evidence-hub.com/study/1762-linezolid-induced-pancytopenia-in-patients-using-dapagliflozin-a-case2026-10-06 https://evidence-hub.com/study/1763-therapeutic-advances-in-neuroinfectious-diseases2026-10-06 https://evidence-hub.com/study/1764-web-based-automated-therapeutic-drug-monitoring-application-for2026-10-06 https://evidence-hub.com/study/1765-clinical-experience-with-off-label-intrathecal-administration-of2026-10-06 https://evidence-hub.com/study/1766-antimicrobial-stewardship-programs-in-pediatric-intensive-care-units2026-10-06 https://evidence-hub.com/study/1767-cefadroxil-and-cephalexin-pharmacokinetics-and-pharmacodynamics-in2026-10-06 https://evidence-hub.com/study/1768-thelaziasis-in-humans-a-systematic-review-of-reported-cases2026-10-06 https://evidence-hub.com/study/1769-therapeutic-drug-monitoring-of-antimicrobials-in-critically-ill-obese2026-10-06 https://evidence-hub.com/study/1770-early-phase-adverse-effects-and-management-of-liposomal-amikacin2026-10-06 https://evidence-hub.com/study/1771-polymyxin-b-in-the-treatment-of-infections-caused-by-multidrug2026-10-06 https://evidence-hub.com/study/1772-treatment-of-non-tuberculosis-mycobacteria-skin-infections2026-10-06 https://evidence-hub.com/study/1773-overcoming-stenotrophomonas-maltophilia-resistance-for-a-more2026-10-08 https://evidence-hub.com/study/1774-tolterodine-warfarin-drug-interaction2026-10-06 https://evidence-hub.com/study/1775-cephalosporin-induced-hemolytic-anemia-a-case-study2026-10-06 https://evidence-hub.com/study/1776-delayed-presentation-of-vincristine-extravasation2026-10-06 https://evidence-hub.com/study/1777-allopurinol-induced-sweet-s-syndrome2026-10-06 https://evidence-hub.com/study/1778-confusion-caused-by-dietary-supplement-lithium-orotate2026-10-06 https://evidence-hub.com/study/1779-rifampin-associated-pseudomembranous-colitis2026-10-06 https://evidence-hub.com/study/1780-penicillin-and-third-generation-cephalosporin-resistant-strains-of2026-10-08 https://evidence-hub.com/study/1781-a-case-of-vagococcus-fluvialis-isolated-from-the-bile-of-a-patient2026-10-06 https://evidence-hub.com/study/1782-metronidazole-induced-bullous-pemphigoid-a-case-report2026-10-06 https://evidence-hub.com/study/1783-antimicrobial-associated-acute-hepatitis2026-10-06 https://evidence-hub.com/study/1784-the-first-case-of-escherichia-fergusonii-with-biofilm-in-china-and2026-10-06 https://evidence-hub.com/study/1785-antibiotic-induced-black-hairy-tongue-two-case-reports-and-a-review2026-10-06 https://evidence-hub.com/study/1786-a-case-report-of-herpes-zoster-ophthalmicus-and-meningitis-after2026-10-08 https://evidence-hub.com/study/1787-disseminated-ureaplasma-polyarthritis-in-a-renal-transplant-recipient2026-10-06 https://evidence-hub.com/study/1788-pythium-insidiosum-an-emerging-pathogen-that-is-easily-misdiagnosed2026-10-06 https://evidence-hub.com/study/1789-investigation-of-the-rapid-emergence-of-colistin-resistance-in-a2026-10-08 https://evidence-hub.com/study/1790-acute-achille-tendon-rupture-after-treatment-of-levofloxacin-for2026-10-06 https://evidence-hub.com/study/1791-fatal-hypoglycemia-associated-with-levofloxacin2026-10-08 https://evidence-hub.com/study/1792-aztreonam-avibactam-therapy-following-surgical-source-control-for-bla2026-10-13 https://evidence-hub.com/study/1793-therapeutic-challenges-in-managing-stenotrophomonas-maltophilia2026-10-06 https://evidence-hub.com/study/1794-therapeutic-role-of-fluconazole-in-immunocompetent-patients-with2026-10-06 https://evidence-hub.com/study/1795-emayella-augustorita-new-member-of-pasteurellaceae-isolated-from2026-10-06 https://evidence-hub.com/study/1796-successful-treatment-of-carbapenem-resistant-acinetobacter-baumannii2026-10-08 https://evidence-hub.com/study/1797-one-rare-warfarin-resistance-case-and-possible-mechanism-exploration2026-10-06 https://evidence-hub.com/study/1798-meropenem-continuous-infusion-in-a-septic-patient-with-periprosthetic2026-10-06 https://evidence-hub.com/study/1799-spectacular-improvement-of-paradoxical-reaction-in-tuberculosis-after2026-10-06 https://evidence-hub.com/study/1800-case-report-synergistic-central-nervous-system-depression-of-baclofen2026-10-06 https://evidence-hub.com/study/1801-case-report-successful-treatment-of-oxa-23-acinetobacter-baumannii2026-10-06 https://evidence-hub.com/study/1802-haematospirillum-jordaniae-cellulitis-and-bacteremia2026-10-06 https://evidence-hub.com/study/1803-vacuum-assisted-closure-therapy-following-mesh-removal-due-to2026-10-13 https://evidence-hub.com/study/1804-disseminated-organ-and-tissue-infection-secondary-to-carbapenem2026-10-06 https://evidence-hub.com/study/1805-phage-therapy-in-a-lung-transplant-recipient-with-cystic-fibrosis2026-10-06 https://evidence-hub.com/study/1806-the-dilemma-of-antibiotic-susceptibility-and-clinical-decision-making2026-10-06 https://evidence-hub.com/study/1807-case-report-persistent-drug-resistant-pseudomonas-aeruginosa2026-10-06 https://evidence-hub.com/study/1808-interstitial-inflammation-and-pulmonary-fibrosis-in-covid-19-the2026-10-06 https://evidence-hub.com/study/1809-treatment-optimization-by-monitoring-vancomycin-concentration-in-the2026-10-06 https://evidence-hub.com/study/1810-therapeutic-drug-monitoring-of-levoffoxacin-in-an-obese-adolescent-a2026-10-06 https://evidence-hub.com/study/1811-intrathecal-or-intraventricular-tigecycline-therapy-for-central2026-10-06 https://evidence-hub.com/study/1812-successful-application-of-argatroban-during-vv-ecmo-in-a-pregnant2026-10-06 https://evidence-hub.com/study/1813-characterization-of-a-rare-bla-vim-4-metallo-lactamase-producing2026-10-06 https://evidence-hub.com/study/1814-successful-use-of-octreotide-therapy-for-refractory-levofloxacin2026-10-08 https://evidence-hub.com/study/1815-elizabethkingia-miricola-as-an-opportunistic-oral-pathogen-associated2026-10-06 https://evidence-hub.com/study/1816-campylobacter-insulaenigrae-bacteremia-with-meningitis-a-case-report2026-10-06 https://evidence-hub.com/study/1817-case-series-of-the-first-three-severe-covid-19-patients-treated-with2026-10-06 https://evidence-hub.com/study/1818-azithromycin-a-promising-treatment-option-for-mycobacterium-avium2026-10-06 https://evidence-hub.com/study/1819-conquering-the-pneumococcal-nemesis-with-oral-antibiotics2026-10-06 https://evidence-hub.com/study/1820-intrathecal-injection-of-tigecycline-and-polymyxin-b-in-the-treatment2026-10-06 https://evidence-hub.com/study/1821-rare-elizabethkingia-anophelis-meningitis-case-in-a-danish-male2026-10-06 https://evidence-hub.com/study/1822-clarithromycin-and-glipizide-drug-drug-interaction-leading-to2026-10-06 https://evidence-hub.com/study/1823-a-dutch-case-report-of-successful-treatment-of-chronic-relapsing2026-10-13 https://evidence-hub.com/study/1824-acute-respiratory-distress-syndrome-complicated-by-amiodarone-induced2026-10-06 https://evidence-hub.com/study/1825-clinafloxacin-for-treatment-of-burkholderia-cenocepacia-infection-in2026-10-06 https://evidence-hub.com/study/1826-polymyxin-combination-therapy-and-the-use-of-serum-bactericidal2026-10-06 https://evidence-hub.com/study/1827-descending-necrotizing-mediastinitis-associated-with-lactobacillus2026-10-06 https://evidence-hub.com/study/1828-moxifloxacin-warfarin-interaction2026-10-06 https://evidence-hub.com/study/1829-emergence-of-high-level-daptomycin-resistance-in-corynebacterium2026-10-06 https://evidence-hub.com/study/1830-an-outbreak-of-yersinia-enterocolitica-in-a-captive-colony-of-african2026-10-06 https://evidence-hub.com/study/1831-high-dose-continuous-infusion-beta-lactam-antibiotics-for-the2026-10-06 https://evidence-hub.com/study/1832-evaluation-of-endocarditis-caused-by-methicillin-susceptible2026-10-06 https://evidence-hub.com/study/1833-treatment-of-drug-resistant-tuberculosis-an-official-ats-cdc-ers-idsa2026-10-08 https://evidence-hub.com/study/1834-guidelines-for-the-management-of-adult-lower-respiratory-tract2026-10-13 https://evidence-hub.com/study/1835-the-2018-lebanese-society-of-infectious-diseases-and-clinical2026-10-13 https://evidence-hub.com/study/1836-antimicrobial-therapy-for-acute-cholecystitis-tokyo-guidelines2026-10-08 https://evidence-hub.com/study/1837-ventilator-associated-pneumonia-diagnosis-treatment-and-prevention2026-10-13 https://evidence-hub.com/study/1838-antimicrobial-therapy-for-acute-cholangitis-tokyo-guidelines2026-10-08 https://evidence-hub.com/study/1839-sexually-transmitted-diseases-treatment-guidelines-20152026-10-13 https://evidence-hub.com/study/1840-recommendation-of-antimicrobial-dosing-optimization-during-continuous2026-10-06 https://evidence-hub.com/study/1841-how-do-i-manage-a-patient-with-stenotrophomonas-maltophilia-infection2026-10-08 https://evidence-hub.com/study/1842-treatment-approaches-for-severe-stenotrophomonas-maltophilia2026-10-06 https://evidence-hub.com/study/1843-bacteroides-the-good-the-bad-and-the-nitty-gritty2026-10-06 https://evidence-hub.com/study/1844-revisiting-systemic-treatment-of-bacterial-endophthalmitis-a-review2026-10-01 https://evidence-hub.com/study/1845-current-management-strategies-for-stenotrophomonas-maltophilia2026-10-06 https://evidence-hub.com/study/1846-fluoroquinolones-blessings-or-curses2026-10-20 https://evidence-hub.com/study/1847-management-of-helicobacter-pylori2026-10-06 https://evidence-hub.com/study/1848-helicobacter-pylori-management-in-20132026-10-06 https://evidence-hub.com/study/1849-remdesivir-covid-19-drug-interactions-in-dentistry2026-10-06 https://evidence-hub.com/study/1850-attempts-to-enhance-the-eradication-rate-of-helicobacter-pylori2026-10-06 https://evidence-hub.com/study/1851-management-of-complex-tuberculosis-cases-a-focus-on-drug-resistant2026-10-06 https://evidence-hub.com/study/1852-what-is-the-clinical-significance-of-heteroresistance-in2026-10-06 https://evidence-hub.com/study/1853-sitafloxacin-in-bacterial-infections2026-10-20 https://evidence-hub.com/study/1854-sitafloxacin-hydrate-for-bacterial-infections2026-10-13 https://evidence-hub.com/study/1855-new-drugs-for-gram-positive-uropathogens2026-10-20 https://evidence-hub.com/study/1856-a-review-of-fluoroquinolones-with-a-focus-on-veterinary-approved2026-10-13 https://evidence-hub.com/study/1857-cefepime-enmetazobactam-for-complicated-urinary-tract-infections2026-10-13 https://evidence-hub.com/study/1858-old-drugs-new-weapons-current-trends-in-repurposing-therapies-against2026-10-06 https://evidence-hub.com/study/1859-drug-drug-interactions-in-recently-approved-antibacterials-a-mini2026-10-13 https://evidence-hub.com/study/1860-hplc-and-ce-procedures-for-the-determination-of-fluoroquinolones-20202026-10-06 https://evidence-hub.com/study/1861-operational-considerations-of-select-new-treatment-recommendations2026-10-06 https://evidence-hub.com/study/1862-stimuli-responsive-nasal-in-situ-gel-drug-delivery-systems-from2026-10-06 https://evidence-hub.com/study/1863-antimicrobial-pharmacokinetic-and-pharmacodynamic-considerations-in2026-10-06 https://evidence-hub.com/study/1864-discovery-and-development-of-voxvoganan-first-in-class-synthetic2026-10-06 https://evidence-hub.com/study/1865-sepsis-in-frail-older-adults-tailored-antimicrobial-stewardship-and2026-10-13 https://evidence-hub.com/study/1866-interaction-of-drug-molecules-with-surfactants-below-benesi2026-10-06 https://evidence-hub.com/study/1867-drug-transporters-and-metabolizing-enzymes-in-antimicrobial-drug2026-10-06 https://evidence-hub.com/study/1868-simulating-the-host-niche-balancing-complexity-and-control-in-the2026-10-06 https://evidence-hub.com/study/1869-hybrid-and-conjugated-antimicrobial-peptides-new-tactics-to-counter2026-10-06 https://evidence-hub.com/study/1870-addressing-challenges-in-standardizing-helicobacter-pylori-treatment2026-10-06 https://evidence-hub.com/study/1871-antibiotics-and-other-drugs-removal-by-the-cytosorb-haemoadsorber-a2026-10-06 https://evidence-hub.com/study/1872-gut-check-antimicrobial-stewardship-opportunities-in-intra-abdominal2026-10-13 https://evidence-hub.com/study/1873-the-effectiveness-of-intravenous-iv-to-oral-po-antibiotic-switch-ivos2026-10-20 https://evidence-hub.com/study/1874-the-progress-of-tuberculous-meningitis-medical-management-in-adults2026-10-06 https://evidence-hub.com/study/1875-probiotics-and-antibiotics-from-empirical-practice-to-a-biological2026-10-06 https://evidence-hub.com/study/1876-acute-myeloid-leukemia-drug-resistance-targetable-nodes-and-the2026-10-06 https://evidence-hub.com/study/1877-antimicrobial-dosing-considerations-in-critically-ill-patients-with2026-10-06 https://evidence-hub.com/study/1878-meropenem-use-and-challenges-in-treating-severe-infections-in2026-10-13 https://evidence-hub.com/study/1879-efflux-mediated-resistance-in-enterobacteriaceae-recent-advances-and2026-10-06 https://evidence-hub.com/study/1880-tuberculosis-in-pregnant-women-after-covid-19-features-of-prevention2026-10-06 https://evidence-hub.com/study/1881-fluoroquinolones-and-biofilm-a-narrative-review2026-10-08 https://evidence-hub.com/study/1882-preclinical-pharmacokinetics-and-pharmacodynamics-of-antibiotic2026-10-08 https://evidence-hub.com/study/1884-the-effects-of-major-burn-related-pathophysiological-changes-on-the2026-10-01 https://evidence-hub.com/study/1885-considerations-for-effect-site-pharmacokinetics-to-estimate-drug2026-10-08 https://evidence-hub.com/study/1886-optimal-dosing-of-antibiotics-in-critically-ill-patients-by-using2026-10-01 https://evidence-hub.com/study/1889-anti-tuberculosis-treatment-strategies-and-drug-development2026-10-03 https://evidence-hub.com/study/1890-inhaled-anti-infective-chemotherapy-for-respiratory-tract-infections2026-10-01 https://evidence-hub.com/study/1891-pharmacologically-active-compounds-in-the-environment-and-their2026-10-01 https://evidence-hub.com/study/1892-systematic-review-and-meta-analysis-of-in-vitro-efficacy-of2026-10-08 https://evidence-hub.com/study/1893-oral-decontamination-for-prevention-of-pneumonia-in-mechanically2026-10-08 https://evidence-hub.com/study/1895-systematic-review-and-meta-analysis-of-in-vitro-synergy-of-polymyxins2026-10-01 https://evidence-hub.com/study/1896-efficacy-and-safety-of-tigecycline-a-systematic-review-and-meta2026-10-08 https://evidence-hub.com/study/1900-artificial-intelligence-to-close-the-gap-between-pharmacokinetic2026-10-05 https://evidence-hub.com/study/1902-heterogeneity-in-tuberculosis-pathology-microenvironments-and2026-10-01 https://evidence-hub.com/study/1903-renal-transporters-in-drug-development2026-10-01 https://evidence-hub.com/study/1904-oral-fluoroquinolone-or-trimethoprim-sulfamethoxazole-vs-lactams-as2026-10-01 https://evidence-hub.com/study/1905-the-use-of-antibiotics-and-antimicrobial-resistance-in-veterinary2026-10-01 https://evidence-hub.com/study/1906-a-systematic-review-of-the-definitions-determinants-and-clinical2026-10-01 https://evidence-hub.com/study/1907-tigecycline-for-the-treatment-of-multidrug-resistant2026-10-01 https://evidence-hub.com/study/1908-development-of-new-tuberculosis-drugs-translation-to-regimen2026-10-01 https://evidence-hub.com/study/1909-bacteriostatic-versus-bactericidal-antibiotics-for-patients-with2026-10-08 https://evidence-hub.com/study/1910-model-informed-precision-dosing-of-antibiotics-in-pediatric-patients2026-10-01 https://evidence-hub.com/study/1911-tuberculosis-and-pharmacological-interactions-a-narrative-review2026-10-01 https://evidence-hub.com/study/1912-fosfomycin-as-partner-drug-for-systemic-infection-management-a2026-10-01 https://evidence-hub.com/study/1913-stenotrophomonas-maltophilia-in-people-with-cystic-fibrosis-a2026-10-01 https://evidence-hub.com/study/1914-tissue-penetration-of-antimicrobials-in-intensive-care-unit-patients2026-10-01 https://evidence-hub.com/study/1916-dynamic-balance-of-pro-and-anti-inflammatory-signals-controls-disease2026-10-01 https://evidence-hub.com/study/1917-targeted-detection-of-helicobacter-pylori-resistance-to2026-10-06 https://evidence-hub.com/study/1918-antimicrobial-resistance-of-helicobacter-pylori-in-an-eastern-german2026-10-06 https://evidence-hub.com/study/1919-resistance-reversal-taiwan-s-helicobacter-pylori-trends-defy-global2026-10-06 https://evidence-hub.com/study/1920-multiclonal-emergence-of-levofloxacin-resistant-group-b-streptococcus2026-10-06 https://evidence-hub.com/study/1921-carbapenem-containing-combination-antibiotic-therapy-against2026-10-20 https://evidence-hub.com/study/1922-looking-for-stenotrophomonas-maltophilia-treatment-in-vitro-activity2026-10-06 https://evidence-hub.com/study/1923-levofloxacin-and-trovafloxacin-the-next-generation-of-fluoroquinolones2026-10-19 https://evidence-hub.com/study/1924-in-vivo-emergence-of-dual-resistance-to-rifampin-and-levofloxacin-in2026-10-08 https://evidence-hub.com/study/1925-evaluation-of-mycobacterium-tuberculosis-cross-resistance-to2026-10-06 https://evidence-hub.com/study/1926-study-on-the-mechanism-of-levofloxacin-combined-with-imipenem-against2026-10-08 https://evidence-hub.com/study/1927-the-role-of-sulopenem-in-the-treatment-of-uncomplicated-urinary-tract2026-10-13 https://evidence-hub.com/study/1928-aerosolized-delivery-of-eskape-pathogens-for-murine-pneumonia-models2026-10-08 https://evidence-hub.com/study/1929-beyond-antibiotics-repurposing-non-antibiotic-drugs-as-novel2026-10-13 https://evidence-hub.com/study/1930-phage-therapy-breathing-new-tactics-into-lower-respiratory-tract2026-10-08 https://evidence-hub.com/study/1931-antibiotic-loaded-ultrahigh-molecular-weight-polyethylenes2026-10-06 https://evidence-hub.com/study/1932-discovery-and-development-of-a-new-oxazolidinone-with-reduced2026-10-06 https://evidence-hub.com/study/1933-mathematical-models-of-ocular-drug-delivery2026-10-03 https://evidence-hub.com/study/1934-recent-advances-in-electric-stimulus-assisted-microneedle-patches-for2026-10-06 https://evidence-hub.com/study/1935-concise-clinical-review-of-hematologic-toxicity-of-linezolid-in2026-10-06 https://evidence-hub.com/study/1936-the-challenges-and-strategies-for-navigating-in-vivo-barriers-to2026-10-08 https://evidence-hub.com/study/1937-development-of-a-natural-product-optimization-strategy-for-inhibitors2026-10-06 https://evidence-hub.com/study/1938-rising-role-of-3d-printing-in-delivery-of-therapeutics-for-infectious2026-10-06 https://evidence-hub.com/study/1939-advances-in-3d-printed-drug-delivery-and-screening-platforms-for-bone2026-10-06 https://evidence-hub.com/study/1940-the-relationship-among-intestinal-bacteria-vitamin-k-and-response-of2026-10-06 https://evidence-hub.com/study/1941-antimicrobial-therapeutic-drug-monitoring-in-critically-ill-adult2026-10-01 https://evidence-hub.com/study/1942-nanoparticle-mediated-pulmonary-drug-delivery-state-of-the-art2026-10-06 https://evidence-hub.com/study/1943-a-review-of-moxifloxacin-for-the-treatment-of-drug-susceptible2026-10-06 https://evidence-hub.com/study/1944-inhalable-nanoparticle-based-dry-powder-formulations-for-respiratory2026-10-01 https://evidence-hub.com/study/1945-advancement-in-nanocarrier-mediated-delivery-of-herbal-bioactives2026-10-06 https://evidence-hub.com/study/1946-liposomal-drug-delivery-to-manage-nontuberculous-mycobacterial2026-10-06 https://evidence-hub.com/study/1947-advances-in-antibiotic-therapy-in-the-critically-ill2026-10-01 https://evidence-hub.com/study/1948-a-novel-approach-to-pharmacodynamic-assessment-of-antimicrobial2026-10-06 https://evidence-hub.com/study/1949-simulated-comparison-of-the-pharmacodynamics-of-ciprofloxacin-and2026-10-06 https://evidence-hub.com/study/1950-characterizing-the-immune-response-to-mycobacterium-tuberculosis-a2026-10-06 https://evidence-hub.com/study/1951-hydrogels-as-drug-delivery-systems-a-review-of-current2026-10-06 https://evidence-hub.com/study/1952-considerations-and-caveats-in-combating-eskape-pathogens-against2026-10-06 https://evidence-hub.com/study/1953-a-comprehensive-atlas-of-immunological-differences-between-humans2026-10-06 https://evidence-hub.com/study/1954-pulmonary-infections-complicating-ards2026-10-06 https://evidence-hub.com/study/1955-clinical-experimentation-with-aerosol-antibiotics-current-and-future2026-10-06 https://evidence-hub.com/study/1956-nanomedicine-fight-against-antibacterial-resistance-an-overview-of2026-10-06 https://evidence-hub.com/study/1957-besifloxacin-ophthalmic-suspension-emerging-evidence-of-its2026-10-06 https://evidence-hub.com/study/1958-evaluation-of-immunocompetent-urinary-tract-infected-balb-c-mouse2026-10-13 https://evidence-hub.com/study/1960-comparison-of-gatifloxacin-and-levofloxacin-administered-at-various2026-10-04 https://evidence-hub.com/study/1961-in-vitro-antibacterial-activity-and-pharmacodynamics-of-new-quinolones2026-10-20 https://evidence-hub.com/study/1962-urinary-pharmacokinetics-and-theoretical-pharmacodynamics-of2026-10-08 https://evidence-hub.com/study/1963-pharmacokinetic-and-pharmacodynamic-properties-of-meropenem2026-10-01 https://evidence-hub.com/study/1964-pharmacokinetic-pharmacodynamic-relationships-of-antimicrobial-drugs2026-10-01 https://evidence-hub.com/study/1965-pharmacodynamics-of-finafloxacin-ciprofloxacin-and-levofloxacin-in2026-10-20 https://evidence-hub.com/study/1966-applying-pharmacokinetic-pharmacodynamic-principles-in-critically-ill2026-10-01 https://evidence-hub.com/study/1967-the-pharmacokinetic-and-pharmacodynamic-profile-of-tigecycline2026-10-01 https://evidence-hub.com/study/1968-infectious-diseases-society-of-america-american-thoracic-society2026-10-03 https://evidence-hub.com/study/1970-management-of-adults-with-hospital-acquired-and-ventilator-associated2026-10-13 https://evidence-hub.com/study/1971-pharmacokinetic-and-pharmacodynamic-implications-of-p-glycoprotein2026-10-01 https://evidence-hub.com/study/1974-photohaptenic-properties-of-fluoroquinolones2026-10-06 https://evidence-hub.com/study/1975-characterization-and-antimicrobial-resistance-of-campylobacter-jejuni2026-10-06 https://evidence-hub.com/study/1976-distribution-of-antimicrobial-resistance-among-different-serovars-of2026-10-06 https://evidence-hub.com/study/1977-antibacterial-tyrosinase-and-dna-photocleavage-studies-of-some2026-10-06 https://evidence-hub.com/study/1978-in-vitro-and-in-vivo-efficacies-of-t-3811me-bms-284756-against2026-10-20 https://evidence-hub.com/study/1979-d-cycloserine-increases-the-effectiveness-of-vancomycin-against2026-10-06 https://evidence-hub.com/study/1980-spermine-conjugated-short-proline-rich-lipopeptides-as-broad-spectrum2026-10-06 https://evidence-hub.com/study/1981-levofloxacin-activity-at-increasing-doses-in-a-murine-model-of2026-10-08 https://evidence-hub.com/study/1982-in-vitro-pharmacodynamics-of-nemonoxacin-and-other-antimicrobial2026-10-06 https://evidence-hub.com/study/1984-correlation-between-in-vitro-and-in-vivo-activity-of-levofloxacin-and2026-10-08 https://evidence-hub.com/study/1985-testing-the-mutant-selection-window-hypothesis-with-escherichia-coli2026-10-08 https://evidence-hub.com/study/1987-a-therapeutic-delivery-system-for-chronic-osteomyelitis-via-a-multi2026-10-08 https://evidence-hub.com/study/1989-in-vivo-efficacy-of-humanized-high-dose-meropenem-and-comparators2026-10-06 https://evidence-hub.com/study/1993-antimicrobial-breakpoints-for-gram-negative-aerobic-bacteria-based-on2026-10-01 https://evidence-hub.com/study/1994-pharmacodynamic-parameters-of-pharmacokinetic-pharmacodynamic-pk-pd2026-10-01 https://evidence-hub.com/study/1995-pharmacodynamic-profile-of-daptomycin-against-enterococcus-species2026-09-26 https://evidence-hub.com/study/1996-importance-of-the-multidrug-and-toxin-extrusion-mate-slc47a-family-to2026-10-01 https://evidence-hub.com/study/1997-clinical-implications-of-pharmacokinetics-and-pharmacodynamics-of2026-10-01 https://evidence-hub.com/study/1998-pharmacodynamic-modeling-of-anti-cancer-activity-of2026-09-26 https://evidence-hub.com/study/1999-pharmacodynamics-of-fluoroquinolones2026-09-26 https://evidence-hub.com/study/2000-synergistic-killing-of-multidrug-resistant-pseudomonas-aeruginosa-at2026-10-01 https://evidence-hub.com/study/2001-the-hollow-fiber-infection-model-for-antimicrobial-pharmacodynamics2026-10-01 https://evidence-hub.com/study/2002-levofloxacin-pharmacodynamics-against-stenotrophomonas-maltophilia-in2026-10-08 https://evidence-hub.com/study/2003-integrating-pharmacokinetics-and-pharmacodynamics-in-operational2026-10-01 https://evidence-hub.com/study/2004-amikacin-pharmacokinetics-pharmacodynamics-in-a-novel-hollow-fiber2026-10-01 https://evidence-hub.com/study/2005-pharmacokinetics-and-pharmacodynamics-of-intranasal-solid-lipid2026-10-01 https://evidence-hub.com/study/2006-double-blind-evaluation-of-the-safety-and-pharmacokinetics-of2026-10-08 https://evidence-hub.com/study/2007-pharmacokinetics-urinary-excretion-and-milk-penetration-of2026-10-13 https://evidence-hub.com/study/2019-eye-drops-and-eye-gels-of-levofloxacin-comparison-of-ocular2026-10-06 https://evidence-hub.com/study/2020-ttp7-07-levofloxacin-based-therapy-vs-hybrid-therapy-in-the2026-10-08 https://evidence-hub.com/study/2021-safety-pharmacokinetics-and-preliminary-pharmacodynamics-of-1-and-32026-10-06 https://evidence-hub.com/study/2022-pharmacokinetics-pharmacodynamics-of-benralizumab-in-chronic2026-10-06 https://evidence-hub.com/study/2023-op20-results-from-the-stenova-trial-a-phase-2a-randomized-placebo2026-10-06 https://evidence-hub.com/study/2025-riluzole-in-spinal-cord-injury-study-riscis-pharmacokinetic-pk-sub2026-10-06 https://evidence-hub.com/study/2026-levofloxacin-tetracycline-quadruple-regimen-for-eradication-of2026-10-08 https://evidence-hub.com/study/2027-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-the2026-10-06 https://evidence-hub.com/study/2028-safety-pharmacokinetics-and-pharmacodynamics-of-etavopivat-ft-4202-an2026-10-06 https://evidence-hub.com/study/2029-the-pharmacokinetics-pharmacodynamics-and-tolerability-of-shr6508-in2026-10-06 https://evidence-hub.com/study/2030-safety-pharmacokinetics-and-pharmacodynamics-of-oral-venglustat-in2026-10-06 https://evidence-hub.com/study/2031-pharmacokinetics-pharmacodynamics-safety-and-tolerability-of-ftp-1982026-10-06 https://evidence-hub.com/study/2032-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-bi2026-10-06 https://evidence-hub.com/study/2033-efficacy-and-safety-of-combined-isoniazid-rifampicin-pyrazinamide2026-10-08 https://evidence-hub.com/study/2034-pharmacokinetics-and-pharmacodynamics-of-intranasal-remimazolam-a2026-10-06 https://evidence-hub.com/study/2035-safety-tolerability-pharmacokinetics-pharmacodynamics-and2026-10-06 https://evidence-hub.com/study/2036-epidural-administration-of-ropivacaine-and-its-effects-on-the2026-10-06 https://evidence-hub.com/study/2037-the-effects-of-vilaprisan-on-the-pharmacodynamics-and2026-10-06 https://evidence-hub.com/study/2038-ten-day-quadruple-therapy-comprising-proton-pump-inhibitor-bismuth2026-10-08 https://evidence-hub.com/study/2039-design-of-conquest-a-novel-randomized-placebo-controlled-phase-2b2026-10-06 https://evidence-hub.com/study/2041-lack-of-improvement-after-short-term-topical-antistaphylococcal2026-10-06 https://evidence-hub.com/study/2042-randomized-placebo-controlled-phase-i-trial-of-safety2026-10-06 https://evidence-hub.com/study/2043-azd8630-amg-104-an-inhaled-anti-thymic-stromal-lymphopoietin-antibody2026-10-06 https://evidence-hub.com/study/2044-first-in-human-phase-1-randomized-double-blind-placebo-controlled2026-10-06 https://evidence-hub.com/study/2045-influence-of-morphine-on-pharmacokinetics-and-pharmacodynamics-of2026-10-06 https://evidence-hub.com/study/2046-effect-of-preoperative-prophylactic-antibiotic-use-on-postoperative2026-10-13 https://evidence-hub.com/study/2047-a-phase-3-active-controlled-trial-of-liposomal-bupivacaine-via2026-10-06 https://evidence-hub.com/study/2048-a-randomized-controlled-trial-of-levofloxacin-terazosin-and2026-10-08 https://evidence-hub.com/study/2049-fri0084-safety-pharmacokinetics-pharmacodynamics-immunogenicity-and2026-10-06 https://evidence-hub.com/study/2050-an-all-oral-6-month-regimen-for-multidrug-resistant-tuberculosis-a2026-10-08 https://evidence-hub.com/study/2051-a-phase-3-active-controlled-trial-of-liposomal-bupivacaine-via2026-10-06 https://evidence-hub.com/study/2052-clinical-and-microbiological-effects-of-levofloxacin-in-the-treatment2026-10-08 https://evidence-hub.com/study/2053-safety-pharmacokinetics-and-pharmacodynamics-of-single-and-multiple2026-10-06 https://evidence-hub.com/study/2054-qt-effects-of-bedaquiline-delamanid-or-both-in-patients-with2026-10-08 https://evidence-hub.com/study/2055-efficacy-safety-and-pharmacodynamic-effects-of-the-bruton-s-tyrosine2026-10-06 https://evidence-hub.com/study/2056-cannabidiol-for-functional-dyspepsia-with-normal-gastric-emptying-a2026-10-06 https://evidence-hub.com/study/2058-safety-of-levofloxacin-as-an-antibiotic-prophylaxis-in-the-induction2026-10-08 https://evidence-hub.com/study/2059-development-of-in-vitro-resistance-to-fluoroquinolones-in-pseudomonas2026-10-06 https://evidence-hub.com/study/2060-in-vitro-evaluation-of-antimicrobial-resistance-selection-in2026-10-06 https://evidence-hub.com/study/2061-in-vitro-resistance-selection-in-shigella-flexneri-by-azithromycin2026-10-06 https://evidence-hub.com/study/2062-in-vitro-activity-of-brucella-melitensis-isolates-to-various2026-10-06 https://evidence-hub.com/study/2063-pharmacokinetics-of-levofloxacin-in-japanese-quails-coturnix-japonica2026-10-06 https://evidence-hub.com/study/2064-sitafloxacin-pharmacokinetics-pharmacodynamics-against-multidrug2026-10-20 https://evidence-hub.com/study/2065-aerosolized-delivery-resulting-in-high-polymyxin-b-concentration2026-10-08 https://evidence-hub.com/study/2066-overcoming-the-drug-resistance-barrier-progress-in-fosfomycin2026-10-13 https://evidence-hub.com/study/2067-dual-drug-delivery-systems-using-hydrogel-nanoparticle-composites2026-10-06 https://evidence-hub.com/study/2068-optimizing-pyrazinamide-use-a-low-hanging-fruit-in-improving-outcomes2026-10-06 https://evidence-hub.com/study/2069-advancement-of-nanofibrous-mats-and-common-useful-drug-delivery2026-10-06 https://evidence-hub.com/study/2070-inflammation-responsive-hydrogels-in-perioperative-pain-and-wound2026-10-06 https://evidence-hub.com/study/2071-drug-induced-liver-injury-in-inflammatory-bowel-disease-challenges-in2026-10-06 https://evidence-hub.com/study/2072-deciphering-the-intricate-interplay-in-the-framework-of-antibiotic2026-10-05 https://evidence-hub.com/study/2073-a-literature-review-on-the-impact-of-the-gut-microbiome-on-cancer2026-10-06 https://evidence-hub.com/study/2074-update-in-tuberculosis-treatment-a-scoping-review-of-current-practices2026-10-06 https://evidence-hub.com/study/2075-infant-exposure-to-antituberculosis-drugs-via-breast-milk-and2026-10-08 https://evidence-hub.com/study/2076-microneedles-as-a-promising-technology-for-disease-monitoring-and2026-10-06 https://evidence-hub.com/study/2077-on-demand-drug-delivery-systems-using-nanofibers2026-10-06 https://evidence-hub.com/study/2078-from-genes-to-clinical-management-a-comprehensive-review-of-long-qt2026-10-06 https://evidence-hub.com/study/2079-development-of-an-amoxicillin-radix-scutellaria-extract-formulation2026-10-06 https://evidence-hub.com/study/2080-optimizing-antimicrobial-drug-dosing-in-critically-ill-patients2026-10-01 https://evidence-hub.com/study/2081-comparative-pharmacodynamics-of-moxifloxacin-and-levofloxacin-in-an2026-10-08 https://evidence-hub.com/study/2082-fluoroquinolone-resistance-in-anaerobic-bacteria-following-exposure2026-09-26 https://evidence-hub.com/study/2083-levofloxacin-plus-metronidazole-administered-once-daily-versus2026-09-26 https://evidence-hub.com/study/2084-in-vitro-pharmacodynamic-evaluation-of-the-mutant-selection-window2026-09-26 https://evidence-hub.com/study/2085-linezolid-levofloxacin-and-vancomycin-against-vancomycin-tolerant-and2026-09-30 https://evidence-hub.com/study/2086-in-vitro-pharmacodynamic-activities-of-abt-492-a-novel-quinolone2026-10-04 https://evidence-hub.com/study/2087-comparative-pharmacodynamics-of-the-new-fluoroquinolone-abt492-and2026-10-08 https://evidence-hub.com/study/2088-pharmacodynamics-of-gatifloxacin-against-streptococcus-pneumoniae-in2026-10-01 https://evidence-hub.com/study/2089-in-vitro-pharmacodynamic-activity-of-gatifloxacin-gemifloxacin2026-09-30 https://evidence-hub.com/study/2090-efficacy-of-high-doses-of-levofloxacin-in-experimental-foreign-body2026-09-26 https://evidence-hub.com/study/2091-computational-and-preclinical-prediction-of-the-antimicrobial2026-10-08 https://evidence-hub.com/study/2092-quinic-acid-a-potential-antibiofilm-agent-against-clinical-resistant2026-10-08 https://evidence-hub.com/study/2093-pharmacodynamic-evaluation-of-i-v-antimicrobials-against-pseudomonas2026-10-08 https://evidence-hub.com/study/2094-discovery-of-psoralen-as-a-quorum-sensing-inhibitor-suppresses2026-10-04 https://evidence-hub.com/study/2095-structural-and-functional-analysis-of-the-promiscuous-acrb-and-adeb2026-10-08 https://evidence-hub.com/study/2096-pharmacokinetic-considerations-and-efficacy-of-levofloxacin-in-an2026-10-08 https://evidence-hub.com/study/2097-discovery-of-fda-approved-drugs-as-inhibitors-of-fatty-acid-binding2026-10-08 https://evidence-hub.com/study/2098-new-potential-pharmacological-targets-of-plant-derived2026-10-08 https://evidence-hub.com/study/2099-8-octyl-berberine-combats-staphylococcus-aureus-by-preventing2026-10-08 https://evidence-hub.com/study/2100-enhancing-antibacterial-efficacy-through-macrocyclic-host2026-10-08 https://evidence-hub.com/study/2101-insights-into-the-evolutionary-trajectories-of-fluoroquinolone2026-10-08 https://evidence-hub.com/study/2102-in-silico-screening-and-analysis-of-broad-spectrum-molecular-targets2026-10-06 https://evidence-hub.com/study/2103-oleocanthal-as-a-multifunctional-anti-cancer-agent-mechanistic2026-10-06 https://evidence-hub.com/study/2104-pharmacokinetics-pharmacodynamics-and-dose-optimization-of2026-10-01 https://evidence-hub.com/study/2105-pharmacokinetics-and-pharmacodynamics-of-anti-tuberculosis-drugs-an2026-10-01 https://evidence-hub.com/study/2106-a-standardised-method-for-interpreting-the-association-between2026-10-08 https://evidence-hub.com/study/2107-pharmacokinetic-aspects-of-retinal-drug-delivery2026-10-01 https://evidence-hub.com/study/2108-prediction-of-the-pharmacokinetics-and-pharmacodynamics-of2026-10-01 https://evidence-hub.com/study/2109-preclinical-pharmacokinetic-pharmacodynamic-studies-and-clinical2026-10-01 https://evidence-hub.com/study/2110-capsaicin-a-novel-inhibitor-of-the-nora-efflux-pump-reduces-the2026-10-01 https://evidence-hub.com/study/2111-development-of-computational-in-silico-model-for-nano-lipid-carrier2026-10-01 https://evidence-hub.com/study/2112-deposition-of-inhaled-levofloxacin-in-cystic-fibrosis-lungs-assessed2026-10-08 https://evidence-hub.com/study/2113-inclusion-of-a-phytomedicinal-flavonoid-in-biocompatible-surface2026-10-01 https://evidence-hub.com/study/2114-amphotericin-b-and-levofloxacin-loaded-chitosan-films-for-potential2026-10-08 https://evidence-hub.com/study/2115-population-pharmacokinetics-and-bayesian-dose-adjustment-to-advance2026-10-01 https://evidence-hub.com/study/2116-results-from-the-survey-of-antibiotic-resistance-soar-2015-17-in2026-10-01 https://evidence-hub.com/study/2117-comprehensive-pharmacokinetic-evaluation-of-high-melanin-binder2026-10-08 https://evidence-hub.com/study/2118-experimental-dft-molecular-docking-and-in-silico-admet-studies-of2026-10-01 https://evidence-hub.com/study/2119-harnessing-hybrid-niosomes-for-improved-oral-bioavailability-of-an2026-10-01 https://evidence-hub.com/study/2120-results-from-the-survey-of-antibiotic-resistance-soar-2016-18-in2026-10-01 https://evidence-hub.com/study/2121-detection-of-drug-drug-interactions-by-modeling-interaction-profile2026-10-01 https://evidence-hub.com/study/2122-leveraging-in-silico-and-artificial-intelligence-models-to-advance2026-10-05 https://evidence-hub.com/study/2123-the-role-of-pk-pd-analysis-in-the-development-and-evaluation-of2026-10-01 https://evidence-hub.com/study/2125-from-therapeutic-drug-monitoring-to-model-informed-precision-dosing2026-10-03 https://evidence-hub.com/study/2126-discovery-of-potent-selective-multidrug-and-toxin-extrusion2026-10-01 https://evidence-hub.com/study/2127-fluoroquinolone-antimicrobial-agent-levofloxacin-in-veterinary2026-10-13 https://evidence-hub.com/study/2128-escaping-eskape-resistance-in-vitro-and-in-silico-studies-of2026-10-08 https://evidence-hub.com/study/2129-comparison-of-the-in-vitro-antibacterial-activity-of-ofloxacin2026-10-13 https://evidence-hub.com/study/2130-fluoroquinolone-analogs-sar-analysis-and-the-antimicrobial-evaluation2026-10-01 https://evidence-hub.com/study/2131-halogenated-antimicrobial-agents-to-combat-drug-resistant-pathogens2026-10-01 https://evidence-hub.com/study/2132-development-of-an-antibiotic-resistance-breaker-to-resensitize-drug2026-10-01 https://evidence-hub.com/study/2133-the-effect-of-levofloxacin-addition-on-the-outcome-of-tuberculous2026-10-08 https://evidence-hub.com/study/2134-fluoroquinolone-resistance-in-escherichia-coli-causing-community2026-10-20 https://evidence-hub.com/study/2135-association-between-fluoroquinolones-and-major-adverse-cardiovascular2026-10-08 https://evidence-hub.com/study/2136-antimicrobial-resistance-pattern-of-moraxella-catarrhalis-and2026-10-08 https://evidence-hub.com/study/2137-achilles-tendon-complications-of-fluoroquinolone-treatment-a-molecule2026-10-13 https://evidence-hub.com/study/2138-the-efficacy-and-safety-of-vonoprazan-and-amoxicillin-dual-therapy2026-10-08 https://evidence-hub.com/study/2139-evaluation-of-genetic-mutations-associated-with-phenotypic-resistance2026-10-08 https://evidence-hub.com/study/2140-the-efficacy-and-safety-of-ceftolozane-tazobactam-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/2141-comparative-efficacy-and-safety-of-antibacterial-regimens-for-severe2026-10-08 https://evidence-hub.com/study/2142-the-emergence-of-multidrug-resistant-helicobacter-pylori-in-southeast2026-10-08 https://evidence-hub.com/study/2143-systematic-review-and-meta-analysis-on-the-frequency-of-antibiotic2026-10-08 https://evidence-hub.com/study/2144-clinical-and-microbiological-efficacy-of-adjunctive-systemic2026-10-08 https://evidence-hub.com/study/2145-antibiotic-resistance-pattern-of-pseudomonas-aeruginosa-wound2026-10-08 https://evidence-hub.com/study/2146-helicobacter-pylori-eradication-following-first-line-treatment2026-10-08 https://evidence-hub.com/study/2147-effect-of-ciprofloxacin-levofloxacin-and-ofloxacin-on-pseudomonas2026-10-08 https://evidence-hub.com/study/2148-risk-for-hypoglycemic-emergency-with-levofloxacin-use-a-population2026-10-08 https://evidence-hub.com/study/2149-risk-factors-for-levofloxacin-nonsusceptible-streptococcus-pneumoniae2026-10-08 https://evidence-hub.com/study/2150-helicobacter-pylori-infection-in-migraine-patients-a-case-control2026-10-08 https://evidence-hub.com/study/2155-risk-factors-for-ambulatory-urinary-tract-infections-caused-by-high2026-10-13 https://evidence-hub.com/study/2156-a-case-of-legionella-pneumonia-complicated-by-pneumatoceles-and2026-10-08 https://evidence-hub.com/study/2157-vaginal-cuff-infection-caused-by-ureaplasma-parvum-after-hysterectomy2026-10-08 https://evidence-hub.com/study/2158-levofloxacin-and-amikacin-adsorption-on-nanodiamonds-mechanism-and2026-10-08 https://evidence-hub.com/study/2159-uropathogenic-pan-drug-resistant-providencia-rettgeri-infection-in-a2026-10-20 https://evidence-hub.com/study/2160-emergence-of-concurrent-levofloxacin-and-trimethoprim2026-10-08 https://evidence-hub.com/study/2161-first-case-of-persistent-stenotrophomonas-maltophilia-bacteremia-due2026-10-08 https://evidence-hub.com/study/2163-levofloxacin-resistant-stenotrophomonas-maltophilia-risk-factors-and2026-10-08 https://evidence-hub.com/study/2167-risk-factors-for-community-onset-pneumonia-caused-by-levofloxacin2026-10-08 https://evidence-hub.com/study/2169-case-report-bilateral-peritonsillar-abscess-with-complications-of2026-10-08 https://evidence-hub.com/study/2170-comparison-of-levofloxacin-versus-clarithromycin-efficacy-in-the2026-10-08 https://evidence-hub.com/study/2175-a-large-outbreak-of-clostridium-difficile-associated-disease-with-an2026-10-08 https://evidence-hub.com/study/2177-description-clinical-impact-and-early-outcome-of-s-maltophilia2026-10-08 https://evidence-hub.com/study/2182-outpatient-gatifloxacin-therapy-and-dysglycemia-in-older-adults2026-10-08 https://evidence-hub.com/study/2184-real-world-multicenter-evaluation-of-the-incidence-and-risk-factors2026-10-08 https://evidence-hub.com/study/2186-curative-efficacy-analysis-of-levofloxacin-injection-in-urinary2026-10-13 https://evidence-hub.com/study/2188-outbreak-of-clostridium-difficile-infection-in-a-long-term-care2026-10-08 https://evidence-hub.com/study/2189-evaluation-of-levofloxacin-prescription-pattern-and-appropriateness2026-10-08 https://evidence-hub.com/study/2190-epidemiological-surveys-antibiotic-resistance-and-related-risk2026-10-08 https://evidence-hub.com/study/2191-patterns-of-bacterial-pathogens-and-their-antimicrobial2026-10-08 https://evidence-hub.com/study/2192-delayed-culture-conversion-predicts-poor-outcomes-for-isoniazid-mono2026-10-08 https://evidence-hub.com/study/2193-frequency-of-antibiotic-resistance-and-virulence-factors-in2026-10-08 https://evidence-hub.com/study/2194-screening-of-microbial-spectrum-of-odontogenic-infections-their2026-10-08 https://evidence-hub.com/study/2195-serotype-distribution-and-antimicrobial-susceptibility-patterns-of2026-10-08 https://evidence-hub.com/study/2196-patterns-of-fluoroquinolone-utilization-and-resistance-in-a-tertiary2026-10-19 https://evidence-hub.com/study/2197-prevalence-and-resistance-profile-of-bacteria-isolated-from-wound2026-10-08 https://evidence-hub.com/study/2198-antibiotic-resistance-of-helicobacter-pylori-and-related-risk-factors2026-10-08 https://evidence-hub.com/study/2199-common-bacterial-isolates-and-their-antibiotic-susceptibility-profile2026-10-08 https://evidence-hub.com/study/2200-antimicrobial-resistance-molecular-mechanisms-of-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/2201-phenotypic-and-genotypic-analysis-of-helicobacter-pylori-resistance2026-10-08 https://evidence-hub.com/study/2202-helicobacter-pylori-antibiotic-resistance-genes-and-virulence-based2026-10-08 https://evidence-hub.com/study/2203-surveillance-study-of-bloodstream-infections-antimicrobial-use-and2026-10-08 https://evidence-hub.com/study/2204-site-specific-bacteriology-of-tropic-ulcers-and-their-antibiotic2026-10-08 https://evidence-hub.com/study/2205-antibiotic-use-for-empirical-therapy-in-the-critical-care-units-in2026-10-08 https://evidence-hub.com/study/2206-current-trends-of-antibiotic-resistance-among-human-skin-infections2026-10-08 https://evidence-hub.com/study/2207-antibiotic-dispensing-practice-by-medicine-sellers-in-dhaka-city-a2026-10-08 https://evidence-hub.com/study/2208-antibiotic-resistance-of-helicobacter-pylori-and-influencing-factors2026-10-08 https://evidence-hub.com/study/2209-epidemiological-characteristics-of-helicobacter-pylori-infection-and2026-10-08 https://evidence-hub.com/study/2210-evaluation-of-antimicrobial-susceptibility-patterns-to-oral2026-10-08 https://evidence-hub.com/study/2211-prevalence-and-possible-predictors-of-drug-resistant-pseudomonas2026-10-08 https://evidence-hub.com/study/2212-gram-negative-bacilli-are-a-major-cause-of-secondary-pneumonia-in2026-10-08 https://evidence-hub.com/study/2213-iddf2019-abs-0317-incidence-of-helicobacter-pylori-antibiotic2026-10-08 https://evidence-hub.com/study/2215-cross-sectional-pilot-study-of-antibiotic-resistance-in2026-10-08 https://evidence-hub.com/study/2216-assessment-of-antimicrobial-self-medication-in-undergraduate-medical2026-10-08 https://evidence-hub.com/study/2217-a-cross-sectional-study-of-isolates-from-sputum-samples-from2026-10-08 https://evidence-hub.com/study/2218-comparison-of-levofloxacin-versus-clarithromycin-based-triple-therapy2026-10-08 https://evidence-hub.com/study/2219-antimicrobial-activity-of-biosynthesized-silver-nanoparticles-from2026-10-08 https://evidence-hub.com/study/2220-cost-effectiveness-of-ceftriaxone-and-levofloxacin-use-in-pneumonia2026-10-08 https://evidence-hub.com/study/2222-pattern-of-antibiotic-use-and-physician-s-opinion-about-the2026-10-08 https://evidence-hub.com/study/2223-prevalence-resistance-profile-of-eskapee-pathogens-and-molecular2026-10-08 https://evidence-hub.com/study/2224-the-application-of-genotypic-resistance-testing-for-clarithromycin2026-10-08 https://evidence-hub.com/study/2225-effect-of-the-temperature-on-the-size-of-inhibition-zone-of-the2026-10-08 https://evidence-hub.com/study/2226-update-on-urinary-tract-infection-antibiotic-resistance-a2026-10-20 https://evidence-hub.com/study/2227-emerging-drug-resistance-in-acinetobacter-species-a-study-on2026-10-08 https://evidence-hub.com/study/2228-benefits-and-harms-of-antibiotic-use-in-end-of-life-patients2026-10-08 https://evidence-hub.com/study/2229-tracking-antibiotic-resistance-in-pseudomonas-aeruginosa-a-four-year2026-10-08 https://evidence-hub.com/study/2230-phenotype-and-molecular-detection-of-clarithromycin-and-levofloxacin2026-10-08 https://evidence-hub.com/study/2233-antimicrobial-consumption-from-2017-to-2021-in-east-trinidad-and2026-10-08 https://evidence-hub.com/study/2234-adsorptive-removal-of-levofloxacin-and-antibiotic-resistance-genes2026-10-08 https://evidence-hub.com/study/2235-adsorption-of-levofloxacin-by-ultraviolet-aging-microplastics2026-10-08 https://evidence-hub.com/study/2236-novel-insights-into-the-mechanism-of-periodate-activation-by2026-10-08 https://evidence-hub.com/study/2237-a-comprehensive-review-on-recent-advances-toward-sequestration-of2026-10-08 https://evidence-hub.com/study/2238-removal-of-levofloxacin-from-aqueous-solution-by-green-synthesized2026-10-08 https://evidence-hub.com/study/2239-trimethoprim-sulfamethoxazole-versus-levofloxacin-for2026-10-08 https://evidence-hub.com/study/2240-sono-photo-hybrid-process-for-the-synergistic-degradation-of2026-10-08 https://evidence-hub.com/study/2241-resource-utilization-of-chicken-manure-to-produce-biochar-for2026-10-08 https://evidence-hub.com/study/2242-biotransformation-of-the-fluoroquinolone-levofloxacin-by-the-white2026-10-08 https://evidence-hub.com/study/2243-a-sustainable-ferromanganese-biochar-adsorbent-for-effective2026-10-08 https://evidence-hub.com/study/2244-the-spectrophotometric-determination-of-lipophilicity-and2026-10-08 https://evidence-hub.com/study/2245-activity-of-cefiderocol-alone-and-in-combination-with-levofloxacin2026-10-08 https://evidence-hub.com/study/2246-cellulose-nanocrystals-graphene-oxide-composite-for-the-adsorption2026-10-08 https://evidence-hub.com/study/2247-bi2wo6-c-dots-tio2-a-novel-z-scheme-photocatalyst-for-the-degradation2026-10-08 https://evidence-hub.com/study/2248-adverse-effects-of-levofloxacin-and-oxytetracycline-on-aquatic2026-10-08 https://evidence-hub.com/study/2250-chitosan-dressings-containing-inorganic-additives-and-levofloxacin-as2026-10-08 https://evidence-hub.com/study/2252-preparation-of-levofloxacin-imprinted-nanoparticles-using-designed2026-10-08 https://evidence-hub.com/study/2253-a-novel-drug-drug-cocrystal-of-levofloxacin-and-metacetamol-reduced2026-10-08 https://evidence-hub.com/study/2254-instantaneous-oxidation-of-levofloxacin-as-toxic-pharmaceutical2026-10-08 https://evidence-hub.com/study/2256-eu3-functionalized-covalent-organic-framework-hybrid-material-as-a2026-10-08 https://evidence-hub.com/study/2257-evaluation-of-multiplex-arms-pcr-for-detection-of-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/2258-electrochemical-degradation-of-antibiotic-levofloxacin-by-pbo22026-10-08 https://evidence-hub.com/study/2259-a-mobile-microvolume-uv-visible-light-spectrophotometer-for-the2026-10-08 https://evidence-hub.com/study/2260-helicobacter-pylori-primary-and-secondary-genotypic-resistance-to2026-10-08 https://evidence-hub.com/study/2261-high-primary-resistance-to-metronidazole-and-levofloxacin-and-a2026-10-08 https://evidence-hub.com/study/2262-impact-of-humic-acid-on-the-degradation-of-levofloxacin-by-aqueous2026-10-08 https://evidence-hub.com/study/2263-tailored-nanocarriers-for-the-pulmonary-delivery-of-levofloxacin2026-10-08 https://evidence-hub.com/study/2264-activity-of-potential-alternative-treatment-agents-for2026-10-08 https://evidence-hub.com/study/2265-effects-of-the-fluoroquinolones-moxifloxacin-and-levofloxacin-on-the2026-10-08 https://evidence-hub.com/study/2269-2002-2022-quinolone-resistance-in-escherichia-coli-of-swine-in2026-10-08 https://evidence-hub.com/study/2270-efficacy-and-safety-of-short-vs-standard-long-regimens-for-multidrug2026-10-08 https://evidence-hub.com/study/2273-comparative-effectiveness-of-multiple-different-first-line-treatment2026-10-08 https://evidence-hub.com/study/2275-meta-analysis-of-gatifloxacin-and-levofloxacin-in-treatment-of2026-10-20 https://evidence-hub.com/study/2279-efficacy-of-a-2-week-therapy-with-levofloxacin-concomitant-versus-a2026-10-08 https://evidence-hub.com/study/2280-levofloxacin-ketorolac-combination-versus-levofloxacin-alone-for2026-10-08 https://evidence-hub.com/study/2281-beat-tuberculosis-a-randomized-controlled-trial-of-a-6-month-strategy2026-10-13 https://evidence-hub.com/study/2283-efficacy-of-two-week-therapy-with-bismuth-quadruple-versus2026-10-08 https://evidence-hub.com/study/2284-efficacy-of-two-week-therapy-with-doxycycline-based-quadruple-versus2026-10-08 https://evidence-hub.com/study/2285-comparing-the-efficacy-of-two-week-therapy-with-modified-bismuth2026-10-08 https://evidence-hub.com/study/2287-efficacy-of-two-week-quadruple-bismuth-treatment-versus-levofloxacin2026-10-08 https://evidence-hub.com/study/2288-comparing-the-efficacy-of-two-week-therapy-with-bismuth-quadruple2026-10-08 https://evidence-hub.com/study/2289-significance-of-targeted-antimicrobial-prophylaxis-using-rectal2026-10-13 https://evidence-hub.com/study/2291-the-effectiveness-of-prophylactic-antibiotics-with-oral-levofloxacin2026-10-13 https://evidence-hub.com/study/2292-the-effectiveness-of-colistin-levofloxacin-compared-to-colistin2026-10-08 https://evidence-hub.com/study/2297-vonoprazan-based-therapy-versus-proton-pump-inhibitor-based-therapy2026-10-08 https://evidence-hub.com/study/2298-efficacy-and-safety-of-1-5-levofloxacin-otic-solution-for-the2026-10-08 https://evidence-hub.com/study/2299-two-nitazoxanide-based-quadruple-regimens-for-eradication-of2026-10-08 https://evidence-hub.com/study/2300-comparison-between-levofloxacin-and-azithromycin-in-short-term2026-10-08 https://evidence-hub.com/study/2301-comparison-of-the-efficacy-of-adding-inhaled-levofloxacin-and2026-10-20 https://evidence-hub.com/study/2302-helicobacter-pylori-eradication-rates-using-clarithromycin-and2026-10-08 https://evidence-hub.com/study/2303-effect-of-oral-moxifloxacin-vs-intravenous-ertapenem-plus-oral2026-10-08 https://evidence-hub.com/study/2304-levofloxacin-versus-ceftriaxone-and-azithromycin-for-treating2026-10-20 https://evidence-hub.com/study/2305-comparing-regimens-based-on-clarithromycin-furazolidone-and2026-10-08 https://evidence-hub.com/study/2306-vonoprazan-dual-or-triple-therapy-versus-bismuth-quadruple-therapy-as2026-10-08 https://evidence-hub.com/study/2307-the-efficacy-safety-and-tolerability-of-levofloxacin-quadruple2026-10-08 https://evidence-hub.com/study/2308-clarithromycin-versus-levofloxacin-based-regimens-for-helicobacter2026-10-08 https://evidence-hub.com/study/2309-effect-of-topical-povidone-iodine-10-plus-levofloxacin-0-5-one-hour2026-10-08 https://evidence-hub.com/study/2310-comparison-of-levofloxacin-based-10-day-sequential-therapy-with-142026-10-08 https://evidence-hub.com/study/2311-levofloxacin-based-vs-clarithromycin-based-sequential-therapy-in2026-10-08 https://evidence-hub.com/study/2312-comparison-of-clinical-cure-rates-of-doxycycline-and-levofloxacin-in2026-10-08 https://evidence-hub.com/study/2313-levofloxacin-containing-versus-clarithromycin-containing-therapy-for2026-10-08 https://evidence-hub.com/study/2314-levofloxacin-based-sequential-therapy-versus-classic-triple-therapy2026-10-08 https://evidence-hub.com/study/2315-comparative-evaluation-of-antimicrobial-corticosteroid-mixture-and2026-10-08 https://evidence-hub.com/study/2316-efficacy-of-two-different-dosages-of-levofloxacin-in-curing2026-10-08 https://evidence-hub.com/study/2317-short-versus-long-duration-levofloxacin-plus-rifampicin-for-acute2026-10-13 https://evidence-hub.com/study/2318-therapeutic-efficacy-and-drug-safety-comparison-of-one-week2026-10-08 https://evidence-hub.com/study/2319-randomized-clinical-trial-esomeprazole-bismuth-levofloxacin-and2026-10-08 https://evidence-hub.com/study/2320-comparison-of-the-efficacy-of-two-week-vonoprazan-versus-lansoprazole2026-10-08 https://evidence-hub.com/study/2321-impact-of-topical-0-05-cyclosporine-a-eye-drops-on-post-femtosecond2026-10-08 https://evidence-hub.com/study/2323-comparative-efficacy-of-amoxicillin-clavulanic-acid-and-levofloxacin2026-10-08 https://evidence-hub.com/study/2324-effect-of-hypochlorous-acid-on-blepharitis-through-ultrasonic2026-10-08 https://evidence-hub.com/study/2325-fourteen-day-optimized-levofloxacin-based-therapy-versus-classical2026-10-08 https://evidence-hub.com/study/2327-levofloxacin-for-bk-virus-prophylaxis-following-kidney2026-10-08 https://evidence-hub.com/study/2329-cost-effectiveness-analysis-of-the-use-of-ciprofloxacin-and2026-10-20 https://evidence-hub.com/study/2330-helicobacter-pylori-secondary-antibiotic-resistance-after-one-or-more2026-10-08 https://evidence-hub.com/study/2331-effect-of-double-coating-on-microencapsulation-of-levofloxacin-using2026-10-08 https://evidence-hub.com/study/2332-cost-effectiveness-analysis-of-ceftriaxone-azithromycin-combination2026-10-08 https://evidence-hub.com/study/2333-comparison-of-clinical-and-safety-outcomes-in-patients-with2026-10-08 https://evidence-hub.com/study/2334-model-guided-dose-optimization-of-cefoperazone-sulbactam-and2026-10-20 https://evidence-hub.com/study/2337-comparative-analysis-of-length-of-stay-and-cost-effectiveness-in2026-10-08 https://evidence-hub.com/study/2340-the-effect-of-levofloxacin-combinations-on-crp-decrease-in-sars-cov-22026-10-08 https://evidence-hub.com/study/2341-analysis-of-cost-effectiveness-of-antibiotic-use-in-typhod-fever2026-10-08 https://evidence-hub.com/study/2342-comparative-analysis-of-length-of-stay-total-costs-and-treatment2026-10-08 https://evidence-hub.com/study/2343-therapeutic-efficacy-and-safety-of-prolonged-macrolide-corticosteroid2026-10-20 https://evidence-hub.com/study/2344-association-of-oral-ciprofloxacin-levofloxacin-ofloxacin-and2026-10-08 https://evidence-hub.com/study/2345-2-day-versus-7-day-course-of-levofloxacin-in-acute-copd-exacerbation2026-10-08 https://evidence-hub.com/study/2347-moxifloxacin-versus-levofloxacin-for-antibacterial-prophylaxis-in2026-10-08 https://evidence-hub.com/study/2348-detection-and-characterization-of-a-multi-drug-and-multi-metal2026-10-08 https://evidence-hub.com/study/2349-phenotypic-and-molecular-characterisation-of-a-novel-species2026-10-08 https://evidence-hub.com/study/2350-in-situ-generation-of-cu-iii-synergized-with-crystalline-amorphous2026-10-08 https://evidence-hub.com/study/2351-spectroscopic-characterization-and-biological-activity-of-mixed2026-10-08 https://evidence-hub.com/study/2353-cost-effectiveness-analysis-of-empiric-antibiotics-in-hospitalized2026-10-08 https://evidence-hub.com/study/2354-analysis-of-the-antimicrobial-stewardship-program-policy-on2026-10-08 https://evidence-hub.com/study/2355-emergence-of-aeromonas-dhakensis-linked-motile-aeromonas-septicemia2026-10-08 https://evidence-hub.com/study/2356-the-validity-of-antibacterial-therapy-in-chronic-keratitis-and-herpes2026-10-08 https://evidence-hub.com/study/2357-infection-incidence-timing-and-predictors-in-newly-diagnosed-multiple2026-10-08 https://evidence-hub.com/study/2358-evaluasi-penggunaan-antibiotik-pada-pasien-pneumonia-rawat-inap-di2026-10-08 https://evidence-hub.com/study/2359-a-pilot-study-randomized-control-trial-on-effect-of-oral-calcium2026-10-08 https://evidence-hub.com/study/2362-results-of-levofloxacin-prophylaxis-timing-in-autologous-and2026-10-08 https://evidence-hub.com/study/2363-high-risk-for-life-threatening-adverse-events-of-fluoroquinolones-in2026-10-08 https://evidence-hub.com/study/2364-explorative-analysis-of-treatment-outcomes-of-levofloxacin-and2026-10-08 https://evidence-hub.com/study/2366-clinical-characteristics-and-mortality-risk-factors-of-streptococcus2026-10-08 https://evidence-hub.com/study/2367-effectiveness-and-safety-of-modified-fully-oral-9-month-treatment2026-10-08 https://evidence-hub.com/study/2368-levofloxacin-to-prevent-bacterial-infection-in-patients-with-acute2026-10-08 https://evidence-hub.com/study/2369-outcomes-of-levofloxacin-based-regimens-in-adults-with-severe2026-10-08 https://evidence-hub.com/study/2370-diminishing-efficacy-of-second-line-levofloxacin-based-quadruple2026-10-08 https://evidence-hub.com/study/2371-evaluating-the-effectiveness-of-low-dose-oral-switch-therapy-for2026-10-08 https://evidence-hub.com/study/2372-treatment-outcomes-among-patients-with-isoniazid-mono-resistant2026-10-08 https://evidence-hub.com/study/2373-antibiotic-prophylaxis-in-patients-undergoing-lung-transplant-single2026-10-08 https://evidence-hub.com/study/2374-ceftazidime-avibactam-polymyxin-or-tigecycline-as-a-rescue-strategy2026-10-08 https://evidence-hub.com/study/2375-effects-of-extended-oral-antibiotic-prophylaxis-on-surgical-site2026-10-08 https://evidence-hub.com/study/2376-the-activities-of-antimicrobials-against-stenotrophomonas-maltophilia2026-10-08 https://evidence-hub.com/study/2377-impact-of-anti-tuberculosis-drug-use-on-treatment-outcomes-in2026-10-08 https://evidence-hub.com/study/2378-association-between-minimum-inhibitory-concentration-values-and2026-10-08 https://evidence-hub.com/study/2379-impact-of-risk-mitigation-measures-on-oral-fluoroquinolone2026-10-13 https://evidence-hub.com/study/2380-risk-factors-and-outcomes-associated-with-difficult-to-treat2026-10-08 https://evidence-hub.com/study/2381-antimicrobial-resistance-bacterial-density-and-eradication-outcomes2026-10-08 https://evidence-hub.com/study/2382-efficacy-of-first-line-levofloxacin-based-therapy-for-helicobacter2026-10-08 https://evidence-hub.com/study/2383-association-between-initiation-of-fluoroquinolones-and-hospital2026-10-13 https://evidence-hub.com/study/2384-adjuvant-interventions-in-levofloxacin-exposed-rabbit-achilles2026-10-08 https://evidence-hub.com/study/2385-comparison-of-different-regimens-with-or-without-fluoroquinolone-in2026-10-08 https://evidence-hub.com/study/2386-clinical-effectiveness-of-beta-lactams-versus-fluoroquinolones-as2026-10-13 https://evidence-hub.com/study/2387-helicobacter-pylori-antimicrobial-resistance-and-cyp2c19-genotypes-in2026-10-08 https://evidence-hub.com/study/2388-evaluating-outcomes-associated-with-revised-fluoroquinolone2026-10-13 https://evidence-hub.com/study/2389-antibiotic-prophylaxis-and-the-gastrointestinal-resistome-in2026-10-08 https://evidence-hub.com/study/2390-impact-of-a-tailored-department-specific-antimicrobial-stewardship2026-10-08 https://evidence-hub.com/study/2391-distinguishing-relapse-from-reinfection-with-whole-genome-sequencing2026-10-08 https://evidence-hub.com/study/2392-evaluation-of-the-effect-of-combination-therapy-on-treatment-of-covid2026-10-08 https://evidence-hub.com/study/2393-high-prevalence-and-risk-factors-of-multiple-antibiotic-resistance-in2026-10-08 https://evidence-hub.com/study/2394-the-association-of-antibiotic-stewardship-with-fluoroquinolone2026-10-19 https://evidence-hub.com/study/2395-epidemiological-trends-and-resistance-associated-with2026-10-08 https://evidence-hub.com/study/2396-adverse-effects-of-fluoroquinolones-a-retrospective-cohort-study-in-a2026-10-08 https://evidence-hub.com/study/2397-comment-on-idiopathic-granulomatous-mastitis-with-skin-rupture-a2026-10-08 https://evidence-hub.com/study/2398-impact-of-safety-warnings-for-fluoroquinolones-on-prescribing2026-10-08 https://evidence-hub.com/study/2399-impact-of-continuous-kidney-replacement-therapy-and-hemoadsorption2026-10-08 https://evidence-hub.com/study/2401-prospective-evaluation-of-improving-fluoroquinolone-exposure-using2026-10-08 https://evidence-hub.com/study/2402-variations-in-antibiotic-susceptibility-of-group-b-streptococcus-in2026-10-08 https://evidence-hub.com/study/2403-decreasing-mrna-hmgb1-expression-in-klebsiella-pneumoniae-infection2026-10-08 https://evidence-hub.com/study/2404-1105-statewide-retrospective-cohort-study-of-medicare-part-b2026-10-13 https://evidence-hub.com/study/2405-1106-assessment-of-fluoroquinolone-appropriateness-for-hospitalized2026-10-08 https://evidence-hub.com/study/2406-rare-but-risky-orthopedic-infections-by-unconventional-gram-positive2026-10-13 https://evidence-hub.com/study/2407-burkholderia-cepacia-infections-at-sites-other-than-the-respiratory2026-10-08 https://evidence-hub.com/study/2408-fixed-drug-eruption-a-case-series-clinical-presentation-and2026-10-08 https://evidence-hub.com/study/2409-therapeutic-response-of-community-acquired-pneumonia-in-geriatrics-a2026-10-08 https://evidence-hub.com/study/2410-nocardia-infection-causing-non-healing-surgical-wounds-a-case-series2026-10-08 https://evidence-hub.com/study/2411-case-series-of-imported-enteric-fever-at-a-referral-center-in-tokyo2026-10-08 https://evidence-hub.com/study/2413-combined-use-of-meropenem-linezolid-and-quinolones-for-non-drug2026-10-08 https://evidence-hub.com/study/2414-neisseria-meningitidis-keratitis-in-adults-a-case-series2026-10-08 https://evidence-hub.com/study/2415-topical-levofloxacin-nepafenac-and-prednisolone-acetate-medication2026-10-08 https://evidence-hub.com/study/2418-twelve-month-visual-and-anatomical-outcomes-of-boston-type-i2026-10-08 https://evidence-hub.com/study/2419-profile-of-antibiotic-use-and-germ-map-in-pneumonia-patients-in2026-10-08 https://evidence-hub.com/study/2420-mycoplasma-hominis-as-cause-of-extragenital-infection-in-patients2026-10-08 https://evidence-hub.com/study/2421-endophthalmitis-caused-by-streptococcal-species-clinical-settings2026-10-08 https://evidence-hub.com/study/2424-emerging-prevalence-of-microsporidial-keratitis-in-singapore2026-10-08 https://evidence-hub.com/study/2425-case-of-endophthalmitis-following-intravitreal-injections-of2026-10-08 https://evidence-hub.com/study/2426-endophthalmitis-caused-by-pseudomonas-aeruginosa-clinical-features2026-10-08 https://evidence-hub.com/study/2427-levofloxacin-induced-gastrocnemius-tendon-rupture-a-case-report2026-10-08 https://evidence-hub.com/study/2428-iga-vasculitis-associated-with-levofloxacin-use-in-an-adult-female-a2026-10-08 https://evidence-hub.com/study/2429-ciprofloxacin-induced-anaphylactic-reaction-followed-by-negative2026-10-08 https://evidence-hub.com/study/2431-bilateral-levofloxacin-induced-achilles-tendon-rupture-an-uncommon2026-10-13 https://evidence-hub.com/study/2432-community-acquired-pneumonia-caused-by-kluyvera-intermedia-a-rare2026-10-08 https://evidence-hub.com/study/2433-successfully-treated-case-of-meningitis-caused-by-elizabethkingia2026-10-08 https://evidence-hub.com/study/2434-successful-fluoroquinolone-based-salvage-therapy-in-the-conservative2026-10-08 https://evidence-hub.com/study/2435-mania-secondary-to-cotrimoxazole-antibiotherapy-a-case-report-and2026-10-13 https://evidence-hub.com/study/2436-unusual-presentation-of-fungal-keratitis-and-endogenous2026-10-08 https://evidence-hub.com/study/2437-levofloxacin-induced-psychosis-in-elderly-case-report2026-10-08 https://evidence-hub.com/study/2438-pseudotumour-cerebri-associated-with-mycoplasma-pneumoniae-infection2026-10-08 https://evidence-hub.com/study/2439-levofloxacin-induced-rhabdomyolysis-in-a-patient-on-concurrent2026-10-08 https://evidence-hub.com/study/2440-levofloxacin-associated-mania-a-case-report2026-10-08 https://evidence-hub.com/study/2441-leave-the-levofloxacin-a-case-report-of-levofloxacin-induced-psychosis2026-10-08 https://evidence-hub.com/study/2442-vagococcus-fluvialis-isolation-from-the-urine-of-a-bladder-cancer2026-10-08 https://evidence-hub.com/study/2443-levofloxacin-induced-stomatitis-a-case-report2026-10-08 https://evidence-hub.com/study/2444-a-case-report-on-drug-induced-pancreatitis-due-to-levofloxacin-and2026-10-08 https://evidence-hub.com/study/2445-a-fatal-case-of-multidrug-resistant-pleural-nocardiosis-by-nocardia2026-10-08 https://evidence-hub.com/study/2446-case-report-a-rare-infection-of-multidrug-resistant-aeromonas-caviae2026-10-08 https://evidence-hub.com/study/2447-periprosthetic-bacterial-and-fugal-infection-after-total-knee2026-10-08 https://evidence-hub.com/study/2448-hemorrhagic-bronchitis-caused-by-carbapenem-resistant-acinetobacter2026-10-08 https://evidence-hub.com/study/2449-posterior-scleritis-following-a-single-infusion-of-zoledronate-for2026-10-08 https://evidence-hub.com/study/2451-hospital-acquired-pneumonia-due-to-burkholderia-cepacia-in-a2026-10-08 https://evidence-hub.com/study/2452-successful-maintenance-treatment-of-disseminated-nocardiosis-with2026-10-08 https://evidence-hub.com/study/2453-spinal-cord-neuromodulation-therapy-for-levofloxacin-reinduced2026-10-08 https://evidence-hub.com/study/2454-nigrospora-oryzae-causing-human-corneal-keratitis-a-case-report2026-10-08 https://evidence-hub.com/study/2455-first-reported-human-case-of-isolation-of-vagococcus-fluvialis-from2026-10-13 https://evidence-hub.com/study/2456-fungal-keratitis-caused-by-neurospora-a-case-report2026-10-08 https://evidence-hub.com/study/2457-possible-omadacycline-induce-acute-pancreatitis-a-case-report-and2026-10-08 https://evidence-hub.com/study/2458-hemophagocytic-lymphohistiocytosis-secondary-to-rifampin-treatment-a2026-10-13 https://evidence-hub.com/study/2460-a-case-of-anaphylactic-shock-due-to-levofloxacin-eye-drops-confirmed2026-10-08 https://evidence-hub.com/study/2461-fluoroquinolone-levofloxacin-induced-tendinopathy-with-partial2026-10-08 https://evidence-hub.com/study/2462-pulp-regenerative-therapy-using-autologous-dental-pulp-stem-cells-in2026-10-08 https://evidence-hub.com/study/2464-probable-levofloxacin-induced-thrombocytopenia-in-a-patient2026-10-08 https://evidence-hub.com/study/2465-cross-immediate-hypersensitivity-between-ciprofloxacin-and2026-10-08 https://evidence-hub.com/study/2466-prescription-of-levofloxacin-and-moxifloxacin-in-select-hospitals-in2026-10-08 https://evidence-hub.com/study/2467-vonoprazan-based-triple-therapy-for-helicobacter-pylori-resistant-to2026-10-08 https://evidence-hub.com/study/2468-success-of-helicobacter-pylori-guideline-based-treatment-of-newly2026-10-08 https://evidence-hub.com/study/2469-economic-evaluation-of-nemonoxacin-moxifloxacin-and-levofloxacin-in2026-10-20 https://evidence-hub.com/study/2470-development-and-validation-of-a-simple-lc-ms-ms-method-for2026-10-08 https://evidence-hub.com/study/2472-a-culture-change-impact-of-a-pediatric-antimicrobial-stewardship2026-10-08 https://evidence-hub.com/study/2473-oral-step-down-therapy-with-levofloxacin-for-febrile-neutropenia-in2026-10-08 https://evidence-hub.com/study/2474-1756-assessment-of-prophylactic-antibiotic-guideline-compliance-in2026-10-08 https://evidence-hub.com/study/2475-outcomes-of-high-dose-levofloxacin-therapy-remain-bound-to-the2026-10-20 https://evidence-hub.com/study/2476-is-more-always-better-effect-of-a-combination-pseudomonas-antibiogram2026-10-08 https://evidence-hub.com/study/2479-anaerobic-antibiotic-coverage-in-aspiration-pneumonia-and-the2026-10-08 https://evidence-hub.com/study/2480-prophylactic-use-of-levofloxacin-during-medicinal-leech-therapy2026-10-08 https://evidence-hub.com/study/2481-modern-rescue-salvage-therapies-in-the-eradication-of-helicobacter2026-10-08 https://evidence-hub.com/study/2482-campylobacter-jejuni-associated-perimyocarditis-in-53-year-old-male2026-10-08 https://evidence-hub.com/study/2483-spinal-tuberculosis-comparative-study-between-surgical-conservative2026-10-08 https://evidence-hub.com/study/2484-evaluation-of-antibiotic-prescribing-practices-in-infection2026-10-08 https://evidence-hub.com/study/2485-appropriateness-of-antibiotic-therapy-in-sepsis-patients-in-the2026-10-08 https://evidence-hub.com/study/2486-efficacy-and-safety-of-levofloxacin-in-patients-with-bacterial2026-10-20 https://evidence-hub.com/study/2488-comparision-of-antibiotic-susceptility-of-levofloxacin-with-other2026-10-08 https://evidence-hub.com/study/2490-opportunities-to-improve-antibiotic-prescribing-for-adults-with-acute2026-10-08 https://evidence-hub.com/study/2491-fluoroquinolone-prophylaxis-in-children-with-cancer-a-pro-con2026-10-08 https://evidence-hub.com/study/2492-levofloxacin-versus-ceftriaxone-plus-clarithromycin-in-the-treatment2026-10-08 https://evidence-hub.com/study/2494-antibiotic-resistance-profile-of-helicobacter-pylori-to-142026-10-08 https://evidence-hub.com/study/2495-simultaneous-quantitative-determination-of-eight-fluoroquinolones-by2026-10-08 https://evidence-hub.com/study/2499-direct-detection-of-antibiotic-resistance-in-chinese-helicobacter2026-10-08 https://evidence-hub.com/study/2500-synergistic-potential-of-antimicrobial-combinations-against2026-10-08 https://evidence-hub.com/study/2501-evaluation-of-antimicrobial-susceptibility-and-integron-carriage-in2026-10-08 https://evidence-hub.com/study/2502-should-we-worry-about-bedaquiline-exposure-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/2503-empiric-antibiotic-therapy-in-the-treatment-of-community-acquired2026-10-08 https://evidence-hub.com/study/2504-investigation-of-in-vitro-activity-of-colistin-and-tygecyclin-against2026-10-08 https://evidence-hub.com/study/2505-comparative-effectiveness-of-different-oral-antibiotics-regimens-for2026-10-18 https://evidence-hub.com/study/2506-oral-antibiotics-for-uncomplicated-acute-appendicitis-the-role-of2026-10-08 https://evidence-hub.com/study/2507-conjunctival-microbiota-in-patients-with-type-2-diabetes-mellitus-and2026-10-08 https://evidence-hub.com/study/2508-clinical-impact-of-levofloxacin-inhalation-solution-in-cystic2026-10-08 https://evidence-hub.com/study/2509-levofloxacin-versus-placebo-for-the-treatment-of-latent-tuberculosis2026-10-08 https://evidence-hub.com/study/2510-evaluation-of-saliva-as-a-potential-alternative-sampling-matrix-for2026-10-08 https://evidence-hub.com/study/2511-optimal-levofloxacin-dosing-regimens-in-critically-ill-patients-with2026-10-19 https://evidence-hub.com/study/2512-cefuroxime-levofloxacin-esomeprazole-and-bismuth-as-first-line2026-10-08 https://evidence-hub.com/study/2513-levofloxacin-versus-ceftriaxone-and-azithromycin-combination-in-the2026-10-20 https://evidence-hub.com/study/2514-the-risk-of-cardiac-events-in-patients-who-received-concomitant2026-10-08 https://evidence-hub.com/study/2515-impact-of-levofloxacin-for-the-prophylaxis-of-bloodstream-infection2026-10-08 https://evidence-hub.com/study/2516-dry-powders-for-the-inhalation-of-ciprofloxacin-or-levofloxacin2026-10-08 https://evidence-hub.com/study/2517-antibiofilm-effects-of-amoxicillin-clavulanic-acid-and-levofloxacin2026-10-08 https://evidence-hub.com/study/2518-levofloxacin-for-febrile-neutropenia-prophylaxis-in-acute-myeloid2026-10-08 https://evidence-hub.com/study/2520-serenoa-repens-associated-with-selenium-and-lycopene-extract-and2026-10-08 https://evidence-hub.com/study/2521-population-pharmacokinetics-of-levofloxacin-in-korean-patients2026-10-08 https://evidence-hub.com/study/2522-pharmacokinetics-and-aqueous-humor-penetration-of-levofloxacin-1-52026-10-08 https://evidence-hub.com/study/2525-impact-of-prophylactic-levofloxacin-on-rates-of-bloodstream-infection2026-10-08 https://evidence-hub.com/study/2526-limited-sampling-strategy-and-target-attainment-analysis-for2026-10-08 https://evidence-hub.com/study/2527-influence-of-daily-dosage-and-frequency-of-administration-of2026-10-08 https://evidence-hub.com/study/2530-second-line-levofloxacin-based-quadruple-therapy-versus-bismuth-based2026-10-08 https://evidence-hub.com/study/2531-clinical-impact-of-fluoroquinolone-resistant-escherichia-coli-in-the2026-10-08 https://evidence-hub.com/study/2532-effect-of-levofloxacin-prophylaxis-for-prevention-of-severe2026-10-08 https://evidence-hub.com/study/2534-antimicrobial-coating-prevents-ventilator-associated-pneumonia-in-a2026-10-08 https://evidence-hub.com/study/2536-3d-printed-gastroretentive-floating-hollow-capsular-device-grf-hcd2026-10-08 https://evidence-hub.com/study/2537-effect-of-delaying-treatment-on-efficacy-of-ciprofloxacin-and2026-10-08 https://evidence-hub.com/study/2538-translational-efficacy-of-humanized-exposures-of-cefepime-ertapenem2026-10-20 https://evidence-hub.com/study/2539-the-potentiation-activity-of-azithromycin-in-combination-with2026-10-13 https://evidence-hub.com/study/2540-efficacy-of-doxycycline-as-monotherapy-or-in-combination-with2026-10-08 https://evidence-hub.com/study/2541-the-efficacy-of-colistin-combined-with-amikacin-or-levofloxacin2026-10-08 https://evidence-hub.com/study/2542-the-african-green-monkey-model-of-pneumonic-plague-and-us-food-and2026-10-08 https://evidence-hub.com/study/2543-corticosteroid-and-antimicrobial-therapy-in-macrolide-resistant2026-10-20 https://evidence-hub.com/study/2546-labeling-and-animal-study-of-fluorine-18-levofloxacin2026-10-08 https://evidence-hub.com/study/2547-respiratory-pathogens-carriage-in-guinea-pigs-raised-as-livestock-in2026-10-08 https://evidence-hub.com/study/2551-pharmacokinetics-of-levofloxacin-in-hypothermic-beagle-dogs-with-open2026-10-08 https://evidence-hub.com/study/2552-pharmacokinetics-of-levofloxacin-in-hypothermic-beagle-dogs-by2026-10-08 https://evidence-hub.com/study/2554-increasing-natural-resistance-associated-macrophage-protein-1-serum2026-10-08 https://evidence-hub.com/study/2555-which-is-the-best-treatment-for-prosthetic-joint-infections-due-to2026-10-08 https://evidence-hub.com/study/2558-in-vitro-and-in-vivo-activities-of-fluoroquinolones-against-aeromonas2026-10-08 https://evidence-hub.com/study/2561-two-bacterial-infection-models-in-tree-shrew-for-evaluating-the2026-10-08 https://evidence-hub.com/study/2566-susceptibility-of-helicobacter-pylori-to-levofloxacin-and-rifampicin2026-10-08 https://evidence-hub.com/study/2567-should-fluoroquinolones-be-feared-during-pregnancy-and-breastfeeding2026-10-08 https://evidence-hub.com/study/2568-new-chemiluminescent-method-of-levofloxacin-and-ofloxacin2026-10-06 https://evidence-hub.com/study/2569-levofloxacin-induced-autoimmune-hemolytic-anemia2026-10-08 https://evidence-hub.com/study/2570-synergistic-effects-of-anionic-cationic-dendrimers-and-levofloxacin2026-10-08 https://evidence-hub.com/study/2571-a-comparison-of-side-effects-of-levofloxacin-to-other-agents2026-10-08 https://evidence-hub.com/study/2572-bactericidal-activity-and-post-antibiotic-effect-of-ozenoxacin2026-10-08 https://evidence-hub.com/study/2573-effect-of-silver-nanoparticles-on-the-antibacterial-activity-of2026-10-08 https://evidence-hub.com/study/2574-synthesis-and-evaluation-of-antimicrobial-activity-of-r4w4k2026-10-20 https://evidence-hub.com/study/2575-targeted-delivery-of-levofloxacin-liposomes-for-the-treatment-of2026-10-20 https://evidence-hub.com/study/2576-levofloxacin-induced-tactile-hallucination-and-acute-anxiety-reaction2026-10-20 https://evidence-hub.com/study/2577-profile-of-gyra-gene-mutation-in-clinical-isolate-of-levofloxacin2026-10-06 https://evidence-hub.com/study/2578-severe-ductopenia-and-cholestasis-from-levofloxacin-drug-induced2026-10-08 https://evidence-hub.com/study/2579-effects-of-gamma-irradiation-on-the-physico-chemical-and-biological2026-10-06 https://evidence-hub.com/study/2580-surveillance-of-levofloxacin-resistance-in-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/2581-measurement-of-levofloxacin-in-human-plasma-samples-for-a-reliable2026-10-06 https://evidence-hub.com/study/2582-update-on-levofloxacin-in-the-management-of-acute-sinusitis-with-risk2026-10-08 https://evidence-hub.com/study/2583-nephrotoxicity-and-purpura-associated-with-levofloxacin2026-10-19 https://evidence-hub.com/study/2584-preparation-of-antibacterial-gelatin-genipin-nanofibrous-membrane-for2026-10-08 https://evidence-hub.com/study/2585-latest-industry-information-on-the-safety-profile-of-levofloxacin-in2026-10-08 https://evidence-hub.com/study/2586-intranasal-delivery-of-topically-acting-levofloxacin-to-rats-a-proof2026-10-06 https://evidence-hub.com/study/2587-the-tlr4-nf-b-nlrp3-pathway-is-involved-in-levofloxacin-induced2026-10-08 https://evidence-hub.com/study/2588-are-current-critical-concentrations-for-mycobacterium-tuberculosis2026-10-08 https://evidence-hub.com/study/2589-a-case-report-of-cavitary-pneumonia-caused-by-legionella-longbeachae2026-10-20 https://evidence-hub.com/study/2590-scrotal-abscess-caused-by-ignavigranum-ruoffiae-a-case-report-and2026-10-08 https://evidence-hub.com/study/2591-therapeutic-ultrasound-versus-levofloxacin-in-lipopolysaccharide2026-10-08 https://evidence-hub.com/study/2592-bioinspired-multi-colored-colloidal-array-for-simultaneous-visual2026-10-08 https://evidence-hub.com/study/2593-heteroaggregation-driven-regulation-of-levofloxacin-adsorption-by2026-10-08 https://evidence-hub.com/study/2594-bioactive-glutathione-modified-carboxymethyl-cellulose-hydrogels-as2026-10-08 https://evidence-hub.com/study/2595-abc-and-mfs-efflux-transporters-mediate-antibiotic-resistance-and2026-10-08 https://evidence-hub.com/study/2596-sex-differences-in-helicobacter-pylori-antimicrobial-resistance-among2026-10-08 https://evidence-hub.com/study/2597-epidemiology-and-predictors-of-fluoroquinolone-resistance-in-esbl2026-10-20 https://evidence-hub.com/study/2598-degradation-of-levofloxacin-by-a-photodeposited-pt-tio2-porous2026-10-08 https://evidence-hub.com/study/2599-characterization-and-treatment-of-polymicrobial-biofilms-in2026-10-08 https://evidence-hub.com/study/2600-epidemiology-and-antimicrobial-resistance-of-salmonella-isolates-from2026-10-08 https://evidence-hub.com/study/2601-effects-of-levofloxacin-combined-with-dexamethasone-ear-drops-on2026-10-08 https://evidence-hub.com/study/2602-high-in-vitro-activity-of-the-novel-pleuromutilin-antibiotic2026-10-20 https://evidence-hub.com/study/2603-spectrophotometric-determination-of-levofloxacin-using-bromophenol2026-10-08 https://evidence-hub.com/study/2604-longitudinal-antimicrobial-susceptibility-shifts-in-environmental2026-10-08 https://evidence-hub.com/study/2605-in-vivo-activity-of-combination-of-n-acetyl-cysteine-and-levofloxacin2026-10-08 https://evidence-hub.com/study/2606-comparative-efficacy-of-second-and-third-generation-fluoroquinolone2026-10-08 https://evidence-hub.com/study/2607-crystal-phase-dependent-interfacial-lattice-matching-in-biobr-bi2o3-s2026-10-08 https://evidence-hub.com/study/2608-stimuli-responsive-biopolymer-carboxymethyl-tamarind-based-hydrogel2026-10-08 https://evidence-hub.com/study/2609-real-world-safety-signals-of-fluoroquinolone-associated-peripheral2026-10-08 https://evidence-hub.com/study/2610-challenges-in-establishing-epidemiological-cut-off-values-for-the2026-10-08 https://evidence-hub.com/study/2611-proteomic-remodeling-of-outer-membrane-vesicles-in-antibiotic2026-10-08 https://evidence-hub.com/study/2612-molecular-characterisation-and-mutational-analysis-of-antimicrobial2026-10-08 https://evidence-hub.com/study/2613-strategies-to-overcome-intrinsic-resistance-in-stenotrophomonas2026-10-08 https://evidence-hub.com/study/2614-evaluation-of-posttreatment-eradication-testing-following2026-10-08 https://evidence-hub.com/study/2615-molecular-epidemiology-of-rifampicin-resistant-mycobacterium2026-10-06 https://evidence-hub.com/study/2616-establishment-of-a-human-osteocyte-model-to-reveal-mechanisms-of2026-10-06 https://evidence-hub.com/study/2617-yersinia-pseudotuberculosis-employs-a-multifaceted-strategy-to2026-10-06 https://evidence-hub.com/study/2618-molecularly-imprinted-polymers-based-on-cyclodextrin-derivatives-and2026-10-06 https://evidence-hub.com/study/2619-lc-ms-ms-method-for-simultaneous-quantification-of-antibiotics-in2026-10-06 https://evidence-hub.com/study/2620-antimicrobial-resistance-profile-of-helicobacter-pylori-in-shenzhen2026-10-06 https://evidence-hub.com/study/2621-trace-level-quantification-of-levofloxacin-ndsris-using-lc-tq-ms-ms-a2026-10-06 https://evidence-hub.com/study/2622-in-vitro-activity-of-delafloxacin-against-enterococcal-isolates-from2026-10-20 https://evidence-hub.com/study/2623-simultaneous-determination-of-levofloxacin-and-ciprofloxacin-in-human2026-10-08 https://evidence-hub.com/study/2624-microextraction-by-packed-molecularly-imprinted-polymer-combined2026-10-08 https://evidence-hub.com/study/2625-one-step-polymerization-of-hydrophilic-ionic-liquid-imprinted-polymer2026-10-08 https://evidence-hub.com/study/2627-pharmacokinetics-safety-and-dosing-of-novel-pediatric-levofloxacin2026-10-08 https://evidence-hub.com/study/2630-the-depressed-central-carbon-and-energy-metabolisms-is-associated-to2026-10-08 https://evidence-hub.com/study/2632-levofloxacin-loaded-mesoporous-silica-microspheres-nano2026-10-08 https://evidence-hub.com/study/2636-levofloxacin-population-pharmacokinetics-in-south-african-children2026-10-08 https://evidence-hub.com/study/2637-levofloxacin-loaded-bone-cement-delivery-system-highly-effective2026-10-08 https://evidence-hub.com/study/2638-levofloxacin-versus-azithromycin-for-treating-legionella-pneumonia-a2026-10-08 https://evidence-hub.com/study/2639-application-of-deep-eutectic-solvents-in-hybrid-molecularly-imprinted2026-10-08 https://evidence-hub.com/study/2640-levofloxacin-loaded-nanoparticles-decrease-emergence-of2026-10-08 https://evidence-hub.com/study/2641-a-randomized-double-blind-multicenter-phase-ii-study-comparing-the2026-10-20 https://evidence-hub.com/study/2642-are-moxifloxacin-and-levofloxacin-equally-effective-to-treat-xdr2026-10-08 https://evidence-hub.com/study/2644-preparation-and-characterization-of-levofloxacin-loaded-nanofibers-as2026-10-08 https://evidence-hub.com/study/2645-determination-of-levofloxacin-in-human-serum-using-liquid2026-10-08 https://evidence-hub.com/study/2646-comparative-activity-of-ciprofloxacin-levofloxacin-and-moxifloxacin2026-10-08 https://evidence-hub.com/study/2647-fluoroquinolone-associated-tendinopathy-does-levofloxacin-pose-the2026-10-08 https://evidence-hub.com/study/2650-repositioning-of-antibiotic-levofloxacin-as-a-mitochondrial2026-10-08 https://evidence-hub.com/study/2653-sugar-based-novel-niosomal-nanocarrier-system-for-enhanced-oral2026-10-08 https://evidence-hub.com/study/2654-a-two-part-double-blind-placebo-controlled-phase-i-study-of-the2026-10-08 https://evidence-hub.com/study/2655-the-efficacy-of-susceptibility-test-driven-sequential-therapy-as-the2026-10-04 https://evidence-hub.com/study/2656-a-pilot-multicenter-open-label-non-comparative-study-of-the-safety2026-10-05 https://evidence-hub.com/study/2657-moxifloxacin-versus-ofloxacin-plus-metronidazole-in-uncomplicated2026-10-08 https://evidence-hub.com/study/2658-penetrance-of-third-generation-fluoroquinolones-in-eyes-with2026-10-04 https://evidence-hub.com/study/2659-ocular-availability-in-human-tears-after-topical-administration-of-12026-10-08 https://evidence-hub.com/study/2660-efficacy-of-tailored-for-helicobacter-pylori-rescue-treatment-based2026-10-08 https://evidence-hub.com/study/2661-efficacy-of-potassium-competitive-acid-blockers-p-cabs-versus-proton2026-10-08 https://evidence-hub.com/study/2662-levofloxacin-pharmacokinetics-in-the-severely-obese2026-10-08 https://evidence-hub.com/study/2663-efficiency-of-antibacterial-prophylaxis-levofloxacin-in-azacitidine2026-10-05 https://evidence-hub.com/study/2664-a-monocentric-open-label-efficacy-and-safety-evaluation-study-of-the2026-10-19 https://evidence-hub.com/study/2665-a-national-multicenter-non-comparative-study-evaluating-the-efficacy2026-09-26 https://evidence-hub.com/study/2666-a-pilot-study-of-ceftolozane-tazobactam-in-conjunction-with-rapid2026-10-08 https://evidence-hub.com/study/2667-prospective-multinational-multicenter-non-comparative-open-study-with2026-10-04 https://evidence-hub.com/study/2668-development-of-an-adjustment-assistance-tool-dosage-of2026-09-29 https://evidence-hub.com/study/2669-phase-iv-study-comparing-the-duration-of-sequential-therapy2026-10-20 https://evidence-hub.com/study/2670-a-study-of-avelox-for-treatment-of-elderly-patients-with-community2026-10-20 https://evidence-hub.com/study/2671-oral-switch-during-treatment-of-left-sided-endocarditis-due-to-multi2026-10-20 https://evidence-hub.com/study/2672-a-randomized-controlled-study-to-explore-the-effect-of-intermittent2026-10-08 https://evidence-hub.com/study/2673-a-national-multicentric-randomised-controlled-trial-applications-of-a2026-10-08 https://evidence-hub.com/study/2674-phase-1b-randomized-single-blind-placebo-controlled-study-to-evaluate2026-09-26 https://evidence-hub.com/study/2675-comparison-of-early-changes-in-ocular-surface-and-inflammatory2026-09-29 https://evidence-hub.com/study/2676-oral-switch-during-treatment-of-left-sided-endocarditis-due-to-multi2026-10-20 https://evidence-hub.com/study/2677-a-phase-3-multi-center-multinational-randomized-double-blind-placebo2026-10-05 https://evidence-hub.com/study/2678-safety-and-efficacy-of-cem-102-with-rifampin-compared-to-standard2026-10-05 https://evidence-hub.com/study/2679-a-randomized-double-blind-comparative-multi-center-study-of-the2026-10-20 https://evidence-hub.com/study/2680-phase-4-study-on-effectiveness-of-topical-0-5-levofloxacin-on2026-10-05 https://evidence-hub.com/study/2681-an-open-label-multicenter-multinational-centrally-randomized-two-arm2026-10-20 https://evidence-hub.com/study/2682-dosing-strategy-of-intravitreal-ranibizumab-for-myopia-choroidal2026-09-26 https://evidence-hub.com/study/2683-prospective-study-on-dextenza-safety-and-efficacy-following2026-10-08 https://evidence-hub.com/study/2684-a-multicenter-randomized-open-label-comparative-study-to-compare-the2026-10-20 https://evidence-hub.com/study/2685-short-term-use-of-antibiotics-and-adherence-level-a-randomized2026-10-08 https://evidence-hub.com/study/2686-visumax-femtosecond-laser-small-incision-lenticule-extraction-for-the2026-10-08 https://evidence-hub.com/study/2687-therapeutic-drug-monitoring-and-pharmacokinetic-compartmental2026-10-04 https://evidence-hub.com/study/2688-phase-ii-study-treatment-of-relapsed-lymphoid-malignancies-with-an2026-10-08 https://evidence-hub.com/study/2689-a-multicenter-randomized-study-to-compare-the-safety-and-efficacy-of2026-10-08 https://evidence-hub.com/study/2690-the-comparison-of-outcomes-of-antibiotic-drugs-and-appendectomy-coda2026-10-04 https://evidence-hub.com/study/2691-multicenter-double-blind-randomized-study-to-compare-the-safety-and2026-10-20 https://evidence-hub.com/study/2692-multi-center-randomized-open-label-trial-to-evaluate-the-efficacy-of2026-10-20 https://evidence-hub.com/study/2693-comparison-of-the-effect-between-levofloxacin-and-moxifloxacin-on-the2026-10-08 https://evidence-hub.com/study/2694-a-multicenter-randomized-double-blind-double-dummy-comparative-trial2026-09-29 https://evidence-hub.com/study/2695-tailored-antibiotic-susceptibility-guided-therapy-via-gastric-juice2026-10-08 https://evidence-hub.com/study/2696-otological-safety-profile-of-100-manuka-honey-application-in2026-10-08 https://evidence-hub.com/study/2697-six-versus-twelve-week-therapy-for-non-surgically-treated-diabetic2026-10-04 https://evidence-hub.com/study/2698-visiting-staff-division-of-gastroenterology-and-department-of2026-10-04 https://evidence-hub.com/study/2699-efficacies-of-hybrid-high-dose-dual-and-bismuth-quadruple-therapies2026-10-08 https://evidence-hub.com/study/2701-biodegradable-levofloxacin-nanoparticles-for-sustained-ocular-drug2026-10-08 https://evidence-hub.com/study/2703-levofloxacin-and-trovafloxacin-inhibition-of-experimental-fracture2026-10-08 https://evidence-hub.com/study/2706-identification-of-influx-transporter-for-the-quinolone-antibacterial2026-10-08 https://evidence-hub.com/study/2707-comparative-roles-of-levofloxacin-and-ofloxacin-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/2708-primary-levofloxacin-resistance-and-gyra-b-mutations-among2026-10-03 https://evidence-hub.com/study/2711-levofloxacin-efficacy-in-the-treatment-of-community-acquired2026-10-20 https://evidence-hub.com/study/2712-activity-of-levofloxacin-and-ciprofloxacin-against-urinary-pathogens2026-10-20 https://evidence-hub.com/study/2713-comparative-pharmacokinetics-of-ciprofloxacin-gatifloxacin2026-10-03 https://evidence-hub.com/study/2716-ciprofloxacin-and-levofloxacin-resistance-among-methicillin-sensitive2026-10-05 https://evidence-hub.com/study/2717-efficacy-of-two-one-week-rabeprazole-levofloxacin-based-triple2026-10-08 https://evidence-hub.com/study/2718-a-population-pharmacokinetic-analysis-of-the-penetration-of-the2026-10-08 https://evidence-hub.com/study/2720-azithromycin-found-to-be-comparable-to-levofloxacin-for-the-treatment2026-10-03 https://evidence-hub.com/study/2721-allergy-to-quinolones-low-cross-reactivity-to-levofloxacin2026-10-08 https://evidence-hub.com/study/2729-levofloxacine-for-the-treatment-of-pneumococcal-pneumonia-results-of2026-10-08 https://evidence-hub.com/study/2730-meta-analysis-of-randomized-controlled-trials-on-effect-of-tanreqing2026-10-08 https://evidence-hub.com/study/2731-clinical-benefits-and-cost-effectiveness-of-moxifloxacin-as-initial2026-10-08 https://evidence-hub.com/study/2732-quinolones-for-treatment-of-nosocomial-pneumonia-a-meta-analysis2026-10-19 https://evidence-hub.com/study/2733-effectiveness-and-safety-of-proton-pump-inhibitor-and-levofloxacin2026-10-08 https://evidence-hub.com/study/2734-fluoroquinolone-prophylaxis-in-haematological-cancer-patients-with2026-10-08 https://evidence-hub.com/study/2735-empiric-antibiotics-for-community-acquired-pneumonia-in-adult2026-10-08 https://evidence-hub.com/study/2736-efficacy-of-moxifloxacin-in-treating-bacterial-conjunctivitis-a-meta2026-10-08 https://evidence-hub.com/study/2737-comparative-effectiveness-and-safety-of-antibiotic-prophylaxis-during2026-10-08 https://evidence-hub.com/study/2738-quinolones-for-uncomplicated-acute-cystitis-in-women2026-10-08 https://evidence-hub.com/study/2739-antibiotic-adjuvant-therapy-for-pulmonary-infection-in-cystic-fibrosis2026-10-08 https://evidence-hub.com/study/2740-epidemiology-of-pathogens-and-antimicrobial-resistanceof-catheter2026-10-13 https://evidence-hub.com/study/2741-evolution-of-helicobacter-pylori-therapy-from-a-meta-analytical2026-10-08 https://evidence-hub.com/study/2742-pneumonia-due-to-pseudomonas-aeruginosa-the-levofloxacin-clinical2026-10-20 https://evidence-hub.com/study/2743-antibiotic-resistance-and-bacterial-co-infections-in-covid-192026-10-08 https://evidence-hub.com/study/2744-a-systematic-literature-review-and-network-meta-analysis-of-the2026-10-13 https://evidence-hub.com/study/2745-comparison-of-treatments-for-preventing-lower-urinary-tract-symptoms2026-10-13 https://evidence-hub.com/study/2746-efficacy-and-safety-of-treatment-regimens-for-drug-resistant2026-10-08 https://evidence-hub.com/study/2747-bedaquiline-and-linezolid-regimens-for-multidrug-resistant2026-10-08 https://evidence-hub.com/study/2748-global-antimicrobial-resistance-trends-in-group-b-streptococcus2026-10-08 https://evidence-hub.com/study/2749-efficacy-and-safety-of-shorter-multidrug-resistant-or-rifampicin2026-10-13 https://evidence-hub.com/study/2750-worldwide-threatening-prevalence-of-carbapenem-resistant-pseudomonas2026-10-13 https://evidence-hub.com/study/2751-clarithromycin-resistant-helicobacter-pylori-in-africa-a-systematic2026-10-08 https://evidence-hub.com/study/2752-a-systematic-review-and-individual-bacterial-species-level-meta2026-10-08 https://evidence-hub.com/study/2753-antimicrobial-resistance-in-meat-and-meat-products-from-asia-an2026-10-13 https://evidence-hub.com/study/2754-effectiveness-of-different-antibiotic-lock-solutions-on-catheter2026-10-08 https://evidence-hub.com/study/2755-a-systematic-review-and-meta-analysis-to-identify-behavioural-content2026-10-13 https://evidence-hub.com/study/2756-antibiotic-resistance-in-helicobacter-pylori-among-children-and2026-10-08 https://evidence-hub.com/study/2757-guideline-based-bismuth-quadruple-therapy-for-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/2758-global-mapping-of-antibiotic-resistance-rates-among-clinical-isolates2026-10-13 https://evidence-hub.com/study/2759-the-corneal-biomechanical-changes-of-phacoemulsification-in-cataract2026-10-08 https://evidence-hub.com/study/2760-effect-of-antibiotics-with-anaerobic-coverage-on-graft-versus-host2026-10-08 https://evidence-hub.com/study/2761-research-mapping-and-comparative-assessment-of-drug-treatment2026-10-08 https://evidence-hub.com/study/2762-the-economics-of-antibiotic-resistance-a-systematic-review-and-meta2026-10-13 https://evidence-hub.com/study/2763-shorter-versus-longer-antibiotic-treatment-in-children-with-community2026-10-08 https://evidence-hub.com/study/2764-lefamulin-versus-omadacycline-for-community-acquired-bacterial2026-10-08 https://evidence-hub.com/study/2765-global-status-of-antimicrobial-resistance-in-clinical-enterococcus2026-10-13 https://evidence-hub.com/study/2766-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials2026-10-08 https://evidence-hub.com/study/2767-global-spread-and-antimicrobial-resistance-of-aeromonas-hydrophila-in2026-10-08 https://evidence-hub.com/study/2768-impact-of-rapid-nucleic-acid-amplification-tests-for-tuberculosis-on2026-10-08 https://evidence-hub.com/study/2769-comparative-efficacy-and-safety-of-high-dose-rifamycin-regimens-for2026-10-06 https://evidence-hub.com/study/2770-establishing-the-safety-and-efficacy-of-bedaquiline-containing2026-10-06 https://evidence-hub.com/study/2771-characteristics-of-children-and-adolescents-with-multidrug-resistant2026-10-08 https://evidence-hub.com/study/2773-is-penicillin-nonsusceptible-streptococcus-pneumoniae-a-significant2026-10-08 https://evidence-hub.com/study/2774-therapeutic-approach-of-chronic-pseudomonas-infection-in-cystic2026-10-08 https://evidence-hub.com/study/2776-meta-analysis-on-the-efficacy-and-safety-of-moxifloxacin-and2026-10-20 https://evidence-hub.com/study/2779-levofloxacin-versus-ciprofloxacin-in-the-treatment-of-urinary-tract2026-10-20 https://evidence-hub.com/study/2781-comparing-therapeutic-and-adverse-effects-of-moxifloxacin-and2026-10-08 https://evidence-hub.com/study/2787-a-meta-analysis-of-treatment-of-bacterial-infections-with-double2026-10-08 https://evidence-hub.com/study/2792-comparative-efficacy-and-acceptability-of-five-anti-tubercular-drugs2026-10-08 https://evidence-hub.com/study/2793-meta-analysis-of-drug-resistance-of-escherichia-coli-to-antibiotics2026-10-08 https://evidence-hub.com/study/2794-meta-analysis-of-two-drugs-in-the-treatment-for-community-acquired2026-10-08 https://evidence-hub.com/study/2795-can-antibiotics-prevent-acute-copd-exacerbation-a-systematic-review2026-10-08 https://evidence-hub.com/study/2798-inhaled-antibiotics-beyond-aminoglycosides-polymyxins-and-aztreonam-a2026-10-08 https://evidence-hub.com/study/2799-worldwide-h-pylori-antibiotic-resistance-a-systematic-review2026-10-08 https://evidence-hub.com/study/2800-helicobacter-pylori-and-gastric-or-duodenal-ulcer2026-10-08 https://evidence-hub.com/study/2801-legionella-pneumonia-in-hospitalized-adults-with-respiratory-failure2026-10-08 https://evidence-hub.com/study/2802-non-standard-treatment-for-uncomplicated-chlamydia-trachomatis2026-10-13 https://evidence-hub.com/study/2803-treatment-of-helicobacter-pylori-infection-20142026-10-08 https://evidence-hub.com/study/2804-systematic-review-would-susceptibility-guided-treatment-achieve2026-10-08 https://evidence-hub.com/study/2805-fluoroquinolones-or-macrolides-in-combination-with-lactams-in-adult2026-10-08 https://evidence-hub.com/study/2806-is-it-time-to-rethink-the-notion-of-carbapenem-sparing-therapy2026-10-08 https://evidence-hub.com/study/2807-what-tendon-pathology-is-seen-on-imaging-in-people-who-have-taken2026-10-08 https://evidence-hub.com/study/2808-elizabethkingia-in-the-mena-region-2000-2024-a-review-of-distribution2026-10-08 https://evidence-hub.com/study/2809-relapsing-polychondritis-following-pd-1-blockade-diagnosed-via-18f2026-10-13 https://evidence-hub.com/study/2810-empirical-therapy-versus-tailored-therapy-for-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/2811-systematic-review-genotypic-and-phenotypic-resistance-of2026-10-08 https://evidence-hub.com/study/2812-determinants-of-pneumococcal-carriage-by-age-in-africa-2000-2021-a2026-10-08 https://evidence-hub.com/study/2813-impact-of-hormonal-treatments-for-endometriosis-on-the-reproductive2026-10-13 https://evidence-hub.com/study/2814-ertapenem-as-an-antibiotic-prophylaxis-for-colectomies-and2026-10-08 https://evidence-hub.com/study/2815-the-efficacy-of-acupuncture-on-endometrial-receptivity-in-infertile2026-10-08 https://evidence-hub.com/study/2816-global-prevalence-and-antibiotic-resistance-profiles-of-carbapenem2026-10-13 https://evidence-hub.com/study/2817-antibiotic-prophylaxis-in-stone-surgery-a-systematic-review-of-the2026-10-13 https://evidence-hub.com/study/2818-assessing-the-economic-burden-of-complicated-urinary-tract-infection2026-10-13 https://evidence-hub.com/study/2819-efficacy-and-safety-of-vonoprazan-amoxicillin-dual-therapy-versus2026-10-08 https://evidence-hub.com/study/2820-global-trends-in-antimicrobial-resistance-of-enterococcus-faecium-a2026-10-13 https://evidence-hub.com/study/2821-delayed-type-hypersensitivity-to-mycobacterium-tuberculosis-antigens2026-10-08 https://evidence-hub.com/study/2822-a-synthetic-cohort-analysis-of-postoperative-management-of-primary2026-10-08 https://evidence-hub.com/study/2823-global-trends-in-carbapenem-resistant-gram-negative-bacteria-research2026-10-13 https://evidence-hub.com/study/2824-network-meta-analysis-of-treatment-interventions-for-helicobacter2026-10-08 https://evidence-hub.com/study/2825-efficacy-and-safety-outcomes-reported-in-human-leptospirosis-studies2026-10-13 https://evidence-hub.com/study/2826-diagnosis-management-and-outcomes-of-drug-induced-erythrocytosis-a2026-10-03 https://evidence-hub.com/study/2827-a-systematic-review-and-meta-analysis-of-phase-iii-randomized2026-10-08 https://evidence-hub.com/study/2829-efficacy-and-safety-of-moxifloxacin-vs-levofloxacin-for-acute2026-10-08 https://evidence-hub.com/study/2830-effectiveness-of-levofloxacin-for-multidrug-resistant-pulmonary2026-10-08 https://evidence-hub.com/study/2835-antibacterial-activity-test-of-bay-leaf-extracts-syzygium-polyanthum2026-10-08 https://evidence-hub.com/study/2836-adverse-events-in-healthy-individuals-and-mdr-tb-contacts-treated2026-10-08 https://evidence-hub.com/study/2837-prophylaxis-and-treatment-of-anthrax-in-pregnant-women-a-systematic2026-10-08 https://evidence-hub.com/study/2838-evaluation-of-the-efficacy-and-safety-of-tigecycline-for-treatment-of2026-10-08 https://evidence-hub.com/study/2839-prs68-a-systematic-review-of-chronic-rhinosinusitis-in-asia-pacfic2026-10-08 https://evidence-hub.com/study/2840-a-comprehensive-review-on-ozenoxacin-cream-for-treatment-of-impetigo2026-10-08 https://evidence-hub.com/study/2842-prevalence-of-antibiotic-resistance-in-helicobacter-pylori-a-recent2026-10-08 https://evidence-hub.com/study/2845-those-who-cannot-remember-the-past-are-condemned-to-repeat-it-drug2026-10-08 https://evidence-hub.com/study/2847-a-controlled-trial-of-levofloxacin-and-lomefloxacin-in-the-treatment2026-10-20 https://evidence-hub.com/study/2848-efficacy-and-safety-of-7-days-versus-10-days-triple-therapy-based-on2026-10-20 https://evidence-hub.com/study/2849-efficacy-of-a-tailored-pcr-guided-triple-therapy-in-the-treatment-of2026-10-06 https://evidence-hub.com/study/2850-a-randomized-control-trial-comparing-2-levofloxacin-containing-second2026-10-08 https://evidence-hub.com/study/2851-effect-of-the-administration-period-of-perioperative-topical2026-10-06 https://evidence-hub.com/study/2852-comparison-of-levofloxacin-based-prophylaxis-regimens-for-transrectal2026-10-13 https://evidence-hub.com/study/2853-aqueous-and-vitreous-penetration-of-levofloxacin-after-oral2026-10-08 https://evidence-hub.com/study/2854-assessing-hepatotoxicity-in-novel-and-standard-short-regimens-for2026-10-08 https://evidence-hub.com/study/2855-a-phase-3-multi-center-multinational-randomized-double-blind-placebo2026-10-08 https://evidence-hub.com/study/2856-comparative-bioavailability-of-two-oral-formulations-of-levofloxacin2026-10-08 https://evidence-hub.com/study/2857-choice-between-levofloxacin-and-moxifloxacin-and-multidrug-resistant2026-10-08 https://evidence-hub.com/study/2858-helicobacter-pylori-eradication-with-levofloxacin-or-clarithromycin2026-10-06 https://evidence-hub.com/study/2859-efficacy-and-safety-of-antofloxacin-based-triple-therapy-for2026-10-08 https://evidence-hub.com/study/2860-prophylactic-antibiotic-therapy-for-fractures-of-the-maxillary-sinus2026-10-08 https://evidence-hub.com/study/2861-evaluation-of-proinflammatory-cytokines-and-adverse-events-in-healthy2026-10-06 https://evidence-hub.com/study/2862-susceptibility-guided-quadruple-therapy-is-not-superior-to-medication2026-10-06 https://evidence-hub.com/study/2863-efficacy-of-levofloxacin-and-rifaximin-based-quadruple-therapy-in2026-10-08 https://evidence-hub.com/study/2864-phase-ii-investigation-of-the-efficacy-of-antimycobacterial-therapy2026-10-08 https://evidence-hub.com/study/2865-comparative-study-of-the-disinfection-effects-of-three-types-of2026-10-08 https://evidence-hub.com/study/2866-the-value-of-melatonin-supplementation-in-postmenopausal-women-with2026-10-13 https://evidence-hub.com/study/2867-high-dose-dual-therapy-is-superior-to-standard-first-line-or-rescue2026-10-08 https://evidence-hub.com/study/2868-a-prospective-randomized-trial-comparing-a-combined-regimen-of2026-10-13 https://evidence-hub.com/study/2869-molecular-testing-guided-therapy-versus-susceptibility-testing-guided2026-10-06 https://evidence-hub.com/study/2870-levofloxacin-does-not-decrease-mortality-in-staphylococcus-aureus2026-10-08 https://evidence-hub.com/study/2871-vonoprazan-versus-rabeprazole-in-dual-therapy-with-amoxicillin-for2026-10-13 https://evidence-hub.com/study/2872-risk-of-tuberculosis-infection-in-young-children-exposed-to-multidrug2026-10-08 https://evidence-hub.com/study/2873-oral-administration-of-enterococcus-lactis-strain-sf68-speeds-the2026-10-08 https://evidence-hub.com/study/2874-effect-and-safety-of-bronchoscopy-based-on-imaging-evaluation-in2026-10-08 https://evidence-hub.com/study/2875-single-access-mini-pcnl-with-flexible-cystoscopy-vs-multi-access-mini2026-10-13 https://evidence-hub.com/study/2876-the-efficacy-of-two-triple-therapy-regimens-and-one-quadruple-regimen2026-10-08 https://evidence-hub.com/study/2877-implementing-an-ai-enhanced-clinical-decision-support-system-for2026-10-13 https://evidence-hub.com/study/2878-phage-therapy-analysis-of-effectiveness-in-comorbid-patients-with2026-10-08 https://evidence-hub.com/study/2879-prognostic-factors-associated-with-primary-non-responsiveness-to2026-10-10 https://evidence-hub.com/study/2880-comparison-of-visual-quality-and-optical-zones-after-transprk-smile2026-10-08 https://evidence-hub.com/study/2881-randomized-multicenter-trial-comparing-minocycline-and-ornidazole2026-10-08 https://evidence-hub.com/study/2882-effect-of-topical-application-of-antimicrobial-peptide-pl-52026-10-08 https://evidence-hub.com/study/2883-efficacy-and-cost-effectiveness-comparison-of-7-days-vonoprazan2026-10-08 https://evidence-hub.com/study/2884-can-lite-procedure-combined-with-a-short-course-antibiotic-treatment2026-10-08 https://evidence-hub.com/study/2885-impact-of-supplementing-limosilactobacillus-fermentum-mn-lf23-on-the2026-10-08 https://evidence-hub.com/study/2886-jueling-mingmu-decoction-combined-with-ranibizumab-for-retinal-vein2026-10-08 https://evidence-hub.com/study/2887-application-value-of-fibro-bronchoscopic-cryosurgery-combined-with2026-10-08 https://evidence-hub.com/study/2888-evaluation-of-the-therapeutic-effect-of-estrogen-replacement-therapy2026-10-08 https://evidence-hub.com/study/2889-comparison-of-the-effectiveness-of-pre-urodynamic-single-dose2026-10-20 https://evidence-hub.com/study/2890-clinical-impact-of-high-dose-esomeprazole-amoxicillin-dual-therapy-as2026-10-08 https://evidence-hub.com/study/2891-long-term-outcomes-in-drug-resistant-tuberculosis-with-bedaquiline2026-10-08 https://evidence-hub.com/study/2892-14-day-tailored-pcr-guided-triple-therapy-versus-14-day-non-bismuth2026-10-08 https://evidence-hub.com/study/2893-effect-of-topical-gentamicin-in-preventing-surgical-site-infection-in2026-10-08 https://evidence-hub.com/study/2894-impact-of-postoperative-dairy-consumption-on-oral-wound-healing2026-10-08 https://evidence-hub.com/study/2895-regional-multi-center-randomized-trial-of-three-vonoprazan2026-10-08 https://evidence-hub.com/study/2896-effects-of-catheter-tracking-management-on-urinary-tract-function-and2026-10-20 https://evidence-hub.com/study/2897-efficacy-and-safety-of-vonoprazan-and-high-dose-amoxicillin-dual2026-10-13 https://evidence-hub.com/study/2898-efficacy-and-safety-of-a-bio-absorbable-antibiotic-delivery-in2026-10-08 https://evidence-hub.com/study/2899-intravenous-metronidazole-levofloxacin-containing-triple-therapy-for2026-10-08 https://evidence-hub.com/study/2900-a-retrospectively-registered-pilot-randomized-controlled-trial-of2026-10-08 https://evidence-hub.com/study/2901-evaluating-the-antibiotic-spectrum-index-in-a-stewardship-focused2026-10-08 https://evidence-hub.com/study/2902-tailored-triple-plus-bismuth-therapy-based-on-previous-antibiotic2026-10-08 https://evidence-hub.com/study/2903-effect-of-femtosecond-laser-assisted-cataract-surgery-for-cataracts2026-10-06 https://evidence-hub.com/study/2904-high-dose-dual-therapy-versus-culture-based-susceptibility-guided2026-10-08 https://evidence-hub.com/study/2905-tailored-susceptibility-guided-therapy-via-gastric-juice-pcr-for-the2026-10-08 https://evidence-hub.com/study/2906-tailored-helicobacter-pylori-therapy-is-more-effective-than2026-10-08 https://evidence-hub.com/study/2907-a-clinical-trial-evaluating-the-usefulness-of-tailored-antimicrobial2026-10-13 https://evidence-hub.com/study/2908-response-to-levofloxacin-containing-versus-clarithromycin-containing2026-10-08 https://evidence-hub.com/study/2909-efficacy-and-safety-of-ningmitai-capsules-in-patients-with-chronic2026-10-08 https://evidence-hub.com/study/2910-escherichia-coli-nissle-1917-as-adjuvant-therapy-in-patients-with2026-10-08 https://evidence-hub.com/study/2912-lb-5-dav132-protects-intestinal-microbiota-of-patients-treated-with2026-10-08 https://evidence-hub.com/study/2913-trial-evaluating-ambulatory-therapy-of-travelers-diarrhea-treat-td2026-10-08 https://evidence-hub.com/study/2914-safety-and-efficacy-of-nemonoxacin-versus-levofloxacin-in-the2026-10-20 https://evidence-hub.com/study/2915-comparison-of-10-day-bismuth-quadruple-therapy-with-high-dose2026-10-08 https://evidence-hub.com/study/2917-efficacy-of-additional-solifenacin-succinate-therapy-for-storage2026-10-20 https://evidence-hub.com/study/2920-intensified-treatment-with-high-dose-rifampicin-and-levofloxacin2026-10-08 https://evidence-hub.com/study/2925-effectiveness-of-jinying-capsule-on-pelvic-inflammatory-disease-in2026-10-08 https://evidence-hub.com/study/2928-six-weeks-of-fluoroquinolone-antibiotic-therapy-for-patients-with2026-10-08 https://evidence-hub.com/study/2932-fovocip-study-a-multicenter-randomized-trial-of-fosfomycin-versus2026-10-13 https://evidence-hub.com/study/2934-impact-of-antibiotic-therapy-on-the-rate-of-negative-test-results-for2026-10-08 https://evidence-hub.com/study/2935-prulifloxacin-versus-levofloxacin-in-the-treatment-of-respiratory-and2026-10-20 https://evidence-hub.com/study/2936-community-acquired-pneumonia-usefulness-of-clinical-presentation-in2026-10-08 https://evidence-hub.com/study/2937-clinical-efficacy-and-safety-of-moxifloxacin-versus-levofloxacin-plus2026-10-20 https://evidence-hub.com/study/2938-the-effect-of-indacaterol-during-an-acute-exacerbation-of-copd2026-10-08 https://evidence-hub.com/study/2939-usefulness-and-problems-of-the-urinary-tract-infection-criteria-for2026-10-20 https://evidence-hub.com/study/2940-penetration-of-levofloxacin-into-skin-tissue-after-oral2026-10-06 https://evidence-hub.com/study/2941-addition-of-a-2-month-low-dose-course-of-levofloxacin-to-long-term2026-10-06 https://evidence-hub.com/study/2942-pharmacokinetics-of-levofloxacin-during-continuous-venovenous2026-10-03 https://evidence-hub.com/study/2943-immunomodulatory-effects-of-levofloxacin-on-patients-with-pneumonia2026-10-08 https://evidence-hub.com/study/2944-comparison-of-levofloxacin-and-moxifloxacin-based-triple-therapies2026-10-06 https://evidence-hub.com/study/2945-comparative-study-of-levofloxacin-in-the-treatment-of-children-with2026-10-20 https://evidence-hub.com/study/2946-efficacy-of-ppi-levofloxacin-and-amoxicillin-in-the-eradication-of2026-10-08 https://evidence-hub.com/study/2947-pharmacokinetics-and-safety-of-oral-levofloxacin-in-human2026-10-06 https://evidence-hub.com/study/2948-ocular-penetration-of-levofloxacin-ofloxacin-and-ciprofloxacin-in2026-10-08 https://evidence-hub.com/study/2949-human-aqueous-humor-levels-of-oral-ciprofloxacin-levofloxacin-and2026-10-06 https://evidence-hub.com/study/2950-comparison-of-short-course-5-days-and-standard-10-days-treatment-for2026-10-06 https://evidence-hub.com/study/2951-optimal-duration-for-the-use-of-0-5-levofloxacineye-drops-before2026-10-06 https://evidence-hub.com/study/2952-prevalence-and-trends-of-multiple-antimicrobial-resistance-of2026-10-08 https://evidence-hub.com/study/2953-tamsulosin-treatment-of-chronic-non-bacterial-prostatitis2026-10-08 https://evidence-hub.com/study/2954-multicenter-evaluation-of-ceftazidime-avibactam-in-pediatric-patients2026-10-13 https://evidence-hub.com/study/2955-steerable-versus-conventional-flexible-and-navigable-suction-ureteral2026-10-13 https://evidence-hub.com/study/2956-quantitative-pcr-of-string-test-collected-gastric-material-a-feasible2026-10-08 https://evidence-hub.com/study/2957-gut-faecalibacterium-abundance-in-patients-with-plasma-cell-disorders2026-10-08 https://evidence-hub.com/study/2958-same-day-ambulatory-c-samba-a-multicenter-prospective-randomized2026-10-08 https://evidence-hub.com/study/2959-comparing-the-efficacy-and-safety-of-the-abc-14-regimen-azacitidine2026-10-08 https://evidence-hub.com/study/2960-intra-articular-antibiotic-infusions-versus-intravenous-antibiotic2026-10-08 https://evidence-hub.com/study/2961-multicentre-controlled-open-randomised-clinical-trial-to-assess2026-10-08 https://evidence-hub.com/study/2962-real-world-applications-of-imipenem-cilastatin-relebactam-insights2026-10-13 https://evidence-hub.com/study/2963-susceptibility-guided-sequential-strategy-versus-empirical-therapy2026-10-08 https://evidence-hub.com/study/2964-management-of-helicobacter-pylori-treatment-failures-a-large2026-10-13 https://evidence-hub.com/study/2965-ceftriaxone-versus-cefazolin-susceptibility-as-a-surrogate-marker-for2026-10-13 https://evidence-hub.com/study/2966-comparative-evaluation-of-intensified-short-course-regimen-and2026-10-08 https://evidence-hub.com/study/2967-alnuctamab-a-bivalent-b-cell-maturation-antigen-targeting-t-cell2026-10-08 https://evidence-hub.com/study/2968-using-the-comparing-oral-versus-parenteral-antimicrobial-therapy2026-10-08 https://evidence-hub.com/study/2969-long-term-oral-suppressive-antimicrobial-therapy-in-infective2026-10-08 https://evidence-hub.com/study/2970-the-effects-of-a-nursing-program-applying-zinc-oxide-mixed-with2026-10-13 https://evidence-hub.com/study/2971-consolidation-of-a-genomic-epidemiological-surveillance-network-for2026-10-08 https://evidence-hub.com/study/2972-comparisons-of-efficacy-and-safety-of-400-or-800-ml-bacterial-count2026-10-08 https://evidence-hub.com/study/2973-population-pharmacokinetic-and-exposure-response-study-of-a-novel2026-10-08 https://evidence-hub.com/study/2974-antibiotic-concentrations-after-massive-transfusion-acme-study-a2026-10-08 https://evidence-hub.com/study/2975-vonoprazan-based-quadruple-therapy-is-non-inferior-to-esomeprazole2026-10-08 https://evidence-hub.com/study/2976-multicenter-phase-ii-trial-of-trastuzumab-and-docetaxel-for-her22026-10-08 https://evidence-hub.com/study/2977-genotype-stratified-adjunctive-dexamethasone-for-tuberculous2026-10-08 https://evidence-hub.com/study/2978-establishing-the-exposure-qt-relationship-during-bedaquiline2026-10-08 https://evidence-hub.com/study/2979-new-all-oral-short-term-regimen-for-multidrug-resistant-tuberculosis2026-10-08 https://evidence-hub.com/study/2980-ruxolitinib-and-decitabine-plus-a-busulfan-cyclophosphamide2026-10-13 https://evidence-hub.com/study/2981-efficacy-of-adaptive-blood-purification-for-septic-shock-eabpss2026-10-08 https://evidence-hub.com/study/2982-magnetic-resonance-imaging-guided-transurethral-ultrasound-ablation2026-10-13 https://evidence-hub.com/study/2983-safety-run-in-and-part-1-of-gimema-aml1718-venetoclax-combined-with2026-10-08 https://evidence-hub.com/study/2984-trial-of-high-dose-oral-rifampin-in-adults-with-tuberculous-meningitis2026-10-08 https://evidence-hub.com/study/2985-pharmaceutical-cost-dynamics-for-the-treatment-of-rifampicin2026-10-08 https://evidence-hub.com/study/2986-antioxidant-support-for-the-corneal-endothelium-evidence-from-vitamin2026-10-08 https://evidence-hub.com/study/2987-a-multicenter-phase-ii-study-of-modified-folfirinox-for-first-line2026-10-08 https://evidence-hub.com/study/2988-optimized-anti-tuberculosis-duration-for-drug-susceptible-pulmonary2026-10-08 https://evidence-hub.com/study/2989-ciprofloxacin-versus-aminoglycoside-ciprofloxacin-for-bubonic-plague2026-10-08 https://evidence-hub.com/study/2990-efficacy-and-safety-of-lascufloxacin-for-nursing-and-healthcare2026-10-08 https://evidence-hub.com/study/2991-exacerbation-of-cmv-and-nontuberculous-mycobacterial-infections2026-10-08 https://evidence-hub.com/study/2992-real-world-effectiveness-of-intravenous-and-oral-antibiotic-stepdown2026-10-13 https://evidence-hub.com/study/2994-levofloxacin-versus-clarithromycin-in-a-10-day-triple-therapy-regimen2026-10-08 https://evidence-hub.com/study/2995-empirical-modified-sequential-therapy-containing-levofloxacin-and2026-10-08 https://evidence-hub.com/study/2996-delamanid-linezolid-levofloxacin-and-pyrazinamide-for-the-treatment2026-10-08 https://evidence-hub.com/study/2997-improving-traditional-registrational-trial-endpoints-development-and2026-10-20 https://evidence-hub.com/study/2999-a-phase-iii-clinical-trial-of-0-5-levofloxacin-ophthalmic-solution2026-10-08 https://evidence-hub.com/study/3001-cumulative-clinical-trial-experience-with-levofloxacin-for-patients2026-10-08 https://evidence-hub.com/study/3002-procalcitonin-for-selecting-the-antibiotic-regimen-in-outpatients2026-10-08 https://evidence-hub.com/study/3003-a-randomized-controlled-multicentre-clinical-trial-of-levofloxacin2026-10-08 https://evidence-hub.com/study/3004-adding-ofloxacin-to-standard-triple-drug-regimens-increased-the2026-10-08 https://evidence-hub.com/study/3013-comparison-of-levofloxacin-based-versus-clarithromycin-based-triple2026-10-08 https://evidence-hub.com/study/3017-different-bismuth-based-therapies-for-eradicating-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/3018-drug-resistance-profiles-population-structure-genomic-clustering-and2026-10-08 https://evidence-hub.com/study/3019-routine-immunization-uptake-and-timeliness-in-young-children-exposed2026-10-08 https://evidence-hub.com/study/3020-antibiotic-stress-affects-the-secretion-and-physicochemical-features2026-10-08 https://evidence-hub.com/study/3021-preventive-effect-of-helicobacter-pylori-treatment-on-colorectal2026-10-08 https://evidence-hub.com/study/3022-chestnut-castanea-sativa-mill-leaf-extract-and-pure-castalagin-reduce2026-10-08 https://evidence-hub.com/study/3023-helicobacter-pylori-infection-in-children-an-overview-of-global2026-10-08 https://evidence-hub.com/study/3024-impact-of-empiric-antibiotics-on-risk-of-clostridioides-difficile-a2026-10-08 https://evidence-hub.com/study/3025-multidrug-resistant-vibrio-spp-carrying-carbapenemase-genes-in2026-10-08 https://evidence-hub.com/study/3026-evaluation-of-two-naturally-occurring-phytochemicals-6-methoxy-22026-10-08 https://evidence-hub.com/study/3027-in-vitro-susceptibility-and-synergistic-effect-of-bismuth-against2026-10-08 https://evidence-hub.com/study/3028-periprosthetic-joint-infection-caused-by-brucella-four-case-reports2026-10-08 https://evidence-hub.com/study/3029-association-between-systemic-blood-pressure-control-and-outcomes-of2026-10-08 https://evidence-hub.com/study/3030-high-resolution-genomics-uncovers-region-specific-evolution-and2026-10-08 https://evidence-hub.com/study/3031-efficacy-and-safety-of-azithromycin-in-treating-sinusitis-patients-a2026-10-08 https://evidence-hub.com/study/3032-validation-of-crownlab-pneumoplex-for-the-detection-of-klebsiella2026-10-13 https://evidence-hub.com/study/3033-characterization-of-canine-otitis-externa-pseudomonas-aeruginosa2026-10-08 https://evidence-hub.com/study/3034-clinical-characteristics-and-genome-epidemiology-of-stenotrophomonas2026-10-13 https://evidence-hub.com/study/3035-quantitative-analysis-of-the-effect-of-icl-orientation-on2026-10-08 https://evidence-hub.com/study/3036-increased-antimicrobial-consumption-isolation-rate-and-resistance2026-10-13 https://evidence-hub.com/study/3037-anti-tb-drugs-for-drug-sensitive-and-drug-resistant-mycobacterium2026-10-08 https://evidence-hub.com/study/3038-exploratory-analysis-of-biofilm-formation-and-virulence-gene2026-10-13 https://evidence-hub.com/study/3039-the-association-between-parenteral-antimicrobials-and-bacterial2026-10-08 https://evidence-hub.com/study/3040-pandemic-associated-shifts-in-microbial-ecology-and-antimicrobial2026-10-13 https://evidence-hub.com/study/3041-necrotic-liver-metastasis-from-anorectal-mucosal-melanoma-mimicking-a2026-10-13 https://evidence-hub.com/study/3042-detection-and-management-of-eosinophilia-in-asthmatic-adults-and2026-10-08 https://evidence-hub.com/study/3043-corneal-surface-changes-after-stromal-lenticule-addition-keratoplasty2026-10-08 https://evidence-hub.com/study/3044-the-phenomenon-of-antimicrobial-resistance-in-southern-italy-an2026-10-13 https://evidence-hub.com/study/3045-vonoprazan-amoxicillin-dual-rifabutin-based-triple-and-bismuth2026-10-08 https://evidence-hub.com/study/3046-community-based-household-surface-sampling-a-citizen-science-approach2026-10-08 https://evidence-hub.com/study/3047-the-future-approach-for-the-management-of-acute-bacterial-skin-and2026-10-08 https://evidence-hub.com/study/3048-canadian-antibiotic-prescribing-for-sepsis-caps-study-a-post-hoc2026-10-13 https://evidence-hub.com/study/3049-fluoroquinolone-prophylaxis-uncovers-high-prevalence-rates-of2026-10-13 https://evidence-hub.com/study/3050-different-patterns-of-antimicrobial-non-susceptibility-of-the2026-10-08 https://evidence-hub.com/study/3051-long-term-macrolides-in-chronic-respiratory-diseases-dusk-or-a-new2026-10-08 https://evidence-hub.com/study/3052-the-effectiveness-and-safety-of-bedaquiline-pretomanid-and-linezolid2026-10-13 https://evidence-hub.com/study/3053-efficacy-of-colistin-based-combinations-against-pandrug-resistant2026-10-08 https://evidence-hub.com/study/3054-assessing-blood-brain-barrier-bbb-integrity-in-an-alzheimer-s-disease2026-10-06 https://evidence-hub.com/study/3055-chitosan-mitigates-pan-drug-resistance-in-citrobacter-freundii2026-10-13 https://evidence-hub.com/study/3056-epidemiology-and-antimicrobial-resistance-of-pathogens-in-pediatric2026-10-08 https://evidence-hub.com/study/3057-bacteriophage-therapy-in-women-with-chronic-recurrent-cystitis-caused2026-10-13 https://evidence-hub.com/study/3058-real-world-comparison-of-intravenous-vs-oral-antimicrobial-therapy2026-10-08 https://evidence-hub.com/study/3059-innovative-strategies-against-superbugs-developing-an-ai-cdss-for2026-10-08 https://evidence-hub.com/study/3060-variability-in-prevalence-of-helicobacter-pylori-strains-resistant-to2026-10-08 https://evidence-hub.com/study/3061-community-acquired-pneumonia-recovery-in-the-elderly-caprie-efficacy2026-10-20 https://evidence-hub.com/study/3062-safety-and-efficacy-of-intravenous-tigecycline-in-subjects-with2026-10-08 https://evidence-hub.com/study/3063-macrolide-antibiotics-and-the-risk-of-ventricular-arrhythmia-in-older2026-10-08 https://evidence-hub.com/study/3067-ikinci-basamak-devlet-hastanesinde-iki-farkli-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/3069-different-antibiotic-susceptibility-between-antrum-and-corpus-of-the2026-10-08 https://evidence-hub.com/study/3071-helicobacter-pylori-antimicrobial-resistance-rates-in-the-central2026-10-08 https://evidence-hub.com/study/3075-1579-burkholderia-returns-are-two-drugs-better-or-back-to-bactrim2026-10-08 https://evidence-hub.com/study/3076-cytotoxic-lesion-of-the-corpus-callosum-involving-splenium2026-10-08 https://evidence-hub.com/study/3077-transition-metal-complexes-of-biologically-active-ligands-preparation2026-10-08 https://evidence-hub.com/study/3078-2425-clinical-and-microbiologic-outcomes-among-patients-with2026-10-08 https://evidence-hub.com/study/3084-success-of-susceptibility-guided-eradication-of-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/3085-herb-drug-interactions-quantitative-analysis-of-levofloxacin2026-10-13 https://evidence-hub.com/study/3086-p-1918-reduction-in-antibiotic-use-due-to-universal-decolonization-in2026-10-08 https://evidence-hub.com/study/3087-treatment-response-of-patients-with-tuberculosis-and-hiv-co-infection2026-10-08 https://evidence-hub.com/study/3088-multi-level-time-varying-causality-analysis-of-secondary-conflicts2026-10-08 https://evidence-hub.com/study/3089-analysis-of-gut-microbiota-and-intestinal-secondary-bile-acids2026-10-08 https://evidence-hub.com/study/3090-determination-of-levofloxacin-norfloxacin-and-moxifloxacin-in2026-10-08 https://evidence-hub.com/study/3092-the-under-investigated-facet-of-the-covid-19-pandemic-molecular2026-10-08 https://evidence-hub.com/study/3094-the-effectiveness-of-levofloxacin-in-prevention-of-febrile-episodes2026-10-08 https://evidence-hub.com/study/3096-trends-in-the-antibiotic-resistance-of-s-aureus-clinical-isolates-a-42026-10-08 https://evidence-hub.com/study/3097-comparison-of-garenoxacin-and-levofloxacin-for-the-prophylaxis-of2026-10-08 https://evidence-hub.com/study/3098-prescription-of-antibiotics-in-acute-respiratory-infections-non2026-10-08 https://evidence-hub.com/study/3099-effect-of-ciprofloxacin-and-levofloxacin-on-the-qt-interval-is-this-a2026-10-13 https://evidence-hub.com/study/3100-the-evolution-of-helicobacter-pylori-antibiotics-resistance-over-102026-10-06 https://evidence-hub.com/study/3101-presence-of-infection-influences-the-epithelial-lining-fluid2026-10-06 https://evidence-hub.com/study/3102-levofloxacin-prophylaxis-vs-no-prophylaxis-in-patients-with2026-10-03 https://evidence-hub.com/study/3103-the-significance-of-age-and-causative-bacterial-morphology-in-the2026-10-06 https://evidence-hub.com/study/3104-population-pharmacokinetics-of-levofloxacin-in-plasma-and-bone-of2026-10-08 https://evidence-hub.com/study/3105-important-rise-in-antibiotic-resistance-rates-inhelicobacter-pyloriin2026-10-08 https://evidence-hub.com/study/3106-levofloxacin-prophylaxis-for-pediatric-leukemia-patients-longitudinal2026-10-03 https://evidence-hub.com/study/3107-ciprofloxacin-vs-levofloxacin-for-prophylaxis-during-hematopoietic2026-10-08 https://evidence-hub.com/study/3108-adequacy-of-empiric-gram-negative-coverage-for-septic-patients-at-an2026-10-06 https://evidence-hub.com/study/3109-factors-influencing-treatment-outcomes-in-patients-with-isoniazid2026-10-08 https://evidence-hub.com/study/3110-antibiotic-susceptibility-of-helicobacter-pylori-in-iceland2026-10-08 https://evidence-hub.com/study/3111-effects-of-rifampicin-plus-levofloxacin-or-isoniazid-on-immune2026-10-05 https://evidence-hub.com/study/3112-levofloxacin-prophylaxis-in-hospitalized-children-with-leukemia-a2026-10-08 https://evidence-hub.com/study/3113-a-prospective-evaluation-of-levofloxacin-based-triple-therapy-for2026-10-06 https://evidence-hub.com/study/3114-impact-of-topical-levofloxacin-rinses-on-chronic-rhinosinusitis2026-10-05 https://evidence-hub.com/study/3115-refractory-helicobacter-pylori-infection-in-australia-updated2026-10-06 https://evidence-hub.com/study/3116-clinical-features-and-treatment-of-endophthalmitis-after-cataract2026-10-06 https://evidence-hub.com/study/3117-infectious-keratitis-after-corneal-crosslinking-for-keratoconus2026-10-08 https://evidence-hub.com/study/3118-cefaclor-as-a-first-line-treatment-for-acute-uncomplicated-cystitis-a2026-10-13 https://evidence-hub.com/study/3119-pseudomonas-aeruginosa-as-the-main-causative-agent-of-osteomyelitis2026-10-08 https://evidence-hub.com/study/3120-levofloxacin-for-nih-category-ii-chronic-bacterial-prostatitis-a-real2026-10-06 https://evidence-hub.com/study/3121-pharmacokinetic-and-dynamic-study-of-levofloxacin-and-rifampicin-in2026-10-06 https://evidence-hub.com/study/3122-ciprofloxacin-vs-levofloxacin-for-prophylaxis-in-recipients-of2026-10-08 https://evidence-hub.com/study/3123-comparative-study-on-the-efficacy-of-two-perioperative-chemotherapy2026-10-06 https://evidence-hub.com/study/3124-empiric-meropenem-based-versus-ceftazidime-based-therapy-for-severe2026-10-08 https://evidence-hub.com/study/3125-antibiotic-treatment-patterns-costs-and-resource-utilization-among2026-10-08 https://evidence-hub.com/study/3127-pharmacokinetics-and-safety-of-levofloxacin-for-treatment-of2026-10-08 https://evidence-hub.com/study/3128-evaluating-the-cost-effectiveness-of-levofloxacin-therapy-for2026-10-08 https://evidence-hub.com/study/3129-the-peak-plasma-concentration-cmax-minimum-inhibitory-concentration2026-10-08 https://evidence-hub.com/study/3130-the-incidence-and-burden-of-peripheral-neuropathy-in-pediatric2026-10-08 https://evidence-hub.com/study/3131-dual-route-levofloxacin-delivery-following-revision-surgery-a2026-10-08 https://evidence-hub.com/study/3132-levofloxacin-at-the-usual-dosage-to-treat-bone-and-joint-infections-a2026-10-08 https://evidence-hub.com/study/3134-levofloxacin-prophylaxis-for-pediatric-leukemia-patients-monitoring2026-10-08 https://evidence-hub.com/study/3136-emergence-of-levofloxacin-non-susceptible-streptococcus-pneumoniae2026-10-08 https://evidence-hub.com/study/3137-effectiveness-of-levofloxacin-in-the-induction-of-chemotherapy-in2026-10-08 https://evidence-hub.com/study/3138-prevalence-of-complications-leading-to-a-health-care-contact-after2026-10-08 https://evidence-hub.com/study/3141-initial-antituberculous-regimen-with-better-drug-penetration-into2026-10-08 https://evidence-hub.com/study/3142-risk-of-acute-liver-injury-associated-with-the-use-of-moxifloxacin2026-10-08 https://evidence-hub.com/study/3143-predictors-of-30-day-hospital-readmission-in-patients-with2026-10-08 https://evidence-hub.com/study/3144-treatment-clinical-outcomes-and-predictors-of-mortality-among-a2026-10-08 https://evidence-hub.com/study/3145-a-clinical-pathway-for-community-acquired-pneumonia-an-observational2026-10-08 https://evidence-hub.com/study/3146-immediate-hypersensitivity-to-fluoroquinolones-a-cohort-assessing2026-10-08 https://evidence-hub.com/study/3147-isoniazid-monoresistant-tuberculosis-treatment-outcomes-in-puducherry2026-10-08 https://evidence-hub.com/study/3149-genomic-epidemiology-and-resistance-determinants-of-pseudomonas2026-10-08 https://evidence-hub.com/study/3150-the-use-of-real-world-evidence-to-generate-cost-analysis-of2026-10-08 https://evidence-hub.com/study/3151-comparative-effectiveness-of-exclusive-exposure-to-nafcillin-or2026-10-08 https://evidence-hub.com/study/3152-fluoroquinolone-and-no-risk-of-achilles-tendinopathy-in-childhood2026-10-08 https://evidence-hub.com/study/3153-treatment-of-ventilator-associated-pneumonia-with-piperacillin2026-10-08 https://evidence-hub.com/study/3154-effect-of-levofloxacin-prophylaxis-on-rates-of-febrile-neutropenia-in2026-10-08 https://evidence-hub.com/study/3155-efficacy-of-oral-levofloxacin-monotherapy-against-low-risk-fn-in2026-10-08 https://evidence-hub.com/study/3156-124-impact-of-levofloxacin-mic-on-outcomes-with-levofloxacin-step2026-10-08 https://evidence-hub.com/study/3158-obesity-is-not-strongly-associated-with-increased-risk-for-febrile2026-10-06 https://evidence-hub.com/study/3159-antituberculosis-drug-prescribing-for-inpatients-in-a-national2026-10-08 https://evidence-hub.com/study/3160-impact-of-antibacterial-prophylaxis-during-reinduction-chemotherapy2026-10-06 https://evidence-hub.com/study/3161-clinical-and-molecular-characterization-of-acinetobacter-seifertii-in2026-10-08 https://evidence-hub.com/study/3162-clinical-and-microbiological-profile-of-infectious-keratitis-in-an2026-10-06 https://evidence-hub.com/study/3163-microbial-etiology-susceptibility-profile-of-postradiation2026-10-06 https://evidence-hub.com/study/3164-analysis-of-helicobacter-pylori-resistance-in-patients-with-different2026-10-05 https://evidence-hub.com/study/3165-effects-of-helicobacter-pylori-treatment-on-incidence-of-gastric2026-10-08 https://evidence-hub.com/study/3166-community-acquired-pneumonia-in-an-intensive-care-unit2026-10-08 https://evidence-hub.com/study/3167-real-world-efficacy-of-second-line-therapies-for-helicobacter-pylori2026-10-06 https://evidence-hub.com/study/3168-growing-antibiotic-resistance-in-fatal-cases-of-staphylococcal2026-10-08 https://evidence-hub.com/study/3169-antibiotic-resistances-and-eradication-rates-in-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/3170-clinical-significance-and-antimicrobial-susceptibilities-of2026-10-20 https://evidence-hub.com/study/3171-risk-of-hepatotoxicity-associated-with-fluoroquinolones-a-national2026-10-06 https://evidence-hub.com/study/3172-efficacy-of-fluoroquinolones-as-substitutes-for-ethambutol-or2026-10-08 https://evidence-hub.com/study/3173-antibiotic-allergy-in-children-with-cystic-fibrosis-a-retrospective2026-10-08 https://evidence-hub.com/study/3174-clinical-features-antibiotic-susceptibility-profile-and-outcomes-of2026-10-06 https://evidence-hub.com/study/3175-prevalence-and-antimicrobial-susceptibility-of-ureaplasma-urealyticum2026-10-06 https://evidence-hub.com/study/3176-the-exposure-of-antibiotics-on-the-eradication-of-bismuth-quadruple2026-10-08 https://evidence-hub.com/study/3177-high-rates-of-quinolone-resistance-among-urinary-tract-infections-in2026-10-13 https://evidence-hub.com/study/3178-prevalence-of-group-b-streptococcus-colonization-in-pregnant-women-in2026-10-08 https://evidence-hub.com/study/3179-levofloxacin-in-the-treatment-of-nosocomial-infection-in-critically2026-10-08 https://evidence-hub.com/study/3180-long-term-effect-of-infection-control-practices-and-associated2026-10-08 https://evidence-hub.com/study/3182-cost-effectiveness-analysis-of-moxifloxacin-and-levofloxacin-for2026-10-20 https://evidence-hub.com/study/3185-emergence-of-fluoroquinolone-resistance-in-outpatient-urinary2026-10-13 https://evidence-hub.com/study/3186-anti-infectives-and-the-risk-of-severe-hypoglycemia-in-users-of2026-10-08 https://evidence-hub.com/study/3187-warfarin-fluoroquinolones-sulfonamides-or-azole-antifungals2026-10-08 https://evidence-hub.com/study/3188-risk-factors-and-outcomes-of-infections-caused-by-extremely-drug2026-10-08 https://evidence-hub.com/study/3189-case-of-legionella-pneumonia-complicated-with-pulmonary2026-10-08 https://evidence-hub.com/study/3190-a-breakthrough-in-the-treatment-of-multidrug-resistant-tuberculosis-a2026-10-08 https://evidence-hub.com/study/3191-fluoroquinolone-therapy-and-idiosyncratic-acute-liver-injury-a2026-10-08 https://evidence-hub.com/study/3192-quinolone-induced-arthropathy-an-update-focusing-on-new-mechanistic2026-10-13 https://evidence-hub.com/study/3194-changes-in-antibiotic-resistance-in-recurrent-pseudomonas-aeruginosa2026-10-08 https://evidence-hub.com/study/3197-fluoroquinolone-susceptibility-in-mycobacterium-tuberculosis-after2026-10-08 https://evidence-hub.com/study/3199-gastrointestinal-tract-colonization-with-fluoroquinolone-resistant2026-10-08 https://evidence-hub.com/study/3200-risk-factors-and-mortality-associated-with-clostridium-difficile2026-10-08 https://evidence-hub.com/study/3214-community-acquired-legionella-pneumophila-pneumonia-a-case-control2026-10-08 https://evidence-hub.com/study/3215-a-case-with-a-trend-of-qt-interval-prolongation-due-to-the2026-10-08 https://evidence-hub.com/study/3216-active-surveillance-pharmacovigilance-for-clostridioides-difficile2026-10-13 https://evidence-hub.com/study/3218-1653-cost-effectiveness-of-levofloxacin-vs-amoxicillin-clavulanate2026-10-08 https://evidence-hub.com/study/3219-risk-factors-for-early-onset-colorectal-cancer-a-population-based2026-10-19 https://evidence-hub.com/study/3220-systemic-quinolones-and-risk-of-retinal-detachment-iii-a-nested-case2026-10-08 https://evidence-hub.com/study/3221-seizures-associated-with-levofloxacin-case-presentation-and2026-10-08 https://evidence-hub.com/study/3222-evaluating-the-efficacy-of-capreomycin-and-levofloxacin-combination2026-10-08 https://evidence-hub.com/study/3223-effectiveness-of-intravenous-insulin-pump-therapy-combined-with2026-10-20 https://evidence-hub.com/study/3224-potential-drug-drug-interactions-in-outpatient-department-of-a2026-10-06 https://evidence-hub.com/study/3225-appropriateness-of-antibiotic-treatment-of-acute-respiratory-tract2026-10-12 https://evidence-hub.com/study/3226-eradication-rates-of-empiric-helicobacter-pylori-treatment-regimens2026-10-08 https://evidence-hub.com/study/3227-olfactory-related-adverse-events-an-analysis-of-the-food-and-drug2026-10-08 https://evidence-hub.com/study/3228-treatment-outcomes-for-isoniazid-monoresistant-tuberculosis-in-peru2026-10-08 https://evidence-hub.com/study/3229-bacterial-flora-and-antibiotics-sensitivity-pattern-in-chronic2026-10-08 https://evidence-hub.com/study/3230-24-loci-miru-vntr-analysis-and-pattern-of-drug-resistance-in-pre2026-10-08 https://evidence-hub.com/study/3231-epidemiology-and-management-of-community-acquired-pneumonia-more-than2026-10-08 https://evidence-hub.com/study/3232-epidemiology-and-antimicrobial-susceptibility-of-gram-negative2026-10-08 https://evidence-hub.com/study/3233-identification-of-a-novel-cassette-array-in-integronbearing2026-10-08 https://evidence-hub.com/study/3234-knowledge-and-practices-of-helicobacter-pylori-infection-management2026-10-08 https://evidence-hub.com/study/3235-gyra-ser83-mutation-among-fluoroquinolone-resistant-salmonella2026-10-08 https://evidence-hub.com/study/3236-assessing-antibiotics-consumption-use-and-outcomes-in-a-yemeni2026-10-08 https://evidence-hub.com/study/3237-plasmid-mediated-quinolone-resistance-determinants-in-clinical2026-10-06 https://evidence-hub.com/study/3238-new-fecal-test-for-non-invasive-helicobacter-pylori-detection-a2026-10-08 https://evidence-hub.com/study/3239-aetiology-and-antibiotic-susceptibility-of-bacterial-keratitis-at-a2026-10-08 https://evidence-hub.com/study/3240-bacteriological-profile-and-antibiotic-susceptibility-of-early-onset2026-10-08 https://evidence-hub.com/study/3241-knowledge-attitude-and-practice-of-clinicians-about-antimicrobial2026-10-06 https://evidence-hub.com/study/3242-fluoroquinolone-resistance-among-fecal-extended-spectrum-eta2026-10-08 https://evidence-hub.com/study/3243-antimicrobial-resistance-burden-pre-and-post-covid-19-pandemic-with2026-10-08 https://evidence-hub.com/study/3244-antibiotic-resistance-of-helicobacter-pylori-among-male-united-states2026-10-08 https://evidence-hub.com/study/3245-bacteriological-profile-of-hospital-acquired-infection-and-their2026-10-19 https://evidence-hub.com/study/3246-oral-bacterial-flora-of-the-chinese-cobra-naja-atra-and-bamboo-pit2026-10-08 https://evidence-hub.com/study/3247-pneumococcal-carriage-and-antibiotic-susceptibility-patterns-from-two2026-10-06 https://evidence-hub.com/study/3248-high-primary-antibiotic-resistance-of-helicobacter-pylori-strains2026-10-06 https://evidence-hub.com/study/3249-the-profile-of-microorganisms-that-associate-with-acute-tonsillitis2026-10-08 https://evidence-hub.com/study/3250-antibacterial-sensitivity-in-sputum-among-acute-exacerbation-of2026-10-06 https://evidence-hub.com/study/3251-photodynamic-therapy-with-rose-bengal-against-resistant2026-10-08 https://evidence-hub.com/study/3252-renaissance-of-conventional-first-line-antibiotics-in-salmonella2026-10-06 https://evidence-hub.com/study/3253-antibiotics-and-antibiotic-resistant-bacteria-in-waters-associated2026-10-08 https://evidence-hub.com/study/3254-prevalence-of-antimicrobial-use-in-us-acute-care-hospitals-may2026-10-13 https://evidence-hub.com/study/3255-surgical-infection-prophylaxis-prior-to-left-ventricular-assist2026-10-08 https://evidence-hub.com/study/3256-evaluation-of-the-presence-of-integrons-sul-and-smqnr-genes-and-the2026-10-08 https://evidence-hub.com/study/3257-effectiveness-of-streptococcus-pneumoniae-urinary-antigen-testing-in2026-10-08 https://evidence-hub.com/study/3258-brand-versus-generic-dispensing-trend-for-ciprofloxacin-500-mg2026-10-08 https://evidence-hub.com/study/3259-antimicrobial-resistance-profiles-of-escherichia-coli-isolated-from2026-10-08 https://evidence-hub.com/study/3260-effectiveness-of-ciprofloxacin-and-levofloxacin-in-treatment-of2026-10-08 https://evidence-hub.com/study/3261-rationality-of-antibiotic-prescriptions-among-outpatients-in-the2026-10-08 https://evidence-hub.com/study/3262-antimicrobial-activity-of-gram-negative-bacteria-in-blood-cultures-a2026-10-08 https://evidence-hub.com/study/3263-stenotrophomonas-maltophilia-complex-genomic-characterization2026-10-08 https://evidence-hub.com/study/3264-microbial-contamination-of-healthcare-personnel-and-devices-a2026-10-08 https://evidence-hub.com/study/3265-drug-related-problems-drps-terapi-antibiotik-pada-pasien-sepsis-di2026-10-08 https://evidence-hub.com/study/3266-a-cost-effectiveness-analysis-of-levofloxacin-and-ceftriaxone2026-10-20 https://evidence-hub.com/study/3267-antibiotic-susceptibility-patterns-in-patients-with-chronic-kidney2026-10-08 https://evidence-hub.com/study/3268-home-visit-survey-on-outpatient-antibiotic-use-assessing-leftover2026-10-08 https://evidence-hub.com/study/3269-drug-related-problems-adverse-drug-reactions-and-drug-drug2026-10-08 https://evidence-hub.com/study/3270-antimicrobial-resistant-genes-in-non-typhoidal-salmonella-species-in2026-10-08 https://evidence-hub.com/study/3271-bacterial-profile-and-antibiotics-susceptibility-pattern-of-ear-swabs2026-10-08 https://evidence-hub.com/study/3272-cost-effectiveness-analysis-of-antibiotic-therapy-for-community2026-10-08 https://evidence-hub.com/study/3273-antibiotic-sensitivity-test-to-bacteria-in-the-postoperative2026-10-08 https://evidence-hub.com/study/3274-ac-iem-va-ket-qua-ieu-tri-viem-phoi-benh-vien-do-acinetobacter2026-10-08 https://evidence-hub.com/study/3275-genetic-characterization-and-biofilm-forming-capacity-of-bacterial2026-10-08 https://evidence-hub.com/study/3276-prevalence-assessment-of-the-mecc-gene-among-mrsa-clinical-isolates2026-10-08 https://evidence-hub.com/study/3277-detection-of-the-psla-and-pela-genes-in-multidrug-resistant2026-10-08 https://evidence-hub.com/study/3278-antimicrobial-susceptibility-and-biofilm-formation-in-clinical2026-10-08 https://evidence-hub.com/study/3279-occurrence-of-klebsiella-species-in-the-urine-of-inpatients-and-their2026-10-08 https://evidence-hub.com/study/3280-using-a-planetary-health-lens-to-quantify-intravenous-use-of2026-10-08 https://evidence-hub.com/study/3281-preliminary-screening-of-conjunctivitis-associated-beta-hemolytic2026-10-08 https://evidence-hub.com/study/3282-are-fluoroquinolones-still-viable-for-empirical-uti-treatment2026-10-08 https://evidence-hub.com/study/3283-inappropriate-empiric-antibiotic-therapy-and-resistance-patterns-in2026-10-08 https://evidence-hub.com/study/3284-evaluasi-penggunaan-antibiotik-pada-pasien-pneumonia-komunitas2026-10-08 https://evidence-hub.com/study/3285-analise-microbiologica-de-cateteres-centrais-de-insercao-periferica-e2026-10-08 https://evidence-hub.com/study/3286-integrated-phenotypic-and-genotypic-drug-susceptibility-profiling-of2026-10-08 https://evidence-hub.com/study/3287-prevalence-of-the-urec-and-hpmagenes-in-proteus-mirabilis-isolated2026-10-13 https://evidence-hub.com/study/3288-molecular-detection-of-efflux-pump-genes-and-antimicrobial-resistance2026-10-13 https://evidence-hub.com/study/3289-analysis-of-chromosomal-genes-and-proteins-of-gyra-and-gyrb-from2026-10-08 https://evidence-hub.com/study/3290-management-of-endophthalmitis-in-french-university-hospitals-a2026-10-08 https://evidence-hub.com/study/3291-efektivitas-antibiotik-pasien-rawat-inap-pneumonia-komunitas-di-rsud2026-10-08 https://evidence-hub.com/study/3292-comparison-of-effectiveness-between-combination-of-beta-lactam-with2026-10-08 https://evidence-hub.com/study/3294-primary-antibiotic-resistance-of-helicobacter-pylori-strains-isolated2026-10-08 https://evidence-hub.com/study/3295-antimicrobial-resistance-patterns-and-risk-factors-associated-with2026-10-08 https://evidence-hub.com/study/3296-biofilm-formation-and-plasmid-mediated-quinolone-resistance-genes-at2026-10-08 https://evidence-hub.com/study/3297-frequency-of-streptococcus-pneumonia-and-haemophilus-influenza-in2026-10-08 https://evidence-hub.com/study/3298-the-study-on-the-prevalence-and-some-factors-related-to-antibiotic2026-10-08 https://evidence-hub.com/study/3299-survey-of-cholera-outbreak-and-its-resistant-pattern-in-baluchistan2026-10-08 https://evidence-hub.com/study/3300-primary-antibiotic-resistance-of-helicobacter-pylori-in-peptic-ulcer2026-10-08 https://evidence-hub.com/study/3301-tb-drug-susceptibility-testing-in-high-fluoroquinolone-resistance2026-10-06 https://evidence-hub.com/study/3302-clinical-characteristics-of-11-patients-with-vibrio-vulnificus2026-10-08 https://evidence-hub.com/study/3303-combined-administration-of-rifampicin-ethambutol-and-clarithromycin2026-10-08 https://evidence-hub.com/study/3304-clinical-and-microbiological-characteristics-of-adult-invasive2026-10-08 https://evidence-hub.com/study/3305-acute-endophthalmitis-in-eyes-treated-prophylactically-with2026-10-08 https://evidence-hub.com/study/3306-endocarditis-caused-by-aerococcus-urinae-a-case-report-and-review-of2026-10-20 https://evidence-hub.com/study/3307-thrombotic-thrombocytopenic-purpura-and-metastatic-malignancy-like2026-10-08 https://evidence-hub.com/study/3308-infectious-endophthalmitis-an-overview-of-clinical-features2026-10-08 https://evidence-hub.com/study/3309-effective-anti-mycobacterial-treatment-for-bcg-disease-in-patients2026-10-08 https://evidence-hub.com/study/3310-endophthalmitis-caused-by-serratia-marcescens-clinical-features2026-10-08 https://evidence-hub.com/study/3311-endophthalmitis-caused-by-streptococcus-pneumoniae2026-10-08 https://evidence-hub.com/study/3312-management-and-microbiological-characteristics-of-membrane-formation2026-10-08 https://evidence-hub.com/study/3313-delayed-intraocular-foreign-body-removal-without-endophthalmitis2026-10-08 https://evidence-hub.com/study/3314-invasive-campylobacter-jejuni-coli-infections-9-case-reports-at-a2026-10-08 https://evidence-hub.com/study/3315-clinical-characteristics-of-treponema-denticola-associated-lung2026-10-08 https://evidence-hub.com/study/3316-community-associated-methicillin-resistant-staphylococcus-aureus2026-10-08 https://evidence-hub.com/study/3317-antibiotic-resistance-of-helicobacter-pylori-in-israeli-children2026-10-08 https://evidence-hub.com/study/3318-brucellar-spondylodiscitis-mimicking-lumbar-discectomy-with-cauda2026-10-08 https://evidence-hub.com/study/3319-incidental-papilledema-revealing-neurotuberculosis-a-case-report-of-a2026-10-08 https://evidence-hub.com/study/3320-staphylococcus-caprae-as-an-emerging-pathogen-in-infective2026-10-08 https://evidence-hub.com/study/3321-human-infections-caused-by-flavobacteriales-clinical-characteristics2026-10-13 https://evidence-hub.com/study/3322-emerging-zoonotic-ocular-sporotrichosis-in-southeast-asia-a-case2026-10-08 https://evidence-hub.com/study/3323-pemphigoid-associated-with-quinolone-antibiotics-a-real-world2026-10-08 https://evidence-hub.com/study/3324-cardinal-lessons-in-cardiac-amyloidosis-diagnostic-pitfalls-across2026-10-08 https://evidence-hub.com/study/3325-testicular-schistosomiasis-mimicking-testicular-tumour-a-case-report2026-10-13 https://evidence-hub.com/study/3326-disseminated-bcgosis-after-intravesical-bcg-installation-for-bladder2026-10-08 https://evidence-hub.com/study/3327-curative-outcomes-with-metal-containing-tcm-in-diabetic-foot-ulcers2026-10-08 https://evidence-hub.com/study/3328-chronic-expanding-hematoma-complicated-by-life-threatening-hemoptysis2026-10-08 https://evidence-hub.com/study/3329-non-invasive-management-of-severe-chlamydia-psittaci-pneumonia2026-10-20 https://evidence-hub.com/study/3330-antimicrobial-resistance-in-eskapee-pathogens-isolated-from2026-10-13 https://evidence-hub.com/study/3331-real-world-use-of-dalbavancin-for-bone-and-joint-infections-a2026-10-08 https://evidence-hub.com/study/3332-insights-into-the-clinical-presentation-imaging-and-management-of2026-10-08 https://evidence-hub.com/study/3333-pre-and-peri-hematopoietic-cell-transplant-management-of-disseminated2026-10-08 https://evidence-hub.com/study/3334-corynebacterium-amycolatum-an-emerging-pathogen-in-chronic-otitis2026-10-08 https://evidence-hub.com/study/3335-severe-corneal-melting-with-necrotic-sloughing-in-acanthamoeba2026-10-08 https://evidence-hub.com/study/3336-clinical-analysis-of-16-patients-with-clostridium-butyricum-isolated2026-10-08 https://evidence-hub.com/study/3337-biliary-sepsis-caused-by-burkholderia-cepacia-a-rare-presentation2026-10-13 https://evidence-hub.com/study/3338-endobronchial-watanabe-spigot-for-acute-empyema-with-bronchopleural2026-10-08 https://evidence-hub.com/study/3339-successful-management-of-achromobacter-associated-periprosthetic2026-10-13 https://evidence-hub.com/study/3340-endoscope-assisted-vitrectomy-using-a-25-gauge-system-for2026-10-08 https://evidence-hub.com/study/3341-severe-fungal-keratitis-caused-by-lasiodiplodia-theobromae-following2026-10-08 https://evidence-hub.com/study/3342-mycoplasma-hominis-infections-in-deep-sternal-wound-infections-post2026-10-13 https://evidence-hub.com/study/3343-successful-management-of-meningitis-and-sepsis-due-to-multidrug2026-10-20 https://evidence-hub.com/study/3344-topical-anesthetic-abuse-keratopathy-an-overlooked-occupational-eye2026-10-08 https://evidence-hub.com/study/3345-clinical-profile-comorbidities-and-antimicrobial-resistance-patterns2026-10-20 https://evidence-hub.com/study/3346-bilateral-otomastoiditis-caused-by-cryptococcus-neoformans-a-rare2026-10-08 https://evidence-hub.com/study/3347-clinical-utility-of-polymerase-chain-reaction-pcr-in-diagnosing-and2026-10-13 https://evidence-hub.com/study/3348-renal-outcomes-following-autologous-stem-cell-transplantation-in2026-10-06 https://evidence-hub.com/study/3349-diesel-siphoner-s-lung-acute-exogenous-lipoid-pneumonia-following2026-10-08 https://evidence-hub.com/study/3350-elizabethkingia-species-as-an-emerging-pathogen-a-comprehensive2026-10-13 https://evidence-hub.com/study/3351-cerebral-and-bone-multidrug-resistant-tuberculosis-treated-with-the2026-10-06 https://evidence-hub.com/study/3352-drug-associated-vanishing-bile-duct-syndrome-screening-for-potential2026-10-08 https://evidence-hub.com/study/3353-clinical-characteristics-and-prognostic-indicators-in-listeria2026-10-06 https://evidence-hub.com/study/3354-successful-treatment-of-carbapenem-resistant-acinetobacter-baumannii2026-10-20 https://evidence-hub.com/study/3356-reactions-weekly-multiple-drugs2026-10-19 https://evidence-hub.com/study/3357-antibacterials-antivirals2026-10-08 https://evidence-hub.com/study/3358-myroides-causing-catheter-associated-urinary-tract-infection-in2026-10-20 https://evidence-hub.com/study/3359-reactions-weekly-multiple-drugs2026-10-08 https://evidence-hub.com/study/3360-successful-treatment-of-refractory-majocchi-s-granuloma-with2026-10-08 https://evidence-hub.com/study/3362-the-aerobic-anaerobic-bacteria-pattern-and-its-sensitivity-pattern-in2026-10-08 https://evidence-hub.com/study/3363-characterization-of-pseudomonas-aeruginosa-isolates-from-patients2026-10-13 https://evidence-hub.com/study/3367-preservation-of-lean-soft-tissue-during-weight-loss-induced-by-glp-12026-10-19 https://evidence-hub.com/study/3368-jejunal-diverticulosis-complications-and-management-a-case-series2026-10-19 https://evidence-hub.com/study/3369-immunotherapy-induced-overlap-syndrome-myositis-myasthenia-gravis-and2026-10-19 https://evidence-hub.com/study/3370-invasive-pneumococcal-disease-in-children-a-case-series-on-clinical2026-10-08 https://evidence-hub.com/study/3371-successful-treatment-of-erosive-lichen-planus-with-tofacitinib-a-case2026-10-19 https://evidence-hub.com/study/3372-a-retrospective-multicenter-case-series-of-real-world-tralokinumab2026-10-19 https://evidence-hub.com/study/3373-plasmapheresis-in-thyrotoxicosis-a-single-center-case-series2026-10-19 https://evidence-hub.com/study/3374-clinical-and-histopathological-spectrum-of-congenital-pulmonary2026-10-19 https://evidence-hub.com/study/3375-patients-perspectives-on-buprenorphine-subcutaneous-implant-a-case2026-10-19 https://evidence-hub.com/study/3376-gastric-lipomas-a-case-series-and-review-of-the-literature2026-10-19 https://evidence-hub.com/study/3377-renal-nutcracker-syndrome-presenting-with-varicocele-a-case-series2026-10-19 https://evidence-hub.com/study/3378-emergence-of-candida-auris-in-vietnam-a-case-series2026-10-19 https://evidence-hub.com/study/3379-initial-experience-with-safety-and-efficacy-of-endoscopic-full2026-10-19 https://evidence-hub.com/study/3380-left-bundle-branch-area-pacing-in-patients-with-transthyretin-cardiac2026-10-19 https://evidence-hub.com/study/3381-acute-gastric-dilatation-a-retrospective-case-series-from-a-single2026-10-19 https://evidence-hub.com/study/3382-radiofrequency-venous-ablation-for-symptomatic-relief-in-postural2026-10-19 https://evidence-hub.com/study/3383-low-dose-naltrexone-as-a-treatment-for-vulvodynia-a-case-series2026-10-19 https://evidence-hub.com/study/3384-infantile-inflammatory-bowel-disease-in-three-syrian-infants-a-case2026-10-19 https://evidence-hub.com/study/3385-belzutifan-induced-regression-of-retinal-capillary-hemangioblastoma-a2026-10-19 https://evidence-hub.com/study/3386-epidermoid-cyst-of-central-nervous-system-a-case-series-and-review-of2026-10-19 https://evidence-hub.com/study/3387-chronic-liver-disease-in-patients-with-prolidase-deficiency-a-case2026-10-19 https://evidence-hub.com/study/3388-role-of-multimodality-cardiac-imaging-for-evaluation-of2026-10-19 https://evidence-hub.com/study/3389-heterotopic-pregnancy-case-series-and-review-of-diagnosis-and2026-10-19 https://evidence-hub.com/study/3390-inflammatory-arthritis-after-covid-19-a-case-series2026-10-19 https://evidence-hub.com/study/3391-levofloxacin-induced-radiation-recall-dermatitis-a-case-report-and-a2026-10-06 https://evidence-hub.com/study/3392-miliary-tuberculosis-and-herpes-pharyngitis-after-a-trip-to-a2026-10-08 https://evidence-hub.com/study/3393-case-report-one-human-streptococcus-suis-occurred-in-shandong2026-10-08 https://evidence-hub.com/study/3394-treatment-outcome-of-severe-respiratory-type-b-tularemia-using2026-10-08 https://evidence-hub.com/study/3395-a-case-of-pleural-effusion-caused-by-mycobacterium-fortuitum-and2026-10-06 https://evidence-hub.com/study/3396-pantoea-dispersa-bacteremia-in-an-immunocompetent-patient-a-case2026-10-06 https://evidence-hub.com/study/3398-dermatomyositis-developed-after-exposure-to-epstein-barr-virus2026-10-08 https://evidence-hub.com/study/3399-levofloxacin-induced-bilateral-achilles-tendonitis2026-10-08 https://evidence-hub.com/study/3400-bordetella-bronchiseptica-infections-in-patients-with-hiv-aids-a-case2026-10-06 https://evidence-hub.com/study/3401-relapsing-legionella-pneumophila-cellulitis-a-case-report-and-review2026-10-06 https://evidence-hub.com/study/3402-intractable-acute-pain-related-to-fluoroquinolone-induced-peripheral2026-10-06 https://evidence-hub.com/study/3403-levofloxacin-induced-hepatotoxicity-and-death2026-10-08 https://evidence-hub.com/study/3404-cervical-spondylodiscitis-mimicking-pott-s-disease-a-case-report2026-10-08 https://evidence-hub.com/study/3405-prolonged-coma-in-a-scrub-typhus-patient2026-10-08 https://evidence-hub.com/study/3406-levofloxacin-induced-delirium-with-psychotic-features2026-10-08 https://evidence-hub.com/study/3407-hospital-acquired-pneumonia-caused-by-multidrug-resistant2026-10-08 https://evidence-hub.com/study/3408-levofloxacin-induced-hypoglycemia-in-a-nondiabetic-patient2026-10-08 https://evidence-hub.com/study/3409-acute-urethritis-caused-by-neisseria-meningitidis2026-10-08 https://evidence-hub.com/study/3410-challenging-case-of-parotitis-a-comprehensive-approach2026-10-08 https://evidence-hub.com/study/3411-s-maltophilia-pneumonia-a-case-report2026-10-08 https://evidence-hub.com/study/3412-haemophilus-parainfluenzae-aortic-prosthetic-valve-endocarditis-pve2026-10-08 https://evidence-hub.com/study/3413-high-direct-bilirubin-associated-with-levoffoxacin-use-in-a-neonate2026-10-08 https://evidence-hub.com/study/3414-sporotrichoid-atypical-mycobacterial-infections-antibiotic-monotherapy2026-10-08 https://evidence-hub.com/study/3415-a-rare-case-of-acute-kidney-injury-due-to-levofloxacin-induced2026-10-13 https://evidence-hub.com/study/3416-endophthalmitis-caused-by-mycobacterium-houstonense-case-report2026-10-08 https://evidence-hub.com/study/3417-pelvic-osteomyelitis-presenting-as-groin-and-medial-thigh-pain-a2026-10-08 https://evidence-hub.com/study/3418-osteomyelitis-of-the-pubic-symphysis-caused-by-methicillin-resistant2026-10-06 https://evidence-hub.com/study/3419-raoultella-planticola-a-rare-cause-of-wound-infection2026-10-06 https://evidence-hub.com/study/3420-levofloxacin-induced-bilateral-achilles-tendon-rupture-a-case-report2026-10-06 https://evidence-hub.com/study/3421-cutaneous-leukocytoclastic-vasculitis-associated-with-levofloxacin2026-10-08 https://evidence-hub.com/study/3422-drug-induced-histiocytoid-sweet-syndrome-two-cases-with-levofloxacin2026-10-08 https://evidence-hub.com/study/3423-fitz-hugh-curtis-syndrome-in-a-man-positive-for-chlamydia-trachomatis2026-10-06 https://evidence-hub.com/study/3424-renal-parenchymal-malacoplakia-a-rare-cause-of-arf-with-a-review-of2026-10-13 https://evidence-hub.com/study/3425-a-case-of-bilateral-leg-edema-associated-with-levofloxacin-a-case2026-10-06 https://evidence-hub.com/study/3426-metronidazole-and-levofloxacin-induced-psychotic-disorders-in-chronic2026-10-08 https://evidence-hub.com/study/3427-mycobacterium-chelonae-infection-treated-with-combined-medication-and2026-10-06 https://evidence-hub.com/study/3428-gitelman-like-syndrome-a-rare-complication-of-using-aminoglycosides2026-10-08 https://evidence-hub.com/study/3429-successful-treatment-of-multidrug-resistant-tuberculous-meningitis-in2026-10-06 https://evidence-hub.com/study/3430-bilateral-acanthamoeba-keratitis-after-orthokeratology2026-10-08 https://evidence-hub.com/study/3431-mycoplasma-pneumoniae-carriage-with-de-novo-macrolide-resistance-and2026-10-08 https://evidence-hub.com/study/3432-a-case-of-linear-iga-bullous-dermatosis-of-childhood-with-ocular2026-10-08 https://evidence-hub.com/study/3433-first-documented-case-of-siphonobacter-curvatus-bloodstream-infection2026-10-08 https://evidence-hub.com/study/3434-a-rare-case-of-stevens-johnson-syndrome-secondary-to-levofloxacin2026-10-08 https://evidence-hub.com/study/3435-repeated-perioperative-airway-management-in-odontogenic-deep-neck2026-10-08 https://evidence-hub.com/study/3436-rare-complications-in-crohn-s-disease-diagnostic-and-therapeutic2026-10-08 https://evidence-hub.com/study/3437-a-rare-case-of-giant-cell-hepatitis-superimposed-on-sickle-cell2026-10-08 https://evidence-hub.com/study/3438-purple-catheter-syndrome-pubs-a-mystery-in-a-post-stroke-patient-with2026-10-20 https://evidence-hub.com/study/3439-tailoring-antitubercular-therapy-in-a-critically-ill-patient-with2026-10-08 https://evidence-hub.com/study/3440-transient-phagocytic-dysfunction-mimicking-chronic-granulomatous2026-10-08 https://evidence-hub.com/study/3441-invasive-pneumococcal-disease-by-serotype-23b-in-an-asplenic2026-10-08 https://evidence-hub.com/study/3442-impact-of-extracorporeal-membrane-oxygenation-on-antituberculosis2026-10-08 https://evidence-hub.com/study/3443-enterococcus-thailandicus-as-an-uncommon-pathogen-in-severe-lower2026-10-08 https://evidence-hub.com/study/3444-detection-of-an-o1-vibrio-cholerae-strain-in-the-blood-of-a-patient2026-10-08 https://evidence-hub.com/study/3445-a-case-of-peritoneal-dialysis-associated-peritonitis-caused-by2026-10-13 https://evidence-hub.com/study/3446-misdiagnosed-acute-q-fever-due-to-coxiella-burnetii-in-guangxi-china2026-10-20 https://evidence-hub.com/study/3447-revisiting-rhinoscleroma-microbiology-a-case-with-concordant-dual2026-10-13 https://evidence-hub.com/study/3448-multiple-presentations-of-drug-resistant-central-nervous-system2026-10-08 https://evidence-hub.com/study/3449-mixed-candida-and-brucella-aortic-valve-endocarditis-with-aortic-root2026-10-08 https://evidence-hub.com/study/3450-ephemeral-urocolpos-radiological-insights-into-a-rare-presentation-of2026-10-20 https://evidence-hub.com/study/3451-levofloxacin-induced-focal-seizure-in-a-patient-with-multidrug2026-10-08 https://evidence-hub.com/study/3452-a-case-of-levofloxacin-injection-induced-lower-limb-edema2026-10-08 https://evidence-hub.com/study/3453-navigating-a-delicate-balance-antibiotic-allergy-in-the-setting-of2026-10-20 https://evidence-hub.com/study/3454-two-cases-of-cupriavidus-gilardii-infection-presenting-as-pneumonia2026-10-08 https://evidence-hub.com/study/3455-adult-case-of-chronic-granulomatous-disease-with-left-axillary2026-10-20 https://evidence-hub.com/study/3456-biochemical-discordance-of-a-urinary-fluoroquinolone-resistant2026-10-20 https://evidence-hub.com/study/3457-thoracic-aortic-rupture-in-a-patient-with-repeated-oral2026-10-13 https://evidence-hub.com/study/3458-severe-pneumococcal-pneumonia-with-human-rhinovirus-enterovirus2026-10-13 https://evidence-hub.com/study/3459-neisseria-meningitidis-associated-chronic-prostatitis-following-oral2026-10-20 https://evidence-hub.com/study/3460-sino-cranial-aspergillosis-in-an-abo-incompatible-renal-transplant2026-10-16 https://evidence-hub.com/study/3461-an-uncommon-case-of-recurring-pulmonary-lymphatic-and-skeletal2026-10-06 https://evidence-hub.com/study/3462-triple-infection-with-pulmonary-tuberculosis-chronic-hepatitis-c-and2026-10-06 https://evidence-hub.com/study/3463-staged-percutaneous-management-of-multiple-postoperative-pyogenic2026-10-06 https://evidence-hub.com/study/3464-low-dose-sulbactam-durlobactam-for-recurrent-crab-pneumonia-in-a2026-10-20 https://evidence-hub.com/study/3465-the-treatment-process-and-clinical-analysis-of-2-cases-of2026-10-06 https://evidence-hub.com/study/3466-brevibacterium-casei-catheter-related-bloodstream-infection-in-an2026-10-06 https://evidence-hub.com/study/3467-pseudomonas-aeruginosa-and-burkholderia-cepacia-complex-co-infection2026-10-08 https://evidence-hub.com/study/3468-lactococcus-garvieae-in-rural-alabama-a-case-report2026-10-08 https://evidence-hub.com/study/3469-septic-shock-and-bacteremia-secondary-to-herbaspirillum-huttiense-a2026-10-08 https://evidence-hub.com/study/3470-legionella-longbeachae-wound-infection-case-report-and-review-of2026-10-08 https://evidence-hub.com/study/3471-coronary-artery-dilation-in-children-with-febrile-illnesses-other2026-10-08 https://evidence-hub.com/study/3472-pseudomonas-otitidis-bacteremia-in-an-immunocompromised-patient-with2026-10-08 https://evidence-hub.com/study/3473-disseminated-staphylococcus-aureus-infection-after-scarification-wet2026-10-08 https://evidence-hub.com/study/3474-temporary-severe-neutropenia-during-administration-of-atezolizumab-a2026-10-08 https://evidence-hub.com/study/3475-misdiagnosis-of-pneumorrhagia-leptospirosis-as-common-cap-a-case2026-10-08 https://evidence-hub.com/study/3476-bloodstream-infection-peritonitis-and-pneumonia-caused-by-pasteurella2026-10-08 https://evidence-hub.com/study/3477-levofloxacin-and-intracranial-hypertension-ina-patient-with2026-10-08 https://evidence-hub.com/study/3478-peritonitis-associated-with-peritoneal-dialysis-following-ureaplasma2026-10-08 https://evidence-hub.com/study/3479-drug-reaction-with-eosinophilia-and-systemic-symptoms-associated2026-10-08 https://evidence-hub.com/study/3481-successful-rechallenge-with-clozapine-after-discontinuation-due-to2026-10-08 https://evidence-hub.com/study/3482-hypoprothrombinemia-during-cefmetazole-treatment-a-case-report2026-10-08 https://evidence-hub.com/study/3483-case-report-the-first-report-on-moraxella-canis-isolation-from2026-10-08 https://evidence-hub.com/study/3484-cerebellar-syndrome-associated-with-legionellosis-a-case-report-and2026-10-08 https://evidence-hub.com/study/3485-clinical-presentation-of-legionella-pneumophila-serogroup-12026-10-08 https://evidence-hub.com/study/3486-acute-fibrinous-and-organizing-pneumonia-in-a-patient-with-sjogren-s2026-10-08 https://evidence-hub.com/study/3487-diagnosis-and-treatment-of-left-ureteral-injury-as-a-rare2026-10-13 https://evidence-hub.com/study/3488-anti-tuberculosis-drug-induced-liver-injury-in-patient-with-hepatitis2026-10-08 https://evidence-hub.com/study/3489-granulomatous-interstitial-nephritis-with-ctla-4-haploinsufficiency-a2026-10-08 https://evidence-hub.com/study/3490-management-of-drug-reaction-with-eosinophilia-and-systemic-symptoms2026-10-08 https://evidence-hub.com/study/3491-epidural-phlegmon-and-iliopsoas-abscess-caused-by-salmonella-enterica2026-10-08 https://evidence-hub.com/study/3492-case-report-evaluation-of-an-open-source-synthetic-data-platform-for2026-10-08 https://evidence-hub.com/study/3493-tavr-infected-pseudomonas-endocarditis-a-case-report2026-10-08 https://evidence-hub.com/study/3494-levofloxacin-induced-psychosis-a-rare-case-report2026-10-13 https://evidence-hub.com/study/3495-case-report-a-prosthetic-valve-endocarditis-caused-by-legionella2026-10-08 https://evidence-hub.com/study/3496-acute-retinal-necrosis-in-a-patient-on-immunosuppressive-treatment2026-10-08 https://evidence-hub.com/study/3497-pyrazinamide-related-prolonged-drug-induced-liver-injury-a-case-report2026-10-08 https://evidence-hub.com/study/3498-dieffenbachia-induced-transient-crystalline-keratopathy-a-case-report2026-10-08 https://evidence-hub.com/study/3499-sphingomonas-paucimobilis-pneumonia-complicated-by-empyema-in-an2026-10-08 https://evidence-hub.com/study/3500-cutaneous-leishmaniasis-presenting-with-painless-ulcer-on-the-right2026-10-08 https://evidence-hub.com/study/3501-spontaneous-rupture-of-rhabdomyosarcoma-of-the-testis-with-unilateral2026-10-08 https://evidence-hub.com/study/3502-a-tick-bite-patient-with-fever-and-meningitis-co-infected-with2026-10-08 https://evidence-hub.com/study/3503-enterobacter-cloacae-infection-of-the-shoulder-in-a-52-year-old-woman2026-10-08 https://evidence-hub.com/study/3504-first-report-of-chronic-invasive-fungal-rhinosinusitis-in-a-patient2026-10-08 https://evidence-hub.com/study/3505-liver-abscess-with-necrosis-in-post-covid-19-a-case-report2026-10-08 https://evidence-hub.com/study/3506-anti-tuberculosis-drug-induced-acute-liver-failure-requiring2026-10-08 https://evidence-hub.com/study/3507-a-rare-case-of-absolute-thrombocytopaenia-in-a-covid-19-patient-case2026-10-08 https://evidence-hub.com/study/3508-travel-trouble-with-legionella-in-the-era-of-covid-19-a-case-report2026-10-08 https://evidence-hub.com/study/3509-corneal-edema-with-anterior-uveitis-after-exposure-to-the-sap-of2026-10-06 https://evidence-hub.com/study/3510-mycoplasma-pneumoniae-and-chlamydia-pneumoniae-coinfection-with-acute2026-10-06 https://evidence-hub.com/study/3511-aga-clinical-practice-update-on-the-management-of-refractory2026-10-13 https://evidence-hub.com/study/3512-clinical-practice-guidelines-for-liver-transplantation-in-saudi-arabia2026-10-13 https://evidence-hub.com/study/3513-guidelines-for-transrectal-ultrasonography-guided-prostate-biopsy2026-10-08 https://evidence-hub.com/study/3514-perforated-and-bleeding-peptic-ulcer-wses-guidelines2026-10-08 https://evidence-hub.com/study/3515-use-of-anthrax-vaccine-in-the-united-states-recommendations-of-the2026-10-08 https://evidence-hub.com/study/3516-diagnosis-and-treatment-of-adults-with-community-acquired-pneumonia2026-10-19 https://evidence-hub.com/study/3517-recommendations-on-cardiopulmonary-resuscitation-in-patients-with2026-10-13 https://evidence-hub.com/study/3518-guidelines-for-the-pharmacological-treatment-of-covid-19-the-task2026-10-08 https://evidence-hub.com/study/3519-primary-prophylaxis-of-bacterial-infections-and-pneumocystis2026-10-13 https://evidence-hub.com/study/3520-executive-summary-official-american-thoracic-society-centers-for2026-10-13 https://evidence-hub.com/study/3521-recommendations-for-the-treatment-of-osteomyelitis2026-10-13 https://evidence-hub.com/study/3522-official-american-thoracic-society-centers-for-disease-control-and2026-10-13 https://evidence-hub.com/study/3523-executive-summary-the-management-of-community-acquired-pneumonia-in2026-10-13 https://evidence-hub.com/study/3524-evidence-based-guidelines-for-empirical-therapy-of-neutropenic-fever2026-10-13 https://evidence-hub.com/study/3525-the-management-of-community-acquired-pneumonia-in-infants-and2026-10-13 https://evidence-hub.com/study/3526-implementing-an-antibiotic-stewardship-program-guidelines-by-the2026-10-13 https://evidence-hub.com/study/3527-expert-consensus-on-acute-exacerbation-of-chronic-obstructive2026-10-08 https://evidence-hub.com/study/3528-diagnosis-and-treatment-of-chronic-bacterial-prostatitis-and-chronic2026-10-13 https://evidence-hub.com/study/3529-mascc-isoo-clinical-practice-guidelines-for-the-management-of2026-10-08 https://evidence-hub.com/study/3530-clinical-practice-guideline-for-the-diagnosis-and-management-of-group2026-10-08 https://evidence-hub.com/study/3531-recommendations-for-treatment-of-childhood-non-severe-pneumonia2026-10-08 https://evidence-hub.com/study/3532-guidelines-for-the-prevention-and-treatment-of-opportunistic2026-10-13 https://evidence-hub.com/study/3533-evidence-based-management-of-anticoagulant-therapy-antithrombotic2026-10-08 https://evidence-hub.com/study/3534-consensus-guidelines-for-the-management-of-community-acquired2026-10-08 https://evidence-hub.com/study/3535-clinical-practice-guideline-for-the-management-of-chronic-kidney2026-10-13 https://evidence-hub.com/study/3536-clinical-practice-guideline-on-the-management-of-patients-with2026-10-08 https://evidence-hub.com/study/3537-multidrug-resistant-stenotrophomonas-maltophilia-changing-sensitivity2026-10-08 https://evidence-hub.com/study/3538-105-fluoroquinolone-stewardship-at-a-community-health-system-a-decade2026-10-08 https://evidence-hub.com/study/3539-antibacterial-prophylaxis-of-febrile-neutropenia-is-not-effective-in2026-10-08 https://evidence-hub.com/study/3540-buruli-ulcer-in-japan2026-10-08 https://evidence-hub.com/study/3542-application-of-the-formula-for-rational-antimicrobial-therapy-frat2026-10-08 https://evidence-hub.com/study/3546-antibiogram-of-klebsiella-pneumoniae-recovered-from-blood-stream2026-10-08 https://evidence-hub.com/study/3549-gambaran-pemakaian-antibiotika-setelah-implementasi-pedoman-pemakaian2026-10-08 https://evidence-hub.com/study/3564-antibacterial-activity-of-pazufloxacin-in-vitro-against-bacteria2026-10-13 https://evidence-hub.com/study/3566-p-1688-differences-in-guideline-concordant-antibiotic-prescribing2026-10-08 https://evidence-hub.com/study/3567-detection-of-levofloxacin-using-a-simple-and-green-electrochemically2026-10-08 https://evidence-hub.com/study/3568-magnetic-fe3o4-cof-ag-sers-substrate-combined-with-machine-learning2026-10-08 https://evidence-hub.com/study/3571-treatment-of-adult-patients-with-acute-bacterial-rhinosinusitis2026-10-08 https://evidence-hub.com/study/3572-evaluating-antibiotic-treatment-guideline-adherence-to-ongoing2026-10-08 https://evidence-hub.com/study/3576-helicobacter-pylori-therapy-a-paradigm-shift2026-10-08 https://evidence-hub.com/study/3577-periprosthetic-joint-infection-a-review-of-antibiotic-treatment2026-10-06 https://evidence-hub.com/study/3578-an-evaluation-of-antibiotic-options-for-the-treatment-of-biothreat2026-10-13 https://evidence-hub.com/study/3579-legionella-macrolides-or-quinolones2026-10-08 https://evidence-hub.com/study/3580-helicobacter-pylori-a-review-of-current-diagnostic-and-management2026-10-08 https://evidence-hub.com/study/3581-the-role-of-solithromycin-in-the-management-of-bacterial-community2026-10-06 https://evidence-hub.com/study/3582-updated-review-on-clinically-relevant-properties-of-delafloxacin2026-10-08 https://evidence-hub.com/study/3583-quinolone-activity-against-anaerobes2026-10-06 https://evidence-hub.com/study/3584-levofloxacin-prophylaxis-in-pediatric-oncology-and-hematopoietic-stem2026-10-05 https://evidence-hub.com/study/3585-new-fluoroquinolone-antibiotics2026-10-08 https://evidence-hub.com/study/3586-dosing-of-antibiotics-in-obesity2026-10-08 https://evidence-hub.com/study/3587-treatment-of-helicobacter-pylori-infection-a-clinical-practice-update2026-10-06 https://evidence-hub.com/study/3588-methods-and-approaches-for-determination-and-enantioseparation-of-rs2026-10-06 https://evidence-hub.com/study/3589-management-of-helicobacter-pylori-infection-what-should-the-surgeon2026-10-06 https://evidence-hub.com/study/3590-history-of-quinolones-and-their-side-effects2026-10-08 https://evidence-hub.com/study/3591-treatment-of-helicobacter-pylori-infection-and-its-long-term-impacts2026-10-06 https://evidence-hub.com/study/3592-an-update-on-eradication-of-helicobacter-pylori-in-iran-a-review2026-10-06 https://evidence-hub.com/study/3593-optimal-treatment-strategy-for-helicobacter-pylori-era-of-antibiotic2026-10-06 https://evidence-hub.com/study/3594-treatment-of-legionnaires-disease2026-10-06 https://evidence-hub.com/study/3595-the-potential-role-of-nemonoxacin-for-treatment-of-common-infections2026-10-20 https://evidence-hub.com/study/3596-fluoroquinolones-for-the-treatment-of-tuberculosis-in-children2026-10-06 https://evidence-hub.com/study/3597-toward-population-specific-and-personalized-treatment-of-helicobacter2026-10-06 https://evidence-hub.com/study/3598-update-on-quinolone-containing-rescue-therapies-for-helicobacter2026-10-08 https://evidence-hub.com/study/3599-bacteriological-studies-of-venomous-snakebite-wounds-in-hangzhou2026-10-08 https://evidence-hub.com/study/3600-an-overview-of-new-antitubercular-drugs-drug-candidates-and-their2026-10-06 https://evidence-hub.com/study/3601-cyp2c19-polymorphism-influences-helicobacter-pylori-eradication2026-10-08 https://evidence-hub.com/study/3602-gram-negative-bacterial-infection-randomized-controlled-trials-rcts2026-10-13 https://evidence-hub.com/study/3603-hand-infections-across-tissue-planes-a-pictorial-review2026-10-08 https://evidence-hub.com/study/3604-therapeutic-advances-and-future-directions-in-helicobacter-pylori2026-10-16 https://evidence-hub.com/study/3605-the-evaluation-of-machine-learning-models-using-matrix-assisted-laser2026-10-08 https://evidence-hub.com/study/3606-what-is-new-in-tuberculosis2026-10-08 https://evidence-hub.com/study/3607-molecular-regulation-of-biofilm-development-in-stenotrophomonas2026-10-08 https://evidence-hub.com/study/3608-advances-in-the-development-of-antibiotic-drug-candidates-for-urinary2026-10-20 https://evidence-hub.com/study/3609-preventing-multidrug-resistant-tuberculosis-the-dawn-of-a-new-era2026-10-08 https://evidence-hub.com/study/3610-high-potency-proton-pump-inhibitor-versus-vonoprazan-in-helicobacter2026-10-08 https://evidence-hub.com/study/3611-safety-of-treatment-regimens-for-drug-resistant-tb-over-a-15-year2026-10-08 https://evidence-hub.com/study/3612-recent-advances-in-tuberculosis-treatment-towards-shorter-safer-and2026-10-08 https://evidence-hub.com/study/3613-what-s-hot-this-year-in-id-clinical-science-20252026-10-13 https://evidence-hub.com/study/3614-acute-bronchopneumonia-with-bordetella-bronchiseptica-bacteremia-in2026-10-08 https://evidence-hub.com/study/3615-acquired-resistance-in-stenotrophomonas-maltophilia-mechanisms2026-10-08 https://evidence-hub.com/study/3616-mycobacterium-fortuitum-infection-of-the-hip-joint-a-case-report-and2026-10-08 https://evidence-hub.com/study/3617-weissella-confusa-infections-and-strain-level-biosafety-clinical2026-10-08 https://evidence-hub.com/study/3618-bacterial-dna-topoisomerase-iv-and-dna-gyrase-inhibitors-history-of2026-10-08 https://evidence-hub.com/study/3619-levofloxacin-levaquin2026-10-08 https://evidence-hub.com/study/3620-meropenem-heparin-lock-therapy-for-ochrobactrum-intermedium-catheter2026-10-08 https://evidence-hub.com/study/3621-fluoroquinolone-induced-achilles-tendon-damage-structural-and2026-10-08 https://evidence-hub.com/study/3622-advanced-statistical-approaches-in-tuberculosis-diagnosis-and2026-10-08 https://evidence-hub.com/study/3623-research-overview-2025-integrating-scientific-progress-to-accelerate2026-10-08 https://evidence-hub.com/study/3624-peritoneal-dialysis-associated-peritonitis-caused-by-eikenella2026-10-13 https://evidence-hub.com/study/3625-antimicrobial-drug-susceptibility-testing-for-the-management-of2026-10-08 https://evidence-hub.com/study/3626-the-emerging-threat-of-antibiotic-residues-in-the-aquatic2026-10-08 https://evidence-hub.com/study/3627-maldi-tof-ms-in-conjunction-with-machine-learning-toward-a-new-era2026-10-08 https://evidence-hub.com/study/3628-the-latest-research-progress-on-the-clinical-application-of2026-10-20 https://evidence-hub.com/study/3629-insights-into-antibiotic-resistance-and-prevalence-of2026-10-08 https://evidence-hub.com/study/3630-current-and-emerging-therapies-for-pulmonary-tuberculosis-in-adults2026-10-06 https://evidence-hub.com/study/3631-antibiotic-induced-manic-episodes-clinical-recognition-mechanistic2026-10-13 https://evidence-hub.com/study/3632-prevalence-and-microbial-spectrum-of-patients-with-spontaneous2026-10-06 https://evidence-hub.com/study/3633-primary-resistance-pattern-of-helicobacter-pylori-to-antibiotics-in2026-10-03 https://evidence-hub.com/study/3634-helicobacter-pylori-in-iran-a-systematic-review-on-the-antibiotic2026-10-03 https://evidence-hub.com/study/3635-update-on-the-second-line-treatment-of-helicobacter-pylori-infection2026-10-08 https://evidence-hub.com/study/3636-fluoroquinolones-compared-with-beta-lactam-antibiotics-for-the2026-10-08 https://evidence-hub.com/study/3637-effectiveness-and-safety-of-tetracyclines-and-quinolones-in-people2026-10-08 https://evidence-hub.com/study/3638-drug-resistance-patterns-of-commonly-used-antibiotics-for-the2026-10-05 https://evidence-hub.com/study/3640-cholera-outbreaks-in-low-and-middle-income-countries-in-the-last2026-10-05 https://evidence-hub.com/study/3641-multidrug-resistant-pulmonary-tuberculosis-treatment-regimens-and2026-10-05 https://evidence-hub.com/study/3643-systematic-review-study-of-the-prescribing-pattern-of-antibiotics-in2026-10-03 https://evidence-hub.com/study/3644-mortality-in-adults-with-multidrug-resistant-tuberculosis-and-hiv-by2026-10-05 https://evidence-hub.com/study/3645-impact-of-fluoroquinolone-treatment-on-delay-of-tuberculosis2026-10-08 https://evidence-hub.com/study/3646-levofloxacin-in-the-treatment-of-community-acquired-pneumonia2026-10-08 https://evidence-hub.com/study/3647-determination-of-levofloxacin-by-hplc-with-fluorescence-detection-in2026-10-08 https://evidence-hub.com/study/3648-compounded-levofloxacin-triple-therapy-is-safe-and-effective-for2026-10-08 https://evidence-hub.com/study/3649-the-evaluation-of-the-short-term-and-long-term-hydroxychloroquine2026-10-19 https://evidence-hub.com/study/3650-the-optimization-of-enzymatic-oxidation-of-levofloxacin-a2026-10-06 https://evidence-hub.com/study/3651-protein-binding-investigation-of-first-line-and-second-line2026-10-06 https://evidence-hub.com/study/3652-an-integrative-review-on-treatment-guidelines-for-complicated-urinary2026-10-13 https://evidence-hub.com/study/3653-comparative-effectiveness-of-piperacillin-tazobactam-or2026-10-08 https://evidence-hub.com/study/3654-development-of-a-system-to-deliver-inhalational-antibiotics-to2026-10-08 https://evidence-hub.com/study/3655-personalized-phage-therapy-in-an-icu-patient-with-polymicrobial2026-10-08 https://evidence-hub.com/study/3656-antibiotics-impact-the-cytotoxicity-and-cytopathic-effect-of2026-10-08 https://evidence-hub.com/study/3657-nanomaterial-enabled-smart-contact-lenses-bridging-sensing-therapy2026-10-08 https://evidence-hub.com/study/3658-two-cases-of-post-kidney-transplantation-thrombotic-microangiopathy2026-10-08 https://evidence-hub.com/study/3659-performance-of-various-pelvic-derived-samples-for-the-diagnosis-of2026-10-08 https://evidence-hub.com/study/3660-the-rise-fall-and-rethink-of-fluoro-quinolones-a-quick-rundown2026-10-13 https://evidence-hub.com/study/3661-prevalence-distribution-and-antimicrobial-resistance-profiles-in2026-10-08 https://evidence-hub.com/study/3662-berkeleylactam-a-total-synthesis-and-in-vitro-and-in-vivo2026-10-08 https://evidence-hub.com/study/3663-genetic-characterization-of-carbapenem-resistant-klebsiella2026-10-08 https://evidence-hub.com/study/3664-wearing-bacteriophages-individually-with-an-adhesive-drug-loadable2026-10-08 https://evidence-hub.com/study/3665-phage-antibiotic-synergy-attenuates-acinetobacter-baumannii2026-10-08 https://evidence-hub.com/study/3666-progress-of-implementation-of-world-health-organization-global2026-10-08 https://evidence-hub.com/study/3667-appendiceal-low-grade-pseudomyxoma-peritonei-recurrence-with-splenic2026-10-08 https://evidence-hub.com/study/3668-antimicrobial-treatment-in-invasive-infections-caused-by-gordonia2026-10-08 https://evidence-hub.com/study/3669-polypropylene-mesh-infection-from-surgical-site-infections-caused-by2026-10-08 https://evidence-hub.com/study/3670-inhaled-formulations-for-bacterial-pneumonia-strategies-and-advances2026-10-08 https://evidence-hub.com/study/3671-vaccinations-included-in-the-national-immunization-calendar-as-a-tool2026-10-13 https://evidence-hub.com/study/3672-vertebral-osteomyelitis-caused-by-nontuberculous-mycobacteria-a-case2026-10-08 https://evidence-hub.com/study/3673-development-of-novel-broad-spectrum-amphipathic-antimicrobial2026-10-08 https://evidence-hub.com/study/3674-managing-multidrug-resistant-pandoraea-spp-current-evidence-and2026-10-08 https://evidence-hub.com/study/3675-mechanism-of-mongolian-medicine-batri-7-on-salmonella-enteritis2026-10-08 https://evidence-hub.com/study/3676-pre-travel-consultation-for-the-prevention-of-infectious-diseases2026-10-08 https://evidence-hub.com/study/3677-incidence-and-predictors-of-acquired-resistance-to-second-line2026-10-08 https://evidence-hub.com/study/3678-cervical-brucella-spondylitis-a-case-report-on-diagnosis-and-surgical2026-10-06 https://evidence-hub.com/study/3679-triboelectric-nanogenerators-for-self-powered-degradation-of-chemical2026-10-08 https://evidence-hub.com/study/3680-coronavirus-in-recent-years-characteristics-outbreaks-and-treatments2026-10-13 https://evidence-hub.com/study/3681-isolated-splenic-sarcoidosis-a-case-report2026-10-13 https://evidence-hub.com/study/3682-randomized-double-blind-multicenter-phase-2-study-comparing-the2026-10-20 https://evidence-hub.com/study/3684-levofloxacin-versus-clarithromycin-for-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/3685-development-of-levofloxacin-inhalation-solution-to-treat-pseudomonas2026-10-08 https://evidence-hub.com/study/3686-effect-of-levofloxacin-on-the-efficacy-and-adverse-events-in2026-10-08 https://evidence-hub.com/study/3687-cefditoren-versus-levofloxacin-in-patients-with-exacerbations-of2026-10-08 https://evidence-hub.com/study/3688-prulifloxacin-versus-levofloxacin-in-the-treatment-of-severe-copd2026-10-08 https://evidence-hub.com/study/3690-safety-and-efficacy-of-levofloxacin-versus-ciprofloxacin-for-the2026-10-08 https://evidence-hub.com/study/3691-levofloxacin-induced-delirium-is-it-a-dangerous-drug-in-patients-with2026-10-08 https://evidence-hub.com/study/3692-switch-therapy-in-hospitalized-patients-with-community-acquired2026-10-08 https://evidence-hub.com/study/3693-levofloxacin-pharmacokinetics-in-saliva-as-measured-by-a-mobile2026-10-08 https://evidence-hub.com/study/3694-tea-polyphenols-and-levofloxacin-alleviate-the-lung-injury-of2026-10-08 https://evidence-hub.com/study/3696-mutations-in-the-antibiotic-target-genes-related-to-clarithromycin2026-10-08 https://evidence-hub.com/study/3699-effect-of-oxygen-limitation-on-the-in-vitro-activity-of-levofloxacin2026-10-08 https://evidence-hub.com/study/3700-comparison-of-7-and-14-day-first-line-therapies-including2026-10-08 https://evidence-hub.com/study/3701-a-multicenter-randomized-double-blind-phase-2-study-of-the-efficacy2026-10-20 https://evidence-hub.com/study/3702-urinary-bactericidal-activity-of-doripenem-versus-that-of2026-10-20 https://evidence-hub.com/study/3703-activity-of-levofloxacin-and-ciprofloxacin-on-biofilms-and-planktonic2026-10-08 https://evidence-hub.com/study/3704-gatifloxacin-is-superior-to-levofloxacin-and-moxifloxacin-in-shorter2026-10-08 https://evidence-hub.com/study/3705-alternative-eradication-regimens-for-helicobacter-pylori-infection-in2026-10-08 https://evidence-hub.com/study/3706-patient-stratification-in-the-management-of-acute-bacterial2026-10-08 https://evidence-hub.com/study/3707-altered-steady-state-pharmacokinetics-of-levofloxacin-in-adult-cystic2026-10-08 https://evidence-hub.com/study/3708-spontaneous-achilles-tendon-rupture-in-patients-treated-with2026-10-08 https://evidence-hub.com/study/3709-susceptibilities-of-bacterial-isolates-from-patients-with-cancer-to2026-10-08 https://evidence-hub.com/study/3710-fluconazole-and-levofloxacin-induced-torsades-de-pointes-in-an2026-10-08 https://evidence-hub.com/study/3711-clinical-effectiveness-of-levofloxacin-in-patients-with-acute2026-10-08 https://evidence-hub.com/study/3712-premarketing-population-pharmacokinetic-study-of-levofloxacin-in2026-10-08 https://evidence-hub.com/study/3713-levofloxacin-and-rhabdomyolysis-in-a-renal-transplant-patient2026-10-08 https://evidence-hub.com/study/3714-full-course-oral-levofloxacin-for-treatment-of-hospitalized-patients2026-10-08 https://evidence-hub.com/study/3715-tissue-and-serum-levofloxacin-concentrations-in-diabetic-foot2026-10-08 https://evidence-hub.com/study/3716-penetration-of-moxifloxacin-and-levofloxacin-into-cancellous-and2026-10-03 https://evidence-hub.com/study/3717-efficacy-and-safety-of-0-5-levofloxacin-ophthalmic-solution-for-the2026-10-03 https://evidence-hub.com/study/3718-prevalence-of-and-risk-factors-for-dysglycemia-in-patients-receiving2026-10-08 https://evidence-hub.com/study/3720-levofloxacin-induced-acute-fulminant-hepatic-failure-in-a-patient2026-10-03 https://evidence-hub.com/study/3721-prospective-randomized-multicentric-open-comparative-study-on-the2026-10-13 https://evidence-hub.com/study/3722-azithromycin-and-the-risk-of-cardiovascular-death2026-10-03 https://evidence-hub.com/study/3723-effects-of-gatifloxacin-and-levofloxacin-on-rates-of-hypoglycemia-and2026-10-08 https://evidence-hub.com/study/3724-effect-of-differences-in-mic-values-on-clinical-outcomes-in-patients2026-10-08 https://evidence-hub.com/study/3725-pharmacokinetics-and-in-vivo-distribution-of-optimized-plga2026-10-06 https://evidence-hub.com/study/3726-chemotherapeutic-activity-of-levofloxacin-hr-355-dr-3355-against2026-10-08 https://evidence-hub.com/study/3727-comparison-of-the-effect-of-intracameral-moxifloxacin-levofloxacin2026-10-06 https://evidence-hub.com/study/3728-exogenous-maltose-enhances-zebrafish-immunity-to-levofloxacin2026-10-08 https://evidence-hub.com/study/3729-development-of-hemiacetal-esterified-levofloxacin-to-prevent2026-10-08 https://evidence-hub.com/study/3730-effect-of-a-combination-of-mometasone-furoate-levofloxacin-and2026-10-06 https://evidence-hub.com/study/3731-chitosan-maleic-anhydride-and-itaconic-acid-super-porous-hydrogels2026-10-06 https://evidence-hub.com/study/3732-zinc-oxide-resveratrol-nanoparticles-ameliorate-levofloxacin-induced2026-10-06 https://evidence-hub.com/study/3733-an-inulin-based-glycovesicle-for-pathogen-targeted-drug-delivery-to2026-10-06 https://evidence-hub.com/study/3734-a-comparative-application-of-spectrophotometric-and2026-10-06 https://evidence-hub.com/study/3735-study-of-the-effect-of-administration-of-narasin-or-antibiotics-on-in2026-10-06 https://evidence-hub.com/study/3736-actinomyces-bowdenii-ulcerative-keratitis-in-a-dog2026-10-08 https://evidence-hub.com/study/3737-in-vivo-challenging-of-polymyxins-and-levofloxacin-eye-drop-against2026-10-06 https://evidence-hub.com/study/3738-antidepressant-anxiogenic-and-antinociceptive-properties-of2026-10-08 https://evidence-hub.com/study/3739-ophthalmotoxicity-and-ototoxicity-of-the-new-quinolone-antibacterial2026-10-06 https://evidence-hub.com/study/3740-herb-drug-interaction-the-effect-of-polygonum-capitatum-extract-on2026-10-13 https://evidence-hub.com/study/3741-the-efficacy-of-intravitreal-levofloxacin-and-intravitreal2026-10-06 https://evidence-hub.com/study/3742-influences-of-tolfenamic-acid-and-flunixin-meglumine-on-the2026-10-08 https://evidence-hub.com/study/3743-punica-granatum-peel-extract-modulates-levofloxacin-induced-oxidative2026-10-06 https://evidence-hub.com/study/3744-pharmacokinetics-of-pericyte-involvement-in-small-molecular-drug2026-10-08 https://evidence-hub.com/study/3745-study-effect-and-mechanism-of-ofloxacin-and-levofloxacin-on2026-10-08 https://evidence-hub.com/study/3746-bioavailability-and-pharmacokinetic-profile-of-levofloxacin-following2026-10-06 https://evidence-hub.com/study/3747-a-recombinant-snake-cathelicidin-derivative-peptide-antibiofilm2026-10-08 https://evidence-hub.com/study/3748-interaction-between-levofloxacin-and-vancomycin-in-rats-study-of2026-10-06 https://evidence-hub.com/study/3749-levofloxacin-induced-seizure-susceptibility-involves-both-enhanced2026-10-08 https://evidence-hub.com/study/3750-hepatobiliary-transported-levofloxacin-loaded-nanoparticles-for2026-10-05 https://evidence-hub.com/study/3751-in-situ-forming-hydrogel-recombination-with-tissue-adhesion-and2026-10-06 https://evidence-hub.com/study/3752-acute-oral-toxicity-of-the-new-quinolone-antibacterial-agent2026-10-08 https://evidence-hub.com/study/3753-prevalence-antibiotic-susceptibility-and-genomic-analysis-of2026-10-06 https://evidence-hub.com/study/3754-characterization-of-the-pharmacokinetic-disposition-of-levofloxacin2026-10-06 https://evidence-hub.com/study/3755-safety-of-intracameral-injection-of-gatifloxacin-levofloxacin-on2026-10-06 https://evidence-hub.com/study/3756-the-effect-and-mechanism-of-variable-particle-size-microplastics-and2026-10-06 https://evidence-hub.com/study/3757-preventive-effect-against-post-cataract-endophthalmitis-drug-delivery2026-10-08 https://evidence-hub.com/study/3758-fixed-combination-eye-drops-based-on-fluorometholone-nanoparticles2026-10-06 https://evidence-hub.com/study/3759-levofloxacin-promotes-extracellular-matrix-remodeling-and-apoptosis2026-10-06 https://evidence-hub.com/study/3760-effects-of-antibiotics-ceftriaxone-and-levofloxacin-on-the-growth-of2026-10-06 https://evidence-hub.com/study/3763-folic-acid-induced-animal-model-of-kidney-disease2026-10-19 https://evidence-hub.com/study/3764-zebrafish-as-an-alternative-animal-model-in-human-and-animal2026-10-19 https://evidence-hub.com/study/3765-quercetin-attenuates-the-reduction-of-parvalbumin-in-middle-cerebral2026-10-19 https://evidence-hub.com/study/3766-variance-component-analysis-of-growth-and-production-traits-in2026-10-19 https://evidence-hub.com/study/3767-animal-models-in-orthopedic-research-the-proper-animal-model-to2026-10-13 https://evidence-hub.com/study/3768-choosing-the-right-animal-model-for-infectious-disease-research2026-10-19 https://evidence-hub.com/study/3769-resveratrol-modulates-the-akt-gsk-3-signaling-pathway-in-a-middle2026-10-19 https://evidence-hub.com/study/3770-real-supermodels-wear-wool-summarizing-the-impact-of-the-pregnant2026-10-19 https://evidence-hub.com/study/3771-the-role-of-the-gut-microbiota-on-animal-model-reproducibility2026-10-19 https://evidence-hub.com/study/3772-to-develop-a-novel-animal-model-of-myocardial-infarction-a-research2026-10-09 https://evidence-hub.com/study/3773-efficacy-of-levofloxacin-loaded-nonionic-surfactant-vesicles-niosomes2026-10-08 https://evidence-hub.com/study/3774-nutritional-value-of-detoxified-jatropha-curcas-seed-cake-protein2026-10-19 https://evidence-hub.com/study/3775-animal-models-of-human-herpesvirus-infection2026-10-08 https://evidence-hub.com/study/3776-antimicrobial-activity-of-solithromycin-and-levofloxacin-against-a2026-10-20 https://evidence-hub.com/study/3777-changes-of-myelin-basic-protein-in-the-hippocampus-of-an-animal-model2026-10-19 https://evidence-hub.com/study/3778-review-animal-model-and-the-current-understanding-of-molecule2026-10-19 https://evidence-hub.com/study/3779-comparison-of-the-in-vivo-activities-of-garenoxacin-and-levofloxacin2026-10-20 https://evidence-hub.com/study/3780-doxycycline-levofloxacin-and-moxifloxacin-are-superior-to2026-10-08 https://evidence-hub.com/study/3781-comparative-study-on-the-time-trends-of-antimicrobial-resistance-at2026-10-08 https://evidence-hub.com/study/3782-animal-models-in-neuroscience-with-alternative-approaches2026-10-19 https://evidence-hub.com/study/3784-synergistic-effects-of-gentamicin-levofloxacin-and-cefotaxime-against2026-10-08 https://evidence-hub.com/study/3785-histopathological-investigation-of-the-effect-of-levofloxacin-and2026-10-08 https://evidence-hub.com/study/3786-in-vitro-and-animal-studies-of-human-natural-killer-cell-derived2026-10-08 https://evidence-hub.com/study/3787-a-review-of-animal-models-utilized-in-preclinical-studies-of-approved2026-10-19 https://evidence-hub.com/study/3788-multimodal-topical-formulations-combining-synthetic-anti-inflammatory2026-10-08 https://evidence-hub.com/study/3789-understanding-and-predicting-animal-movements-and-distributions-in2026-10-19 https://evidence-hub.com/study/3790-role-of-animal-models-in-biomedical-research-a-review2026-10-19 https://evidence-hub.com/study/3791-doxycycline-levofloxacin-or-moxifloxacin-are-superior-to2026-10-08 https://evidence-hub.com/study/3792-development-and-evaluation-of-edta-treated-rabbits-for2026-10-08 https://evidence-hub.com/study/3793-molecular-epidemiology-of-levofloxacin-resistant-klebsiella2026-10-20 https://evidence-hub.com/study/3794-local-multifunctional-hydrogel-therapy-in-experimental2026-10-08 https://evidence-hub.com/study/3796-review-to-be-or-not-to-be-an-identifiable-model-is-this-a-relevant2026-10-19 https://evidence-hub.com/study/3797-development-of-osteoporosis-animal-model-using-micropigs2026-10-19 https://evidence-hub.com/study/3799-levofloxacin-ceftriaxone-combination-attenuates-lung-inflammation-in2026-10-20 https://evidence-hub.com/study/3800-p-1830-the-first-in-class-anti-staphylococcal-antibiotic-afabicin2026-10-08 https://evidence-hub.com/study/3801-knee-osteoarthritis-a-review-of-animal-models-and-intervention-of2026-10-19 https://evidence-hub.com/study/3802-nutritional-composition-of-various-insects-and-potential-uses-as2026-10-19 https://evidence-hub.com/study/3803-p-647-comparative-efficacy-of-antibiotic-regimens-against-ureaplasma2026-10-08 https://evidence-hub.com/study/3804-the-nephroprotective-effect-of-clove-oil-oleum-caryophylli-against2026-10-08 https://evidence-hub.com/study/3805-preparation-of-thermosensitive-gel-for-controlled-release-of2026-10-08 https://evidence-hub.com/study/3806-optimization-of-levofloxacin-loaded-crosslinked-chitosan-microspheres2026-10-08 https://evidence-hub.com/study/3807-drug-induced-liver-injury-in-children-clinical-observations-animal2026-10-03 https://evidence-hub.com/study/3808-the-pharmacokinetic-interaction-between-levofloxacin-and-sunitinib2026-10-08 https://evidence-hub.com/study/3809-ceftriaxone-acts-synergistically-with-levofloxacin-in-experimental2026-10-08 https://evidence-hub.com/study/3810-antistaphylococcal-activity-of-wck-771-a-tricyclic-fluoroquinolone-in2026-10-03 https://evidence-hub.com/study/3811-in-vitro-activity-of-the-ketolide-hmr-3647-ru-6647-for-legionella-spp2026-10-04 https://evidence-hub.com/study/3812-severe-legionnaires-disease-successfully-treated-with-levofloxacin2026-10-08 https://evidence-hub.com/study/3813-intact-blood-brain-barrier-transport-of-small-molecular-drugs-in2026-10-03 https://evidence-hub.com/study/3815-the-guinea-pig-as-a-model-of-infectious-diseases2026-10-03 https://evidence-hub.com/study/3816-bactericidal-activity-of-the-combination-of-levofloxacin-with2026-10-08 https://evidence-hub.com/study/3817-management-of-postirradiation-infection-lessons-learned-from-animal2026-10-08 https://evidence-hub.com/study/3818-combination-treatment-with-meropenem-plus-levofloxacin-is-synergistic2026-10-08 https://evidence-hub.com/study/3819-the-role-of-pk-pd-parameters-to-avoid-selection-and-increase-of2026-10-03 https://evidence-hub.com/study/3820-cethromycin-mediated-protection-against-the-plague-pathogen-yersinia2026-10-08 https://evidence-hub.com/study/3821-effect-of-antibiotics-levofloxacin-and-fosfomycin-on-a-mouse-model2026-10-08 https://evidence-hub.com/study/3822-successful-treatment-of-murine-listeriosis-and-salmonellosis-with2026-10-08 https://evidence-hub.com/study/3823-a-review-of-current-bacterial-resistance-to-antibiotics-in-food2026-10-03 https://evidence-hub.com/study/3824-antibiotic-activity-against-small-colony-variants-of-staphylococcus2026-10-03 https://evidence-hub.com/study/3825-evaluation-of-the-levofloxacin-release-characters-from-a-rabbit2026-10-03 https://evidence-hub.com/study/3826-the-spread-of-antibiotic-resistance-genes-in-vivo-model2026-10-03 https://evidence-hub.com/study/3827-stroke-propagates-bacterial-aspiration-to-pneumonia-in-a-model-of2026-10-08 https://evidence-hub.com/study/3828-combination-therapy-with-antibiotics-and-anthrax-immune-globulin2026-10-03 https://evidence-hub.com/study/3829-pleiotropic-effects-of-levofloxacin-fluoroquinolone-antibiotics2026-10-08 https://evidence-hub.com/study/3830-comparative-in-vivo-activity-of-gemifloxacin-in-a-rat-model-of2026-10-08 https://evidence-hub.com/study/3831-animal-models-of-pneumococcal-pneumonia2026-10-08 https://evidence-hub.com/study/3832-assessment-of-antimicrobial-combinations-for-klebsiella-pneumoniae2026-10-19 https://evidence-hub.com/study/3833-levofloxacin-associated-hypoglycaemia-complicated-by-pontine2026-10-08 https://evidence-hub.com/study/3834-linezolid-alone-or-combined-with-rifampin-against-methicillin2026-09-26 https://evidence-hub.com/study/3835-effects-of-androgen-deprivation-on-chronic-bacterial-prostatitis-in-a2026-09-26 https://evidence-hub.com/study/3836-retrospective-comparison-of-levofloxacin-and-moxifloxacin-on2026-10-03 https://evidence-hub.com/study/3837-levofloxacin-might-be-safe-to-use-for-oscc-patients2026-10-08 https://evidence-hub.com/study/3838-inhalable-solid-lipid-nanoparticles-of-levofloxacin-for-potential2026-10-05 https://evidence-hub.com/study/3839-endothelial-cell-compatibility-of-trovafloxacin-and-levofloxacin-for2026-10-08 https://evidence-hub.com/study/3840-in-vitro-and-in-vivo-evaluation-of-clastogenicity-of-second-line2026-10-06 https://evidence-hub.com/study/3841-chlamydia-trachomatis-antimicrobial-susceptibility-in-colorectal-and2026-10-06 https://evidence-hub.com/study/3842-in-vitro-and-ex-vivo-antibacterial-activity-of-levofloxacin-against2026-10-01 https://evidence-hub.com/study/3843-in-vitro-activity-of-a-novel-diaminopyrimidine-compound-iclaprim2026-10-06 https://evidence-hub.com/study/3844-in-vitro-activity-of-fluoroquinolones-against-common-respiratory2026-10-08 https://evidence-hub.com/study/3845-3d-printed-chitosan-based-hydrogels-loaded-with-levofloxacin-for2026-10-05 https://evidence-hub.com/study/3846-tnf-enhances-trovafloxacin-induced-in-vitro-hepatotoxicity-by2026-10-08 https://evidence-hub.com/study/3847-characterization-of-the-carrier-mediated-transport-of-levofloxacin-a2026-10-06 https://evidence-hub.com/study/3848-effect-of-levofloxacin-on-serum-glucose-concentration-in-rats2026-10-08 https://evidence-hub.com/study/3849-nanoparticles-encapsulation-of-phoenix-dactylifera-date-palm-mucilage2026-10-08 https://evidence-hub.com/study/3850-in-vitro-and-intracellular-activities-of-peptide-deformylase2026-10-08 https://evidence-hub.com/study/3851-in-vitro-and-in-vivo-activity-of-olamufloxacin-hsr-903-against2026-10-06 https://evidence-hub.com/study/3852-organometallic-rhenium-tricarbonyl-enrofloxacin-and-levofloxacin2026-10-06 https://evidence-hub.com/study/3853-molecular-characterization-of-fluoroquinolone-resistant-moraxella2026-10-06 https://evidence-hub.com/study/3854-in-vitro-efficacy-of-levofloxacin-alone-or-in-combination-tested2026-10-06 https://evidence-hub.com/study/3855-combating-multidrug-resistant-pathogens-with-host-directed2026-10-20 https://evidence-hub.com/study/3856-dual-delivery-of-tuberculosis-drugs-via-cyclodextrin-conjugated2026-10-08 https://evidence-hub.com/study/3857-in-vitro-antimicrobial-activity-of-a-new-quinolone-levofloxacin2026-10-06 https://evidence-hub.com/study/3858-in-vitro-activity-of-levofloxacin-against-recent-gram-negative2026-10-08 https://evidence-hub.com/study/3859-in-vitro-susceptibility-of-anaerobes-to-quinolones-in-the-united2026-10-06 https://evidence-hub.com/study/3860-a-comparative-study-of-the-in-vitro-activity-of-levofloxacin-against2026-10-08 https://evidence-hub.com/study/3861-temperature-dependent-specific-transport-of-levofloxacin-in-human2026-10-06 https://evidence-hub.com/study/3862-comparative-in-vitro-activity-of-levofloxacin-ofloxacin-and2026-10-20 https://evidence-hub.com/study/3863-in-vitro-activity-of-levofloxacin-against-streptococcus-pneumoniae2026-10-08 https://evidence-hub.com/study/3864-glycol-chitosan-oxidized-hyaluronic-acid-hydrogel-film-for-topical2026-10-06 https://evidence-hub.com/study/3865-photophysical-and-phototoxic-properties-of-the-antibacterial2026-10-06 https://evidence-hub.com/study/3866-effects-of-levofloxacin-and-doxycycline-on-interleukin-6-production2026-10-06 https://evidence-hub.com/study/3867-analysis-of-the-effect-of-urine-on-the-in-vitro-activity-of2026-10-13 https://evidence-hub.com/study/3868-in-vitro-activity-of-levofloxacin-ofloxacin-and-other-quinolones2026-10-08 https://evidence-hub.com/study/3869-multidrug-resistance-and-clinical-predictors-of-mortality-in2026-10-08 https://evidence-hub.com/study/3870-orbital-cellulitis-associated-with-scleral-buckle-infection-caused-by2026-10-08 https://evidence-hub.com/study/3871-realizing-precise-molecular-differentiation-in-heterogeneous2026-10-08 https://evidence-hub.com/study/3872-novel-management-of-post-laparoscopic-sacrocolpopexy-associated2026-10-08 https://evidence-hub.com/study/3873-modified-polymeric-biomaterials-with-antimicrobial-and2026-10-08 https://evidence-hub.com/study/3874-clinical-effectiveness-of-penicillin-free-therapies-in-first-line-and2026-10-08 https://evidence-hub.com/study/3875-a-rare-oral-metastatic-lesion-as-the-initial-diagnosis-of-small-cell2026-10-08 https://evidence-hub.com/study/3876-repurposing-niclosamide-ethanolamine-for-alveolar-echinococcosis2026-10-08 https://evidence-hub.com/study/3877-the-interplay-between-obstructive-sleep-apnea-and-respiratory2026-10-08 https://evidence-hub.com/study/3878-effectiveness-of-rifabutin-based-regimens-in-treating-helicobacter2026-10-08 https://evidence-hub.com/study/3879-infection-after-endovascular-repair-of-complex-aortic-and2026-10-13 https://evidence-hub.com/study/3880-bioactive-potential-of-pulicaria-undulata-from-arid-regions-against2026-10-08 https://evidence-hub.com/study/3881-engineering-ofloxacin-bioavailability-through-spray-dried-hpmc-and2026-10-08 https://evidence-hub.com/study/3882-microwave-assisted-synthesis-of-nanosized-ce-zno-anchored-on-porous2026-10-08 https://evidence-hub.com/study/3883-designing-antibiotics-with-inherent-resistance-to-efflux-as-a2026-10-08 https://evidence-hub.com/study/3884-the-headband-that-held-in-the-brain-illustrative-case2026-10-08 https://evidence-hub.com/study/3885-diagnostic-challenges-of-pneumocystis-jirovecii-pneumonia-in2026-10-08 https://evidence-hub.com/study/3886-in-vitro-and-in-vivo-drug-release-from-a-nano-hydroxyapatite2026-10-06 https://evidence-hub.com/study/3887-chromatographic-characterization-of-nasal-and-inhalation-drug2026-10-06 https://evidence-hub.com/study/3888-mucolytic-and-antibiotic-combination-therapy-using-silica-based2026-10-13 https://evidence-hub.com/study/3889-fungal-keratitis-treatment-unveiling-strategies-and-emerging-trends-a2026-10-05 https://evidence-hub.com/study/3891-toxic-effects-of-levofloxacin-on-rat-annulus-fibrosus-cells-an-in2026-10-08 https://evidence-hub.com/study/3893-the-in-vitro-activity-of-delafloxacin-and-comparator-agents-against2026-10-08 https://evidence-hub.com/study/3894-cefotaxime-acts-synergistically-with-levofloxacin-in-experimental2026-10-08 https://evidence-hub.com/study/3895-electrospun-nanofiber-composite-for-levofloxacin-in-ocular-drug2026-10-08 https://evidence-hub.com/study/3896-in-vitro-activities-of-antimicrobial-combinations-against-planktonic2026-10-08 https://evidence-hub.com/study/3899-robust-antibacterial-activity-of-functionalized-carbon-nanotube2026-10-08 https://evidence-hub.com/study/3900-global-update-on-the-in-vitro-activity-of-tigecycline-and-comparators2026-10-08 https://evidence-hub.com/study/3901-evaluation-of-levofloxacin-release-characteristics-from-a-human2026-10-08 https://evidence-hub.com/study/3902-development-of-topical-chitosan-glycerophosphate-based-hydrogel2026-10-08 https://evidence-hub.com/study/3903-in-vitro-susceptibilities-to-levofloxacin-and-various-antibacterial2026-10-13 https://evidence-hub.com/study/3904-comparative-in-vitro-efficacies-of-ethanol-edta-and-levofloxacin2026-10-08 https://evidence-hub.com/study/3905-omadacycline-is-highly-active-in-vitro-against-mycoplasma-genitalium2026-10-08 https://evidence-hub.com/study/3906-in-vitro-activity-of-mrx-8-and-comparators-against-clinical-isolated2026-10-08 https://evidence-hub.com/study/3907-effect-of-baicalein-combined-with-levofloxacin-on-staphylococcus2026-10-08 https://evidence-hub.com/study/3908-a-phytoanticipin-derivative-sodium-houttuyfonate-induces-in-vitro2026-10-08 https://evidence-hub.com/study/3910-influence-of-antibiotics-on-functionality-and-viability-of-liver2026-10-08 https://evidence-hub.com/study/3911-the-activity-of-liposomal-linolenic-acid-against-helicobacter-pylori2026-10-08 https://evidence-hub.com/study/3912-the-effects-of-levofloxacin-on-rabbit-anterior-cruciate-ligament2026-10-08 https://evidence-hub.com/study/3913-the-in-vitro-antimicrobial-and-antibiofilm-activities-of-lysozyme2026-10-08 https://evidence-hub.com/study/3915-chitosan-coated-liposome-with-lysozyme-responsive-properties-for-on2026-10-08 https://evidence-hub.com/study/3916-levofloxacin-loaded-poly-ethylene-oxide-chitosan-quercetin-loaded2026-10-08 https://evidence-hub.com/study/3917-biogenic-synthesis-of-levofloxacin-loaded-copper-oxide-nanoparticles2026-10-08 https://evidence-hub.com/study/3918-emergence-of-high-level-fluoroquinolone-resistance-in-emm62026-10-08 https://evidence-hub.com/study/3919-comparison-of-the-in-vitro-and-in-vivo-susceptibilities-of2026-10-08 https://evidence-hub.com/study/3920-comparative-in-vitro-antimicrobial-activities-of-the-newly2026-10-08 https://evidence-hub.com/study/3921-comparison-of-antibiotic-effect-and-corneal-epithelial-toxicity-of2026-10-08 https://evidence-hub.com/study/3922-in-vitro-selection-of-resistance-in-pseudomonas-aeruginosa-and2026-10-08 https://evidence-hub.com/study/3923-activities-of-trovafloxacin-gatifloxacin-clinafloxacin-sparfloxacin2026-09-26 https://evidence-hub.com/study/3925-in-vitro-activity-of-levofloxacin-ofloxacin-and-d-ofloxacin-against2026-10-08 https://evidence-hub.com/study/3926-in-vitro-activity-of-levofloxacin-against-a-selected-group-of2026-09-26 https://evidence-hub.com/study/3927-comparative-in-vitro-activity-of-levofloxacin-other-fluoroquinolones2026-09-26 https://evidence-hub.com/study/3928-the-effects-of-nora-inhibition-on-the-activities-of-levofloxacin2026-09-26 https://evidence-hub.com/study/3930-in-vitro-antibacterial-activity-of-levofloxacin-against-hospital2026-10-08 https://evidence-hub.com/study/3931-in-vitro-infection-model-characterizing-the-effect-of-efflux-pump2026-10-04 https://evidence-hub.com/study/3932-comparative-in-vitro-activities-of-ciprofloxacin-clinafloxacin2026-10-01 https://evidence-hub.com/study/3933-in-vitro-susceptibilites-to-levofloxacin-and-various-antibacterial2026-09-26 https://evidence-hub.com/study/3935-anti-mutant-efficacy-of-combination-therapy-with-doripenem-and2026-10-08 https://evidence-hub.com/study/3936-key-properties-outlook-of-a-levofloxacin-loaded-acrylic-bone-cement2026-10-08 https://evidence-hub.com/study/3937-antimicrobial-activity-and-metabolomic-analysis-of-linalool-against2026-10-06 https://evidence-hub.com/study/3938-microwave-assisted-synthesis-of-ruthenium-ii-complexes-containing2026-10-08 https://evidence-hub.com/study/3939-tackling-antibiotic-contaminations-in-wastewater-with-novel-modified2026-10-06 https://evidence-hub.com/study/3940-lysozyme-binding-with-amikacin-and-levofloxacin-studied-by-tritium2026-10-08 https://evidence-hub.com/study/3941-biodesulfurization-and-activation-of-a-thionated-levofloxacin2026-10-08 https://evidence-hub.com/study/3942-computational-screening-of-selected-phytochemicals-against2026-10-06 https://evidence-hub.com/study/3943-design-and-synthesis-of-thionated-levofloxacin-insights-into-a-new2026-10-06 https://evidence-hub.com/study/3944-molecular-dynamics-simulations-to-investigate-mycobacterium2026-10-06 https://evidence-hub.com/study/3945-bioassay-and-qsar-based-screening-of-toxic-transformation-products2026-10-08 https://evidence-hub.com/study/3946-genomic-analysis-of-fluoroquinolone-resistant-leclercia2026-10-08 https://evidence-hub.com/study/3947-molecular-characterization-and-mutational-analysis-of-clarithromycin2026-10-08 https://evidence-hub.com/study/3948-clinical-applications-of-population-pharmacokinetic-models-of2026-10-08 https://evidence-hub.com/study/3949-m1ukstreptococcus-pyogenes-causing-community-acquired-pneumonia2026-10-08 https://evidence-hub.com/study/3950-genomic-characterization-of-respiratory-elizabethkingia-antimicrobial2026-10-06 https://evidence-hub.com/study/3951-on-two-sample-mcnemar-test2026-10-08 https://evidence-hub.com/study/3952-diffusion-based-design-of-multi-layered-ophthalmic-lenses-for2026-10-08 https://evidence-hub.com/study/3953-design-synthesis-antibacterial-evaluation-and-molecular-docking2026-10-08 https://evidence-hub.com/study/3954-elucidating-the-bioremediation-potential-of-laccase-and-peroxidase2026-10-08 https://evidence-hub.com/study/3955-discovery-of-clinical-isolation-of-drug-resistant-klebsiella2026-10-08 https://evidence-hub.com/study/3956-the-study-on-interactions-between-levofloxacin-and-model-proteins-by2026-10-08 https://evidence-hub.com/study/3957-biocatalytic-asymmetric-synthesis-of-diversely-substituted-dihydro-12026-10-06 https://evidence-hub.com/study/3958-synthesis-antimycobacterial-activity-and-computational-insight-of2026-10-08 https://evidence-hub.com/study/3959-multidrug-resistant-escherichia-coli-antagonized-by-luteolin-a2026-10-08 https://evidence-hub.com/study/3960-bioactive-pyrone-analogs-from-the-endophytic-fungus-diaporthe-sp2026-10-08 https://evidence-hub.com/study/3961-identification-of-novel-drug-targets-for-helicobacter-pylori2026-10-13 https://evidence-hub.com/study/3963-a-sophisticated-virulence-repertoire-and-colistin-resistance-of2026-10-08 https://evidence-hub.com/study/3964-unraveling-the-role-of-toxin-antitoxin-systems-in-burkholderia2026-10-08 https://evidence-hub.com/study/3965-the-application-of-arbutin-in-elimination-resistance-gramm-negative2026-10-08 https://evidence-hub.com/study/3966-using-explainable-machine-learning-and-integrons-to-predict2026-10-08 https://evidence-hub.com/study/3967-icesag37-a-novel-integrative-and-conjugative-element-carrying2026-10-08 https://evidence-hub.com/study/3968-determination-of-antimicrobial-activity-of-fruits-of-citrullus2026-10-08 https://evidence-hub.com/study/3969-molecular-characterization-of-fluoroquinolone-resistance-of2026-10-08 https://evidence-hub.com/study/3970-patient-specific-prediction-of-3d-ablation-zones-via-oncological2026-10-19 https://evidence-hub.com/study/3971-in-silico-study-of-inhibition-of-activation-of-1a52-ethanol-extract2026-10-19 https://evidence-hub.com/study/3973-b7h6-is-the-predominant-activating-ligand-driving-natural-killer-cell2026-10-19 https://evidence-hub.com/study/3974-in-silico-and-in-vitro-multiple-analysis-approach-for-screening2026-10-19 https://evidence-hub.com/study/3975-an-in-silico-guided-approach-for-assessing-herb-drug-interaction2026-10-19 https://evidence-hub.com/study/3976-identification-of-anticancer-peptides-from-the-genome-of-candida2026-10-19 https://evidence-hub.com/study/3977-antiepileptic-and-neuroprotective-effects-of-rheum-tanguticum-root2026-10-19 https://evidence-hub.com/study/3978-in-silico-identification-of-novel-antimicrobial-peptides-from-the2026-10-19 https://evidence-hub.com/study/3979-in-silico-based-design-of-a-hybrid-peptide-with-antimicrobial2026-10-19 https://evidence-hub.com/study/3980-in-silico-identification-of-cry1ac-hot-spot-amino-acid-residues-to2026-10-19 https://evidence-hub.com/study/3981-phytochemistry-and-biological-activities-of-hibiscus-sabdariffa-leaf2026-10-08 https://evidence-hub.com/study/3982-in-silico-characterization-of-the-phytochemicals-of-phyllanthus2026-10-13 https://evidence-hub.com/study/3983-powerai-cvd-the-first-chinese-specific-validated-artificial2026-10-19 https://evidence-hub.com/study/3985-in-silico-repurposed-drugs-against-monkeypox-virus2026-10-19 https://evidence-hub.com/study/3986-the-regulation-of-hypoxia-inducible-factor-hif-1-expression-by2026-10-19 https://evidence-hub.com/study/3988-therapeutic-assessment-chemical-characterization-and-in-silico2026-10-19 https://evidence-hub.com/study/3989-relationship-between-macrophage-and-radiosensitivity-in-human-primary2026-10-19 https://evidence-hub.com/study/3991-synthesis-characterization-in-vitro-and-in-silico-studies-of-a-novel2026-10-13 https://evidence-hub.com/study/3992-antiviral-activity-of-two-marine-carotenoids-against-sars-cov-2-virus2026-10-19 https://evidence-hub.com/study/3993-comprehensive-in-silico-analysis-of-lactic-acid-bacteria-for-the2026-10-19 https://evidence-hub.com/study/3994-targeted-metabolic-and-in-silico-analyses-highlight-distinct2026-10-19 https://evidence-hub.com/study/3995-novel-anti-melanogenic-compounds-z-5-substituted-benzylidene-42026-10-19 https://evidence-hub.com/study/3996-in-silico-strategic-curation-retrieval-and-prediction-of-novel2026-10-19 https://evidence-hub.com/study/3997-synthesis-characterization-molecular-docking-and-biological2026-10-08 https://evidence-hub.com/study/3999-development-of-a-program-for-in-silico-optimized-selection-of2026-10-19 https://evidence-hub.com/study/4000-comparing-the-synergistic-and-antagonistic-interactions-of2026-10-08 https://evidence-hub.com/study/4001-curation-of-cancer-hallmark-based-genes-and-pathways-for-in-silico2026-10-19 https://evidence-hub.com/study/4002-antimicrobial-phytochemical-analysis-and-molecular-docking-in-silico2026-10-08 https://evidence-hub.com/study/4003-determination-of-in-vitro-and-in-silico-indexes-for-the-modeling-of2026-10-01 https://evidence-hub.com/study/4004-the-acute-toxicity-and-cardiotoxic-effects-of-levofloxacin-on2026-10-08 https://evidence-hub.com/study/4007-moving-forward-through-the-in-silico-modeling-of-tuberculosis-a2026-10-01 https://evidence-hub.com/study/4008-unveiling-the-potential-of-algal-extracts-as-promising-antibacterial2026-10-08 https://evidence-hub.com/study/4009-identification-of-potential-drug-targets-in-helicobacter-pylori-using2026-10-04 https://evidence-hub.com/study/4011-molecular-characterization-and-differential-effects-of-levofloxacin2026-10-08 https://evidence-hub.com/study/4012-efflux-pump-effects-on-levofloxacin-resistance-in-mycobacterium2026-10-13 https://evidence-hub.com/study/4013-eco-friendly-synthesis-biological-evaluation-and-in-silico-molecular2026-10-01 https://evidence-hub.com/study/4014-in-silico-study-for-algerian-essential-oils-as-antimicrobial-agents2026-10-08 https://evidence-hub.com/study/4015-drug-resistant-e-coli-bacteremia-transmitted-by-fecal-microbiota2026-10-01 https://evidence-hub.com/study/4016-differential-performance-and-lung-deposition-of-levofloxacin-with2026-10-08 https://evidence-hub.com/study/4017-evaluation-of-the-influence-of-fluoroquinolone-chemical-structure-on2026-10-13 https://evidence-hub.com/study/4018-exploring-the-potential-of-propanamide-sulfonamide-based-drug2026-10-01 https://evidence-hub.com/study/4019-computational-and-experimental-approaches-for-assessing-the2026-10-08 https://evidence-hub.com/study/4020-design-synthesis-in-vitro-and-in-silico-studies-of-42026-10-13 https://evidence-hub.com/study/4021-synthesis-characterization-biological-evaluation-and-in-silico2026-10-04 https://evidence-hub.com/study/4022-levofloxacin-reposition-based-design-synthesis-biological-evaluation2026-10-04 https://evidence-hub.com/study/4023-pegylated-triarylmethanes-synthesis-antimicrobial-activity-anti2026-10-01 https://evidence-hub.com/study/4024-the-ph-solubility-profiles-of-levofloxacin-hemihydrate-and2026-10-08 https://evidence-hub.com/study/4025-green-wastewater-treatment-of-repurposed-covid-19-therapy2026-10-08 https://evidence-hub.com/study/4026-in-vitro-and-in-silico-evaluation-of-the-serrapeptase-effect-on2026-10-08 https://evidence-hub.com/study/4027-chalcone-derivatives-as-potential-inhibitors-of-p-glycoprotein-and2026-10-01 https://evidence-hub.com/study/4028-defect-engineered-c-n-zno-co3o4-cofe2o4-fe3o4-for-ultra-fast2026-10-03 https://evidence-hub.com/study/4030-antibiotic-efficacy-is-linked-to-bacterial-cellular-respiration2026-10-01 https://evidence-hub.com/study/4031-the-cytogenetic-effects-of-levofloxacin-in-male-rats2026-10-13 https://evidence-hub.com/study/4032-assessing-the-potential-of-gallic-acid-and-methyl-gallate-to-enhance2026-10-08 https://evidence-hub.com/study/4033-efficacy-of-levofloxacin-on-macrolide-unresponsive-and-corticosteroid2026-10-20 https://evidence-hub.com/study/4034-pyridylpiperazine-efflux-pump-inhibitor-boosts-in-vivo-antibiotic2026-10-20 https://evidence-hub.com/study/4035-doripenem-a-review-of-its-use-in-the-treatment-of-bacterial-infections2026-10-19 https://evidence-hub.com/study/4036-doripenem-a-new-carbapenem-antibiotic2026-10-20 https://evidence-hub.com/study/4037-fluoroquinolones-in-children-update-of-the-literature2026-10-20 https://evidence-hub.com/study/4038-new-insights-in-the-treatment-by-levofloxacin2026-10-19 https://evidence-hub.com/study/4039-review-of-nemonoxacin-with-special-focus-on-clinical-development2026-10-19 https://evidence-hub.com/study/4040-the-efficacy-of-cefdinir-in-acute-bacterial-rhinosinusitis2026-10-20 https://evidence-hub.com/study/4041-pharmacokinetics-and-pharmacodynamics-of-the-new-fluoroquinolones2026-10-19 https://evidence-hub.com/study/4042-injectable-quinolones2026-10-20 https://evidence-hub.com/study/4043-treatment-of-rhinosinusitis-in-the-outpatient-setting2026-10-19 https://evidence-hub.com/study/4044-efficacy-and-safety-of-nemonoxacin-versus-levofloxacin-for-community2026-10-20 https://evidence-hub.com/study/4045-efficacy-of-zoliflodacin-a-spiropyrimidinetrione-antibiotic-against2026-10-20 https://evidence-hub.com/study/4046-efficacy-and-safety-of-tigecycline-versus-levofloxacin-for-community2026-10-20 https://evidence-hub.com/study/4047-antimicrobial-treatment-of-lower-respiratory-tract-infections-in-the2026-10-19 https://evidence-hub.com/study/4048-levofloxacin-update-and-perspectives-on-one-of-the-original2026-10-19 https://evidence-hub.com/study/4049-efficacy-and-pharmacodynamics-of-gemifloxacin-versus-levofloxacin-in2026-10-20 https://evidence-hub.com/study/4050-new-fluoroquinolones-in-lower-respiratory-tract-infections-and2026-10-08 https://evidence-hub.com/study/4051-clinical-efficacy-and-tolerability-of-levofloxacin-in-patients-with2026-10-20 https://evidence-hub.com/study/4052-advances-in-the-management-of-chlamydia-pneumoniae-infections2026-10-19 https://evidence-hub.com/study/4053-principles-of-antibiotic-treatment-of-community-acquired-pneumonia-in2026-10-08 https://evidence-hub.com/study/4054-gallium-iii-and-iron-iii-complexes-of-quinolone-antimicrobials2026-10-19 https://evidence-hub.com/study/4055-retrospective-analysis-of-azithromycin-versus-fluoroquinolones-for2026-10-20 https://evidence-hub.com/study/4056-tryptophan-rich-short-peptide-amphiphile-mediated-synthesis-of-silver2026-10-20 https://evidence-hub.com/study/4057-gatifloxacin-a-review-of-its-use-in-the-management-of-bacterial2026-10-19 https://evidence-hub.com/study/4058-acinetobacter-baumannii-ventilator-associated-pneumonia-clinical2026-10-20 https://evidence-hub.com/study/4059-cefiderocol-as-an-alternative-antibiotic-therapy-for-treating-severe2026-10-19 https://evidence-hub.com/study/4060-levofloxacin-loaded-chitosan-and-poly-lactic-co-glycolic-acid-nano2026-10-08 https://evidence-hub.com/study/4061-efficacy-and-safety-of-levofloxacin-treatment-of-community-acquired2026-10-20 https://evidence-hub.com/study/4062-in-vitro-susceptibility-to-different-topical-ophthalmic-antibiotics2026-10-08 https://evidence-hub.com/study/4063-the-treatment-of-macrolide-resistant-mycoplasma-pneumoniae-pneumonia2026-10-20 https://evidence-hub.com/study/4064-in-vivo-and-in-vitro-efficacy-of-minocycline-based-combination2026-10-20 https://evidence-hub.com/study/4065-susceptibility-of-various-gram-negative-bacteria-to-antibacterial2026-10-19 https://evidence-hub.com/study/4066-clinical-efficacy-and-in-vitro-drug-sensitivity-test-results-of2026-10-20 https://evidence-hub.com/study/4067-synthesis-and-structure-activity-relationship-of-novel-bisindole2026-10-08 https://evidence-hub.com/study/4068-the-yield-of-tigecycline-in-the-treatment-of-community-acquired2026-10-08 https://evidence-hub.com/study/4069-tigecycline-in-the-treatment-of-ventilator-associated-pneumonia-due2026-10-20 https://evidence-hub.com/study/4070-antimicrobial-resistance-in-patients-with-odontogenic-infections-a2026-10-08 https://evidence-hub.com/study/4071-clinical-contribution-of-the-newer-fluoroquinolones-in-acute2026-10-06 https://evidence-hub.com/study/4072-interim-study-comparison-of-safety-and-efficacy-of-levofloxacin-plus2026-10-20 https://evidence-hub.com/study/4073-efficacy-and-safety-of-doripenem-versus-piperacillin-tazobactam-in2026-10-20 https://evidence-hub.com/study/4074-pneumocystis-pneumonia-with-multiple-nodules-on-computed-tomography2026-10-20 https://evidence-hub.com/study/4075-efficacy-of-delafloxacin-alone-and-in-combination-with-cefotaxime2026-10-20 https://evidence-hub.com/study/4076-clinical-application-and-safety-observation-of-levofloxacin-in2026-10-20 https://evidence-hub.com/study/4077-beta-lactam-plus-azithromycin-or-doxycycline-vs-fluoroquinolones-in2026-10-20 https://evidence-hub.com/study/4078-efficacy-and-short-term-safety-of-intravenous-omadacycline-as-second2026-10-20 https://evidence-hub.com/study/4079-beyond-plasma-defining-the-translation-value-of-epithelial-lining2026-10-20 https://evidence-hub.com/study/4080-evaluation-of-in-vitro-activity-of-delafloxacin-against2026-10-20 https://evidence-hub.com/study/4081-efficacy-of-garenoxacin-in-patients-with-macrolide-resistant2026-10-20 https://evidence-hub.com/study/4082-efficacy-of-high-dose-versus-conventional-dose-methylprednisolone-in2026-10-20 https://evidence-hub.com/study/4083-evaluation-of-antimicrobial-peptide-antibiotic-combination-treatment2026-10-20 https://evidence-hub.com/study/4084-treatment-outcomes-of-combination-versus-monotherapy-in2026-10-20 https://evidence-hub.com/study/4085-multiple-pulmonary-nodules-caused-by-pasteurella-multocida-pneumonia2026-10-20 https://evidence-hub.com/study/4086-design-and-validation-of-revised-medication-assessment-tool-for2026-10-20 https://evidence-hub.com/study/4087-evaluation-of-multifaceted-interventions-on-antibiotic-prescribing-in2026-10-20 https://evidence-hub.com/study/4088-lower-respiratory-tract-microbiota-characteristics-in-patients-with2026-10-20 https://evidence-hub.com/study/4089-inhalable-dry-powders-of-antimicrobial-agents-in-respiratory-diseases2026-10-20 https://evidence-hub.com/study/4090-navigating-the-challenges-of-stenotrophomonas-maltophilia-infections2026-10-20 https://evidence-hub.com/study/4091-pan-ras-in-1-triggers-cell-wall-lysis-to-eradicate-staphylococcus2026-10-20 https://evidence-hub.com/study/4092-early-diagnosis-and-successful-treatment-of-influenza-coinfection2026-10-20 https://evidence-hub.com/study/4093-in-vitro-antibiofilm-and-intracellular-activity-of-delafloxacin2026-10-20 https://evidence-hub.com/study/4094-comparison-of-adverse-events-associated-with-six-common-antibiotics2026-10-20 https://evidence-hub.com/study/4095-case-report-pulmonary-brucellosis-presenting-as-multiple-cavitary2026-10-20 https://evidence-hub.com/study/4096-case-report-omadacycline-in-the-treatment-of-community-acquired2026-10-20 https://evidence-hub.com/study/4097-serum-interferon-is-associated-with-refractory-mycoplasma-pneumoniae2026-10-20 https://evidence-hub.com/study/4098-assessment-of-susceptibility-of-methicillin-resistant-staphylococcus2026-10-20 https://evidence-hub.com/study/4099-artificial-intelligence-guided-phenotypic-drug-repurposing-against2026-10-20 https://evidence-hub.com/study/4100-a-case-of-severe-legionella-pneumonia-treated-with-omadacycline-and2026-10-20 https://evidence-hub.com/study/4101-clinical-efficacy-comparison-of-doxycycline-versus-azithromycin2026-10-20 https://evidence-hub.com/study/4102-case-report-cavitary-legionella-pneumophila-pneumonia-in-a-kidney2026-10-20 https://evidence-hub.com/study/4103-distribution-of-isolated-pathogens-and-resistance-patterns-in-non2026-10-20 https://evidence-hub.com/study/4104-antibiotic-associated-adverse-events-in-bone-and-joint-infections-a2026-10-20 https://evidence-hub.com/study/4105-eradication-efficacy-of-empiric-bismuth-quadruple-therapy-containing2026-10-20 https://evidence-hub.com/study/4106-optimized-aptamer-based-impedimetric-assay-for-sensitive-and2026-10-20 https://evidence-hub.com/study/4107-severe-chlamydia-psittaci-pneumonia-complicated-by-deep-vein2026-10-20 https://evidence-hub.com/study/4108-injection-site-abscess-caused-by-mycobacterium-abscessus-following2026-10-20 https://evidence-hub.com/study/4109-combination-of-ceftazidime-avibactam-and-meropenem-for-the-treatment2026-10-20 https://evidence-hub.com/study/4110-risk-stratification-and-source-classification-in-staphylococcus2026-10-20 https://evidence-hub.com/study/4111-cedecea-lapagei-pneumonia-the-first-reported-case-in-italy-and2026-10-20 https://evidence-hub.com/study/4112-in-vitro-characterization-of-delafloxacin-activity-against2026-10-20 https://evidence-hub.com/study/4113-development-of-a-novel-ultrashort-antimicrobial-peptide-levofloxacin2026-10-20 https://evidence-hub.com/study/4114-wbp-encoded-lps-o-antigen-architecture-as-a-prognostic-and2026-10-20 https://evidence-hub.com/study/4115-successful-dual-therapy-of-aztreonam-and-ceftazidime-avibactam-for2026-10-20 https://evidence-hub.com/study/4116-landouzy-sepsis-in-a-young-adult-with-multiorgan-failure-successful2026-10-20 https://evidence-hub.com/study/4117-prevalence-and-antimicrobial-susceptibility-profile-of2026-10-20 https://evidence-hub.com/study/4118-initial-presentation-etiology-and-risk-factors-for-adverse-outcomes2026-10-20 https://evidence-hub.com/study/4119-case-report-fatal-osimertinib-related-interstitial-lung-disease2026-10-20 https://evidence-hub.com/study/4120-a-new-preview-of-antibiotic-resistant-spectrum-in-community-acquired2026-10-20 https://evidence-hub.com/study/4121-molecular-insights-into-macrolide-resistant-mycoplasma-pneumoniae2026-10-20 https://evidence-hub.com/study/4122-application-of-metagenomic-next-generation-sequencing-in-the2026-10-16 https://evidence-hub.com/study/4123-risk-factors-associated-with-mortality-in-nosocomial-stenotrophomonas2026-10-14 https://evidence-hub.com/study/4124-antibiotics-accumulate-in-klebsiella-pneumoniae-liver-abscesses-but2026-10-20 https://evidence-hub.com/study/4125-extracorporeal-near-infrared-activated-antimicrobial-photodynamic2026-10-08 https://evidence-hub.com/study/4126-evolving-antimicrobial-resistance-patterns-in-group-b-streptococci-a2026-10-06 https://evidence-hub.com/study/4127-phage-antibiotic-combination-a-possible-approach-to-combatting2026-10-06 https://evidence-hub.com/study/4128-long-term-trends-in-ceftolozane-tazobactam-susceptibility-among-gram2026-10-06 https://evidence-hub.com/study/4129-cost-analysis-of-a-sequential-antimicrobial-therapy-protocol-in2026-10-06 https://evidence-hub.com/study/4130-comparative-efficacy-of-levofloxacin-versus-amoxycillin-clavulanic2026-10-20 https://evidence-hub.com/study/4131-efficacy-of-azithromycin-injection-combined-with-levofloxacin-capsule2026-10-20 https://evidence-hub.com/study/4132-clinical-effects-of-moxifloxacin-and-levofloxacin-in-the-treatment-of2026-10-20 https://evidence-hub.com/study/4133-the-efficacy-of-antimicrobial-therapies-in-the-treatment-of-mixed2026-10-20 https://evidence-hub.com/study/4134-quantitative-performance-of-humanized-serum-and-epithelial-lining2026-10-20 https://evidence-hub.com/study/4135-evaluating-the-clinical-effectiveness-of-third-generation2026-10-20 https://evidence-hub.com/study/4136-efficacy-of-pudilan-xiaoyan-oral-liquid-in-the-treatment-of-pneumonia2026-10-20 https://evidence-hub.com/study/4138-levofloxacin-versus-amoxycillin-clavulanic-acid-combined-with2026-10-20 https://evidence-hub.com/study/4139-a-monte-carlo-pharmacokinetic-pharmacodynamic-simulation-to-evaluate2026-10-20 https://evidence-hub.com/study/4140-the-antibiotic-efficacy-of-levofloxacin-tablet-was-determined2026-10-20 https://evidence-hub.com/study/4141-impact-of-qnra1-qnrb1-and-qnrs1-on-the-efficacy-of-ciprofloxacin-and2026-10-20 https://evidence-hub.com/study/4142-comparative-efficacy-of-levofloxacin-and-ceftriaxone-in-the-treatment2026-10-20 https://evidence-hub.com/study/4145-efficacy-analysis-of-tanreqing-combined-with-levofloxacin-on2026-10-20 https://evidence-hub.com/study/4147-propensity-matched-comparison-of-timely-vs-delayed-antibiotic-therapy2026-10-20 https://evidence-hub.com/study/4150-safety-and-efficacy-of-intravenous-tigecycline-in-treatment-of2026-10-20 https://evidence-hub.com/study/4151-efficacy-analysis-of-levofloxacin-combined-with-tanreqing-injection2026-10-20 https://evidence-hub.com/study/4152-low-dose-trimethoprim-sulfamethoxazole-prophylaxis-for-pneumocystis2026-10-20 https://evidence-hub.com/study/4153-efficacy-of-750-mg-5-day-levofloxacin-in-the-treatment-of-community2026-10-20 https://evidence-hub.com/study/4154-multicenter-open-label-randomized-study-to-compare-the-safety-and2026-10-20 https://evidence-hub.com/study/4155-a-prospective-study-of-the-efficacy-safety-and-pharmacokinetics-of2026-10-20 https://evidence-hub.com/study/4156-a-randomized-open-multicenter-clinical-study-on-the-short-course-of2026-10-20 https://evidence-hub.com/study/4157-microbiological-efficacy-of-levofloxacin-for-treatment-of-community2026-10-20 https://evidence-hub.com/study/4158-efficacy-and-safety-of-high-dosage-levofloxacin-injection-in-the2026-10-20 https://evidence-hub.com/study/4159-clinical-efficacy-of-levofloxacin-and-azithromycinin-in-the-treatment2026-10-20 https://evidence-hub.com/study/4160-efficacy-of-piperacillin-tazobactam-combined-with-levofloxacin-for2026-10-20 https://evidence-hub.com/study/4163-efficacy-of-the-combination-of-levofloxacin-plus-ceftazidime-in-the2026-10-20 https://evidence-hub.com/study/4165-outcome-of-levofloxacin-in-the-treatment-of-lower-respiratory-tract2026-10-20 https://evidence-hub.com/study/4169-correction-to-dunbar-lm-khashab-mm-kahn-jb-et-al-efficacy-of-750-mg-52026-10-20 https://evidence-hub.com/study/4171-abiflox-efficacy-in-complex-therapy-of-patients-with-community2026-10-20 https://evidence-hub.com/study/4176-biosynthesis-characterization-and-antibiofilm-activity-of-copper2026-10-20 https://evidence-hub.com/study/4177-evaluation-of-the-efficacy-of-novel-drugs-and-combinations-against2026-10-20 https://evidence-hub.com/study/4178-bms-284756-t-3811me-a-new-fluoroquinolone-in-vitro-activity-against2026-10-20 https://evidence-hub.com/study/4179-effect-of-ethanol-on-fluoroquinolone-efficacy-in-a-rat-model-of2026-10-20 https://evidence-hub.com/study/4180-therapeutic-experience-with-levofloxacin-in-pneumonia-and-copd2026-10-20 https://evidence-hub.com/study/4182-non-adherence-in-adult-male-patients-with-community-acquired2026-10-20 https://evidence-hub.com/study/4183-a-multi-center-randomized-double-blind-double-dummy-parallel2026-10-20 https://evidence-hub.com/study/4184-a-multicenter-randomized-double-blind-double-dummy-comparative-trial2026-10-20 https://evidence-hub.com/study/4185-a-phase-3-multicenter-randomized-double-blind-comparative-study-of2026-10-20 https://evidence-hub.com/study/4186-a-multicenter-active-controlled-randomized-study-to-evaluate-the2026-10-20 https://evidence-hub.com/study/4187-a-phase-3-multicenter-randomized-double-blind-placebo-controlled2026-10-20 https://evidence-hub.com/study/4188-a-randomized-double-blind-multi-center-study-to-evaluate-the-efficacy2026-10-20 https://evidence-hub.com/study/4189-antibiotic-treatment-of-community-acquired-pneumonia-a-prospective2026-10-20 https://evidence-hub.com/study/4190-a-randomized-multicenter-open-label-trial-comparing-intravenous2026-10-20 https://evidence-hub.com/study/4191-a-multicenter-open-label-randomized-active-controlled-parallel-group2026-10-20 https://evidence-hub.com/study/4192-a-phase-2-multi-dose-double-blind-double-dummy-active-control2026-10-20 https://evidence-hub.com/study/4193-a-multinational-prospective-randomized-double-blind-study-to2026-10-20 https://evidence-hub.com/study/4194-a-multicenter-randomized-open-label-study-to-compare-the-safety-and2026-10-20 https://evidence-hub.com/study/4195-pneumococcal-vaccination-of-multiple-myeloma-patients-on-novel-agents2026-10-20 https://evidence-hub.com/study/4196-an-international-multicenter-randomized-double-blind-double-dummy-two2026-10-20 https://evidence-hub.com/study/4197-a-phase-3-multicenter-randomized-double-blind-comparative-study-of2026-10-20 https://evidence-hub.com/study/4198-practice-guidelines-for-the-management-of-community-acquired2026-10-08 https://evidence-hub.com/study/4199-international-ers-esicm-escmid-alat-guidelines-for-the-management-of2026-09-30 https://evidence-hub.com/study/4200-pneumococcal-bacteremia-with-especial-reference-to-bacteremic2026-09-30 https://evidence-hub.com/study/4201-comparative-efficacies-and-tolerabilities-of-intravenous-azithromycin2026-10-20 https://evidence-hub.com/study/4202-bts-guidelines-for-the-management-of-community-acquired-pneumonia-in2026-10-01 https://evidence-hub.com/study/4204-community-acquired-pneumonia-in-adults-guidelines-for-management2026-10-08 https://evidence-hub.com/study/4205-update-of-practice-guidelines-for-the-management-of-community2026-10-01 https://evidence-hub.com/study/4206-british-thoracic-society-guidelines-for-the-management-of-community2026-10-01 https://evidence-hub.com/study/4208-integrated-results-of-2-phase-3-studies-comparing-tigecycline-and2026-10-20 https://evidence-hub.com/study/4209-a-multicenter-randomized-study-comparing-the-efficacy-and-safety-of2026-10-20 https://evidence-hub.com/study/4210-linezolid-in-methicillin-resistant-staphylococcus-aureus-nosocomial2026-10-01 https://evidence-hub.com/study/4211-a-multicenter-open-label-randomized-comparison-of-levofloxacin-and2026-10-20 https://evidence-hub.com/study/4212-a-critical-review-of-the-fluoroquinolones-focus-on-respiratory2026-10-19 https://evidence-hub.com/study/4213-corticosteroids-for-pneumonia2026-10-13 https://evidence-hub.com/study/4214-clinical-practice-guidelines-for-hospital-acquired-pneumonia-and2026-10-01 https://evidence-hub.com/study/4216-doxycycline-vs-levofloxacin-in-the-treatment-of-community-acquired2026-10-20 https://evidence-hub.com/study/4217-duration-of-antibiotic-treatment-in-community-acquired-pneumonia2026-10-01 https://evidence-hub.com/study/4218-guidelines-for-the-management-of-hospital-acquired-pneumonia-in-the2026-10-01 https://evidence-hub.com/study/4219-in-vivo-activity-of-levofloxacin-alone-or-in-combination-with2026-10-20 https://evidence-hub.com/study/4220-levofloxacin-750-mg-for-5-days-for-the-treatment-of-hospitalized-fine2026-10-08 https://evidence-hub.com/study/4221-severe-community-acquired-pneumonia-due-to-staphylococcus-aureus-20032026-10-01 https://evidence-hub.com/study/4222-update-of-the-treatment-of-nosocomial-pneumonia-in-the-icu2026-10-01 https://evidence-hub.com/study/4223-efficacy-and-safety-of-levofloxacin-in-patients-with-nursing-and2026-10-20 https://evidence-hub.com/study/4224-etiology-of-community-acquired-pneumonia-in-adults-a-systematic-review2026-10-08 https://evidence-hub.com/study/4225-a-controlled-double-blind-multicenter-study-comparing-clarithromycin2026-10-08 https://evidence-hub.com/study/4226-risk-factors-of-treatment-failure-in-community-acquired-pneumonia2026-10-01 https://evidence-hub.com/study/4227-nursing-home-acquired-pneumonia2026-09-26 https://evidence-hub.com/study/4228-procalcitonin-for-reduced-antibiotic-exposure-in-ventilator2026-10-01 https://evidence-hub.com/study/4230-update-on-the-treatment-of-pseudomonas-aeruginosa-pneumonia2026-10-08 https://evidence-hub.com/study/4231-ers-esicm-escmid-alat-guidelines-for-the-management-of-severe2026-10-01 https://evidence-hub.com/study/4232-efficacy-of-moxifloxacin-trovafloxacin-clinafloxacin-and-levofloxacin2026-10-20 https://evidence-hub.com/study/4233-clinical-presentation-of-legionella-pneumonia-evaluation-of-clinical2026-09-26 https://evidence-hub.com/study/4234-moxifloxacin-monotherapy-is-effective-in-hospitalized-patients-with2026-10-08 https://evidence-hub.com/study/4235-strain-specificity-and-disease-specificity-of-probiotic-efficacy-a2026-10-08 https://evidence-hub.com/study/4237-once-a-day-levofloxacin-in-the-treatment-of-mild-to-moderate-and2026-10-20 https://evidence-hub.com/study/4238-efficacy-and-safety-of-doxycycline-for-severe-mycoplasma-pneumoniae2026-10-08 https://evidence-hub.com/study/4239-definitional-ambiguity-and-the-dual-threat-of-hypervirulent2026-10-13 https://evidence-hub.com/study/4240-efficacy-and-safety-of-different-polymyxin-containing-regimens-for2026-10-08 https://evidence-hub.com/study/4241-current-trends-in-the-epidemiology-of-multidrug-resistant-and-beta2026-10-13 https://evidence-hub.com/study/4242-prevalence-of-phenotypic-drug-resistance-profiles-and-multi-drug2026-10-08 https://evidence-hub.com/study/4243-bronchial-artery-embolization-versus-conservative-treatment-for2026-10-08 https://evidence-hub.com/study/4244-omadacycline-for-treatment-of-acute-bacterial-infections-a-meta2026-10-13 https://evidence-hub.com/study/4245-the-efficacy-and-safety-of-minocycline-as-adjuvant-therapy-in2026-10-08 https://evidence-hub.com/study/4246-improving-antibiotic-utilization-in-west-africa-enhancing2026-10-13 https://evidence-hub.com/study/4247-optimal-duration-of-antibiotic-treatment-for-community-acquired2026-10-08 https://evidence-hub.com/study/4248-a-meta-analysis-on-clinical-outcomes-of-ceftolozane-versus2026-10-13 https://evidence-hub.com/study/4249-extracorporeal-membrane-oxygenation-ecmo-in-patients-with2026-10-13 https://evidence-hub.com/study/4250-efficacy-and-safety-of-yinqiao-powder-combined-with-western-medicine2026-10-08 https://evidence-hub.com/study/4251-bedaquiline-for-treatment-of-non-tuberculous-mycobacteria-ntm-a2026-10-08 https://evidence-hub.com/study/4252-global-analysis-on-the-mutations-associated-with-multidrug-resistant2026-10-08 https://evidence-hub.com/study/4253-clinical-outcomes-and-surgical-strategy-for-spine-tuberculosis-a2026-10-08 https://evidence-hub.com/study/4254-pneumolysin-as-a-target-for-new-therapies-against-pneumococcal2026-10-08 https://evidence-hub.com/study/4255-comparative-effectiveness-of-daptomycin-versus-vancomycin-among2026-10-08 https://evidence-hub.com/study/4256-interventions-for-bk-virus-infection-in-kidney-transplant-recipients2026-10-13 https://evidence-hub.com/study/4257-efficacy-of-tetracyclines-and-fluoroquinolones-for-the-treatment-of2026-10-13 https://evidence-hub.com/study/4258-comparative-effectiveness-and-safety-of-32-pharmacological2026-10-08 https://evidence-hub.com/study/4259-a-meta-analysis-of-the-clinical-efficacy-of-tanreqing-injection2026-10-08 https://evidence-hub.com/study/4260-interventions-to-reduce-infections-in-patients-with-hematological2026-10-08 https://evidence-hub.com/study/4261-infection-risks-in-multiple-myeloma-a-systematic-review-and-meta2026-10-08 https://evidence-hub.com/study/4262-perioperative-antibiotics-in-clean-contaminated-head-and-neck-surgery2026-10-08 https://evidence-hub.com/study/4263-appendectomy-versus-antibiotic-treatment-for-acute-appendicitis2026-10-08 https://evidence-hub.com/study/4264-adjunctive-rifampin-for-the-treatment-of-staphylococcus-aureus2026-10-13 https://evidence-hub.com/study/4265-systematic-review-and-meta-analysis-of-the-efficacy-of-short-course2026-10-08 https://evidence-hub.com/study/4266-interferon-therapy-in-patients-with-sars-mers-and-covid-19-a2026-10-13 https://evidence-hub.com/study/4267-chinese-herbal-medicine-for-covid-19-current-evidence-with-systematic2026-10-08 https://evidence-hub.com/study/4268-contribution-of-traditional-chinese-medicine-combined-with2026-10-08 https://evidence-hub.com/study/4269-tocilizumab-and-covid-19-a-meta-analysis-of-2120-patients-with-severe2026-10-08 https://evidence-hub.com/study/4270-clinical-failure-with-and-without-empiric-atypical-bacteria-coverage2026-10-08 https://evidence-hub.com/study/4271-the-efficacy-and-safety-of-tigecycline-for-the-treatment-of2026-10-08 https://evidence-hub.com/study/4272-shorter-versus-longer-courses-of-antibiotics-for-infection-in2026-10-13 https://evidence-hub.com/study/4273-efficacy-and-safety-of-antibiotics-for-treatment-of-scrub-typhus-a2026-10-08 https://evidence-hub.com/study/4274-current-views-on-the-potentials-of-convalescent-plasma-therapy-cpt-as2026-10-08 https://evidence-hub.com/study/4275-chloroquine-or-hydroxychloroquine-for-prevention-and-treatment-of2026-10-13 https://evidence-hub.com/study/4276-a-meta-analysis-of-efficacy-and-safety-of-doripenem-for-treating2026-10-13 https://evidence-hub.com/study/4277-chinese-herbal-medicine-for-coronavirus-disease-2019-a-systematic2026-10-08 https://evidence-hub.com/study/4278-updated-living-systematic-review-and-meta-analysis-of-controlled2026-10-08 https://evidence-hub.com/study/4279-eradication-therapy-for-burkholderia-cepacia-complex-in-people-with2026-10-08 https://evidence-hub.com/study/4280-antibiotics-for-exacerbations-of-chronic-obstructive-pulmonary-disease2026-10-13 https://evidence-hub.com/study/4281-adjunctive-systemic-corticosteroids-for-hospitalized-community2026-10-08 https://evidence-hub.com/study/4282-convalescent-plasma-or-hyperimmune-immunoglobulin-for-people-with2026-10-19 https://evidence-hub.com/study/4283-evidence-based-assessment-of-proton-pump-inhibitors-in-helicobacter2026-10-08 https://evidence-hub.com/study/4284-the-efficacy-of-prophylactic-antibiotics-on-post-stroke-infections-an2026-10-13 https://evidence-hub.com/study/4285-antibiotics-for-persistent-cough-or-wheeze-following-acute2026-10-08 https://evidence-hub.com/study/4286-antibiotic-therapy-for-preventing-infections-in-people-with-acute2026-10-13 https://evidence-hub.com/study/4287-systematic-review-and-meta-analysis-of-the-effectiveness-and-safety2026-10-13 https://evidence-hub.com/study/4288-antibiotics-for-community-acquired-pneumonia-in-children2026-10-08 https://evidence-hub.com/study/4289-empiric-antibiotic-coverage-of-atypical-pathogens-for-community2026-10-08 https://evidence-hub.com/study/4290-short-course-versus-prolonged-course-antibiotic-therapy-for-hospital2026-10-08 https://evidence-hub.com/study/4291-excess-deaths-associated-with-tigecycline-after-approval-based-on2026-10-08 https://evidence-hub.com/study/4292-protecting-the-tuberculosis-drug-pipeline-stating-the-case-for-the2026-10-13 https://evidence-hub.com/study/4293-antibiotics-for-community-acquired-lower-respiratory-tract-infections2026-10-08 https://evidence-hub.com/study/4294-andrographis-paniculata-chuan-xin-lian-for-symptomatic-relief-of2026-10-08 https://evidence-hub.com/study/4295-antimicrobial-agents-for-preventing-urinary-tract-infections-in2026-10-13 https://evidence-hub.com/study/4296-duration-of-antibiotic-therapy-for-bacteremia-a-systematic-review-and2026-10-08 https://evidence-hub.com/study/4297-is-there-any-association-between-sarcoidosis-and-infectious-agents-a2026-10-08 https://evidence-hub.com/study/4298-interventions-for-treating-genital-chlamydia-trachomatis-infection-in2026-10-08 https://evidence-hub.com/study/4299-impact-of-antibiotic-mic-on-infection-outcome-in-patients-with2026-10-08 https://evidence-hub.com/study/4300-probiotics-for-the-prevention-of-pediatric-antibiotic-associated2026-10-13 https://evidence-hub.com/study/4301-data-in-brief-of-clinical-benefits-of-moxifloxacin-as-initial2026-10-08 https://evidence-hub.com/study/4303-the-diagnostic-efficacy-of-metagenomic-next-generation-sequencing2026-10-08 https://evidence-hub.com/study/4304-efficacy-and-safety-of-glucocorticoids-therapy-of-severe-community2026-10-08 https://evidence-hub.com/study/4305-efficacy-and-safety-of-reduning-injection-for-severe-pneumonia-a2026-10-08 https://evidence-hub.com/study/4306-efficacy-and-safety-of-adjunctive-corticosteroids-in-non-hiv2026-10-08 https://evidence-hub.com/study/4307-the-efficacy-and-adverse-reactions-of-minocycline-against-mycoplasma2026-10-08 https://evidence-hub.com/study/4308-the-efficacy-and-safety-of-acetylcysteine-combined-with-budesonide2026-10-08 https://evidence-hub.com/study/4309-efficacy-and-safety-of-modified-xuanbai-chengqi-decoction-as-an2026-10-08 https://evidence-hub.com/study/4310-efficacy-of-acupuncture-for-stroke-associated-pneumonia-a-systematic2026-10-08 https://evidence-hub.com/study/4311-efficacy-and-safety-of-nebulized-drugs-in-the-treatment-of-non-severe2026-10-08 https://evidence-hub.com/study/4312-enhanced-efficacy-of-lung-cancer-treatment-with-radiotherapy-and2026-10-08 https://evidence-hub.com/study/4313-n-acetylcysteine-efficacy-in-patients-hospitalized-with-covid-192026-10-08 https://evidence-hub.com/study/4314-efficacy-of-azithromycin-combined-with-intravenous-immunoglobulin-in2026-10-08 https://evidence-hub.com/study/4315-comparative-efficacy-of-various-oral-hygiene-care-methods-in2026-10-08 https://evidence-hub.com/study/4316-efficacy-of-adjunctive-inhaled-colistin-and-tobramycin-for-ventilator2026-10-08 https://evidence-hub.com/study/4317-the-efficacy-and-safety-of-inhaled-antibiotics-for-pneumonia-a2026-10-08 https://evidence-hub.com/study/4318-efficacy-and-safety-of-vitamin-c-supplementation-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/4319-comparative-efficacy-and-safety-of-treatment-regimens-for2026-10-08 https://evidence-hub.com/study/4320-comparative-efficacy-and-safety-of-pneumocystis-jirovecii-pneumonia2026-10-08 https://evidence-hub.com/study/4321-the-efficacy-of-azithromycin-combined-with-seven-types-of-chinese2026-10-08 https://evidence-hub.com/study/4322-efficacy-and-inflammatory-levels-il-6-il-10-of-adjuvant-application2026-10-08 https://evidence-hub.com/study/4323-efficacy-and-safety-of-antibiotics-targeting-gram-negative-bacteria2026-10-08 https://evidence-hub.com/study/4324-efficacy-and-safety-of-traditional-chinese-medicine-combined-with2026-10-08 https://evidence-hub.com/study/4325-comparing-the-efficacy-of-corticosteroids-among-patients-with2026-10-08 https://evidence-hub.com/study/4326-efficacy-and-safety-of-lianhua-qingwen-granule-combined-with2026-10-08 https://evidence-hub.com/study/4327-efficacy-and-safety-of-adjunctive-corticosteroids-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/4329-efficacy-and-safety-of-corticosteroids-for-the-treatment-of-community2026-10-08 https://evidence-hub.com/study/4330-efficacy-and-safety-of-tanreqing-injection-combined-with-conventional2026-10-08 https://evidence-hub.com/study/4331-efficacy-and-safety-of-airway-clearance-techniques-in-chinese-adult2026-10-08 https://evidence-hub.com/study/4333-determining-the-efficacy-of-n-acetyl-cysteine-in-treatment-of2026-10-08 https://evidence-hub.com/study/4334-the-efficacy-of-subglottic-secretion-drainage-in-preventing2026-10-08 https://evidence-hub.com/study/4335-efficacy-and-safety-of-human-umbilical-cord-derived-mesenchymal-stem2026-10-08 https://evidence-hub.com/study/4336-efficacy-and-safety-of-intravenous-combined-with-aerosolised2026-10-08 https://evidence-hub.com/study/4337-efficacy-of-traditional-chinese-medicine-in-treating-severe-pneumonia2026-10-08 https://evidence-hub.com/study/4338-efficacy-of-prokinetics-in-preventing-pneumonia-in-post-stroke2026-10-08 https://evidence-hub.com/study/4339-efficacy-of-intermittent-and-continuous-subglottic-secretion-drainage2026-10-08 https://evidence-hub.com/study/4340-comparative-efficacy-and-safety-of-non-polymyxin-antibiotics-against2026-10-08 https://evidence-hub.com/study/4341-efficacy-of-corticosteroids-as-an-adjunctive-therapy-in-the-treatment2026-10-08 https://evidence-hub.com/study/4342-efficacy-and-safety-of-tigecycline-doses-for-ventilator-associated2026-10-08 https://evidence-hub.com/study/4343-meta-analysis-of-the-efficacy-of-budesonide-and-ambroxol2026-10-08 https://evidence-hub.com/study/4344-efficacy-and-safety-of-integrated-maxing-shigan-decoction-and2026-10-08 https://evidence-hub.com/study/4345-comparative-effect-of-different-corticosteroids-in-severe-community2026-10-08 https://evidence-hub.com/study/4346-letter-to-the-editor-regarding-efficacy-and-safety-of-adjunctive2026-10-08 https://evidence-hub.com/study/4348-evaluating-short-course-antibiotic-therapy-for-pediatric-community2026-10-08 https://evidence-hub.com/study/4349-systemic-corticosteroids-in-children-with-pneumonia-a-systematic2026-10-08 https://evidence-hub.com/study/4350-efficacy-and-safety-of-corticosteroids-in-critically-ill-patients-a2026-10-08 https://evidence-hub.com/study/4351-oropharyngeal-interventions-in-intubated-patients-for-preventing2026-10-08 https://evidence-hub.com/study/4352-strategies-for-preventing-ventilator-associated-pneumonia-in-adults2026-10-08 https://evidence-hub.com/study/4354-the-role-of-systemic-antibiotics-in-preventing-ventilator-associated2026-10-08 https://evidence-hub.com/study/4355-comparison-of-initial-empirical-antibiotic-regimens-in-severe2026-10-08 https://evidence-hub.com/study/4356-systematic-review-and-meta-analysis-of-dysregulated-mirnas-in2026-10-08 https://evidence-hub.com/study/4357-efficacy-and-safety-of-shenfu-injection-for-severe-pneumonia-in-the2026-10-08 https://evidence-hub.com/study/4358-efficacy-of-trimethoprim-sulfamethoxazole-in-combination-with-an2026-10-08 https://evidence-hub.com/study/4359-efficacy-and-safety-of-selective-decontamination-of-the-digestive2026-10-08 https://evidence-hub.com/study/4360-meta-analysis-of-the-efficacy-and-safety-of-chlorhexidine-for2026-10-08 https://evidence-hub.com/study/4361-efficacy-immunogenicity-and-safety-of-pneumococcal-conjugate-vaccine2026-10-08 https://evidence-hub.com/study/4362-efficacy-and-safety-of-low-dose-rituximab-in-pemphigus-an-updated2026-10-08 https://evidence-hub.com/study/4363-short-course-versus-long-course-antibiotic-treatment-for-ventilator2026-10-08 https://evidence-hub.com/study/4364-efficacy-and-safety-of-normobaric-hyperoxia-for-acute-ischemic-stroke2026-10-08 https://evidence-hub.com/study/4365-effects-of-tanreqing-injection-against-ventilator-associated2026-10-08 https://evidence-hub.com/study/4366-efficacy-and-safety-of-reduning-injection-combined-with-azithromycin2026-10-08 https://evidence-hub.com/study/4367-efficacy-and-safety-of-antibiotics-in-the-treatment-of-methicillin2026-10-08 https://evidence-hub.com/study/4368-efficacy-of-empiric-macrolides-versus-fluoroquinolones-in-community2026-10-08 https://evidence-hub.com/study/4369-efficacy-of-erythromycin-compared-to-clarithromycin-and-azithromycin2026-10-08 https://evidence-hub.com/study/4370-efficacy-and-safety-of-chinese-herbal-medicine-for-pneumonia2026-10-08 https://evidence-hub.com/study/4371-comparative-efficacy-of-chinese-herbal-injections-for-treating-severe2026-10-08 https://evidence-hub.com/study/4372-diabetes-as-a-risk-factor-for-pneumococcal-disease-and-severe-related2026-10-08 https://evidence-hub.com/study/4373-low-dose-trimethoprim-sulfamethoxazole-for-prophylaxis-of2026-10-08 https://evidence-hub.com/study/4374-efficacy-and-safety-of-tanreqing-injection-combined-with-antibiotics2026-10-08 https://evidence-hub.com/study/4375-efficacy-and-safety-of-il-6-inhibitors-in-patients-with-covid-192026-10-08 https://evidence-hub.com/study/4376-recent-advances-in-efficacy-of-corticosteroids-as-adjunct-therapy-for2026-10-08 https://evidence-hub.com/study/4377-comparative-efficacy-and-safety-of-antiviral-traditional-chinese2026-10-08 https://evidence-hub.com/study/4378-impact-of-different-corticosteroids-on-severe-community-acquired2026-10-08 https://evidence-hub.com/study/4379-efficacy-and-safety-of-trimethoprim-sulfamethoxazole-for-the2026-10-08 https://evidence-hub.com/study/4380-research-status-of-the-safety-and-efficacy-of-mesenchymal-stem-cells2026-10-08 https://evidence-hub.com/study/4381-utility-of-pneumonia-severity-assessment-tools-for-mortality2026-10-08 https://evidence-hub.com/study/4382-wuhu-decoction-combined-with-azithromycin-for-treatment-of-mycoplasma2026-10-08 https://evidence-hub.com/study/4383-azithromycin-sequential-therapy-plus-inhaled-terbutaline-for2026-10-08 https://evidence-hub.com/study/4384-pathogenic-mechanisms-and-resistance-profiles-of-microbial-pulmonary2026-10-08 https://evidence-hub.com/study/4385-resistance-of-acinetobacter-baumannii-complex-clinical-isolates-to2026-10-13 https://evidence-hub.com/study/4386-impact-of-invasive-mechanical-ventilation-on-the-lung-microbiome2026-10-08 https://evidence-hub.com/study/4387-pemphigoid-diseases-in-patients-with-end-stage-kidney-diseases2026-10-08 https://evidence-hub.com/study/4388-treatment-of-mild-to-moderate-community-acquired-pneumonia-in2026-10-08 https://evidence-hub.com/study/4389-a-systematic-review-of-efficacy-and-safety-of-newer-drugs-approved2026-10-13 https://evidence-hub.com/study/4390-resistance-of-gram-negative-bacteria-to-eravacycline-a-systematic2026-10-08 https://evidence-hub.com/study/4391-contribution-of-veterinary-sector-to-antimicrobial-resistance-in-one2026-10-08 https://evidence-hub.com/study/4392-a-perspective-current-and-past-modes-of-inhalation-therapy2026-10-08 https://evidence-hub.com/study/4393-a-systematic-review-of-diabetic-foot-infections-pathogenesis2026-10-08 https://evidence-hub.com/study/4394-therapeutical-strategies-in-cavitary-legionnaires-disease-two-cases2026-10-08 https://evidence-hub.com/study/4395-fatal-outcome-related-to-drug-reaction-with-eosinophilia-and-systemic2026-10-13 https://evidence-hub.com/study/4396-the-efficacy-and-adverse-events-of-delafloxacin-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/4397-global-prevalence-and-antibiotic-resistance-in-clinical-isolates-of2026-10-13 https://evidence-hub.com/study/4398-immunosuppressant-use-in-infective-endocarditis-associated2026-10-13 https://evidence-hub.com/study/4399-etiologic-profile-of-the-pneumococcus-in-ghana-a-systematic-review2026-10-08 https://evidence-hub.com/study/4400-a-systematic-review-of-acute-and-emergency-care-interventions-for2026-10-08 https://evidence-hub.com/study/4401-comparative-efficacy-of-azithromycin-versus-clarithromycin-in2026-10-08 https://evidence-hub.com/study/4402-novel-vitreous-substitutes-in-animal-and-human-models-a-systematic2026-10-08 https://evidence-hub.com/study/4403-a-systematic-review-of-antimicrobial-therapy-in-children-with2026-10-13 https://evidence-hub.com/study/4404-the-microbiology-of-acute-exacerbations-in-chronic-rhinosinusitis-a2026-10-08 https://evidence-hub.com/study/4405-combination-of-chinese-herbal-medicine-and-conventional-western2026-10-08 https://evidence-hub.com/study/4406-applications-of-lab-on-a-chip-in-antimicrobial-susceptibility-of2026-10-08 https://evidence-hub.com/study/4407-vitamin-d-as-an-adjunct-to-antibiotics-for-the-treatment-of-acute2026-10-08 https://evidence-hub.com/study/4408-antibiotics-for-hospital-acquired-pneumonia-in-neonates-and-children2026-10-08 https://evidence-hub.com/study/4409-identification-of-drug-interaction-adverse-events-in-patients-with2026-10-08 https://evidence-hub.com/study/4410-respiratory-fluoroquinolones-monotherapy-vs-lactams-with-or-without2026-10-08 https://evidence-hub.com/study/4411-the-spectrum-of-antibiotic-prescribing-during-covid-19-pandemic-a2026-10-08 https://evidence-hub.com/study/4412-ceftolozane-tazobactam-for-the-treatment-of-bacteremia-a-systematic2026-10-13 https://evidence-hub.com/study/4413-a-systematic-review-of-the-clinical-profile-of-patients-with-bubonic2026-10-08 https://evidence-hub.com/study/4414-omadacycline-and-clostridioides-difficile-a-systematic-review-of2026-10-08 https://evidence-hub.com/study/4415-examining-family-planning-and-adverse-pregnancy-outcomes-for-women2026-10-08 https://evidence-hub.com/study/4416-development-of-evidence-based-covid-19-management-guidelines-for2026-10-08 https://evidence-hub.com/study/4417-liver-injury-in-covid-19-patients-with-drugs-as-causatives-a2026-10-08 https://evidence-hub.com/study/4418-topical-pharmacologic-interventions-versus-placebo-for-epidemic2026-10-08 https://evidence-hub.com/study/4419-economic-evaluation-of-community-acquired-pneumonia-management2026-10-08 https://evidence-hub.com/study/4420-models-for-delivery-and-co-ordination-of-primary-or-secondary-health2026-10-13 https://evidence-hub.com/study/4421-isolated-pulmonary-mucormycosis-in-an-immunocompetent-patient-a-case2026-10-08 https://evidence-hub.com/study/4422-current-state-of-knowledge-regarding-who-high-priority-pathogens2026-10-08 https://evidence-hub.com/study/4423-infectious-complications-in-paediatric-haematopoetic-cell2026-10-08 https://evidence-hub.com/study/4424-human-granulocytotropic-anaplasmosis-a-systematic-review-and-analysis2026-10-08 https://evidence-hub.com/study/4425-reducing-biofilm-infections-in-burn-patients-wounds-and-biofilms-on2026-10-08 https://evidence-hub.com/study/4426-oral-fluoroquinolones-in-the-treatment-of-pneumonia-bronchitis-and2026-10-20 https://evidence-hub.com/study/4428-pulmonary-histopathological-changes-and-their-impact-on-antibiotic2026-10-08 https://evidence-hub.com/study/4429-the-efficacy-of-cotrimoxazole-for-the-prevention-of-pneumocystis2026-10-08 https://evidence-hub.com/study/4430-efficacy-of-nurse-led-sedation-protocols-in-preventing-ventilator2026-10-08 https://evidence-hub.com/study/4431-efficacy-and-safety-of-xiaoer-feike-granules-combined-with2026-10-08 https://evidence-hub.com/study/4432-efficacy-of-ruxolitinib-with-corticosteroids-in-idiopathic-pneumonia2026-10-08 https://evidence-hub.com/study/4433-efficacy-of-antibiotic-regimens-for-pneumonia-in-young-infants-aged-02026-10-08 https://evidence-hub.com/study/4434-efficacy-of-artificial-intelligence-in-the-categorisation-of2026-10-08 https://evidence-hub.com/study/4435-efficacy-of-high-dose-vitamin-d-supplementation-as-an-adjuvant2026-10-08 https://evidence-hub.com/study/4436-tocilizumab-in-patients-hospitalized-with-covid-19-pneumonia2026-10-08 https://evidence-hub.com/study/4437-efficacy-of-inhaled-antibiotics-in-children-with-ventilator2026-10-08 https://evidence-hub.com/study/4438-efficacy-and-safety-of-newer-antibiotics-versus-generic-antibiotics2026-10-08 https://evidence-hub.com/study/4440-evidence-for-the-efficacy-and-safety-of-tigecycline-for-the-treatment2026-10-08 https://evidence-hub.com/study/4441-the-efficacy-and-safety-of-fiberoptic-bronchoscopy-guided-bronchial2026-10-08 https://evidence-hub.com/study/4442-efficacy-of-higher-dose-versus-lower-dose-corticosteroids-in2026-10-08 https://evidence-hub.com/study/4443-pharyngeal-electrical-stimulation-for-neurogenic-dysphagia-a2026-10-08 https://evidence-hub.com/study/4444-the-efficacy-of-respiratory-therapist-led-protocols-in-reducing2026-10-08 https://evidence-hub.com/study/4446-effectiveness-of-tocilizumab-in-covid-19-patients-with-pneumonia-a2026-10-08 https://evidence-hub.com/study/4447-p-1163-the-efficacy-and-safety-of-tosufloxacin-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/4448-effect-of-perioperative-oral-care-on-postoperative-pneumonia-in2026-10-08 https://evidence-hub.com/study/4449-comments-on-efficacy-and-safety-of-adjunctive-corticosteroids-in-the2026-10-08 https://evidence-hub.com/study/4450-tocilizumab-in-patients-with-covid-19-pneumonia-a-systematic-review-a2026-10-08 https://evidence-hub.com/study/4452-association-between-various-types-of-corticosteroids-and-mortality2026-10-08 https://evidence-hub.com/study/4453-efficacy-and-safety-of-corticosteroids-in-covid-19-based-on-evidence2026-10-08 https://evidence-hub.com/study/4454-carbapenem-vs-non-carbapenem-antibiotics-for-ventilator-associated2026-10-08 https://evidence-hub.com/study/4455-intermittent-versus-daily-trimethoprim-sulfamethoxazole-regimens-for2026-10-08 https://evidence-hub.com/study/4457-low-dose-trimethoprim-sulfamethoxazole-treatment-for-pneumocystis2026-10-06 https://evidence-hub.com/study/4458-immunomodulatory-effects-of-pidotimod-in-adults-with-community2026-10-20 https://evidence-hub.com/study/4459-safety-and-efficacy-of-colistin-versus-meropenem-in-the-empirical2026-10-20 https://evidence-hub.com/study/4460-efficacy-of-levofloxacin-versus-cefuroxime-in-treating-acute2026-10-20 https://evidence-hub.com/study/4461-efficacy-and-safety-of-moxifloxacin-in-uncomplicated-pelvic2026-10-20 https://evidence-hub.com/study/4462-high-dose-levofloxacin-in-community-acquired-pneumonia-a-randomized2026-10-20 https://evidence-hub.com/study/4463-predictors-of-symptom-resolution-in-patients-with-community-acquired2026-10-20 https://evidence-hub.com/study/4464-a-randomized-crossover-design-study-of-the-pharmacology-of-extended2026-10-08 https://evidence-hub.com/study/4465-levofloxacin-versus-cefuroxime-axetil-in-the-treatment-of-acute2026-10-08 https://evidence-hub.com/study/4466-a-multicenter-randomized-double-blind-retrospective-comparison-of-52026-10-08 https://evidence-hub.com/study/4467-efficacy-and-safety-of-a-novel-single-dose-azithromycin-microsphere2026-10-20 https://evidence-hub.com/study/4468-outcome-of-treatment-of-respiratory-tract-infections-due-to2026-10-08 https://evidence-hub.com/study/4469-an-open-label-randomized-comparative-study-of-levofloxacin-and2026-10-08 https://evidence-hub.com/study/4470-an-ex-vivo-pharmacodynamic-study-comparing-bactericidal-activity-of2026-10-08 https://evidence-hub.com/study/4471-management-of-ventilator-associated-pneumonia-caused-by-pseudomonas2026-10-13 https://evidence-hub.com/study/4472-drtb-hdt-a-randomized-controlled-trial-of-two-adjunctive-host2026-10-08 https://evidence-hub.com/study/4473-carbapenem-resistant-enterobacterales-cre-acquisition-and-molecular2026-10-13 https://evidence-hub.com/study/4474-belantamab-mafodotin-lenalidomide-and-dexamethasone-in-transplant2026-10-08 https://evidence-hub.com/study/4475-etiology-and-efficacy-of-anti-microbial-treatment-for-community2026-10-08 https://evidence-hub.com/study/4476-clinical-study-on-the-treatment-of-qingfei-paidu-granules-combined2026-10-08 https://evidence-hub.com/study/4477-multiplex-real-time-pcr-in-non-invasive-respiratory-samples-to-reduce2026-10-08 https://evidence-hub.com/study/4478-efficacy-of-empirical-ciprofloxacin-or-cefixime-plus-metronidazole2026-10-08 https://evidence-hub.com/study/4479-effectiveness-of-the-modified-tawai-mobile-application-for-reporting2026-10-08 https://evidence-hub.com/study/4480-a-randomized-non-inferiority-study-comparing-imipenem-cilastatin2026-10-13 https://evidence-hub.com/study/4481-fecal-microbiota-transplantation-promotes-reduction-of-antimicrobial2026-10-13 https://evidence-hub.com/study/4482-long-acting-granulocyte-colony-stimulating-factor-in-primary2026-10-08 https://evidence-hub.com/study/4483-safety-and-efficacy-of-ceftolozane-tazobactam-plus-metronidazole2026-10-13 https://evidence-hub.com/study/4484-virgin-coconut-oil-vco-supplementation-relieves-symptoms-and2026-10-08 https://evidence-hub.com/study/4485-clinical-efficacy-of-ulinastatin-in-the-treatment-of-unliquefied2026-10-13 https://evidence-hub.com/study/4486-the-effect-of-melatonin-on-thrombosis-sepsis-and-mortality-rate-in2026-10-08 https://evidence-hub.com/study/4487-randomized-double-blind-phase-ii-trial-of-fecal-microbiota2026-10-08 https://evidence-hub.com/study/4488-combination-antibiotic-therapy-versus-monotherapy-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/4489-lefamulin-vs-moxifloxacin-for-community-acquired-bacterial-pneumonia2026-10-08 https://evidence-hub.com/study/4490-combined-use-of-a-broad-panel-respiratory-multiplex-pcr-and2026-10-08 https://evidence-hub.com/study/4491-vitamin-d-supplementation-among-bangladeshi-children-under-five-years2026-10-08 https://evidence-hub.com/study/4492-idasanutlin-plus-cytarabine-in-relapsed-or-refractory-acute-myeloid2026-10-08 https://evidence-hub.com/study/4493-anti-bacterial-antibodies-in-multiple-myeloma-patients-at-disease2026-10-08 https://evidence-hub.com/study/4494-pentoxifylline-decreases-serum-ldh-levels-and-increases-lymphocyte2026-10-08 https://evidence-hub.com/study/4495-management-of-adverse-events-in-patients-with-acute-myeloid-leukemia2026-10-13 https://evidence-hub.com/study/4496-efficacy-immunogenicity-and-safety-of-ic43-recombinant-pseudomonas2026-10-13 https://evidence-hub.com/study/4497-analysis-of-pooled-phase-iii-efficacy-data-for-delafloxacin-in-acute2026-10-08 https://evidence-hub.com/study/4498-a-randomized-phase-i-pharmacokinetic-trial-comparing-the-potential2026-10-08 https://evidence-hub.com/study/4499-solithromycin-in-children-and-adolescents-with-community-acquired2026-10-08 https://evidence-hub.com/study/4500-in-vitro-activity-of-ceftazidime-avibactam-against-isolates-from2026-10-13 https://evidence-hub.com/study/4501-a-multicenter-randomized-open-label-controlled-trial-to-evaluate-the2026-10-08 https://evidence-hub.com/study/4502-in-vitro-activity-of-ceftazidime-avibactam-against-isolates-from2026-10-13 https://evidence-hub.com/study/4503-evaluation-of-a-molecular-point-of-care-testing-for-viral-and2026-10-13 https://evidence-hub.com/study/4504-characterization-of-baseline-polybacterial-versus-monobacterial2026-10-08 https://evidence-hub.com/study/4505-a-randomized-controlled-study-to-investigate-the-efficacy-and-safety2026-10-08 https://evidence-hub.com/study/4506-aerosolized-amikacin-as-adjunctive-therapy-of-ventilator-associated2026-10-08 https://evidence-hub.com/study/4507-a-comparison-of-the-efficacy-and-safety-of-intravenous-followed-by2026-10-08 https://evidence-hub.com/study/4508-glasdegib-plus-low-dose-cytarabine-for-acute-myeloid-leukemia2026-10-08 https://evidence-hub.com/study/4509-pharmacokinetics-and-safety-of-intravenous-murepavadin-infusion-in2026-10-08 https://evidence-hub.com/study/4510-zabofloxacin-versus-moxifloxacin-in-patients-with-copd-exacerbation-a2026-10-08 https://evidence-hub.com/study/4511-treatment-with-macrolides-and-glucocorticosteroids-in-severe2026-10-08 https://evidence-hub.com/study/4512-high-dose-versus-standard-dose-amoxicillin-clavulanate-for-clinically2026-10-08 https://evidence-hub.com/study/4513-xuebijing-injection-in-the-treatment-of-severe-pneumonia-study2026-10-08 https://evidence-hub.com/study/4514-effects-of-probenecid-and-cimetidine-on-the-pharmacokinetics-of2026-10-08 https://evidence-hub.com/study/4515-fosfomycin-for-injection-zti-01-versus-piperacillin-tazobactam-for2026-10-13 https://evidence-hub.com/study/4516-triple-combination-of-interferon-beta-1b-lopinavir-ritonavir-and2026-10-08 https://evidence-hub.com/study/4517-exposure-to-ceftobiprole-is-associated-with-microbiological2026-10-08 https://evidence-hub.com/study/4518-the-impact-of-an-antimicrobial-utilization-program-on-antimicrobial2026-10-08 https://evidence-hub.com/study/4519-effect-of-corticosteroids-on-the-clinical-course-of-community2026-10-08 https://evidence-hub.com/study/4523-efficacy-and-safety-of-anemoside-b4-in-canine-pneumonia-treatment-a2026-10-08 https://evidence-hub.com/study/4524-comparison-of-efficacy-and-safety-profiles-between-omadacycline-and2026-10-08 https://evidence-hub.com/study/4525-efficacy-of-an-herbal-preparation-atomy-s-hemohim-against-ventilator2026-10-08 https://evidence-hub.com/study/4526-a-randomized-controlled-multicenter-clinical-trial-to-evaluate-the2026-10-08 https://evidence-hub.com/study/4527-a-prospective-phase-iia-multicenter-double-blinded-randomized-placebo2026-10-08 https://evidence-hub.com/study/4528-efficacy-of-anakinra-in-reducing-progression-to-organ-dysfunction-in2026-10-08 https://evidence-hub.com/study/4529-respiratory-multiplex-pcr-and-procalcitonin-to-reduce-antibiotic2026-10-08 https://evidence-hub.com/study/4530-efficacy-and-safety-of-aerosol-inhalation-of-recombinant-human2026-10-08 https://evidence-hub.com/study/4531-yinma-jiedu-granules-combined-with-antibacterial-drugs-for-patients2026-10-08 https://evidence-hub.com/study/4532-efficacy-of-adjunctive-zinc-in-improving-the-treatment-outcomes-in2026-10-08 https://evidence-hub.com/study/4533-a-randomized-controlled-non-inferiority-trial-of-placebo-versus2026-10-08 https://evidence-hub.com/study/4534-efficacy-and-safety-of-remdesivir-in-people-with-impaired-kidney2026-10-10 https://evidence-hub.com/study/4535-efficacy-of-continuous-versus-intermittent-subglottic-secretion2026-10-08 https://evidence-hub.com/study/4537-safety-and-efficacy-of-favipiravir-in-covid-19-patients-with2026-10-08 https://evidence-hub.com/study/4538-efficacy-and-safety-of-a-chinese-herbal-formula-maxing-ganshi2026-10-08 https://evidence-hub.com/study/4539-efficacy-and-safety-of-lianhua-qingwen-granule-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/4540-efficacy-and-safety-of-ly3127804-an-anti-angiopoietin-2-antibody-in-a2026-10-08 https://evidence-hub.com/study/4541-clinical-efficacy-protocol-of-yinhuapinggan-granules-a-randomized2026-10-08 https://evidence-hub.com/study/4542-efficacy-and-safety-of-low-molecular-weight-collagen-peptides-in-knee2026-10-19 https://evidence-hub.com/study/4543-convalescent-plasma-in-the-treatment-of-moderate-to-severe-covid-192026-10-08 https://evidence-hub.com/study/4545-evaluation-of-the-safety-and-efficacy-of-xav-19-in-patients-with2026-10-08 https://evidence-hub.com/study/4546-remote-ischemic-conditioning-in-the-prevention-for-stroke-associated2026-10-08 https://evidence-hub.com/study/4548-meropenem-for-children-with-severe-pneumonia-protocol-for-a2026-10-08 https://evidence-hub.com/study/4549-efficacy-and-safety-of-tinzaparin-in-prophylactic-intermediate-and2026-10-08 https://evidence-hub.com/study/4550-weaker-response-to-xuebijing-treatment-in-severe-community-acquired2026-10-08 https://evidence-hub.com/study/4551-outcomes-in-participants-with-ventilated-nosocomial-pneumonia-and2026-10-08 https://evidence-hub.com/study/4552-efficacy-and-safety-of-xiyanping-injection-in-the-treatment-of-covid2026-10-08 https://evidence-hub.com/study/4553-a-randomized-double-blind-placebo-controlled-multicenter-clinical2026-10-08 https://evidence-hub.com/study/4554-efficacy-of-a-probiotic-consisting-of-lacticaseibacillus-rhamnosus2026-10-08 https://evidence-hub.com/study/4555-efficacy-and-safety-of-trimodulin-a-novel-polyclonal-antibody2026-10-08 https://evidence-hub.com/study/4556-efficacy-and-safety-of-ivermectin-and-hydroxychloroquine-in-patients2026-10-08 https://evidence-hub.com/study/4557-effectiveness-of-yinhua-pinggan-granules-in-community-acquired2026-10-08 https://evidence-hub.com/study/4558-evaluation-of-efficacy-and-safety-of-rituximab-in-combination-with2026-10-06 https://evidence-hub.com/study/4559-symptom-relief-and-cytokine-modulation-by-clarithromycin-in-mild2026-10-08 https://evidence-hub.com/study/4560-high-dose-dexamethasone-versus-tocilizumab-in-moderate-to-severe2026-10-08 https://evidence-hub.com/study/4562-addition-of-probiotics-to-antibiotics-improves-the-clinical-course-of2026-10-08 https://evidence-hub.com/study/4563-safety-and-efficacy-of-n-acetyl-cysteine-for-prophylaxis-of2026-10-08 https://evidence-hub.com/study/4564-efficacy-and-safety-of-andrographis-paniculata-extract-in-patients2026-10-08 https://evidence-hub.com/study/4565-randomized-controlled-trial-comparing-rhodococcus-equi-and-poly-n2026-10-08 https://evidence-hub.com/study/4566-the-effect-and-safety-of-corticosteroid-treatment-for-severe2026-10-08 https://evidence-hub.com/study/4567-the-safety-and-efficacy-of-stem-cells-for-the-treatment-of-severe2026-10-08 https://evidence-hub.com/study/4568-the-safety-and-efficacy-of-chinese-herbal-medicine-for-pneumonia2026-10-08 https://evidence-hub.com/study/4569-efficacy-of-kegan-liyan-oral-liquid-vs-lianhuaqingwen-capsules-for2026-10-08 https://evidence-hub.com/study/4570-the-safety-and-efficacy-of-inspiratory-muscle-training-for-patients2026-10-08 https://evidence-hub.com/study/4571-auxora-versus-standard-of-care-for-the-treatment-of-severe-or2026-10-08 https://evidence-hub.com/study/4572-efficacy-and-safety-of-a-decision-rule-for-using-antibiotics-in2026-10-08 https://evidence-hub.com/study/4573-anti-granulocyte-macrophage-colony-stimulating-factor-monoclonal2026-10-08 https://evidence-hub.com/study/4574-adjunctive-intravenous-then-oral-vitamin-c-for-moderate-and-severe2026-10-08 https://evidence-hub.com/study/4576-inhaled-antibiotics-for-treating-pneumonia-in-invasively-ventilated2026-10-08 https://evidence-hub.com/study/4577-acupressure-therapy-and-liu-zi-jue-qigong-for-pulmonary-function-and2026-10-06 https://evidence-hub.com/study/4578-efficacy-of-perilla-frutescens-l-britton-var-frutescens-extract-on2026-10-19 https://evidence-hub.com/study/4579-efficacy-of-osteopathic-manipulation-as-an-adjunctive-treatment-for2026-10-06 https://evidence-hub.com/study/4580-ceftriaxone-to-prevent-pneumonia-and-inflammation-after-cardiac2026-10-06 https://evidence-hub.com/study/4581-levofloxacin-in-the-treatment-of-community-acquired-pneumococcal2026-10-20 https://evidence-hub.com/study/4582-efficacy-of-levofloxacin-tavanic-in-the-treatment-of-children-with2026-10-08 https://evidence-hub.com/study/4583-open-label-assessment-of-levofloxacin-for-the-treatment-of-acute2026-10-08 https://evidence-hub.com/study/4584-gatifloxacin-phase-iv-surveillance-trial-teqces-study-utilizing-50002026-10-08 https://evidence-hub.com/study/4585-an-open-label-double-tympanocentesis-study-of-levofloxacin-therapy-in2026-10-08 https://evidence-hub.com/study/4586-clinical-evaluation-of-oral-levofloxacin-500-mg-once-daily-dosage-for2026-10-20 https://evidence-hub.com/study/4587-do-intensive-care-patients-need-an-individualized-dosing-regimen-for2026-10-08 https://evidence-hub.com/study/4588-characterization-of-acinetobacter-baumannii-calcoaceticus-complex2026-10-08 https://evidence-hub.com/study/4589-evaluation-of-the-efficacy-and-safety-of-oral-n-acetylcysteine-in2026-10-13 https://evidence-hub.com/study/4590-phase-1-study-of-talquetamab-a-humanized-gprc5d-x-cd3-bispecific2026-10-08 https://evidence-hub.com/study/4591-protocol-of-a-multicenter-single-blind-randomized-parallel-controlled2026-10-08 https://evidence-hub.com/study/4592-long-term-follow-up-of-a-phase-2-study-of-all-trans-retinoic-acid2026-10-08 https://evidence-hub.com/study/4593-safety-feasibility-and-impact-on-the-gut-microbiome-of-kefir2026-10-13 https://evidence-hub.com/study/4594-efficacy-and-safety-of-tisagenlecleucel-in-adult-japanese-patients2026-10-08 https://evidence-hub.com/study/4596-efficacy-and-safety-of-isatuximab-plus-bortezomib-lenalidomide-and2026-10-08 https://evidence-hub.com/study/4597-study-on-metabonomics-of-chinese-herbal-medicine-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/4598-delamanid-added-to-an-optimized-background-regimen-in-children-with2026-10-08 https://evidence-hub.com/study/4599-mechanisms-of-reduced-susceptibility-to-cefiderocol-among-isolates2026-10-13 https://evidence-hub.com/study/4600-third-party-fecal-microbiota-transplantation-for-high-risk-treatment2026-10-13 https://evidence-hub.com/study/4601-the-value-of-post-operative-antibiotic-therapy-after-laparoscopic2026-10-08 https://evidence-hub.com/study/4602-a-multi-centre-open-label-two-arm-randomised-superiority-clinical2026-10-08 https://evidence-hub.com/study/4603-cost-effectiveness-analysis-of-oral-versus-intravenous-drip-infusion2026-10-08 https://evidence-hub.com/study/4604-levofloxacin-versus-placebo-for-the-prevention-of-tuberculosis2026-10-08 https://evidence-hub.com/study/4605-prophylaxis-in-healthcare-workers-during-a-pandemic-a-model-for-a2026-10-13 https://evidence-hub.com/study/4606-bortezomib-and-rituximab-in-de-novo-adolescent-adult-cd20-positive-ph2026-10-08 https://evidence-hub.com/study/4607-cd19-car-t-cell-therapy-and-prophylactic-anakinra-in-relapsed-or2026-10-08 https://evidence-hub.com/study/4608-hydroxychloroquine-versus-azithromycin-for-hospitalized-patients-with2026-10-08 https://evidence-hub.com/study/4609-decitabine-induction-with-myeloablative-conditioning-and-allogeneic2026-10-08 https://evidence-hub.com/study/4610-impact-of-comprehensive-molecular-testing-to-reduce-antibiotic-use-in2026-10-13 https://evidence-hub.com/study/4611-phase-2-study-of-venetoclax-plus-carfilzomib-and-dexamethasone-in2026-10-08 https://evidence-hub.com/study/4612-bloodstream-infections-in-adult-patients-with-malignancy-epidemiology2026-10-08 https://evidence-hub.com/study/4613-increased-doses-lead-to-higher-drug-exposures-of-levofloxacin-for2026-10-08 https://evidence-hub.com/study/4614-pomalidomide-cyclophosphamide-and-dexamethasone-for-elderly-patients2026-10-08 https://evidence-hub.com/study/4615-oral-switch-versus-standard-intravenous-antibiotic-therapy-in-left2026-10-13 https://evidence-hub.com/study/4616-venetoclax-combined-with-low-dose-cytarabine-compared-to-standard-of2026-10-08 https://evidence-hub.com/study/4617-safety-and-efficacy-of-immunoadsorption-as-an-add-on-to-medical2026-10-08 https://evidence-hub.com/study/4618-intrapulmonary-pharmacokinetics-of-lascufloxacin-in-healthy-adult2026-10-08 https://evidence-hub.com/study/4619-once-daily-oral-levofloxacin-monotherapy-for-low-risk-neutropenic2026-10-08 https://evidence-hub.com/study/4620-effectiveness-of-xin-jia-xuan-bai-cheng-qi-decoction-in-treating2026-10-08 https://evidence-hub.com/study/4621-an-open-label-trial-of-anakinra-to-prevent-respiratory-failure-in2026-10-08 https://evidence-hub.com/study/4622-reduced-intensity-single-unit-unrelated-cord-blood-transplant-with2026-10-08 https://evidence-hub.com/study/4623-low-dose-anti-thymocyte-globulin-plus-low-dose-posttransplant2026-10-08 https://evidence-hub.com/study/4624-randomised-controlled-trial-of-conditioning-regimen-for-cord-blood2026-10-08 https://evidence-hub.com/study/4625-intrapulmonary-pharmacokinetics-of-levonadifloxacin-following-oral2026-10-08 https://evidence-hub.com/study/4626-clinical-effects-of-gemifloxacin-on-the-delay-of-tuberculosis2026-10-08 https://evidence-hub.com/study/4627-bedaquiline-for-multidrug-resistant-tb-in-paediatric-patients2026-10-08 https://evidence-hub.com/study/4628-extended-follow-up-and-impact-of-high-risk-prognostic-factors-from2026-10-13 https://evidence-hub.com/study/4629-prospective-study-of-a-novel-radiation-free-reduced-intensity-bone2026-10-08 https://evidence-hub.com/study/4630-consolidation-therapy-for-newly-diagnosed-pediatric-patients-with2026-10-13 https://evidence-hub.com/study/4631-an-open-label-phase-i-ii-study-of-cyclophosphamide-bortezomib2026-10-13 https://evidence-hub.com/study/4632-safety-and-efficacy-of-daclizumab-in-relapsing-remitting-multiple2026-10-13 https://evidence-hub.com/study/4633-clinical-and-bacteriological-efficacies-of-sitafloxacin-against2026-10-08 https://evidence-hub.com/study/4634-multicentre-clinical-study-on-levofloxacin-intravenous-injection-for2026-10-08 https://evidence-hub.com/study/4635-multicenter-postmarketing-assessment-of-levofloxacin-in-the-treatment2026-10-20 https://evidence-hub.com/study/4638-efficacy-and-safety-of-lianhua-qingke-tablets-in-children-with2026-10-08 https://evidence-hub.com/study/4639-exclusive-oral-antibiotic-treatment-for-hospitalized-community2026-10-08 https://evidence-hub.com/study/4640-randomized-clinical-trial-of-nafamostat-mesylate-a-potent2026-10-08 https://evidence-hub.com/study/4642-efficacy-and-safety-comparison-of-two-different-doses-of2026-10-08 https://evidence-hub.com/study/4643-a-randomized-clinical-trial-to-evaluate-the-efficacy-of-l-carnitine-l2026-10-08 https://evidence-hub.com/study/4644-prevention-and-treatment-for-covid-19-associated-severe-pneumonia-in2026-10-08 https://evidence-hub.com/study/4645-belantamab-mafodotin-plus-lenalidomide-dexamethasone-in-newly2026-10-08 https://evidence-hub.com/study/4646-safety-and-efficacy-of-radiotherapy-combined-with-anlotinib-in2026-10-08 https://evidence-hub.com/study/4647-enpatoran-in-covid-19-pneumonia-safety-and-efficacy-results-from-a2026-10-08 https://evidence-hub.com/study/4648-clinical-efficacy-of-the-postbiotic-drug-biodonatum-in-children-with2026-10-08 https://evidence-hub.com/study/4649-ivermectin-and-outcomes-from-covid-19-pneumonia-a-systematic-review2026-10-08 https://evidence-hub.com/study/4650-breakthrough-chloroquine-phosphate-has-shown-apparent-efficacy-in2026-10-08 https://evidence-hub.com/study/4651-probiotic-prophylaxis-to-prevent-ventilator-associated-pneumonia-in2026-10-08 https://evidence-hub.com/study/4652-severe-pneumonia-management-and-bronchoalveolar-lavage-efficacy-in2026-10-08 https://evidence-hub.com/study/4653-efficacy-and-safety-of-rp1-combined-with-nivolumab-in-patients-with2026-10-19 https://evidence-hub.com/study/4654-clinical-study-on-modified-shenzhe-zhenqi-decoction-combined-with2026-10-08 https://evidence-hub.com/study/4656-effectiveness-of-hyperbaric-oxygen-therapy-in-sars-cov-2-pneumonia2026-10-08 https://evidence-hub.com/study/4657-preliminary-efficacy-and-safety-of-camrelizumab-combined-with2026-10-08 https://evidence-hub.com/study/4658-oral-lefamulin-vs-moxifloxacin-for-early-clinical-response-among2026-10-08 https://evidence-hub.com/study/4659-results-of-a-double-blind-prospective-comparative-randomized-phase-32026-10-08 https://evidence-hub.com/study/4660-efficacy-and-safety-of-smet12-in-combination-with-toripalimab-and2026-10-08 https://evidence-hub.com/study/4661-a-randomized-double-blind-multicenter-trial-comparing-efficacy-and2026-10-08 https://evidence-hub.com/study/4662-efficacy-and-safety-of-oxiracetam-in-patients-with-vascular-cognitive2026-10-19 https://evidence-hub.com/study/4664-the-therapeutic-efficacy-of-abatacept-for-rheumatoid-arthritis2026-10-08 https://evidence-hub.com/study/4665-evaluating-the-effectiveness-and-safety-of-xiyanping-injection-for2026-10-06 https://evidence-hub.com/study/4666-comparative-efficacy-of-ceftolozane-tazobactam-versus-ceftazidime2026-10-13 https://evidence-hub.com/study/4667-treatment-of-carbapenem-resistant-gram-negative-bacterial-infections2026-10-13 https://evidence-hub.com/study/4668-streamlining-antibiotic-use-in-community-acquired-pneumonia-a-quality2026-10-08 https://evidence-hub.com/study/4669-infectious-inflammatory-and-clinical-outcomes-among-patients2026-10-13 https://evidence-hub.com/study/4670-real-world-use-of-novel-lactams-in-immunologically-vulnerable2026-10-13 https://evidence-hub.com/study/4671-nanomaterial-strategies-for-antibiotic-resistant-infections2026-10-13 https://evidence-hub.com/study/4672-perspectives-on-the-use-of-ceftolozane-tazobactam-a-review-of2026-10-13 https://evidence-hub.com/study/4673-the-role-of-combination-antibiotic-therapy-in-combatting-drug2026-10-13 https://evidence-hub.com/study/4674-mycobacterium-intracellulare-infection-in-a-japanese-patient-with2026-10-08 https://evidence-hub.com/study/4675-beyond-traditional-tetracyclines-a-real-world-evaluation-of2026-10-13 https://evidence-hub.com/study/4676-innovative-antibiotics-the-experience-of-cefiderocol-in-carbapenem2026-10-13 https://evidence-hub.com/study/4677-management-of-extensively-drug-resistant-acinetobacter-baumannii2026-10-13 https://evidence-hub.com/study/4678-optimized-green-zinc-oxide-chitosan-amoxicillin-nanocomposite-against2026-10-13 https://evidence-hub.com/study/4679-compassionate-use-of-encapsulated-mkb-01-fecal-microbiota2026-10-13 https://evidence-hub.com/study/4680-eravacycline-treatment-for-carbapenem-resistant-acinetobacter2026-10-08 https://evidence-hub.com/study/4681-n-acetylcysteine-evidence-based-consensus-document-on-the-therapeutic2026-10-08 https://evidence-hub.com/study/4682-consensus-guidelines-and-recommendations-for-the-anti-cd38-based2026-10-08 https://evidence-hub.com/study/4683-clinical-and-evidence-based-considerations-for-choosing-a2026-10-08 https://evidence-hub.com/study/4684-guideline-concordant-antibiotic-use-in-children-with-community2026-10-08 https://evidence-hub.com/study/4685-intravenous-fosfomycin-for-gram-negative-and-gram-positive-bacterial2026-10-13 https://evidence-hub.com/study/4686-bactericidal-versus-bacteriostatic-antibacterials-clinical2026-10-08 https://evidence-hub.com/study/4687-balancing-efficacy-and-safety-in-multiple-myeloma-patients-receiving2026-10-08 https://evidence-hub.com/study/4688-granulocyte-transfusions-in-neutropenic-infections-insights-from-a2026-10-08 https://evidence-hub.com/study/4689-omadacycline-for-diverse-infections-in-china-a-real-world-analysis-of2026-10-13 https://evidence-hub.com/study/4690-guidelines-for-antibacterial-treatment-of-carbapenem-resistant2026-10-13 https://evidence-hub.com/study/4691-acinetobacter-baumannii-treatment-strategies-a-review-of-therapeutic2026-10-13 https://evidence-hub.com/study/4692-nosocomial-lower-respiratory-tract-infections-in-patients-with2026-10-08 https://evidence-hub.com/study/4693-bloodstream-infection-and-gram-negative-resistance-the-role-for-newer2026-10-13 https://evidence-hub.com/study/4694-suicidal-thoughts-and-behaviors-associated-with-fluoroquinolone2026-10-13 https://evidence-hub.com/study/4695-antibacterial-potential-dna-binding-and-molecular-docking2026-10-08 https://evidence-hub.com/study/4696-venetoclax-combined-with-cladribine-idarubicin-cytarabine-clia-ven2026-10-08 https://evidence-hub.com/study/4697-efficacy-and-safety-of-plazomicin-in-the-treatment-of2026-10-13 https://evidence-hub.com/study/4698-assessment-of-predictive-factors-that-shorten-duration-of-treatment2026-10-08 https://evidence-hub.com/study/4699-a-bacteriophage-cocktail-targeting-yersinia-pestis-provides-strong2026-10-08 https://evidence-hub.com/study/4700-successful-salvage-of-a-severe-covid-19-patient-previously-with-lung2026-10-08 https://evidence-hub.com/study/4701-utilization-of-inhaled-antibiotics-in-pediatric-non-cystic-fibrosis2026-10-08 https://evidence-hub.com/study/4702-antimicrobial-resistance-among-children-in-southeast-asia-a2026-10-13 https://evidence-hub.com/study/4703-ceftolozane-tazobactam-when-how-and-why-using-it2026-10-08 https://evidence-hub.com/study/4704-current-evidence-on-the-usefulness-of-potential-therapies-in-the2026-10-08 https://evidence-hub.com/study/4705-bacterial-and-antibiotic-sensitivity-pattern-in-secondary-peritonitis2026-10-08 https://evidence-hub.com/study/4706-ureaplasma-urealyticum-infection-following-organ-transplantation-a2026-10-13 https://evidence-hub.com/study/4707-antimicrobial-treatment-of-pseudomonas-aeruginosa-severe-sepsis2026-10-08 https://evidence-hub.com/study/4708-a-review-of-omadacycline-for-potential-utility-in-the-military-health2026-10-08 https://evidence-hub.com/study/4709-korean-guidelines-for-the-management-and-antibiotic-therapy-in-adult2026-10-08 https://evidence-hub.com/study/4710-neutropenia-and-infection-prophylaxis-in-childhood-cancer2026-10-08 https://evidence-hub.com/study/4711-antibiotic-prescribing-for-adults-with-group-a-streptococcal2026-10-08 https://evidence-hub.com/study/4712-combined-use-of-respiratory-multiplex-pcr-and-procalcitonin-to-reduce2026-10-13 https://evidence-hub.com/study/4713-antimicrobial-usage-among-acutely-ill-hospitalized-children-aged-2-232026-10-08 https://evidence-hub.com/study/4714-clinical-evaluation-of-omadacycline-for-pulmonary-mycobacterium2026-10-08 https://evidence-hub.com/study/4715-the-safety-of-ceftolozane-tazobactam-for-the-treatment-of-acute2026-10-08 https://evidence-hub.com/study/4716-macrolide-antibiotic-mediated-cardiac-arrhythmias-emerging-concepts2026-10-08 https://evidence-hub.com/study/4717-new-antibiotics-against-multidrug-resistant-gram-negative-bacteria-in2026-10-08 https://evidence-hub.com/study/4718-secukinumab-for-the-treatment-of-generalized-pustular-psoriasis-a2026-10-08 https://evidence-hub.com/study/4719-meropenem-vaborbactam-lactam-lactamase-inhibitor-combination-the2026-10-08 https://evidence-hub.com/study/4720-the-effectiveness-of-combination-therapy-for-treating-methicillin2026-10-08 https://evidence-hub.com/study/4721-controversies-in-the-management-of-esbl-producing-enterabacterales2026-10-08 https://evidence-hub.com/study/4722-supportive-care-in-myeloma-when-treating-the-clone-alone-is-not-enough2026-10-06 https://evidence-hub.com/study/4723-efficacy-of-recombinant-thrombomodulin-for-poor-prognostic-cases-of2026-10-08 https://evidence-hub.com/study/4724-fibroblast-growth-factor-21-predicts-outcome-in-community-acquired2026-10-08 https://evidence-hub.com/study/4725-efficacy-analysis-of-ultrashort-wave-therapy-as-adjunctive-treatment2026-10-08 https://evidence-hub.com/study/4726-efficacy-of-lefamulin-for-community-acquired-bacterial-pneumonia-cabp2026-10-08 https://evidence-hub.com/study/4727-prediction-of-antibiotic-efficacy-in-cerebral-hemorrhage-associated2026-10-08 https://evidence-hub.com/study/4728-clinical-efficacy-and-safety-of-omadacycline-versus-tigecycline-in2026-10-08 https://evidence-hub.com/study/4729-efficacy-of-tocilizumab-for-hospitalized-patients-with-covid-192026-10-08 https://evidence-hub.com/study/4730-multicentre-open-label-randomised-controlled-trial-comparing-the2026-10-08 https://evidence-hub.com/study/4731-efficacy-and-safety-of-echinocandins-combined-with-trimethoprim2026-10-08 https://evidence-hub.com/study/4732-safety-and-efficacy-of-antimicrobial-optimization-based-on-negative2026-10-08 https://evidence-hub.com/study/4733-pragmatic-open-label-single-center-randomized-phase-ii-clinical-trial2026-10-08 https://evidence-hub.com/study/4734-comparative-prospective-cohort-study-of-efficacy-and-safety-according2026-10-08 https://evidence-hub.com/study/4735-efficacy-and-nephrotoxicity-of-extended-versus-intermittent-infusion2026-10-08 https://evidence-hub.com/study/4736-effect-of-a-texture-modified-and-controlled-bolus-volume-diet-on-all2026-10-08 https://evidence-hub.com/study/4737-efficacy-safety-and-economic-evaluation-of-originator-versus-generic2026-10-08 https://evidence-hub.com/study/4738-imipenem-cilastatin-relebactam-dosing-regimen-justification-using2026-10-08 https://evidence-hub.com/study/4739-efficacy-and-safety-of-omadacycline-in-community-acquired-pneumonia2026-10-08 https://evidence-hub.com/study/4740-statistical-analysis-plan-for-the-empirical-treatment-against2026-10-08 https://evidence-hub.com/study/4741-clinical-efficacy-of-patients-with-secondary-bacteremia-treated-with2026-10-08 https://evidence-hub.com/study/4742-efficacy-of-instilled-saline-in-conjunction-with-chest-physiotherapy2026-10-08 https://evidence-hub.com/study/4743-efficacy-and-safety-of-intravenous-to-oral-lascufloxacin-switch2026-10-08 https://evidence-hub.com/study/4744-beta-lactam-plus-macrolide-treatment-versus-beta-lactam-monotherapy2026-10-08 https://evidence-hub.com/study/4745-study-of-the-efficacy-and-safety-of-hexapeptide-succinate-in2026-10-08 https://evidence-hub.com/study/4746-efficacy-and-safety-of-ceftaroline-fosamil-in-hospitalized-patients2026-10-08 https://evidence-hub.com/study/4747-efficacy-of-comprehensive-unit-based-safety-program-to-prevent2026-10-08 https://evidence-hub.com/study/4748-the-prediction-of-lymphocyte-count-and-neutrophil-count-on-the2026-10-08 https://evidence-hub.com/study/4750-clinical-efficacy-of-doripenem-in-treating-hospital-acquired2026-10-08 https://evidence-hub.com/study/4751-intravenous-combined-with-aerosolised-polymyxins-versus-intravenous2026-10-08 https://evidence-hub.com/study/4752-a55-50-a-biomarker-based-ai-tool-that-predicts-corticosteroid2026-10-08 https://evidence-hub.com/study/4753-effects-of-prophylactic-nebulized-antibiotics-on-the-prevention-of2026-10-08 https://evidence-hub.com/study/4754-efficacy-and-safety-of-il-6-inhibitors-in-patients-with-covid-192026-10-08 https://evidence-hub.com/study/4756-safety-and-efficacy-of-incentive-spirometer-in-covid-19-pneumonia-a2026-10-08 https://evidence-hub.com/study/4758-impact-of-multisite-colonization-and-comparative-microbiological2026-10-08 https://evidence-hub.com/study/4759-multicentre-prospective-randomised-open-label-endpoint-blinded-study2026-10-08 https://evidence-hub.com/study/4760-nebulized-colistin-as-the-adjunctive-treatment-for-ventilator2026-10-08 https://evidence-hub.com/study/4762-p-1331-efficacy-of-levofloxacin-for-levofloxacin-susceptible2026-10-08 https://evidence-hub.com/study/4763-a-phase-2-open-label-multicenter-single-arm-study-of-tocilizumab-on2026-10-08 https://evidence-hub.com/study/4764-zinc-supplementation-in-adult-mechanically-ventilated-trauma-patients2026-10-08 https://evidence-hub.com/study/4765-efficacy-and-safety-of-ceftaroline-for-the-treatment-of-community2026-10-06 https://evidence-hub.com/study/4766-trends-and-implications-of-antimicrobial-resistance-in-pseudomonas2026-10-08 https://evidence-hub.com/study/4767-epidemiology-and-antimicrobial-susceptibility-profiles-of-gram2026-10-13 https://evidence-hub.com/study/4768-fluoroquinolone-therapy-for-bloodstream-infections-caused-by-extended2026-10-08 https://evidence-hub.com/study/4769-comparative-in-vitro-efficacy-of-fluoroquinolones-against2026-10-08 https://evidence-hub.com/study/4770-the-clinical-value-of-two-combination-regimens-in-the-management-of2026-10-08 https://evidence-hub.com/study/4771-antimicrobial-susceptibilities-of-extended-spectrum-beta-lactamase2026-10-17 https://evidence-hub.com/study/4772-treatment-for-legionnaires-disease-macrolides-or-quinolones2026-10-08 https://evidence-hub.com/study/4773-the-relationship-between-the-alveolar-epithelial-lining-fluid2026-10-08 https://evidence-hub.com/study/4774-efficacy-and-safety-of-polymyxin-b-sulfate-versus-colistin-sulfate-in2026-10-08 https://evidence-hub.com/study/4775-efficacy-and-safety-of-ceftazidime-avibactam-alone-versus-ceftazidime2026-10-08 https://evidence-hub.com/study/4776-a-prospective-observational-cohort-study-of-the-efficacy-of2026-10-08 https://evidence-hub.com/study/4777-clinical-efficacy-of-ulinastatin-combined-with-azithromycin-in-the2026-10-08 https://evidence-hub.com/study/4778-a-matched-pilot-cohort-study-of-intravenous-omadacycline-in-the2026-10-08 https://evidence-hub.com/study/4779-comparison-of-the-clinical-efficacy-and-toxicity-of-nebulized2026-10-08 https://evidence-hub.com/study/4780-dynamically-monitoring-pneumonia-severity-scores-to-predict-the2026-10-08 https://evidence-hub.com/study/4781-high-loading-dose-colistin-with-nebulized-administration-for2026-10-08 https://evidence-hub.com/study/4782-prevalence-of-skin-and-mucosal-lesions-in-adults-with-mycoplasma2026-10-08 https://evidence-hub.com/study/4783-comparison-of-different-colistin-sulfate-regimens-for-carbapenem2026-10-08 https://evidence-hub.com/study/4784-clinical-score-for-early-escalation-in-pediatric-a2063g-mycoplasma2026-10-08 https://evidence-hub.com/study/4785-artificial-liver-plasma-adsorption-improves-survival-in-elderly2026-10-08 https://evidence-hub.com/study/4786-investigating-the-effectiveness-of-combining-high-frequency-chest2026-10-08 https://evidence-hub.com/study/4787-the-incidence-of-fungal-infections-in-patients-treated-with2026-10-08 https://evidence-hub.com/study/4788-efficacy-and-safety-of-adjunctive-nebulized-colistin-sulfate-for2026-10-08 https://evidence-hub.com/study/4789-a-retrospective-observational-cohort-study-on-the-efficacy-and-safety2026-10-08 https://evidence-hub.com/study/4791-clinical-efficacy-of-arbidol-in-patients-with-2019-novel-coronavirus2026-10-08 https://evidence-hub.com/study/4792-efficacy-evaluation-of-early-low-dose-short-term-corticosteroids-in2026-10-08 https://evidence-hub.com/study/4793-efficacy-analysis-of-arbidol-treatment-in-patients-with-2019-novel2026-10-08 https://evidence-hub.com/study/4794-real-world-efficacy-and-safety-of-cefepime-for-pediatric-community2026-10-08 https://evidence-hub.com/study/4795-safety-and-efficacy-of-tocilizumab-in-the-treatment-of-severe-acute2026-10-08 https://evidence-hub.com/study/4796-efficacy-and-adverse-effects-of-remdesivir-in-patients-with-covid-192026-10-08 https://evidence-hub.com/study/4797-low-versus-conventional-dose-trimethoprim-sulfamethoxazole-treatment2026-10-08 https://evidence-hub.com/study/4798-association-between-adjunctive-corticosteroid-therapy-and-clinical2026-10-08 https://evidence-hub.com/study/4799-inhalation-devices-and-inhaled-corticosteroids-particle-size2026-10-08 https://evidence-hub.com/study/4800-effects-of-bronchoalveolar-lavage-on-mycoplasma-pneumoniae-pneumonia2026-10-08 https://evidence-hub.com/study/4801-reduced-risk-of-pneumonia-and-influenza-infection-after-bariatric2026-10-08 https://evidence-hub.com/study/4802-use-of-defibrotide-in-covid-19-pneumonia-comparison-of-a-phase-ii2026-10-08 https://evidence-hub.com/study/4803-association-between-gustave-roussy-immune-score-and-delay-in2026-10-08 https://evidence-hub.com/study/4804-invasive-pulmonary-aspergillosis-among-patients-with-severe-community2026-10-08 https://evidence-hub.com/study/4805-association-between-antibiotic-prescriptions-for-acute-upper2026-10-08 https://evidence-hub.com/study/4806-prospective-cohort-study-on-the-clinical-significance-of-interferon-d2026-10-08 https://evidence-hub.com/study/4807-efficacy-and-safety-of-eravacycline-combination-therapy-for2026-10-08 https://evidence-hub.com/study/4808-efficacy-and-safety-of-early-prone-positioning-combined-with-hfnc-or2026-10-08 https://evidence-hub.com/study/4809-clinical-efficacy-of-invimestrocel-for-acute-respiratory-distress2026-10-08 https://evidence-hub.com/study/4811-severe-pneumonia-in-picu-admissions-the-pediatric-acute-and-critical2026-10-08 https://evidence-hub.com/study/4812-the-efficacy-of-andrographis-paniculata-burm-f-wall-ex-nees-crude2026-10-08 https://evidence-hub.com/study/4813-mechanical-insufflation-exsufflation-for-the-prevention-of-ventilator2026-10-08 https://evidence-hub.com/study/4814-mesenchymal-stromal-cell-treatment-improves-outcomes-in-children-with2026-10-08 https://evidence-hub.com/study/4815-efficacy-of-prophylactic-antibiotics-during-extracorporeal-membrane2026-10-08 https://evidence-hub.com/study/4816-interleukin-6-blockade-with-sarilumab-in-severe-covid-19-pneumonia2026-10-19 https://evidence-hub.com/study/4817-anakinra-combined-with-methylprednisolone-in-patients-with-severe2026-10-08 https://evidence-hub.com/study/4818-risk-factors-associated-with-increased-discontinuation-rate-of2026-10-08 https://evidence-hub.com/study/4819-the-efficacy-of-daily-administration-of-nebulized-heparin-on-the2026-10-08 https://evidence-hub.com/study/4820-left-vagus-nerve-magnetic-stimulation-facilitates-nasogastric-tube2026-10-08 https://evidence-hub.com/study/4821-minocycline-based-therapy-for-carbapenem-resistant-acinetobacter2026-10-08 https://evidence-hub.com/study/4823-the-impact-of-concurrent-bacterial-lung-infection-on-immunotherapy-in2026-10-08 https://evidence-hub.com/study/4824-clinical-effectiveness-and-outcomes-of-azithromycin-versus2026-10-08 https://evidence-hub.com/study/4825-combined-vitamin-c-hydrocortisone-and-thiamine-therapy-for-patients2026-10-08 https://evidence-hub.com/study/4826-efficacy-and-safety-of-dolutegravir-based-regimens-in-advanced-hiv2026-10-08 https://evidence-hub.com/study/4827-denosumab-treatment-and-infection-risks-in-patients-with-osteoporosis2026-10-08 https://evidence-hub.com/study/4828-evaluation-of-the-efficacy-safety-and-economy-of-nemonoxacin2026-10-08 https://evidence-hub.com/study/4829-sphingolipid-metabolism-related-genes-as-diagnostic-markers-in2026-10-08 https://evidence-hub.com/study/4830-efficacy-of-adjunctive-nebulized-colistin-in-critically-ill-patients2026-10-08 https://evidence-hub.com/study/4831-clinical-efficacy-of-immunoglobulin-in-pediatric-patients-with-severe2026-10-08 https://evidence-hub.com/study/4833-the-real-world-effectiveness-of-fluvoxamine-therapy-in-mild-to2026-10-08 https://evidence-hub.com/study/4837-safety-and-efficacy-of-human-umbilical-cord-mesenchymal-stem-cells2026-10-06 https://evidence-hub.com/study/4838-low-dose-trimethoprim-sulfamethoxazole-treatment-for-pneumocystis2026-10-06 https://evidence-hub.com/study/4839-efficacy-of-tocilizumab-in-treatment-of-covid-19-pneumonia-a-case2026-10-08 https://evidence-hub.com/study/4840-bundled-care-combined-with-animated-educational-videos-can-promote2026-10-08 https://evidence-hub.com/study/4841-efficacy-of-bronchoalveolar-lavage-as-adjunct-therapy-in-the2026-10-08 https://evidence-hub.com/study/4842-development-of-a-predictive-model-based-on-clinical-indicators-for2026-10-08 https://evidence-hub.com/study/4843-tocilizumab-in-severe-covid-19-pneumonia-a-retrospective-case-control2026-10-08 https://evidence-hub.com/study/4844-janus-kinase-inhibitors-vs-abatacept-about-safety-and-efficacy-for2026-10-08 https://evidence-hub.com/study/4845-clinical-value-of-metagenomics-next-generation-sequencing-in2026-10-08 https://evidence-hub.com/study/4846-low-dose-intravenous-plus-inhaled-versus-intravenous-polymyxin-b-for2026-10-08 https://evidence-hub.com/study/4847-remdesivir-treatment-in-hospitalized-patients-affected-by-covid-192026-10-08 https://evidence-hub.com/study/4848-canakinumab-as-treatment-for-covid-19-related-pneumonia-a-prospective2026-10-08 https://evidence-hub.com/study/4849-interleukin-6-receptor-blockade-with-subcutaneous-tocilizumab-in2026-10-08 https://evidence-hub.com/study/4850-intravenous-vs-intravenous-plus-aerosolized-colistin-for-treatment-of2026-10-08 https://evidence-hub.com/study/4851-effects-of-bronchoalveolar-lavage-on-pediatric-refractory-mycoplasma2026-10-08 https://evidence-hub.com/study/4852-rheumatoid-arthritis-associated-interstitial-pneumonia-refractory-to2026-10-08 https://evidence-hub.com/study/4854-risk-factors-for-aspiration-pneumonia-after-definitive2026-10-08 https://evidence-hub.com/study/4855-study-on-the-clinical-efficacy-of-levofloxacin-combined-with-ambroxol2026-10-08 https://evidence-hub.com/study/4856-a-case-of-hospital-acquired-pneumonia-associated-with2026-10-08 https://evidence-hub.com/study/4857-lianhua-qingke-tablet-in-severe-pneumonia-clinical-efficacy-and2026-10-08 https://evidence-hub.com/study/4859-efficacy-of-traditional-chinese-medicine-in-reducing-readmission-in2026-10-08 https://evidence-hub.com/study/4860-efficacy-and-safety-analysis-of-montelukast-sodium-added-on2026-10-08 https://evidence-hub.com/study/4861-efficacy-of-the-pdca-cyclic-care-model-in-improving-lung-function-and2026-10-08 https://evidence-hub.com/study/4862-direct-effectiveness-of-pneumococcal-polysaccharide-vaccine-against2026-10-08 https://evidence-hub.com/study/4863-efficacy-of-different-doses-of-corticosteroids-in-treating-severe2026-10-08 https://evidence-hub.com/study/4865-efficacy-of-sulfasalazine-for-the-prevention-of-pneumocystis2026-10-08 https://evidence-hub.com/study/4866-atorvastatin-reduces-the-severity-of-covid-19-a-nationwide-total2026-10-08 https://evidence-hub.com/study/4867-clinical-efficacy-of-chemotherapy-regimen-combined-with-levofloxacin2026-10-08 https://evidence-hub.com/study/4868-clinical-efficacy-and-immune-function-of-andrographolide-sulfonate-in2026-10-08 https://evidence-hub.com/study/4869-efficacy-of-glutathione-therapy-in-relieving-dyspnea-associated-with2026-10-08 https://evidence-hub.com/study/4870-meta-analysis-of-vancomycin-versus-linezolid-in-pneumonia-with-proven2026-10-08 https://evidence-hub.com/study/4871-safety-and-efficacy-of-continuous-intrathecal-baclofen-via-cervical2026-10-08 https://evidence-hub.com/study/4872-machine-learning-based-prediction-model-for-bronchoalveolar-lavage2026-10-08 https://evidence-hub.com/study/4874-evaluation-of-the-clinical-efficacy-of-a-water-soluble-formulation-of2026-10-08 https://evidence-hub.com/study/4876-meta-analysis-of-the-clinical-efficacy-and-safety-of-high-and-low2026-10-08 https://evidence-hub.com/study/4877-efficacy-of-a-chlorhexidine-based-oral-prevention-protocol-in2026-10-08 https://evidence-hub.com/study/4878-aerosolized-plus-intravenous-colistin-versus-intravenous-colistin2026-10-08 https://evidence-hub.com/study/4880-efficacy-analysis-of-levofloxacin-combined-with-cefoperazone2026-10-08 https://evidence-hub.com/study/4882-the-value-of-macrogene-second-generation-sequencing-in-the-diagnosis2026-10-08 https://evidence-hub.com/study/4883-efficacy-of-jiedu-pingsou-decoction-combined-with-azithromycin-in-the2026-10-08 https://evidence-hub.com/study/4884-high-dose-inhaled-no-for-the-prevention-of-nosocomial-pneumonia-after2026-10-08 https://evidence-hub.com/study/4885-an-observational-study-on-multidrug-resistance-in-pediatric-patients2026-10-13 https://evidence-hub.com/study/4886-the-role-of-transfer-motivation-and-self-efficacy-on-student2026-10-19 https://evidence-hub.com/study/4887-lateral-positioning-in-covid-19-pneumonia-a-cross-sectional-study2026-10-08 https://evidence-hub.com/study/4889-covid-19-vaccines-side-effects-among-the-general-population-during2026-10-08 https://evidence-hub.com/study/4890-clinical-and-proteomic-associations-of-sars-cov-2-infection-and-covid2026-10-08 https://evidence-hub.com/study/4891-factors-influencing-the-perception-of-shared-decision-making-among2026-10-19 https://evidence-hub.com/study/4892-efficacy-of-compliance-with-ventilator-associated-pneumonia-care2026-10-08 https://evidence-hub.com/study/4893-burden-of-hospitalized-childhood-community-acquired-pneumonia-a2026-10-08 https://evidence-hub.com/study/4894-a-comparative-cross-sectional-study-to-compare-the-isolated-organism2026-10-08 https://evidence-hub.com/study/4895-trends-in-antibiotic-use-in-a-uk-secondary-care-prior-to-and-during2026-10-08 https://evidence-hub.com/study/4896-regional-insights-on-the-prevalence-and-antimicrobial-susceptibility2026-10-08 https://evidence-hub.com/study/4897-waning-immunity-prevailing-non-vaccine-type-ptxp3-and-macrolide2026-10-08 https://evidence-hub.com/study/4898-exploring-how-older-adults-perceived-the-impact-of-infectious2026-10-08 https://evidence-hub.com/study/4899-clinical-utility-of-the-platelet-to-neutrophil-ratio-in2026-10-08 https://evidence-hub.com/study/4900-association-of-perceived-threat-negative-emotions-and-self-efficacy2026-10-19 https://evidence-hub.com/study/4901-expert-perspectives-on-the-usage-of-co-amoxiclav-and-cefuroxime-in2026-10-08 https://evidence-hub.com/study/4902-factors-affecting-the-performance-of-standard-precautions-focusing-on2026-10-19 https://evidence-hub.com/study/4903-comparative-efficacy-of-ceftriaxone-and-cefotaxime-klebsiella2026-10-08 https://evidence-hub.com/study/4904-the-psychological-status-and-self-efficacy-of-nurses-during-covid-192026-10-08 https://evidence-hub.com/study/4905-hospital-based-antibiogram-profile-and-resistance-patterns-of-gram2026-10-13 https://evidence-hub.com/study/4906-analysis-of-antibiotic-therapy-accuracy-and-drug-interaction-in2026-10-08 https://evidence-hub.com/study/4907-effect-of-combined-colistin-and-meropenem-against-meropenem-resistant2026-10-08 https://evidence-hub.com/study/4908-cross-sectional-analysis-of-exome-sequencing-diagnosis-in-patients2026-10-19 https://evidence-hub.com/study/4909-exploring-the-correlation-between-systemic-inflammatory-markers-and2026-10-19 https://evidence-hub.com/study/4910-association-of-perceived-threat-negative-emotions-and-self-efficacy2026-10-19 https://evidence-hub.com/study/4911-complications-of-measles-in-malnourished-children-a-descriptive-cross2026-10-08 https://evidence-hub.com/study/4912-association-of-chest-ct-severity-scores-and-vaccination-status-in2026-10-08 https://evidence-hub.com/study/4913-community-acquired-pneumonia-in-bangladesh-sensitivity-pattern2026-10-08 https://evidence-hub.com/study/4914-effect-of-respiratory-physiotherapy-in-preventing-pulmonary2026-10-08 https://evidence-hub.com/study/4915-clinical-value-of-transthoracic-ultrasonography-in-identifying-causes2026-10-08 https://evidence-hub.com/study/4916-the-anatomical-site-of-perforation-peritonitis-and-their2026-10-08 https://evidence-hub.com/study/4917-prevalence-of-covid-19-in-patients-with-rheumatoid-arthritis-ra2026-10-08 https://evidence-hub.com/study/4918-development-and-validation-of-the-digital-sensitivity-scale-for2026-10-19 https://evidence-hub.com/study/4919-are-primary-outcomes-really-primary-an-exploratory-cross-sectional2026-10-19 https://evidence-hub.com/study/4920-major-pulmonary-resection-for-non-small-cell-lung-carcinoma-during2026-10-08 https://evidence-hub.com/study/4921-efficacy-of-chest-ultrasonography-versus-chest-x-ray-in-the-diagnosis2026-10-08 https://evidence-hub.com/study/4922-antibiotic-susceptibility-profile-of-streptococcus-pneumoniae2026-10-08 https://evidence-hub.com/study/4923-differences-in-pcv13-recommendation-practices-between-pediatric-care2026-10-08 https://evidence-hub.com/study/4924-appropriateness-of-antibiotic-prescribing-in-veterans-with-community2026-10-08 https://evidence-hub.com/study/4925-efficacy-of-methylprednisolone-with-dexamethasoneiin-patients-with2026-10-08 https://evidence-hub.com/study/4926-exploring-pneumonia-in-less-than-two-year-olds-comparing-respiratory2026-10-08 https://evidence-hub.com/study/4927-development-of-model-on-mothers-self-efficacy-in-preventing2026-10-08 https://evidence-hub.com/study/4928-high-prevalence-of-antibiotic-resistance-in-nasopharyngeal-bacterial2026-10-08 https://evidence-hub.com/study/4929-retrospective-evaluation-of-the-efficacy-of-combined-antiviral2026-10-08 https://evidence-hub.com/study/4930-faktor-yang-mempengaruhi-perilaku-ibu-dalam-deteksi-dini-pneumonia2026-10-08 https://evidence-hub.com/study/4932-p-1499-patient-characteristics-and-clinical-outcomes-associated-with2026-10-08 https://evidence-hub.com/study/4934-comparative-analysis-of-antimicrobial-susceptibility-profiles-in2026-10-08 https://evidence-hub.com/study/4935-efficacy-of-antibiotics-against-pseudomonas-aeruginosa-isolated-from2026-10-08 https://evidence-hub.com/study/4936-a-cognitive-model-of-alcohol-use-among-taiwanese-adolescents-the2026-10-19 https://evidence-hub.com/study/4937-comparison-between-the-combination-therapy-in-terms-of-therapeutic2026-10-08 https://evidence-hub.com/study/4938-efektivitas-antibiotik-terhadap-parameter-klinis-pasien-pneumonia2026-10-08 https://evidence-hub.com/study/4940-prevalence-molecular-detection-and-therapeutic-efficacy-against2026-10-08 https://evidence-hub.com/study/4941-covid-19-preventive-practices-among-nursing-students-integrating2026-10-19 https://evidence-hub.com/study/4942-in-vitro-efficacy-of-quinolones-and-carbapenems-against-nonfermenting2026-10-08 https://evidence-hub.com/study/4943-self-efficacy-of-genetic-counselors-and-genetic-counseling-students2026-10-19 https://evidence-hub.com/study/4944-comparative-efficacy-of-5-dextrose-and-corticosteroid-injections-in2026-10-19 https://evidence-hub.com/study/4945-hubungan-rasionalitas-penggunaan-antibiotik-terhadap-luaran-klinis2026-10-08 https://evidence-hub.com/study/4946-in-vitro-efficacy-of-colistin-against-multidrug-resistant-pseudomonas2026-10-08 https://evidence-hub.com/study/4948-common-pathogens-and-their-resistance-to-antimicrobials-in-community2026-10-08 https://evidence-hub.com/study/4949-di-011-evaluation-of-the-use-of-levofloxacin-and-moxifloxacin-in-the2026-10-08 https://evidence-hub.com/study/4950-evaluation-of-antibiotic-use-with-quantitative-methods-in2026-10-08 https://evidence-hub.com/study/4951-pola-penggunaan-antibiotik-pada-pasien-pneumonia-rawat-inap-di-rsud2026-10-08 https://evidence-hub.com/study/4952-maternal-perception-of-medicinal-foods-in-child-feeding-practices-a2026-10-08 https://evidence-hub.com/study/4953-assesment-of-the-use-of-antibiotics-in-patients-pneumonia-inpatients2026-10-08 https://evidence-hub.com/study/4955-the-efficacy-of-probiotics-in-treatment-of-helicobacter2026-10-08 https://evidence-hub.com/study/4956-prevalence-incidence-and-clinical-outcome-of-klebsiella-and2026-10-08 https://evidence-hub.com/study/4957-association-of-knowledge-about-epilepsy-with-mood-and-self-efficacy2026-10-19 https://evidence-hub.com/study/4958-evaluasi-penggunaan-antibiotik-pada-pasien-pneumonia-di-rsud-dr2026-10-08 https://evidence-hub.com/study/4959-naso-pharyngeal-carriage-and-antimicrobial-susceptibility-of2026-10-08 https://evidence-hub.com/study/4960-antimicrobial-utilization-among-hospitalized-patients-according-to2026-10-08 https://evidence-hub.com/study/4961-epidemiologic-evaluation-of-pediatric-patients-receiving-high-flow2026-10-08 https://evidence-hub.com/study/4962-community-acquired-pneumonia-among-adult-patients-at-an-egyptian2026-10-08 https://evidence-hub.com/study/4963-cognitive-factors-associated-with-willingness-to-receive-three2026-10-06 https://evidence-hub.com/study/4964-sulbactam-durlobactam-in-the-treatment-of-bloodstream-infection-due2026-10-13 https://evidence-hub.com/study/4965-doxycycline-for-legionella-pneumonia-expanding-treatment-horizons2026-10-13 https://evidence-hub.com/study/4966-successful-management-of-severe-covid-19-in-a-kidney-transplant2026-10-08 https://evidence-hub.com/study/4967-severe-numbness-of-the-mouth-and-tongue-induced-by-piperacillin2026-10-08 https://evidence-hub.com/study/4968-a-rare-case-of-staphylococcus-aureus-associated-lemierre-s-disease2026-10-08 https://evidence-hub.com/study/4969-disseminated-melioidosis-complicated-by-symmetrical-peripheral2026-10-13 https://evidence-hub.com/study/4970-resistant-mycoplasma-pneumoniae-in-children2026-10-08 https://evidence-hub.com/study/4971-clinical-outcomes-of-omadacycline-in-critically-ill-patients-treated2026-10-08 https://evidence-hub.com/study/4972-a-rare-case-of-h-syndrome-with-severe-multisystem-involvement2026-10-08 https://evidence-hub.com/study/4973-eravacycline-as-a-novel-option-for-treating-multidrug-resistant-gram2026-10-08 https://evidence-hub.com/study/4974-investigating-outcomes-and-treatment-of-long-coronavirus-disease-20192026-10-08 https://evidence-hub.com/study/4975-beyond-infection-and-malignancy-diagnostic-pitfalls-in-pulmonary2026-10-08 https://evidence-hub.com/study/4976-first-experience-of-hemadsorption-with-ha60-cartridges-in-newborns2026-10-08 https://evidence-hub.com/study/4977-mixed-infection-with-burkholderia-cepacia-and-cutibacterium-acnes2026-10-13 https://evidence-hub.com/study/4978-beyond-fifth-disease-atypical-parvovirus-b19-neurological-syndromes2026-10-08 https://evidence-hub.com/study/4979-treatment-of-central-nervous-system-infections-caused-by-pseudomonas2026-10-13 https://evidence-hub.com/study/4980-rifampin-monotherapy-for-multidrug-resistant-chryseobacterium2026-10-08 https://evidence-hub.com/study/4981-moraxella-catarrhalis-an-underestimated-culprit-for-community2026-10-08 https://evidence-hub.com/study/4982-managing-pneumonia-due-to-rare-non-fermenting-gram-negative-bacteria2026-10-13 https://evidence-hub.com/study/4983-effects-of-prolonged-antibiotic-therapy-in-lung-abscesses-analysis-of2026-10-13 https://evidence-hub.com/study/4984-diffuse-alveolar-haemorrhage-as-a-rare-pulmonary-manifestation-of2026-10-08 https://evidence-hub.com/study/4985-eravacycline-as-salvage-therapy-for-severe-intra-abdominal-infections2026-10-08 https://evidence-hub.com/study/4986-chylothorax-in-a-57-year-old-female-patient-after-a-car-accident2026-10-13 https://evidence-hub.com/study/4987-fecal-microbiota-transplantation-in-refractory-immune-mediated2026-10-08 https://evidence-hub.com/study/4988-pulmonary-glue-embolism-and-interstitial-pneumonitis-following2026-10-08 https://evidence-hub.com/study/4989-appropriateness-and-abuse-of-antipyretics-anti-inflammatory-drugs-and2026-10-13 https://evidence-hub.com/study/4990-what-drives-mortality-in-s-maltophilia-bloodstream-infections-an2026-10-08 https://evidence-hub.com/study/4991-antimicrobial-pharmacokinetics-in-pediatric-patients-on-kidney2026-10-08 https://evidence-hub.com/study/4992-combination-of-ceftazidime-avibactam-and-aztreonam-effectively2026-10-08 https://evidence-hub.com/study/4993-severe-pertussis-during-early-infancy-from-a-high-altitude-region-two2026-10-08 https://evidence-hub.com/study/4994-efficacy-of-cefiderocol-in-murine-models-of-ventilator-associated2026-10-08 https://evidence-hub.com/study/4995-outpatient-parenteral-antimicrobial-therapy-for-pseudomonas2026-10-13 https://evidence-hub.com/study/4996-postoperative-intra-abdominal-clostridium-tertium-infection-following2026-10-08 https://evidence-hub.com/study/4997-successful-hemostasis-with-platelet-transfusion-and-tranexamic-acid2026-10-08 https://evidence-hub.com/study/4998-relapse-and-emergent-resistance-with-novel-short-course-regimens-for2026-10-08 https://evidence-hub.com/study/4999-management-of-acute-myeloid-leukemia-in-a-dialysis-dependent-patient2026-10-08 https://evidence-hub.com/study/5000-mycobacterium-florentinum-pulmonary-disease-a-case-report-and-review2026-10-08 https://evidence-hub.com/study/5001-enterovirus-d68-pneumonia-in-two-older-patients-a-case-report-and2026-10-08 https://evidence-hub.com/study/5002-cefiderocol-for-the-treatment-of-nosocomial-bloodstream-infections2026-10-08 https://evidence-hub.com/study/5003-septic-shock-caused-by-elizabethkingia-miricola-in-an-elderly-trauma2026-10-13 https://evidence-hub.com/study/5004-a-76-year-old-man-with-hemoptysis-and-a-groin-nodule-a-case-report2026-10-08 https://evidence-hub.com/study/5005-care-of-patients-with-bacteremia-in-the-setting-of-a-telemedicine2026-10-08 https://evidence-hub.com/study/5006-myasthenia-gravis-and-community-acquired-pneumonia-therapeutic2026-10-08 https://evidence-hub.com/study/5007-real-world-evidence-and-multidrug-resistant-infections-how-can-we2026-10-08 https://evidence-hub.com/study/5008-non-antibiotic-management-of-bacterial-keratitis2026-10-08 https://evidence-hub.com/study/5009-successful-long-term-use-of-isavuconazole-in-a-tacrolimus-treated2026-10-08 https://evidence-hub.com/study/5010-fungemia-caused-by-cyberlindnera-fabianii-clinical-and2026-10-13 https://evidence-hub.com/study/5011-markedly-elevated-serum-level-of-presepsin-in-agranulocytosis-with2026-10-08 https://evidence-hub.com/study/5012-wound-debridement-with-copper-oxide-dressings-bridging-the-gap2026-10-08 https://evidence-hub.com/study/5013-clinical-features-and-prognostic-factors-of-anti-mda5-antibody2026-10-08 https://evidence-hub.com/study/5014-autologous-stem-cell-transplantation-in-hiv-positive-and-hiv-negative2026-10-08 https://evidence-hub.com/study/5015-safe-treatment-of-an-extensive-stage-small-cell-lung-cancer-with2026-10-08 https://evidence-hub.com/study/5016-a-case-of-tuberculous-meningitis-with-concomitant-spinal-co-infection2026-10-08 https://evidence-hub.com/study/5017-difficult-to-treat-pseudomonas-aeruginosa-infections-in-critically2026-10-08 https://evidence-hub.com/study/5018-analysis-of-clinical-and-imaging-features-and-prognosis-of-patients2026-10-08 https://evidence-hub.com/study/5019-outcome-of-sutureless-amniotic-membrane-dressing-ring-for-acute2026-10-08 https://evidence-hub.com/study/5020-case-report-psoas-abscess-caused-by-carbapenem-resistant2026-10-06 https://evidence-hub.com/study/5021-what-is-new-in-pleural-infections2026-10-06 https://evidence-hub.com/study/5022-isavuconazole-as-an-optimal-treatment-option-for-multiple-pathogens2026-10-08 https://evidence-hub.com/study/5023-use-of-echinocandins-combined-with-clindamycin-in-pneumocystis2026-10-08 https://evidence-hub.com/study/5024-safety-and-efficacy-of-gefitinib-administration-after-osimertinib2026-10-08 https://evidence-hub.com/study/5025-paradoxical-role-of-glucocorticoids-in-severe-pneumocystis-jirovecii2026-10-10 https://evidence-hub.com/study/5026-efficacy-of-upadacitinib-as-a-second-line-jak-inhibitor-in-ulcerative2026-10-08 https://evidence-hub.com/study/5027-real-world-efficacy-and-safety-of-mezigdomide-dexamethasone-in2026-10-08 https://evidence-hub.com/study/5028-adaptive-phage-therapy-for-the-prevention-of-recurrent-nosocomial2026-10-08 https://evidence-hub.com/study/5029-canakinumab-for-the-management-of-pyoderma-gangrenosum-a-case-series2026-10-08 https://evidence-hub.com/study/5030-ravulizumab-in-treatment-naive-patients-with-atypical-hemolytic2026-10-08 https://evidence-hub.com/study/5031-65-atropine-for-the-treatment-of-paediatric-sialorrhea-a2026-10-08 https://evidence-hub.com/study/5032-clinical-diagnosis-and-treatment-of-seven-patients-diagnosed2026-10-08 https://evidence-hub.com/study/5033-articular-manifestations-related-to-anti-interleukin-5-therapies-in2026-10-08 https://evidence-hub.com/study/5034-high-dose-glucocorticoids-pulse-therapy-for-beta-coronaviridae2026-10-08 https://evidence-hub.com/study/5035-efficacy-of-hybrid-closed-loop-insulin-delivery-system-in-a-hospital2026-10-08 https://evidence-hub.com/study/5036-ibrutinib-as-a-secondary-treatment-for-steroid-refractory-or-steroid2026-10-08 https://evidence-hub.com/study/5037-efficacy-and-safety-of-azathioprine-in-patients-with-cronkhite-canada2026-10-08 https://evidence-hub.com/study/5038-covid-19-pneumonia-after-sars-cov-2-vaccination-with-coronavac-a-case2026-10-08 https://evidence-hub.com/study/5039-efficacy-of-enteral-feeding-by-gastrostomy-tube-placement-in-patients2026-10-19 https://evidence-hub.com/study/5040-cd19-car-t-cell-therapy-in-autoimmune-disease-a-case-series-with2026-10-08 https://evidence-hub.com/study/5042-efficacy-and-safety-of-everolimus-in-advanced-unresectable-and2026-10-08 https://evidence-hub.com/study/5043-efficacy-and-safety-of-ropeginterferon-alfa-2b-in-pregnant-women-with2026-10-19 https://evidence-hub.com/study/5044-non-invasive-vagus-nerve-magnetic-stimulation-combined-with2026-10-08 https://evidence-hub.com/study/5045-successful-treatment-with-steroid-pulse-therapy-for-secondary2026-10-08 https://evidence-hub.com/study/5046-efficacy-and-safety-of-low-dose-rituximab-as-induction-therapy-for2026-10-08 https://evidence-hub.com/study/5047-combination-therapy-for-multidrug-resistant-mycoplasma-genitalium2026-10-19 https://evidence-hub.com/study/5048-pharmacokinetics-pharmacodynamics-of-cefiderocol-administered-by2026-10-08 https://evidence-hub.com/study/5049-case-report-cytosorb-hemoadsorption-as-an-adjunctive-therapy-in2026-10-08 https://evidence-hub.com/study/5050-clinical-outcome-and-safety-of-combined-radiation-therapy-and2026-10-08 https://evidence-hub.com/study/5051-therapeutic-efficacy-of-transpedicular-intracorporeal-cement2026-10-08 https://evidence-hub.com/study/5052-combined-extracorporeal-therapy-with-pathogen-hemoadsorption-and-cell2026-10-08 https://evidence-hub.com/study/5053-shape-sensing-robotic-assisted-bronchoscopic-microwave-ablation-for2026-10-08 https://evidence-hub.com/study/5054-simplified-left-cardiac-sympathetic-denervation-as-an-acute-strategy2026-10-19 https://evidence-hub.com/study/5055-lessons-from-recurrent-dropped-head-syndrome-after-inadequate-short2026-10-08 https://evidence-hub.com/study/5056-improvement-of-triceps-muscle-weakness-in-patients-with-cervical2026-10-19 https://evidence-hub.com/study/5057-retrospective-case-series-analysis-of-clinical-outcomes-associated2026-10-08 https://evidence-hub.com/study/5058-efficacy-and-safety-of-ercp-in-patients-with-situs-inversus-totalis2026-10-08 https://evidence-hub.com/study/5059-nursing-evaluation-during-treatment-with-helmet-continuous-positive2026-10-08 https://evidence-hub.com/study/5060-efficacy-of-tilapia-skin-xenograft-compared-to-paraffin-impregnated2026-10-08 https://evidence-hub.com/study/5061-654-clinical-efficacy-and-safety-of-high-dose-ampicillin-sulbactam2026-10-08 https://evidence-hub.com/study/5063-the-use-of-peripheral-parenteral-nutrition-in-hospitalized-patients-a2026-10-08 https://evidence-hub.com/study/5064-platelet-rich-plasma-for-non-invasive-closure-of-tracheal-and2026-10-08 https://evidence-hub.com/study/5065-chili-pepper-aspiration-in-elderly-patients-a-case-series2026-10-08 https://evidence-hub.com/study/5066-a-descriptive-case-series-of-pk-pd-target-attainment-and2026-10-08 https://evidence-hub.com/study/5067-195-tocilizumab-for-cytokine-release-syndrome-in-severe-covid-192026-10-08 https://evidence-hub.com/study/5068-combination-of-tofacitinib-and-tacrolimus-therapy-in-refractory2026-10-08 https://evidence-hub.com/study/5069-dacron-vascular-grafts-a-long-term-solution-for-short-renal-vein2026-10-08 https://evidence-hub.com/study/5070-effectiveness-of-sotrovimab-in-the-omicron-storm-time-a-case-series2026-10-08 https://evidence-hub.com/study/5071-reply-to-successful-early-use-of-anti-sars-cov-2-monoclonal2026-10-08 https://evidence-hub.com/study/5072-subcutaneous-emphysema-in-covid-19-managed-with-surgical-tracheostomy2026-10-08 https://evidence-hub.com/study/5073-ab1319-efficacy-and-safety-of-the-treatment-with-jak-inhibitors-in2026-10-08 https://evidence-hub.com/study/5074-revolutionizing-fistula-treatment-a-case-series-on-the-application-of2026-10-19 https://evidence-hub.com/study/5075-advancing-intracranial-tumor-treatment-through-gyroscopic2026-10-08 https://evidence-hub.com/study/5076-case-report-robust-and-durable-response-to-the-combination-of2026-10-08 https://evidence-hub.com/study/5077-combination-of-liposomal-mitoxantrone-venetoclax-homoharringtonine2026-10-08 https://evidence-hub.com/study/5078-the-use-of-inhaled-epoprostenol-for-acute-respiratory-distress2026-10-08 https://evidence-hub.com/study/5079-early-covid-19-treatment-with-sotrovimab-in-high-risk-beta2026-10-08 https://evidence-hub.com/study/5081-emergency-awake-laparotomy-using-neuraxial-anaesthesia-a-case-series2026-10-08 https://evidence-hub.com/study/5082-efficacy-and-safety-of-hand-suturing-technique-application-in-the2026-10-08 https://evidence-hub.com/study/5084-d107-20-ivig-for-rituximab-treated-patients-with-prolonged-covid-19-a2026-10-08 https://evidence-hub.com/study/5085-cerebellar-perfusion-changes-after-repetitive-deep-transcranial2026-10-19 https://evidence-hub.com/study/5086-simultaneous-bilateral-endobronchial-valve-insertion-for-management2026-10-08 https://evidence-hub.com/study/5087-clinical-characteristics-and-assessment-of-risk-factors-in-patients2026-10-08 https://evidence-hub.com/study/5088-steroid-sparing-effect-of-anakinra-in-giant-cell-arteritis-a-case2026-10-08 https://evidence-hub.com/study/5089-ab0690-use-of-mycophenolate-in-systemic-sclerosis-case-series2026-10-08 https://evidence-hub.com/study/5090-ab0161-early-initiation-of-quadruple-therapy-in-patients-with-anti2026-10-08 https://evidence-hub.com/study/5092-bronchoscopic-improvement-of-tracheobronchitis-due-to-methicillin2026-10-06 https://evidence-hub.com/study/5093-three-cases-of-hospitalized-legionella-pneumonia-patients2026-10-08 https://evidence-hub.com/study/5094-rhodococcus-equi-pneumonia-in-a-patient-with-human-immunodeficiency2026-10-08 https://evidence-hub.com/study/5095-cutaneous-phaeohyphomycosis-in-a-hematopoietic-stem-cell-transplant2026-10-08 https://evidence-hub.com/study/5096-case-report-acute-interstitial-pneumonia-as-the-initial-presentation2026-10-08 https://evidence-hub.com/study/5097-diagnosis-and-management-of-mixed-chlamydia-abortus-and-psittaci2026-10-08 https://evidence-hub.com/study/5098-giant-abdominal-haematoma-and-rapid-multidrug-resistant-infection2026-10-13 https://evidence-hub.com/study/5099-novel-use-of-oral-delafloxacin-monotherapy-in-staphylococcal2026-10-08 https://evidence-hub.com/study/5100-managing-multidrug-resistant-stenotrophomonas-maltophilia-sepsis-in-a2026-10-13 https://evidence-hub.com/study/5101-avoidance-of-tracheal-intubation-using-awake-prone-positioning-in-a2026-10-08 https://evidence-hub.com/study/5102-chlamydia-psittaci-pneumonia-without-cough-recovery-case-report-and2026-10-08 https://evidence-hub.com/study/5103-effective-sequential-therapy-of-linezolid-and-contezolid-against-ha2026-10-08 https://evidence-hub.com/study/5104-case-report-effective-use-of-omadacycline-in-japanese-spotted-fever2026-10-08 https://evidence-hub.com/study/5105-case-report-from-a-pediatric-multidrug-resistant-tuberculosis-case2026-10-08 https://evidence-hub.com/study/5106-case-report-co-infection-of-tuberculosis-and-pertussis-in-a-47-day2026-10-08 https://evidence-hub.com/study/5107-amiodarone-induced-pulmonary-toxicity-with-severe-pulmonary-fibrosis2026-10-08 https://evidence-hub.com/study/5108-subcutaneous-apomorphine-induced-pneumonitis-an-uncommon-pulmonary2026-10-08 https://evidence-hub.com/study/5109-dalbavancin-to-complete-a-prolonged-antibiotic-course-for-persistent2026-10-08 https://evidence-hub.com/study/5110-voriconazole-induced-pancreatitis-despite-therapeutic-trough2026-10-08 https://evidence-hub.com/study/5111-persistent-sars-cov-2-infection-in-an-immunocompromised-host-treated2026-10-08 https://evidence-hub.com/study/5112-fatal-catheter-related-hematogenous-disseminated-mssa-sepsis-in-an2026-10-08 https://evidence-hub.com/study/5113-community-acquired-legionnaires-disease-presenting-with2026-10-08 https://evidence-hub.com/study/5114-when-prior-exposure-doesn-t-protect-imported-plasmodium-falciparum2026-10-08 https://evidence-hub.com/study/5115-treatment-of-post-neurosurgical-ventriculitis-and-scalp-infection2026-10-08 https://evidence-hub.com/study/5116-aortoesophageal-fistula-caused-by-mycobacterium-bovis-following2026-10-08 https://evidence-hub.com/study/5117-salvage-treatment-of-ventilator-associated-pneumonia-using-sulbactam2026-10-08 https://evidence-hub.com/study/5118-severe-legionnaires-disease-refractory-to-azithromycin-are-quinolones2026-10-08 https://evidence-hub.com/study/5119-diagnosis-of-chlamydia-psittaci-pneumonia-using-targeted-next2026-10-08 https://evidence-hub.com/study/5120-successful-use-of-sulbactam-durlobactam-in-treating-carbapenem2026-10-08 https://evidence-hub.com/study/5121-a-case-of-septicaemia-infection-induced-by-vancomycin-resistant2026-10-08 https://evidence-hub.com/study/5122-adjuvant-molecular-hydrogen-facilitates-immunosuppressant-tapering2026-10-13 https://evidence-hub.com/study/5123-secondary-spontaneous-pneumothorax-due-to-extensive-pulmonary2026-10-08 https://evidence-hub.com/study/5124-atypical-presentation-of-multidrug-resistant-acinetobacter-baumannii2026-10-08 https://evidence-hub.com/study/5125-corynebacterium-jeikeium-empyema-in-an-immunocompetent-adult-first2026-10-08 https://evidence-hub.com/study/5126-fulminant-aeromonas-caviae-bacteremia-with-migratory-myalgia-a-case2026-10-08 https://evidence-hub.com/study/5127-lethal-legionella-pneumonia-with-bacteremia-due-to-serotype-3-co2026-10-08 https://evidence-hub.com/study/5128-a-clinically-significant-interaction-between-voriconazole-and2026-10-08 https://evidence-hub.com/study/5129-pseudomonas-aeruginosa-a-rare-cause-of-necrotizing-fasciitis2026-10-08 https://evidence-hub.com/study/5130-challenge-of-cupriavidus-gilardii-infection-in-an-immunocompromised2026-10-08 https://evidence-hub.com/study/5131-intramedullary-spinal-cord-abscess-with-brain-abscess-secondary-to2026-10-08 https://evidence-hub.com/study/5132-successful-treatment-with-sulbactam-durlobactam-for-severe-acute2026-10-08 https://evidence-hub.com/study/5133-finegoldia-magna-infection-in-the-lumbar-intervertebral-disc2026-10-08 https://evidence-hub.com/study/5134-revumenib-induced-qtc-prolongation-leading-to-multiple-episodes-of2026-10-19 https://evidence-hub.com/study/5135-severe-pneumonia-caused-by-legionella-pneumophila-associated-with2026-10-08 https://evidence-hub.com/study/5136-unusual-case-of-myroides-odoratimimus-infection-in-a-cancer-patient2026-10-13 https://evidence-hub.com/study/5137-sepsis-after-the-altemeier-procedure-a-case-report2026-10-08 https://evidence-hub.com/study/5138-aztreonam-plus-ceftazidime-avibactam-for-post-neurosurgical2026-10-08 https://evidence-hub.com/study/5139-igg4-related-disease-with-lung-and-kidney-involvement-a-case-report2026-10-08 https://evidence-hub.com/study/5140-lung-squamous-cell-carcinoma-complicated-with-immune-checkpoint2026-10-08 https://evidence-hub.com/study/5141-tuberculosis-associated-immune-reconstitution-inflammatory-syndrome2026-10-08 https://evidence-hub.com/study/5142-omadacycline-associated-anticardiolipin-antibody-positivity-and2026-10-08 https://evidence-hub.com/study/5143-challenging-manifestations-of-anca-associated-vasculitis-treated-with2026-10-08 https://evidence-hub.com/study/5144-favorable-clinical-outcome-of-recurrent-deep-chest-wall-infection2026-10-08 https://evidence-hub.com/study/5145-a-56-year-old-male-farmer-from-china-with-severe-fever-with2026-10-08 https://evidence-hub.com/study/5146-an-acute-case-of-exogenous-lipoid-pneumonia-which-developed-in-tent2026-10-08 https://evidence-hub.com/study/5147-elizabethkingia-meningoseptica-case-report-on-an-emerging-pathogen2026-10-08 https://evidence-hub.com/study/5148-case-report-expanded-spectrum-beta-lactamase-producing-klebsiella2026-10-08 https://evidence-hub.com/study/5154-navigating-laboratory-investigations-for-an-accurate-assessment-of2026-10-08 https://evidence-hub.com/study/5155-efficacy-of-omadacycline-in-the-treatment-of-legionella-pneumonia-a2026-10-08 https://evidence-hub.com/study/5156-severe-pneumonia-due-to-concurrent-legionella-pneumophila-and2026-10-08 https://evidence-hub.com/study/5157-nocardia-nova-bacteremia-and-viral-pneumonia-in-a-breast-cancer2026-10-08 https://evidence-hub.com/study/5158-severe-rhodococcus-equi-pneumonia-following-hepatic-arterial-infusion2026-10-08 https://evidence-hub.com/study/5159-bronchoscopic-resolution-of-refractory-atelectasis-in-a-toddler-with2026-10-08 https://evidence-hub.com/study/5160-deucravacitinib-improved-interstitial-pneumonia-along-with-kl-62026-10-08 https://evidence-hub.com/study/5161-community-acquired-pneumonia-caused-by-micrococcus-antarcticus-a-rare2026-10-08 https://evidence-hub.com/study/5162-mycoplasma-hominis-pneumonia-presented-as-a-cavitary-mass-with-a-halo2026-10-08 https://evidence-hub.com/study/5163-case-report-disitamab-vedotin-combined-with-immunotherapy2026-10-08 https://evidence-hub.com/study/5164-combined-intravenous-ribavirin-and-recombinant-human-interferon-1b2026-10-08 https://evidence-hub.com/study/5165-case-report-of-severe-chlamydia-psittaci-pneumonia-treated-with2026-10-08 https://evidence-hub.com/study/5166-c57-07-a-chill-in-the-air-a-fire-in-the-lungs-legionella-pneumonia2026-10-08 https://evidence-hub.com/study/5167-late-onset-cytomegalovirus-pneumonia-after-autologous-stem-cell2026-10-08 https://evidence-hub.com/study/5168-levofloxacin-induced-fatal-hypoglycaemia-in-a-non-diabetic-patient-a2026-10-08 https://evidence-hub.com/study/5169-acquired-subglottic-stenosis-in-a-2-month-old-infant-after-prolonged2026-10-08 https://evidence-hub.com/study/5170-case-report-omadacycline-in-the-treatment-of-macrolide-unresponsive2026-10-08 https://evidence-hub.com/study/5171-oritavancin-as-rescue-therapy-in-severe-methicillin-resistant2026-10-08 https://evidence-hub.com/study/5172-a-case-of-chronic-eosinophilic-pneumonia-associated-with-rheumatoid2026-10-08 https://evidence-hub.com/study/5173-severe-community-acquired-pneumonia-caused-by-methicillin-sensitive2026-10-08 https://evidence-hub.com/study/5174-omadacycline-in-the-treatment-of-severe-q-fever-pneumonia-during-an2026-10-08 https://evidence-hub.com/study/5175-mycoplasma-pneumoniae-associated-cerebral-infarction-in-a-child-a2026-10-08 https://evidence-hub.com/study/5176-broncho-biliary-fistula-caused-by-a-left-hydatic-cyst-a-case-report2026-10-08 https://evidence-hub.com/study/5177-caspofungin-combined-with-tmp-smz-in-treatment-of-intractable-acute2026-10-08 https://evidence-hub.com/study/5178-successful-management-of-chronic-eosinophilic-pneumonia-triggered-by2026-10-08 https://evidence-hub.com/study/5179-case-report-bacteriophage-antibiotic-therapy-for-extensively-drug2026-10-08 https://evidence-hub.com/study/5180-efficacy-of-pola-r-chp-and-autologous-stem-cell-transplantation-in2026-10-08 https://evidence-hub.com/study/5181-a-case-report-of-telitacicept-in-the-treatment-of-immunocompromised2026-10-08 https://evidence-hub.com/study/5182-efficacy-of-caspofungin-combined-with-clindamycin-for-pneumocystis2026-10-08 https://evidence-hub.com/study/5183-case-report-intra-aortic-balloon-pump-in-a-patient-with-refractory2026-10-08 https://evidence-hub.com/study/5184-fecal-microbiota-transplantation-in-severe-pneumonia-a-case-report-on2026-10-08 https://evidence-hub.com/study/5185-enfortumab-vedotin-induced-interstitial-lung-disease-a-first-case2026-10-08 https://evidence-hub.com/study/5186-combination-therapy-with-toripalimab-and-lenvatinib-in-metastatic2026-10-08 https://evidence-hub.com/study/5187-case-report-acute-exacerbation-of-interstitial-pneumonia-related-to2026-10-08 https://evidence-hub.com/study/5188-japanese-spotted-fever-complicated-with-pleural-effusion-in-zhejiang2026-10-08 https://evidence-hub.com/study/5189-infantile-achalasia-cardia-a-rare-case-report-of-a-3-month-old-female2026-10-08 https://evidence-hub.com/study/5190-venetoclax-in-the-treatment-of-secondary-plasma-cell-leukemia-with2026-10-08 https://evidence-hub.com/study/5191-spanish-experience-on-the-efficacy-of-airways-clearance-techniques-in2026-10-08 https://evidence-hub.com/study/5192-a-rare-case-of-legionella-bozemanae-leading-to-necrotizing-pneumonia2026-10-08 https://evidence-hub.com/study/5193-efficacy-of-convalescent-plasma-therapy-in-immunocompromised-patients2026-10-08 https://evidence-hub.com/study/5194-infliximab-in-the-treatment-of-tislelizumab-induced-steroid2026-10-08 https://evidence-hub.com/study/5195-successful-treatment-of-rheumatoid-arthritis-associated-interstitial2026-10-08 https://evidence-hub.com/study/5196-telitacicept-treatment-refractory-lupus-nephritis-a-case-report2026-10-08 https://evidence-hub.com/study/5197-re-challenging-with-nivolumab-in-metastatic-renal-cell-carcinoma2026-10-08 https://evidence-hub.com/study/5198-case-report-afatinib-induced-interstitial-pneumonia-experiences-and2026-10-08 https://evidence-hub.com/study/5199-ct-manifestations-of-novel-coronavirus-pneumonia-a-case-report2026-10-08 https://evidence-hub.com/study/5200-pediatric-exogenous-lipoid-pneumonia-caused-by-paraffin-oil2026-10-08 https://evidence-hub.com/study/5201-covid-19-pneumonia-during-long-term-migraine-prophylaxis-with2026-10-08 https://evidence-hub.com/study/5202-isolated-igg4-related-lung-disease-a-case-report2026-10-08 https://evidence-hub.com/study/5203-effect-of-chest-physiotherapy-technique-on-bilateral-bronchial2026-10-08 https://evidence-hub.com/study/5204-atypical-legionella-pneumophila-encephalopathy-lacking-respiratory2026-10-08 https://evidence-hub.com/study/5205-severe-polymicrobial-pneumonia-with-septicemia-after-interruption-of2026-10-08 https://evidence-hub.com/study/5206-bimekizumab-and-progressive-pulmonary-fibrosis-in-severe-psoriasis-a2026-10-08 https://evidence-hub.com/study/5207-voriconazole-pseudotoxicity-a-case-report-highlighting-the-importance2026-10-08 https://evidence-hub.com/study/5208-neonatal-methicillin-resistant-staphylococcus-aureus-pneumonia2026-10-08 https://evidence-hub.com/study/5209-overreliance-on-eeg-normalization-a-case-report-of-dee-swas-treated2026-10-08 https://evidence-hub.com/study/5210-rhodococcus-equi-pneumonia-in-kidney-transplant-recipient-affected-by2026-10-06 https://evidence-hub.com/study/5211-drug-induced-interstitial-pneumonia-due-to-application-of-folfox-as2026-10-06 https://evidence-hub.com/study/5215-solithromycin-a-novel-fluoroketolide-for-the-treatment-of-community2026-10-19 https://evidence-hub.com/study/5216-a-review-of-the-comparative-in-vitro-activities-of-12-antimicrobial2026-10-08 https://evidence-hub.com/study/5217-proof-of-concept-performance-testing-in-models2026-10-19 https://evidence-hub.com/study/5218-the-safety-profile-of-moxifloxacin-and-other-fluoroquinolones-in2026-10-19 https://evidence-hub.com/study/5219-current-management-of-acute-bacterial-rhinosinusitis-and-the-role-of2026-10-19 https://evidence-hub.com/study/5220-streptococcus-pneumoniae-as-an-agent-of-nosocomial-infection2026-10-08 https://evidence-hub.com/study/5221-comparing-several-treatments-with-antibiotics-for-community-acquired2026-10-08 https://evidence-hub.com/study/5222-new-developments-in-antibacterial-choice-for-lower-respiratory-tract2026-10-19 https://evidence-hub.com/study/5223-why-do-we-need-to-eradicate-pathogens-in-respiratory-tract-infections2026-10-08 https://evidence-hub.com/study/5224-clinical-efficacy-and-cost-benefit-ratio-of-current-treatment-of-mrsa2026-10-08 https://evidence-hub.com/study/5225-tigecycline-for-the-treatment-of-patients-with-community-acquired2026-10-19 https://evidence-hub.com/study/5226-blood-and-respiratory-diffusion-of-antibiotics-a-critical-analysis-of2026-10-08 https://evidence-hub.com/study/5227-clarithromycin-biaxin-extended-release-tablet-a-therapeutic-review2026-10-19 https://evidence-hub.com/study/5228-from-pneumococcus-to-pseudomonas-the-antibacterial-behaviour-through2026-10-08 https://evidence-hub.com/study/5229-immunopathogenesis-molecular-phenotyping-and-host-directed2026-10-13 https://evidence-hub.com/study/5230-bacterial-spectrum-and-antibiotic-susceptibility-infection-patterns2026-10-08 https://evidence-hub.com/study/5231-nanotechnology-enabled-strategies-to-overcome-antibiotic-resistance2026-10-08 https://evidence-hub.com/study/5232-resistance-to-lefamulin-an-evaluation-of-data-from-in-vitro2026-10-08 https://evidence-hub.com/study/5233-avibactam-based-combinations-for-the-treatment-of-multidrug-resistant2026-10-08 https://evidence-hub.com/study/5234-antibiotic-antagonism-in-orientia-tsutsugamushi-infection-a-narrative2026-10-08 https://evidence-hub.com/study/5235-plazomicin-a-promising-novel-antimicrobial-in-the-era-of-bacterial2026-10-13 https://evidence-hub.com/study/5236-chlamydia-beyond-the-genital-tract-a-major-contributor-to-community2026-10-08 https://evidence-hub.com/study/5237-therapeutic-strategies-for-multi-resistant-escherichia-coli-in2026-10-13 https://evidence-hub.com/study/5238-practical-recommendations-for-infectious-prophylaxis-and-vaccination2026-10-08 https://evidence-hub.com/study/5239-legionellosis-global-epidemiology-and-current-perspectives-on2026-10-13 https://evidence-hub.com/study/5240-epidemiology-treatment-and-outcomes-of-antimicrobial-resistant2026-10-08 https://evidence-hub.com/study/5241-comparison-of-the-effect-of-co-trimoxazole-versus-co-trimoxazole-and2026-10-13 https://evidence-hub.com/study/5242-diagnostic-methods-and-therapeutics-strategies-of-legionella2026-10-08 https://evidence-hub.com/study/5243-unusual-susceptibility-to-vancomycin-in-elizabethkingia2026-10-08 https://evidence-hub.com/study/5244-advanced-multiscale-inhalation-platforms-for-treatment-of-pulmonary2026-10-08 https://evidence-hub.com/study/5245-phage-therapy-against-klebsiella-pneumoniae-infections-integrating2026-10-13 https://evidence-hub.com/study/5246-clinical-and-epidemiological-landscape-of-antimicrobial-resistance2026-10-08 https://evidence-hub.com/study/5247-the-silent-threat-unveiling-pathogenicity-and-antimicrobial2026-10-13 https://evidence-hub.com/study/5248-rifampicin-as-an-antivirulence-adjunct-in-hypervirulent2026-10-08 https://evidence-hub.com/study/5249-taming-the-inflammation-the-role-of-corticosteroids-in-pediatric2026-10-08 https://evidence-hub.com/study/5250-aconitum-tanguticum-maxim-stapf-a-review-of-its-traditional-uses2026-10-08 https://evidence-hub.com/study/5251-integrative-traditional-chinese-medicine-strategies-for-refractory2026-10-08 https://evidence-hub.com/study/5252-addressing-antimicrobial-resistance-current-challenges-emerging2026-10-08 https://evidence-hub.com/study/5253-molecular-epidemiology-and-multilevel-drug-resistance-mechanisms-of2026-10-13 https://evidence-hub.com/study/5254-animal-venom-pharmacological-resources-exploiting-bioactive-peptides2026-10-08 https://evidence-hub.com/study/5255-a-comprehensive-review-of-emerging-therapeutic-strategies-against2026-10-08 https://evidence-hub.com/study/5256-advancements-in-superparamagnetic-iron-oxide-nanoparticles-for2026-10-08 https://evidence-hub.com/study/5257-infections-and-car-t-cells-for-the-treatment-of-lymphoid-malignancies2026-10-08 https://evidence-hub.com/study/5258-evolution-of-antimicrobial-resistance-in-acinetobacter-baumannii-and2026-10-13 https://evidence-hub.com/study/5259-current-status-of-antimicrobial-resistance-in-indian-healthcare2026-10-13 https://evidence-hub.com/study/5260-bispecific-antibodies-in-b-cell-lymphomas-mechanisms-efficacy2026-10-08 https://evidence-hub.com/study/5261-therapeutic-management-of-health-care-associated-pneumonia2026-10-13 https://evidence-hub.com/study/5262-acinetobacter-baumannii-mechanisms-of-antibiotic-resistance-quorum2026-10-08 https://evidence-hub.com/study/5263-virulence-and-resistance-mechanisms-in-multidrug-resistant2026-10-08 https://evidence-hub.com/study/5264-overcoming-antibiotic-resistance-and-treating-bacterial-infections2026-10-08 https://evidence-hub.com/study/5265-antibiotic-prophylaxis-in-patients-undergoing-oncologic-head-and-neck2026-10-06 https://evidence-hub.com/study/5266-gut-microbiota-and-sarcoidosis-a-concise-review2026-10-06 https://evidence-hub.com/study/5267-clinical-and-epidemiological-features-and-antimicrobial2026-10-08 https://evidence-hub.com/study/5268-cardiac-complications-in-patients-with-community-acquired-pneumonia-a2026-10-08 https://evidence-hub.com/study/5270-prevalence-of-atypical-pathogens-in-patients-with-cough-and-community2026-10-08 https://evidence-hub.com/study/5271-blood-cultures-for-community-acquired-pneumonia-are-they-worthy-of2026-10-08 https://evidence-hub.com/study/5272-systematic-review-of-the-efficacy-and-safety-of-antiretroviral-drugs2026-10-08 https://evidence-hub.com/study/5273-imipenem-resistance-of-pseudomonas-in-pneumonia-a-systematic2026-10-08 https://evidence-hub.com/study/5274-corticosteroid-therapy-for-severe-community-acquired-pneumonia-a-meta2026-10-08 https://evidence-hub.com/study/5275-cardiovascular-events-after-community-acquired-pneumonia-a-global2026-10-08 https://evidence-hub.com/study/5276-systematic-review-on-antibiotic-therapy-for-pneumonia-in-children2026-10-08 https://evidence-hub.com/study/5277-methicillin-resistant-staphylococcus-aureus-an-overview-of-basic-and2026-09-29 https://evidence-hub.com/study/5278-antibacterial-class-is-not-obviously-important-in-outpatient2026-10-08 https://evidence-hub.com/study/5279-ventilator-associated-pneumonia-prevention-in-pediatric-patients2026-10-08 https://evidence-hub.com/study/5280-potential-rapid-diagnostics-vaccine-and-therapeutics-for-2019-novel2026-10-01 https://evidence-hub.com/study/5281-treatment-of-severe-hospital-acquired-and-ventilator-associated2026-10-08 https://evidence-hub.com/study/5282-atypical-pathogens-in-adult-community-acquired-pneumonia-and2026-10-08 https://evidence-hub.com/study/5283-ventilator-associated-pneumonia-in-critically-ill-patients-with-covid2026-10-08 https://evidence-hub.com/study/5284-stenotrophomonas-maltophilia-infections-a-systematic-review-and-meta2026-10-08 https://evidence-hub.com/study/5285-estimating-the-burden-of-antimicrobial-resistance-a-systematic2026-10-01 https://evidence-hub.com/study/5286-aetiological-agents-of-adult-community-acquired-pneumonia-in-japan2026-10-08 https://evidence-hub.com/study/5287-advancements-in-the-management-of-severe-community-acquired-pneumonia2026-10-08 https://evidence-hub.com/study/5288-five-day-antibiotic-treatment-for-community-acquired-bacterial2026-10-08 https://evidence-hub.com/study/5289-efficacy-of-chinese-herbal-injections-for-elderly-patients-with2026-10-08 https://evidence-hub.com/study/5290-chinese-patent-medicine-shufeng-jiedu-capsules-as-an-adjuvant-therapy2026-10-08 https://evidence-hub.com/study/5291-a-quality-assessment-of-evidence-based-guidelines-for-the-prevention2026-10-08 https://evidence-hub.com/study/5292-efficacy-and-safety-of-sitafloxacin-in-the-treatment-of-acute2026-10-13 https://evidence-hub.com/study/5293-could-xuebijing-injection-reduce-the-mortality-of-severe-pneumonia2026-10-08 https://evidence-hub.com/study/5294-macrolides-for-better-resolution-of-community-acquired-pneumonia-a2026-10-08 https://evidence-hub.com/study/5295-nanoparticles-in-antibacterial-therapy-a-systematic-review-of2026-10-08 https://evidence-hub.com/study/5296-guideline-concordant-therapy-for-community-acquired-pneumonia-in-the2026-10-08 https://evidence-hub.com/study/5297-efficacy-and-safety-of-hydroxychloroquine-for-hospitalized-covid-192026-10-08 https://evidence-hub.com/study/5298-value-of-hospital-antimicrobial-stewardship-programs-asps-a2026-10-01 https://evidence-hub.com/study/5299-the-efficacy-and-safety-of-doripenem-in-the-treatment-of-acute2026-10-13 https://evidence-hub.com/study/5300-colistin-nephrotoxicity-meta-analysis-of-randomized-controlled-trials2026-10-01 https://evidence-hub.com/study/5301-community-acquired-pneumonia-similarities-and-differences-between2026-10-08 https://evidence-hub.com/study/5302-efficacy-and-safety-of-tigecycline-for-complicated-urinary-tract2026-10-13 https://evidence-hub.com/study/5303-comparative-efficacy-of-oral-chinese-patent-medicine-for-chronic2026-10-02 https://evidence-hub.com/study/5304-duration-of-antimicrobial-treatment-in-adult-patients-with-pneumonia2026-10-08 https://evidence-hub.com/study/5305-comparative-efficacy-and-safety-of-potassium-competitive-acid2026-10-16 https://evidence-hub.com/study/5306-systematic-review-and-meta-analysis-of-the-efficacy-and-safety-of2026-10-08 https://evidence-hub.com/study/5307-systematic-review-of-antimicrobial-combination-options-for-pandrug2026-10-08 https://evidence-hub.com/study/5308-the-multifaceted-nature-of-antimicrobial-peptides-current-synthetic2026-10-01 https://evidence-hub.com/study/5309-empiric-antibiotic-therapy-for-moderate-to-severe-community-acquired2026-10-08 https://evidence-hub.com/study/5310-systematic-review-on-estimated-rates-of-nephrotoxicity-and2026-10-05 https://evidence-hub.com/study/5311-in-vitro-and-in-vivo-antibacterial-activities-of-dc-159a-a-new2026-10-20 https://evidence-hub.com/study/5312-prediction-of-antimicrobial-resistance-in-klebsiella-pneumoniae-using2026-10-19 https://evidence-hub.com/study/5313-performance-in-practice-bacteriological-efficacy-in-patients-with2026-10-06 https://evidence-hub.com/study/5314-in-vitro-and-in-vivo-antibacterial-activity-of-modithromycin-against2026-10-08 https://evidence-hub.com/study/5315-in-vitro-and-in-vivo-antibacterial-activities-of-cs-023-ro4908463-a2026-10-08 https://evidence-hub.com/study/5316-in-vivo-efficacy-of-human-simulated-regimens-of-carbapenems-and2026-10-20 https://evidence-hub.com/study/5317-protecting-newborns-from-multidrug-resistant-infections-the-emerging2026-10-13 https://evidence-hub.com/study/5318-development-of-membrane-targeting-cannabigerol-derivatives-as-potent2026-10-13 https://evidence-hub.com/study/5319-nanomedicines-for-pulmonary-drug-delivery-overcoming-barriers-in-the2026-10-08 https://evidence-hub.com/study/5320-advances-in-inhaled-nanoparticle-drug-delivery-for-pulmonary-disease2026-10-08 https://evidence-hub.com/study/5321-pulmonary-drug-delivery-for-infectious-diseases-cutting-edge2026-10-08 https://evidence-hub.com/study/5322-antimicrobial-peptides-in-preventive-medicine-current-perspectives-on2026-10-13 https://evidence-hub.com/study/5323-clinical-implementation-of-endolysins-targeting-gram-positive2026-10-08 https://evidence-hub.com/study/5324-prophylactic-and-therapeutic-efficacy-of-acinetobacter-phage-rm-a12026-10-13 https://evidence-hub.com/study/5325-precision-nanomedicine-for-pulmonary-diseases-from-molecular2026-10-08 https://evidence-hub.com/study/5326-re-emergence-of-bacteriophages-and-their-products-as-antibacterial2026-10-13 https://evidence-hub.com/study/5327-rare-or-unusual-non-fermenting-gram-negative-bacteria-therapeutic2026-10-13 https://evidence-hub.com/study/5328-in-vitro-genomic-characterization-and-pre-clinical-evaluation-of-a2026-10-13 https://evidence-hub.com/study/5329-isolation-and-characterization-of-ecm-vb1-bacteriophage-targeting2026-10-08 https://evidence-hub.com/study/5330-case-report-a-case-of-spinal-muscular-atrophy-with-extensively-drug2026-10-08 https://evidence-hub.com/study/5331-ventilator-associated-pneumonia-after-cardiac-arrest-and-prevention2026-10-08 https://evidence-hub.com/study/5332-pathobiology-of-eskape-biofilms-in-implant-infections-current2026-10-13 https://evidence-hub.com/study/5333-pulmonary-delivery-of-antibiotics-to-the-lungs-current-state-and2026-10-08 https://evidence-hub.com/study/5334-combination-therapy-versus-monotherapy-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/5335-unveiling-the-potential-of-spirulina-algal-extract-as-promising2026-10-13 https://evidence-hub.com/study/5336-natural-macrophage-membrane-coated-nanoparticles-as-a-multifaceted2026-10-08 https://evidence-hub.com/study/5337-therapeutic-management-strategies-among-immunocompetent-infants-with2026-10-08 https://evidence-hub.com/study/5338-a-systematic-review-of-recent-outbreaks-and-the-efficacy-and-safety2026-10-13 https://evidence-hub.com/study/5339-combating-klebsiella-pneumoniae-from-antimicrobial-resistance2026-10-13 https://evidence-hub.com/study/5340-stenotrophomonas-maltophilia-infection-associated-with-covid-19-a2026-10-13 https://evidence-hub.com/study/5341-proteome-mining-of-yersinia-enterocolitica-for-drug-targets-and2026-10-08 https://evidence-hub.com/study/5342-multifunctional-3d-printed-wound-dressings-containing-a-combination2026-10-08 https://evidence-hub.com/study/5343-pharmacological-evaluation-of-phage-antibiotic-synergism-against2026-10-08 https://evidence-hub.com/study/5344-zinc-oxide-resveratrol-nanoparticles-ameliorate-testicular2026-10-13 https://evidence-hub.com/study/5345-a-systematic-review-of-controlled-trials-can-patient-adherence-to2026-10-08 https://evidence-hub.com/study/5346-a-dual-challenge-coxiella-burnetii-endocarditis-in-a-patient-with2026-10-08 https://evidence-hub.com/study/5347-actinobacillus-ureae-may-be-a-critical-pathogen-in-patients-with2026-10-08 https://evidence-hub.com/study/5348-navigating-available-treatment-options-for-carbapenem-resistant2026-10-13 https://evidence-hub.com/study/5349-bacteria-responsive-nanostructured-drug-delivery-systems-for-targeted2026-10-13 https://evidence-hub.com/study/5350-cyclodextrin-a-prospective-nanocarrier-for-the-delivery-of2026-10-08 https://evidence-hub.com/study/5351-recent-advances-in-pharmaceutical-approaches-of-antimicrobial-agents2026-10-13 https://evidence-hub.com/study/5352-achyranthes-aspera-extracts-as-adjuvants-for-the-redressal-of2026-10-18 https://evidence-hub.com/study/5353-unraveling-topoisomerase-ia-gate-dynamics-in-presence-of-ppef-and-its2026-10-08 https://evidence-hub.com/study/5354-enteric-fever-diagnostic-challenges-and-the-importance-of-early2026-10-08 https://evidence-hub.com/study/5355-characterizing-the-bacteriophage-pkp-v1-as-a-potential-treatment-for2026-10-08 https://evidence-hub.com/study/5356-unlocking-the-potential-of-microalgae-derived-therapeutic-carriers2026-10-08 https://evidence-hub.com/study/5357-characterization-of-phage-hzy2308-against-acinetobacter-baumannii-and2026-10-08 https://evidence-hub.com/study/5358-monitoring-intracellular-replication-dynamics-unveils-high-proportion2026-10-08 https://evidence-hub.com/study/5359-gram-positive-pneumonia-possibilities-offered-by-phage-therapy2026-10-08 https://evidence-hub.com/study/5360-prosthetic-joint-infection-research-models-in-nzw-rabbits2026-10-08 https://evidence-hub.com/study/5361-effectiveness-of-a-novel-liposomal-methylglyoxal-tobramycin2026-10-08 https://evidence-hub.com/study/5362-invasive-infections-associated-with-the-use-of-probiotics-in-children2026-10-08 https://evidence-hub.com/study/5363-cyclodextrin-based-nanotransporters-as-a-versatile-tool-to-manage2026-10-08 https://evidence-hub.com/study/5364-opportunities-and-challenges-for-inhalable-nanomedicine-formulations2026-10-08 https://evidence-hub.com/study/5365-blood-stream-infections-from-mdr-bacteria2026-10-13 https://evidence-hub.com/study/5366-convalescent-plasma-therapy-as-a-conventional-trick-for-treating2026-10-08 https://evidence-hub.com/study/5367-potential-use-of-selected-natural-compounds-with-anti-biofilm-activity2026-10-13 https://evidence-hub.com/study/5369-comparison-of-levofloxacin-alone-and-azithromycin-combined-with2026-10-08 https://evidence-hub.com/study/5370-clinical-evaluation-of-levofloxacin-combined-with-ceftriaxone-sodium2026-10-08 https://evidence-hub.com/study/5371-comparison-of-levofloxacin-alone-and-cefuroxime-combined-with2026-10-08 https://evidence-hub.com/study/5372-observation-of-levofloxacin-in-the-treatment-of-elderly-diabetic2026-10-20 https://evidence-hub.com/study/5373-levofloxacin-for-patients-with-ventilator-associated-pneumonia-in-icu2026-10-20 https://evidence-hub.com/study/5378-assessment-of-the-combination-of-doripenem-plus-a-fluoroquinolone2026-10-08 https://evidence-hub.com/study/5381-an-open-label-uncontrolled-multicenter-study-to-evaluate-the-efficacy2026-10-20 https://evidence-hub.com/study/5382-efficacy-and-safety-of-carbostyril-in-patients-with-community2026-10-08 https://evidence-hub.com/study/5388-2002-guidelines-for-the-use-of-antimicrobial-agents-in-neutropenic2026-10-01 https://evidence-hub.com/study/5390-management-of-pneumonia-in-critically-ill-patients2026-10-01 https://evidence-hub.com/study/5391-secondary-bacterial-infections-in-patients-with-viral-pneumonia2026-10-01 https://evidence-hub.com/study/5392-surviving-sepsis-campaign-international-guidelines-for-management-of2026-10-01 https://evidence-hub.com/study/5393-preexisting-autoantibodies-to-type-i-ifns-underlie-critical-covid-192026-10-01 https://evidence-hub.com/study/5394-statins-and-outcomes-in-patients-admitted-to-hospital-with-community2026-09-30 https://evidence-hub.com/study/5395-executive-summary-management-of-adults-with-hospital-acquired-and2026-09-29 https://evidence-hub.com/study/5396-association-of-adverse-events-with-antibiotic-use-in-hospitalized2026-10-01 https://evidence-hub.com/study/5397-early-mortality-in-patients-with-community-acquired-pneumonia-causes2026-10-01 https://evidence-hub.com/study/5398-comparison-between-pathogen-directed-antibiotic-treatment-and2026-10-01 https://evidence-hub.com/study/5399-in-vitro-and-in-vivo-antibacterial-activities-of-dk-507k-a-novel2026-10-20 https://evidence-hub.com/study/5400-in-vitro-and-in-vivo-activities-of-am-1155-a-new-fluoroquinolone2026-10-08 https://evidence-hub.com/study/5401-in-vivo-efficacy-of-telithromycin-hmr3647-against-streptococcus2026-10-08 https://evidence-hub.com/study/5402-in-vitro-and-in-vivo-antibacterial-activities-of-l-084-a-novel-oral2026-10-08 https://evidence-hub.com/study/5403-serum-and-mucosal-nitric-oxide-levels-and-efficacy-of-sodium2026-10-08 https://evidence-hub.com/study/5404-pithecellobium-clypearia-extract-enriched-in-gallic-acid-and-luteolin2026-10-08 https://evidence-hub.com/study/5405-in-vivo-antibacterial-activity-of-nemonoxacin-a-novel-non-fluorinated2026-10-19 https://evidence-hub.com/study/5406-in-vivo-antibacterial-activity-of-chinfloxacin-a-new-fluoroquinolone2026-10-19 https://evidence-hub.com/study/5407-establishment-of-a-diverse-pheno-genotypic-challenge-set-of2026-10-08 https://evidence-hub.com/study/5408-meropenem-prevents-levofloxacin-induced-resistance-in-penicillin2026-10-08 https://evidence-hub.com/study/5409-in-vivo-activity-of-gemifloxacin-moxifloxacin-and-levofloxacin2026-10-08 https://evidence-hub.com/study/5410-macrolides-and-lactam-antibiotics-enhance-c3b-deposition-on-the2026-10-08 https://evidence-hub.com/study/5411-therapeutic-effect-of-oral-levofloxacin-ciprofloxacin-and-ampicillin2026-10-08 https://evidence-hub.com/study/5412-active-uptake-of-ulifloxacin-from-plasma-to-lung-that-controls-its2026-10-08 https://evidence-hub.com/study/5413-therapeutic-efficacy-of-levofloxacin-against-a-model-of-replicable2026-10-08 https://evidence-hub.com/study/5414-evaluation-of-survival-and-pharmacodynamic-relationships-for-five2026-10-08 https://evidence-hub.com/study/5415-antibacterial-activity-of-am-1155-against-penicillin-resistant2026-10-08 https://evidence-hub.com/study/5416-effect-of-tongue-exercise-on-improving-age-related-decline-in2026-10-08 https://evidence-hub.com/study/5417-3-3-diindolylmethane-improves-the-viral-pneumonia-outcomes-after2026-10-08 https://evidence-hub.com/study/5419-in-vivo-efficacy-of-phage-cocktails-against-carbapenem-resistance2026-10-08 https://evidence-hub.com/study/5420-exploring-the-mechanisms-of-the-huangqin-qingfei-decoction-in2026-10-08 https://evidence-hub.com/study/5421-the-lethal-k18-hace2-knock-in-mouse-model-mimicking-the-severe2026-10-08 https://evidence-hub.com/study/5422-efficacy-of-the-interferon-inducer-tilorone-and-its-combination-with2026-10-08 https://evidence-hub.com/study/5423-the-safety-and-efficacy-of-imatinib-a-tyrosine-kinase-inhibitor-for2026-10-08 https://evidence-hub.com/study/5424-the-combine-pneumonia-model-a-multicenter-study-to-standardize-a2026-10-08 https://evidence-hub.com/study/5426-development-and-validation-of-a-rabbit-model-of-pseudomonas2026-10-08 https://evidence-hub.com/study/5427-a-robust-pneumonia-model-in-immunocompetent-rodents-to-evaluate2026-10-08 https://evidence-hub.com/study/5428-preclinical-evaluation-of-the-safety-toxicity-and-efficacy-of2026-10-08 https://evidence-hub.com/study/5430-development-of-a-new-acinetobacter-baumannii-pneumonia-rabbit-model2026-10-08 https://evidence-hub.com/study/5431-pharmacological-mechanisms-of-ma-xing-shi-gan-decoction-in-treating2026-10-08 https://evidence-hub.com/study/5433-enhanced-anti-biofilm-activity-of-the-minocycline-and-gallium-nitrate2026-10-08 https://evidence-hub.com/study/5434-a-comprehensive-review-of-clinical-advances-in-the-antifibrotic-role2026-10-08 https://evidence-hub.com/study/5435-properties-of-18f-fapi-monitoring-of-acute-radiation-pneumonia-versus2026-10-08 https://evidence-hub.com/study/5436-examining-protective-efficacy-of-influenza-virus-na-containing-virus2026-10-08 https://evidence-hub.com/study/5437-inhaled-amikacin-for-pneumonia-treatment-and-dissemination-prevention2026-10-08 https://evidence-hub.com/study/5438-efficacy-of-ceftolozane-tazobactam-in-comparison-with-piperacillin2026-10-08 https://evidence-hub.com/study/5439-macrophage-induced-reduction-of-bacteriophage-density-limits-the2026-10-08 https://evidence-hub.com/study/5441-efficacy-and-safety-of-treamid-in-the-rehabilitation-of-patients2026-10-08 https://evidence-hub.com/study/5442-a-novel-in-vitro-metric-predicts-in-vivo-efficacy-of-inhaled-silver2026-10-08 https://evidence-hub.com/study/5445-bioactive-sesquiterpene-lactones-from-elephantopus-scaber-semi2026-10-08 https://evidence-hub.com/study/5446-gamma-irradiated-honey-its-medicinal-efficacy-and-biological2026-10-08 https://evidence-hub.com/study/5447-in-vivo-efficacy-and-pk-pd-modeling-of-kbp-7072-an-aminomethylcycline2026-10-08 https://evidence-hub.com/study/5448-macrocyclic-peptides-exhibit-antiviral-effects-against-influenza2026-10-08 https://evidence-hub.com/study/5449-in-vitro-modelling-of-bacterial-pneumonia-a-comparative-analysis-of2026-10-08 https://evidence-hub.com/study/5450-efficacy-and-safety-of-human-skin-microbiome-derived-strains-as2026-10-19 https://evidence-hub.com/study/5451-inhalation-of-n-chlorotaurine-is-an-effective-treatment-of2026-10-08 https://evidence-hub.com/study/5453-p-1260-beyond-plasma-defining-the-translation-value-of-epithelial2026-10-08 https://evidence-hub.com/study/5454-rezafungin-as-primary-prophylaxis-of-pneumocystis-jirovecii-pneumonia2026-10-08 https://evidence-hub.com/study/5455-efficacy-of-linezolid-in-monotherapy-q12h-versus-q8h-versus-combined2026-10-08 https://evidence-hub.com/study/5458-adaptation-of-sars-cov-2-in-balb-c-mice-for-testing-vaccine-efficacy2026-10-08 https://evidence-hub.com/study/5459-therapeutic-effectiveness-of-bacteriophage-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/5460-pharmacokinetics-and-efficacy-of-liposomal-polymyxin-b-in-a-murine2026-10-08 https://evidence-hub.com/study/5461-syrian-golden-hamsters-a-model-for-assessing-the-efficacy-of2026-10-08 https://evidence-hub.com/study/5462-rapid-adaptation-of-sars-cov-2-in-balb-c-mice-novel-mouse-model-for2026-10-08 https://evidence-hub.com/study/5464-996-p-therapeutic-effect-of-a-novel-long-acting-glp-1-gip-glucagon2026-10-19 https://evidence-hub.com/study/5465-the-engineered-lysin-cf-370-is-active-against-antibiotic-resistant2026-10-08 https://evidence-hub.com/study/5466-hmscs-treatment-attenuates-murine-herpesvirus-68-mhv-68-pneumonia2026-10-08 https://evidence-hub.com/study/5468-meropenem-loaded-cement-is-effective-in-preventing-gram-negative2026-10-08 https://evidence-hub.com/study/5469-medi3902-correlates-of-protection-against-severe-pseudomonas2026-10-08 https://evidence-hub.com/study/5470-rapid-and-broad-immune-efficacy-of-a-recombinant-five-antigen-vaccine2026-10-08 https://evidence-hub.com/study/5471-antibiotic-efficacy-varies-based-on-the-infection-model-and-treatment2026-10-08 https://evidence-hub.com/study/5472-hydrogen-therapy-and-its-future-prospects-for-ameliorating-covid-192026-10-08 https://evidence-hub.com/study/5473-combination-of-qingfei-huayu-decoction-and-targeted-nursing-care2026-10-08 https://evidence-hub.com/study/5474-efficacy-of-bacteriophage-treatment-against-carbapenem-resistant2026-10-08 https://evidence-hub.com/study/5475-antibiotic-resistance-of-pseudomonas-aeruginosa-in-pneumonia-at-a2026-10-01 https://evidence-hub.com/study/5476-the-resistance-mechanisms-of-bacteria-against-ciprofloxacin-and-new2026-10-08 https://evidence-hub.com/study/5477-recommendations-and-guidelines-for-the-treatment-of-pneumonia-in2026-10-08 https://evidence-hub.com/study/5478-antibiotic-resistance-threats-in-the-united-states-20192026-09-29 https://evidence-hub.com/study/5479-clinical-efficacy-of-newer-agents-in-short-duration-therapy-for2026-10-08 https://evidence-hub.com/study/5480-pseudomonas-aeruginosa-ventilator-associated-pneumonia-management2026-10-01 https://evidence-hub.com/study/5481-interaction-of-drug-and-granulocyte-mediated-killing-of-pseudomonas2026-10-08 https://evidence-hub.com/study/5482-optimal-exposures-of-ceftazidime-predict-the-probability-of2026-10-01 https://evidence-hub.com/study/5483-impact-of-initial-antibiotic-choice-on-mortality-from-pneumococcal2026-10-08 https://evidence-hub.com/study/5484-treatment-of-highly-virulent-extraintestinal-pathogenic-escherichia2026-10-01 https://evidence-hub.com/study/5485-possible-role-for-the-new-fluoroquinolones-levofloxacin-grepafloxacin2026-10-08 https://evidence-hub.com/study/5487-glycine-serine-and-threonine-metabolism-confounds-efficacy-of2026-10-01 https://evidence-hub.com/study/5488-the-treatment-of-legionnaires-disease2026-09-29 https://evidence-hub.com/study/5490-efficacy-and-tolerability-of-once-daily-oral-therapy-with2026-10-06 https://evidence-hub.com/study/5491-application-of-a-mathematical-model-to-prevent-in-vivo-amplification2026-10-01 https://evidence-hub.com/study/5492-the-implication-of-oxidative-stress-and-ampk-nrf2-antioxidative2026-10-01 https://evidence-hub.com/study/5493-aminoglycosides-an-overview2026-10-01 https://evidence-hub.com/study/5494-efficacy-of-levofloxacin-in-the-treatment-of-experimental2026-10-08 https://evidence-hub.com/study/5497-multi-drug-resistant-gram-negative-bacterial-pneumonia-etiology-risk2026-10-01 https://evidence-hub.com/study/5499-murine-oropharyngeal-aspiration-model-of-ventilator-associated-and2026-10-08 https://evidence-hub.com/study/5500-variability-of-murine-bacterial-pneumonia-models-used-to-evaluate2026-10-08 https://evidence-hub.com/study/5501-the-antimicrobial-activity-of-nanoparticles-present-situation-and2026-10-01 https://evidence-hub.com/study/5502-macaque-models-of-human-infectious-disease2026-10-01 https://evidence-hub.com/study/5503-feedback-dose-alteration-significantly-affects-probability-of2026-10-01 https://evidence-hub.com/study/5504-the-bactericidal-action-of-penicillin-in-vivo-the-participation-of2026-09-26 https://evidence-hub.com/study/5507-maximizing-efficacy-and-reducing-the-emergence-of-resistance2026-09-26 https://evidence-hub.com/study/5508-treatment-of-infections-caused-by-extended-spectrum-beta-lactamase2026-10-01 https://evidence-hub.com/study/5510-quantitative-assessment-of-combination-antimicrobial-therapy-against2026-10-01 https://evidence-hub.com/study/5511-infective-endocarditis-in-adults-diagnosis-antimicrobial-therapy-and2026-10-01 https://evidence-hub.com/study/5512-the-pulmonary-physician-in-critical-care-4-nosocomial-pneumonia2026-10-01 https://evidence-hub.com/study/5513-innovations-in-osteomyelitis-research-a-review-of-animal-models2026-10-19 https://evidence-hub.com/study/5514-a-risk-benefit-assessment-of-levofloxacin-in-respiratory-skin-and2026-10-20 https://evidence-hub.com/study/5515-global-strategy-for-the-diagnosis-management-and-prevention-of2026-10-01 https://evidence-hub.com/study/5516-antibiotics-and-bacterial-resistance-in-the-21st-century2026-10-01 https://evidence-hub.com/study/5517-baicalin-inhibits-biofilm-formation-attenuates-the-quorum-sensing2026-10-01 https://evidence-hub.com/study/5518-clinical-pharmacology-of-the-fluoroquinolones-studies-in-human2026-09-26 https://evidence-hub.com/study/5520-in-vitro-activity-of-antimicrobial-impregnated-catheters-against2026-10-19 https://evidence-hub.com/study/5521-synergy-of-fosfomycin-with-other-antibiotics-for-gram-positive-and2026-10-08 https://evidence-hub.com/study/5522-in-vitro-activity-of-bioactive-extracts-from-rare-actinomycetes2026-10-19 https://evidence-hub.com/study/5523-in-vitro-pharmacodynamic-evaluation-of-garenoxacin-against-quinolone2026-10-19 https://evidence-hub.com/study/5524-scutellaria-petiolata-hemsl-ex-lace-prain-lamiaceae-a-new-insight-in2026-10-08 https://evidence-hub.com/study/5525-acrab-tolc-inhibition-by-peptide-conjugated-phosphorodiamidate2026-10-08 https://evidence-hub.com/study/5526-endophytic-fungi-from-alstonia-boonei-de-wild-and-greenwayodendron2026-10-08 https://evidence-hub.com/study/5527-use-of-the-respiratory-fluoroquinolones-for-the-outpatient-management2026-10-08 https://evidence-hub.com/study/5528-antibiotic-activity-against-naive-and-induced-streptococcus2026-10-08 https://evidence-hub.com/study/5529-experience-accumulated-in-hospital-setting-with-levofloxacin-in2026-10-12 https://evidence-hub.com/study/5530-the-new-fluoroquinolones-a-critical-review2026-10-19 https://evidence-hub.com/study/5531-comparative-study-on-resistant-pattern-of-clinical-isolates-against2026-10-06 https://evidence-hub.com/study/5532-machine-learning-powered-profiling-rapid-identification-of-klebsiella2026-10-19 https://evidence-hub.com/study/5533-doripenem-in-hospital-infections-a-focus-on-nosocomial-pneumonia2026-10-13 https://evidence-hub.com/study/5534-in-vitro-activity-of-telithromycin-hmr3647-a-new-ketolide-against2026-10-08 https://evidence-hub.com/study/5535-activity-of-the-new-quinolone-wck-771-against-pneumococci2026-10-19 https://evidence-hub.com/study/5536-effect-of-levofloxacin-on-the-viability-of-intracellular-chlamydia2026-10-08 https://evidence-hub.com/study/5537-pharmacokinetic-pharmacodynamic-modelling-of-the-bactericidal2026-10-08 https://evidence-hub.com/study/5538-in-vitro-activity-of-beta-lactams-macrolides-telithromycin-and2026-10-08 https://evidence-hub.com/study/5539-ph-responsive-micelles-as-theranostic-agents-for-sonodynamic-therapy2026-10-06 https://evidence-hub.com/study/5540-evaluation-of-bacterial-kill-when-modelling-the-bronchopulmonary2026-10-08 https://evidence-hub.com/study/5541-circulating-outer-membrane-vesicles-from-gut-colonized-carbapenem2026-10-08 https://evidence-hub.com/study/5542-structural-basis-of-topoisomerase-targeting-by-delafloxacin2026-10-08 https://evidence-hub.com/study/5543-the-role-of-lactam-lactamase-inhibitor-combinations-in-multidrug2026-10-13 https://evidence-hub.com/study/5544-systematic-review-and-meta-analysis-of-colistin-plus-meropenem2026-10-08 https://evidence-hub.com/study/5545-readmissions-and-emergency-room-visits-following-outpatient-and2026-10-13 https://evidence-hub.com/study/5546-haemoptysis-as-a-presentation-of-an-infected-aortic-aneurysm-rupture2026-10-08 https://evidence-hub.com/study/5547-risk-factors-and-prescription-patterns-analysis-for-macrolide2026-10-08 https://evidence-hub.com/study/5548-flavonifractor-plautii-a-rare-cause-of-anaerobic-bacteremia2026-10-08 https://evidence-hub.com/study/5549-surfactant-therapy-using-vibrating-mesh-nebulizers-in-adults-with2026-10-08 https://evidence-hub.com/study/5550-multidrug-resistant-gram-negative-bacteria-in-lung-transplantation-a2026-10-13 https://evidence-hub.com/study/5551-tuberculosis-in-lung-and-heart-transplant-recipients2026-10-08 https://evidence-hub.com/study/5552-phage-cocktail-antibiotic-synergism-a-new-frontier-in-addressing2026-10-08 https://evidence-hub.com/study/5553-the-antibacterial-and-anti-biofilm-effects-of-novel-synthetized2026-10-12 https://evidence-hub.com/study/5554-acute-generalized-exanthematous-pustulosis-an-integrated-study-of-5032026-10-08 https://evidence-hub.com/study/5555-characterization-and-antimicrobial-activity-of-a-novel-lytic-phage-vb2026-10-08 https://evidence-hub.com/study/5556-endobronchial-closure-of-broncho-biliary-fistula-using-amplatzer2026-10-08 https://evidence-hub.com/study/5557-serotype-distribution-and-antimicrobial-resistance-of-streptococcus2026-10-08 https://evidence-hub.com/study/5558-pulmonary-inhalation-for-disease-treatment-basic-research-and2026-10-08 https://evidence-hub.com/study/5559-aminoglycosides-for-the-treatment-of-severe-infection-due-to2026-10-08 https://evidence-hub.com/study/5560-isolation-characterization-and-genomic-analysis-of-a-novel2026-10-08 https://evidence-hub.com/study/5561-unraveling-the-secrets-behind-the-multidrug-resistant-tuberculosis2026-10-08 https://evidence-hub.com/study/5562-1533-is-cation-adjusted-mueller-hinton-broth-camhb-appropriate-for2026-10-08 https://evidence-hub.com/study/5563-levofloxacin-use-in-the-elderly-focus-on-pneumonia2026-10-20 https://evidence-hub.com/study/5566-bacterial-infections-in-the-elderly-patient-focus-on-sitafloxacin2026-10-08 https://evidence-hub.com/study/5567-in-vitro-and-in-vivo-efficacy-studies-of-an-engineered-endolysin2026-10-19 https://evidence-hub.com/study/5568-in-vitro-evaluation-of-stability-and-hemostatic-efficacy-of-single2026-10-19 https://evidence-hub.com/study/5570-toxicity-and-efficacy-of-type-i-interferons-on-the-ocular-surface-in2026-10-19 https://evidence-hub.com/study/5571-in-vitro-irradiated-cancer-vaccine-enhances-anti-tumor-efficacy-of2026-10-19 https://evidence-hub.com/study/5572-the-efficacy-of-10-carbamide-peroxide-in-reversing-common-dietary2026-10-19 https://evidence-hub.com/study/5573-antibiofilm-efficacy-of-1-064-nm-neodymium-doped-yttrium-aluminum2026-10-19 https://evidence-hub.com/study/5574-skin-lightening-efficacy-of-leatherleaf-fern-extract-and-a2026-10-19 https://evidence-hub.com/study/5575-in-vitro-and-in-vivo-exploration-of-microbiome-derived-yeast-extract2026-10-19 https://evidence-hub.com/study/5576-cf33-hnis-antipdl1-enhances-immunogenicity-and-anti-tumor-efficacy-in2026-10-19 https://evidence-hub.com/study/5577-therapeutic-potential-of-fucoidan-in-cervical-cancer-as-a-modulatory2026-10-19 https://evidence-hub.com/study/5578-establishment-of-a-vsv-based-pseudovirus-platform-for-in-vitro-and-in2026-10-19 https://evidence-hub.com/study/5580-the-in-vitro-and-in-vivo-efficacy-of-ct-p59-against-gamma-delta-and2026-10-19 https://evidence-hub.com/study/5581-efficacy-of-glucocorticoids-for-the-treatment-of-macrolide-refractory2026-10-08 https://evidence-hub.com/study/5582-antimicrobial-efficacy-of-fruit-peels-eco-enzyme-against-enterococcus2026-10-19 https://evidence-hub.com/study/5583-mixture-of-mastic-gum-and-peppermint-extracts-promotes-hair-growth2026-10-19 https://evidence-hub.com/study/5584-reply-the-efficacy-of-penicillins-with-lactamase-inhibitor-or2026-10-08 https://evidence-hub.com/study/5585-oncolytic-adenovirus-co-expressing-il-12-and-shvegf-potentiates2026-10-19 https://evidence-hub.com/study/5586-cordycepin-enriched-cordyceps-militaris-extract-ara815-induces2026-10-19 https://evidence-hub.com/study/5587-pre-clinical-safety-and-efficacy-of-human-induced-pluripotent-stem2026-10-19 https://evidence-hub.com/study/5589-efficacy-of-copeptin-in-distinguishing-covid-19-pneumonia-from2026-10-08 https://evidence-hub.com/study/5590-antioxidant-anti-inflammatory-and-anti-wrinkle-effects-of-sargassum2026-10-19 https://evidence-hub.com/study/5591-abstract-7286-a-first-in-class-pd-1-vegf-il-2v-tri-specific-fusion2026-10-08 https://evidence-hub.com/study/5592-a-novel-strategy-to-enhance-the-bone-healing-efficacy-of-composite2026-10-19 https://evidence-hub.com/study/5594-fadraciclib-a-cdk2-cdk9-inhibitor-shows-efficacy-in-biliary-tract2026-10-19 https://evidence-hub.com/study/5595-exploring-the-safety-and-efficacy-of-organic-light-emitting-diode-in2026-10-19 https://evidence-hub.com/study/5596-selected-coffee-coffea-arabica-l-extracts-inhibit-intestinal2026-10-19 https://evidence-hub.com/study/5597-evaluation-of-the-efficacy-of-anthelmintic-drugs-against-trichinella2026-10-19 https://evidence-hub.com/study/5598-safety-and-efficacy-of-mg-dy-membrane-with-poly-l-lactic-acid-coating2026-10-19 https://evidence-hub.com/study/5599-evaluation-of-efficacy-safety-and-withdrawal-period-of-enrofloxacin2026-10-19 https://evidence-hub.com/study/5600-antagonistic-efficacy-of-symbiotic-bacterium-xenorhabdus-sp-scg2026-10-19 https://evidence-hub.com/study/5601-1651-in-vitro-synergy-test-and-clinical-outcome-of-antibiotics2026-10-08 https://evidence-hub.com/study/5602-efficacy-of-early-steroid-use-in-mycoplasma-pneumoniae-pneumonia2026-10-08 https://evidence-hub.com/study/5603-neuroprotective-effect-of-geijigadaehwang-tang-against-trimethyltin2026-10-19 https://evidence-hub.com/study/5604-tissue-resident-memory-car-t-cells-with-stem-like-characteristics2026-10-19 https://evidence-hub.com/study/5605-in-vitro-replication-inhibitory-activity-of-xanthorrhizol-against2026-10-19 https://evidence-hub.com/study/5606-polydatin-a-glycoside-of-resveratrol-induces-apoptosis-and-inhibits2026-10-19 https://evidence-hub.com/study/5607-a-review-of-in-vitro-and-in-vivo-studies-on-the-efficacy-of-herbal2026-10-19 https://evidence-hub.com/study/5608-safety-and-efficacy-of-a-novel-anti-cd19-chimeric-antigen-receptor-t2026-10-19 https://evidence-hub.com/study/5609-cd44-targeting-biocompatible-and-biodegradable-hyaluronic-acid-cross2026-10-19 https://evidence-hub.com/study/5610-uncovering-critical-properties-of-the-human-respiratory-syncytial2026-10-19 https://evidence-hub.com/study/5611-efficacy-and-safety-of-persimmon-leaf-formulated-with-green-tea-and2026-10-19 https://evidence-hub.com/study/5612-multi-functional-polymer-nanoparticles-with-enhanced-adipocyte-uptake2026-10-19 https://evidence-hub.com/study/5613-brc-mediated-rnai-targeting-of-use1-inhibits-tumor-growth-in-vitro2026-10-19 https://evidence-hub.com/study/5614-efficacy-of-serum-apelin-and-galectin-3-as-potential-predictors-of2026-10-08 https://evidence-hub.com/study/5615-real-world-evidence-of-levofloxacin-prophylaxis-in-elderly-patients2026-10-08 https://evidence-hub.com/study/5617-annual-and-seasonal-patterns-in-etiologies-of-pediatric-community2026-10-06 https://evidence-hub.com/study/5619-rational-stepwise-approach-for-mycoplasma-pneumoniae-pneumonia-in2026-10-01 https://evidence-hub.com/study/5621-chinese-guidelines-for-the-diagnosis-and-treatment-of-hospital2026-10-01 https://evidence-hub.com/study/5622-epidemiology-treatment-and-prevention-of-nosocomial-bacterial2026-10-01 https://evidence-hub.com/study/5624-refractory-mycoplasma-pneumoniae-pneumonia-in-children-early2026-10-01 https://evidence-hub.com/study/5625-susceptibilities-of-legionella-spp-to-newer-antimicrobials-in-vitro2026-10-01 https://evidence-hub.com/study/5626-maintaining-fluoroquinolone-class-efficacy-review-of-influencing2026-10-01 https://evidence-hub.com/study/5627-expert-consensus-on-the-diagnosis-and-treatment-of-macrolide2026-10-08 https://evidence-hub.com/study/5629-clinical-practice-guidelines-for-nursing-and-healthcare-associated2026-10-01 https://evidence-hub.com/study/5631-efficacy-and-safety-of-gemifloxacin-in-the-treatment-of-community2026-10-08 https://evidence-hub.com/study/5632-development-of-chitosan-cyclodextrin-nanospheres-for-levofloxacin2026-10-08 https://evidence-hub.com/study/5633-multidrug-resistant-gram-negative-bacteria-in-community-acquired2026-10-01 https://evidence-hub.com/study/5634-infectious-diseases-society-of-america-and-the-society-for-healthcare2026-10-01 https://evidence-hub.com/study/5635-in-vitro-evaluation-of-antibiotics-combinations-for-empirical-therapy2026-10-04 https://evidence-hub.com/study/5636-antimicrobial-peptides-ri8-and-rw8-target-bacterial-membranes-and2026-10-08 https://evidence-hub.com/study/5637-evaluation-of-resistance-modulation-in-mdr-pseudomonas-aeruginosa-and2026-10-13 https://evidence-hub.com/study/5638-a-systematic-review-of-antibiotic-resistance-trends-and-treatment2026-10-13 https://evidence-hub.com/study/5639-impact-of-a-pharmacist-driven-antimicrobial-stewardship-program-on2026-10-08 https://evidence-hub.com/study/5640-isolation-and-in-silico-prediction-of-potential-drug-like-compounds2026-10-19 https://evidence-hub.com/study/5641-efficacy-and-mechanism-of-chinese-herbal-medicine-banxia-houpo-tang2026-10-19 https://evidence-hub.com/study/5642-population-pharmacokinetics-and-exposure-response-analyses-for2026-10-08 https://evidence-hub.com/study/5644-radiologic-findings-as-a-determinant-and-no-effect-of-macrolide2026-10-08 https://evidence-hub.com/study/5645-emergence-of-multidrug-resistant-clones-in-levofloxacin2026-10-08 https://evidence-hub.com/study/5646-the-multi-herbal-decoction-sh003-alleviates-lps-induced-acute-lung2026-10-19 https://evidence-hub.com/study/5647-stress-ulcer-prophylaxis-during-invasive-mechanical-ventilation2026-10-08 https://evidence-hub.com/study/5651-design-and-preliminary-immunogenicity-evaluation-of-nipah-virus2026-10-19 https://evidence-hub.com/study/5652-dose-response-relationship-of-stereotactic-body-radiotherapy-for2026-10-19 https://evidence-hub.com/study/5653-antimicrobial-resistance-patterns-and-determinants-of-helicobacter2026-10-08 https://evidence-hub.com/study/5654-clinical-outcomes-associated-with-conditioning-regimens-in-patients2026-10-08 https://evidence-hub.com/study/5656-the-identification-of-effective-tumor-suppressing-neoantigens-using-a2026-10-19 https://evidence-hub.com/study/5657-a-review-of-different-vaccines-and-strategies-to-combat-covid-192026-10-08 https://evidence-hub.com/study/5660-commentary-on-efficacy-of-endoscopic-submucosal-dissection-of2026-10-08 https://evidence-hub.com/study/5661-engineering-receptor-binding-domain-and-heptad-repeat-domains-towards2026-10-19 https://evidence-hub.com/study/5662-thoracoscopic-segmentectomy-in-children-with-congenital-lung2026-10-08 https://evidence-hub.com/study/5663-injectable-basic-fibroblast-growth-factor-loaded-alginate-hyaluronic2026-10-08 https://evidence-hub.com/study/5665-novel-colistin-edta-combination-for-successful-eradication-of2026-10-08 https://evidence-hub.com/study/5672-label-free-affinity-screening-design-and-synthesis-of-inhibitors2026-10-19 https://evidence-hub.com/study/5673-attenuated-folfirinox-in-the-salvage-treatment-of-gemcitabine2026-10-06 https://evidence-hub.com/study/5675-effective-use-of-an-advanced-isolation-unit-during-the-covid-192026-10-19 https://evidence-hub.com/study/5677-randomized-phase-ii-study-comparing-weekly-docetaxel-cisplatin-vs2026-10-08 https://evidence-hub.com/study/5679-comparison-between-monitored-anesthesia-care-and-general-anesthesia2026-10-08 https://evidence-hub.com/study/5680-self-expandable-metal-stent-of-esophagogastric-junction-versus2026-10-08 https://evidence-hub.com/study/5683-irinotecan-leucovorin-and-5-fluorouracil-modified-folfiri-as-salvage2026-10-08 https://evidence-hub.com/study/5687-percutaneous-endoscopic-gastrostomy-for-enteral-nutrition2026-10-08 https://evidence-hub.com/study/5693-q-marker-identification-strategies-in-traditional-chinese-medicines-a2026-10-19 https://evidence-hub.com/study/5694-1053-biofilm-production-and-clinical-characteristics-of-s-maltophilia2026-10-08 https://evidence-hub.com/study/5696-the-therapeutic-effects-of-naringenin-on-bronchial-pneumonia-in2026-10-08 https://evidence-hub.com/study/5697-the-art-of-war-with-pseudomonas-aeruginosa-targeting-mex-efflux-pumps2026-10-08 https://evidence-hub.com/study/5698-efficacy-of-oseltamivir-in-the-treatment-of-patients-infected-with2026-10-08 https://evidence-hub.com/study/5699-from-q-fever-to-coxiella-burnetii-infection-a-paradigm-change2026-10-01 https://evidence-hub.com/study/5700-syzygium-aromaticum-extracts-as-a-potential-antibacterial-inhibitors2026-10-13 https://evidence-hub.com/study/5701-antimicrobial-activity-and-resistance-influencing-factors2026-10-01 https://evidence-hub.com/study/5703-review-on-multiple-facets-of-drug-resistance-a-rising-challenge-in2026-10-01 https://evidence-hub.com/study/5704-immunomodulatory-effects-of-fluoroquinolones-in-community-acquired2026-10-08 https://evidence-hub.com/study/5705-characterization-and-comparative-genomics-analysis-of-a-new2026-10-08 https://evidence-hub.com/study/5706-in-vitro-antibacterial-efficacy-of-plants-used-by-an-indian2026-10-08 https://evidence-hub.com/study/5707-antimicrobial-resistance-of-pseudomonas-aeruginosa-navigating2026-10-03 https://evidence-hub.com/study/5708-microbial-biofilm-a-review-on-formation-infection-antibiotic2026-10-13 https://evidence-hub.com/study/5709-pathfx-provides-mechanistic-insights-into-drug-efficacy-and-safety2026-10-08 https://evidence-hub.com/study/5711-genomic-characterization-of-a-new-phage-buct541-against-klebsiella2026-10-08 https://evidence-hub.com/study/5712-engineered-phage-with-antibacterial-crispr-cas-selectively-reduce-e2026-10-01 https://evidence-hub.com/study/5713-antibiotics-and-bacterial-resistance-a-short-story-of-an-endless-arms2026-10-01 https://evidence-hub.com/study/5714-phenotypic-molecular-and-in-silico-characterization-of-coumarin-as2026-10-08 https://evidence-hub.com/study/5715-impact-of-bolus-dosing-versus-continuous-infusion-of-piperacillin-and2026-10-01 https://evidence-hub.com/study/5716-efficacy-in-galleria-mellonella-larvae-and-application-potential2026-10-08 https://evidence-hub.com/study/5717-liposomes-based-drug-delivery-systems-of-anti-biofilm-agents-to2026-10-01 https://evidence-hub.com/study/5718-elizabethkingia-infections-in-humans-from-genomics-to-clinics2026-10-13 https://evidence-hub.com/study/5719-combined-system-for-the-simultaneous-delivery-of-levofloxacin-and2026-10-08 https://evidence-hub.com/study/5720-rnd-type-drug-efflux-pumps-from-gram-negative-bacteria-molecular2026-10-01 https://evidence-hub.com/study/5721-recent-advances-toward-a-molecular-mechanism-of-efflux-pump-inhibition2026-10-01 https://evidence-hub.com/study/5722-murraya-koenigii-l-sprengel-seeds-and-pericarps-in-relation-to-their2026-10-08 https://evidence-hub.com/study/5723-traditional-herbal-medicines-bioactive-metabolites-and-plant-products2026-10-01 https://evidence-hub.com/study/5724-antimicrobial-peptides-from-design-to-clinical-application2026-10-01 https://evidence-hub.com/study/5725-acinetobacter-baumannii-biofilms-effects-of-physicochemical-factors2026-10-01 https://evidence-hub.com/study/5726-the-role-of-chitosan-based-materials-in-interactions-with-antibiotics2026-10-13 https://evidence-hub.com/study/5727-sars-cov-2-covid-19-and-advances-in-developing-potential-therapeutics2026-10-01 https://evidence-hub.com/study/5728-a-review-of-the-mechanisms-that-confer-antibiotic-resistance-in2026-10-01 https://evidence-hub.com/study/5729-gram-negative-bacterial-lysins2026-10-01 https://evidence-hub.com/study/5730-antibiotic-resistance-breakers-current-approaches-and-future2026-10-01 https://evidence-hub.com/study/5731-ecil-guidelines-for-the-prevention-diagnosis-and-treatment-of-bk2026-10-01 https://evidence-hub.com/study/5732-design-synthesis-and-in-silico-studies-of-new-norfloxacin-analogues2026-10-08 https://evidence-hub.com/study/5733-azithromycin-in-viral-infections2026-10-01 https://evidence-hub.com/study/5734-translational-model-to-predict-lung-and-prostate-distribution-of2026-10-08 https://evidence-hub.com/study/5735-antibacterial-antifungal-antiviral-activity-and-mechanisms-of-action2026-10-01 https://evidence-hub.com/study/5736-changing-epidemiology-of-carbapenemases-among-carbapenem-resistant2026-10-08 https://evidence-hub.com/study/5737-tuberculosis-drugs-distribution-and-emergence-of-resistance-in2026-10-01 https://evidence-hub.com/study/5738-clinical-efficacy-and-safety-of-antiviral-drugs-in-the-extended-use2026-10-08 https://evidence-hub.com/study/5739-pharmacological-basis-and-new-insights-of-taxifolin-a-comprehensive2026-10-01 https://evidence-hub.com/study/5740-amikacin-uses-resistance-and-prospects-for-inhibition2026-10-01 https://evidence-hub.com/study/5741-in-silico-and-in-vitro-activity-of-ceftolozane-tazobactam-against2026-10-13 https://evidence-hub.com/study/5742-synthesis-in-vitro-antimicrobial-activity-and-in-silico-studies-of-12026-10-08 https://evidence-hub.com/study/5743-the-effects-of-airway-disease-on-the-deposition-of-inhaled-drugs2026-10-08 https://evidence-hub.com/study/5744-role-of-efflux-pumps-on-antimicrobial-resistance-in-pseudomonas2026-10-01 https://evidence-hub.com/study/5745-genomic-characterization-of-multidrug-resistant-acinetobacter2026-10-08 https://evidence-hub.com/study/5746-review-on-the-antibacterial-mechanism-of-plant-derived-compounds2026-10-01 https://evidence-hub.com/study/5747-interaction-of-antibacterial-compounds-with-rnd-efflux-pumps-in2026-10-01 https://evidence-hub.com/study/5748-futuristic-non-antibiotic-therapies-to-combat-antibiotic-resistance-a2026-10-01 https://evidence-hub.com/study/5749-epidemiology-and-characteristics-of-elizabethkingia-spp-infections-in2026-10-13 https://evidence-hub.com/study/5750-staphylococcus-aureus-epidemiology-pathophysiology-clinical2026-10-06 https://evidence-hub.com/study/5751-optimization-in-vitro-and-in-silico-characterization-of-theophylline2026-10-08 https://evidence-hub.com/study/5752-the-derivative-difluoroboranyl-fluoroquinolone-7a-generates-effective2026-10-08 https://evidence-hub.com/study/5753-the-potential-role-of-fluoroquinolones-in-the-management-of-covid-192026-10-01 https://evidence-hub.com/study/5754-antibiotic-resistance-profiles-molecular-mechanisms-and-innovative2026-10-01 https://evidence-hub.com/study/5755-strain-level-characterization-of-bacterial-pathogens-using2026-10-08 https://evidence-hub.com/study/5756-fluoroquinolones-hybrid-molecules-as-promising-antibacterial-agents2026-10-01 https://evidence-hub.com/study/5757-spread-of-hypervirulent-multidrug-resistant-st147-klebsiella2026-10-01 https://evidence-hub.com/study/5758-distribution-of-virulence-associated-genes-and-antimicrobial2026-10-01 https://evidence-hub.com/study/5759-flavonols-and-flavones-as-potential-anti-inflammatory-antioxidant-and2026-10-01 https://evidence-hub.com/study/5760-evaluation-of-levofloxacin-prescription-pattern-based-on2026-10-13 https://evidence-hub.com/study/5761-designing-a-recombinant-vaccine-against-providencia-rettgeri-using2026-10-01 https://evidence-hub.com/study/5762-zebrafish-as-a-screening-model-to-study-the-single-and-joint-effects2026-10-01 https://evidence-hub.com/study/5763-carbon-quantum-dots-in-bioimaging-and-biomedicines2026-10-05 https://evidence-hub.com/study/5764-high-rates-of-nonsusceptibility-to-common-oral-antibiotics-in2026-10-08 https://evidence-hub.com/study/5765-biofilm-formation-mechanistic-insights-and-therapeutic-targets2026-10-01 https://evidence-hub.com/study/5766-synthesis-and-evaluation-of-antibacterial-and-antifungal-activities2026-10-13 https://evidence-hub.com/study/5767-dna-gyrase-as-a-target-for-quinolones2026-10-01 https://evidence-hub.com/study/5768-synthesis-antimicrobial-evaluation-dft-in-silico-docking-and-admet2026-10-08 https://evidence-hub.com/study/5770-a-systematic-review-with-meta-analysis-and-indirect-comparison-of-the2026-10-06 https://evidence-hub.com/study/5771-comparison-of-efficacy-and-safety-of-endoscopic-retrograde2026-10-08 https://evidence-hub.com/study/5772-the-efficacy-of-ceftazidime-avibactam-combination-therapy-vs-colistin2026-10-06 https://evidence-hub.com/study/5773-efficacy-and-safety-of-enteral-nutrition-in-prone-position-among2026-10-06 https://evidence-hub.com/study/5774-meta-analysis-of-combined-azithromycin-and-inhaled-budesonide2026-10-08 https://evidence-hub.com/study/5775-efficacy-safety-and-tolerability-of-antifibrotic-agents-in-rheumatoid2026-10-06 https://evidence-hub.com/study/5776-comparative-efficacy-of-budesonide-formoterol-versus-fluticasone2026-10-06 https://evidence-hub.com/study/5777-updated-meta-analysis-of-phase-iii-randomized-controlled-trials-rcts2026-10-08 https://evidence-hub.com/study/5778-efficacy-of-probiotics-or-synbiotics-in-critically-ill-patients-a2026-10-06 https://evidence-hub.com/study/5779-efficacy-of-preventive-interventions-against-ventilator-associated2026-10-06 https://evidence-hub.com/study/5780-vaccine-efficacy-in-ckd-patients-not-on-dialysis-a-systematic-review2026-10-06 https://evidence-hub.com/study/5781-comparison-of-efficacy-and-costs-between-robotic-assisted-and2026-10-06 https://evidence-hub.com/study/5782-efficacy-and-safety-of-systemic-prophylactic-antibacterials-in2026-10-06 https://evidence-hub.com/study/5783-efficacy-and-safety-of-pantoprazole-for-stress-ulcer-prophylaxis-in2026-10-06 https://evidence-hub.com/study/5784-nebulized-heparin-for-inhalation-injury-in-burn-patients-an-updated2026-10-06 https://evidence-hub.com/study/5785-is-administration-of-anti-mrsa-drugs-recommended-for-patients-with2026-10-06 https://evidence-hub.com/study/5787-yl-1-puncture-needle-based-minimally-invasive-drainage-versus-burr2026-10-06 https://evidence-hub.com/study/5788-oral-versus-parenteral-antibiotic-therapy-in-adult-patients-with2026-10-06 https://evidence-hub.com/study/5789-a-systematic-review-and-meta-analysis-comparing-the-safety-and2026-10-06 https://evidence-hub.com/study/5790-incidence-of-pneumonia-sepsis-and-febrile-neutropenia-in-transplant2026-10-06 https://evidence-hub.com/study/5791-meta-analysis-of-randomized-controlled-trials-to-evaluate-the2026-10-06 https://evidence-hub.com/study/5792-efficacy-and-safety-of-mesenchymal-stem-cells-therapy-in-covid-192026-10-06 https://evidence-hub.com/study/5793-the-preventive-effect-of-inhaled-antibiotic-against-ventilator2026-10-06 https://evidence-hub.com/study/5794-effect-of-different-mouthwashes-on-ventilator-related-outcomes-and2026-10-06 https://evidence-hub.com/study/5795-efficacy-and-safety-of-extracorporeal-membrane-oxygenation-for2026-10-06 https://evidence-hub.com/study/5796-comparison-of-the-efficacy-and-tolerability-of-different-repetitive2026-10-06 https://evidence-hub.com/study/5798-dexamethasone-vs-methylprednisolone-in-treating-covid-19-pneumonia-a2026-10-06 https://evidence-hub.com/study/5799-bts-clinical-statement-on-aspiration-pneumonia2026-10-01 https://evidence-hub.com/study/5800-hospital-acquired-pneumonia-and-ventilator-associated-pneumonia-a2026-10-01 https://evidence-hub.com/study/5801-efficacy-of-doxycycline-therapy-for-macrolide-resistant-mycoplasma2026-10-01 https://evidence-hub.com/study/5802-monitoring-prophylaxis-and-treatment-of-infections-in-patients-with2026-10-01 https://evidence-hub.com/study/5803-global-research-trends-of-mycoplasma-pneumoniae-pneumonia-in-children2026-10-01 https://evidence-hub.com/study/5804-atypical-pneumonia-review2026-10-08 https://evidence-hub.com/study/5805-a-retrospective-study-of-the-efficacy-and-safety-of-levofloxacin-in2026-10-08 https://evidence-hub.com/study/5806-antimicrobial-resistance-a-growing-serious-threat-for-global-public2026-10-01 https://evidence-hub.com/study/5807-infectious-diseases-society-of-america-2023-guidance-on-the-treatment2026-10-01 https://evidence-hub.com/study/5808-recent-updates-regarding-the-management-and-treatment-of-pneumonia-in2026-10-08 https://evidence-hub.com/study/5809-the-combination-of-antibiotic-and-non-antibiotic-compounds-improves2026-10-01 https://evidence-hub.com/study/5810-risk-factors-and-mortality-of-elderly-patients-with-hospital-acquired2026-10-01 https://evidence-hub.com/study/5811-in-vitro-antibiotic-combinations-of-colistin-meropenem-amikacin-and2026-10-01 https://evidence-hub.com/study/5813-preparation-of-co-amorphous-levofloxacin-systems-for-pulmonary2026-10-08 https://evidence-hub.com/study/5814-daily-fosfomycin-versus-levofloxacin-for-complicated-urinary-tract2026-10-20 https://evidence-hub.com/study/5815-outbreak-of-mycoplasma-pneumoniae-pneumonia-in-hospitalized-patients2026-10-01 https://evidence-hub.com/study/5816-antibiotic-resistance-of-streptococcus-pneumoniae-in-vietnamese2026-10-04 https://evidence-hub.com/study/5817-ten-issues-for-updating-in-community-acquired-pneumonia-an-expert2026-10-01 https://evidence-hub.com/study/5818-teclistamab-impairs-humoral-immunity-in-patients-with-heavily2026-10-01 https://evidence-hub.com/study/5819-enhanced-zn-co-fe-layered-double-hydroxides-for-effective2026-10-08 https://evidence-hub.com/study/5820-nitrocellulose-for-prolonged-permeation-of-levofloxacin-hcl-salicylic2026-10-08 https://evidence-hub.com/study/5821-translational-predictions-of-phase-2a-first-in-patient-efficacy2026-10-01 https://evidence-hub.com/study/5822-personalized-bacteriophage-therapy-outcomes-for-100-consecutive-cases2026-10-13 https://evidence-hub.com/study/5823-assessment-of-the-relative-benefits-of-monotherapy-and-combination2026-10-01 https://evidence-hub.com/study/5824-advances-in-polymeric-and-non-polymeric-nanocarriers-for-the2026-10-08 https://evidence-hub.com/study/5825-in-vivopharmacokinetic-pharmacodynamic-evaluation-of-cefepime2026-10-01 https://evidence-hub.com/study/5826-rationale-and-evidence-for-the-use-of-new-beta-lactam-beta-lactamase2026-10-01 https://evidence-hub.com/study/5827-impact-of-antibiotics-corticosteroids-and-microbiota-on-immunotherapy2026-10-01 https://evidence-hub.com/study/5828-prolonged-sars-cov-2-infection-and-organizing-pneumonia-in-a-patient2026-10-01 https://evidence-hub.com/study/5829-gut-microbiota-disruption-in-hematologic-cancer-therapy-molecular2026-10-01 https://evidence-hub.com/study/5830-characterization-of-novel-bacteriophage-pskp16-and-its-therapeutic2026-10-01 https://evidence-hub.com/study/5831-sequential-therapy-of-linezolid-and-contezolid-to-treat-vancomycin2026-10-01 https://evidence-hub.com/study/5832-severe-community-acquired-pneumonia-current-concepts-and-controversies2026-10-01 https://evidence-hub.com/study/5833-in-vitro-antimicrobial-activity-and-dose-optimization-of-eravacycline2026-10-13 https://evidence-hub.com/study/5834-clinical-characteristics-and-predictive-indictors-of-macrolide2026-10-01 https://evidence-hub.com/study/5835-effects-of-antibiotics-ceftriaxone-and-levofloxacin-on-the-growth-of2026-10-01 https://evidence-hub.com/study/5836-a-novel-antibiotic-class-targeting-the-lipopolysaccharide-transporter2026-10-03 https://evidence-hub.com/study/5837-a-long-lasting-porcine-model-of-ards-caused-by-pneumonia-and2026-10-08 https://evidence-hub.com/study/5838-risk-factors-for-mortality-in-intensive-care-unit-patients-with2026-10-01 https://evidence-hub.com/study/5839-biofilm-eradication-of-stenotrophomonas-maltophilia-by-levofloxacin2026-10-08 https://evidence-hub.com/study/5840-cefiderocol-efficacy-in-a-real-life-setting-single-centre2026-10-01 https://evidence-hub.com/study/5841-performance-of-a-hybrid-capture-based-target-enrichment-next2026-10-01 https://evidence-hub.com/study/5842-management-of-the-diagnosis-and-treatment-of-pneumonia-in-an-aging2026-10-01 https://evidence-hub.com/study/5843-acinetobacter-baumannii-in-the-critically-ill-complex-infections-get2026-10-01 https://evidence-hub.com/study/5844-antibiotic-resistance-in-patients-with-cystic-fibrosis-past-present2026-10-01 https://evidence-hub.com/study/5845-individualized-antibiotic-dosage-regimens-for-patients-with-augmented2026-10-01 https://evidence-hub.com/study/5846-tocilizumab-prophylaxis-for-patients-with-multiple-myeloma-treated2026-10-01 https://evidence-hub.com/study/5847-compare-clinical-characteristics-of-psittacosis-pneumonia-in-352026-10-01 https://evidence-hub.com/study/5848-chest-ct-characterization-of-children-with-necrotizing-pneumonia-due2026-10-01 https://evidence-hub.com/study/5849-evaluation-of-efficacy-and-safety-of-lascufloxacin-for-nursing-and2026-10-01 https://evidence-hub.com/study/5850-effect-of-an-accidental-colchicine-overdose-in-a-covid-19-inpatient2026-10-01 https://evidence-hub.com/study/5851-development-and-characterization-of-spray-dried-combined-levofloxacin2026-10-08 https://evidence-hub.com/study/5853-role-of-vitamin-c-in-treatment-of-community-acquired-pneumonia-in2026-10-06 https://evidence-hub.com/study/5854-pengukuran-tekanan-cuff-endotracheal-tube-kontinyu-dan-intermiten2026-10-06 https://evidence-hub.com/study/5855-corticosteroid-therapy-for-patients-hospitalized-with-community2026-10-06 https://evidence-hub.com/study/5856-the-clinical-efficacy-and-safety-of-nintedanib-in-the-treatment-of2026-10-06 https://evidence-hub.com/study/5857-efficacy-of-electrical-stimulation-es-on-dysphagia-in-post-stroke2026-10-06 https://evidence-hub.com/study/5858-safety-and-efficacy-of-umbilical-cord-derived-stem-cell-therapy-for2026-10-06 https://evidence-hub.com/study/5859-safety-and-efficacy-of-flag-ida-based-therapy-combined-with2026-10-06 https://evidence-hub.com/study/5860-amoxicillin-versus-cotrimoxazole-for-treating-non-severe-pneumonia-a2026-10-06 https://evidence-hub.com/study/5861-proton-pump-inhibitors-for-gastrointestinal-bleeding-prophylaxis-in2026-10-13 https://evidence-hub.com/study/5864-triple-therapy-de-escalation-and-withdrawal-of-inhaled2026-10-06 https://evidence-hub.com/study/5865-evaluation-of-the-efficacy-of-perioperative-tranexamic-acid-in2026-10-06 https://evidence-hub.com/study/5866-efficacy-and-safety-of-combined-nebulization-of-unfractionated2026-10-08 https://evidence-hub.com/study/5868-a-phase-iii-randomized-controlled-non-inferiority-trial-to-study-the2026-10-08 https://evidence-hub.com/study/5870-randomized-controlled-trial-the-safety-and-efficacy-of-adjunctive2026-10-08 https://evidence-hub.com/study/5871-efficacy-and-safety-of-a-3-day-once-daily-regimen-of-oral2026-10-08 https://evidence-hub.com/study/5872-efficacy-and-safety-of-andrographolide-and-favipiravir-versus2026-10-06 https://evidence-hub.com/study/5874-remimazolam-versus-midazolam-for-sedation-in-mechanically-ventilated2026-10-08 https://evidence-hub.com/study/5875-efficacy-of-lignocaine-nebulization-in-patients-with-covid-192026-10-06 https://evidence-hub.com/study/5876-efficacy-and-safety-of-adding-fluoxetine-to-the-treatment-regimen-of2026-10-06 https://evidence-hub.com/study/5877-comparison-of-inhaled-colistin-versus-intravenous-colistin-for-gram2026-10-08 https://evidence-hub.com/study/5879-high-flow-nasal-cannula-combined-with-non-invasive-ventilation-versus2026-10-06 https://evidence-hub.com/study/5880-influence-of-anti-spike-protein-antibody-levels-on-tocilizumab2026-10-06 https://evidence-hub.com/study/5881-efficacy-of-low-intensity-pulsed-ultrasound-for-the-treatment-of2026-10-06 https://evidence-hub.com/study/5883-efficacy-of-laryngeal-mask-airway-versus-endotracheal-tube-during2026-10-06 https://evidence-hub.com/study/5884-the-application-of-two-drainage-angles-in-neurocritical-care-patients2026-10-08 https://evidence-hub.com/study/5885-study-design-and-protocol-for-a-randomized-controlled-trial-to-assess2026-10-19 https://evidence-hub.com/study/5886-bacterial-colonization-of-silver-additive-ventilator-circuit-in2026-10-06 https://evidence-hub.com/study/5888-oral-pentoxifylline-as-a-novel-adjunct-to-standard-therapy-in2026-10-08 https://evidence-hub.com/study/5889-high-dose-inhaled-nitric-oxide-for-severe-pneumonia-caused-by2026-10-08 https://evidence-hub.com/study/5890-efficacy-and-safety-of-metformin-and-atorvastatin-combination-therapy2026-10-19 https://evidence-hub.com/study/5891-sodium-oxybate-as-a-potential-new-treatment-for-catatonia-in-patients2026-10-06 https://evidence-hub.com/study/5892-efficacy-of-pharyngeal-balloon-muscle-resistance-treatment-in-post2026-10-06 https://evidence-hub.com/study/5893-efficacy-and-safety-of-fixed-dose-combination-therapy-with-cilostazol2026-10-19 https://evidence-hub.com/study/5894-anti-c5a-antibody-stsa-1002-for-patients-with-acute-respiratory2026-10-08 https://evidence-hub.com/study/5895-efficacy-and-safety-of-lurasidone-vs-quetiapine-xr-in-acutely2026-10-19 https://evidence-hub.com/study/5896-remote-ischemic-conditioning-for-the-prevention-of-stroke-associated2026-10-08 https://evidence-hub.com/study/5897-efficacy-and-safety-of-postoperative-autologous-blood-transfusion-in2026-10-06 https://evidence-hub.com/study/5898-2519-a-multi-national-phase-3-randomized-double-blind-active2026-10-06 https://evidence-hub.com/study/5899-efficacy-and-safety-of-step-by-step-baduanjin-exercise-based-on2026-10-06 https://evidence-hub.com/study/5900-high-flow-nasal-cannula-versus-conventional-oxygen-therapy-for2026-10-06 https://evidence-hub.com/study/5901-efficacy-and-metabolomic-analysis-of-the-pneumonia-compound2026-10-06 https://evidence-hub.com/study/5902-safety-and-efficacy-of-pulmonary-physiotherapy-in-hospitalized2026-10-06 https://evidence-hub.com/study/5903-tongue-acupuncture-to-treat-dysphagia-in-patients-with-parkinson-s2026-10-06 https://evidence-hub.com/study/5904-efficacy-of-oral-20-hydroxyecdysone-bio101-a-mas-receptor-activator2026-10-06 https://evidence-hub.com/study/5905-efficacy-and-safety-of-korean-herbal-medicine-for-patients-with-post2026-10-19 https://evidence-hub.com/study/5906-adjunctive-terlipressin-versus-placebo-in-the-treatment-of-refractory2026-10-06 https://evidence-hub.com/study/5907-nebulized-inhalation-of-plasma-activated-water-in-the-treatment-of2026-10-06 https://evidence-hub.com/study/5908-a-randomized-controlled-trial-of-a-digital-lifestyle-intervention2026-10-19 https://evidence-hub.com/study/5909-efficacy-and-safety-of-a-novel-antiviral-herbal-preparation-in-icu2026-10-06 https://evidence-hub.com/study/5910-phase-2-3-open-label-randomized-active-controlled-clinical-trial2026-10-06 https://evidence-hub.com/study/5911-effect-of-topical-application-of-povidone-iodine-on-the-number-of2026-10-06 https://evidence-hub.com/study/5912-the-efficacy-and-safety-of-mars-pd-meridian-activation-remedy-system2026-10-19 https://evidence-hub.com/study/5914-perioperative-nitric-oxide-conditioning-reduces-acute-kidney-injury2026-10-06 https://evidence-hub.com/study/5915-small-dose-trimethoprim-sulfamethoxazole-prevents-pneumocystis2026-10-06 https://evidence-hub.com/study/5916-efficacy-and-safety-of-anti-cd38-monoclonal-antibodies-in-patients2026-10-06 https://evidence-hub.com/study/5917-probiotics-to-reduce-ventilator-associated-pneumonia-in-adults-with2026-10-06 https://evidence-hub.com/study/5918-efficacy-of-topical-hemostatic-powder-on-hemorrhagic-complications2026-10-19 https://evidence-hub.com/study/5919-a-multicentre-double-blind-placebo-controlled-randomized-parallel2026-10-19 https://evidence-hub.com/study/5921-clinical-efficacy-and-safety-of-an-automatic-closed-suction-system-in2026-10-06 https://evidence-hub.com/study/5922-efficacy-of-neoadjuvant-folfirinox-in-resectable-pancreatic-cancer2026-10-19 https://evidence-hub.com/study/5923-807-trimethoprim-sulfamethoxazole-for-pneumocystis-jirovecii2026-10-06 https://evidence-hub.com/study/5924-press-needle-for-aspiration-pneumonia-prevention-in-older-adults2026-10-06 https://evidence-hub.com/study/5926-nebulized-gentamicin-for-reducing-colonization-of-tracheostomy-tubes2026-10-06 https://evidence-hub.com/study/5927-efficacy-and-safety-of-skcpt-in-patients-with-knee-osteoarthritis-a2026-10-19 https://evidence-hub.com/study/5928-phase-i-ii-clinical-trial-of-efficacy-and-safety-of-egcg-oxygen2026-10-06 https://evidence-hub.com/study/5929-tocilizumab-in-combination-with-standard-of-care-in-patients-with2026-10-06 https://evidence-hub.com/study/5930-the-efficacy-of-inhaled-phage-cocktail-to-prevent-ventilator2026-10-06 https://evidence-hub.com/study/5931-cyclosporine-a-in-hospitalized-covid-19-pneumonia-patients-to-prevent2026-10-06 https://evidence-hub.com/study/5932-efficacy-and-safety-of-sulbactam-durlobactam-versus-colistin-for-the2026-10-06 https://evidence-hub.com/study/5933-exploring-the-efficacy-of-convalescent-plasma-therapy-in-covid-192026-10-06 https://evidence-hub.com/study/5934-evaluating-the-impact-of-enteral-glutamine-supplementation-on2026-10-06 https://evidence-hub.com/study/5935-efficacy-and-safety-of-ceftazidime-avibactam-in-patients-with2026-10-06 https://evidence-hub.com/study/5936-clinical-efficacy-of-sitafloxacin-colistin-meropenem-and-colistin2026-10-06 https://evidence-hub.com/study/5937-azithromycin-versus-doxycycline-in-hospitalised-adult-patients-with2026-10-06 https://evidence-hub.com/study/5938-efficacy-of-preoperative-immunonutrition-in-malnourished-patients2026-10-19 https://evidence-hub.com/study/5939-a-novel-reduce-toxity-myeloablative-conditioning-regimen-f-bmt2026-10-06 https://evidence-hub.com/study/5940-pirfenidone-in-post-covid-19-pulmonary-fibrosis-fibro-covid-a-phase-22026-10-06 https://evidence-hub.com/study/5941-empagliflozin-in-patients-with-type-2-diabetes-undergoing-on-pump2026-10-06 https://evidence-hub.com/study/5942-cyclosporin-a-as-an-add-on-therapy-to-a-corticosteroid-based2026-10-08 https://evidence-hub.com/study/5943-evaluation-of-the-effect-of-montelukast-drug-in-improving-the2026-10-06 https://evidence-hub.com/study/5944-anti-cd14-treatment-in-patients-with-severe-covid-19-clinical-and2026-10-06 https://evidence-hub.com/study/5945-efficacy-and-safety-of-electroacupuncture-through-nerve-stimulation2026-10-19 https://evidence-hub.com/study/5946-a-randomized-active-controlled-multicenter-phase-3-clinical-trial-to2026-10-19 https://evidence-hub.com/study/5947-synergistic-immunomodulatory-effects-of-cistanche-deserticola2026-10-06 https://evidence-hub.com/study/5948-intravenous-umbilical-cord-derived-mesenchymal-stromal-cell-therapy2026-10-06 https://evidence-hub.com/study/5949-evaluating-the-efficacy-of-inhaled-colistin-via-two-nebulizer-types2026-10-06 https://evidence-hub.com/study/5951-comparison-of-two-different-doses-of-ampicillin-sulbactam-as-part-of2026-10-06 https://evidence-hub.com/study/5952-impact-of-doxycycline-on-mycoplasma-pneumonia-treatment-and-cancer2026-10-06 https://evidence-hub.com/study/5953-updated-results-from-a-phase-ii-clinical-trial-safety-and-efficacy-of2026-10-06 https://evidence-hub.com/study/5954-safety-and-efficacy-of-convalescent-plasma-for-covid-19-in-the-pre2026-10-06 https://evidence-hub.com/study/5955-anlotinib-plus-benmelstobart-as-adjuvant-therapy-in-patients-with2026-10-06 https://evidence-hub.com/study/5956-aspirin-for-acute-pneumonia-in-the-elderly-aspapy-protocol-of-a2026-10-06 https://evidence-hub.com/study/5957-the-efficacy-of-high-dose-pulse-therapy-vs-low-dose-intravenous2026-10-06 https://evidence-hub.com/study/5958-clinical-trial-assessing-the-safety-and-efficacy-of-human-bone-marrow2026-10-06 https://evidence-hub.com/study/5959-efficacy-and-safety-of-inetetamab-plus-pertuzumab-and-nab-paclitaxel2026-10-06 https://evidence-hub.com/study/5960-p-111-promising-efficacy-of-nasal-spraying-bacillus-spore-probiotics2026-10-06 https://evidence-hub.com/study/5961-efficacy-and-safety-of-high-doses-of-inhaled-nitric-oxide-in-patients2026-10-06 https://evidence-hub.com/study/5962-effectiveness-and-safety-of-ceftazidime-avibactam-in-chinese-patients2026-10-06 https://evidence-hub.com/study/5963-coenrollment-of-critically-ill-patients-in-prospect-characteristics2026-10-06 https://evidence-hub.com/study/5964-efficacy-of-20-valent-pneumococcal-vaccination-in-chemotherapy2026-10-06 https://evidence-hub.com/study/5965-time-in-therapeutic-range-of-unfractionated-heparin-based-therapy-in2026-10-06 https://evidence-hub.com/study/5966-a-machine-learning-model-integrating-systemic-immune-inflammation2026-10-06 https://evidence-hub.com/study/5967-low-dose-atovaquone-for-prophylaxis-of-pneumocystis-jirovecii2026-10-06 https://evidence-hub.com/study/5968-evaluation-of-antibiotic-use-in-hospitalized-patients-with-pneumonia2026-10-08 https://evidence-hub.com/study/5970-p05-predictive-factors-of-early-and-late-mortality-and-evaluation-of2026-10-06 https://evidence-hub.com/study/5971-efficacy-and-safety-of-ultra-short-wave-diathermy-on-covid-192026-10-06 https://evidence-hub.com/study/5972-impact-of-glucocorticoid-therapy-on-short-and-long-term-mortality-in2026-10-06 https://evidence-hub.com/study/5973-comparative-analysis-of-clinical-manifestations-and-ct-scores-in2026-10-06 https://evidence-hub.com/study/5974-network-meta-analysis-on-4-types-of-traditional-chinese-medicine2026-10-06 https://evidence-hub.com/study/5975-clinical-analysis-of-12-cases-of-acute-exogenous-lipoid-pneumonia-in2026-10-06 https://evidence-hub.com/study/5976-clinical-outcomes-after-switching-from-sulfamethoxazole-trimethoprim2026-10-06 https://evidence-hub.com/study/5977-p-1071-renal-hyperfiltration-increases-mortality-in-patients-with2026-10-06 https://evidence-hub.com/study/5978-multiarm-multistage-randomised-controlled-trial-of-inflammatory2026-10-06 https://evidence-hub.com/study/5979-the-safety-and-efficacy-of-neutral-electrolyzed-water-solution-for2026-10-06 https://evidence-hub.com/study/5980-comprehensive-narrative-analysis-of-antimicrobial-resistance-in2026-10-06 https://evidence-hub.com/study/5981-inhalable-nanoparticle-based-delivery-systems-for-the-treatment-of2026-10-06 https://evidence-hub.com/study/5982-inhalable-microparticles-as-drug-delivery-systems-to-the-lungs-in-a2026-10-10 https://evidence-hub.com/study/5983-clinical-impact-of-staphylococcus-aureus-skin-and-soft-tissue2026-10-06 https://evidence-hub.com/study/5984-antibacterial-activity-of-peptide-derivatives-of-phosphinothricin2026-10-06 https://evidence-hub.com/study/5985-efficacy-of-lyophilised-bacteria-rich-faecal-sediment-and-supernatant2026-10-06 https://evidence-hub.com/study/5986-biological-properties-of-12-newly-isolated-acinetobacter-baumannii2026-10-06 https://evidence-hub.com/study/5987-characteristics-and-key-features-of-antimicrobial-materials-and2026-10-06 https://evidence-hub.com/study/5989-efficacy-and-safety-of-low-dose-trimethoprim-sulfamethoxazole-tmp-smz2026-10-06 https://evidence-hub.com/study/5990-efficacy-of-monocyte-distribution-width-in-predicting-critical2026-10-06 https://evidence-hub.com/study/5992-efficacy-of-dexamethasone-and-methylprednisolone-in-covid-192026-10-06 https://evidence-hub.com/study/5993-efficacy-of-baricitinib-in-patients-treated-with-corticosteroids-for2026-10-06 https://evidence-hub.com/study/5994-comparative-outcomes-of-polymyxins-in-neurocritical-care-patients2026-10-08 https://evidence-hub.com/study/5995-comparisons-of-mortality-predictions-of-mrox-curb-65-and-apache-ii-in2026-10-06 https://evidence-hub.com/study/5997-impact-of-individualized-nursing-interventions-on-ventilator-weaning2026-10-06 https://evidence-hub.com/study/5998-remdesivir-versus-favipiravir-in-hospitalized-patients-with-moderate2026-10-06 https://evidence-hub.com/study/6000-effectiveness-of-corticosteroid-strategy-in-three-community-acquired2026-10-06 https://evidence-hub.com/study/6001-empirical-antibiotic-therapy-for-spontaneous-intracerebral-hemorrhage2026-10-06 https://evidence-hub.com/study/6002-a-single-cycle-of-intravenous-immunoglobulin-as-adjuvant-to-rituximab2026-10-06 https://evidence-hub.com/study/6003-association-between-rocuronium-administration-and-clinical-outcomes2026-10-06 https://evidence-hub.com/study/6004-intravenous-combined-with-nebulized-polymyxin-b-may-be-effective-in2026-10-06 https://evidence-hub.com/study/6005-cystatin-c-as-a-predictor-of-severe-hospital-acquired-pneumonia-in2026-10-06 https://evidence-hub.com/study/6006-efficacy-and-safety-of-different-colistin-administration-routes-for2026-10-06 https://evidence-hub.com/study/6007-efficacy-and-safety-of-different-colistin-administration-routes-for2026-10-06 https://evidence-hub.com/study/6008-steroid-pulse-therapy-leads-to-secondary-infections-and-poor-outcomes2026-10-06 https://evidence-hub.com/study/6009-diagnostic-efficacy-of-monocyte-distribution-width-to-high2026-10-06 https://evidence-hub.com/study/6010-comparative-effectiveness-of-tocilizumab-vs-standard-care-in-patients2026-10-06 https://evidence-hub.com/study/6011-analysis-of-risk-factors-associated-with-in-hospital-mortality-in2026-10-06 https://evidence-hub.com/study/6012-efficacy-of-adding-intravenous-methylprednisolone-to-nebulized2026-10-06 https://evidence-hub.com/study/6013-efficacy-and-safety-of-post-mastectomy-radiation-therapy-for-patients2026-10-06 https://evidence-hub.com/study/6014-efficacy-and-safety-of-sorafenib-combined-with-standard-chemotherapy2026-10-06 https://evidence-hub.com/study/6015-2808-remdesivir-for-moderate-to-severe-covid-19-pneumonia-in2026-10-06 https://evidence-hub.com/study/6016-the-efficacy-of-the-collaborative-respiratory-assessment-score-coras2026-10-06 https://evidence-hub.com/study/6017-age-stratified-efficacy-of-upadacitinib-in-refractory-pediatric-crohn2026-10-06 https://evidence-hub.com/study/6018-association-of-antipsychotic-dose-with-surrogate-efficacy-and-safety2026-10-06 https://evidence-hub.com/study/6020-short-term-safety-of-gastric-endoscopic-submucosal-dissection-in2026-10-06 https://evidence-hub.com/study/6021-doxycycline-versus-azithromycin-as-combination-therapy-in-the2026-10-06 https://evidence-hub.com/study/6022-p-1488-clinical-efficacy-of-minocycline-in-the-treatment-of2026-10-06 https://evidence-hub.com/study/6023-efficacy-and-safety-of-immune-checkpoint-inhibitors-in-advanced-non2026-10-06 https://evidence-hub.com/study/6024-eosinophil-count-combined-with-routine-indicators-enhances-early-risk2026-10-06 https://evidence-hub.com/study/6025-a-nomogram-for-individualized-prediction-of-acute-respiratory2026-10-06 https://evidence-hub.com/study/6026-preoperative-lung-ultrasound-score-and-multifactorial-predictors-of-12026-10-06 https://evidence-hub.com/study/6027-feasibility-of-methotrexate-discontinuation-following-tocilizumab-and2026-10-06 https://evidence-hub.com/study/6028-efficacy-of-scoring-systems-for-routing-and-predicting-length-of-icu2026-10-06 https://evidence-hub.com/study/6029-clinical-effectiveness-and-safety-of-dupilumab-in-chronic-obstructive2026-10-06 https://evidence-hub.com/study/6030-the-real-world-clinical-outcomes-of-favipiravir-treatment-with2026-10-06 https://evidence-hub.com/study/6031-retrospective-cohort-study-to-evaluate-the-efficacy-and-safety-of-t2026-10-06 https://evidence-hub.com/study/6032-3d-technology-assisted-minimally-invasive-surgery-for-the-treatment2026-10-19 https://evidence-hub.com/study/6033-sivelestat-in-patients-at-a-high-risk-of-postoperative-acute-lung2026-10-06 https://evidence-hub.com/study/6034-real-world-efficacy-of-baricitinib-among-patients-with-severe-and2026-10-06 https://evidence-hub.com/study/6035-preliminary-analysis-on-efficacy-of-ritonavir-boosted-nirmatrelvir-on2026-10-06 https://evidence-hub.com/study/6036-analysis-of-the-effects-of-azithromycin-combined-with-budesonide-and2026-10-06 https://evidence-hub.com/study/6037-exploring-the-efficacy-of-interferon-nebulization-combined-with2026-10-06 https://evidence-hub.com/study/6038-a-randomized-case-control-study-on-high-frequency-chest-wall2026-10-06 https://evidence-hub.com/study/6039-protection-and-duration-of-23-valent-pneumococcal-polysaccharide2026-10-06 https://evidence-hub.com/study/6040-pos0949-clinical-factors-associated-with-pneumocystis-pneumonia2026-10-06 https://evidence-hub.com/study/6042-clinical-efficacy-of-azithromycin-budesonide-combination-therapy-in2026-10-06 https://evidence-hub.com/study/6043-efficacy-and-safety-of-carrimycin-in-ten-patients-with-severe2026-10-06 https://evidence-hub.com/study/6044-analysis-of-the-efficacy-of-xuebijing-combined-with-antimicrobials-in2026-10-06 https://evidence-hub.com/study/6046-effect-of-electronic-fibrobronchoscope-alveolar-lavage-combined-with2026-10-06 https://evidence-hub.com/study/6047-severe-community-acquired-pneumonia-complicated-by-co-infection-with2026-10-08 https://evidence-hub.com/study/6048-pneumocystis-pneumonia-in-stage-iiia-lung-adenocarcinoma-with-immune2026-10-06 https://evidence-hub.com/study/6049-feasibility-analysis-of-pharmacy-practice-based-on-the-evidence-based2026-10-06 https://evidence-hub.com/study/6050-clinical-study-of-evaluating-the-efficacy-of-zinc-supplementation-as2026-10-06 https://evidence-hub.com/study/6051-effect-of-early-pulmonary-rehabilitation-therapy-on-the-pulmonary2026-10-06 https://evidence-hub.com/study/6052-complicated-klebsiella-pneumonia-infection-causing-lung-abscess-case2026-10-08 https://evidence-hub.com/study/6053-evaluation-of-inhaled-antimicrobials-as-adjunctive-therapy-in-the2026-10-06 https://evidence-hub.com/study/6054-evaluation-of-the-rationality-of-antibiotic-use-in-pneumonia-patients2026-10-08 https://evidence-hub.com/study/6055-houttuynia-drip-improves-clinical-outcome-in-elderly-patients-with2026-10-06 https://evidence-hub.com/study/6056-po-10-149-efficacy-of-anifrolumab-in-a-case-of-systemic-lupus2026-10-06 https://evidence-hub.com/study/6057-management-of-sepsis-patients-due-to-community-acquired-pneumonia-in2026-10-08 https://evidence-hub.com/study/6058-occupational-community-acquired-pneumonia-in-a-fitter-splicer-with-a2026-10-08 https://evidence-hub.com/study/6059-cotrimoxazole-as-a-preventative-intervention-for-pneumocystis2026-10-06 https://evidence-hub.com/study/6060-clinical-characteristics-and-glucocorticoids-efficacy-in-covid-192026-10-06 https://evidence-hub.com/study/6061-short-course-vs-long-course-antibiotic-treatment-for-paediatric2026-10-06 https://evidence-hub.com/study/6062-genomic-characterization-and-virulence-determinants-of-staphylococcus2026-10-08 https://evidence-hub.com/study/6063-mri-guided-stereotactic-body-radiation-therapy-for-very-elderly2026-10-06 https://evidence-hub.com/study/6064-clinical-characteristics-of-mycoplasma-pneumoniae-pneumonia-in2026-10-06 https://evidence-hub.com/study/6065-clinical-observation-of-xiaochaihu-decoction-combined-with2026-10-06 https://evidence-hub.com/study/6066-evaluation-of-the-efficacy-and-safety-of-botulinum-toxin-type-a2026-10-06 https://evidence-hub.com/study/6067-a-report-on-the-clinical-efficacy-of-rituximab-administration-in2026-10-06 https://evidence-hub.com/study/6068-clinical-application-of-blood-lactate-c-reactive-protein-and-the-age2026-10-06 https://evidence-hub.com/study/6070-comparative-observation-between-roxithromycin-and-azithromycin2026-10-06 https://evidence-hub.com/study/6072-efficacy-and-safety-of-pegcetacoplan-in-pnh-patients-with-extra2026-10-06 https://evidence-hub.com/study/6073-thu126-sars-cov-2-infection-and-vaccination-in-patients-with2026-10-06 https://evidence-hub.com/study/6074-a-study-on-serum-vitamin-d-level-in-patients-suffering-from-various2026-10-06 https://evidence-hub.com/study/6075-awareness-uptake-and-barriers-to-vaccination-against-respiratory2026-10-06 https://evidence-hub.com/study/6076-microbiological-profile-and-antibiotic-susceptibility-of-body-fluids2026-10-06 https://evidence-hub.com/study/6078-exploring-the-synergistic-effects-of-plant-extracts-and-silver2026-10-06 https://evidence-hub.com/study/6079-khao-sat-viec-ieu-tri-viem-phoi-mac-phai-cong-ong-tai-benh-vien-a2026-10-06 https://evidence-hub.com/study/6080-clinical-practices-and-treatment-preferences-of-meropenem-in-the2026-10-06 https://evidence-hub.com/study/6081-the-use-of-central-venous-catheters-in-the-management-of-pleural2026-10-06 https://evidence-hub.com/study/6082-p-1685-knowledge-attitudes-and-practice-of-healthcare-providers2026-10-06 https://evidence-hub.com/study/6083-effectiveness-of-lung-ultrasound-for-diagnosis-of-acute-respiratory2026-10-06 https://evidence-hub.com/study/6084-diagnosis-of-intestinal-tuberculosis-in-patient-with-ileocolonic2026-10-06 https://evidence-hub.com/study/6085-identification-of-gram-positive-and-gram-negative-bacteria-in-post2026-10-06 https://evidence-hub.com/study/6086-antimicrobial-susceptibility-pattern-of-bacteria-isolated-from2026-10-06 https://evidence-hub.com/study/6087-surveillance-of-antimicrobial-utilization-trends-in-tertiary-health2026-10-06 https://evidence-hub.com/study/6088-vaccine-hesitancy-affecting-pneumococcal-vaccine-refusal-in-older2026-10-06 https://evidence-hub.com/study/6089-comparing-screening-tests-for-pharyngeal-dysphagia-in-stroke-patients2026-10-06 https://evidence-hub.com/study/6090-fibrosing-progressive-interstitial-lung-disease-in-rheumatoid2026-10-06 https://evidence-hub.com/study/6091-a-case-of-hypercalcemia-from-pneumocystis-jirovecii-in-an2026-10-06 https://evidence-hub.com/study/6092-real-time-assessment-of-dentinal-fluid-flow-reduction-by2026-10-19 https://evidence-hub.com/study/6093-pelvic-infections-with-intrauterine-device-microbiological-profile2026-10-06 https://evidence-hub.com/study/6094-mobile-phones-and-multidrug-resistant-bacteria-a-growing-concern-for2026-10-06 https://evidence-hub.com/study/6095-current-practice-in-the-diagnosis-and-management-of-mycoplasma2026-10-06 https://evidence-hub.com/study/6096-antibiotic-use-and-prescribing-patterns-for-respiratory-tract2026-10-06 https://evidence-hub.com/study/6097-prevalence-of-enteric-bacteria-and-their-antimicrobial-susceptibility2026-10-06 https://evidence-hub.com/study/6098-isolation-and-antibiotic-sensitivity-of-klebsiella-pneumoniae-among2026-10-06 https://evidence-hub.com/study/6099-outcome-and-severity-of-covid-19-in-vaccinated-and-unvaccinated2026-10-06 https://evidence-hub.com/study/6100-p-56-clinical-and-microbiological-profile-of-enterococcal-bacteremia2026-10-06 https://evidence-hub.com/study/6101-p-1072-epidemiology-of-stenotrophomonas-maltophilia-infections-in2026-10-06 https://evidence-hub.com/study/6102-a-simulated-patient-study-of-antibiotic-utilization-within-the2026-10-06 https://evidence-hub.com/study/6103-occurrence-and-antimicrobial-profiling-of-k-pneumoniae-in-burn2026-10-06 https://evidence-hub.com/study/6104-antimicrobial-resistance-patterns-among-healthcare-associated2026-10-06 https://evidence-hub.com/study/6105-post-vaccination-surveillance-of-invasive-pneumococcal-disease-in2026-10-06 https://evidence-hub.com/study/6106-prevalence-and-antibiotic-susceptibility-pattern-of-multidrug2026-10-06 https://evidence-hub.com/study/6107-study-of-bacteriological-profile-and-their-antibiotic-susceptibility2026-10-06 https://evidence-hub.com/study/6108-pos1053-prevalence-of-fibrosing-progressive-interstitial-lung-disease2026-10-06 https://evidence-hub.com/study/6109-assessment-of-cefuroxime-and-cefuroxime-clavulanic-acid-prescription2026-10-06 https://evidence-hub.com/study/6110-there-s-the-rub-a-narrative-review-of-the-benefits-and-complications2026-10-06 https://evidence-hub.com/study/6111-analysis-of-positioning-techniques-in-thoracic-radiography2026-10-06 https://evidence-hub.com/study/6114-efficacy-and-safety-outcomes-of-car-t-cell-therapies-in-patients-with2026-10-06 https://evidence-hub.com/study/6115-correspondence-on-management-of-nirmatrelvir-ritonavir-and-tacrolimus2026-10-06 https://evidence-hub.com/study/6116-abstract-p1-06-12-efficacy-and-safety-of-the-addition-of-prophylactic2026-10-06 https://evidence-hub.com/study/6117-interstitial-pneumonia-with-autoimmune-features-and-histologic-usual2026-10-06 https://evidence-hub.com/study/6118-efficacy-of-modified-transforaminal-lumbar-interbody-fusion-in-three2026-10-06 https://evidence-hub.com/study/6119-malignant-airway-obstruction-and-the-use-of-nd-yag-laser-a-systematic2026-10-06 https://evidence-hub.com/study/6120-abstract-3112-pralsetinib-induces-opportunistic-infection-in-ret2026-10-06 https://evidence-hub.com/study/6121-a63-49-therapeutic-effect-of-adding-inhaled-treprostinil-to-pde52026-10-19 https://evidence-hub.com/study/6123-pneumonia-in-children-under-five-years-old-in-kpk-symptoms-and2026-10-06 https://evidence-hub.com/study/6124-salivary-gland-botulinum-toxin-a-injections-for-treating-sialorrhea2026-10-06 https://evidence-hub.com/study/6125-outcomes-of-car-t-cell-therapies-after-prior-treatment-with-fixed2026-10-06 https://evidence-hub.com/study/6127-fungal-infection-in-patients-treated-with-bruton-s-tyrosine-kinase2026-10-06 https://evidence-hub.com/study/6128-the-effect-of-plasma-exchange-on-recovery-of-patients-with2026-10-06 https://evidence-hub.com/study/6130-ceftazidime-avibactam-and-ceftolozane-tazobactam-for-severe-pediatric2026-10-06 https://evidence-hub.com/study/6131-a41-17-a-case-of-afatinib-associated-pneumonitis-in-a-patient-with2026-10-06 https://evidence-hub.com/study/6132-car-t-cell-therapy-in-systemic-sclerosis-the-next-frontier-in-immune2026-10-06 https://evidence-hub.com/study/6133-abstract-4998-pralsetinib-induces-opportunistic-infection-in-ret2026-10-06 https://evidence-hub.com/study/6134-population-pharmacokinetics-of-vancomycin-in-hemodialysis-patients2026-10-06 https://evidence-hub.com/study/6136-intravenous-immunoglobulin-therapy-in-icu-managed-guillain-barre2026-10-06 https://evidence-hub.com/study/6137-immunotherapy-in-bellini-duct-carcinoma-a-systematic-review2026-10-06 https://evidence-hub.com/study/6138-safety-and-efficacy-of-stereotactic-body-radiotherapy-for-ultra2026-10-06 https://evidence-hub.com/study/6139-baricitinib-in-polymyalgia-rheumatica-and-giant-cell-arteritis-report2026-10-06 https://evidence-hub.com/study/6140-comparison-of-clinical-efficacy-between-reconstruction-of-the2026-10-19 https://evidence-hub.com/study/6141-determining-the-clinical-characteristics-treatment-strategies-and2026-10-06 https://evidence-hub.com/study/6142-exploring-the-efficacy-of-benralizumab-in-chronic-eosinophilic2026-10-06 https://evidence-hub.com/study/6143-pneumocystis-jirovecii-pneumonia-in-a-patient-with-hr-her2-advanced2026-10-06 https://evidence-hub.com/study/6144-successful-outpatient-treatment-of-legionella-pneumophila-pneumonia2026-10-06 https://evidence-hub.com/study/6145-abrupt-breathlessness-pneumocystis-jirovecii-pneumonia-associated2026-10-06 https://evidence-hub.com/study/6146-fulminant-macrolide-resistant-mycoplasma-pneumoniae-pneumonia-in-a2026-10-08 https://evidence-hub.com/study/6147-role-of-subcutaneous-adrenaline-in-reducing-bleeding-risks-during2026-10-06 https://evidence-hub.com/study/6148-surgical-intervention-for-patients-with-fibrinopurulent-pleural2026-10-06 https://evidence-hub.com/study/6149-adjunctive-diagnosis-of-mycobacterium-gordonae-pneumonia-by2026-10-08 https://evidence-hub.com/study/6150-cryptogenic-organizing-pneumonia-a-case-report2026-10-06 https://evidence-hub.com/study/6151-refractory-mycoplasma-pneumoniae-with-cytokine-storm-a-case-report2026-10-08 https://evidence-hub.com/study/6152-case-report-infective-endocarditis-caused-by-streptococcus-pneumonia2026-10-08 https://evidence-hub.com/study/6153-benralizumab-for-acute-thromboembolism-in-hypereosinophilic-syndrome2026-10-06 https://evidence-hub.com/study/6154-successful-endovascular-repair-of-a-symptomatic-descending-thoracic2026-10-06 https://evidence-hub.com/study/6155-multiple-brain-lesions-in-a-patient-with-relapsed-hairy-cell-leukemia2026-10-06 https://evidence-hub.com/study/6157-full-recovery-of-lung-tissue-after-severe-viral-pneumonia-h1n1-a-case2026-10-06 https://evidence-hub.com/study/6158-the-efficacy-of-high-flow-nasal-cannula-hfnc-in-chronic-obstructive2026-10-06 https://evidence-hub.com/study/6159-a-case-report-on-stenotrophomonas-maltophilia2026-10-08 https://evidence-hub.com/study/6160-pneumomediastinum-and-subcutaneous-emphysema-as-initial-presentations2026-10-08 https://evidence-hub.com/study/6161-clinical-pharmacist-involved-in-the-treatment-of-pneumocystis-carinii2026-10-06 https://evidence-hub.com/study/6162-rapid-diagnosis-of-pulmonary-chlamydia-psittaci-infection-using2026-10-08 https://evidence-hub.com/study/6163-delayed-onset-of-linezolid-induced-peripheral-neuropathy-a-case2026-10-06 https://evidence-hub.com/study/6165-problems-with-diagnosis-and-management-of-pneumonia-in-sle-patients2026-10-08 https://evidence-hub.com/study/6166-efficacy-and-safety-of-dostarlimab-in-elderly-patients-with-multiple2026-10-06 https://evidence-hub.com/study/6167-treatment-approaches-for-mdr-acinetobacter-baumannii-cns-in-an-infant2026-10-06 https://evidence-hub.com/study/6168-successful-treatment-of-cheilitis-glandularis-accompanied-by2026-10-06 https://evidence-hub.com/study/6169-clinical-case-report-on-the-use-of-rezafungin-in-pneumocystis2026-10-06 https://evidence-hub.com/study/6170-pharmacokinetics-of-dolutegravir-tenofovir-and-lamivudine-during2026-10-06 https://evidence-hub.com/study/6171-systemic-lupus-erythematosus-associated-with-posterior-reversible2026-10-08 https://evidence-hub.com/study/6172-bilateral-lung-transplantation-for-severe-lung-disease-caused-by-a2026-10-06 https://evidence-hub.com/study/6173-an-emerging-bacterium-chryseobacterium-indologenes-a-case-report-and2026-10-08 https://evidence-hub.com/study/6174-long-term-complete-response-in-stage-iva-esophageal-squamous-cell2026-10-06 https://evidence-hub.com/study/6175-spinal-cord-metastasis-in-a-long-term-survivor-of-primary-malignant2026-10-06 https://evidence-hub.com/study/6176-metastatic-gestational-trophoblastic-neoplasia-leading-to-acute2026-10-06 https://evidence-hub.com/study/6177-nivolumab-induced-organizing-pneumonia-in-management-of-non-small2026-10-06 https://evidence-hub.com/study/6178-ventilator-associated-pneumonia-vap-and-pleural-empyema-caused-by2026-10-06 https://evidence-hub.com/study/6179-case-report-long-term-survival-in-synchronous-double-primary2026-10-06 https://evidence-hub.com/study/6180-a83-plant-based-enteral-nutrition-a-potential-method-of-secretion2026-10-06 https://evidence-hub.com/study/6181-glucocorticoid-pulse-therapy-in-an-elderly-patient-with-post-covid-192026-10-06 https://evidence-hub.com/study/6182-integrative-postural-rehabilitation-for-kyphotic-deformity-in-a2026-10-19 https://evidence-hub.com/study/6183-mechanized-pneumonia-secondary-to-legionella-infection-with-diarrhea2026-10-06 https://evidence-hub.com/study/6184-ropeginterferon-alfa-2b-as-a-promising-alternative-to-conventional2026-10-19 https://evidence-hub.com/study/6185-abstract-4364158-a-ticking-time-bomb-acute-amiodarone-induced2026-10-06 https://evidence-hub.com/study/6186-an-implementation-effectiveness-trial-investigating-feasibility2026-10-06 https://evidence-hub.com/study/6188-the-evolution-of-pneumocystis-jirovecii-pneumonia-prophylaxis-for2026-10-06 https://evidence-hub.com/study/6189-prognostic-significance-of-an-integrated-diagnostic-and-therapeutic2026-10-06 https://evidence-hub.com/study/6190-2590-efficacy-of-doxycycline-versus-azithromycin-in-community2026-10-06 https://evidence-hub.com/study/6191-p11-establishing-the-dose-and-empirical-efficacy-of-benzylpenicillin2026-10-06 https://evidence-hub.com/study/6192-large-language-model-based-clinical-decision-support-for-antibiotic2026-10-06 https://evidence-hub.com/study/6193-ventilator-associated-pneumonia-how-long-is-long-enough2026-10-06 https://evidence-hub.com/study/6194-prevalence-and-antibiotic-susceptibility-patterns-of-streptococcus2026-10-06 https://evidence-hub.com/study/6195-treatment-of-rheumatoid-arthritis-associated-interstitial-lung2026-10-06 https://evidence-hub.com/study/6196-aarc-clinical-practice-guideline-patient-ventilator-assessment2026-10-06 https://evidence-hub.com/study/6197-the-effectiveness-of-intravenous-iv-to-oral-po-antibiotic-switch2026-10-06 https://evidence-hub.com/study/6198-optimal-infection-prophylaxis-strategy-for-relapsed-refractory2026-10-06 https://evidence-hub.com/study/6199-role-of-antipsychotic-agents-in-dementia-associated-neuropsychiatric2026-10-06 https://evidence-hub.com/study/6200-effectiveness-of-low-dose-sglt2-inhibitors-in-diabetic-patients-with2026-10-19 https://evidence-hub.com/study/6201-a-study-to-assess-the-efficacy-and-prescribing-pattern-of-antibiotics2026-10-06 https://evidence-hub.com/study/6202-feasibility-and-safety-of-vertebrobasilar-artery-cooling-infusion2026-10-06 https://evidence-hub.com/study/6203-pasteurella-multocida-pneumonia-with-hemoptysis-in-an-immunocompetent2026-10-06 https://evidence-hub.com/study/6204-empiric-antibiotic-selection-for-community-acquired-pneumonia-in-us2026-10-08 https://evidence-hub.com/study/6205-management-of-gastrointestinal-symptoms-in-patients-with-movement2026-10-08 https://evidence-hub.com/study/6206-clinical-outcome-and-genomic-biomarkers-of-immune-checkpoint2026-10-06 https://evidence-hub.com/study/6207-clinical-practice-guidelines-for-dysphagia-management-in-intensive2026-10-06 https://evidence-hub.com/study/6208-acinetobacter-baumannii-infections-among-patients-in-intensive-care2026-10-08 https://evidence-hub.com/study/6209-abstract-p4-05-08-impact-of-antiemetic-prophylaxis-on-maintaining2026-10-06 https://evidence-hub.com/study/6210-ertugliflozin-for-functional-mitral-regurgitation-associated-with2026-10-06 https://evidence-hub.com/study/6211-variability-in-bacteremia-prophylaxis-use-and-regimens-in-pediatric2026-10-06 https://evidence-hub.com/study/6215-population-pharmacokinetics-and-monte-carlo-based-dosing-optimization2026-10-06 https://evidence-hub.com/study/6216-corticosteroids-in-non-viral-acute-respiratory-distress-syndrome-ards2026-10-06 https://evidence-hub.com/study/6217-b73-43-empyema-in-older-adult-diagnostic-delay-and-rapid-resolution2026-10-06 https://evidence-hub.com/study/6218-a-questionnaire-based-survey-to-understand-the-role-of-ceftazidime2026-10-06 https://evidence-hub.com/study/6220-overview-of-lactam-resistance-genes-in-pandemic-multidrug-resistant2026-10-06 https://evidence-hub.com/study/6221-tocilizumab-treatment-in-a-patient-of-refractory-anti-ej-positive2026-10-06 https://evidence-hub.com/study/6222-abstract-278-patterns-of-mechanical-thrombectomy-for-stroke-before2026-10-06 https://evidence-hub.com/study/6224-infectious-complications-and-antibiotic-prophylaxis-during-induction2026-10-08 https://evidence-hub.com/study/6225-multidisciplinary-management-of-concurrent-small-cell-lung-cancer-and2026-10-06 https://evidence-hub.com/study/6227-brave-new-world-of-artificial-intelligence-its-use-in-antimicrobial2026-10-13 https://evidence-hub.com/study/6228-what-is-the-role-of-microbial-biotechnology-and-genetic-engineering2026-10-06 https://evidence-hub.com/study/6229-chlamydia-trachomatis-an-emerging-old-entity2026-10-06 https://evidence-hub.com/study/6230-efficacy-and-treatment-outcome-of-infected-patients-with-pulmonary2026-10-08 https://evidence-hub.com/study/6231-individualized-trimethoprim-sulfamethoxazole-dosing-in-non-hiv2026-10-08 https://evidence-hub.com/study/6235-resistance-in-pseudomonas-aeruginosa-a-narrative-review-of2026-10-01 https://evidence-hub.com/study/6236-antibiotic-duration-for-common-bacterial-infections-a-systematic2026-10-13 https://evidence-hub.com/study/6237-risk-factors-for-mortality-in-stenotrophomonas-maltophilia-bacteremia2026-10-08 https://evidence-hub.com/study/6238-therapeutic-options-for-adult-patients-with-persistent-methicillin2026-10-01 https://evidence-hub.com/study/6239-efficacy-of-antimicrobials-or-placebo-compared-to-amoxicillin2026-10-06 https://evidence-hub.com/study/6240-risk-factors-associated-with-antibiotic-exposure-variability-in2026-10-05 https://evidence-hub.com/study/6241-mortality-risk-and-antibiotic-therapy-for-patients-with-infections2026-10-08 https://evidence-hub.com/study/6242-current-practices-and-challenges-of-outpatient-parenteral2026-10-08 https://evidence-hub.com/study/6243-piperacillin-tazobactam-versus-carbapenems-in-patients-with-severe2026-10-01 https://evidence-hub.com/study/6244-antibiotic-therapy-strategies-for-treating-gram-negative-severe2026-10-01 https://evidence-hub.com/study/6245-comparison-of-short-course-versus-long-course-antibiotic-treatment2026-10-08 https://evidence-hub.com/study/6246-point-prevalence-of-evidence-based-antimicrobial-use-among2026-10-05 https://evidence-hub.com/study/6247-the-impact-of-antibiotic-prophylaxis-on-antibiotic-resistance2026-10-08 https://evidence-hub.com/study/6248-drugs-for-treating-infections-caused-by-non-tubercular-mycobacteria-a2026-10-03 https://evidence-hub.com/study/6249-the-uselessness-of-anaerobic-antibiotic-coverage-in-aspiration2026-10-08 https://evidence-hub.com/study/6250-comparing-the-outcomes-of-cefoperazone-sulbactam-based-and-non2026-10-08 https://evidence-hub.com/study/6252-microbiome-modulation-in-pediatric-leukemia-impact-on-graft-versus2026-10-01 https://evidence-hub.com/study/6253-tetracyclines-the-old-and-the-new-a-narrative-review2026-10-08 https://evidence-hub.com/study/6254-eosinophilic-complications-during-dupilumab-therapy-for-type-22026-10-08 https://evidence-hub.com/study/6255-drug-induced-lung-disease-a-narrative-review2026-10-08 https://evidence-hub.com/study/6256-optimizing-pharmacotherapy-regimens-in-adult-patients-receiving2026-10-01 https://evidence-hub.com/study/6257-rationale-for-contemporary-antimicrobial-treatment-of2026-10-08 https://evidence-hub.com/study/6258-efficacy-of-antimicrobials-in-preventing-resistance-in-solid-organ2026-10-01 https://evidence-hub.com/study/6259-ophthalmic-aspects-of-stevens-johnson-syndrome-and-toxic-epidermal2026-10-01 https://evidence-hub.com/study/6260-appropriate-duration-of-antimicrobial-treatment-for-prosthetic-joint2026-10-08 https://evidence-hub.com/study/6261-comparative-efficacy-and-safety-of-carbapenems-vs-noncarbapenem2026-10-08 https://evidence-hub.com/study/6262-the-role-of-the-oral-microbiome-and-dental-caries-in-respiratory2026-10-08 https://evidence-hub.com/study/6263-contemporary-pharmacotherapies-for-nontuberculosis-mycobacterial2026-10-01 https://evidence-hub.com/study/6264-emerging-prevalence-and-clinical-features-of-elizabethkingia2026-10-01 https://evidence-hub.com/study/6265-new-antimicrobials-for-the-treatment-of-neonatal-sepsis-caused-by2026-10-01 https://evidence-hub.com/study/6266-a-systematic-review-and-bayesian-meta-analysis-of-the-antibiotic2026-10-01 https://evidence-hub.com/study/6267-global-trends-of-ceftazidime-avibactam-resistance-in-gram-negative2026-10-08 https://evidence-hub.com/study/6268-rationale-and-evidence-for-the-adjunctive-use-of-n-acetylcysteine-in2026-10-01 https://evidence-hub.com/study/6269-systematic-review-of-efficacy-and-safety-of-shorter-regimens-for-drug2026-10-01 https://evidence-hub.com/study/6270-recent-advance-on-nanoparticles-or-nanomaterials-with-anti-multidrug2026-10-05 https://evidence-hub.com/study/6271-burden-and-management-of-multi-drug-resistant-organism-infections-in2026-10-08 https://evidence-hub.com/study/6272-comparative-efficacy-and-safety-of-colistin-based-and-alternative2026-10-08 https://evidence-hub.com/study/6273-network-meta-analysis-of-antibiotic-resistance-patterns-in-gram2026-10-01 https://evidence-hub.com/study/6274-tonsillitis-and-sinusitis-a-narrative-review-of-pathogenesis2026-10-01 https://evidence-hub.com/study/6275-association-between-point-mutations-of-macrolide-resistant-mycoplasma2026-10-01 https://evidence-hub.com/study/6276-safety-and-tolerability-of-pivmecillinam-during-more-than-four2026-10-13 https://evidence-hub.com/study/6277-immune-checkpoint-inhibitor-associated-pneumonitis-a-narrative-review2026-10-01 https://evidence-hub.com/study/6278-a-systematic-review-quercetin-secondary-metabolite-of-the-flavonol2026-10-13 https://evidence-hub.com/study/6279-behavior-change-interventions-to-improve-antimicrobial-stewardship-in2026-10-01 https://evidence-hub.com/study/6280-dynamic-in-vitro-pk-pd-infection-models-for-the-development-and2026-10-08 https://evidence-hub.com/study/6281-to-heal-or-harm-a-systematic-review-of-the-role-of-fluoroquinolones2026-10-13 https://evidence-hub.com/study/6282-guarding-minds-a-narrative-review-on-how-n-acetylcyteine-and-ketones2026-10-05 https://evidence-hub.com/study/6284-therapeutic-potential-of-2-2-benzofuranyl-2-imidazoline-in2026-10-19 https://evidence-hub.com/study/6285-galleria-mellonella-greater-wax-moth-as-a-reliable-animal-model-to2026-10-09 https://evidence-hub.com/study/6286-galleria-mellonella-intracellular-bacteria-pathogen-infection-models2026-10-01 https://evidence-hub.com/study/6287-a-chronic-acinetobacter-baumannii-pneumonia-model-to-study-long-term2026-10-08 https://evidence-hub.com/study/6288-algae-and-bacteria-consortia-for-wastewater-decontamination-and2026-10-01 https://evidence-hub.com/study/6289-emerging-challenges-in-antimicrobial-resistance-implications-for2026-10-03 https://evidence-hub.com/study/6290-synergistic-effects-of-candida-albicans-and-porphyromonas-gingivalis2026-10-08 https://evidence-hub.com/study/6291-phage-delivery-strategies-for-biocontrolling-human-animal-and-plant2026-10-08 https://evidence-hub.com/study/6292-enhanced-antibacterial-activity-of-carbon-dots-a-hybrid-approach-with2026-10-08 https://evidence-hub.com/study/6293-efficacy-of-new-generation-biosorbents-for-the-sustainable-treatment2026-10-01 https://evidence-hub.com/study/6294-pharmacokinetic-pharmacodynamic-analysis-of-sulbactam-against2026-10-08 https://evidence-hub.com/study/6295-bacteriophages-the-promising-therapeutic-approach-for-enhancing2026-10-01 https://evidence-hub.com/study/6296-who-s-essential-medicines-and-aware-recommendations-on-first-and2026-10-05 https://evidence-hub.com/study/6297-synergistic-action-of-antimicrobial-peptides-and-antibiotics-current2026-10-01 https://evidence-hub.com/study/6298-use-of-nanotechnology-based-nanomaterial-as-a-substitute-for2026-10-08 https://evidence-hub.com/study/6299-cost-effectiveness-analysis-of-ctz-taz-for-the-treatment-of2026-10-08 https://evidence-hub.com/study/6300-marmosets-as-models-of-infectious-diseases2026-10-08 https://evidence-hub.com/study/6301-selected-strategies-to-fight-pathogenic-bacteria2026-10-01 https://evidence-hub.com/study/6302-near-infrared-in-vivo-imaging-system-for-dynamic-visualization-of2026-10-08 https://evidence-hub.com/study/6303-development-and-confirmation-of-humanized-plasma-and-epithelial2026-10-08 https://evidence-hub.com/study/6304-ceftobiprole-medocaril-is-an-effective-post-exposure-treatment-in-the2026-10-01 https://evidence-hub.com/study/6305-understanding-blandm-1-gene-regulation-in-crkp-infections-toward2026-10-08 https://evidence-hub.com/study/6306-evaluating-the-antimicrobial-efficacy-of-ceftriaxone-regimens-1-g2026-10-08 https://evidence-hub.com/study/6307-integrative-population-pharmacokinetic-pharmacodynamic-analysis-of2026-10-01 https://evidence-hub.com/study/6308-recombinant-gm-csf-enhances-the-bactericidal-ability-of-pmns-by2026-10-01 https://evidence-hub.com/study/6309-pulsed-electric-field-at-resonance-frequency-combat-klebsiella2026-10-08 https://evidence-hub.com/study/6310-identification-and-preclinical-efficacy-evaluation-of-two-lytic2026-10-01 https://evidence-hub.com/study/6311-in-vivo-dose-response-and-efficacy-of-the-lactamase-inhibitor2026-10-01 https://evidence-hub.com/study/6312-carbapenem-resistant-klebsiella-pneumoniae-virulence-factors2026-10-01 https://evidence-hub.com/study/6313-efficacy-of-intravenously-administered-gepotidacin-in-cynomolgus2026-10-01 https://evidence-hub.com/study/6314-inhibitors-of-the-elastase-lasb-for-the-treatment-of-pseudomonas2026-10-01 https://evidence-hub.com/study/6315-efficacy-of-delafloxacin-against-the-biothreat-pathogenbacillus2026-10-01 https://evidence-hub.com/study/6316-a-review-of-the-resistance-mechanisms-for-lactams-macrolides-and2026-10-01 https://evidence-hub.com/study/6317-sars-cov-2-affects-both-humans-and-animals-what-is-the-potential2026-10-01 https://evidence-hub.com/study/6318-specific-inhibition-of-orai1-mediated-calcium-signalling-resolves2026-10-01 https://evidence-hub.com/study/6319-formulation-and-evaluation-of-3d-printed-dressings-loaded-with2026-10-08 https://evidence-hub.com/study/6320-clinical-efficacy-of-combination-therapy-of-fuxi-tiandi-wuxing2026-10-01 https://evidence-hub.com/study/6321-mechanisms-of-antibiotic-resistance-and-developments-in-therapeutic2026-10-01 https://evidence-hub.com/study/6322-strategy-to-combat-biofilms-a-focus-on-biofilm-dispersal-enzymes2026-10-01 https://evidence-hub.com/study/6323-genomic-investigation-of-lactococcus-formosensis-lactococcus-garvieae2026-10-03 https://evidence-hub.com/study/6324-evaluating-the-safety-pharmacokinetics-and-efficacy-of-phage-therapy2026-10-01 https://evidence-hub.com/study/6325-pharmacokinetic-and-pharmacodynamic-properties-of-polymyxin-b-in2026-10-01 https://evidence-hub.com/study/6326-pneumocystis-jirovecii-pneumonia-complicated-a-case-of-sars-cov-22026-10-04 https://evidence-hub.com/study/6327-examining-the-efficacy-and-safety-of-combined-locoregional-therapy2026-10-01 https://evidence-hub.com/study/6328-green-synthesis-of-polyethylene-glycol-coated-ciprofloxacin-loaded2026-10-01 https://evidence-hub.com/study/6329-breathing-new-life-nanomedicines-for-pulmonary-drug-delivery2026-10-01 https://evidence-hub.com/study/6330-conjugates-of-chitosan-with-cyclodextrins-as-promising-carriers-for2026-10-01 https://evidence-hub.com/study/6331-antibacterial-effect-of-vitamin-c-against-uropathogenic-e-coli-in2026-10-01 https://evidence-hub.com/study/6332-in-vitro-in-vivo-and-clinical-studies-comparing-the-efficacy-of2026-10-01 https://evidence-hub.com/study/6333-novel-mechanisms-of-macrolide-resistance-revealed-by-in-vitro2026-10-01 https://evidence-hub.com/study/6334-in-vitro-activity-of-cefiderocol-on-multiresistant-bacterial-strains2026-10-01 https://evidence-hub.com/study/6335-combination-therapy-with-ciprofloxacin-and-pentamidine-against2026-10-01 https://evidence-hub.com/study/6336-current-treatment-options-for-pneumonia-caused-by-carbapenem2026-10-01 https://evidence-hub.com/study/6337-7-year-2015-21-longitudinal-surveillance-of-lefamulin-in-vitro2026-10-01 https://evidence-hub.com/study/6338-in-vitro-activities-of-omadacycline-eravacycline-cefiderocol2026-10-01 https://evidence-hub.com/study/6339-in-vitro-activity-of-ceftazidime-avibactam-cefiderocol-meropenem2026-10-03 https://evidence-hub.com/study/6340-oxiconazole-potentiates-gentamicin-against-gentamicin-resistant2026-10-01 https://evidence-hub.com/study/6341-novel-siderophore-cephalosporin-and-combinations-of-cephalosporins2026-10-01 https://evidence-hub.com/study/6342-clinical-and-epidemiologic-features-of-mycoplasma-pneumoniae2026-10-01 https://evidence-hub.com/study/6343-levofloxacin-niflumate-salt-development-as-a-strategy-for-improving2026-10-08 https://evidence-hub.com/study/6344-thionated-levofloxacin-derivative-potential-repurposing-for-cancer2026-10-05 https://evidence-hub.com/study/6345-pulmonary-pharmacokinetic-and-pharmacodynamic-evaluation-of2026-10-01 https://evidence-hub.com/study/6346-tackling-the-outer-membrane-facilitating-compound-entry-into-gram2026-10-01 https://evidence-hub.com/study/6347-low-generation-cationic-phosphorus-dendrimers-novel-approach-to2026-10-01 https://evidence-hub.com/study/6348-carbapenem-resistant-acinetobacter-baumannii-and-ventilator2026-10-01 https://evidence-hub.com/study/6349-in-vitro-effects-of-deferoxamine-on-antibiotic-susceptibility-in-gram2026-10-08 https://evidence-hub.com/study/6350-bacterial-efflux-pump-inhibitors-reduce-antibiotic-resistance2026-10-03 https://evidence-hub.com/study/6351-machine-learning-and-feature-extraction-for-rapid-antimicrobial2026-10-08 https://evidence-hub.com/study/6352-biosynthesis-and-characterization-of-copper-oxide-nanoparticles-from2026-10-01 https://evidence-hub.com/study/6353-comprehensive-approaches-to-combatting-acinetobacter-baumannii2026-10-01 https://evidence-hub.com/study/6354-thwarting-resistance-mgra-inhibition-with-methylophiopogonanone-a2026-10-08 https://evidence-hub.com/study/6355-navigating-fluoroquinolone-resistance-in-gram-negative-bacteria-a2026-10-03 https://evidence-hub.com/study/6356-synthesis-and-antibacterial-evaluation-of-an-indole-triazole2026-10-08 https://evidence-hub.com/study/6357-antimicrobial-activity-of-arthrospira-platensis-mediated-gold2026-10-08 https://evidence-hub.com/study/6358-recent-advances-in-advanced-oxidation-processes-for-degrading2026-10-01 https://evidence-hub.com/study/6359-development-in-the-synthesis-of-bioactive-thiazole-based-heterocyclic2026-10-01 https://evidence-hub.com/study/6360-synthesis-characterization-quantum-chemical-modelling-molecular2026-10-08 https://evidence-hub.com/study/6361-antibacterial-properties-of-copper-oxide-nanoparticles-review2026-10-01 https://evidence-hub.com/study/6362-potentiation-and-mechanism-of-berberine-as-an-antibiotic-adjuvant2026-10-01 https://evidence-hub.com/study/6363-the-design-and-functional-characterization-of-a-novel-hybrid2026-10-08 https://evidence-hub.com/study/6364-extending-the-potency-and-lifespan-of-antibiotics-inhibitors-of-gram2026-10-03 https://evidence-hub.com/study/6365-anti-urease-therapy-a-targeted-approach-to-mitigating-antibiotic2026-10-01 https://evidence-hub.com/study/6366-clonal-background-and-routes-of-plasmid-transmission-underlie2026-10-08 https://evidence-hub.com/study/6367-antimicrobial-peptides-and-cell-penetrating-peptides-non-antibiotic2026-10-01 https://evidence-hub.com/study/6368-recent-advances-in-the-development-of-antibiotics-coated-gold2026-10-01 https://evidence-hub.com/study/6369-combating-antimicrobial-resistance-innovative-strategies-using2026-10-01 https://evidence-hub.com/study/6370-chemistry-and-pharmacology-of-fluorinated-drugs-approved-by-the-fda2026-10-01 https://evidence-hub.com/study/6371-in-silico-docking-and-toxicity-analysis-of-n-acetyl-d-glucosamine2026-10-08 https://evidence-hub.com/study/6372-repurposing-the-angiotensin-ii-receptor-blocker-valsartan-to-inhibit2026-10-08 https://evidence-hub.com/study/6373-in-vitro-anti-inflammatory-and-antagonistic-efficacy-of-polymyxin-b2026-10-08 https://evidence-hub.com/study/6374-translational-pk-pd-for-the-development-of-novel-antibiotics-a-drug2026-10-01 https://evidence-hub.com/study/6375-niosome-as-an-effective-nanoscale-solution-for-the-treatment-of2026-10-13 https://evidence-hub.com/study/6376-carbapenem-resistant-acinetobacter-baumannii-raises-global-alarm-for2026-10-01 https://evidence-hub.com/study/6377-anti-qs-strategies-against-pseudomonas-aeruginosa-infections2026-10-08 https://evidence-hub.com/study/6378-biofilm-mediated-infections-by-multidrug-resistant-microbes-a2026-10-08 https://evidence-hub.com/study/6379-fluoroquinolone-resistance-determinants-in-carbapenem-resistant2026-10-13 https://evidence-hub.com/study/6381-micro-nanoemulsion-and-nanoparticle-assisted-drug-delivery-against2026-10-01 https://evidence-hub.com/study/6383-efficacy-of-oseltamivir-in-the-treatment-of-patients-infected-with2026-10-08 https://evidence-hub.com/study/6384-induced-heteroresistance-in-carbapenem-resistant-acinetobacter2026-10-01 https://evidence-hub.com/study/6385-fighting-cytokine-storm-and-immunomodulatory-deficiency-by-using2026-10-01 https://evidence-hub.com/study/6386-biofilm-antimicrobial-susceptibility-testing-where-are-we-and-where2026-10-01 https://evidence-hub.com/study/6387-antimicrobial-susceptibility-and-molecular-features-of-colonizing2026-10-01 https://evidence-hub.com/study/6388-small-schiff-base-molecules-a-possible-strategy-to-combat-biofilm2026-10-08 https://evidence-hub.com/study/6389-colistin-resistance-mechanism-and-management-strategies-of-colistin2026-10-08 https://evidence-hub.com/study/6390-harnessing-subtractive-genomics-for-drug-target-identification-in2026-10-08 https://evidence-hub.com/study/6391-new-antimicrobial-strategies-to-treat-multi-drug-resistant-infections2026-10-01 https://evidence-hub.com/study/6392-the-role-of-artificial-intelligence-and-machine-learning-in2026-10-01 https://evidence-hub.com/study/6393-carbapenem-resistance-in-acinetobacter-baumannii-mechanisms2026-10-01 https://evidence-hub.com/study/6394-voriconazole-loaded-spanlastics-design-formulation-optimization-and2026-10-01 https://evidence-hub.com/study/6395-carbapenem-resistant-acinetobacter-baumannii-virulence-factors2026-10-01 https://evidence-hub.com/study/6396-evolving-biofilm-inhibition-and-eradication-in-clinical-settings2026-10-01 https://evidence-hub.com/study/6397-antimicrobial-action-mechanisms-of-natural-compounds-isolated-from2026-10-01 https://evidence-hub.com/study/6398-facile-synthesis-of-5-bromo-n-alkylthiophene-2-sulfonamides-and-its2026-10-08 https://evidence-hub.com/study/6399-oral-versus-intravenous-antibiotic-treatment-for-febrile-neutropenia2026-10-06 https://evidence-hub.com/study/6400-antibiotic-prophylaxis-for-elective-hysterectomy2026-10-13 https://evidence-hub.com/study/6401-fluoroquinolones-for-treating-typhoid-and-paratyphoid-fever-enteric2026-10-06 https://evidence-hub.com/study/6402-prophylactic-antibiotic-therapy-for-chronic-obstructive-pulmonary2026-10-06 https://evidence-hub.com/study/6403-antibiotic-prophylaxis-for-bacterial-infections-in-afebrile2026-10-06 https://evidence-hub.com/study/6404-medical-and-chemical-efficacy-of-respiratory-physiotherapy-and2026-10-06 https://evidence-hub.com/study/6405-xiyanping-plus-azithromycin-chemotherapy-in-pediatric-patients-with2026-10-06 https://evidence-hub.com/study/6406-efficacy-and-effectiveness-of-ceftaroline-fosamil-in-patients-with2026-10-06 https://evidence-hub.com/study/6408-short-course-versus-long-course-therapy-of-the-same-antibiotic-for2026-10-06 https://evidence-hub.com/study/6409-treatment-of-enteric-fever-typhoid-and-paratyphoid-fever-with2026-10-06 https://evidence-hub.com/study/6410-bacillus-calmette-guerin-treatment-of-bladder-cancer-a-systematic2026-10-06 https://evidence-hub.com/study/6411-continuous-versus-intermittent-antibiotics-for-bronchiectasis2026-10-06 https://evidence-hub.com/study/6412-low-bacterial-diet-versus-control-diet-to-prevent-infection-in-cancer2026-10-06 https://evidence-hub.com/study/6413-non-surgical-interventions-for-late-rectal-problems-proctopathy-of2026-10-06 https://evidence-hub.com/study/6414-systematic-review-of-evidence-based-guidelines-on-medication-therapy2026-10-06 https://evidence-hub.com/study/6415-drugs-for-preventing-tuberculosis-in-people-at-risk-of-multiple-drug2026-10-06 https://evidence-hub.com/study/6416-safety-and-efficacy-of-omadacycline-by-body-mass-index-in-patients2026-10-08 https://evidence-hub.com/study/6417-optimal-thromboprophylaxis-strategies-in-non-critically-ill-patients2026-10-06 https://evidence-hub.com/study/6418-efficacy-and-safety-of-oral-melatonin-in-patients-with-severe-covid2026-10-06 https://evidence-hub.com/study/6419-a-multicenter-phase-2-randomized-controlled-study-on-the-efficacy-and2026-10-06 https://evidence-hub.com/study/6420-ceftolozane-tazobactam-versus-meropenem-in-patients-with-ventilated2026-10-06 https://evidence-hub.com/study/6421-efficacy-of-traditional-chinese-medicine-maxingshigan-weijing-in-the2026-10-06 https://evidence-hub.com/study/6422-safety-and-efficacy-assessment-of-allogeneic-human-dental-pulp-stem2026-10-06 https://evidence-hub.com/study/6423-evaluation-of-the-efficacy-and-safety-of-melatonin-in-moderately-ill2026-10-06 https://evidence-hub.com/study/6424-efficacy-and-safety-of-inhaled-ciclesonide-in-treating-patients-with2026-10-06 https://evidence-hub.com/study/6425-marked-reduction-in-28-day-mortality-among-elderly-patients-with2026-10-08 https://evidence-hub.com/study/6426-efficacy-of-dexamethasone-treatment-for-patients-with-the-acute2026-10-06 https://evidence-hub.com/study/6427-efficacy-and-safety-of-favipiravir-in-moderate-covid-19-pneumonia2026-10-06 https://evidence-hub.com/study/6428-tocilizumab-in-patients-hospitalised-with-covid-19-pneumonia-efficacy2026-10-06 https://evidence-hub.com/study/6429-auxora-vs-placebo-for-the-treatment-of-patients-with-severe-covid-192026-10-08 https://evidence-hub.com/study/6430-efficacy-of-short-course-colchicine-treatment-in-hospitalized2026-10-06 https://evidence-hub.com/study/6431-benefits-and-harm-of-probiotics-and-synbiotics-in-adult-critically2026-10-06 https://evidence-hub.com/study/6433-treatment-effect-of-nafamostat-mesylate-in-patients-with-covid-192026-10-08 https://evidence-hub.com/study/6434-efficacy-of-hydroxychloroquine-in-patients-with-covid-19-results-of-a2026-10-06 https://evidence-hub.com/study/6435-three-day-icatibant-on-top-of-standard-care-in-patients-with2026-10-06 https://evidence-hub.com/study/6436-safety-and-efficacy-of-the-ezh1-2-inhibitor-valemetostat-tosylate-ds2026-10-06 https://evidence-hub.com/study/6437-efficacy-and-safety-of-sid142-in-patients-with-peripheral-arterial2026-10-19 https://evidence-hub.com/study/6438-meplazumab-treats-covid-19-pneumonia-an-open-labelled-concurrent2026-10-06 https://evidence-hub.com/study/6439-omadacycline-in-the-treatment-of-community-acquired-bacterial2026-10-06 https://evidence-hub.com/study/6440-the-efficacy-and-safety-of-sitafloxacin-and-garenoxacin-for-the2026-10-06 https://evidence-hub.com/study/6441-the-phase-1-clinical-trial-of-anti-pd-1-ab-plus-intrahepatic2026-10-06 https://evidence-hub.com/study/6442-2021-guideline-for-the-management-of-copd-exacerbations-emergency2026-10-06 https://evidence-hub.com/study/6443-the-rationale-and-evidence-for-use-of-inhaled-antibiotics-to-control2026-10-06 https://evidence-hub.com/study/6445-preventive-and-therapeutic-strategies-in-critically-ill-patients-with2026-10-06 https://evidence-hub.com/study/6447-effectiveness-of-methylprednisolone-therapy-in-patients-with-a-high2026-10-06 https://evidence-hub.com/study/6448-the-efficacy-of-early-additional-hemoperfusion-therapy-for-severe2026-10-06 https://evidence-hub.com/study/6449-remdesivir-for-patients-hospitalized-with-covid-19-severe-pneumonia-a2026-10-06 https://evidence-hub.com/study/6450-refining-patient-selection-for-prophylactic-cranial-irradiation-in2026-10-19 https://evidence-hub.com/study/6451-efficacy-and-safety-of-dupilumab-as-add-on-therapy-for-patients-with2026-10-19 https://evidence-hub.com/study/6452-real-life-use-of-tocilizumab-with-or-without-corticosteroid-in2026-10-06 https://evidence-hub.com/study/6453-efficacy-and-safety-of-lifileucel-an-autologous-tumor-infiltrating2026-10-19 https://evidence-hub.com/study/6454-correspondence-on-interleukin-6-receptor-blockade-with-subcutaneous2026-10-06 https://evidence-hub.com/study/6455-a-case-control-study-of-real-life-experience-with-ceftolozane2026-10-06 https://evidence-hub.com/study/6456-early-treatment-of-favipiravir-in-covid-19-patients-without-pneumonia2026-10-06 https://evidence-hub.com/study/6458-efficacy-of-hi-lo-evac-endotracheal-tube-in-prevention-of-ventilator2026-10-06 https://evidence-hub.com/study/6459-clinical-efficacy-and-nursing-experience-of-treating-pulmonary2026-10-06 https://evidence-hub.com/study/6460-treatment-profiles-and-risk-factors-for-clinical-outcomes-of2026-10-06 https://evidence-hub.com/study/6461-bacterial-and-antibiotics-sensitivity-patterns-among-pneumonia2026-10-06 https://evidence-hub.com/study/6462-a-survey-of-genotype-and-resistance-patterns-of-ventilator-associated2026-10-06 https://evidence-hub.com/study/6464-assessing-decision-of-inpatient-or-outpatient-care-in-community2026-10-06 https://evidence-hub.com/study/6465-the-characteristics-of-hospitalized-pneumonia-patients-among2026-10-06 https://evidence-hub.com/study/6466-efficacy-of-three-different-regimens-in-eradication-of-helicobacter2026-10-06 https://evidence-hub.com/study/6467-625-efficacy-of-myotomy-in-patients-with-sigmoid-megaesophagus-a2026-10-06 https://evidence-hub.com/study/6468-diagnostic-value-of-hrct-thorax-for-pandemic-covid-19-pneumonia-in2026-10-06 https://evidence-hub.com/study/6469-usage-evaluation-study-on-vancomycin-among-hospitalized-pediatric2026-10-06 https://evidence-hub.com/study/6470-role-of-hrct-imaging-in-diagnosis-and-prognosis-of-novel-corona-covid2026-10-06 https://evidence-hub.com/study/6471-acute-and-severe-ribavirin-associated-hyperuricemia-and-acute-kidney2026-10-06 https://evidence-hub.com/study/6472-antiviral-therapy-in-management-of-covid-19-a-systematic-review-on2026-10-06 https://evidence-hub.com/study/6473-a-guide-for-urogynecologic-patient-care-utilizing-telemedicine-during2026-10-06 https://evidence-hub.com/study/6474-inhaled-antibiotics-for-gram-negative-respiratory-infections2026-10-06 https://evidence-hub.com/study/6475-the-management-of-intra-abdominal-infections-from-a-global2026-10-06 https://evidence-hub.com/study/6476-current-concept-of-abdominal-sepsis-wses-position-paper2026-10-06 https://evidence-hub.com/study/6477-clinical-significance-and-pathogenesis-of-staphylococcal-small-colony2026-10-06 https://evidence-hub.com/study/6478-spontaneous-bacteremia-and-spontaneous-bacterial-peritonitis-share2026-10-08 https://evidence-hub.com/study/6479-paget-s-disease-of-the-cervical-spine-case-report-and-review2026-10-06 https://evidence-hub.com/study/6480-fecal-microbiota-transplantation-for-refractory-and-recurrent2026-10-06 https://evidence-hub.com/study/6481-compassionate-use-of-gc5131-hyperimmunoglobulin-therapy-in-critically2026-10-06 https://evidence-hub.com/study/6482-onabotulinum-toxin-a-injections-into-the-salivary-glands-for-spinal2026-10-06 https://evidence-hub.com/study/6483-experience-of-pleurodesis-with-a-50-glucose-solution-in-patients-with2026-10-06 https://evidence-hub.com/study/6484-critically-ill-patient-with-multidrug-resistant-acinetobacter2026-10-06 https://evidence-hub.com/study/6485-echinocandins-for-pneumocystis-jirovecii-pneumonia-in-non-hiv2026-10-06 https://evidence-hub.com/study/6486-feasibility-of-continued-treatment-with-dupilumab-in-patients-with2026-10-06 https://evidence-hub.com/study/6487-cavitary-pneumonia-mimicking-aspergilloma-a-case-report2026-10-08 https://evidence-hub.com/study/6488-a-fatal-infection-caused-by-dolosigranulum-pigrum-in-a-patient-with2026-10-06 https://evidence-hub.com/study/6489-levofloxacin-induced-hepatotoxicity-in-patients-with-legionnaires2026-10-05 https://evidence-hub.com/study/6490-a-case-of-legionella-pneumonia-suspected-as-typical-pneumonia-after2026-10-08 https://evidence-hub.com/study/6491-effectiveness-of-mesenchymal-stem-cell-therapy-for-covid-19-induced2026-10-06 https://evidence-hub.com/study/6492-efficacy-of-combination-antibiotic-therapy-including-inhaled2026-10-06 https://evidence-hub.com/study/6493-local-radiotherapy-in-extensive-stage-small-cell-lung-cancer2026-10-06 https://evidence-hub.com/study/6494-early-out-of-bed-rehabilitation-in-severe-psittacosis-to-enhance2026-10-06 https://evidence-hub.com/study/6495-case-report-a-rare-case-of-pneumocystis-jirovecii-infection-with-left2026-10-06 https://evidence-hub.com/study/6496-thoracic-segmental-spinal-anesthesia-for-bullectomy-in-a-patient-with2026-10-06 https://evidence-hub.com/study/6497-legionella-myocarditis-with-reversible-left-ventricular-dysfunction2026-10-08 https://evidence-hub.com/study/6498-efficacy-and-validity-of-guideline-concordant-treatment-according-to2026-10-06 https://evidence-hub.com/study/6499-or32-efficacy-and-safety-of-therapeutic-versus-prophylactic-dose-of2026-10-06 https://evidence-hub.com/study/6504-efficacy-and-safety-of-fondaparinux-versus-unfractionated-heparin-in2026-10-06 https://evidence-hub.com/study/6506-efficacy-of-dao-yin-in-patients-with-2019-novel-coronavirus-pneumonia2026-10-06 https://evidence-hub.com/study/6507-appropriate-use-of-high-flow-nasal-oxygen-in-hospitalized-patients2026-10-06 https://evidence-hub.com/study/6508-566-the-impact-of-a-clinical-practice-guideline-and-educational2026-10-06 https://evidence-hub.com/study/6509-a-meta-analysis-of-treatment-effects-on-viral-pneumonia-using-tcm2026-10-06 https://evidence-hub.com/study/6511-the-search-for-novel-treatment-strategies-for-streptococcus2026-10-06 https://evidence-hub.com/study/6512-a-roadmap-to-pulmonary-delivery-strategies-for-the-treatment-of2026-10-06 https://evidence-hub.com/study/6513-biofilms-formation-research-models-potential-targets-and-methods-for2026-10-06 https://evidence-hub.com/study/6514-study-of-ongoing-registered-clinical-trials-on-covid-19-a-narrative2026-10-06 https://evidence-hub.com/study/6516-conjunctivitis-a-systematic-review2026-10-01 https://evidence-hub.com/study/6517-lemierre-syndrome-clinical-update-and-protocol-for-a-systematic2026-10-01 https://evidence-hub.com/study/6518-short-course-antibiotic-treatment-in-acute-exacerbations-of-chronic2026-10-05 https://evidence-hub.com/study/6519-the-risk-of-seizures-among-the-carbapenems-a-meta-analysis2026-09-26 https://evidence-hub.com/study/6521-a-systematic-review-and-meta-analysis-of-animal-studies-testing-intra2026-10-06 https://evidence-hub.com/study/6522-efficacy-of-phage-therapy-in-preclinical-models-of-bacterial2026-10-06 https://evidence-hub.com/study/6523-efficacy-of-early-prone-position-on-non-intubated-covid-19-patients2026-10-06 https://evidence-hub.com/study/6524-meta-analysis-convalescent-blood-products-for-spanish-influenza2026-10-06 https://evidence-hub.com/study/6525-moxifloxacin-a-review-of-its-use-in-the-management-of-bacterial2026-10-08 https://evidence-hub.com/study/6529-t219-the-role-of-melatonin-and-melatonin-agonists-in-counteracting2026-10-06 https://evidence-hub.com/study/6531-magic-bullets-and-surrogate-biomarkers-circa-20092026-10-06 https://evidence-hub.com/study/6532-domperidone-parkinson-disease-and-sudden-cardiac-death-mice-and-men2026-10-06 https://evidence-hub.com/study/6535-the-authors-reply-to-the-addition-of-prophylactic-antibiotics-can2026-10-08 https://evidence-hub.com/study/6537-model-based-on-the-automated-ai-driven-ct-quantification-is-effective2026-10-01 https://evidence-hub.com/study/6538-levofloxacin-induced-oromandibular-dystonia-in-a-9-year-old-patient2026-10-08 https://evidence-hub.com/study/6539-investigation-of-carbapenemase-encoding-genes-in-burkholderia-cepacia2026-10-03 https://evidence-hub.com/study/6540-clinical-efficacy-of-isatuximab-plus-carfilzomib-and-dexamethasone-in2026-10-01 https://evidence-hub.com/study/6541-effectiveness-of-drip-infusion-of-lascufloxacin-a-novel2026-10-01 https://evidence-hub.com/study/6542-stenotrophomonas-maltophilia-the-landscape-in-critically-ill-patients2026-10-01 https://evidence-hub.com/study/6543-omadacycline-in-the-treatment-of-chlamydia-psittaci-pneumonia-a2026-10-01 https://evidence-hub.com/study/6544-spectrum-and-antimicrobial-resistance-in-acute-exacerbation-of2026-10-04 https://evidence-hub.com/study/6545-approach-to-febrile-neutropenia-in-patients-undergoing-treatments-for2026-10-01 https://evidence-hub.com/study/6546-optimizing-antibiotic-therapy-for-stenotrophomonas-maltophilia2026-10-03 https://evidence-hub.com/study/6547-clinical-outcomes-of-trimethoprim-sulfamethoxazole-in-critically-ill2026-10-01 https://evidence-hub.com/study/6548-enhanced-efficacy-of-some-antibiotics-in-the-presence-of-silver2026-10-05 https://evidence-hub.com/study/6549-a-retrospective-closed-cohort-study-on-distribution-of-multidrug2026-10-01 https://evidence-hub.com/study/6550-clinical-and-microbiological-profile-of-hospital-acquired-and2026-10-01 https://evidence-hub.com/study/6551-anti-inflammatory-effects-of-moxifloxacin-and-levofloxacin-on-cadmium2026-10-08 https://evidence-hub.com/study/6552-new-perspectives-on-antimicrobial-agents-omadacycline-for-community2026-10-01 https://evidence-hub.com/study/6553-stroke-associated-pneumonia-according-to-mcdc-criteria-impact-on2026-10-01 https://evidence-hub.com/study/6554-massive-deep-venous-thrombosis-in-a-child-with-necrotizing-pneumonia2026-10-01 https://evidence-hub.com/study/6555-pros-and-cons-of-the-use-of-fluoroquinolone-antibiotics-in-patients2026-10-01 https://evidence-hub.com/study/6556-safety-efficacy-and-predictive-factors-of-venetoclax-based-regimens2026-10-06 https://evidence-hub.com/study/6558-efficacy-of-azithromycin-sequential-therapy-combined-with-montelukast2026-10-06 https://evidence-hub.com/study/6559-the-efficacy-and-safety-of-folate-receptor-targeted-antibody-drug2026-10-19 https://evidence-hub.com/study/6560-the-efficacy-and-safety-of-jak-inhibitors-in-patients-with-adult2026-10-06 https://evidence-hub.com/study/6561-efficacy-and-safety-of-vancomycin-linezolid-and-ceftaroline-in-the2026-10-06 https://evidence-hub.com/study/6562-efficacy-of-ultrasound-guided-pharmacopuncture-a-systematic-review2026-10-19 https://evidence-hub.com/study/6563-corticosteroids-and-severe-community-acquired-pneumonia-a-systematic2026-10-06 https://evidence-hub.com/study/6564-efficacy-and-safety-of-daratumumab-based-quadruplet-therapy-vs-non2026-10-06 https://evidence-hub.com/study/6565-efficacy-and-safety-of-fibroblast-growth-factor-21-analogs-for-the2026-10-19 https://evidence-hub.com/study/6566-effectiveness-of-antibiotic-prophylaxis-in-polytrauma-patients-a2026-10-06 https://evidence-hub.com/study/6568-efficacy-and-safety-of-proton-pump-inhibitors-ppis-for-stress-ulcer2026-10-06 https://evidence-hub.com/study/6569-covid-19-immunologic-antiviral-therapy-with-omalizumab-ciao-a2026-10-06 https://evidence-hub.com/study/6570-effect-of-the-maxing-huoqiao-granule-on-nonsevere-community-acquired2026-10-06 https://evidence-hub.com/study/6571-evaluating-air-leakage-from-staple-line-reinforcements-in-anatomical2026-10-06 https://evidence-hub.com/study/6572-molnupiravir-in-the-treatment-of-patients-with-influenza-or-acute2026-10-06 https://evidence-hub.com/study/6573-p-2298-daily-single-strength-vs-thrice-weekly-double-strength2026-10-06 https://evidence-hub.com/study/6574-effect-of-herbal-medicine-hwanglyeonhaedok-tang-on-insomnia-patients2026-10-06 https://evidence-hub.com/study/6575-effects-of-hip-joint-motion-style-acupuncture-treatment-in-patients2026-10-19 https://evidence-hub.com/study/6576-abstract-number-esoc2026lb39-effects-of-transcranial-direct-current2026-10-06 https://evidence-hub.com/study/6577-pragmatic-randomized-controlled-trial-of-pharmacopuncture-therapy-for2026-10-06 https://evidence-hub.com/study/6579-enhanced-recovery-after-surgery-versus-conventional-approach-in2026-10-06 https://evidence-hub.com/study/6580-secukinumab-efficacy-predictors-in-korean-hidradenitis-suppurativa-a2026-10-19 https://evidence-hub.com/study/6581-efficacy-and-safety-of-asunercept-a-cd95l-selective-inhibitor-in2026-10-06 https://evidence-hub.com/study/6582-adrenomedullin-therapy-for-moderate-to-severe-covid-19-pneumonia2026-10-06 https://evidence-hub.com/study/6583-randomized-double-blind-active-controlled-parallel-phase-3-clinical2026-10-19 https://evidence-hub.com/study/6584-angiotensin-1-7-infusion-in-covid-19-patients-admitted-to-the-icu-a2026-10-06 https://evidence-hub.com/study/6585-efficacy-and-safety-of-trimodulin-in-patients-with-severe-covid-192026-10-06 https://evidence-hub.com/study/6587-targeting-vascular-inflammation-in-patients-with-community-acquired2026-10-06 https://evidence-hub.com/study/6588-colchicine-for-secondary-prevention-of-ischaemic-stroke-and2026-10-06 https://evidence-hub.com/study/6589-high-flow-nasal-cannula-versus-non-invasive-positive-pressure2026-10-06 https://evidence-hub.com/study/6590-a-phase-2-multi-center-randomized-double-blind-parallel-group-trial2026-10-19 https://evidence-hub.com/study/6591-efficacy-and-safety-of-pleurodesis-for-lung-cancer-patients-with2026-10-06 https://evidence-hub.com/study/6592-real-world-efficacy-of-1st-line-nivolumab-plus-ipilimumab-and-its2026-10-19 https://evidence-hub.com/study/6593-efficacy-and-safety-of-acalabrutinib-treatment-in-very-old-80y-and-or2026-10-06 https://evidence-hub.com/study/6594-p-163-trimethoprim-sulfamethoxazole-is-associated-with-decreased2026-10-06 https://evidence-hub.com/study/6595-efficacy-and-safety-of-odronextamab-monotherapy-in-patients-pts-with2026-10-06 https://evidence-hub.com/study/6596-assessing-the-efficacy-of-a-graded-pulmonary-rehabilitation-protocol2026-10-06 https://evidence-hub.com/study/6597-preserving-health-beyond-infection-control-frailty-weight-and2026-10-06 https://evidence-hub.com/study/6598-ep197-ece-1768-effective-cortisol-synthesis-control-with-markedly-low2026-10-06 https://evidence-hub.com/study/6599-survey-on-the-current-usage-of-ultrasound-guided-procedures-in-korean2026-10-19 https://evidence-hub.com/study/6600-b46-01-bridging-the-gap-amplatzer-occluder-as-a-life-saving2026-10-06 https://evidence-hub.com/study/6601-role-of-hyperbaric-oxygen-therapy-in-traumatic-brain-injury-a2026-10-06 https://evidence-hub.com/study/6602-asciminib-and-pregnancy-in-cml-preliminary-human-data-and-clinical2026-10-06 https://evidence-hub.com/study/6603-uniportal-vats-for-early-stage-nsclc-in-octogenarians-a-single-center2026-10-06 https://evidence-hub.com/study/6604-a102-16-transvenous-diaphragmatic-neurostimulation-to-facilitate2026-10-06 https://evidence-hub.com/study/6605-partial-oral-therapy-for-pediatric-infective-endocarditis2026-10-06 https://evidence-hub.com/study/6606-how-to-preserve-the-native-or-reconstructed-esophagus-after2026-10-06 https://evidence-hub.com/study/6607-bezlotoxumab-as-treatment-for-recurrent-chronic-clostridioides2026-10-06 https://evidence-hub.com/study/6608-reconstruction-of-all-hepatic-arteries-in-right-lobe-grafts-with-22026-10-19 https://evidence-hub.com/study/6609-b35-46-last-line-significant-impact-obinutuzumab-in-refractory2026-10-06 https://evidence-hub.com/study/6610-c60-17-persistent-air-leak-in-a-pediatric-patient-innovative-use-of2026-10-06 https://evidence-hub.com/study/6611-pharmacologic-treatment-of-malignant-catatonia-without2026-10-06 https://evidence-hub.com/study/6612-efficacy-of-a-single-agent-ts1-tegafur-gimeracil-and-oteracil-in2026-10-06 https://evidence-hub.com/study/6613-surgical-treatment-intracardiac-thrombosis-and-pulmonary-embolism2026-10-06 https://evidence-hub.com/study/6614-chlamydia-psittaci-pneumonia-manifested-as-pulmonary-nodules-and2026-10-06 https://evidence-hub.com/study/6615-alternative-management-of-persistent-hyperinsulinemic-hypoglycemia-in2026-10-06 https://evidence-hub.com/study/6616-unusual-cause-of-wheezing-in-a-middle-aged-woman-a-case-report2026-10-06 https://evidence-hub.com/study/6617-evaluation-of-the-efficacy-and-safety-of-icatibant-and-c1-esterase2026-10-08 https://evidence-hub.com/study/6618-interferon-1a-ifn-1a-in-covid-19-patients-intercop-study-protocol-for2026-10-06 https://evidence-hub.com/study/6619-bangpungtongsung-san-for-patients-with-major-depressive-disorder2026-10-19 https://evidence-hub.com/study/6624-remdesivir-for-5-or-10-days-in-patients-with-severe-covid-192026-10-06 https://evidence-hub.com/study/6625-clinical-guidance-and-practical-recommendations-for-probiotic-use-in2026-10-19 https://evidence-hub.com/study/6627-sulfonylurea-drugs-for-people-with-severe-hemispheric-ischemic-stroke2026-10-08 https://evidence-hub.com/study/6629-turning-the-phage-on-treatment-of-antimicrobial-resistant-pneumonia2026-10-06 https://evidence-hub.com/study/6630-novel-therapeutic-interventions-in-treating-patients-with-covid-192026-10-06 https://evidence-hub.com/study/6631-roles-of-the-clinical-pharmacist-during-the-covid-19-pandemic2026-10-06 https://evidence-hub.com/study/6638-ventilator-associated-pneumonia-caused-by-pseudomonas-aeruginosa-cap2026-10-06 https://evidence-hub.com/study/6643-sars-patients-and-need-for-treatment2026-10-06 https://evidence-hub.com/study/6646-recent-advances-in-the-management-of-aids-related-opportunistic2026-10-06 https://evidence-hub.com/study/6647-fda-silicone-breast-implants-seem-safe2026-10-06 https://evidence-hub.com/study/6648-effects-of-allium-fistulosum-l-green-onion-root-and-avena-sativa-l2026-10-19 https://evidence-hub.com/study/6650-injectable-particulated-human-acellular-dermal-matrix-booster-for2026-10-19 https://evidence-hub.com/study/6652-a-comprehensive-analysis-of-in-hospital-adverse-events-after2026-10-06 https://evidence-hub.com/study/6653-treatment-of-renal-artery-aneurysm-by-ex-situ-repair-and2026-10-06 https://evidence-hub.com/study/6654-the-efficacy-and-safety-of-homoharringtonine-added-to-venetoclax-and2026-10-06 https://evidence-hub.com/study/6655-the-clinical-efficacy-of-adding-ceftazidime-avibactam-to-standard2026-10-06 https://evidence-hub.com/study/6657-efficacy-of-inhaled-colistin-in-critically-ill-children-with2026-10-06 https://evidence-hub.com/study/6658-effect-of-regdanvimab-on-mortality-in-patients-infected-with-sars-cov2026-10-06 https://evidence-hub.com/study/6659-exploring-clinical-characteristics-and-risk-factors-of-mycoplasma2026-10-06 https://evidence-hub.com/study/6660-comparative-real-world-safety-of-nivolumab-versus-pembrolizumab-in2026-10-06 https://evidence-hub.com/study/6661-real-world-outcomes-and-prognostic-factors-of-polymyxin-b2026-10-06 https://evidence-hub.com/study/6662-efficacy-and-survival-of-nivolumab-treatment-for-recurrent2026-10-06 https://evidence-hub.com/study/6663-bacterial-infections-and-antibiotic-sensitivity-patterns-in-cancer2026-10-05 https://evidence-hub.com/study/6664-effectiveness-of-bairui-granules-in-the-treatment-of-respiratory2026-10-01 https://evidence-hub.com/study/6665-anthrax-a-narrative-review2026-10-04 https://evidence-hub.com/study/6666-n-acetylcysteine-as-a-promising-treatment-for-covid-19-a2026-10-05 https://evidence-hub.com/study/6667-a-narrative-review-of-bedaquiline-and-delamanid-new-arsenals-against2026-10-01 https://evidence-hub.com/study/6668-nano-scaffold-based-delivery-systems-of-antimicrobial-agents-in-the2026-10-05 https://evidence-hub.com/study/6669-antibiotic-resistance-in-klebsiella-pneumoniae-in-iraq-a-narrative2026-10-01 https://evidence-hub.com/study/6670-burden-of-antimicrobial-resistance-in-japan-a-systematic-literature2026-10-01 https://evidence-hub.com/study/6671-global-epidemiology-and-antimicrobial-resistance-of-metallo-lactamase2026-10-13 https://evidence-hub.com/study/6672-actively-targeted-nanoparticles-for-enhanced-diagnosis-treatment-and2026-10-06 https://evidence-hub.com/study/6673-incidence-and-influencing-factors-of-tooth-discoloration-in-children2026-10-08 https://evidence-hub.com/study/6674-structural-and-functional-diversity-of-resistance-nodulation-division2026-10-01 https://evidence-hub.com/study/6675-the-therapeutic-potential-of-cefiderocol-in-the-treatment-of2026-10-01 https://evidence-hub.com/study/6676-protegrin-1-and-analogues-against-acinetobacter-baumannii-a-narrative2026-10-01 https://evidence-hub.com/study/6677-association-of-variant-vitamin-statuses-and-tuberculosis-development2026-10-01 https://evidence-hub.com/study/6678-comparative-effectiveness-of-single-dual-and-multi-antibiotic2026-10-08 https://evidence-hub.com/study/6679-nephrotoxicity-of-new-antibiotics-a-systematic-review2026-10-01 https://evidence-hub.com/study/6680-advances-in-understanding-recurrent-pulmonary-infections-following2026-10-01 https://evidence-hub.com/study/6681-global-trends-in-macrolide-and-lincosamide-resistance-in2026-10-01 https://evidence-hub.com/study/6682-the-effect-of-periodontal-treatment-on-helicobacter-pylori-infection2026-10-08 https://evidence-hub.com/study/6683-strategies-for-tuberculosis-prevention-in-healthcare-settings-a2026-10-01 https://evidence-hub.com/study/6684-studying-intrapulmonary-pharmacokinetics-for-tuberculosis-treatment-a2026-10-01 https://evidence-hub.com/study/6685-hospital-acquired-pneumonia-a-narrative-review2026-10-08 https://evidence-hub.com/study/6686-mortality-outcomes-of-extended-spectrum-lactamase-in-bacteremia-with2026-10-08 https://evidence-hub.com/study/6687-repurposing-of-anti-malarial-drugs-for-the-treatment-of-tuberculosis2026-10-08 https://evidence-hub.com/study/6688-clinical-trial-findings-and-drug-development-challenges-for-curcumin2026-10-01 https://evidence-hub.com/study/6689-new-frontiers-for-old-medications-repurposing-approved-drugs-against2026-10-08 https://evidence-hub.com/study/6690-chitosan-based-formulations-for-therapeutic-applications-a-recent2026-10-01 https://evidence-hub.com/study/6691-deciphering-multidrug-resistant-pseudomonas-aeruginosa-mechanistic2026-10-01 https://evidence-hub.com/study/6692-nanoformulations-loaded-with-phytochemicals-for-combating-wound2026-10-01 https://evidence-hub.com/study/6693-antimicrobial-activity-and-mechanistic-insights-of-amp-17-against2026-10-06 https://evidence-hub.com/study/6694-discovery-of-broad-spectrum-repurposed-drug-combinations-against2026-09-27 https://evidence-hub.com/study/6695-bromhexine-hydrochloride-enhances-the-therapeutic-efficacy-of2026-10-06 https://evidence-hub.com/study/6696-leading-paediatric-infectious-diseases-current-trends-gaps-and-future2026-10-01 https://evidence-hub.com/study/6697-turning-the-tide-against-carbapenem-resistant-acinetobacter-baumannii2026-10-01 https://evidence-hub.com/study/6698-a-survey-of-isatin-hybrids-and-their-biological-properties2026-10-01 https://evidence-hub.com/study/6699-the-dark-side-of-drug-repurposing-from-clinical-trial-challenges-to2026-10-01 https://evidence-hub.com/study/6700-analysis-of-icu-resistome-dynamics-in-patients-staff-and-environment2026-10-08 https://evidence-hub.com/study/6701-polyphenolic-compounds-in-glycyrrhiza-spp-a-potential-weapon-against2026-10-01 https://evidence-hub.com/study/6702-distribution-and-genetic-characterization-of-fluoroquinolone2026-10-01 https://evidence-hub.com/study/6703-genome-analyses-of-colistin-resistant-high-risk-blandm-5-producing2026-10-01 https://evidence-hub.com/study/6704-opportunities-for-helicobacter-pylori-eradication-beyond-conventional2026-10-01 https://evidence-hub.com/study/6705-targeting-urease-a-promising-adjuvant-strategy-for-effective2026-10-01 https://evidence-hub.com/study/6706-therapeutic-potential-of-cinnamon-oil-chemical-composition2026-10-01 https://evidence-hub.com/study/6707-novel-antibacterial-approaches-and-therapeutic-strategies2026-10-01 https://evidence-hub.com/study/6708-population-structure-and-antibiotic-resistance-of-swine2026-10-01 https://evidence-hub.com/study/6709-exploring-the-potential-of-bis-thiazol-5-yl-phenylmethane-derivatives2026-10-01 https://evidence-hub.com/study/6710-antibacterial-and-antibiofilm-potentials-of-vancomycin-loaded2026-10-01 https://evidence-hub.com/study/6711-potential-of-venom-derived-compounds-for-the-development-of-new2026-10-01 https://evidence-hub.com/study/6712-applications-of-peptides-in-nanosystems-for-diagnosing-and-managing2026-10-01 https://evidence-hub.com/study/6713-computational-design-of-pore-forming-peptides-with-potent2026-10-01 https://evidence-hub.com/study/6714-multidrug-resistant-acinetobacter-baumannii-a-study-on-its2026-10-01 https://evidence-hub.com/study/6715-the-current-landscape-of-phage-antibiotic-synergistic-pas-interactions2026-10-01 https://evidence-hub.com/study/6716-characterization-of-bacteriophage-vb-abas-sa1-and-its-synergistic2026-10-08 https://evidence-hub.com/study/6717-unveiling-the-nanoworld-of-antimicrobial-resistance-integrating2026-10-01 https://evidence-hub.com/study/6718-efficacy-of-liu-zi-jue-in-patients-with-2019-novel-coronavirus2026-10-06 https://evidence-hub.com/study/6719-adding-colchicine-to-tocilizumab-in-hospitalized-patients-with-severe2026-10-06 https://evidence-hub.com/study/6720-effects-of-different-doses-of-methylprednisolone-on-clinical-outcomes2026-10-06 https://evidence-hub.com/study/6721-evaluation-of-the-efficacy-and-safety-of-intravenous-remdesivir-in2026-10-06 https://evidence-hub.com/study/6722-efficacy-and-safety-of-fixed-combination-of-hydroxychloroquine-with2026-10-06 https://evidence-hub.com/study/6723-efficacy-of-oral-amoxicillin-versus-parenteral-ceftriaxone-in2026-10-06 https://evidence-hub.com/study/6724-efficacy-of-colchicine-in-patients-with-moderate-covid-19-a-double2026-10-06 https://evidence-hub.com/study/6725-letter-to-the-editor-regarding-a-multicentric-phase-2-randomized2026-10-06 https://evidence-hub.com/study/6726-a-randomized-open-label-trial-to-evaluate-the-efficacy-and-safety-of2026-10-06 https://evidence-hub.com/study/6727-efficacy-of-clarithromycin-on-covid-19-pneumonia-without-oxygen2026-10-06 https://evidence-hub.com/study/6728-efficacy-and-safety-of-a-novel-antiviral-preparation-in-icu-admitted2026-10-06 https://evidence-hub.com/study/6729-randomized-clinical-trial-to-evaluate-safety-and-efficacy-of2026-10-06 https://evidence-hub.com/study/6730-efficacy-and-safety-of-levamisole-treatment-in-clinical-presentations2026-10-06 https://evidence-hub.com/study/6731-a-phase-2-multicenter-randomized-controlled-study-to-evaluate-the2026-10-06 https://evidence-hub.com/study/6732-treatment-with-convalescent-plasma-for-covid-19-patients-in-wuhan2026-10-01 https://evidence-hub.com/study/6733-early-low-dose-and-short-term-application-of-corticosteroid-treatment2026-10-01 https://evidence-hub.com/study/6734-intravenous-infusion-of-human-umbilical-cord-wharton-s-jelly-derived2026-10-01 https://evidence-hub.com/study/6735-association-of-radiologic-findings-with-mortality-of-patients2026-10-01 https://evidence-hub.com/study/6736-community-acquired-pneumonia-in-critically-ill-very-old-patients-a2026-10-01 https://evidence-hub.com/study/6737-short-course-antimicrobial-therapy-for-pediatric-community-acquired2026-10-01 https://evidence-hub.com/study/6738-impact-of-viral-coinfection-and-macrolide-resistant-mycoplasma2026-10-01 https://evidence-hub.com/study/6739-bloodstream-infections-in-critically-ill-patients-with-covid-192026-10-01 https://evidence-hub.com/study/6740-is-ventilated-hospital-acquired-pneumonia-a-worse-entity-than2026-10-01 https://evidence-hub.com/study/6742-management-of-immune-related-adverse-events-in-patients-treated-with2026-10-01 https://evidence-hub.com/study/6743-intrapulmonary-concentrations-of-meropenem-administered-by-continuous2026-10-01 https://evidence-hub.com/study/6745-microbiological-profile-of-ventilator-associated-pneumonia-among2026-10-01 https://evidence-hub.com/study/6746-extended-spectrum-beta-lactamases-among-klebsiella-pneumoniae-from2026-10-01 https://evidence-hub.com/study/6747-current-treatment-of-nosocomial-pneumonia-and-ventilator-associated2026-10-01 https://evidence-hub.com/study/6748-efficacy-of-0-5-levofloxacin-and-5-0-povidone-iodine-eyedrops-in2026-10-01 https://evidence-hub.com/study/6749-nanomaterials-for-delivering-antibiotics-in-the-therapy-of-pneumonia2026-10-01 https://evidence-hub.com/study/6750-clinical-efficacy-of-antivirals-against-novel-coronavirus-covid-19-a2026-10-01 https://evidence-hub.com/study/6751-international-perspective-on-the-new-2019-american-thoracic-society2026-10-01 https://evidence-hub.com/study/6752-the-minimum-inhibitory-concentration-of-antibiotics-methods2026-10-01 https://evidence-hub.com/study/6753-carbapenem-resistant-klebsiella-pneumoniae-among-patients-with2026-10-01 https://evidence-hub.com/study/6755-prognostic-implications-of-preoperative-pneumonia-for-geriatric2026-10-01 https://evidence-hub.com/study/6756-extended-spectrum-lactamases-an-update-on-their-characteristics2026-10-01 https://evidence-hub.com/study/6757-lefamulin-efficacy-and-safety-in-a-pooled-phase-3-clinical-trial2026-10-01 https://evidence-hub.com/study/6758-first-12-patients-with-coronavirus-disease-2019-covid-19-in-the2026-10-01 https://evidence-hub.com/study/6759-molecular-characterization-of-methicillin-resistant-staphylococcus2026-10-01 https://evidence-hub.com/study/6760-biofilm-formation-by-pathogens-causing-ventilator-associated2026-10-01 https://evidence-hub.com/study/6761-tpgs-based-and-s-thanatin-functionalized-nanorods-for-overcoming-drug2026-10-01 https://evidence-hub.com/study/6762-construction-of-a-nomogram-for-identifying-refractory-mycoplasma2026-10-01 https://evidence-hub.com/study/6763-pharmacokinetics-of-favipiravir-in-critically-ill-patients-with-covid2026-10-01 https://evidence-hub.com/study/6765-case-series-efficacy-and-safety-of-hemoadsorption-with-ha-3302026-10-01 https://evidence-hub.com/study/6766-community-acquired-bacterial-pneumonia-changing-epidemiology2026-10-01 https://evidence-hub.com/study/6770-safety-and-efficacy-of-tocilizumab-4-or-8-mg-kg-in-hospitalized2026-10-06 https://evidence-hub.com/study/6771-efficacy-and-safety-of-sarilumab-in-patients-with-covid19-pneumonia-a2026-10-06 https://evidence-hub.com/study/6772-dfv890-a-new-oral-nlrp3-inhibitor-tested-in-an-early-phase-2a2026-10-06 https://evidence-hub.com/study/6773-tocilizumab-plus-dexamethasone-versus-dexamethasone-in-patients-with2026-10-06 https://evidence-hub.com/study/6774-efficacy-of-noble-metal-alloy-endotracheal-tubes-in-ventilator2026-10-06 https://evidence-hub.com/study/6775-effect-of-high-versus-low-dose-of-dexamethasone-on-clinical-worsening2026-10-06 https://evidence-hub.com/study/6776-phase-1-clinical-trial-for-intravenous-administration-of-mesenchymal2026-10-06 https://evidence-hub.com/study/6777-a-four-probiotic-preparation-for-ventilator-associated-pneumonia-in2026-10-06 https://evidence-hub.com/study/6778-early-use-of-sarilumab-in-patients-hospitalized-with-covid-192026-10-06 https://evidence-hub.com/study/6779-a-multicenter-open-label-randomized-proof-of-concept-phase-ii2026-10-06 https://evidence-hub.com/study/6780-efficacy-and-safety-of-convalescent-plasma-and-intravenous2026-10-06 https://evidence-hub.com/study/6781-a-phase-i-ii-clinical-trial-to-evaluate-the-efficacy-of-baricitinib2026-10-06 https://evidence-hub.com/study/6782-efficacy-of-zinc-as-adjuvant-therapy-in-the-treatment-of-severe2026-10-06 https://evidence-hub.com/study/6783-a-feasibility-trial-to-evaluate-the-composite-efficacy-of-inhaled2026-10-06 https://evidence-hub.com/study/6784-the-clinical-efficacy-of-low-dose-whole-lung-irradiation-in-moderate2026-10-06 https://evidence-hub.com/study/6786-probiotic-in-the-prevention-of-ventilator-associated-pneumonia-in2026-10-06 https://evidence-hub.com/study/6787-testing-the-efficacy-and-safety-of-bio101-for-the-prevention-of2026-10-06 https://evidence-hub.com/study/6788-evaluation-of-the-efficacy-of-methylprednisolone-pulse-therapy-in2026-10-06 https://evidence-hub.com/study/6789-efficacy-and-safety-of-arbidol-in-treatment-of-patients-with-covid-192026-10-06 https://evidence-hub.com/study/6791-the-efficacy-of-hydroxychloroquine-and-azithromycin-combination2026-10-06 https://evidence-hub.com/study/6792-efficacy-and-safety-of-pirfenidone-in-the-treatment-of-idiopathic2026-10-06 https://evidence-hub.com/study/6793-safety-and-revisit-related-to-discharge-the-sixty-one-spanish2026-10-06 https://evidence-hub.com/study/6794-efficacy-of-a-recombinant-humanized-anti-il-6-receptor-monoclonal2026-10-06 https://evidence-hub.com/study/6795-pantohematogen-efficacy-evaluation-in-complex-sanatorium2026-10-06 https://evidence-hub.com/study/6796-patients-with-a-high-risk-common-type-covid-19-pneumonia-may-be-the2026-10-06 https://evidence-hub.com/study/6797-effect-of-tocilizumab-on-intensive-care-patients-with-covid-192026-10-06 https://evidence-hub.com/study/6798-the-clinical-outcomes-of-high-neutralizing-antibodies-titer2026-10-06 https://evidence-hub.com/study/6799-the-efficacy-of-zinc-as-an-adjuvant-therapy-in-the-treatment-of2026-10-06 https://evidence-hub.com/study/6800-clinical-and-epidemiological-features-of-community-acquired-pneumonia2026-10-06 https://evidence-hub.com/study/6802-clinical-experience-with-use-of-remdesivir-in-the-treatment-of-severe2026-10-06 https://evidence-hub.com/study/6803-pneumocystis-jirovecii-pneumonia-prophylaxis-with-intravenous2026-10-06 https://evidence-hub.com/study/6804-therapeutic-plasma-exchange-in-patients-with-covid-19-pneumonia-in2026-10-06 https://evidence-hub.com/study/6806-non-invasive-positive-pressure-ventilation-nippv-in-the-pregnant2026-10-06 https://evidence-hub.com/study/6807-the-role-of-ascorbic-acid-in-reducing-mortality-in-patients-with2026-10-06 https://evidence-hub.com/study/6809-case-report-effectiveness-of-tocilizumab-in-obese-patient-for2026-10-06 https://evidence-hub.com/study/6810-probiotic-as-an-adjuvant-preventive-treatment-for-ventilator2026-10-06 https://evidence-hub.com/study/6811-comparative-efficacy-and-safety-of-pharmacological-interventions-for2026-10-06 https://evidence-hub.com/study/6812-efficacy-and-safety-of-gastrointestinal-bleeding-prophylaxis-in2026-10-06 https://evidence-hub.com/study/6814-association-of-doxycycline-and-mortality-in-patients-hospitalized2026-10-06 https://evidence-hub.com/study/6815-comparison-between-monotherapy-and-combination-therapy-among2026-10-06 https://evidence-hub.com/study/6816-acute-high-risk-pulmonary-embolism-requiring-thrombolytic-therapy-in2026-10-06 https://evidence-hub.com/study/6817-multidisciplinary-collaboration-for-the-optimization-of-antibiotic2026-10-01 https://evidence-hub.com/study/6818-the-effect-observation-of-lianhua-qingwen-granule-in-the-adjuvant2026-10-06 https://evidence-hub.com/study/6819-corticosteroids-in-community-acquired-pneumonia-a-review-of-current2026-10-06 https://evidence-hub.com/study/6820-patterns-of-mechanical-thrombectomy-for-stroke-before-and-after-the2026-10-06 https://evidence-hub.com/study/6821-an-inpatient-covid-19-prophylaxis-protocol-and-its-outcomes-adherence2026-10-06 https://evidence-hub.com/study/6822-therapeutic-monitoring-of-vancomycin-for-serious-methicillin2026-10-06 https://evidence-hub.com/study/6823-preliminary-data-on-the-efficacy-and-safety-of-9-month-treatment2026-10-06 https://evidence-hub.com/study/6824-macrolide-resistant-mycoplasma-pneumoniae-in-adults-with-community2026-10-06 https://evidence-hub.com/study/6825-prevalence-of-carbapenemase-producing-klebsiella-pneumonia-in-gomel2026-10-06 https://evidence-hub.com/study/6826-current-issues-of-empirical-therapy-of-severe-bacterial-community2026-10-08 https://evidence-hub.com/study/6827-bronchoalveolar-lavage-improved-ventilation-perfusion-matching-in2026-10-06 https://evidence-hub.com/study/6828-evaluating-the-efficacy-of-human-bronchiectasisbased-antibiotic2026-10-06 https://evidence-hub.com/study/6830-detection-of-blatem-blashv-and-blactx-m-genes-among-the-extended2026-10-06 https://evidence-hub.com/study/6831-real-life-experience-with-ceftolozane-tazobactam-therapy-for2026-10-06 https://evidence-hub.com/study/6832-1684-antimicrobial-activity-of-aztreonam-avibactam-against-a-large2026-10-06 https://evidence-hub.com/study/6833-1687-omadacycline-in-female-adults-with-acute-pyelonephritis-results2026-10-06 https://evidence-hub.com/study/6834-cost-effectiveness-analysis-of-antibiotics-used-for-lower-respiratory2026-10-06 https://evidence-hub.com/study/6835-sars-cov-22026-10-06 https://evidence-hub.com/study/6836-extracorporeal-photopheresis-in-the-treatment-of-the-novel2026-10-06 https://evidence-hub.com/study/6837-are-antibiotics-appropriately-dosed-in-critically-ill-patients-with2026-10-05 https://evidence-hub.com/study/6838-therapeutic-use-of-chloroquine-and-hydroxychloroquine-in-covid-19-and2026-10-01 https://evidence-hub.com/study/6839-ventricular-repolarization-heterogeneity-in-patients-with-covid-192026-10-01 https://evidence-hub.com/study/6840-does-dose-reduction-of-renally-cleared-antibiotics-in-patients-with2026-09-27 https://evidence-hub.com/study/6841-mortality-benefit-of-convalescent-plasma-in-covid-19-a-systematic2026-10-01 https://evidence-hub.com/study/6842-berberine-for-diarrhea-in-children-and-adults-a-systematic-review-and2026-10-01 https://evidence-hub.com/study/6843-the-effect-of-combination-therapy-on-mortality-and-adverse-events-in2026-10-01 https://evidence-hub.com/study/6844-shorter-versus-longer-durations-of-antibiotic-treatment-for-patients2026-10-08 https://evidence-hub.com/study/6845-an-amphipathic-peptide-with-antibiotic-activity-against-multidrug2026-10-01 https://evidence-hub.com/study/6846-antimicrobial-peptide-loaded-nanoparticles-as-inhalation-therapy-for2026-10-01 https://evidence-hub.com/study/6847-could-azithromycin-be-part-of-pseudomonas-aeruginosa-acute-pneumonia2026-10-01 https://evidence-hub.com/study/6848-plga-carriers-for-controlled-release-of-levofloxacin-in-anti2026-10-08 https://evidence-hub.com/study/6849-the-influence-of-lipid-matrix-composition-on-the-microenvironment-of2026-10-08 https://evidence-hub.com/study/6851-antibiotic-removal-processes-from-water-wastewater-for-the-protection2026-10-01 https://evidence-hub.com/study/6852-new-cephalosporins-for-the-treatment-of-pneumonia-in-internal2026-10-01 https://evidence-hub.com/study/6853-nosocomial-pneumonia-in-the-era-of-multidrug-resistance-updates-in2026-10-01 https://evidence-hub.com/study/6854-infectious-diseases-society-of-america-guidance-on-the-treatment-of2026-10-01 https://evidence-hub.com/study/6855-antimicrobial-resistance-prevalence-economic-burden-mechanisms-of2026-10-01 https://evidence-hub.com/study/6856-antibiotic-resistance-in-bacteria-a-review2026-10-01 https://evidence-hub.com/study/6857-integrating-the-human-and-animal-sides-of-mycoplasmas-resistance-to2026-10-01 https://evidence-hub.com/study/6858-model-informed-drug-development-for-anti-infectives-state-of-the-art2026-10-01 https://evidence-hub.com/study/6859-enhanced-efficacy-of-some-antibiotics-in-presence-of-silver2026-10-01 https://evidence-hub.com/study/6860-acinetobacter-baumannii-resistance-a-real-challenge-for-clinicians2026-10-01 https://evidence-hub.com/study/6862-bactericidal-activity-of-ceragenin-in-combination-with-ceftazidime2026-10-03 https://evidence-hub.com/study/6863-successful-high-dosage-monotherapy-of-tigecycline-in-a-multidrug2026-10-01 https://evidence-hub.com/study/6864-immunoglobulin-y-for-potential-diagnostic-and-therapeutic2026-10-01 https://evidence-hub.com/study/6865-rescuing-the-last-line-polymyxins-achievements-and-challenges2026-10-01 https://evidence-hub.com/study/6866-new-antibiotics-for-multidrug-resistant-bacterial-strains-latest2026-10-01 https://evidence-hub.com/study/6867-model-based-efficacy-and-toxicity-comparisons-of-moxifloxacin-for2026-10-01 https://evidence-hub.com/study/6868-nano-based-drug-delivery-or-targeting-to-eradicate-bacteria-for2026-10-01 https://evidence-hub.com/study/6869-emergence-of-blandm-1-and-blavim-producing-gram-negative-bacilli-in2026-10-01 https://evidence-hub.com/study/6870-applications-of-lysozyme-an-innate-immune-defense-factor-as-an2026-10-01 https://evidence-hub.com/study/6871-which-analysis-approach-is-adequate-to-leverage-clinical2026-10-01 https://evidence-hub.com/study/6872-cefiderocol-a-review-in-serious-gram-negative-bacterial-infections2026-10-01 https://evidence-hub.com/study/6873-dose-selection-in-a-pandemic-a-framework-informed-by-the-fda-animal2026-10-01 https://evidence-hub.com/study/6874-acinetobacter-baumannii-antibiotic-resistance-mechanisms2026-10-01 https://evidence-hub.com/study/6875-efficacy-and-in-vitro-activity-of-novel-antibiotics-for-infections2026-10-01 https://evidence-hub.com/study/6876-synergistic-activity-of-capsaicin-and-colistin-against-colistin2026-10-01 https://evidence-hub.com/study/6877-role-of-cold-atmospheric-plasma-in-microbial-inactivation-and-the2026-10-01 https://evidence-hub.com/study/6878-in-vitro-susceptibilities-of-methicillin-susceptible-and-resistant2026-10-01 https://evidence-hub.com/study/6879-efficacy-and-safety-of-nemonoxacin-in-outpatients-with-community2026-10-06 https://evidence-hub.com/study/6880-global-threat-of-carbapenem-resistant-gram-negative-bacteria2026-10-01 https://evidence-hub.com/study/6881-correlation-between-mycoplasma-pneumoniae-drug-resistance-and2026-10-01 https://evidence-hub.com/study/6882-infectious-diseases-society-of-america-2022-guidance-on-the-treatment2026-10-01 https://evidence-hub.com/study/6883-in-vitro-and-in-vivo-efficacy-of-minocycline-based-therapy-for2026-10-01 https://evidence-hub.com/study/6884-pooled-microbiological-findings-and-efficacy-outcomes-by-pathogen-in2026-10-01 https://evidence-hub.com/study/6885-therapeutic-strategies-for-emerging-multidrug-resistant-pseudomonas2026-10-01 https://evidence-hub.com/study/6886-bacterial-stress-responses-as-potential-targets-in-overcoming2026-10-01 https://evidence-hub.com/study/6887-epidemiological-and-phylogenetic-analysis-reveals-flavobacteriaceae2026-10-01 https://evidence-hub.com/study/6888-stenotrophomonas-maltophilia-and-its-ability-to-form-biofilms2026-10-08 https://evidence-hub.com/study/6890-addressing-antimicrobial-resistance-with-the-identif-ai-platform2026-10-08 https://evidence-hub.com/study/6892-the-effectiveness-of-moxifloxacin-in-the-treatment-of-community2026-10-08 https://evidence-hub.com/study/6893-bacteriophage-derived-depolymerases-against-bacterial-biofilm2026-10-01 https://evidence-hub.com/study/6894-exploring-phytochemicals-for-combating-antibiotic-resistance-in2026-10-01 https://evidence-hub.com/study/6895-stenotrophomonas-maltophilia-infections-in-pediatric-patients2026-10-08 https://evidence-hub.com/study/6896-beneficial-properties-of-bromelain2026-10-01 https://evidence-hub.com/study/6897-different-classes-of-antibiotics-given-to-women-routinely-for2026-10-13 https://evidence-hub.com/study/6898-oral-is-the-new-iv-challenging-decades-of-blood-and-bone-infection2026-10-06 https://evidence-hub.com/study/6899-meta-analysis-on-the-chinese-herbal-formula-xiaoer-feike-granules-as2026-10-06 https://evidence-hub.com/study/6900-lacticaseibacillus-paracasei-glu-07-a-promising-probiotic-candidate2026-10-06 https://evidence-hub.com/study/6901-prevalence-and-resistance-profiles-of-acinetobacter-baumannii-in-icu2026-10-13 https://evidence-hub.com/study/6902-a-novel-antimicrobial-peptide-displaying-broad-spectrum-activity2026-10-06 https://evidence-hub.com/study/6903-biofunctionalized-zinc-nanoparticles-from-alangium-salvifolium-seeds2026-10-06 https://evidence-hub.com/study/6904-clinical-significance-of-rare-non-candida-yeasts-in-pediatric2026-10-06 https://evidence-hub.com/study/6905-real-world-use-of-eravacycline-for-the-treatment-of-mono-and2026-10-06 https://evidence-hub.com/study/6906-from-cognition-to-response-clinical-challenges-antibiotic-resistance2026-10-06 https://evidence-hub.com/study/6907-a-rare-case-of-concurrent-tropheryma-whipplei-and-pneumocystis2026-10-06 https://evidence-hub.com/study/6908-sequential-acinetobacter-lwoffii-bacteremia-and-early-carbapenem2026-10-06 https://evidence-hub.com/study/6909-severe-corticosteroid-induced-mania-with-psychotic-features-in-an-hiv2026-10-06 https://evidence-hub.com/study/6910-burkholderia-arboris-bacteremia-initially-identified-as-burkholderia2026-10-13 https://evidence-hub.com/study/6911-perioperative-considerations-for-patients-with-multiple-myeloma2026-10-08 https://evidence-hub.com/study/6912-the-convergence-of-antimicrobial-resistance-and-virulence-in2026-10-06 https://evidence-hub.com/study/6913-the-chemorepellent-effect-of-metformin-limits-bacterial-penetration2026-10-08 https://evidence-hub.com/study/6914-proteomics-to-uncover-new-actors-in-the-antifungal-action-of2026-10-08 https://evidence-hub.com/study/6915-ccd-optimized-high-performance-thin-layer-chromatographic-method-for2026-10-08 https://evidence-hub.com/study/6916-expected-and-unexpected-outcomes-of-probiotics-and-metformin2026-10-08 https://evidence-hub.com/study/6917-divergent-retrograde-signaling-pathways-coordinate-longevity-and2026-10-08 https://evidence-hub.com/study/6918-randomized-metformin-and-cognitive-outcomes-in-the-diabetes2026-10-08 https://evidence-hub.com/study/6919-protective-effect-of-oral-antidiabetic-medicines-against-mechanical2026-10-08 https://evidence-hub.com/study/6920-comparative-effects-of-dapagliflozin-versus-linagliptin-as-add-on-to2026-10-08 https://evidence-hub.com/study/6921-comparative-effects-of-metformin-and-dienogest-on-pi3k-akt-signaling2026-10-08 https://evidence-hub.com/study/6922-a-randomized-clinical-trial-of-metformin-to-reduce-frailty-in-older2026-10-08 https://evidence-hub.com/study/6923-metformin-modulates-autophagy-in-heterozygous-and-crispr-edited-tsc22026-10-08 https://evidence-hub.com/study/6924-metformin-enhances-differentiation-and-function-of-skeletal-muscle-in2026-10-08 https://evidence-hub.com/study/6925-effects-of-rifampicin-itraconazole-and-metformin-on-the2026-10-08 https://evidence-hub.com/study/6926-simultaneous-estimation-of-pioglitazone-glimepiride-metformin2026-10-08 https://evidence-hub.com/study/6927-early-identification-of-suboptimal-responders-to-metformin-in-type-22026-10-08 https://evidence-hub.com/study/6928-metformin-antibiotics-painkillers-and-proton-pump-inhibitors-shape2026-10-08 https://evidence-hub.com/study/6929-metformin-associated-lactic-acidosis-in-patients-with-ckd-with2026-10-08 https://evidence-hub.com/study/6930-acquired-brafi-resistance-increases-melanoma-cell-sensitivity-to2026-10-08 https://evidence-hub.com/study/6931-drug-induced-vitamin-b12-deficiency-current-evidence-diagnostic2026-10-08 https://evidence-hub.com/study/6932-a-phase-iii-randomized-double-blind-clinical-trial-of-a-novel-triple2026-10-08 https://evidence-hub.com/study/6933-metformin-for-fatigue-and-cognitive-dysfunction-associated-with2026-10-08 https://evidence-hub.com/study/6934-metformin-and-severe-post-covid-19-outcomes-among-individuals-with2026-10-08 https://evidence-hub.com/study/6935-lipasin-ameliorates-insulin-resistance-in-gestational-diabetes2026-10-08 https://evidence-hub.com/study/6936-establishment-of-a-human-pluripotent-stem-cell-derived-sensory-neuron2026-10-08 https://evidence-hub.com/study/6937-nanoformulation-of-cerium-oxide-nanoparticles-using-pink-pepper2026-10-08 https://evidence-hub.com/study/6938-oct1-variants-are-associated-with-metformin-clearance-and2026-10-08 https://evidence-hub.com/study/6939-measuring-implementation-of-clinical-guidelines-through-the-covid-192026-10-08 https://evidence-hub.com/study/6940-glycemic-response-trajectories-on-metformin-monotherapy-in-real-world2026-10-08 https://evidence-hub.com/study/6941-serum-periostin-as-a-novel-biomarker-of-metabolic-and-atherogenic2026-10-08 https://evidence-hub.com/study/6942-gestational-diabetes-mellitus-and-intrahepatic-cholestasis-of2026-10-08 https://evidence-hub.com/study/6943-metformin-modulates-systemic-lipid-remodeling-after-traumatic-brain2026-10-08 https://evidence-hub.com/study/6944-glycated-hemoglobin-and-retinal-microvascular-changes-in-type-22026-10-08 https://evidence-hub.com/study/6945-cell-type-resolved-transcriptomic-map-of-skeletal-muscle-in-women2026-10-08 https://evidence-hub.com/study/6946-from-clinical-question-to-testable-hypothesis-using-ai-co-scientist2026-10-08 https://evidence-hub.com/study/6947-investigating-the-synergistic-effects-of-telmisartan-and-amlodipine2026-10-08 https://evidence-hub.com/study/6948-metformin-mediated-modulation-of-the-ampk-mtor-axis-in-hashimoto-s2026-10-08 https://evidence-hub.com/study/6949-metformin-redirects-autophagy-from-bulk-turnover-to-mitochondrial2026-10-08 https://evidence-hub.com/study/6950-efficacy-and-safety-of-metformin-for-melasma-acne-vulgaris-and2026-10-08 https://evidence-hub.com/study/6951-impact-of-antidiabetic-medications-on-igg-and-plasma-protein-n2026-10-08 https://evidence-hub.com/study/6952-metformin-pharmacokinetics-in-the-rat-brain-dose-and-time-dependent2026-10-08 https://evidence-hub.com/study/6953-acute-kidney-injury-risk-with-sglt2-inhibitors-versus-sulfonylureas2026-10-08 https://evidence-hub.com/study/6954-phosphoproteomic-insights-into-trpv4-ampk-signaling-axis-in-the2026-10-08 https://evidence-hub.com/study/6955-trustfedkg-health-explainability-aware-personalized-federated2026-10-08 https://evidence-hub.com/study/6956-targeting-metainflammation-in-hidradenitis-suppurativa-the-emerging2026-10-08 https://evidence-hub.com/study/6957-cell-type-specific-placental-signatures-in-polyendocrine-metabolic2026-10-08 https://evidence-hub.com/study/6958-evaluation-of-the-efficacy-and-safety-of-combination-therapy-of-vamha2026-10-08 https://evidence-hub.com/study/6959-metformin-is-associated-with-reduced-mortality-and-systemic2026-10-08 https://evidence-hub.com/study/6960-biphasic-temporal-remodeling-of-the-proteome-in-a-polyglutamine2026-10-08 https://evidence-hub.com/study/6961-preparation-and-use-of-activated-carbon-based-on-pinus-nigra-cones2026-10-08 https://evidence-hub.com/study/6962-twelve-hallmarks-one-target-the-metadichol-approach-to-systems-level2026-10-08 https://evidence-hub.com/study/6963-metformin-use-inflammatory-markers-and-mortality-in-u-s-adults-with2026-10-08 https://evidence-hub.com/study/6964-lower-respiratory-infections-in-diabetes-which-hypoglycemic-agents2026-10-08 https://evidence-hub.com/study/6965-cancer-cell-line-heterogeneity-imposes-a-primary-bottleneck-for2026-10-08 https://evidence-hub.com/study/6966-itaconate-delays-type-2-diabetes-progression-by-alkylating-ripk3-to2026-10-08 https://evidence-hub.com/study/6967-additional-effects-of-bariatric-surgery-and-metformin-on-glucose2026-10-08 https://evidence-hub.com/study/6968-vitamin-d-supplementation-on-metabolic-and-endocrine-profiles-in2026-10-08 https://evidence-hub.com/study/6969-adjuvant-s-1-plus-metformin-after-pancreatic-cancer-resection-a2026-10-08 https://evidence-hub.com/study/6970-machine-learning-modeling-of-d-optimal-design-data-for-metformin2026-10-08 https://evidence-hub.com/study/6971-enhanced-radio-sensitization-of-glioblastoma-using-a-dendrimer-based2026-10-08 https://evidence-hub.com/study/6972-drugset-a-validated-r-shiny-application-for-reproducible-drug2026-10-08 https://evidence-hub.com/study/6973-effect-of-metformin-on-sleep-architecture-in-patients-with-comorbid2026-10-08 https://evidence-hub.com/study/6974-comparative-effectiveness-of-metformin-versus-glp-1-receptor-agonists2026-10-08 https://evidence-hub.com/study/6975-can-a-large-language-model-serve-as-the-missing-second-reviewer2026-10-08 https://evidence-hub.com/study/6976-metformin-attenuates-behavioral-deficits-and-oxidative-stress-in-a2026-10-08 https://evidence-hub.com/study/6977-engineered-trophoblast-organoids-recapitulate-molecular-and2026-10-08 https://evidence-hub.com/study/6978-evidence-for-reduced-migraine-reporting-with-glp-1-receptor-agonists2026-10-08 https://evidence-hub.com/study/6979-molecular-insights-into-the-interaction-between-metformin-and2026-10-08 https://evidence-hub.com/study/6980-is-routine-metformin-discontinuation-necessary-before-elective2026-10-08 https://evidence-hub.com/study/6981-metformin-as-a-chemopreventive-agent-for-colorectal-adenoma2026-10-08 https://evidence-hub.com/study/6982-feasibility-of-managing-diabetes-patients-identified-through2026-10-08 https://evidence-hub.com/study/6983-neurosensory-risk-after-semaglutide-or-tirzepatide-is-lower-than2026-10-08 https://evidence-hub.com/study/6984-cytolethal-distending-toxin-promotes-epithelial-to-mesenchymal2026-10-08 https://evidence-hub.com/study/6985-transcriptome-wide-identification-of-hub-genes-and-therapeutic2026-10-08 https://evidence-hub.com/study/6986-clinician-awareness-and-implementation-of-mhra-guidance-on-vitamin2026-10-08 https://evidence-hub.com/study/6987-metformin-and-tirzepatide-in-lipedema-targeting-fibrosis-and2026-10-08 https://evidence-hub.com/study/6988-circulating-micrornas-as-putative-causal-regulators-of-peripheral2026-10-08 https://evidence-hub.com/study/6989-in-silico-design-of-phosphorus-doped-endohedral-fullerenes-sc3p-c802026-10-08 https://evidence-hub.com/study/6990-targeting-cancer-metabolism-modulation-of-metformin-antitumor-effects2026-10-08 https://evidence-hub.com/study/6991-baicalin-restores-metformin-responsiveness-by-inhibiting-ceramide2026-10-08 https://evidence-hub.com/study/6992-incident-frailty-and-mortality-risk-with-significant-tirzepatide2026-10-08 https://evidence-hub.com/study/6993-intracapsular-metformin-bioactivity-and-its-role-in-posterior-capsule2026-10-08 https://evidence-hub.com/study/6994-inter-organ-communication-shapes-human-metabolic-tissue-states-and2026-10-08 https://evidence-hub.com/study/6995-therapeutic-potential-of-anti-obesity-drugs-in-obesity-associated2026-10-08 https://evidence-hub.com/study/6996-bscl2-associated-congenital-generalized-lipodystrophy-real-world-data2026-10-08 https://evidence-hub.com/study/6997-effectiveness-of-an-educational-intervention-in-the-integral-care-of2026-10-08 https://evidence-hub.com/study/6998-off-trial-real-world-weight-loss-on-tirzepatide-and-semaglutide2026-10-06 https://evidence-hub.com/study/6999-metformin-suppresses-metastatic-potential-and-sensitizes-ovarian2026-10-06 https://evidence-hub.com/study/7000-oral-wegovy-broadens-care-continuum-across-first-time-glp-starters2026-10-06 https://evidence-hub.com/study/7001-evaluating-metformin-efficacy-in-als-using-real-world-data-a-causal2026-10-06 https://evidence-hub.com/study/7002-combination-therapy-potential-of-htd1801-berbe-rine-ursodeoxycholate2026-10-06 https://evidence-hub.com/study/7003-maternal-metformin-treatment-in-obese-pregnant-dams-normalizes2026-10-06 https://evidence-hub.com/study/7004-exploring-the-therapeutic-applications-of-metformin-in-articular2026-10-08 https://evidence-hub.com/study/7005-oleanolic-acid-as-an-adjunct-in-type-2-diabetes2026-10-06 https://evidence-hub.com/study/7006-same-result-different-price-compounded-versus-branded-tirzepatide2026-10-06 https://evidence-hub.com/study/7007-comparison-between-metformin-and-intermittent-fasting-for2026-10-06 https://evidence-hub.com/study/7008-severe-metformin-intoxication-resulting-in-extreme-lactic-acidosis2026-10-08 https://evidence-hub.com/study/7009-rate-and-characteristics-of-metformin-use-in-gestational-diabetes2026-10-06 https://evidence-hub.com/study/7010-metformin-potentiates-arsenic-disulfide-in-diffuse-large-b-cell2026-10-06 https://evidence-hub.com/study/7011-metformin-stabilizes-the-abdominal-aorta-in-aneurysm-by-restoring2026-10-06 https://evidence-hub.com/study/7012-neuroprotective-effects-of-empagliflozin-and-metformin-combined2026-10-04 https://evidence-hub.com/study/7013-reduction-in-the-incidence-of-type-2-diabetes-with-lifestyle2026-10-08 https://evidence-hub.com/study/7014-role-of-amp-activated-protein-kinase-in-mechanism-of-metformin-action2026-10-08 https://evidence-hub.com/study/7015-metformin-decelerates-aging-clock-in-male-monkeys2026-10-08 https://evidence-hub.com/study/7016-metformin-update-on-mechanisms-of-action-and-repurposing-potential2026-10-08 https://evidence-hub.com/study/7017-the-mechanisms-of-action-of-metformin2026-10-08 https://evidence-hub.com/study/7019-low-dose-metformin-targets-the-lysosomal-ampk-pathway-through-pen22026-10-08 https://evidence-hub.com/study/7020-ph-glucose-dual-responsive-metformin-release-hydrogel-dressings-with2026-10-08 https://evidence-hub.com/study/7021-glycemic-durability-of-rosiglitazone-metformin-or-glyburide2026-10-08 https://evidence-hub.com/study/7022-metformin-a-review-of-potential-mechanism-and-therapeutic-utility2026-10-08 https://evidence-hub.com/study/7023-metformin-and-cancer-hallmarks-shedding-new-lights-on-therapeutic2026-10-08 https://evidence-hub.com/study/7024-cellular-and-molecular-mechanisms-of-metformin-action2026-10-08 https://evidence-hub.com/study/7025-metformin-alters-the-gut-microbiome-of-individuals-with-treatment2026-10-08 https://evidence-hub.com/study/7026-metformin-inhibition-of-mitochondrial-atp-and-dna-synthesis-abrogates2026-10-08 https://evidence-hub.com/study/7027-metformin-induces-ferroptosis-by-inhibiting-ufmylation-of-slc7a11-in2026-10-08 https://evidence-hub.com/study/7028-benefits-of-metformin-in-attenuating-the-hallmarks-of-aging2026-10-08 https://evidence-hub.com/study/7029-is-it-still-worth-pursuing-the-repurposing-of-metformin-as-a-cancer2026-10-08 https://evidence-hub.com/study/7030-metformin-and-its-benefits-for-various-diseases2026-10-08 https://evidence-hub.com/study/7031-gut-microbiota-and-intestinal-fxr-mediate-the-clinical-benefits-of2026-10-08 https://evidence-hub.com/study/7032-metformin-is-it-a-drug-for-all-reasons-and-diseases2026-10-08 https://evidence-hub.com/study/7033-gdf15-mediates-the-effects-of-metformin-on-body-weight-and-energy2026-10-08 https://evidence-hub.com/study/7036-metformin-and-insulin-resistance-a-review-of-the-underlying2026-10-08 https://evidence-hub.com/study/7037-metformin-inhibits-the-nlrp3-inflammasome-via-ampk-mtor-dependent2026-10-08 https://evidence-hub.com/study/7038-mitochondria-as-an-important-target-of-metformin-the-mechanism-of2026-10-08 https://evidence-hub.com/study/7039-metformin-historical-overview2026-10-08 https://evidence-hub.com/study/7040-metformin-attenuated-sepsis-related-liver-injury-by-modulating-gut2026-10-08 https://evidence-hub.com/study/7041-long-term-metformin-therapy-and-vitamin-b12-deficiency-an-association2026-10-08 https://evidence-hub.com/study/7042-metformin-promotes-antitumor-immunity-via-endoplasmic-reticulum2026-10-08 https://evidence-hub.com/study/7043-the-kinase-lkb1-mediates-glucose-homeostasis-in-liver-and-therapeutic2026-10-08 https://evidence-hub.com/study/7044-metformin-and-reduced-risk-of-cancer-in-diabetic-patients2026-10-08 https://evidence-hub.com/study/7046-a-critical-review-of-the-evidence-that-metformin-is-a-putative-anti2026-10-08 https://evidence-hub.com/study/7047-metformin-reverses-established-lung-fibrosis-in-a-bleomycin-model2026-10-08 https://evidence-hub.com/study/7048-effects-of-long-term-metformin-and-lifestyle-interventions-on2026-10-08 https://evidence-hub.com/study/7049-metformin-affects-gut-microbiome-composition-and-function-and2026-10-08 https://evidence-hub.com/study/7050-metformin-alleviates-oxidative-stress-and-enhances-autophagy-in2026-10-08 https://evidence-hub.com/study/7051-disentangling-type-2-diabetes-and-metformin-treatment-signatures-in2026-10-08 https://evidence-hub.com/study/7052-glycemic-control-with-diet-sulfonylurea-metformin-or-insulin-in2026-10-08 https://evidence-hub.com/study/7053-metformin-treatment-was-associated-with-decreased-mortality-in-covid2026-10-08 https://evidence-hub.com/study/7054-metformin-limits-osteoarthritis-development-and-progression-through2026-10-08 https://evidence-hub.com/study/7055-metformin-protects-against-myocardial-ischemia-reperfusion-injury-and2026-10-08 https://evidence-hub.com/study/7056-metformin-protects-against-intestinal-ischemia-reperfusion-injury-and2026-10-08 https://evidence-hub.com/study/7057-hexokinase-2-depletion-inhibits-glycolysis-and-induces-oxidative2026-10-08 https://evidence-hub.com/study/7058-metformin-prevents-age-associated-ovarian-fibrosis-by-modulating-the2026-10-08 https://evidence-hub.com/study/7059-metformin-improves-mitochondrial-respiratory-activity-through2026-10-08 https://evidence-hub.com/study/7060-evidence-that-metformin-exerts-its-anti-diabetic-effects-through2026-10-08 https://evidence-hub.com/study/7061-metformin-activates-ampk-sirt1-nf-b-pathway-and-induces-mitochondrial2026-10-08 https://evidence-hub.com/study/7062-association-between-preadmission-metformin-use-and-outcomes-in2026-10-08 https://evidence-hub.com/study/7063-mechanism-of-metformin-regulation-in-central-nervous-system2026-10-08 https://evidence-hub.com/study/7064-gastrointestinal-adverse-events-of-metformin-treatment-in-patients2026-10-08 https://evidence-hub.com/study/7065-metformin-restores-tetracyclines-susceptibility-against-multidrug2026-10-08 https://evidence-hub.com/study/7066-metformin-as-an-emerging-concern-in-wastewater-occurrence-analysis2026-10-08 https://evidence-hub.com/study/7067-targeting-bcaa-metabolism-to-potentiate-metformin-s-therapeutic2026-10-08 https://evidence-hub.com/study/7068-metformin-mechanisms-in-human-obesity-and-weight-loss2026-10-08 https://evidence-hub.com/study/7069-the-effects-of-metformin-on-autophagy2026-10-08 https://evidence-hub.com/study/7070-metformin-activates-chaperone-mediated-autophagy-and-improves-disease2026-10-08 https://evidence-hub.com/study/7071-metformin-use-and-prostate-cancer-risk-a-meta-analysis-of-cohort2026-10-08 https://evidence-hub.com/study/7072-the-beneficial-effects-of-metformin-on-cancer-prevention-and-therapy2026-10-08 https://evidence-hub.com/study/7073-role-of-mitochondria-in-the-mechanism-s-of-action-of-metformin2026-10-08 https://evidence-hub.com/study/7074-metformin-induces-lipogenic-differentiation-in-myofibroblasts-to2026-10-08 https://evidence-hub.com/study/7075-should-metformin-remain-the-first-line-therapy-for-treatment-of-type2026-10-08 https://evidence-hub.com/study/7076-cellular-and-molecular-mechanisms-of-metformin-an-overview2026-10-08 https://evidence-hub.com/study/7077-metformin-and-systemic-metabolism2026-10-08 https://evidence-hub.com/study/7078-the-current-and-potential-therapeutic-use-of-metformin-the-good-old2026-10-08 https://evidence-hub.com/study/7079-effect-of-metformin-on-all-cause-and-cardiovascular-mortality-in2026-10-08 https://evidence-hub.com/study/7080-metformin-use-is-associated-with-slowed-cognitive-decline-and-reduced2026-10-08 https://evidence-hub.com/study/7081-metformin-from-mechanisms-of-action-to-therapies2026-10-08 https://evidence-hub.com/study/7082-combination-of-hypoglycemia-and-metformin-impairs-tumor-metabolic2026-10-08 https://evidence-hub.com/study/7083-metformin-a-novel-weapon-against-inflammation2026-10-08 https://evidence-hub.com/study/7084-metformin-treatment-before-and-during-ivf-or-icsi-in-women-with2026-10-08 https://evidence-hub.com/study/7085-metformin-macrophage-dysfunction-and-atherosclerosis2026-10-08 https://evidence-hub.com/study/7086-metformin-treatment-in-late-middle-age-improves-cognitive-function2026-10-08 https://evidence-hub.com/study/7087-metformin-facilitates-mesenchymal-stem-cell-derived-extracellular2026-10-08 https://evidence-hub.com/study/7089-the-intersection-of-metformin-and-inflammation2026-10-08 https://evidence-hub.com/study/7090-metformin-attenuates-silica-induced-pulmonary-fibrosis-via-ampk2026-10-08 https://evidence-hub.com/study/7091-mechanism-and-application-of-metformin-in-kidney-diseases-an-update2026-10-08 https://evidence-hub.com/study/7092-phase-ii-clinical-trial-of-metformin-as-a-cancer-stem-cell-targeting2026-10-08 https://evidence-hub.com/study/7093-metformin-induces-cell-cycle-arrest-apoptosis-and-autophagy-through2026-10-08 https://evidence-hub.com/study/7094-metformin-is-associated-with-higher-incidence-of-acidosis-but-not2026-10-08 https://evidence-hub.com/study/7096-covid-19-and-risk-of-acute-ischemic-stroke-and-acute-lung-injury-in2026-10-08 https://evidence-hub.com/study/7097-host-microbe-drug-nutrient-screen-identifies-bacterial-effectors-of2026-10-08 https://evidence-hub.com/study/7098-microbial-imidazole-propionate-affects-responses-to-metformin-through2026-10-08 https://evidence-hub.com/study/7099-metformin-associated-lactic-acidosis-current-perspectives-on-causes2026-10-08 https://evidence-hub.com/study/7100-an-increase-in-the-akkermansia-spp-population-induced-by-metformin2026-10-08 https://evidence-hub.com/study/7101-the-metformin-mechanism-on-gluconeogenesis-and-ampk-activation-the2026-10-08 https://evidence-hub.com/study/7103-metformin-and-the-gastrointestinal-tract2026-10-08 https://evidence-hub.com/study/7104-metformin-suppresses-gluconeogenesis-by-inhibiting-mitochondrial2026-10-08 https://evidence-hub.com/study/7105-metformin-as-anti-aging-therapy-is-it-for-everyone2026-10-08 https://evidence-hub.com/study/7106-dual-inhibition-of-the-lactate-transporters-mct1-and-mct4-is2026-10-08 https://evidence-hub.com/study/7107-observational-study-of-metformin-and-risk-of-mortality-in-patients2026-10-08 https://evidence-hub.com/study/7108-neonatal-infant-and-childhood-growth-following-metformin-versus2026-10-08 https://evidence-hub.com/study/7109-effects-of-metformin-on-the-gut-microbiota-in-obesity-and-type-22026-10-08 https://evidence-hub.com/study/7110-metformin-induces-human-esophageal-carcinoma-cell-pyroptosis-by2026-10-08 https://evidence-hub.com/study/7111-metformin-enhances-the-antitumor-activity-of-cd8-t-lymphocytes-via2026-10-08 https://evidence-hub.com/study/7112-structural-alteration-of-gut-microbiota-during-the-amelioration-of2026-10-08 https://evidence-hub.com/study/7113-improving-metabolic-parameters-of-antipsychotic-child-treatment-impact2026-09-27 https://evidence-hub.com/study/7114-a-single-dose-open-label-randomized-3-way-crossover-pivotal-study-to2026-09-27 https://evidence-hub.com/study/7115-myo-inositol-versus-metformin-effects-of-six-months-treatment-on2026-10-06 https://evidence-hub.com/study/7116-pilot-trial-of-chromium-metformin-combination-in-type-2-diabetes2026-09-27 https://evidence-hub.com/study/7117-an-open-label-multicenter-trial-assessing-the-acceptability-of-a-new2026-09-27 https://evidence-hub.com/study/7118-effects-of-combined-resveratrol-and-myo-inositol-on-altered-metabolic2026-10-08 https://evidence-hub.com/study/7119-a-trial-comparing-the-efficacy-and-safety-of-insulin-degludec-once2026-09-27 https://evidence-hub.com/study/7120-a-26-week-randomised-confirmatory-controlled-open-label-multicentre2026-09-27 https://evidence-hub.com/study/7121-a-multicenter-double-blind-randomized-parallel-group-study-to-compare2026-09-30 https://evidence-hub.com/study/7122-vildagliptin-compared-to-glimepiride-in-combination-with-metformin-in2026-09-27 https://evidence-hub.com/study/7123-randomized-open-label-two-parallel-arms-intervention-trial-comparing2026-09-27 https://evidence-hub.com/study/7124-effect-of-metformin-with-or-without-folate-addiction-on-uterine-blood2026-09-27 https://evidence-hub.com/study/7125-monitoring-parameters-beyond-glycemic-control-impact-of-sitagliptin2026-09-27 https://evidence-hub.com/study/7126-differences-in-endothelial-function-amongst-sitagliptin-and2026-09-27 https://evidence-hub.com/study/7127-drug-drug-interaction-study-of-multiple-doses-of-pacritinib-and2026-09-27 https://evidence-hub.com/study/7128-a-phase-1-single-center-repeat-dose-open-label-fixed-sequence-drug2026-09-27 https://evidence-hub.com/study/7129-efficacity-and-safety-of-metformin-xr-in-ckd-stage-1-to-32026-09-27 https://evidence-hub.com/study/7130-a-phase-iii-randomized-double-blind-parallel-group-study-to-evaluate2026-10-04 https://evidence-hub.com/study/7131-phase-i-study-of-tak-228-mln0128-in-combination-with-metformin-in2026-09-27 https://evidence-hub.com/study/7132-multi-centre-randomised-controlled-trial-of-the-effectiveness-of2026-09-27 https://evidence-hub.com/study/7133-comparison-of-switching-to-premixed-insulin-with-add-on-rapid-acting2026-09-27 https://evidence-hub.com/study/7134-clinical-investigation-of-herbal-formulation-and-its-efficacy-in2026-10-06 https://evidence-hub.com/study/7135-phase-4-study-of-metformin-on-obesity-and-metabolic-disturbance-in2026-09-27 https://evidence-hub.com/study/7136-bedtime-insulin-glargine-or-bedtime-neutral-protamine-lispro-combined2026-09-27 https://evidence-hub.com/study/7137-effect-of-white-mulberry-leaf-extract-supplementation-on-metabolic2026-09-27 https://evidence-hub.com/study/7138-effect-of-metformin-and-probiotics-on-gut-microbiome-in-healthy2026-09-27 https://evidence-hub.com/study/7139-a-phase-3-multicenter-randomized-double-blind-active-controlled2026-09-27 https://evidence-hub.com/study/7140-randomized-clinical-trial-to-evaluate-safety-tolerability-and-pk-pd2026-09-27 https://evidence-hub.com/study/7141-a-phase-ii-double-blind-randomized-placebo-controlled-study-of-the2026-09-27 https://evidence-hub.com/study/7142-cross-over-study-to-assess-the-difference-in-fasting-plasma-glucose2026-09-27 https://evidence-hub.com/study/7143-a-multicenter-randomized-double-blind-placebo-and-active-controlled2026-09-30 https://evidence-hub.com/study/7144-a-randomized-placebo-controlled-double-blind-multicenter-phase-ii2026-09-27 https://evidence-hub.com/study/7145-multicenter-prospective-cohort-study-of-the-hypoglycemic-efficacy2026-09-27 https://evidence-hub.com/study/7146-comparison-of-the-efficacy-on-glycaemic-control-and-safety-profile-of2026-09-29 https://evidence-hub.com/study/7147-the-effect-of-januvia-sitagliptin-on-oxidative-stress-in-obese-type-22026-10-08 https://evidence-hub.com/study/7148-study-to-evaluate-the-effect-of-metformin-in-the-prevention-of2026-09-27 https://evidence-hub.com/study/7149-a-multicenter-randomized-double-blind-double-dummy-active-controlled2026-09-30 https://evidence-hub.com/study/7150-an-open-comparative-randomized-crossover-bioequivalence-study-of2026-09-27 https://evidence-hub.com/study/7151-a-randomized-phase-3-open-label-trial-comparing-the-effect-of-the2026-09-27 https://evidence-hub.com/study/7152-metformin-for-the-treatment-of-endometrial-hyperplasia2026-09-27 https://evidence-hub.com/study/7153-a-56-week-multicenter-open-label-active-controlled-randomized-study2026-09-27 https://evidence-hub.com/study/7154-a-multicenter-randomized-double-blind-placebo-controlled-parallel2026-09-27 https://evidence-hub.com/study/7155-a-randomized-open-label-cross-over-clinical-trial-to-investigate2026-09-27 https://evidence-hub.com/study/7156-randomized-clinical-trial-evaluating-the-impact-of-pretreatment-with2026-09-27 https://evidence-hub.com/study/7157-a-randomised-controlled-trial-for-people-with-established-type-22026-09-27 https://evidence-hub.com/study/7158-a-multicenter-open-label-randomised-trial-to-compare-the-efficacy-and2026-09-27 https://evidence-hub.com/study/7159-the-effect-of-remote-self-monitoring-of-blood-glucose-smbg-combined2026-09-27 https://evidence-hub.com/study/7160-a-clinical-trial-to-compare-the-pharmacokinetic-and-pharmacodynamic2026-09-27 https://evidence-hub.com/study/7161-research-of-intensive-lifestyle-intervention-for-overweight-pcos2026-10-06 https://evidence-hub.com/study/7162-comparison-of-two-therapeutic-strategies-for-treating-type-2-diabetic2026-09-27 https://evidence-hub.com/study/7163-a-multi-national-open-labelled-randomised-parallel-group-4-week-run2026-09-27 https://evidence-hub.com/study/7164-a-open-label-single-sequence-clinical-trial-to-investigate-the2026-09-27 https://evidence-hub.com/study/7165-diazoxide-mediated-insulin-suppression-in-hyperinsulinemic-obese-men2026-09-27 https://evidence-hub.com/study/7166-a-relative-bioavailability-study-of-5-mg-glyburide-500-mg-metformin2026-09-27 https://evidence-hub.com/study/7167-multicentre-randomised-comparative-open-three-armed-parallel-group2026-09-27 https://evidence-hub.com/study/7168-does-metformin-improve-pregnancy-outcomes-incidence-of-lga-90-birth2026-10-06 https://evidence-hub.com/study/7169-the-effect-of-metformin-in-pregnant-women-who-received-antenatal2026-09-27 https://evidence-hub.com/study/7170-a-pilot-study-metformin-as-an-inflammatory-modulating-therapy-in2026-09-27 https://evidence-hub.com/study/7171-mk-0431-ono-5435-phase-iii-clinical-study-metformin-add-on-study-for2026-09-27 https://evidence-hub.com/study/7172-effects-of-metformin-on-body-weight-composition-and-metabolic2026-09-27 https://evidence-hub.com/study/7173-a-multicenter-randomized-double-blind-placebo-controlled-parallel2026-09-27 https://evidence-hub.com/study/7174-a-randomized-double-blind-study-of-the-effect-of-the-dpp-iv-inhibitor2026-09-27 https://evidence-hub.com/study/7175-a-12-week-multi-center-open-label-single-arm-study-to-assess-the2026-09-27 https://evidence-hub.com/study/7176-a-double-blind-placebo-controlled-dose-ranging-study-to-investigate2026-09-27 https://evidence-hub.com/study/7177-implementation-and-evaluation-of-a-diabetes-prevention-clinical2026-09-27 https://evidence-hub.com/study/7178-a-randomized-parallel-group-open-label-active-controlled-study2026-09-27 https://evidence-hub.com/study/7179-an-open-label-randomized-two-part-two-period-crossover-study-to2026-09-27 https://evidence-hub.com/study/7180-effect-of-treatment-with-insulin-sensitizer-on-arterial-properties2026-09-27 https://evidence-hub.com/study/7181-inkretineffekten-hos-patienter-med-polycystisk-ovariesyndrom-f-r-og2026-09-27 https://evidence-hub.com/study/7182-a-randomized-open-label-single-dose-2-way-cross-over-study-to-compare2026-09-30 https://evidence-hub.com/study/7183-medical-optimization-of-management-of-type-2-diabetes-complicating2026-09-27 https://evidence-hub.com/study/7184-a-phase-1-open-label-sequential-design-study-to-evaluate-the2026-09-27 https://evidence-hub.com/study/7185-a-single-dose-open-label-randomized-4-way-crossover-pivotal-study-to2026-10-08 https://evidence-hub.com/study/7186-effects-of-metformin-on-mood-and-cognition-during-nicotine-withdrawal2026-09-27 https://evidence-hub.com/study/7187-the-effect-of-dpp4-inhibitor-on-glycemic-variability-in-patients-with2026-09-27 https://evidence-hub.com/study/7188-a-randomized-double-blind-trial-comparing-the-effect-of-the-addition2026-09-27 https://evidence-hub.com/study/7189-the-effect-of-metformin-on-clinical-course-of-ischemic-etiology2026-09-27 https://evidence-hub.com/study/7190-insulin-glargine-rdna-origin-injection-vs-pioglitazone-as-add-on2026-09-27 https://evidence-hub.com/study/7191-a-32-week-randomised-multinational-treat-to-target-open-label2026-09-27 https://evidence-hub.com/study/7192-bioequivalence-study-of-the-fixed-dose-combination-of-2-5-mg2026-09-27 https://evidence-hub.com/study/7193-a-multicenter-open-label-sub-study-to-lmf237a2302-to-assess-the2026-09-27 https://evidence-hub.com/study/7194-a-phase-1-clinical-trial-to-compare-and-evaluate-the-safety-and2026-10-04 https://evidence-hub.com/study/7195-a-randomized-double-blind-double-dummy-2-arm-parallel-group2026-09-27 https://evidence-hub.com/study/7196-a-multicenter-double-blind-randomized-parallel-group-study-to-compare2026-09-27 https://evidence-hub.com/study/7197-open-comparative-randomized-crossover-single-dose-bioequivalence2026-09-27 https://evidence-hub.com/study/7198-a-phase-3-randomized-double-blind-placebo-controlled-multicenter2026-09-27 https://evidence-hub.com/study/7199-the-role-of-adding-metformin-in-insulin-resistant-diabetic-pregnant2026-09-27 https://evidence-hub.com/study/7200-a-phase-1-open-label-two-cohort-study-to-assess-the-effect-of-a2026-09-27 https://evidence-hub.com/study/7201-efficacy-and-long-term-safety-of-vildagliptin-as-add-on-therapy-to2026-09-27 https://evidence-hub.com/study/7202-a-randomized-open-label-two-period-crossover-study-to-evaluate-the2026-09-29 https://evidence-hub.com/study/7203-a-26-week-randomised-open-labelled-two-arm-parallel-group-treat-to2026-09-27 https://evidence-hub.com/study/7204-continuous-glucose-monitoring-system-cgms-in-type-2-diabetic-patients2026-09-29 https://evidence-hub.com/study/7205-long-term-comparative-effectiveness-of-once-weekly-semaglutide-versus2026-09-27 https://evidence-hub.com/study/7206-a-prospective-randomized-double-blind-multi-centre-study-where-the2026-10-06 https://evidence-hub.com/study/7207-evaluation-of-the-role-of-pyridoxine-adjuvant-therapy-on-the-blood2026-09-27 https://evidence-hub.com/study/7208-a-drug-drug-interaction-study-between-the-novel-anti-hepatitis-c2026-09-27 https://evidence-hub.com/study/7209-coordinating-cardiology-clinics-randomized-trial-of-interventions-to2026-10-04 https://evidence-hub.com/study/7210-a-phase-iii-multicenter-double-blind-randomized-study-to-evaluate-the2026-09-27 https://evidence-hub.com/study/7211-comparison-of-efficacy-and-safety-of-biphasic-insulin-aspart-30-plus2026-09-27 https://evidence-hub.com/study/7212-elmi-prospective-randomized-controlled-parallel-arm-study-to-assess2026-10-04 https://evidence-hub.com/study/7214-clinical-pharmacokinetics-of-metformin2026-10-08 https://evidence-hub.com/study/7215-effect-of-intensive-blood-glucose-control-with-metformin-on2026-10-08 https://evidence-hub.com/study/7217-metformin-an-update2026-10-08 https://evidence-hub.com/study/7218-metformin-mode-of-action-and-clinical-implications-for-diabetes-and2026-10-08 https://evidence-hub.com/study/7219-metformin-versus-insulin-for-the-treatment-of-gestational-diabetes2026-10-08 https://evidence-hub.com/study/7220-efficacy-of-metformin-in-patients-with-non-insulin-dependent-diabetes2026-10-08 https://evidence-hub.com/study/7221-clomiphene-metformin-or-both-for-infertility-in-the-polycystic-ovary2026-10-08 https://evidence-hub.com/study/7222-new-users-of-metformin-are-at-low-risk-of-incident-cancer2026-10-08 https://evidence-hub.com/study/7223-loss-of-metabolic-plasticity-underlies-metformin-toxicity-in-aged2026-10-08 https://evidence-hub.com/study/7224-metabolic-effects-of-metformin-in-non-insulin-dependent-diabetes2026-10-01 https://evidence-hub.com/study/7225-metformin-is-an-amp-kinase-dependent-growth-inhibitor-for-breast2026-10-01 https://evidence-hub.com/study/7226-clinical-pharmacokinetics-of-metformin2026-10-08 https://evidence-hub.com/study/7227-mechanism-by-which-metformin-reduces-glucose-production-in-type-22026-09-30 https://evidence-hub.com/study/7228-metformin-an-old-drug-for-the-treatment-of-diabetes-but-a-new-drug2026-09-30 https://evidence-hub.com/study/7229-metformin-retards-aging-in-c-elegans-by-altering-microbial-folate-and2026-10-01 https://evidence-hub.com/study/7231-effect-of-genetic-variation-in-the-organic-cation-transporter-1-oct12026-10-01 https://evidence-hub.com/study/7232-effect-of-vitamin-e-or-metformin-for-treatment-of-nonalcoholic-fatty2026-09-30 https://evidence-hub.com/study/7233-metformin-in-polycystic-ovary-syndrome-systematic-review-and-meta2026-10-08 https://evidence-hub.com/study/7234-metformin-and-the-risk-of-cancer-time-related-biases-in-observational2026-10-08 https://evidence-hub.com/study/7235-metformin-inhibits-hepatic-gluconeogenesis-in-mice-independently-of2026-10-01 https://evidence-hub.com/study/7236-anti-inflammatory-effects-of-metformin-irrespective-of-diabetes-status2026-10-08 https://evidence-hub.com/study/7237-metformin-and-cancer-risk-in-diabetic-patients-a-systematic-review2026-10-08 https://evidence-hub.com/study/7238-effects-of-exenatide-exendin-4-on-glycemic-control-and-weight-over-302026-10-08 https://evidence-hub.com/study/7239-efficacy-and-safety-comparison-of-liraglutide-glimepiride-and-placebo2026-09-30 https://evidence-hub.com/study/7240-metformin-a-review-of-its-pharmacological-properties-and-therapeutic2026-10-08 https://evidence-hub.com/study/7241-metformin-and-pathologic-complete-responses-to-neoadjuvant2026-10-08 https://evidence-hub.com/study/7243-metformin-inhibits-mammalian-target-of-rapamycin-dependent2026-09-30 https://evidence-hub.com/study/7244-metformin-selectively-targets-cancer-stem-cells-and-acts-together2026-10-01 https://evidence-hub.com/study/7245-efficacy-and-metabolic-effects-of-metformin-and-troglitazone-in-type2026-10-01 https://evidence-hub.com/study/7246-effects-of-metformin-and-other-biguanides-on-oxidative2026-10-01 https://evidence-hub.com/study/7247-metformin-in-cancer-treatment-and-prevention2026-10-08 https://evidence-hub.com/study/7248-systemic-treatment-with-the-antidiabetic-drug-metformin-selectively2026-10-01 https://evidence-hub.com/study/7250-efficacy-and-safety-of-the-dipeptidyl-peptidase-4-inhibitor2026-10-08 https://evidence-hub.com/study/7251-effects-of-metformin-on-spontaneous-and-clomiphene-induced-ovulation2026-10-06 https://evidence-hub.com/study/7252-risk-of-fatal-and-nonfatal-lactic-acidosis-with-metformin-use-in-type2026-10-08 https://evidence-hub.com/study/7253-prevention-of-diabetes-in-women-with-a-history-of-gestational2026-09-30 https://evidence-hub.com/study/7254-the-effect-of-metformin-and-intensive-lifestyle-intervention-on-the2026-09-30 https://evidence-hub.com/study/7255-metformin-as-adjunct-antituberculosis-therapy2026-10-08 https://evidence-hub.com/study/7256-efficacy-of-metformin-in-type-ii-diabetes-results-of-a-double-blind2026-10-08 https://evidence-hub.com/study/7257-metformin-action-concentrations-matter2026-10-08 https://evidence-hub.com/study/7259-metformin-in-patients-with-type-2-diabetes-and-kidney-disease-a2026-10-08 https://evidence-hub.com/study/7260-metformin-clinical-use-in-type-2-diabetes2026-10-08 https://evidence-hub.com/study/7262-metformin-new-understandings-new-uses2026-10-08 https://evidence-hub.com/study/7264-single-phosphorylation-sites-in-acc1-and-acc2-regulate-lipid2026-09-30 https://evidence-hub.com/study/7265-effects-of-exenatide-exendin-4-on-glycemic-control-over-30-weeks-in2026-09-30 https://evidence-hub.com/study/7266-metformin-increases-amp-activated-protein-kinase-activity-in-skeletal2026-10-01 https://evidence-hub.com/study/7267-thiazolidinediones-like-metformin-inhibit-respiratory-complex-i2026-10-01 https://evidence-hub.com/study/7268-diabetes-medications-as-monotherapy-or-metformin-based-combination2026-10-08 https://evidence-hub.com/study/7269-metformin-an-old-but-still-the-best-treatment-for-type-2-diabetes2026-10-01 https://evidence-hub.com/study/7270-molecular-mechanism-of-action-of-metformin-old-or-new-insights2026-10-08 https://evidence-hub.com/study/7271-metformin-in-cancer-translational-challenges2026-10-08 https://evidence-hub.com/study/7272-metformin-inhibits-the-senescence-associated-secretory-phenotype-by2026-10-08 https://evidence-hub.com/study/7273-metformin-kinetics-in-healthy-subjects-and-in-patients-with-diabetes2026-10-08 https://evidence-hub.com/study/7274-the-anti-diabetic-drugs-rosiglitazone-and-metformin-stimulate-amp2026-09-30 https://evidence-hub.com/study/7275-investigating-metformin-for-cancer-prevention-and-treatment-the-end2026-09-30 https://evidence-hub.com/study/7276-metformin-associated-with-lower-cancer-mortality-in-type-2-diabetes2026-10-01 https://evidence-hub.com/study/7279-understanding-the-benefit-of-metformin-use-in-cancer-treatment2026-10-08 https://evidence-hub.com/study/7280-metformin-use-and-mortality-among-patients-with-diabetes-and2026-10-08 https://evidence-hub.com/study/7281-metformin-independent-of-ampk-induces-mtor-inhibition-and-cell-cycle2026-09-30 https://evidence-hub.com/study/7282-electroporation-mediated-metformin-for-effective-anticancer-treatment2026-10-08 https://evidence-hub.com/study/7283-unique-features-of-metformin-a-combined-experimental-theoretical-and2026-10-08 https://evidence-hub.com/study/7284-considerations-of-automated-machine-learning-in-clinical-metabolic2026-10-08 https://evidence-hub.com/study/7285-entitymetrics-measuring-the-impact-of-entities2026-10-08 https://evidence-hub.com/study/7286-a-series-acceleration-algorithm-for-the-gamma-pareto-type-i2026-10-08 https://evidence-hub.com/study/7287-selection-bias-when-using-instrumental-variable-methods-to-compare2026-10-08 https://evidence-hub.com/study/7288-bayesian-benefit-risk-assessment-with-dependent-outcomes-via-latent2026-10-08 https://evidence-hub.com/study/7289-gene-set-proximity-analysis-expanding-gene-set-enrichment-analysis2026-10-08 https://evidence-hub.com/study/7290-structural-mean-models-for-instrumented-difference-in-differences2026-10-08 https://evidence-hub.com/study/7291-thesis-the-effects-of-hypoxia-metabolic-restriction-and-magnetic2026-10-08 https://evidence-hub.com/study/7292-determination-of-personalized-diabetes-treatment-plans-using-a-two2026-10-08 https://evidence-hub.com/study/7293-extra-low-frequency-magnetic-fields-alter-cancer-cells-through2026-10-08 https://evidence-hub.com/study/7294-increased-hepatic-pdgf-aa-signaling-mediates-liver-insulin-resistance2026-10-08 https://evidence-hub.com/study/7295-development-and-optimization-of-low-power-non-thermal-plasma-jet2026-10-08 https://evidence-hub.com/study/7296-data-driven-allocation-of-preventive-care-with-application-to2026-10-08 https://evidence-hub.com/study/7297-glucose-availability-but-not-changes-in-pancreatic-hormones2026-10-08 https://evidence-hub.com/study/7298-identification-of-patient-characteristics-associated-with-survival2026-10-06 https://evidence-hub.com/study/7299-metformin-monotherapy-versus-predominantly-older-non-metformin2026-10-06 https://evidence-hub.com/study/7300-interaction-between-metformin-folate-and-vitamin-b12-and-the2026-10-06 https://evidence-hub.com/study/7301-prenatal-metformin-exposure-or-organic-cation-transporter-3-knock-out2026-10-06 https://evidence-hub.com/study/7302-metformin-modifies-disparity-in-hepatocellular-carcinoma-incidence-in2026-10-06 https://evidence-hub.com/study/7303-association-between-metformin-use-and-mortality-in-patients-with-type2026-10-06 https://evidence-hub.com/study/7304-metformin-induces-apoptosis-through-ampk-dependent-inhibition-of-upr2026-10-06 https://evidence-hub.com/study/7305-sargassum-polycystum-reduces-hyperglycaemia-dyslipidaemia-and2026-10-06 https://evidence-hub.com/study/7306-metformin-in-vitro-and-in-vivo-increases-adenosine-signaling-in2026-10-08 https://evidence-hub.com/study/7307-differing-effects-of-metformin-on-glycemic-control-by-race-ethnicity2026-10-06 https://evidence-hub.com/study/7308-gut-microbiota-derived-udca-enhanced-by-metformin-inhibits-fxr-to2026-10-06 https://evidence-hub.com/study/7309-high-throughput-study-for-molecular-mechanism-of-metformin-pre2026-10-06 https://evidence-hub.com/study/7310-diabetes-metformin-use-and-colorectal-cancer-survival-in2026-10-06 https://evidence-hub.com/study/7311-targeting-of-the-diabetes-prevention-program-leads-to-substantial2026-10-06 https://evidence-hub.com/study/7312-reports-of-lactic-acidosis-attributed-to-metformin-2015-20182026-10-08 https://evidence-hub.com/study/7313-metformin-improves-skeletal-muscle-microvascular-insulin-resistance2026-10-08 https://evidence-hub.com/study/7314-rationale-and-protocol-of-the-metnet-1-trial-a-prospective-single2026-10-06 https://evidence-hub.com/study/7315-vitamin-d-potentiation-of-metformin-hepatoprotective-activities2026-10-06 https://evidence-hub.com/study/7316-chronic-administration-of-metformin-exerts-cytostatic-and-cytotoxic2026-10-06 https://evidence-hub.com/study/7317-metformin-s-role-in-hyperlactatemia-and-lactic-acidosis-in-icu2026-10-06 https://evidence-hub.com/study/7318-metformin-inhibits-cell-motility-and-proliferation-of-triple-negative2026-10-06 https://evidence-hub.com/study/7319-metformin-pre-treatment-of-stem-cells-from-human-exfoliated-deciduous2026-10-06 https://evidence-hub.com/study/7320-effects-of-metformin-on-wild-fathead-minnows-pimephales-promelas2026-10-06 https://evidence-hub.com/study/7321-metformin-modulates-the-unfolded-protein-responses-altering-lifespan2026-10-06 https://evidence-hub.com/study/7322-metformin-attenuates-tgf-1-induced-fibrosis-in-salivary-gland-a2026-10-06 https://evidence-hub.com/study/7323-emerging-strategies-in-drug-repurposing-for-decreasing-the-risk-of2026-10-06 https://evidence-hub.com/study/7324-protocol-for-a-randomized-phase-ii-iii-double-blind-placebo2026-10-08 https://evidence-hub.com/study/7325-novel-mechanistic-insights-of-the-potential-role-of-gasotransmitters2026-10-06 https://evidence-hub.com/study/7326-review-of-interventions-for-the-frailty-syndrome-and-the-role-of2026-10-06 https://evidence-hub.com/study/7327-targeted-disruption-of-organic-cation-transporter-3-attenuates-the2026-10-06 https://evidence-hub.com/study/7328-metformin-inhibits-metastatic-breast-cancer-progression-and-improves2026-10-06 https://evidence-hub.com/study/7329-modulation-of-the-antitumor-response-to-metformin-caffeine-and-sodium2026-10-06 https://evidence-hub.com/study/7330-metformin-for-endothelial-dysfunction-in-non-diabetic-disorders-a2026-10-06 https://evidence-hub.com/study/7331-metformin-inhibits-hacat-cell-viability-via-the-mir-21-pten-akt2026-10-08 https://evidence-hub.com/study/7332-metformin-suppress-th17-differentiation-and-function-to-improve2026-10-06 https://evidence-hub.com/study/7333-regulation-of-metformin-response-by-breast-cancer-associated-gene-22026-10-06 https://evidence-hub.com/study/7334-evaluation-for-clinical-benefit-of-metformin-in-patients-with2026-10-06 https://evidence-hub.com/study/7335-repurposing-metformin-in-precision-oncology-mechanistic-insights2026-10-06 https://evidence-hub.com/study/7336-outpatient-metformin-use-is-associated-with-reduced-severity-of-covid2026-10-06 https://evidence-hub.com/study/7337-metformin-use-in-prediabetes-a-review-of-evidence-and-a-focus-on2026-10-08 https://evidence-hub.com/study/7338-metformin-induced-rbms3-expression-enhances-ferroptosis-and2026-10-06 https://evidence-hub.com/study/7339-the-molecular-mechanisms-of-metformin-s-action-on-blood-lipid-profile2026-10-08 https://evidence-hub.com/study/7340-the-potential-therapeutic-impact-of-metformin-in-glioblastoma2026-10-08 https://evidence-hub.com/study/7341-implantable-drug-reservoir-devices-for-inner-ear-delivery-of2026-10-08 https://evidence-hub.com/study/7342-utility-of-support-vector-machine-and-decision-tree-to-identify-the2026-10-06 https://evidence-hub.com/study/7343-transcriptomic-landscape-profiling-of-metformin-treated-healthy-mice2026-10-08 https://evidence-hub.com/study/7344-tangeretin-boosts-the-anticancer-activity-of-metformin-in-breast2026-10-06 https://evidence-hub.com/study/7345-elucidating-metformin-action-on-the-ovary-and-fertility-in-healthy2026-10-06 https://evidence-hub.com/study/7346-metformin-inhibits-gluconeogenesis-via-a-redox-dependent-mechanism-in2026-10-08 https://evidence-hub.com/study/7347-lactic-acidosis-induced-by-excessive-ingestion-of-metformin2026-10-06 https://evidence-hub.com/study/7348-pck1-and-slc22a2-gene-variants-associated-with-response-to-metformin2026-10-06 https://evidence-hub.com/study/7349-the-effect-of-metformin-on-vestibular-schwannoma-growth-a-systematic2026-10-08 https://evidence-hub.com/study/7350-combination-therapy-of-systemic-and-local-metformin-improves2026-10-08 https://evidence-hub.com/study/7351-metformin-inhibits-ige-and-aryl-hydrocarbon-receptor-mediated-mast2026-10-08 https://evidence-hub.com/study/7352-applying-a-hypothetical-strategy-to-the-intercurrent-event-of-non2026-10-08 https://evidence-hub.com/study/7353-effect-of-metformin-on-hypoxia-associated-gene-expression-in-oral2026-10-06 https://evidence-hub.com/study/7354-prognostic-significance-of-ampk-activation-and-therapeutic-effects-of2026-10-06 https://evidence-hub.com/study/7355-metformin-protects-against-noise-induced-hearing-loss-in-male-mice2026-10-06 https://evidence-hub.com/study/7356-metformin-and-the-atm-dna-damage-response-ddr-accelerating-the-onset2026-10-06 https://evidence-hub.com/study/7357-new-insight-into-metformin-action-regulation-of-chrebp-and-foxo12026-10-01 https://evidence-hub.com/study/7358-metformin-s-effects-beyond-ischemia-evaluating-cardioprotection-in2026-10-06 https://evidence-hub.com/study/7359-metformin-and-exercise-effects-on-postprandial-insulin-sensitivity2026-10-06 https://evidence-hub.com/study/7360-action-of-metformin-on-glucose-transport-and-glucose-transporter2026-10-06 https://evidence-hub.com/study/7361-deciphering-signaling-pathway-networks-to-understand-the-molecular2026-10-06 https://evidence-hub.com/study/7362-metformin-s-protection-against-blood-brain-barrier-disruption-and2026-10-06 https://evidence-hub.com/study/7363-impact-of-immediate-release-versus-extended-release-metformin-on2026-10-06 https://evidence-hub.com/study/7364-enhancement-of-metformin-s-efficacy-by-betel-nut-polyphenols-in-type2026-10-06 https://evidence-hub.com/study/7365-metformin-and-carotid-intima-media-thickness-in-never-smokers-with2026-10-06 https://evidence-hub.com/study/7366-proangiogenic-effect-of-metformin-in-endothelial-cells-is-via2026-10-06 https://evidence-hub.com/study/7367-mirna-21-mediates-the-antiangiogenic-activity-of-metformin-through2026-10-06 https://evidence-hub.com/study/7368-human-periodontal-ligament-stem-cells-and-metformin-to-enhance2026-10-06 https://evidence-hub.com/study/7369-mechanisms-of-metformin-s-anti-tumor-activity-against-gemcitabine2026-10-08 https://evidence-hub.com/study/7370-dose-dependent-relation-between-metformin-and-the-risk-of-hormone2026-10-06 https://evidence-hub.com/study/7371-the-effect-of-metformin-on-survival-outcomes-of-non-metastatic-breast2026-10-06 https://evidence-hub.com/study/7372-metformin-and-myocardial-injury-in-patients-with-diabetes-and-st2026-10-06 https://evidence-hub.com/study/7373-the-efficacy-of-metformin-in-counteracting-olanzapine-induced2026-10-08 https://evidence-hub.com/study/7374-cardiovascular-safety-and-benefits-of-noninsulin-antihyperglycemic2026-10-06 https://evidence-hub.com/study/7375-metformin-induced-oxidative-stress-inhibits-lncap-prostate-cancer2026-10-06 https://evidence-hub.com/study/7376-metformin-and-energy-metabolism-in-breast-cancer-from-insulin2026-10-06 https://evidence-hub.com/study/7377-targeting-the-intestinal-microbiota-to-prevent-type-2-diabetes-and2026-10-06 https://evidence-hub.com/study/7378-endobarrier-gastrointestinal-liner-delineation-of-underlying2026-10-06 https://evidence-hub.com/study/7379-metformin-and-incidence-of-age-related-macular-degeneration-in-people2026-10-08 https://evidence-hub.com/study/7380-the-effect-of-metformin-on-triple-negative-breast-cancer-cells-and2026-10-06 https://evidence-hub.com/study/7381-metformin-benefits-another-example-for-alternative-energy-substrate2026-10-08 https://evidence-hub.com/study/7382-metformine-for-psychosis-associated-with-the-menstrual-cycle-in-a2026-10-06 https://evidence-hub.com/study/7383-metformin-mechanisms-of-its-glycemia-reducing-effect2026-10-08 https://evidence-hub.com/study/7384-protection-by-metformin-against-severe-covid-19-an-in-depth2026-10-08 https://evidence-hub.com/study/7385-metformin-as-a-booster-of-cancer-immunotherapy2026-10-08 https://evidence-hub.com/study/7386-exploring-the-effects-of-metformin-on-the-body-via-the-urine-proteome2026-10-06 https://evidence-hub.com/study/7387-inhibition-of-hepatic-gluconeogenesis-in-type-2-diabetes-by-metformin2026-10-06 https://evidence-hub.com/study/7388-metformin-modulate-immune-fitness-in-hepatocellular-carcinoma2026-10-06 https://evidence-hub.com/study/7389-convergence-of-ipmk-and-lkb1-ampk-signaling-pathways-on-metformin2026-10-06 https://evidence-hub.com/study/7390-metformin-overcomes-high-glucose-induced-insulin-resistance-of2026-10-06 https://evidence-hub.com/study/7391-metformin-augments-major-cytoplasmic-organization-except-for-spindle2026-10-06 https://evidence-hub.com/study/7392-toward-repurposing-metformin-as-a-precision-anti-cancer-therapy-using2026-10-06 https://evidence-hub.com/study/7393-cardiovascular-protection-by-metformin-latest-advances-in-basic-and2026-10-08 https://evidence-hub.com/study/7394-prolonged-metformin-treatment-leads-to-reduced-transcription-of-nrf22026-10-06 https://evidence-hub.com/study/7395-metformin-suppresses-atherosclerosis-by-dampening-extramedullary2026-10-06 https://evidence-hub.com/study/7396-metformin-induced-preferential-killing-of-breast-cancer-initiating2026-10-06 https://evidence-hub.com/study/7397-association-of-metformin-use-and-cancer-incidence-a-systematic-review2026-10-08 https://evidence-hub.com/study/7398-metformin-in-prevention-and-treatment-of-antipsychotic-induced-weight2026-10-08 https://evidence-hub.com/study/7399-association-between-metformin-use-and-risk-of-lung-cancer-in-patients2026-10-08 https://evidence-hub.com/study/7400-preconception-and-first-trimester-metformin-on-pregnancy-outcomes-in2026-10-08 https://evidence-hub.com/study/7401-effects-of-metformin-on-endometrial-cancer-systematic-review-and-meta2026-10-08 https://evidence-hub.com/study/7402-metformin-use-and-survival-of-lung-cancer-patients-meta-analysis2026-10-08 https://evidence-hub.com/study/7403-metformin-and-body-weight2026-10-08 https://evidence-hub.com/study/7404-metformin-and-colorectal-cancer-a-systematic-review-meta-analysis-and2026-10-08 https://evidence-hub.com/study/7405-efficacy-of-metformin-on-glycemic-control-and-weight-in-drug-naive2026-10-08 https://evidence-hub.com/study/7406-efficacy-and-safety-of-metformin-for-patients-with-type-1-diabetes2026-10-08 https://evidence-hub.com/study/7407-antidiabetic-medications-and-the-risk-of-endometrial-cancer-in2026-10-08 https://evidence-hub.com/study/7408-effects-of-metformin-and-exercise-in-polycystic-ovary-syndrome2026-10-08 https://evidence-hub.com/study/7409-the-effect-of-metformin-on-thyroid-associated-serum-hormone-levels2026-10-08 https://evidence-hub.com/study/7410-comparison-of-the-efficacy-between-nac-and-metformin-in-treating-pcos2026-10-08 https://evidence-hub.com/study/7411-meta-analysis-of-metformin-on-recurrence-risk-and-long-term-survival2026-10-08 https://evidence-hub.com/study/7412-metformin-and-the-risk-of-neurodegenerative-diseases-in-patients-with2026-10-08 https://evidence-hub.com/study/7413-metformin-and-risk-of-cancer-among-patients-with-type-2-diabetes2026-10-08 https://evidence-hub.com/study/7414-metformin-use-and-mortality-in-women-with-ovarian-cancer-an-updated2026-10-06 https://evidence-hub.com/study/7415-comparison-of-the-effects-of-metformin-and-thiazolidinediones-on-bone2026-10-08 https://evidence-hub.com/study/7416-metformin-use-may-moderate-the-effect-of-dpp-4-inhibitors-on2026-10-08 https://evidence-hub.com/study/7417-effect-of-metformin-treatment-during-pregnancy-on-women-with-pcos-a2026-10-08 https://evidence-hub.com/study/7418-effect-of-metformin-on-plasma-fibrinogen-concentrations-a-systematic2026-10-06 https://evidence-hub.com/study/7419-metformin-for-clozapine-associated-obesity-a-systematic-review-and2026-10-08 https://evidence-hub.com/study/7420-meta-analysis-of-studies-using-metformin-as-a-reducer-for-liver2026-10-08 https://evidence-hub.com/study/7421-first-trimester-exposure-to-metformin-and-risk-of-birth-defects-a2026-10-08 https://evidence-hub.com/study/7422-effect-of-metformin-use-on-the-risk-and-prognosis-of-endometrial2026-10-08 https://evidence-hub.com/study/7423-the-efficacy-and-safety-of-metformin-alone-or-as-an-add-on-therapy-to2026-10-06 https://evidence-hub.com/study/7424-metformin-versus-insulin-for-gestational-diabetes-a-systematic-review2026-10-08 https://evidence-hub.com/study/7425-the-effect-of-chinese-herbal-formulas-combined-with-metformin-on2026-10-06 https://evidence-hub.com/study/7426-systematic-review-and-meta-analysis-of-the-effect-of-metformin2026-10-06 https://evidence-hub.com/study/7427-the-efficacy-and-safety-of-metformin-combined-with-simvastatin-in-the2026-10-06 https://evidence-hub.com/study/7428-metformin-versus-insulin-for-gestational-diabetes-mellitus-a-meta2026-10-06 https://evidence-hub.com/study/7429-cardiovascular-risk-associated-with-the-use-of-glitazones-metformin2026-10-06 https://evidence-hub.com/study/7430-efficacy-and-safety-of-metformin-compared-to-insulin-in-gestational2026-10-06 https://evidence-hub.com/study/7431-the-effects-of-metformin-on-endogenous-androgens-and-shbg-in-women-a2026-10-06 https://evidence-hub.com/study/7432-efficacy-and-safety-of-liraglutide-versus-sitagliptin-both-in2026-10-06 https://evidence-hub.com/study/7433-effects-of-metformin-on-bone-mineral-density-and-bone-turnover2026-10-08 https://evidence-hub.com/study/7434-efficacy-of-metformin-therapy-in-patients-with-cancer-a-meta-analysis2026-10-06 https://evidence-hub.com/study/7435-role-of-metformin-in-the-treatment-of-patients-with-thyroid-nodules2026-10-06 https://evidence-hub.com/study/7436-the-effect-of-metformin-on-mortality-and-severity-in-covid-192026-10-06 https://evidence-hub.com/study/7437-association-between-oral-metformin-use-and-the-development-of-age2026-10-06 https://evidence-hub.com/study/7438-the-effect-of-metformin-on-carotid-intima-media-thickness-cimt-a2026-10-06 https://evidence-hub.com/study/7439-the-association-between-metformin-and-survival-of-head-and-neck2026-10-06 https://evidence-hub.com/study/7440-can-metformin-use-reduce-the-risk-of-stroke-in-diabetic-patients-a2026-10-08 https://evidence-hub.com/study/7441-safety-and-effectiveness-of-metformin-in-patients-with-reduced-renal2026-10-08 https://evidence-hub.com/study/7442-the-effect-of-concomitant-use-of-statins-nsaids-low-dose-aspirin2026-10-06 https://evidence-hub.com/study/7443-association-of-metformin-with-pregnancy-outcomes-in-women-with2026-10-08 https://evidence-hub.com/study/7444-association-of-metformin-with-the-mortality-and-incidence-of2026-10-06 https://evidence-hub.com/study/7445-glp-1-receptor-agonists-for-cardiovascular-outcomes-with-and-without2026-10-06 https://evidence-hub.com/study/7446-effects-of-metformin-treatment-on-serum-levels-of-c-reactive-protein2026-10-06 https://evidence-hub.com/study/7447-effect-of-metformin-on-clinical-metabolic-and-endocrine-outcomes-in2026-10-06 https://evidence-hub.com/study/7448-the-effect-of-metformin-therapy-on-serum-thyrotropin-and-free2026-10-08 https://evidence-hub.com/study/7449-evaluating-the-effects-of-metformin-use-on-height-in-children-and2026-10-06 https://evidence-hub.com/study/7450-quantifying-the-effect-of-metformin-treatment-and-dose-on-glycemic2026-10-06 https://evidence-hub.com/study/7451-the-effects-of-metformin-on-insulin-resistance-in-overweight-or-obese2026-10-06 https://evidence-hub.com/study/7452-metformin-for-prevention-of-hypertensive-disorders-of-pregnancy-in2026-10-06 https://evidence-hub.com/study/7453-efficacy-and-safety-of-dipeptidyl-peptidase-4-inhibitors-and2026-10-06 https://evidence-hub.com/study/7454-the-prognostic-value-of-metformin-for-cancer-patients-with-concurrent2026-10-08 https://evidence-hub.com/study/7455-effects-of-metformin-on-body-weight-in-polycystic-ovary-syndrome2026-10-06 https://evidence-hub.com/study/7456-association-of-metformin-use-with-fracture-risk-in-type-2-diabetes-a2026-10-08 https://evidence-hub.com/study/7457-ppar-agonists-as-add-on-treatment-with-metformin-in-management-of2026-10-08 https://evidence-hub.com/study/7458-the-effect-of-metformin-on-biomarkers-and-survivals-for-breast-cancer2026-10-06 https://evidence-hub.com/study/7459-efficacy-and-safety-of-metformin-for-treatment-of-overweight-and2026-10-06 https://evidence-hub.com/study/7460-relationship-of-serum-adiponectin-levels-and-metformin-therapy-in2026-10-06 https://evidence-hub.com/study/7461-metformin-versus-insulin-in-gestational-diabetes-mellitus-a-meta2026-10-06 https://evidence-hub.com/study/7462-influence-of-metformin-on-hyperandrogenism-in-women-with-polycystic2026-10-08 https://evidence-hub.com/study/7463-comparative-efficacy-and-safety-of-antidiabetic-drugs-for-obese2026-10-06 https://evidence-hub.com/study/7464-cardiometabolic-outcomes-in-offspring-of-women-treated-with-metformin2026-10-08 https://evidence-hub.com/study/7465-comparative-efficacy-of-metformin-combined-with-cabergoline-versus2026-10-08 https://evidence-hub.com/study/7466-effect-of-adjuvant-use-of-metformin-on-periodontal-treatment-a2026-10-08 https://evidence-hub.com/study/7467-metformin-for-covid-19-an-updated-systematic-review-and-meta-analysis2026-10-08 https://evidence-hub.com/study/7468-the-relationship-between-prostate-cancer-and-metformin-consumption-a2026-10-06 https://evidence-hub.com/study/7469-effect-comparison-of-metformin-with-insulin-treatment-for-gestational2026-10-06 https://evidence-hub.com/study/7470-major-malformation-risk-pregnancy-outcomes-and-neurodevelopmental2026-10-08 https://evidence-hub.com/study/7471-metformin-reduces-decline-in-the-estimated-glomerular-filtration-rate2026-10-06 https://evidence-hub.com/study/7472-exploring-the-comparative-efficacy-of-metformin-and-resveratrol-in2026-10-06 https://evidence-hub.com/study/7473-a-combination-of-metformin-and-insulin-improve-cardiovascular-and2026-10-06 https://evidence-hub.com/study/7474-impact-of-treatment-with-metformin-on-adipocytokines-in-patients-with2026-10-06 https://evidence-hub.com/study/7475-the-efficacy-and-safety-of-insulin-sensitizing-drugs-in-hiv2026-10-06 https://evidence-hub.com/study/7476-metformin-treatment-in-heart-failure-with-preserved-ejection-fraction2026-10-01 https://evidence-hub.com/study/7477-metformin-versus-oral-contraceptive-pill-in-polycystic-ovary-syndrome2026-10-08 https://evidence-hub.com/study/7478-pregnancy-outcome-after-first-trimester-exposure-to-metformin-a-meta2026-10-06 https://evidence-hub.com/study/7479-an-updated-systematic-review-and-meta-analysis-on-the-efficacy-and2026-10-08 https://evidence-hub.com/study/7480-effect-of-metformin-on-the-mortality-of-colorectal-cancer-patients2026-10-06 https://evidence-hub.com/study/7481-paternal-use-of-metformin-and-risk-of-major-congenital-malformations2026-10-08 https://evidence-hub.com/study/7482-effect-of-sglt2-inhibitors-and-metformin-on-inflammatory-and2026-10-06 https://evidence-hub.com/study/7483-metformin-in-pregnancy-to-avert-gestational-diabetes-in-women-at-high2026-10-06 https://evidence-hub.com/study/7484-a-network-meta-analysis-for-efficacy-and-safety-of-seven-regimens-in2026-10-06 https://evidence-hub.com/study/7485-rapamycin-not-metformin-mirrors-dietary-restriction-driven-lifespan2026-10-08 https://evidence-hub.com/study/7486-immortal-time-bias-exaggerates-the-effect-of-metformin-on-the-risk-of2026-10-06 https://evidence-hub.com/study/7487-do-we-have-enough-evidence-that-metformin-is-superior-to-other2026-10-08 https://evidence-hub.com/study/7488-associations-between-metformin-use-and-vitamin-b12-levels-anemia-and2026-10-08 https://evidence-hub.com/study/7489-metformin-increases-pathological-responses-to-rectal-cancers-with2026-10-08 https://evidence-hub.com/study/7490-does-metformin-affect-outcomes-in-covid-19-patients-with-new-or-pre2026-10-06 https://evidence-hub.com/study/7491-cardiovascular-risk-following-metformin-treatment-in-patients-with2026-10-06 https://evidence-hub.com/study/7492-efficacy-of-metformin-in-prevention-of-glucocorticoid-induced2026-10-08 https://evidence-hub.com/study/7493-the-metformin-has-no-significant-anticancer-effect-on-patients-with2026-10-06 https://evidence-hub.com/study/7494-metformin-and-progestins-in-women-with-atypical-hyperplasia-or2026-10-08 https://evidence-hub.com/study/7495-association-of-metformin-use-with-osteoarthritis-incidence2026-10-06 https://evidence-hub.com/study/7496-metformin-in-high-metabolic-risk-pregnancies-a-patient-level-meta2026-10-08 https://evidence-hub.com/study/7497-evidence-based-ranking-of-diabetes-prevention-in-prediabetes-a2026-10-08 https://evidence-hub.com/study/7498-heterogeneous-associations-of-antidiabetic-medications-with-cancer2026-10-08 https://evidence-hub.com/study/7499-metformin-as-a-neoadjuvant-to-chemotherapy-in-locally-advanced-and2026-10-08 https://evidence-hub.com/study/7500-pharmacological-interventions-for-weight-reduction-in-patients-with2026-10-08 https://evidence-hub.com/study/7501-effect-of-medications-for-type-2-diabetes-on-cardiovascular-events2026-10-08 https://evidence-hub.com/study/7502-obesity-management-pharmacotherapies-and-lifestyle-treatment-for2026-10-08 https://evidence-hub.com/study/7503-weight-lowering-drugs-and-natural-female-fertility-a-systematic2026-10-08 https://evidence-hub.com/study/7504-efficacy-of-gegen-qinlian-decoction-plus-metformin-for-type-22026-10-08 https://evidence-hub.com/study/7505-impact-of-metformin-on-bone-turnover-markers-a-systematic-review-and2026-10-08 https://evidence-hub.com/study/7506-comparative-neuroprotective-effects-of-antidiabetic-medications-on2026-10-08 https://evidence-hub.com/study/7507-metformin-for-knee-osteoarthritis-in-overweight-and-obese-adults-a2026-10-08 https://evidence-hub.com/study/7508-influence-of-metformin-on-exercise-metabolism-and-capacity-a2026-10-08 https://evidence-hub.com/study/7509-effects-of-metformin-on-head-and-neck-cancer-an-umbrella-review2026-10-08 https://evidence-hub.com/study/7510-effects-of-metformin-on-anthropometric-indices-and-hormones-and2026-10-08 https://evidence-hub.com/study/7511-a-systematic-review-and-meta-analysis-of-the-relative-benefit-of-dual2026-10-08 https://evidence-hub.com/study/7512-glucagon-like-peptide-1-receptor-agonists-and-the-risk-of-parkinson-s2026-10-08 https://evidence-hub.com/study/7513-impact-of-metformin-use-during-pregnancy-on-fetal-congenital2026-10-08 https://evidence-hub.com/study/7514-pharmacological-interventions-for-the-treatment-of-obesity-in2026-10-08 https://evidence-hub.com/study/7515-current-evidence-on-medical-therapy-for-sporadic-vestibular2026-10-08 https://evidence-hub.com/study/7516-genetic-evidence-for-the-benefits-and-risks-of-glucose-lowering-drugs2026-10-08 https://evidence-hub.com/study/7517-associations-of-antidiabetic-medications-with-abdominal-aortic2026-10-08 https://evidence-hub.com/study/7518-effect-of-metformin-treatment-on-gonadotropin-levels-in-women-with2026-10-08 https://evidence-hub.com/study/7519-preventive-and-therapeutic-effects-of-metformin-in-cancer-a-meta2026-10-08 https://evidence-hub.com/study/7520-comparative-analysis-of-glucagon-like-peptide-1-receptor-agonists2026-10-08 https://evidence-hub.com/study/7521-antidiabetic-medications-and-the-risk-of-bladder-cancer-in-patients2026-10-08 https://evidence-hub.com/study/7522-the-impact-of-metformin-on-vitamin-b12-levels-in-children-and2026-10-08 https://evidence-hub.com/study/7523-glycaemic-and-cardiometabolic-outcomes-of-empagliflozin-versus2026-10-08 https://evidence-hub.com/study/7524-metformin-use-and-risk-of-glaucoma-a-systematic-review-and-meta2026-10-08 https://evidence-hub.com/study/7525-association-of-preadmission-metformin-use-and-prognosis-in-patients2026-10-08 https://evidence-hub.com/study/7526-dipeptidyl-peptidase-4-inhibitors-associated-heart-failure-events-in2026-10-08 https://evidence-hub.com/study/7527-triple-oral-therapy-combining-metformin-sglt-2-and-dpp-4-inhibitors2026-10-08 https://evidence-hub.com/study/7528-efficacy-and-safety-of-orforglipron-12-mg-versus-orforglipron-36-mg2026-10-08 https://evidence-hub.com/study/7529-the-efficacy-and-safety-of-novel-antidiabetic-agents-in-polycystic2026-10-08 https://evidence-hub.com/study/7530-efficacy-and-safety-of-once-weekly-basal-insulin-analogs-versus-daily2026-10-08 https://evidence-hub.com/study/7531-effectiveness-of-metformin-in-the-management-of-osteoarthritis-in2026-10-08 https://evidence-hub.com/study/7532-effects-of-probiotic-and-metformin-co-administration-versus-metformin2026-10-08 https://evidence-hub.com/study/7533-metformin-insulin-vs-insulin-for-gdm-and-t2dm-during-pregnancy2026-10-08 https://evidence-hub.com/study/7534-incremental-effects-of-sglt2-inhibitors-glp-1-receptor-agonists-and2026-10-08 https://evidence-hub.com/study/7535-comparative-effects-of-antidiabetic-drugs-on-body-composition-a2026-10-08 https://evidence-hub.com/study/7536-glp-1-receptor-agonist-treatment-in-women-with-polycystic-ovary2026-10-08 https://evidence-hub.com/study/7537-a-systematic-review-and-meta-analysis-of-the-significance-of-diabetes2026-10-08 https://evidence-hub.com/study/7538-the-impact-of-antidiabetic-drugs-on-dementia-risk-a-bayesian-network2026-10-08 https://evidence-hub.com/study/7539-the-efficacy-of-metformin-for-pain-function-and-quality-of-life-in2026-10-08 https://evidence-hub.com/study/7540-sglt2-versus-dpp-4-inhibitors-in-type-2-diabetes-a-meta-analysis-of2026-10-08 https://evidence-hub.com/study/7541-anti-diabetic-drug-target-perturbation-modulates-susceptibility-to2026-10-08 https://evidence-hub.com/study/7542-effect-of-metformin-on-central-arterial-stiffness-in-individuals-with2026-10-08 https://evidence-hub.com/study/7543-efficacy-and-safety-of-anti-prediabetic-drugs-in-patients-with2026-10-08 https://evidence-hub.com/study/7544-safety-of-metformin-in-chronic-kidney-disease-and-type-2-diabetes2026-10-08 https://evidence-hub.com/study/7545-comparison-of-pregnancy-outcomes-and-physical-conditions-of-infants2026-10-08 https://evidence-hub.com/study/7546-effect-of-oral-semaglutide-on-cardiometabolic-risk-factors-in2026-10-08 https://evidence-hub.com/study/7547-efficacy-of-liraglutide-on-metabolic-and-reproductive-outcomes-in2026-10-08 https://evidence-hub.com/study/7548-effectiveness-and-safety-of-auricular-therapy-for-polycystic-ovary2026-10-08 https://evidence-hub.com/study/7549-comparing-sglt2i-and-other-oral-antidiabetic-drugs-as-dual-therapy2026-10-08 https://evidence-hub.com/study/7550-prevalence-and-factors-associated-with-microvascular-and2026-10-08 https://evidence-hub.com/study/7551-efficacy-of-continuous-glucose-monitoring-in-comparison-to-self-blood2026-10-08 https://evidence-hub.com/study/7552-sodium-glucose-cotransporter-2-inhibitors-and-gastrointestinal2026-10-08 https://evidence-hub.com/study/7553-inflammatory-biomarker-response-to-glp-1-receptor-agonists-versus2026-10-08 https://evidence-hub.com/study/7554-the-effects-of-glp-1-receptor-agonists-on-metabolic-inflammatory2026-10-08 https://evidence-hub.com/study/7555-the-impact-of-comorbid-type-2-diabetes-on-survival-outcomes-in2026-10-08 https://evidence-hub.com/study/7556-comparison-of-the-concomitant-use-of-anti-obesity-medications-with2026-10-08 https://evidence-hub.com/study/7557-diabetes-is-associated-with-elevated-mortality-stroke-and2026-10-08 https://evidence-hub.com/study/7558-short-term-low-dose-spironolactone-for-treatment-of-hyperandrogenic2026-10-08 https://evidence-hub.com/study/7559-a-network-meta-analysis-of-randomized-controlled-trials-evaluating2026-10-08 https://evidence-hub.com/study/7560-the-microbial-regulation-spectrum-of-metformin-in-patients-with-type2026-10-08 https://evidence-hub.com/study/7561-a-network-meta-analysis-of-interventions-for-anxiety-and-depression2026-10-08 https://evidence-hub.com/study/7562-pharmacotherapy-for-children-and-adolescents-with-overweight-or2026-10-08 https://evidence-hub.com/study/7563-metformin-in-non-diabetic-patients-with-autosomal-dominant-polycystic2026-10-08 https://evidence-hub.com/study/7564-paternal-exposure-to-antidiabetic-medications-during-reproductive2026-10-08 https://evidence-hub.com/study/7565-glp-1ra-and-incretin-based-therapies-within-lifestyle-interventions2026-10-08 https://evidence-hub.com/study/7566-therapeutic-effects-of-chromium-supplementation-on-women-with2026-10-08 https://evidence-hub.com/study/7567-metformin-safety-during-pregnancy-in-women-with-gestational-diabetes2026-10-08 https://evidence-hub.com/study/7568-efficacy-of-dpp-4-inhibitors-on-seated-and-ambulatory-blood-pressure2026-10-08 https://evidence-hub.com/study/7569-the-effect-of-obesity-interventions-on-male-fertility-a-systematic2026-10-08 https://evidence-hub.com/study/7570-the-effect-of-exercise-on-reproductive-and-metabolic-outcomes-in2026-10-08 https://evidence-hub.com/study/7571-cardiovascular-outcomes-with-tirzepatide-versus-glp-1-receptor2026-10-08 https://evidence-hub.com/study/7572-comparison-of-the-efficacy-of-antidiabetic-agents-in-type-2-diabetes2026-10-08 https://evidence-hub.com/study/7573-the-effect-of-medical-therapies-for-subthreshold-abdominal-aortic2026-10-08 https://evidence-hub.com/study/7574-comparative-efficacy-of-tirzepatide-versus-semaglutide-for-weight2026-10-08 https://evidence-hub.com/study/7575-rash-associated-with-epidermal-growth-factor-receptor-inhibitors-a2026-10-08 https://evidence-hub.com/study/7576-weight-reduction-heterogenicity-and-mediators-of-glp-1ras-and-dual2026-10-08 https://evidence-hub.com/study/7577-gestational-weight-gain-according-to-treatment-in-gestational2026-10-08 https://evidence-hub.com/study/7578-efficacy-and-safety-of-variable-dose-metformin-as-adjunctive-therapy2026-10-08 https://evidence-hub.com/study/7579-dose-response-of-acupuncture-on-ovulation-rates-in-polycystic-ovary2026-10-08 https://evidence-hub.com/study/7580-associations-of-modifiable-preconception-pregnancy-and-postpartum2026-10-08 https://evidence-hub.com/study/7581-efficacy-and-safety-of-pharmacological-and-non-pharmacological2026-10-08 https://evidence-hub.com/study/7582-comparative-efficacy-and-safety-of-glucagon-like-pepetide-1-receptor2026-10-08 https://evidence-hub.com/study/7583-gegen-qinlian-decoction-ameliorates-insulin-resistance-in-type-22026-10-08 https://evidence-hub.com/study/7584-the-impact-of-metformin-use-on-survival-outcomes-in-colorectal-cancer2026-10-06 https://evidence-hub.com/study/7585-effects-of-sglt2-inhibitors-on-body-composition-and-potential2026-10-08 https://evidence-hub.com/study/7586-the-effects-of-glucagon-like-peptide-1-receptor-agonists-and-sodium2026-10-06 https://evidence-hub.com/study/7587-pre-conception-weight-loss-interventions-in-women-with-polycystic2026-10-06 https://evidence-hub.com/study/7588-combined-liraglutide-and-metformin-therapy-in-overweight-or-obese2026-10-08 https://evidence-hub.com/study/7589-associations-between-glucagon-like-peptide-1-receptor-agonists-glp2026-10-06 https://evidence-hub.com/study/7590-efficacy-and-safety-of-qingre-lishi-decoction-for-type-2-diabetes-a2026-10-06 https://evidence-hub.com/study/7591-potential-efficacy-of-metformin-for-age-related-macular-degeneration2026-10-08 https://evidence-hub.com/study/7592-intrauterine-metformin-exposure-and-adiposity-outcomes-in-children-a2026-10-08 https://evidence-hub.com/study/7593-metformin-s-overall-effectiveness-and-combined-action-with-lifestyle2026-10-08 https://evidence-hub.com/study/7594-association-of-metformin-use-with-risk-of-dementia-in-patients-with2026-10-08 https://evidence-hub.com/study/7595-comparison-of-glp-1-receptor-agonists-combined-with-metformin-versus2026-10-08 https://evidence-hub.com/study/7596-efficacy-and-safety-of-pioglitazone-add-on-in-patients-with-type-22026-10-08 https://evidence-hub.com/study/7597-comparative-effects-of-acupuncture-and-metformin-on-insulin2026-10-08 https://evidence-hub.com/study/7598-effect-of-metformin-on-the-clinical-outcomes-of-stroke-in-patients2026-10-08 https://evidence-hub.com/study/7599-the-impact-of-metformin-on-weight-and-metabolic-parameters-in2026-10-08 https://evidence-hub.com/study/7600-effects-of-exercise-metformin-and-their-combination-on-glucose2026-10-08 https://evidence-hub.com/study/7601-association-of-metformin-use-with-risk-and-survival-outcome-of2026-10-08 https://evidence-hub.com/study/7602-the-safety-and-efficacy-of-liraglutide-combined-with-metformin-in2026-10-08 https://evidence-hub.com/study/7603-systematic-review-and-meta-analysis-of-current-guidelines-and-their2026-10-08 https://evidence-hub.com/study/7604-gastrointestinal-adverse-events-of-metformin-treatment-in-patients2026-10-08 https://evidence-hub.com/study/7605-metformin-associated-gastrointestinal-adverse-events-are-reduced-by2026-10-08 https://evidence-hub.com/study/7606-the-clinical-potentials-of-combining-paclitaxel-based-chemotherapy2026-10-08 https://evidence-hub.com/study/7607-metformin-plus-lifestyle-interventions-versus-lifestyle-interventions2026-10-08 https://evidence-hub.com/study/7608-metformin-co-commencement-at-time-of-antipsychotic-initiation-for2026-10-08 https://evidence-hub.com/study/7609-metformin-therapy-for-acne-vulgaris-a-meta-analysis2026-10-08 https://evidence-hub.com/study/7610-metformin-in-pregnancy-and-childhood-neurodevelopmental-outcomes-a2026-10-08 https://evidence-hub.com/study/7611-associations-of-metformin-therapy-treatment-with-endometrial-cancer2026-10-08 https://evidence-hub.com/study/7613-long-term-impact-on-offspring-5-to-11-years-of-age-of-metformin-use2026-10-08 https://evidence-hub.com/study/7614-comparative-efficacy-and-safety-of-metformin-anti-obesity-agents-and2026-10-08 https://evidence-hub.com/study/7615-the-impact-of-pre-stroke-metformin-use-on-clinical-outcomes-after2026-10-08 https://evidence-hub.com/study/7616-association-of-metformin-use-with-abdominal-aortic-aneurysm-a2026-10-08 https://evidence-hub.com/study/7617-metformin-as-an-adjunct-to-progestin-therapy-in-endometrial2026-10-08 https://evidence-hub.com/study/7618-the-role-of-oral-metformin-in-preventing-and-treating-age-related2026-10-08 https://evidence-hub.com/study/7619-efficacy-of-metformin-drug-in-preventing-metabolic-syndrome2026-10-08 https://evidence-hub.com/study/7620-association-of-metformin-and-statin-uses-with-the-prognosis-of-colon2026-10-08 https://evidence-hub.com/study/7621-does-metformin-reduce-the-risk-of-cancer-in-obesity-and-diabetes-a2026-10-08 https://evidence-hub.com/study/7622-efficacy-and-safety-of-glp-1-receptor-agonists-on-weight-management2026-10-08 https://evidence-hub.com/study/7623-association-of-metformin-use-with-asthma-development-and-adverse2026-10-08 https://evidence-hub.com/study/7624-pharmacological-interventions-for-addressing-pediatric-and-adolescent2026-10-08 https://evidence-hub.com/study/7625-risk-factors-for-hepatocellular-carcinoma-an-umbrella-review-of2026-10-08 https://evidence-hub.com/study/7626-effects-of-metformin-on-cimt-and-fmd-in-pcos-patients-a-systematic2026-10-08 https://evidence-hub.com/study/7627-the-impact-of-metformin-with-or-without-lifestyle-modification-versus2026-10-08 https://evidence-hub.com/study/7628-meta-analysis-chemoprevention-of-hepatocellular-carcinoma-with2026-10-08 https://evidence-hub.com/study/7630-metformin-and-combined-oral-contraceptive-pills-in-the-management-of2026-10-08 https://evidence-hub.com/study/7631-effects-of-combined-treatment-of-probiotics-and-metformin-in2026-10-08 https://evidence-hub.com/study/7632-metformin-and-pancreatic-neuroendocrine-tumors-a-systematic-review2026-10-08 https://evidence-hub.com/study/7633-impact-of-metformin-on-melanoma-a-meta-analysis-and-systematic-review2026-10-08 https://evidence-hub.com/study/7634-the-effectiveness-of-metformin-in-diabetes-prevention-a-systematic2026-10-08 https://evidence-hub.com/study/7635-effect-of-metformin-use-on-survival-and-recurrence-rate-of-gastric2026-10-08 https://evidence-hub.com/study/7636-short-term-neonatal-outcomes-in-women-with-gestational-diabetes2026-10-08 https://evidence-hub.com/study/7637-the-relationship-between-the-use-of-metformin-and-the-risk-of2026-10-08 https://evidence-hub.com/study/7638-major-malformations-risk-following-early-pregnancy-exposure-to2026-10-08 https://evidence-hub.com/study/7639-occurrence-of-pharmaceuticals-illicit-drugs-and-pfas-in-global2026-10-08 https://evidence-hub.com/study/7640-association-between-organic-cation-transporter-genetic-polymorphisms2026-10-08 https://evidence-hub.com/study/7641-a-meta-analysis-of-metformin-and-insulin-on-maternal-outcome-and2026-10-08 https://evidence-hub.com/study/7642-progestin-plus-metformin-improves-outcomes-in-patients-with2026-10-08 https://evidence-hub.com/study/7643-effects-of-myo-inositol-vs-metformin-on-hormonal-and-metabolic2026-10-08 https://evidence-hub.com/study/7644-comparison-of-exenatide-alone-or-combined-with-metformin-versus2026-10-08 https://evidence-hub.com/study/7645-efficacy-and-safety-of-metformin-in-combination-with-chemotherapy-in2026-10-08 https://evidence-hub.com/study/7646-the-benefit-of-metformin-in-the-treatment-of-pediatric-non-alcoholic2026-10-08 https://evidence-hub.com/study/7648-association-between-oral-metformin-use-and-the-risk-of-age-related2026-10-08 https://evidence-hub.com/study/7649-metformin-combined-with-spironolactone-vs-metformin-alone-in2026-10-08 https://evidence-hub.com/study/7650-the-effectiveness-and-safety-of-exenatide-versus-metformin-in2026-10-08 https://evidence-hub.com/study/7651-effects-of-food-on-pharmacokinetics-and-safety-of-metformin2026-10-08 https://evidence-hub.com/study/7652-the-potential-effect-of-metformin-on-cognitive-and-other-symptom2026-10-08 https://evidence-hub.com/study/7653-the-use-of-metformin-sulfonylurea-compounds-and-insulin-and-the-risk2026-10-08 https://evidence-hub.com/study/7654-comparing-the-effectiveness-of-metformin-with-lifestyle-modification2026-10-08 https://evidence-hub.com/study/7655-is-metformin-use-associated-with-low-mortality-in-patients-with-type2026-10-08 https://evidence-hub.com/study/7656-the-efficacy-of-metformin-for-the-treatment-of-psoriasis-a-meta2026-10-08 https://evidence-hub.com/study/7657-comparison-of-the-efficacy-of-metformin-and-lifestyle-modification2026-10-08 https://evidence-hub.com/study/7658-oral-contraceptives-ocs-in-combination-with-metformin-versus-ocs2026-10-08 https://evidence-hub.com/study/7659-ppar-alpha-gamma-agonists-glucagon-like-peptide-1-receptor-agonists2026-10-08 https://evidence-hub.com/study/7660-prophylactic-administration-of-metformin-reduces-gestational-diabetes2026-10-08 https://evidence-hub.com/study/7661-the-effect-of-metformin-on-adipokines-levels-a-systematic-review-and2026-10-08 https://evidence-hub.com/study/7663-the-effects-of-metformin-on-anti-mullerian-hormone-levels-in-patients2026-10-08 https://evidence-hub.com/study/7664-renal-complications-after-percutaneous-coronary-interventions-on2026-10-08 https://evidence-hub.com/study/7665-comparison-of-the-efficacy-and-safety-of-metformin-based-combination2026-10-08 https://evidence-hub.com/study/7666-improvement-of-endocrine-and-metabolic-conditions-in-patients-with2026-10-08 https://evidence-hub.com/study/7667-metformin-and-covid-19-a-systematic-review-of-systematic-reviews-with2026-10-08 https://evidence-hub.com/study/7668-effect-of-metformin-on-nonalcoholic-fatty-liver-based-on-meta2026-10-08 https://evidence-hub.com/study/7669-effect-of-metformin-on-cardiovascular-outcomes-a-systematic-review2026-10-08 https://evidence-hub.com/study/7670-effect-of-metformin-on-anti-mullerian-hormone-levels-in-women-with2026-10-08 https://evidence-hub.com/study/7671-does-metformin-improve-reproduction-outcomes-for-non-obese-infertile2026-10-06 https://evidence-hub.com/study/7672-efficacy-and-safety-of-metformin-for-melasma-treatment-a-systematic2026-10-08 https://evidence-hub.com/study/7673-metformin-reduces-all-cause-mortality-and-diseases-of-ageing2026-10-08 https://evidence-hub.com/study/7674-the-optimal-dosage-and-duration-of-metformin-for-prevention-and2026-10-08 https://evidence-hub.com/study/7675-the-effect-of-metformin-on-cognitive-function-a-systematic-review-and2026-10-08 https://evidence-hub.com/study/7676-treating-prediabetes-with-metformin-systematic-review-and-meta2026-10-08 https://evidence-hub.com/study/7677-the-efficacy-and-potential-mechanisms-of-metformin-in-the-treatment2026-10-06 https://evidence-hub.com/study/7678-evaluating-the-costs-of-glycemic-response-with-canagliflozin-versus2026-10-04 https://evidence-hub.com/study/7679-association-between-metformin-and-neurodegenerative-diseases-of2026-10-08 https://evidence-hub.com/study/7680-effects-of-metformin-on-the-gut-microbiota-a-systematic-review2026-10-08 https://evidence-hub.com/study/7681-the-protective-effect-of-metformin-on-abdominal-aortic-aneurysm-a2026-10-08 https://evidence-hub.com/study/7682-reduction-in-hba1c-with-sglt2-inhibitors-vs-dpp-4-inhibitors-as-add2026-10-06 https://evidence-hub.com/study/7683-a-systematic-review-and-meta-analysis-of-metformin-among-patients2026-10-08 https://evidence-hub.com/study/7684-association-of-metformin-use-with-ovarian-cancer-incidence-and2026-10-08 https://evidence-hub.com/study/7685-metformin-use-improves-survival-of-diabetic-liver-cancer-patients2026-10-08 https://evidence-hub.com/study/7686-meta-analysis-of-randomized-controlled-trials-of-pharmacologic-agents2026-10-08 https://evidence-hub.com/study/7687-metformin-and-thyroid-carcinoma-incidence-and-prognosis-a-systematic2026-10-06 https://evidence-hub.com/study/7688-effect-of-metformin-on-microvascular-outcomes-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/7689-prevention-and-treatment-of-antipsychotic-induced-weight-gain2026-10-06 https://evidence-hub.com/study/7690-sglt2-inhibitors-and-glp1-agonists-administered-without-metformin2026-10-06 https://evidence-hub.com/study/7691-anti-tumor-effects-of-metformin-in-animal-models-of-hepatocellular2026-10-08 https://evidence-hub.com/study/7692-metformin-vs-insulin-in-the-management-of-gestational-diabetes-a2026-10-08 https://evidence-hub.com/study/7693-impact-of-metformin-treatment-during-pregnancy-on-maternal-outcomes-a2026-10-06 https://evidence-hub.com/study/7694-systematic-review-of-the-benefits-and-risks-of-metformin-in-treating2026-10-06 https://evidence-hub.com/study/7695-metformin-for-endometrial-hyperplasia2026-10-08 https://evidence-hub.com/study/7696-comparison-of-glyburide-with-metformin-in-treating-gestational2026-10-06 https://evidence-hub.com/study/7697-the-effect-of-metformin-consumption-on-mortality-in-hospitalized2026-10-01 https://evidence-hub.com/study/7698-effect-of-metformin-intervention-on-circulating-irisin-levels-in2026-10-06 https://evidence-hub.com/study/7699-metformin-and-breast-cancer-risk-a-meta-analysis-and-critical2026-10-08 https://evidence-hub.com/study/7700-aspirin-metformin-and-statin-use-on-the-risk-of-gastric-cancer-a2026-10-08 https://evidence-hub.com/study/7701-impact-of-metformin-on-the-incidence-of-human-cholangiocarcinoma-in2026-10-06 https://evidence-hub.com/study/7702-impact-of-metformin-on-clinical-outcomes-among-men-with-prostate2026-10-06 https://evidence-hub.com/study/7703-short-period-administration-of-myo-inositol-and-metformin-on-hormonal2026-10-06 https://evidence-hub.com/study/7704-vitamin-b12-status-in-metformin-treated-patients-systematic-review2026-10-08 https://evidence-hub.com/study/7705-advances-in-metformin-for-the-treatment-of-non-alcoholic-fatty-liver2026-10-08 https://evidence-hub.com/study/7706-impact-of-metformin-on-cancer-biomarkers-in-non-diabetic-cancer2026-10-06 https://evidence-hub.com/study/7707-the-effect-of-metformin-on-homocysteine-levels-in-patients-with2026-10-06 https://evidence-hub.com/study/7708-metformin-therapy-reduces-obesity-indices-in-children-and-adolescents2026-10-06 https://evidence-hub.com/study/7709-effect-of-metformin-and-statin-use-on-survival-in-pancreatic-cancer2026-10-06 https://evidence-hub.com/study/7710-the-role-of-metformin-on-lung-cancer-survival-the-first-systematic2026-10-06 https://evidence-hub.com/study/7711-the-effectiveness-of-metformin-ovulation-induction-treatment-in2026-10-06 https://evidence-hub.com/study/7712-effect-of-metformin-on-circulating-levels-of-inflammatory-markers-in2026-10-06 https://evidence-hub.com/study/7713-efficacy-of-platelet-rich-fibrin-with-and-without-metformin-in-the2026-10-06 https://evidence-hub.com/study/7714-metformin-extended-release-versus-metformin-immediate-release-for2026-10-08 https://evidence-hub.com/study/7715-the-impact-of-bariatric-surgery-compared-to-metformin-therapy-on2026-10-06 https://evidence-hub.com/study/7716-long-term-effects-of-prenatal-exposure-to-metformin-on-the-health-of2026-10-06 https://evidence-hub.com/study/7717-the-efficacy-and-safety-of-dpp4-inhibitors-compared-to-sulfonylureas2026-10-06 https://evidence-hub.com/study/7718-the-effect-of-adding-metformin-to-insulin-therapy-for-type-1-diabetes2026-10-08 https://evidence-hub.com/study/7719-clinical-review-safety-and-efficacy-comparison-between-sulfonylureas2026-10-06 https://evidence-hub.com/study/7720-cost-utility-of-sodium-glucose-cotransporter-2-inhibitors-in-the2026-10-06 https://evidence-hub.com/study/7721-metformin-for-olanzapine-induced-weight-gain-a-systematic-review-and2026-10-08 https://evidence-hub.com/study/7722-association-of-metformin-intake-with-bladder-cancer-risk-and2026-10-06 https://evidence-hub.com/study/7723-comparative-efficacy-of-glp-1-ras-sglt-2-inhibitors-in-reducing2026-10-08 https://evidence-hub.com/study/7724-effectiveness-and-safety-of-glimepiride-and-idpp4-associated-with2026-10-08 https://evidence-hub.com/study/7725-risk-of-fatal-and-nonfatal-lactic-acidosis-with-metformin-use-in-type2026-10-06 https://evidence-hub.com/study/7726-comparison-of-metformin-and-insulin-versus-insulin-alone-for-type-22026-10-06 https://evidence-hub.com/study/7727-efficacy-and-safety-of-metformin-during-pregnancy-in-women-with2026-10-06 https://evidence-hub.com/study/7728-cancer-outcomes-and-all-cause-mortality-in-adults-allocated-to2026-10-08 https://evidence-hub.com/study/7729-serum-lactate-level-and-mortality-in-metformin-associated-lactic2026-10-08 https://evidence-hub.com/study/7730-neuroprotective-effects-of-metformin-in-stroke-patients-a-systematic2026-10-06 https://evidence-hub.com/study/7731-clomiphene-citrate-metformin-or-both-as-first-step-approach-in2026-10-06 https://evidence-hub.com/study/7732-effects-of-metformin-in-women-with-polycystic-ovary-syndrome-treated2026-10-06 https://evidence-hub.com/study/7733-the-role-of-diabetes-mellitus-on-delirium-onset-a-systematic-review2026-10-06 https://evidence-hub.com/study/7734-diabetes-antidiabetic-medications-and-risk-of-dementia-a-systematic2026-10-06 https://evidence-hub.com/study/7735-risk-of-dementia-and-alzheimer-s-disease-associated-with2026-10-06 https://evidence-hub.com/study/7736-is-metformin-poised-for-a-second-career-as-an-antimicrobial2026-10-08 https://evidence-hub.com/study/7737-common-medications-and-survival-in-women-with-ovarian-cancer-a2026-10-06 https://evidence-hub.com/study/7738-effect-of-metformin-on-serum-interleukin-6-levels-in-polycystic-ovary2026-10-06 https://evidence-hub.com/study/7739-metformin-for-type-2-diabetes-mellitus-systematic-review-and-meta2026-10-06 https://evidence-hub.com/study/7740-risk-of-fatal-and-nonfatal-lactic-acidosis-with-metformin-use-in-type2026-10-06 https://evidence-hub.com/study/7741-managing-pediatric-metabolic-syndrome-a-systematic-review-of-current2026-10-06 https://evidence-hub.com/study/7742-metformin-therapy-and-cognitive-dysfunction-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/7743-risk-of-fatal-and-nonfatal-lactic-acidosis-with-metformin-use-in-type2026-10-06 https://evidence-hub.com/study/7745-effect-of-metformin-on-all-cause-mortality-and-major-adverse2026-10-06 https://evidence-hub.com/study/7746-gestational-metformin-administration-in-women-with-polycystic-ovary2026-10-08 https://evidence-hub.com/study/7747-metformin-for-weight-gain-associated-with-second-generation2026-10-06 https://evidence-hub.com/study/7748-metformin-association-with-lower-prostate-cancer-recurrence-in-type-22026-10-06 https://evidence-hub.com/study/7749-metformin-improves-survival-in-patients-with-concurrent-diabetes-and2026-10-06 https://evidence-hub.com/study/7750-prognostic-role-of-metformin-intake-in-diabetic-patients-with2026-10-06 https://evidence-hub.com/study/7751-the-effect-of-metformin-therapy-for-preventing-gestational-diabetes2026-10-06 https://evidence-hub.com/study/7752-effects-of-different-insulin-sensitisers-in-the-management-of2026-10-06 https://evidence-hub.com/study/7753-metformin-for-liver-cancer-prevention-in-patients-with-type-22026-09-30 https://evidence-hub.com/study/7754-the-addition-of-metformin-to-systemic-anticancer-therapy-in-advanced2026-10-06 https://evidence-hub.com/study/7755-metformin-s-modulatory-effects-on-mirnas-function-in-cancer-stem2026-10-08 https://evidence-hub.com/study/7756-cost-effectiveness-of-second-line-antihyperglycemic-therapy-in2026-10-06 https://evidence-hub.com/study/7757-clinical-outcomes-of-metformin-use-in-populations-with-chronic-kidney2026-10-06 https://evidence-hub.com/study/7758-distinct-prognostic-impact-of-diabetes-subtypes-metformin-use-and2026-10-08 https://evidence-hub.com/study/7759-network-meta-analysis-of-metformin-probiotics-krill-oil-celecoxib-and2026-10-08 https://evidence-hub.com/study/7760-metabolic-dysfunction-antidiabetic-drugs-and-asthma-bibliometric2026-10-08 https://evidence-hub.com/study/7761-dapagliflozin-pioglitazone-combination-therapy-in-t2dm-with-or2026-10-08 https://evidence-hub.com/study/7762-glucagon-like-peptide-1-receptor-agonist-based-regimens-compared-with2026-10-08 https://evidence-hub.com/study/7763-effects-of-acupuncture-related-therapies-on-endocrine-and-metabolic2026-10-08 https://evidence-hub.com/study/7764-preconception-and-first-trimester-metformin-for-improving-pregnancy2026-10-08 https://evidence-hub.com/study/7765-systematic-review-of-antifibrotic-effects-of-metformin-insights-from2026-10-08 https://evidence-hub.com/study/7766-efficacy-of-metformin-as-an-adjuvant-therapy-in-gynecologic2026-10-08 https://evidence-hub.com/study/7767-efficacy-and-safety-of-huanglian-wendan-decoction-as-an-adjuvant2026-10-08 https://evidence-hub.com/study/7768-effectiveness-of-metformin-as-an-adjunctive-therapy-in-rheumatoid2026-10-08 https://evidence-hub.com/study/7769-adjunctive-berberine-for-schizophrenia-with-metabolic-syndrome-a2026-10-08 https://evidence-hub.com/study/7770-the-role-of-hypoglycemic-phytochemicals-in-improving-male2026-10-10 https://evidence-hub.com/study/7771-early-insulin-initiation-in-type-2-diabetes-efficacy-safety-and2026-10-08 https://evidence-hub.com/study/7772-ocular-disorders-during-treatment-with-glp-1-receptor-agonists-a2026-10-08 https://evidence-hub.com/study/7773-a-systematic-review-of-semaglutide-associated-kidney-injury-case2026-10-08 https://evidence-hub.com/study/7774-harnessing-probiotic-metformin-synergy-targeting-the-gut-microbiota2026-10-08 https://evidence-hub.com/study/7775-metformin-use-in-gestational-diabetes-mellitus-and-neonatal-outcomes2026-10-08 https://evidence-hub.com/study/7776-risk-factors-for-age-related-macular-degeneration-an-umbrella2026-10-08 https://evidence-hub.com/study/7777-a-systematic-review-of-pregnancy-outcomes-and-management-in2026-10-08 https://evidence-hub.com/study/7778-traditional-herbal-medicine-for-obesity-related-polycystic-ovary2026-10-08 https://evidence-hub.com/study/7779-investigation-of-trends-hot-spots-and-effective-therapies-for2026-10-08 https://evidence-hub.com/study/7780-the-role-of-antidiabetic-therapies-in-mild-cognitive-impairment-and2026-10-08 https://evidence-hub.com/study/7781-effects-of-intermittent-fasting-on-hba1c-and-weight-in-insulin-versus2026-10-08 https://evidence-hub.com/study/7782-effects-of-nutritional-interventions-on-biomarkers-of-cellular2026-10-08 https://evidence-hub.com/study/7783-treatment-options-for-patients-with-maturity-onset-diabetes-of-the2026-10-08 https://evidence-hub.com/study/7784-glp-1-receptor-agonists-in-pediatric-obesity-and-diabetes-a2026-10-08 https://evidence-hub.com/study/7785-effects-of-folic-acid-with-vitamin-b12-vitamin-b6-intervention-on2026-10-08 https://evidence-hub.com/study/7786-metformin-for-primary-prevention-of-colorectal-neoplasms-in-adenoma2026-10-08 https://evidence-hub.com/study/7787-periconceptional-use-of-glp-1-receptor-agonists-and-the-risk-of-major2026-10-08 https://evidence-hub.com/study/7788-the-efficacy-and-safety-of-chaihu-guizhi-ganjiang-tang-for-type-22026-10-08 https://evidence-hub.com/study/7790-efficacy-of-pharmacological-and-microbiota-based-therapies-in2026-10-08 https://evidence-hub.com/study/7791-the-effect-of-metformin-in-clinical-studies-on-knee-osteoarthritis-an2026-10-08 https://evidence-hub.com/study/7792-effect-of-common-diabetes-medications-on-metabolic-dysfunction2026-10-08 https://evidence-hub.com/study/7793-digital-twin-technologies-for-supporting-self-care-in-adults-with2026-10-08 https://evidence-hub.com/study/7794-non-hormonal-pharmacological-interventions-in-adolescent-polycystic2026-10-08 https://evidence-hub.com/study/7795-two-decades-of-nutrition-research-in-polycystic-ovary-syndrome2026-10-08 https://evidence-hub.com/study/7796-efficacy-of-glyburide-vs-metformin-in-preventing-neonatal-birth2026-10-08 https://evidence-hub.com/study/7797-essential-micronutrients-and-biguanides-metformin-synergistic-and2026-10-10 https://evidence-hub.com/study/7798-mapping-glp-1-receptor-agonist-research-across-the-masld-mash-hcc2026-10-08 https://evidence-hub.com/study/7799-unveiling-the-relationship-of-the-comorbidity-between-depression-and2026-10-08 https://evidence-hub.com/study/7800-efficacy-and-mechanisms-of-gynostemma-pentaphyllum-as-a-medicine-food2026-10-08 https://evidence-hub.com/study/7801-does-metformin-administration-improve-fracture-healing-a-systematic2026-10-08 https://evidence-hub.com/study/7802-effectiveness-of-drug-loaded-poly-ethylene-glycol-and-poly-lactic-co2026-10-08 https://evidence-hub.com/study/7803-drug-repurposing-for-reducing-the-size-of-benign-thyroid-nodules-a2026-10-08 https://evidence-hub.com/study/7804-efficacy-and-safety-of-traditional-chinese-classic-prescriptions2026-10-08 https://evidence-hub.com/study/7805-exploring-the-impact-of-metformin-on-the-central-nervous-system-and2026-10-08 https://evidence-hub.com/study/7806-diabetes-mellitus-and-covid-19-in-adults-a-systematic-review-of2026-10-08 https://evidence-hub.com/study/7807-induced-diabetic-neurogenic-bladder-animal-models-application2026-10-08 https://evidence-hub.com/study/7808-metabolic-reversal-of-functional-hypogonadism-glp-1-receptor-agonists2026-10-08 https://evidence-hub.com/study/7809-mechanism-of-ganoderma-lucidum-polysaccharides-in-the-mangement-of2026-10-08 https://evidence-hub.com/study/7810-efficacy-of-selected-dietary-supplements-and-pharmacological-agents2026-10-08 https://evidence-hub.com/study/7811-cangfu-daotan-decoction-with-diane-35-in-phlegm-dampness-polycystic2026-10-06 https://evidence-hub.com/study/7812-association-between-metabolic-risk-factors-and-hepatocellular2026-10-06 https://evidence-hub.com/study/7813-metabolic-effects-of-testosterone-replacement-therapy-in-men-with2026-10-06 https://evidence-hub.com/study/7814-immunomodulation-as-a-novel-treatment-strategy-for-periodontal2026-10-08 https://evidence-hub.com/study/7819-efficacy-and-safety-of-pharmacological-treatments-for-gestational2026-10-08 https://evidence-hub.com/study/7820-exploring-multifaceted-roles-of-metformin-in-therapeutic-applications2026-10-08 https://evidence-hub.com/study/7822-metformin-as-a-disease-modifying-agent-in-autosomal-dominant2026-10-08 https://evidence-hub.com/study/7823-metformin-for-the-treatment-of-type-2-diabetes-in-asian-adults-a2026-10-08 https://evidence-hub.com/study/7824-metformin-for-covid-19-systematic-review-and-meta-analysis-of2026-10-08 https://evidence-hub.com/study/7825-metformin-for-treating-gestational-diabetes-what-have-we-learned2026-10-08 https://evidence-hub.com/study/7826-evaluation-of-the-effect-of-metformin-as-a-radiosensitiser-in-solid2026-10-08 https://evidence-hub.com/study/7828-biological-anti-tumoral-mechanisms-of-metformin-in-head-and-neck2026-10-08 https://evidence-hub.com/study/7829-synergistic-anticancer-effects-of-doxorubicin-and-metformin2026-10-08 https://evidence-hub.com/study/7830-comparative-effectiveness-of-antidiabetic-drugs-as-an-additional2026-10-08 https://evidence-hub.com/study/7831-impact-of-prior-metformin-use-on-stroke-outcomes-a-systematic-review2026-10-08 https://evidence-hub.com/study/7832-comparing-psilocybin-to-metformin-as-neuroprotective-agents-against2026-10-08 https://evidence-hub.com/study/7833-antiproliferative-mechanisms-of-metformin-in-breast-cancer-a2026-10-08 https://evidence-hub.com/study/7834-metformin-use-and-vitamin-b12-deficiency-in-people-with-type-22026-10-08 https://evidence-hub.com/study/7835-a-systematic-review-on-clinical-evidence-for-topical-metformin-old2026-10-08 https://evidence-hub.com/study/7836-diabetes-medications-as-monotherapy-or-metformin-based-combination2026-10-08 https://evidence-hub.com/study/7837-the-efficacy-of-metformin-as-a-therapeutic-agent-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/7838-comparison-of-metformin-with-inositol-versus-metformin-alone-in-women2026-10-08 https://evidence-hub.com/study/7839-efficacy-and-safety-of-semaglutide-combined-with-metformin-in2026-10-08 https://evidence-hub.com/study/7840-metformin-for-treatment-of-acute-covid-19-systematic-review-of2026-10-08 https://evidence-hub.com/study/7841-comparison-of-the-efficacy-and-safety-of-10-glucagon-like-peptide-12026-10-08 https://evidence-hub.com/study/7842-evidence-for-biological-effects-of-metformin-in-operable-breast2026-10-06 https://evidence-hub.com/study/7843-cost-effectiveness-of-saxagliptin-onglyza-in-type-2-diabetes-in-sweden2026-10-06 https://evidence-hub.com/study/7844-pharmacokinetics-of-alogliptin-when-administered-with-food-metformin2026-10-06 https://evidence-hub.com/study/7845-comparison-of-four-different-treatment-regimens-on-coagulation2026-10-06 https://evidence-hub.com/study/7846-five-weeks-of-treatment-with-the-glp-1-analogue-liraglutide-improves2026-10-06 https://evidence-hub.com/study/7847-comparison-of-insulin-monotherapy-and-combination-therapy-with2026-10-06 https://evidence-hub.com/study/7848-metformin-increases-serum-concentration-of-high-molecular-weight-hmw2026-10-08 https://evidence-hub.com/study/7849-effect-of-metformin-vs-placebo-treatment-on-serum-fatty-acids-in-non2026-10-06 https://evidence-hub.com/study/7850-triple-fixed-dose-combination-empagliflozin-linagliptin-and-metformin2026-10-04 https://evidence-hub.com/study/7851-comparison-of-metformin-and-repaglinide-monotherapy-in-the-treatment2026-10-06 https://evidence-hub.com/study/7852-metformin-treatment-before-ivf-icsi-in-women-with-polycystic-ovary2026-10-06 https://evidence-hub.com/study/7853-metformin-as-an-adjunct-therapy-in-adolescents-with-type-1-diabetes2026-10-06 https://evidence-hub.com/study/7854-efficacy-and-safety-of-rosiglitazone-plus-metformin-in-mexicans-with2026-10-06 https://evidence-hub.com/study/7855-saxagliptin-versus-glipizide-as-add-on-therapy-to-metformin2026-10-08 https://evidence-hub.com/study/7856-safety-pharmacokinetics-and-pharmacodynamics-of-remogliflozin2026-10-06 https://evidence-hub.com/study/7857-predicting-metformin-efficacy-in-improving-insulin-sensitivity-among2026-10-06 https://evidence-hub.com/study/7858-a-randomized-controlled-trial-of-mediterranean-diet-and-metformin-to2026-10-08 https://evidence-hub.com/study/7859-comparison-of-fixed-dose-rosiglitazone-metformin-combination-therapy2026-10-06 https://evidence-hub.com/study/7860-effects-of-metformin-and-curcumin-in-women-with-polycystic-ovary2026-10-06 https://evidence-hub.com/study/7861-metformin-reduces-the-rate-of-small-intestinal-glucose-absorption-in2026-10-06 https://evidence-hub.com/study/7862-cognitive-function-in-metformin-exposed-children-born-to-mothers-with2026-10-06 https://evidence-hub.com/study/7863-comparison-of-myo-inositol-and-metformin-on-glycemic-control-lipid2026-10-08 https://evidence-hub.com/study/7864-metformin-as-adjuvant-therapy-in-obese-knee-osteoarthritis-patients2026-10-06 https://evidence-hub.com/study/7865-metformin-placebo-and-endocrine-therapy-discontinuation-among2026-10-06 https://evidence-hub.com/study/7866-effects-of-metformin-rosiglitazone-and-insulin-on-bone-metabolism-in2026-10-08 https://evidence-hub.com/study/7867-efficacy-and-safety-of-monotherapy-of-sitagliptin-compared-with2026-10-08 https://evidence-hub.com/study/7868-slc47a1-gene-rs2289669-g-a-variants-enhance-the-glucose-lowering2026-10-06 https://evidence-hub.com/study/7869-centratherum-anthelminticum-seeds-administration-improved-risk-factor2026-10-06 https://evidence-hub.com/study/7870-safety-and-tolerability-of-dapagliflozin-saxagliptin-and-metformin-in2026-10-06 https://evidence-hub.com/study/7871-glibenclamide-and-metformin-versus-standard-care-in-gestational2026-10-06 https://evidence-hub.com/study/7872-linagliptin-plus-metformin-in-patients-with-newly-diagnosed-type-22026-10-06 https://evidence-hub.com/study/7873-continuation-versus-discontinuation-of-insulin-secretagogues-when2026-10-06 https://evidence-hub.com/study/7874-relating-in-vitro-in-vivo-data-of-two-controlled-release-metformin2026-10-06 https://evidence-hub.com/study/7875-metformin-improves-peripheral-vascular-flow-in-nonhyperlipidemic2026-10-06 https://evidence-hub.com/study/7876-metformin-treatment-in-different-phenotypes-of-polycystic-ovary2026-10-06 https://evidence-hub.com/study/7877-a-comparison-between-sitagliptin-or-glibenclamide-in-addition-to2026-10-06 https://evidence-hub.com/study/7878-metformin-use-in-children-with-obesity-and-normal-glucose-tolerance2026-10-06 https://evidence-hub.com/study/7879-bioequivalence-and-pharmacokinetic-comparison-of-3-metformin-extended2026-10-06 https://evidence-hub.com/study/7880-c-reactive-protein-levels-are-unaffected-by-metformin-during2026-10-06 https://evidence-hub.com/study/7881-metformin-increases-total-serum-homocysteine-levels-in-non-diabetic2026-10-06 https://evidence-hub.com/study/7882-metformin-versus-insulin-in-the-management-of-pre-gestational2026-10-08 https://evidence-hub.com/study/7883-both-glimepiride-and-high-dose-metformin-are-important-for-sustained2026-10-06 https://evidence-hub.com/study/7884-the-use-of-berberine-for-women-with-polycystic-ovary-syndrome2026-10-06 https://evidence-hub.com/study/7885-concomitant-oral-antihyperglycemic-agent-use-and-associated-treatment2026-10-06 https://evidence-hub.com/study/7886-a-pilot-randomized-controlled-trial-of-metformin-versus-insulin-in2026-10-06 https://evidence-hub.com/study/7887-lymphocyte-suppressing-endothelial-protective-and-systemic-anti2026-10-06 https://evidence-hub.com/study/7888-experience-of-malignancies-with-oral-glucose-lowering-drugs-in-the2026-10-06 https://evidence-hub.com/study/7889-the-effect-of-metformin-on-blood-glucose-control-in-overweight2026-10-06 https://evidence-hub.com/study/7890-combining-a-diet-rich-in-fermentable-carbohydrates-with-metformin2026-10-08 https://evidence-hub.com/study/7891-physiologically-based-metformin-pharmacokinetics-model-of-mice-and2026-10-06 https://evidence-hub.com/study/7892-gender-differential-effects-on-blood-glucose-levels-between-acarbose2026-10-06 https://evidence-hub.com/study/7893-metformin-added-to-intensive-insulin-therapy-improves-metabolic2026-10-06 https://evidence-hub.com/study/7894-the-primary-glucose-lowering-effect-of-metformin-resides-in-the-gut2026-10-06 https://evidence-hub.com/study/7895-effects-of-metformin-plus-gliclazide-compared-with-metformin-alone-on2026-10-06 https://evidence-hub.com/study/7896-the-effect-of-pioglitazone-as-add-on-therapy-to-metformin-or2026-10-06 https://evidence-hub.com/study/7897-insulin-counter-regulatory-factors-fibrinogen-and-c-reactive-protein2026-10-06 https://evidence-hub.com/study/7898-effect-of-metformin-in-pediatric-patients-with-type-2-diabetes-a2026-10-08 https://evidence-hub.com/study/7899-effects-of-metformin-therapy-on-coronary-endothelial-dysfunction-in2026-10-08 https://evidence-hub.com/study/7900-health-related-quality-of-life-in-women-with-newly-diagnosed2026-10-06 https://evidence-hub.com/study/7901-effects-of-metformin-metformin-plus-rosiglitazone-and-metformin-plus2026-10-08 https://evidence-hub.com/study/7902-morning-exercise-and-pre-breakfast-metformin-interact-to-reduce2026-10-06 https://evidence-hub.com/study/7903-randomized-trial-comparing-the-effects-of-gliclazide-liraglutide-and2026-10-06 https://evidence-hub.com/study/7904-metformin-alters-skeletal-muscle-transcriptome-adaptations-to2026-10-06 https://evidence-hub.com/study/7905-assessment-of-the-drug-interaction-potential-of-ertugliflozin-with2026-10-06 https://evidence-hub.com/study/7906-protocol-for-a-pilot-randomised-controlled-trial-of-metformin-in-pre2026-10-06 https://evidence-hub.com/study/7907-pharmacokinetic-comparison-between-a-fixed-dose-combination-of2026-10-04 https://evidence-hub.com/study/7908-childhood-follow-up-of-the-grow-randomized-trial-metformin-in2026-10-06 https://evidence-hub.com/study/7909-enzalutamide-plus-metformin-versus-enzalutamide-alone-in-metastatic2026-10-08 https://evidence-hub.com/study/7910-metformin-does-not-affect-postabsorptive-hepatic-free-fatty-acid2026-10-06 https://evidence-hub.com/study/7911-long-term-effects-of-lifestyle-and-metformin-interventions-in-dpp-on2026-10-06 https://evidence-hub.com/study/7912-metformin-to-augment-strength-training-effective-response-in-seniors2026-10-08 https://evidence-hub.com/study/7913-the-effect-of-metformin-on-perinatal-outcomes-in-pregnant-women-with2026-10-08 https://evidence-hub.com/study/7914-hyperreninemia-characterizing-women-with-polycystic-ovary-syndrome2026-10-06 https://evidence-hub.com/study/7915-a-randomized-double-blind-placebo-controlled-trial-of-metformin2026-10-06 https://evidence-hub.com/study/7916-pre-surgical-metformin-in-uterine-malignancy-premium-a-multi-center2026-10-08 https://evidence-hub.com/study/7917-metformin-does-not-reduce-markers-of-cell-proliferation-in-esophageal2026-10-06 https://evidence-hub.com/study/7918-initial-therapy-with-the-fixed-dose-combination-of-sitagliptin-and2026-10-06 https://evidence-hub.com/study/7919-effects-of-initiating-insulin-and-metformin-on-glycemic-control-and2026-10-06 https://evidence-hub.com/study/7920-the-effect-of-metformin-in-treatment-of-adenomas-in-patients-with2026-10-06 https://evidence-hub.com/study/7921-efficacy-of-glimepiride-metformin-combination-versus-glibenclamide2026-10-08 https://evidence-hub.com/study/7922-ovarian-function-and-metabolic-factors-in-women-with-oligomenorrhea2026-10-06 https://evidence-hub.com/study/7923-metformin-in-the-treatment-of-hiv-lipodystrophy-syndrome-a-randomized2026-10-08 https://evidence-hub.com/study/7924-metformin-anticipates-peak-of-lactate-during-high-intensity-interval2026-10-06 https://evidence-hub.com/study/7925-prevent-dm-comparative-effectiveness-trial-of-lifestyle-intervention2026-10-06 https://evidence-hub.com/study/7926-short-term-antidiabetic-treatment-with-insulin-or-metformin-has-a2026-10-06 https://evidence-hub.com/study/7927-pioglitazone-metabolic-effect-in-metformin-intolerant-obese-patients2026-10-06 https://evidence-hub.com/study/7928-metformin-improves-blood-lipid-pattern-in-nondiabetic-patients-with2026-10-08 https://evidence-hub.com/study/7929-capabilities-of-hypoglycemic-therapy-in-women-with-decompensated-type2026-10-06 https://evidence-hub.com/study/7930-liver-dysfunction-in-paediatric-obesity-a-randomized-controlled-trial2026-10-06 https://evidence-hub.com/study/7931-preparation-and-in-vitro-in-vivo-evaluation-of-sustained-release2026-10-08 https://evidence-hub.com/study/7932-continuing-metformin-when-starting-insulin-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/7933-metformin-therapy-increases-insulin-stimulated-release-of-d-chiro2026-10-06 https://evidence-hub.com/study/7934-midpregnancy-doppler-ultrasound-of-the-uterine-artery-in-metformin2026-10-06 https://evidence-hub.com/study/7935-protective-effect-of-metformin-on-myocardial-injury-in-metabolic2026-10-06 https://evidence-hub.com/study/7936-effect-of-insulin-versus-triple-oral-therapy-on-the-progression-of2026-10-06 https://evidence-hub.com/study/7937-metformin-should-be-considered-in-the-treatment-of-gestational2026-10-06 https://evidence-hub.com/study/7938-rosiglitazone-reduces-microalbuminuria-and-blood-pressure2026-10-06 https://evidence-hub.com/study/7939-metformin-improves-endothelial-function-in-patients-with-metabolic2026-10-08 https://evidence-hub.com/study/7940-efficacy-and-safety-of-acarbose-in-metformin-treated-patients-with2026-10-06 https://evidence-hub.com/study/7941-effect-of-weight-change-and-metformin-on-fibrinolysis-and-the-von2026-10-06 https://evidence-hub.com/study/7942-impact-of-oral-contraceptives-and-metformin-on-advanced-lipid2026-10-08 https://evidence-hub.com/study/7943-metformin-added-to-lifestyle-intervention-for-physical-function-in2026-10-08 https://evidence-hub.com/study/7944-lung-function-after-randomization-to-metformin-lifestyle-intervention2026-10-08 https://evidence-hub.com/study/7945-effects-of-pharmacological-gip-infusion-on-insulin-glucagon-and2026-10-08 https://evidence-hub.com/study/7946-efficacy-and-safety-of-add-on-topiramate-vs-metformin-on2026-10-08 https://evidence-hub.com/study/7947-determinants-of-dropout-from-lifestyle-interventions-for-overweight2026-10-08 https://evidence-hub.com/study/7948-multimodal-therapy-with-metformin-inositol-and-dietary-restriction2026-10-08 https://evidence-hub.com/study/7949-first-line-dapagliflozin-metformin-or-combination-therapy-in-type-22026-10-08 https://evidence-hub.com/study/7950-does-metformin-interfere-with-cardiorespiratory-and-substrate2026-10-08 https://evidence-hub.com/study/7951-effects-of-udca-and-probiotics-on-metabolic-outcomes-in-type-22026-10-08 https://evidence-hub.com/study/7952-multi-strain-probiotic-enhances-metformin-tolerance-by-modulating-gut2026-10-08 https://evidence-hub.com/study/7953-metformin-repurposing-in-gout-enhancing-febuxostat-efficacy-through2026-10-08 https://evidence-hub.com/study/7954-adjunctive-melatonin-and-sildenafil-enhances-antioxidant-defense-in2026-10-08 https://evidence-hub.com/study/7955-the-effect-of-metformin-on-the-pharmacokinetics-of-rifampicin2026-10-08 https://evidence-hub.com/study/7956-a-phase-ii-feasibility-study-combining-pembrolizumab-and-metformin-in2026-10-08 https://evidence-hub.com/study/7957-comparative-pharmacokinetics-and-bioequivalence-assessment-of2026-10-08 https://evidence-hub.com/study/7958-metformin-enhances-the-pathological-response-in-nondiabetic-patients2026-10-08 https://evidence-hub.com/study/7959-global-and-partitioned-polygenic-risk-scores-associations-with2026-10-08 https://evidence-hub.com/study/7960-metformin-blunts-vascular-insulin-sensitivity-after-exercise-training2026-10-08 https://evidence-hub.com/study/7961-beyond-glycemic-control-differential-effects-of-empagliflozin-and2026-10-08 https://evidence-hub.com/study/7962-metabolic-profiling-of-healthy-vs-syndrome-associated-obesity-and2026-10-08 https://evidence-hub.com/study/7963-effects-of-combined-metformin-and-cabergoline-versus-metformin-alone2026-10-08 https://evidence-hub.com/study/7964-the-anti-obesogenic-metabolite-lac-phe-is-elevated-by-metformin2026-10-08 https://evidence-hub.com/study/7965-adjunctive-effects-of-apple-cider-vinegar-on-metabolic-syndrome-and2026-10-08 https://evidence-hub.com/study/7966-metformin-increases-glycolysis-and-the-stress-induced-cytokine-gdf152026-10-08 https://evidence-hub.com/study/7967-orforglipron-added-to-titrated-insulin-glargine-in-type-2-diabetes2026-10-08 https://evidence-hub.com/study/7968-the-role-of-male-foetal-sex-on-maternal-and-neonatal-outcomes-in2026-10-08 https://evidence-hub.com/study/7969-effect-of-high-dose-n-acetyl-cysteine-supplementation-on-markers-of2026-10-08 https://evidence-hub.com/study/7970-effects-of-premeal-versus-postmeal-metformin-administration-on2026-10-08 https://evidence-hub.com/study/7971-neither-metformin-nor-ursodeoxycholic-acid-effectively-treats2026-10-08 https://evidence-hub.com/study/7972-the-usefulness-of-metformin-and-ganwei-for-metabolic-dysfunction2026-10-08 https://evidence-hub.com/study/7973-short-term-combined-treatment-with-tirzepatide-and-metformin-for2026-10-08 https://evidence-hub.com/study/7974-htd1801-in-combination-with-metformin-for-type-2-diabetes2026-10-08 https://evidence-hub.com/study/7975-quality-of-life-and-patient-reported-outcomes-after-non-surgical2026-10-08 https://evidence-hub.com/study/7976-multi-strain-probiotic-reduces-gastrointestinal-side-effects-in-women2026-10-08 https://evidence-hub.com/study/7977-association-of-cancer-antigen-15-3-with-distant-recurrence-in2026-10-08 https://evidence-hub.com/study/7978-exploration-of-body-mass-index-and-circulating-metabolic-factors-as2026-10-08 https://evidence-hub.com/study/7979-liver-fat-changes-in-patients-with-type-2-diabetes-by-presence-of2026-10-08 https://evidence-hub.com/study/7980-endogenous-glucagon-like-peptide-1-enhanced-by-vildagliptin-reduces2026-10-08 https://evidence-hub.com/study/7981-bioequivalence-assessment-between-two-formulations-of-a-film-coated2026-10-08 https://evidence-hub.com/study/7982-effects-of-5-2-intermittent-fasting-meal-replacement-on-body2026-10-08 https://evidence-hub.com/study/7983-pharmacokinetic-comparison-between-fixed-dose-combination-and-loose2026-10-08 https://evidence-hub.com/study/7984-dulaglutide-versus-empagliflozin-as-add-on-therapy-to-metformin-and2026-10-08 https://evidence-hub.com/study/7985-long-term-safety-of-oral-orforglipron-in-japanese-participants-with2026-10-08 https://evidence-hub.com/study/7986-tirzepatide-versus-intensified-conventional-care-after-2-years-of2026-10-08 https://evidence-hub.com/study/7987-metformin-attenuates-metabolic-insulin-sensitivity-and-insulin2026-10-08 https://evidence-hub.com/study/7988-comparative-effects-of-metformin-and-lifestyle-therapy-on-bone2026-10-08 https://evidence-hub.com/study/7989-effect-of-insulin-sensitizers-on-glycemic-and-lipid-profile-in2026-10-08 https://evidence-hub.com/study/7990-metformin-reduces-the-incidence-of-shoulder-stiffness-after2026-10-09 https://evidence-hub.com/study/7991-efficacy-and-safety-of-combining-olorigliflozin-with-metformin-in2026-10-08 https://evidence-hub.com/study/7992-efficacy-and-safety-of-anagliptin-added-to-metformin-and2026-10-08 https://evidence-hub.com/study/7993-the-effectiveness-of-care-coordination-on-medication-adherence-among2026-10-08 https://evidence-hub.com/study/7994-lifestyle-and-metformin-interventions-and-risk-of-multimorbidity-in2026-10-08 https://evidence-hub.com/study/7995-effects-of-ziziphus-jujuba-metformin-and-myoinositol-on-pregnancy2026-10-08 https://evidence-hub.com/study/7996-empagliflozin-as-an-alternative-to-metformin-for-antipsychotic2026-10-08 https://evidence-hub.com/study/7997-ketone-supplementation-dose-dependently-lowers-postprandial-blood2026-10-08 https://evidence-hub.com/study/7998-circulating-profiles-of-the-bile-acid-metabolomics-in-patients-with2026-10-08 https://evidence-hub.com/study/7999-efficacy-and-safety-of-glimepiride-voglibose-and-metformin-er-in-type2026-10-08 https://evidence-hub.com/study/8000-multiparameter-mri-assessment-of-metformin-and-exercise-effects-on2026-10-08 https://evidence-hub.com/study/8001-the-impact-of-different-oral-antidiabetic-drugs-on-insulin-pump2026-10-08 https://evidence-hub.com/study/8002-sex-differences-in-cardiac-structure-and-function-following-st2026-10-08 https://evidence-hub.com/study/8003-effects-of-metformin-and-denosumab-on-bone-and-glucose-metabolism-in2026-10-08 https://evidence-hub.com/study/8004-oral-polychemotherapy-to-induce-remission-in-newly-diagnosed-type-22026-10-08 https://evidence-hub.com/study/8005-the-effect-of-oral-magnesium-supplementation-on-glycemic-control-and2026-10-08 https://evidence-hub.com/study/8006-efficacy-and-safety-of-adding-a-fourth-oral-antidiabetic-drug-versus2026-10-08 https://evidence-hub.com/study/8007-adjuvant-potential-of-metformin-with-standard-anti-seizure2026-10-08 https://evidence-hub.com/study/8008-efficacy-and-safety-of-once-weekly-subcutaneous-zenagamtide-a-novel2026-10-08 https://evidence-hub.com/study/8009-impact-of-a-pharmacist-adherence-intervention-on-medication-beliefs2026-10-06 https://evidence-hub.com/study/8010-efficacy-and-safety-of-once-daily-oral-zenagamtide-a-novel2026-10-08 https://evidence-hub.com/study/8011-efficacy-of-combined-nutritional-and-pharmacological-interventions-in2026-10-08 https://evidence-hub.com/study/8012-an-intervention-study-of-the-general-practice-management-of-older2026-10-08 https://evidence-hub.com/study/8013-effects-of-short-term-tofogliflozin-treatment-on-the-insulin2026-10-08 https://evidence-hub.com/study/8014-hrs-7535-for-type-2-diabetes-inadequately-controlled-with-metformin-a2026-10-08 https://evidence-hub.com/study/8015-the-effects-of-bifidobacterium-animalis-subsp-lactis-bla80-on2026-10-08 https://evidence-hub.com/study/8016-effect-of-metformin-on-insulin-resistance-in-adults-with-type-12026-10-08 https://evidence-hub.com/study/8017-comparison-of-the-continuous-glucose-monitoring-profiles-of-four2026-10-08 https://evidence-hub.com/study/8018-association-between-neonatal-hypoglycemia-and-30-day-breastfeeding2026-10-08 https://evidence-hub.com/study/8019-the-effect-of-fluvoxamine-and-metformin-for-fatigue-in-patients-with2026-10-08 https://evidence-hub.com/study/8020-impact-of-iglarlixi-on-glycaemic-control-depth-and-variability-in2026-10-08 https://evidence-hub.com/study/8021-sitagliptin-metformin-and-glimepiride-fixed-dose-combination-compared2026-10-08 https://evidence-hub.com/study/8022-a-randomized-controlled-trial-of-real-time-continuous-glucose2026-10-08 https://evidence-hub.com/study/8023-metformin-alters-exercise-training-induced-blood-pressure-and-aortic2026-10-08 https://evidence-hub.com/study/8024-combination-metformin-and-liraglutide-in-pcos-clinical-efficacy-in2026-10-08 https://evidence-hub.com/study/8025-effects-of-insulin-and-exenatide-therapy-on-glycemic-control-and-cell2026-10-08 https://evidence-hub.com/study/8026-effect-of-probiotics-derivatives-postbiotics-and-metabiotics-on2026-10-08 https://evidence-hub.com/study/8027-the-effects-of-chiglitazar-and-metformin-on-insulin-resistance-in2026-10-08 https://evidence-hub.com/study/8028-efficacy-and-tolerability-of-metformin-as-an-adjuvant-therapy-in2026-10-08 https://evidence-hub.com/study/8029-community-health-worker-led-versus-facility-based-type-2-diabetes2026-10-08 https://evidence-hub.com/study/8030-impact-of-albuminuria-lowering-treatments-on-cardiovascular2026-10-08 https://evidence-hub.com/study/8031-can-maternal-metformin-protect-the-developing-fetal-brain2026-10-08 https://evidence-hub.com/study/8032-medication-count-including-statin-or-metformin-use-is-not-associated2026-10-08 https://evidence-hub.com/study/8033-orforglipron-compared-with-dapagliflozin-in-adults-with-type-22026-10-08 https://evidence-hub.com/study/8034-addition-of-sitagliptin-to-ongoing-metformin-improved-metabolic2026-10-08 https://evidence-hub.com/study/8035-effect-of-a-medication-adherence-education-intervention-on-clinical2026-10-08 https://evidence-hub.com/study/8036-evaluation-of-horizontal-ridge-augmentation-using-1-metformin-gel-and2026-10-08 https://evidence-hub.com/study/8037-metformin-with-neoadjuvant-chemotherapy-in-localized-triple-negative2026-10-08 https://evidence-hub.com/study/8038-neonatal-outcomes-in-case-of-euglycemic-control-in-gestational2026-10-08 https://evidence-hub.com/study/8039-metformin-improves-sarcopenia-related-quality-of-life-in-geriatric2026-10-08 https://evidence-hub.com/study/8041-efficacy-of-wechat-based-digital-intervention-versus-metformin-in2026-10-08 https://evidence-hub.com/study/8042-effects-of-metformin-and-donepezil-on-the-prevention-of-doxorubicin2026-10-08 https://evidence-hub.com/study/8043-efficacy-and-safety-of-dulaglutide-3-0-mg-and-4-5-mg-versus2026-10-08 https://evidence-hub.com/study/8044-effect-of-metformin-on-oxidative-stress-and-left-ventricular-geometry2026-10-08 https://evidence-hub.com/study/8045-efficacy-of-metformin-in-prevention-of-paclitaxel-induced-peripheral2026-10-08 https://evidence-hub.com/study/8046-a-randomized-controlled-trial-comparing-myoinositol-with-metformin2026-10-08 https://evidence-hub.com/study/8047-canagliflozin-combined-with-metformin-versus-metformin-monotherapy2026-10-08 https://evidence-hub.com/study/8048-metformin-testosterone-or-both-in-men-with-obesity-and-low2026-10-08 https://evidence-hub.com/study/8049-metformin-and-n-terminal-pro-b-type-natriuretic-peptide-in-type-22026-10-08 https://evidence-hub.com/study/8050-the-impact-of-metformin-use-on-the-outcomes-of-locally-advanced2026-10-08 https://evidence-hub.com/study/8051-repurposing-metformin-as-anticancer-drug-randomized-controlled-trial2026-10-08 https://evidence-hub.com/study/8052-a-96-week-double-blind-randomized-controlled-trial-comparing2026-10-08 https://evidence-hub.com/study/8053-pioglitazone-as-add-on-therapy-in-patients-with-type-2-diabetes2026-10-08 https://evidence-hub.com/study/8054-metformin-for-knee-osteoarthritis-in-patients-with-overweight-or2026-10-08 https://evidence-hub.com/study/8055-effect-of-acupuncture-and-metformin-on-insulin-sensitivity-in-women2026-10-08 https://evidence-hub.com/study/8056-a-randomized-controlled-trial-of-metformin-in-women-with-components2026-10-08 https://evidence-hub.com/study/8057-antecedent-metabolic-health-and-metformin-anthem-aging-study2026-10-08 https://evidence-hub.com/study/8058-ipragliflozin-additively-ameliorates-non-alcoholic-fatty-liver2026-10-08 https://evidence-hub.com/study/8059-therapeutic-effect-of-curcumin-in-women-with-polycystic-ovary2026-10-08 https://evidence-hub.com/study/8060-a-randomized-controlled-trial-of-metformin-on-left-ventricular2026-10-08 https://evidence-hub.com/study/8062-effects-of-short-term-metformin-treatment-on-brown-adipose-tissue2026-10-08 https://evidence-hub.com/study/8063-evaluation-of-the-gut-microbiota-after-metformin-intervention-in2026-10-08 https://evidence-hub.com/study/8064-metformin-and-insulin-treatment-of-gestational-diabetes-effects-on2026-10-08 https://evidence-hub.com/study/8065-a-metformin-add-on-clinical-study-in-multiple-sclerosis-to-evaluate2026-10-08 https://evidence-hub.com/study/8066-short-term-effect-of-polyethylene-glycol-loxenatide-on-weight-loss-in2026-10-08 https://evidence-hub.com/study/8067-comparing-the-individual-effects-of-metformin-and-rosiglitazone-and2026-10-08 https://evidence-hub.com/study/8068-outcomes-and-safety-of-concomitant-topiramate-or-metformin-for2026-10-08 https://evidence-hub.com/study/8069-a-randomized-controlled-trial-on-the-efficacy-safety-and2026-10-08 https://evidence-hub.com/study/8070-comparison-of-metformin-plus-myoinositol-vs-metformin-alone-in-pcos2026-10-08 https://evidence-hub.com/study/8071-n-acetylcysteine-and-or-ursodeoxycholic-acid-associated-with2026-10-08 https://evidence-hub.com/study/8072-a-52-week-randomized-controlled-trial-of-ipragliflozin-or-sitagliptin2026-10-08 https://evidence-hub.com/study/8073-feasibility-and-acceptability-of-metformin-to-augment-low-milk-supply2026-10-08 https://evidence-hub.com/study/8075-a-26-week-randomized-controlled-trial-of-semaglutide-once-daily2026-10-08 https://evidence-hub.com/study/8076-safety-and-efficacy-of-exenatide-once-weekly-plus-dapagliflozin-once2026-10-08 https://evidence-hub.com/study/8077-improved-mobility-with-metformin-in-patients-with-myotonic-dystrophy2026-10-08 https://evidence-hub.com/study/8078-repurposing-metformin-as-adjuvant-therapy-in-patients-with-ulcerative2026-10-08 https://evidence-hub.com/study/8080-effect-of-metformin-on-handgrip-strength-gait-speed-myostatin-serum2026-10-08 https://evidence-hub.com/study/8083-a-randomized-controlled-trial-comparing-the-metformin-oral2026-10-08 https://evidence-hub.com/study/8084-empagliflozin-compared-with-glimepiride-in-metformin-treated-patients2026-10-08 https://evidence-hub.com/study/8085-the-effect-of-metformin-and-cinnamon-on-serum-anti-mullerian-hormone2026-10-08 https://evidence-hub.com/study/8086-increased-metformin-clearance-in-overweight-and-obese-adolescents-a2026-10-08 https://evidence-hub.com/study/8087-efficacy-and-safety-of-adding-evogliptin-versus-sitagliptin-for2026-10-08 https://evidence-hub.com/study/8088-the-effects-of-vildagliptin-compared-with-metformin-on-vascular2026-10-08 https://evidence-hub.com/study/8089-efficacy-and-safety-of-ipragliflozin-as-an-add-on-therapy-to2026-10-08 https://evidence-hub.com/study/8090-efficacy-and-safety-of-voglibose-plus-metformin-in-patients-with-type2026-10-08 https://evidence-hub.com/study/8091-efficacy-and-safety-of-metformin-plus-low-dose-temozolomide-in2026-10-08 https://evidence-hub.com/study/8092-metformin-for-sepsis-associated-aki-a-protocol-for-the-randomized2026-10-08 https://evidence-hub.com/study/8094-the-ampk-modulator-metformin-as-adjunct-to-methotrexate-in-patients2026-10-08 https://evidence-hub.com/study/8096-dorzagliatin-add-on-therapy-to-metformin-in-patients-with-type-22026-10-08 https://evidence-hub.com/study/8097-phase-ii-study-of-metformin-for-reduction-of-obesity-associated2026-10-08 https://evidence-hub.com/study/8098-metformin-in-women-with-type-2-diabetes-in-pregnancy-mity-a-multi2026-10-08 https://evidence-hub.com/study/8099-treating-insulin-resistance-with-metformin-as-a-strategy-to-improve2026-10-08 https://evidence-hub.com/study/8101-effect-of-metformin-for-decreasing-proliferative-marker-in-women-with2026-10-08 https://evidence-hub.com/study/8102-antioxidant-effects-of-astaxanthin-and-metformin-combined-therapy-in2026-10-08 https://evidence-hub.com/study/8104-metformin-blunts-muscle-hypertrophy-in-response-to-progressive2026-10-08 https://evidence-hub.com/study/8105-early-metformin-in-gestational-diabetes-a-randomized-clinical-trial2026-10-08 https://evidence-hub.com/study/8108-a-randomized-controlled-trial-of-clomifene-citrate-metformin-and2026-10-08 https://evidence-hub.com/study/8110-metformin-in-gestational-diabetes-mellitus-a-double-blind-placebo2026-10-08 https://evidence-hub.com/study/8111-impact-of-metformin-on-anti-mullerian-hormone-in-women-with2026-10-08 https://evidence-hub.com/study/8113-the-effect-of-vitamin-c-and-or-e-supplementations-on-type-2-diabetic2026-10-08 https://evidence-hub.com/study/8114-the-effect-of-metformin-versus-placebo-in-combination-with-insulin2026-10-08 https://evidence-hub.com/study/8115-effect-of-calcium-and-vitamin-d-supplements-as-an-adjuvant-therapy-to2026-10-08 https://evidence-hub.com/study/8116-clomiphene-citrate-metformin-or-a-combination-of-both-as-the-first2026-10-08 https://evidence-hub.com/study/8117-effect-of-metformin-vs-placebo-on-invasive-disease-free-survival-in2026-10-08 https://evidence-hub.com/study/8118-vitamin-b12-supplementation-in-diabetic-neuropathy-a-1-year2026-10-08 https://evidence-hub.com/study/8122-randomized-trial-of-metformin-ivermectin-and-fluvoxamine-for-covid-192026-10-08 https://evidence-hub.com/study/8123-liraglutide-and-sitagliptin-have-no-effect-on-intestinal-microbiota2026-10-08 https://evidence-hub.com/study/8124-efficacy-and-safety-of-polyethylene-glycol-loxenatide-as-add-on-to2026-10-08 https://evidence-hub.com/study/8125-efficacy-and-safety-benefits-of-iglarlixi-versus-insulin-glargine-1002026-10-08 https://evidence-hub.com/study/8126-long-term-treatment-with-metformin-in-type-2-diabetes-and2026-10-08 https://evidence-hub.com/study/8127-dapagliflozin-effect-on-endothelial-dysfunction-in-diabetic-patients2026-10-08 https://evidence-hub.com/study/8128-efficacy-and-safety-of-mazdutide-in-chinese-patients-with-type-22026-10-08 https://evidence-hub.com/study/8130-the-asamet-trial-a-randomized-phase-ii-double-blind-placebo2026-10-08 https://evidence-hub.com/study/8132-effect-of-once-weekly-semaglutide-versus-thrice-daily-insulin-aspart2026-10-06 https://evidence-hub.com/study/8133-long-term-treatment-with-metformin-in-obese-insulin-resistant2026-10-06 https://evidence-hub.com/study/8134-metformin-associated-lactic-acidosis-undergoing-renal-replacement2026-10-06 https://evidence-hub.com/study/8135-metformin-maintains-intrahepatic-triglyceride-content-through2026-10-08 https://evidence-hub.com/study/8136-effects-of-pioglitazone-in-combination-with-metformin-or-a2026-10-06 https://evidence-hub.com/study/8137-effect-of-diane-35-alone-or-in-combination-with-orlistat-or-metformin2026-10-08 https://evidence-hub.com/study/8138-in-pcos-patients-the-addition-of-low-dose-spironolactone-induces-a2026-10-06 https://evidence-hub.com/study/8139-long-term-safety-and-efficacy-of-empagliflozin-sitagliptin-and2026-10-04 https://evidence-hub.com/study/8140-metformin-decreases-plasma-resistin-concentrations-in-pediatric2026-10-06 https://evidence-hub.com/study/8141-increased-insulin-like-growth-factor-i-levels-in-women-with2026-10-06 https://evidence-hub.com/study/8142-effect-of-metformin-on-methylglyoxal-metabolism-in-patients-with-type2026-10-08 https://evidence-hub.com/study/8143-metformin-versus-sibutramine-in-the-treatment-of-hyperinsulinemia-in2026-10-06 https://evidence-hub.com/study/8144-metformin-adjunctive-therapy-with-insulin-improves-glycemic-control2026-10-06 https://evidence-hub.com/study/8145-comparison-of-metformin-and-n-acetyl-cysteine-as-an-adjuvant-to2026-10-06 https://evidence-hub.com/study/8146-saxagliptin-and-metformin-xr-combination-therapy-provides-glycemic2026-10-06 https://evidence-hub.com/study/8147-the-efficacy-and-safety-of-saxagliptin-when-added-to-metformin2026-10-08 https://evidence-hub.com/study/8148-improvements-in-glycemic-control-in-type-2-diabetes-patients-switched2026-10-06 https://evidence-hub.com/study/8149-disuse-induced-muscle-fibrosis-cellular-senescence-and-senescence2026-10-06 https://evidence-hub.com/study/8150-growth-body-composition-and-metabolic-profile-of-8-year-old-children2026-10-06 https://evidence-hub.com/study/8151-sustained-maternal-hyperandrogenism-during-pcos-pregnancy-reduced-by2026-10-08 https://evidence-hub.com/study/8152-march2-comparative-assessment-of-therapeutic-effects-of-acarbose-and2026-10-06 https://evidence-hub.com/study/8153-the-effect-of-metformin-on-short-chain-fatty-acid-levels-in-patients2026-10-06 https://evidence-hub.com/study/8154-relation-between-augmentation-index-and-adiponectin-during-one-year2026-10-06 https://evidence-hub.com/study/8155-oral-antidiabetic-drugs-effect-of-food-on-absorption-of-pioglitazone2026-10-06 https://evidence-hub.com/study/8156-comparison-of-pioglitazone-and-metformin-efficacy-using-homeostasis2026-10-06 https://evidence-hub.com/study/8157-clinical-and-endocrinological-effects-of-6-months-of-metformin2026-10-06 https://evidence-hub.com/study/8158-prospective-randomized-trial-of-metformin-and-vitamins-for-the2026-10-06 https://evidence-hub.com/study/8159-metformin-for-patients-with-advanced-stage-ovarian-cancer-a2026-10-08 https://evidence-hub.com/study/8160-metformin-for-obese-insulin-treated-diabetic-patients-improvement-in2026-10-06 https://evidence-hub.com/study/8161-changes-in-the-gut-microbiome-influence-the-hypoglycemic-effect-of2026-10-06 https://evidence-hub.com/study/8162-metformin-downregulates-the-stat-pathway-and-reduces-bone-marrow2026-10-08 https://evidence-hub.com/study/8163-pharmacokinetics-of-metformin-in-patients-with-chronic-kidney-disease2026-10-06 https://evidence-hub.com/study/8164-rapid-determination-of-metformin-in-human-plasma-using-ion-pair-hplc2026-10-06 https://evidence-hub.com/study/8165-metformin-in-the-treatment-of-non-alcoholic-steatohepatitis-a-pilot2026-10-06 https://evidence-hub.com/study/8166-sensitization-to-insulin-induces-ovulation-in-nonobese-adolescents2026-10-06 https://evidence-hub.com/study/8167-the-administration-of-metformin-during-pregnancy-reduces-polycystic2026-10-06 https://evidence-hub.com/study/8168-the-effect-of-metformin-on-hypothalamic-pituitary-thyroid-axis2026-10-06 https://evidence-hub.com/study/8169-continuation-of-metformin-reduces-early-pregnancy-loss-in-obese2026-10-06 https://evidence-hub.com/study/8170-effect-of-fish-oil-as-an-adjunct-therapy-to-metformin-on-vascular-and2026-10-08 https://evidence-hub.com/study/8171-metformin-and-weight-changes-in-non-diabetic-older-people-with-hiv2026-10-08 https://evidence-hub.com/study/8172-geroprotective-effects-of-diet-and-exercise-plus-metformin-in-frail2026-10-08 https://evidence-hub.com/study/8173-association-between-preoperative-metformin-exposure-and-postoperative2026-10-08 https://evidence-hub.com/study/8174-efsubaglutide-alfa-added-to-metformin-improves-glycaemia-with-cell2026-10-08 https://evidence-hub.com/study/8175-efficacy-and-safety-of-saroglitazar-as-an-add-on-medication-to2026-10-08 https://evidence-hub.com/study/8176-reprogram-resilience-promotion-with-geroprotectors-assessment-of2026-10-08 https://evidence-hub.com/study/8177-efficacy-and-safety-of-topical-metformin-vs-kligman-formula-in-the2026-10-08 https://evidence-hub.com/study/8178-emerge-mothers-and-kids-a-longitudinal-cohort-study-of-mothers-and2026-10-08 https://evidence-hub.com/study/8179-optimising-metformin-use-in-polycystic-ovary-syndrome-met-pcos-study2026-10-08 https://evidence-hub.com/study/8180-polyethylene-glycol-loxenatide-selectively-reduces-adiposity-while2026-10-08 https://evidence-hub.com/study/8181-study-protocol-role-of-the-blood-brain-barrier-in-stress-resilience2026-10-08 https://evidence-hub.com/study/8182-the-role-of-short-term-metformin-in-regulating-zinc-and-adipose2026-10-08 https://evidence-hub.com/study/8183-metformin-inhibits-proliferation-of-residing-fibroadipogenic2026-10-08 https://evidence-hub.com/study/8184-the-5-2-diet-reduces-risk-factors-for-cardiovascular-disease-in2026-10-08 https://evidence-hub.com/study/8185-adding-empagliflozin-to-ongoing-metformin-improves-metabolic-profile2026-10-08 https://evidence-hub.com/study/8186-effects-of-combined-oral-contraceptives-and-metformin-on-paraoxonase2026-10-08 https://evidence-hub.com/study/8187-divine-pilot-trial-a-phase-2-multicentre-randomised-pilot-trial-of2026-10-08 https://evidence-hub.com/study/8188-mazdutide-versus-semaglutide-for-the-treatment-of-type-2-diabetes-and2026-10-08 https://evidence-hub.com/study/8189-is-metformin-therapy-in-conjunction-with-lifestyle-modifications-more2026-10-08 https://evidence-hub.com/study/8190-metformin-for-the-treatment-of-unruptured-vertebrobasilar-dissecting2026-10-08 https://evidence-hub.com/study/8191-letrozole-abemaciclib-and-metformin-in-endometrial-cancer-a-non2026-10-08 https://evidence-hub.com/study/8192-the-life-met-trial-effect-of-insulin-sensitization-on-pubertal2026-10-08 https://evidence-hub.com/study/8193-the-cambridge-centre-for-myelin-repair-trial-two-ccmr-two-a-trial2026-10-08 https://evidence-hub.com/study/8194-study-protocol-of-a-multicenter-randomized-non-inferiority-open-label2026-10-08 https://evidence-hub.com/study/8195-randomized-controlled-trial-of-effects-of-metformin-in-nafld-patients2026-10-08 https://evidence-hub.com/study/8196-metformin-to-improve-walking-performance-in-lower-extremity2026-10-08 https://evidence-hub.com/study/8197-metformin-impact-on-maternal-and-infant-cardiometabolic-health-mimich2026-10-08 https://evidence-hub.com/study/8198-cagrilintide-semaglutide-cagrisema-versus-semaglutide-or-cagrilintide2026-10-08 https://evidence-hub.com/study/8199-a-phase-ii-study-of-nivolumab-plus-metformin-in-pre-treated2026-10-08 https://evidence-hub.com/study/8200-effectiveness-of-metformin-prolonged-release-formulation-on2026-10-08 https://evidence-hub.com/study/8201-cagrilintide-semaglutide-cagrisema-as-an-add-on-to-basal-insulin-in2026-10-08 https://evidence-hub.com/study/8202-hydroxychloroquine-as-an-adjunct-therapy-in-the-management-of-type-22026-10-08 https://evidence-hub.com/study/8203-elecoglipron-an-oral-small-molecule-glp-1-receptor-agonist-in-adults2026-10-08 https://evidence-hub.com/study/8204-safety-and-feasibility-trial-protocol-of-metformin-in-infants-after2026-10-08 https://evidence-hub.com/study/8205-insulin-sensitivity-and-beta-cell-function-with-macupatide-alone-or2026-10-08 https://evidence-hub.com/study/8206-efficacy-and-safety-of-efsubaglutide-alfa-in-overrun-patients-in-the2026-10-08 https://evidence-hub.com/study/8207-prediction-of-time-to-insulin-initiation-in-gestational-diabetes2026-10-08 https://evidence-hub.com/study/8208-efficacy-and-safety-of-fixed-dose-combinations-of-sitagliptin-and2026-10-08 https://evidence-hub.com/study/8209-metformin-for-overweight-and-obese-children-and-adolescents-with2026-10-08 https://evidence-hub.com/study/8210-impact-of-combined-hormonal-contraceptives-and-metformin-on-metabolic2026-10-08 https://evidence-hub.com/study/8211-basta-trial-protocol-for-a-randomised-double-blind-placebo-controlled2026-10-08 https://evidence-hub.com/study/8212-implementation-of-metformin-therapy-to-ease-decline-of-kidney2026-10-08 https://evidence-hub.com/study/8213-diabetes-prevention-in-the-caribbean-using-lifestyle-intervention-and2026-10-08 https://evidence-hub.com/study/8214-semaglutide-injection-in-indian-patients-with-type-2-diabetes2026-10-08 https://evidence-hub.com/study/8215-anti-diabetic-medications-to-fight-parkinson-s-disease-and-dementia2026-10-08 https://evidence-hub.com/study/8216-dual-glucagon-and-glp-1-receptor-agonist-survodutide-improves2026-10-08 https://evidence-hub.com/study/8217-time-restricted-eating-and-metformin-in-invasive-breast-cancer-or2026-10-08 https://evidence-hub.com/study/8218-safety-and-efficacy-of-gzr18-a-long-acting-glp-1-analog-in-chinese2026-10-08 https://evidence-hub.com/study/8219-safety-and-tolerability-of-metformin-in-overweight-and-obese-patients2026-10-08 https://evidence-hub.com/study/8220-inpatient-safety-effectiveness-of-sglt2-inhibitors-and-glp-1-ras-in2026-10-06 https://evidence-hub.com/study/8221-rationale-design-and-baseline-characteristics-of-the-transcend-ckd2026-10-08 https://evidence-hub.com/study/8222-lobeglitazone-improves-glycaemic-control-as-add-on-therapy-to2026-10-08 https://evidence-hub.com/study/8223-repair-getug-p16-relapse-in-previously-irradiated-prostate-bed-a2026-10-08 https://evidence-hub.com/study/8224-metaaa-trial-patients-receiving-metformin-therapy-show-limited2026-10-08 https://evidence-hub.com/study/8225-efficacy-and-safety-of-high-dose-pioglitazone-as-add-on-therapy-in2026-10-08 https://evidence-hub.com/study/8226-efficacy-and-safety-of-combining-empagliflozin-in-people-with-type-22026-10-19 https://evidence-hub.com/study/8227-pharmacokinetics-pharmacodynamics-and-safety-of-single-dose2026-10-08 https://evidence-hub.com/study/8228-metformin-active-surveillance-trial-in-low-risk-prostate-cancer2026-10-08 https://evidence-hub.com/study/8229-phase-ib-dose-finding-and-pharmacokinetic-trial-of-metformin-combined2026-10-08 https://evidence-hub.com/study/8230-a-better-system-managing-the-adverse-effects-of-prescribed-medicines2026-10-08 https://evidence-hub.com/study/8231-effect-of-efsubaglutide-alfa-on-the-pharmacokinetics-of-metformin-and2026-10-08 https://evidence-hub.com/study/8232-repurposing-nitazoxanide-in-type-2-diabetes-mellitus-a-randomized2026-10-08 https://evidence-hub.com/study/8233-effectiveness-and-safety-of-metformin-teneligliptin-and-glimepiride2026-10-08 https://evidence-hub.com/study/8234-efficacy-and-safety-of-chiglitazar-add-on-to-metformin-in-type-22026-10-08 https://evidence-hub.com/study/8235-text-messaging-support-for-patients-diagnosed-with-impaired-glucose2026-10-08 https://evidence-hub.com/study/8236-association-of-race-and-survival-in-patients-treated-with-apalutamide2026-10-08 https://evidence-hub.com/study/8237-combined-gpr40-and-gpr119-full-agonism-with-k-757-and-k-833-results2026-10-08 https://evidence-hub.com/study/8238-a-randomized-phase-3-trial-of-metformin-in-patients-initiating2026-10-08 https://evidence-hub.com/study/8239-safety-analyses-of-the-inavo120-randomised-phase-iii-trial-of2026-10-08 https://evidence-hub.com/study/8240-efficacy-and-safety-benefits-of-hr17031-a-fixed-ratio-combination-of2026-10-08 https://evidence-hub.com/study/8241-repairing-myelin-after-irradiated-pediatric-brain-tumor-a2026-10-08 https://evidence-hub.com/study/8242-randomized-study-of-metformin-and-intensive-lifestyle-intervention-on2026-10-08 https://evidence-hub.com/study/8243-acute-metformin-intake-on-exercise-performance-in-healthy2026-10-06 https://evidence-hub.com/study/8244-gly-200-an-oral-pharmacologic-duodenal-exclusion-drug-resulted-in2026-10-06 https://evidence-hub.com/study/8245-metformin-clinical-trial-in-hpv-and-hpv-head-and-neck-squamous-cell2026-10-08 https://evidence-hub.com/study/8246-metformin-plus-insulin-for-preexisting-diabetes-or-gestational2026-10-08 https://evidence-hub.com/study/8247-clinical-trial-probiotics-in-metformin-intolerant-patients-with-type2026-10-08 https://evidence-hub.com/study/8248-addition-of-metformin-to-concurrent-chemoradiation-in-patients-with2026-10-08 https://evidence-hub.com/study/8249-metformin-in-combination-with-chemoradiotherapy-in-locally-advanced2026-10-08 https://evidence-hub.com/study/8250-the-anti-aging-mechanism-of-metformin-from-molecular-insights-to2026-10-08 https://evidence-hub.com/study/8251-effect-of-early-treatment-with-metformin-on-risk-of-emergency-care2026-10-08 https://evidence-hub.com/study/8252-low-dose-metformin-reprograms-the-tumor-immune-microenvironment-in2026-10-19 https://evidence-hub.com/study/8253-a-phase-ib-clinical-trial-of-metformin-and-chloroquine-in-patients2026-10-08 https://evidence-hub.com/study/8254-effect-of-additional-oral-semaglutide-vs-sitagliptin-on-glycated2026-10-08 https://evidence-hub.com/study/8255-assessment-of-cognitive-and-neural-recovery-in-survivors-of-pediatric2026-10-08 https://evidence-hub.com/study/8256-metformin-for-early-comorbid-glucose-dysregulation-and-schizophrenia2026-10-08 https://evidence-hub.com/study/8257-metformin-plus-lrinotecan-in-patients-with-refractory-colorectal2026-10-08 https://evidence-hub.com/study/8258-effect-of-metformin-plus-tyrosine-kinase-inhibitors-compared-with2026-10-08 https://evidence-hub.com/study/8259-a-phase-ii-randomized-clinical-trial-of-the-effect-of-metformin2026-10-08 https://evidence-hub.com/study/8260-mechanistic-phase-ii-clinical-trial-of-metformin-in-pulmonary2026-10-08 https://evidence-hub.com/study/8261-metformin-induces-weight-loss-associated-with-gut-microbiota2026-10-08 https://evidence-hub.com/study/8262-rationale-and-study-design-of-a-randomized-clinical-trial-of2026-10-08 https://evidence-hub.com/study/8263-the-combination-of-linagliptin-metformin-and-lifestyle-modification2026-10-08 https://evidence-hub.com/study/8265-study-protocol-of-a-phase-ii-clinical-trial-of-oral-metformin-for-the2026-10-08 https://evidence-hub.com/study/8266-metformin-treatment-significantly-enhances-intestinal-glucose-uptake2026-10-08 https://evidence-hub.com/study/8267-study-protocol-of-a-phase-ib-ii-clinical-trial-of-metformin-and2026-10-08 https://evidence-hub.com/study/8268-treatment-with-metformin-and-combination-of-metformin-plus2026-10-08 https://evidence-hub.com/study/8269-a-multimodal-precision-prevention-approach-combining-lifestyle2026-10-08 https://evidence-hub.com/study/8270-topical-metformin-in-the-treatment-of-melasma-a-preliminary-clinical2026-10-08 https://evidence-hub.com/study/8271-a-randomized-clinical-trial-of-metformin-to-treat-autosomal-dominant2026-10-08 https://evidence-hub.com/study/8272-the-synergistic-effects-of-saxagliptin-and-metformin-on-cd342026-10-08 https://evidence-hub.com/study/8273-randomised-clinical-trial-a-leucine-metformin-sildenafil-combination2026-10-10 https://evidence-hub.com/study/8276-effects-of-conjugated-linoleic-acid-and-metformin-on-insulin2026-10-06 https://evidence-hub.com/study/8277-the-efficacy-of-metformin-compared-with-insulin-in-regulating-blood2026-10-08 https://evidence-hub.com/study/8279-a-randomised-clinical-trial-comparing-myoinositol-and-metformin-in2026-10-08 https://evidence-hub.com/study/8281-effect-of-subcutaneous-tirzepatide-vs-placebo-added-to-titrated2026-10-08 https://evidence-hub.com/study/8282-metformin-in-amnestic-mild-cognitive-impairment-results-of-a-pilot2026-10-08 https://evidence-hub.com/study/8284-randomized-clinical-trial-of-the-safety-and-efficacy-of-sitagliptin2026-10-08 https://evidence-hub.com/study/8285-comparing-the-effects-of-agnugol-and-metformin-on-oligomenorrhea-in2026-10-08 https://evidence-hub.com/study/8290-letter-by-mordi-et-al-regarding-article-metformin-use-and-clinical2026-10-08 https://evidence-hub.com/study/8291-the-effects-of-prebiotics-on-gastrointestinal-side-effects-of2026-10-08 https://evidence-hub.com/study/8292-metformin-for-the-minimization-of-geographic-atrophy-progression2026-10-08 https://evidence-hub.com/study/8293-effect-of-metformin-versus-placebo-on-new-primary-cancers-in-canadian2026-10-08 https://evidence-hub.com/study/8295-lobeglitazone-and-pioglitazone-as-add-ons-to-metformin-for-patients2026-10-08 https://evidence-hub.com/study/8296-metformin-use-and-clinical-outcomes-among-patients-with-diabetes2026-10-08 https://evidence-hub.com/study/8297-metformin-evidence-from-preclinical-and-clinical-studies-for2026-10-08 https://evidence-hub.com/study/8299-antiproliferative-effect-of-metformin-on-the-endometrium-a-clinical2026-10-08 https://evidence-hub.com/study/8301-complete-pathological-response-following-levonorgestrel-intrauterine2026-10-08 https://evidence-hub.com/study/8303-neonatal-outcomes-in-women-with-gestational-diabetes-mellitus-treated2026-10-08 https://evidence-hub.com/study/8304-effect-of-metformin-on-thyroid-stimulating-hormone-and-thyroid-volume2026-10-08 https://evidence-hub.com/study/8306-effect-of-vitamin-e-and-metformin-on-fatty-liver-disease-in-obese2026-10-08 https://evidence-hub.com/study/8307-diabetes-metformin-and-the-clinical-course-of-covid-19-outcomes2026-10-08 https://evidence-hub.com/study/8309-antiproliferative-and-metabolic-effects-of-metformin-in-a2026-10-08 https://evidence-hub.com/study/8310-mediges-study-metformin-versus-insulin-in-gestational-diabetes2026-10-08 https://evidence-hub.com/study/8311-primary-results-of-the-randomized-trial-of-metformin-administration2026-10-08 https://evidence-hub.com/study/8312-inhibition-of-mtor-signaling-and-clinical-activity-of-metformin-in2026-10-08 https://evidence-hub.com/study/8314-the-effect-of-pioglitazone-and-metformin-on-liver-function-tests2026-10-08 https://evidence-hub.com/study/8315-effects-of-once-weekly-semaglutide-vs-once-daily-canagliflozin-on2026-10-08 https://evidence-hub.com/study/8316-metformin-versus-chromium-picolinate-in-clomiphene-citrate-resistant2026-10-08 https://evidence-hub.com/study/8319-randomized-trial-of-metformin-with-anti-tuberculosis-drugs-for-early2026-10-08 https://evidence-hub.com/study/8320-the-metformin-in-tuberous-sclerosis-mits-study-a-randomised-double2026-10-08 https://evidence-hub.com/study/8322-efficacy-and-safety-of-once-weekly-semaglutide-versus-once-daily2026-10-08 https://evidence-hub.com/study/8323-effect-of-a-probiotic-and-metformin-on-liver-aminotransferases-in-non2026-10-08 https://evidence-hub.com/study/8324-tirzepatide-and-muscle-composition-changes-in-people-with-type-22026-10-08 https://evidence-hub.com/study/8325-long-term-efficacy-and-safety-of-tirzepatide-in-participants-with2026-10-08 https://evidence-hub.com/study/8326-early-onset-type-2-diabetes-and-tirzepatide-treatment-a-post-hoc2026-10-08 https://evidence-hub.com/study/8327-for-colorectal-cancer-patients-with-type-ii-diabetes-could-metformin2026-10-08 https://evidence-hub.com/study/8328-a-pooled-analysis-of-two-phase-ii-trials-evaluating-metformin-plus2026-10-06 https://evidence-hub.com/study/8329-metformin-use-is-associated-with-reduced-incidence-and-improved2026-10-06 https://evidence-hub.com/study/8330-the-effect-of-metformin-on-gastric-cancer-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/8331-improvement-of-cell-function-after-switching-from-dpp-4-inhibitors-to2026-10-06 https://evidence-hub.com/study/8332-impacts-of-metformin-on-tuberculosis-incidence-and-clinical-outcomes2026-10-06 https://evidence-hub.com/study/8333-effects-of-exenatide-plus-metformin-versus-metformin-alone-on-insulin2026-10-06 https://evidence-hub.com/study/8334-metformin-can-be-safely-used-in-patients-exposed-to-contrast-media-a2026-10-06 https://evidence-hub.com/study/8335-impact-of-diabetes-on-the-outcomes-of-patients-with-castration2026-10-06 https://evidence-hub.com/study/8336-a-gene-variant-near-atm-affects-the-response-to-metformin-and2026-10-06 https://evidence-hub.com/study/8337-metformin-s-impact-on-statin-associated-muscle-symptoms-an-analysis2026-10-08 https://evidence-hub.com/study/8338-semaglutide-reduces-cardiovascular-events-regardless-of-metformin-use2026-10-06 https://evidence-hub.com/study/8339-combination-therapy-with-pioglitazone-plus-metformin-or-sulfonylurea2026-10-06 https://evidence-hub.com/study/8341-impact-of-metformin-plus-lifestyle-intervention-compared-with2026-10-08 https://evidence-hub.com/study/8342-fatty-liver-index-and-differential-glycemic-responses-to2026-10-08 https://evidence-hub.com/study/8343-potential-mediators-of-efpeglenatide-s-cardiovascular-benefit-an2026-10-06 https://evidence-hub.com/study/8344-preventing-gestational-diabetes-mellitus-a-systematic-review-and-meta2026-10-06 https://evidence-hub.com/study/8345-comparative-effectiveness-of-combining-antidiabetic-medications-to2026-10-06 https://evidence-hub.com/study/8346-impact-of-baseline-alanine-aminotransferase-levels-on-the-efficacy-of2026-10-06 https://evidence-hub.com/study/8347-exploring-the-anthelmintic-and-antidiabetic-effects-of-rosarin-in2026-10-08 https://evidence-hub.com/study/8348-risk-factors-for-bone-fractures-in-type-2-diabetes-and-the-impact-of2026-10-08 https://evidence-hub.com/study/8349-a-fasting-mimicking-diet-programme-reduces-liver-fat-and-liver2026-10-06 https://evidence-hub.com/study/8350-impact-of-duration-of-treatments-with-metformin-and-sulfonylureas2026-10-06 https://evidence-hub.com/study/8351-carnosine-supplementation-has-no-effect-on-inflammatory-markers-in2026-10-06 https://evidence-hub.com/study/8352-association-of-hyperautofluorescence-signals-with-geographic-atrophy2026-10-08 https://evidence-hub.com/study/8353-obesity-related-asthma-a-pathobiology-based-overview-of-existing-and2026-10-08 https://evidence-hub.com/study/8354-changes-in-tubular-biomarkers-with-dietary-intervention-and-metformin2026-10-06 https://evidence-hub.com/study/8355-preexisting-diabetes-mellitus-and-all-cause-mortality-in-adult2026-10-06 https://evidence-hub.com/study/8356-effect-of-metformin-and-lifestyle-intervention-on-adipokines-and2026-10-06 https://evidence-hub.com/study/8357-effect-of-concomitant-medications-on-treatment-response-and-survival2026-10-08 https://evidence-hub.com/study/8358-raised-thyroid-stimulating-hormone-in-girls-with-polycystic-ovary2026-10-06 https://evidence-hub.com/study/8359-the-role-of-metformin-in-treatment-of-weight-gain-associated-with2026-10-06 https://evidence-hub.com/study/8360-chronic-metformin-intake-and-gastric-cancer-a-pooled-analysis-within2026-10-06 https://evidence-hub.com/study/8361-effect-of-metformin-on-arginine-and-dimethylarginines-in-patients2026-10-06 https://evidence-hub.com/study/8362-relationships-of-glucose-glp-1-and-insulin-secretion-with-gastric2026-10-06 https://evidence-hub.com/study/8363-title-gestational-weight-gain-in-women-with-type-2-diabetes-and2026-10-08 https://evidence-hub.com/study/8364-impact-of-intensive-lifestyle-intervention-on-gut-microbiota2026-10-06 https://evidence-hub.com/study/8365-pharmacometabolomic-profiles-in-type-2-diabetic-subjects-treated-with2026-10-08 https://evidence-hub.com/study/8366-effects-of-18-months-metformin-versus-placebo-in-combination-with2026-10-06 https://evidence-hub.com/study/8367-improved-survival-with-post-diagnostic-metformin-and-statin-use-in-a2026-10-06 https://evidence-hub.com/study/8368-maintenance-of-glycaemic-control-with-liraglutide-versus-oral2026-10-06 https://evidence-hub.com/study/8369-efficacy-of-iglarlixi-in-adults-with-type-2-diabetes-inadequately2026-10-06 https://evidence-hub.com/study/8370-effect-of-canagliflozin-on-n-terminal-pro-brain-natriuretic-peptide2026-10-06 https://evidence-hub.com/study/8371-glycaemic-efficacy-of-an-expanded-dose-range-of-dulaglutide-according2026-10-08 https://evidence-hub.com/study/8372-pancreatic-safety-of-once-weekly-dulaglutide-in-chinese-patients-with2026-10-08 https://evidence-hub.com/study/8373-the-dawn-phenomenon-in-type-2-diabetes-its-association-with-glucose2026-10-06 https://evidence-hub.com/study/8374-a-clinical-diabetes-risk-prediction-model-for-prediabetic-women-with2026-10-08 https://evidence-hub.com/study/8375-effect-of-liraglutide-treatment-on-body-mass-index-and-weight2026-10-06 https://evidence-hub.com/study/8376-efficacy-of-once-daily-glucagon-like-peptide-1-receptor-agonist2026-10-06 https://evidence-hub.com/study/8377-no-effects-of-dapagliflozin-metformin-or-exercise-on-plasma-glucagon2026-10-06 https://evidence-hub.com/study/8378-effects-of-metformin-on-disease-flares-in-patients-with-systemic2026-10-06 https://evidence-hub.com/study/8379-the-association-of-metformin-use-with-keratinocyte-carcinoma2026-10-08 https://evidence-hub.com/study/8380-impact-of-concomitant-medications-on-biochemical-outcome-in-localised2026-10-06 https://evidence-hub.com/study/8381-effects-of-dipeptidyl-peptidase-4-inhibitor-linagliptin-versus2026-10-08 https://evidence-hub.com/study/8382-iglarlixi-effectively-reduces-residual-hyperglycaemia-in-patients2026-10-06 https://evidence-hub.com/study/8383-safety-and-efficacy-of-exenatide-once-weekly-in-participants-with2026-10-06 https://evidence-hub.com/study/8384-once-weekly-semaglutide-reduces-hba1c-and-body-weight-in-patients2026-10-06 https://evidence-hub.com/study/8385-beta-cell-function-and-insulin-sensitivity-in-obese-youth-with2026-10-08 https://evidence-hub.com/study/8386-exenatide-and-dapagliflozin-combination-improves-markers-of-liver2026-10-06 https://evidence-hub.com/study/8387-efficacy-and-safety-of-iglarlixi-in-hispanics-and-non-hispanic-whites2026-10-06 https://evidence-hub.com/study/8388-incidence-and-risk-factors-for-hyperlactatemia-in-ed-patients-with2026-10-08 https://evidence-hub.com/study/8389-baseline-nocturnal-glucose-change-a-predictor-of-the-treatment-effect2026-10-06 https://evidence-hub.com/study/8390-association-of-metformin-sulfonylurea-and-insulin-use-with-brain2026-10-08 https://evidence-hub.com/study/8391-weight-loss-in-patients-with-type-2-diabetes-receiving-once-weekly2026-10-06 https://evidence-hub.com/study/8392-statins-are-associated-with-increased-biochemical-recurrence-after2026-10-06 https://evidence-hub.com/study/8393-effect-of-vitamin-d-supplementation-on-cardiovascular-risk-in-type-22026-10-08 https://evidence-hub.com/study/8394-efficacy-and-safety-of-sitagliptin-added-to-treatment-of-patients2026-10-06 https://evidence-hub.com/study/8395-metformin-does-not-affect-clinically-relevant-outcomes-in-patients2026-10-08 https://evidence-hub.com/study/8396-association-between-insulin-resistance-and-preeclampsia-in-obese-non2026-10-08 https://evidence-hub.com/study/8397-fetal-growth-and-birth-anthropometrics-in-metformin-exposed-offspring2026-10-08 https://evidence-hub.com/study/8398-effectiveness-of-vildagliptin-in-clinical-practice-pooled-analysis-of2026-10-06 https://evidence-hub.com/study/8399-safety-and-efficacy-of-the-combination-of-the-glucagon-like-peptide-12026-10-06 https://evidence-hub.com/study/8400-continuation-of-non-essential-medications-in-actively-dying2026-10-08 https://evidence-hub.com/study/8401-efficacy-and-safety-of-ideglira-in-participants-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/8402-effects-of-metformin-and-a-mammalian-target-of-rapamycin-mtor-atp2026-10-06 https://evidence-hub.com/study/8403-quality-measure-attainment-with-dapagliflozin-plus-metformin-extended2026-10-06 https://evidence-hub.com/study/8404-associations-between-changes-in-glucagon-like-peptide-1-and2026-10-06 https://evidence-hub.com/study/8405-impact-of-bromocriptine-qr-therapy-on-cardiovascular-outcomes-in-type2026-10-08 https://evidence-hub.com/study/8406-insulin-lispro-low-mixture-twice-daily-vs-basal-insulin-glargine-once2026-10-06 https://evidence-hub.com/study/8407-efficacy-and-safety-of-canagliflozin-in-patients-with-type-2-diabetes2026-10-08 https://evidence-hub.com/study/8408-testosterone-and-depressive-symptoms-among-men-in-the-diabetes2026-10-08 https://evidence-hub.com/study/8409-efficacy-and-safety-of-canagliflozin-in-patients-with-type-2-diabetes2026-10-08 https://evidence-hub.com/study/8410-improving-diabetes-prevention-with-benefit-based-tailored-treatment2026-10-06 https://evidence-hub.com/study/8411-a-comparison-of-glycaemic-effects-of-sitagliptin-and-sulfonylureas-in2026-10-06 https://evidence-hub.com/study/8412-plasma-metformin-concentration-as-a-determinant-of-metabolic-response2026-10-08 https://evidence-hub.com/study/8413-ovulatory-recovery-following-weight-loss-in-women-with-polycystic2026-10-08 https://evidence-hub.com/study/8414-systematic-review-of-influence-of-ethnicity-on-efficacy-and-safety-of2026-10-08 https://evidence-hub.com/study/8415-glucagon-like-peptide-1-receptor-agonists-their-potential-role-in2026-10-08 https://evidence-hub.com/study/8416-perivascular-administration-of-metformin-through-3d-minichannels2026-10-08 https://evidence-hub.com/study/8417-concomitant-medication-effects-on-immunotherapy-outcomes-in-sarcoma-a2026-10-08 https://evidence-hub.com/study/8418-associations-between-the-gut-microbiome-and-diet-body-composition-and2026-10-08 https://evidence-hub.com/study/8419-obesity-and-women-s-health-across-the-lifespan-a-clinical-review-of2026-10-08 https://evidence-hub.com/study/8420-circulating-gdf15-and-hba1c-response-to-add-on-exenatide-therapy-in2026-10-08 https://evidence-hub.com/study/8421-imeglimin-treatment-may-improve-whole-blood-fluidity-and-influence2026-10-08 https://evidence-hub.com/study/8422-mycobacterium-tuberculosis-diversity-and-macrophage-heterogeneity2026-10-08 https://evidence-hub.com/study/8423-imeglimin-associated-temporal-changes-in-glutamyl-transferase-and2026-10-08 https://evidence-hub.com/study/8424-metformin-alleviates-diastolic-dysfunction-in-mice-with-experimental2026-10-08 https://evidence-hub.com/study/8425-a-real-world-cohort-study-on-the-association-of-the-use-of-sodium2026-10-08 https://evidence-hub.com/study/8426-metformin-exposure-in-pregnancy-and-fetal-programming-a-focused2026-10-08 https://evidence-hub.com/study/8427-fenofibrate-protects-against-antipsychotic-induced-hyperglycemia2026-10-08 https://evidence-hub.com/study/8428-safety-and-efficacy-of-glucagon-like-peptide-1-receptor-agonists-use2026-10-08 https://evidence-hub.com/study/8429-annual-pharmacy-cost-per-patient-achieving-composite-treatment2026-10-08 https://evidence-hub.com/study/8430-evaluating-cost-effectiveness-in-relation-to-the-supporting-clinical2026-10-08 https://evidence-hub.com/study/8431-11-oxygenated-androgens-in-pcos-impact-of-pcos-phenotypes-and-first2026-10-08 https://evidence-hub.com/study/8432-metformin-and-insulin-exacerbate-one-carbon-metabolism-deficits-in2026-10-08 https://evidence-hub.com/study/8433-predictors-of-initial-and-sustained-glycemic-and-weight-response-to2026-10-08 https://evidence-hub.com/study/8434-association-of-metformin-with-lung-function-decline-and-mortality-in2026-10-08 https://evidence-hub.com/study/8435-clinical-characteristics-of-sarcopenic-obesity-in-japanese-people2026-10-08 https://evidence-hub.com/study/8436-metabolic-protective-strategies-for-antipsychotic-associated-weight2026-10-08 https://evidence-hub.com/study/8437-impact-of-semaglutide-liraglutide-and-tirzepatide-on-cardiometabolic2026-10-08 https://evidence-hub.com/study/8438-effects-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-on-lipid2026-10-08 https://evidence-hub.com/study/8439-iglarlixi-a-titrateable-fixed-ratio-combination-of-basal-insulin-glp2026-10-08 https://evidence-hub.com/study/8440-efficacy-and-safety-of-metformin-versus-empagliflozin-on-chronic2026-10-08 https://evidence-hub.com/study/8441-evidence-of-a-protective-effect-of-metformin-on-abdominal-aortic2026-10-08 https://evidence-hub.com/study/8442-meta-analysis-of-the-effect-of-metformin-on-the-progression-of2026-10-08 https://evidence-hub.com/study/8443-cgm-derived-postprandial-glucose-with-icosema-versus-other-insulin2026-10-08 https://evidence-hub.com/study/8444-co-prescription-of-metformin-and-glucagon-like-peptide-1-receptor2026-10-08 https://evidence-hub.com/study/8445-circulating-propionate-and-butyrate-are-associated-with-metabolic2026-10-08 https://evidence-hub.com/study/8446-effectiveness-of-glp-1-receptor-agonists-in-patients-with-polycystic2026-10-08 https://evidence-hub.com/study/8447-glucagon-like-peptide-1-receptor-agonists-and-risk-of-depression-a2026-10-08 https://evidence-hub.com/study/8448-combination-of-glp-1-receptor-agonists-and-sglt2-inhibitors-in2026-10-08 https://evidence-hub.com/study/8449-cardioprotective-effect-of-diabetic-medication-on-cancer-patients2026-10-08 https://evidence-hub.com/study/8450-lap-defined-hepatic-steatosis-and-cardiometabolic-risk-in-rheumatoid2026-10-08 https://evidence-hub.com/study/8451-metformin-and-flutamide-combination-therapy-s-efficacy-and-safety-in2026-10-08 https://evidence-hub.com/study/8452-the-extent-and-phenotype-of-coronary-artery-disease-in-diabetes-and2026-10-08 https://evidence-hub.com/study/8453-comparative-response-to-pharmacological-management-of-asthma-in2026-10-08 https://evidence-hub.com/study/8454-metformin-and-hypertensive-disorders-of-pregnancy-a-phenotype-based2026-10-08 https://evidence-hub.com/study/8455-dorema-aucheri-extract-modulates-unfolded-protein-response-pathways2026-10-08 https://evidence-hub.com/study/8456-comparative-risk-of-hepatocellular-carcinoma-and-mortality-among2026-10-08 https://evidence-hub.com/study/8457-mechanistic-insights-into-the-cardioprotective-effects-of-modern2026-10-08 https://evidence-hub.com/study/8458-observational-studies-on-the-association-of-outpatient-antidiabetic2026-10-08 https://evidence-hub.com/study/8459-withholding-or-continuing-glucose-lowering-drugs-for-elective-surgery2026-10-08 https://evidence-hub.com/study/8460-efficacy-and-safety-of-iglarlixi-versus-idegasp-by-baseline-age2026-10-08 https://evidence-hub.com/study/8461-beyond-cardiovascular-protection-a-conceptual-and-translational2026-10-08 https://evidence-hub.com/study/8462-immunological-drug-drug-interactions-in-immune-checkpoint-inhibitor2026-10-08 https://evidence-hub.com/study/8463-betanin-modulates-the-leptin-adiponectin-axis-and-improves-glycemic2026-10-08 https://evidence-hub.com/study/8464-taurine-reduces-intracellular-glucose-accumulation-in-fructose2026-10-08 https://evidence-hub.com/study/8465-long-term-stability-of-the-triglyceride-glucose-index-in-cancer2026-10-08 https://evidence-hub.com/study/8466-current-insights-and-future-directions-on-the-role-of-glp-1-receptor2026-10-08 https://evidence-hub.com/study/8467-tirzepatide-as-an-add-on-for-participants-with-inadequate-glycemic2026-10-08 https://evidence-hub.com/study/8468-the-effects-of-metformin-and-exercise-training-on-cardiorespiratory2026-10-08 https://evidence-hub.com/study/8469-clinical-and-dermoscopic-evaluation-of-the-effectiveness-of-metformin2026-10-08 https://evidence-hub.com/study/8470-effects-of-metformin-monotherapy-versus-metformin-plus-sglt-22026-10-08 https://evidence-hub.com/study/8471-empagliflozin-and-its-impact-on-hepatic-and-metabolic-outcomes-in2026-10-08 https://evidence-hub.com/study/8472-targeting-a-hypothetical-estimand-based-on-adherence-with-the2026-10-08 https://evidence-hub.com/study/8473-sglt2-inhibitor-role-in-cardio-metabolic-renal-diseases-a-narrative2026-10-08 https://evidence-hub.com/study/8474-comparative-efficacy-and-safety-of-finerenone-in-diabetic-kidney2026-10-08 https://evidence-hub.com/study/8475-disease-modifying-anti-diabetic-drugs-dmadds-bridging-the-simple2026-10-08 https://evidence-hub.com/study/8476-cgm-based-metrics-and-mortality-in-older-adults-living-with-type-22026-10-06 https://evidence-hub.com/study/8477-association-between-oral-antihyperglycemic-medications-and-erectile2026-10-08 https://evidence-hub.com/study/8478-safety-and-efficacy-of-metformin-for-the-treatment-of-pain-protocol2026-10-08 https://evidence-hub.com/study/8479-correlations-between-metformin-and-prognosis-and-adverse-reactions-in2026-10-06 https://evidence-hub.com/study/8480-comparative-cardiovascular-outcomes-and-safety-of-hypoglycemic-drug2026-10-06 https://evidence-hub.com/study/8481-effects-of-glp-1-receptor-agonists-vs-metformin-in-polycystic-ovary2026-10-08 https://evidence-hub.com/study/8482-the-need-for-novel-therapeutic-directions-in-autosomal-dominant2026-10-06 https://evidence-hub.com/study/8483-glucagon-like-receptor-1-agonists-and-impotence-a-meta-analysis2026-10-08 https://evidence-hub.com/study/8484-longitudinal-associations-of-dietary-fiber-and-its-source-with-482026-10-08 https://evidence-hub.com/study/8485-postnatal-cardiometabolic-health-after-metformin-use-in-gestational2026-10-08 https://evidence-hub.com/study/8487-jinlida-granules-combined-with-metformin-improved-the-standard2026-10-08 https://evidence-hub.com/study/8488-low-bmi-patients-with-advanced-egfr-mutation-positive-nsclc-can-get-a2026-10-08 https://evidence-hub.com/study/8489-effects-of-metformin-and-statins-on-outcomes-in-men-with-castration2026-10-08 https://evidence-hub.com/study/8490-early-metformin-for-gestational-diabetes-mellitus-does-not-alter2026-10-08 https://evidence-hub.com/study/8491-metformin-s-therapeutic-potential-in-spinal-cord-injury-a-systematic2026-10-08 https://evidence-hub.com/study/8492-breastfeeding-patterns-among-parturients-with-diabetes-a-secondary2026-10-08 https://evidence-hub.com/study/8493-prices-of-anti-diabetic-drugs-sold-in-private-pharmacies-in-cote-d2026-10-08 https://evidence-hub.com/study/8494-546-p-effects-of-metformin-on-heart-rate-variability-in-adolescents2026-10-08 https://evidence-hub.com/study/8495-insulin-clearance-at-randomization-and-in-response-to-treatment-in2026-10-08 https://evidence-hub.com/study/8496-lactic-acidosis-secondary-to-metformin-toxicity-a-case-report2026-10-08 https://evidence-hub.com/study/8497-effect-of-concomitant-medications-on-treatment-response-and-survival2026-10-08 https://evidence-hub.com/study/8498-abstract-p131-individualized-risk-prediction-for-type-2-diabetes-a2026-10-08 https://evidence-hub.com/study/8499-effectiveness-of-glipizide-and-glipizide-plus-metformin-formulation2026-10-08 https://evidence-hub.com/study/8500-pioglitazone-as-add-on-to-metformin-and-dapagliflozin-yields2026-10-08 https://evidence-hub.com/study/8501-secondary-analysis-of-newly-diagnosed-type-2-diabetes-subgroups-and2026-10-08 https://evidence-hub.com/study/8502-efficacy-of-metformin-for-the-treatment-of-melasma-a-systematic2026-10-08 https://evidence-hub.com/study/8503-metformin-use-in-type-2-diabetics-and-delirium-after-noncardiac2026-10-08 https://evidence-hub.com/study/8504-metformin-use-and-preeclampsia-risk-in-women-with-diabetes-a-two2026-10-08 https://evidence-hub.com/study/8505-efficacy-and-safety-of-dpp-4-inhibitors-and-metformin-combinations-in2026-10-08 https://evidence-hub.com/study/8506-evaluation-of-jinlida-granules-in-improvements-to-standard-reaching2026-10-08 https://evidence-hub.com/study/8507-impact-of-metformin-on-outcomes-with-immune-checkpoint-inhibitors-in2026-10-08 https://evidence-hub.com/study/8508-revisiting-metformin-as-a-chemotherapy-adjuvant-a-systematic-review2026-10-08 https://evidence-hub.com/study/8509-effectiveness-of-metformin-in-preventing-type-2-diabetes-in-children2026-10-08 https://evidence-hub.com/study/8510-neoadjuvant-metformin-on-clinical-and-pathological-response-in-non2026-10-08 https://evidence-hub.com/study/8511-comparative-effects-of-acupuncture-and-metformin-on-insulin2026-10-08 https://evidence-hub.com/study/8512-prescription-patterns-and-therapeutic-effects-of-second-line-drugs-in2026-10-08 https://evidence-hub.com/study/8513-maternal-serum-levels-of-prokineticin-1-related-to-pregnancy2026-10-08 https://evidence-hub.com/study/8514-sglt2-inhibition-versus-sulfonylurea-treatment-effects-on-electrolyte2026-10-08 https://evidence-hub.com/study/8515-different-effects-of-metformin-and-insulin-on-primary-and-secondary2026-10-08 https://evidence-hub.com/study/8516-secondary-metformin-monotherapy-failure-in-individuals-with-type-22026-10-08 https://evidence-hub.com/study/8517-characterization-of-changes-in-hba1c-in-patients-with-and-without2026-10-08 https://evidence-hub.com/study/8518-metformin-in-patients-with-covid-19-a-systematic-review-and-meta2026-10-08 https://evidence-hub.com/study/8519-outcomes-of-women-treated-with-progestin-and-metformin-for-atypical2026-10-08 https://evidence-hub.com/study/8520-effectiveness-and-mechanism-of-metformin-in-animal-models-of2026-10-08 https://evidence-hub.com/study/8521-olaparib-combined-to-metronomic-cyclophosphamide-and-metformin-in2026-10-08 https://evidence-hub.com/study/8522-systematic-review-and-meta-analysis-of-coptis-chinensis-franch2026-10-08 https://evidence-hub.com/study/8523-comparison-of-the-effects-on-cardiovascular-events-between-use-of2026-10-08 https://evidence-hub.com/study/8524-effect-and-safety-of-adding-metformin-to-insulin-therapy-in-treating2026-10-08 https://evidence-hub.com/study/8525-the-function-of-metformin-in-endometrial-receptivity-er-of-patients2026-10-08 https://evidence-hub.com/study/8526-efficacy-of-metformin-in-patients-with-breast-cancer-receiving2026-10-08 https://evidence-hub.com/study/8527-effects-of-lifestyle-modification-in-polycystic-ovary-syndrome2026-10-08 https://evidence-hub.com/study/8528-abstract-3482-correlative-analysis-of-metformin-and-nivolumab2026-10-08 https://evidence-hub.com/study/8529-comparative-efficacy-and-safety-of-metformin-glyburide-and-insulin-in2026-10-08 https://evidence-hub.com/study/8530-metformin-treatment-for-patients-with-diabetes-and-chronic-kidney2026-10-08 https://evidence-hub.com/study/8531-glucagon-like-peptide-1-receptor-agonists-and-cardioprotective2026-10-08 https://evidence-hub.com/study/8532-a-randomized-phase-ii-iii-study-of-paclitaxel-carboplatin-metformin2026-10-08 https://evidence-hub.com/study/8533-meta-analysis-the-efficacy-of-metformin-and-other-anti-hyperglycemic2026-10-08 https://evidence-hub.com/study/8534-novel-antidiabetic-drugs-and-risk-of-cardiovascular-events-in2026-10-08 https://evidence-hub.com/study/8535-metformin-dose-increase-versus-added-linagliptin-in-non-alcoholic2026-10-08 https://evidence-hub.com/study/8536-comparison-of-visceral-fat-reduction-by-ipragliflozin-and-metformin2026-10-08 https://evidence-hub.com/study/8537-dose-dependent-relationship-between-long-term-metformin-use-and-the2026-10-08 https://evidence-hub.com/study/8538-composite-cardiovascular-risk-and-bmi-affected-comparative-profiles2026-10-08 https://evidence-hub.com/study/8540-glucagon-like-peptide-1-receptor-agonists-and-cardioprotective2026-10-08 https://evidence-hub.com/study/8541-association-of-metformin-use-with-asthma-exacerbation-in-patients2026-10-08 https://evidence-hub.com/study/8543-metformin-s-impact-on-tumor-regression-grade-in-diabetic-patients2026-10-08 https://evidence-hub.com/study/8544-enhancing-diabetes-treatment-comparing-pioglitazone-metformin-with2026-10-08 https://evidence-hub.com/study/8545-benefits-and-disadvantages-of-combination-therapy-with-imeglimin-and2026-10-08 https://evidence-hub.com/study/8546-variants-in-pharmacokinetic-transporters-and-glycaemic-response-to2026-10-08 https://evidence-hub.com/study/8547-metformin-was-associated-with-lower-all-cause-mortality-in-type-22026-10-08 https://evidence-hub.com/study/8548-fixed-dose-combination-of-dapagliflozin-and-linagliptin-in2026-10-08 https://evidence-hub.com/study/8549-effects-of-metformin-use-on-aneurysmal-subarachnoid-hemorrhage2026-10-08 https://evidence-hub.com/study/8550-abstract-4357554-association-between-metformin-exposure-and-outcomes2026-10-08 https://evidence-hub.com/study/8551-metformin-and-small-for-gestational-age-babies-findings-of-a2026-10-08 https://evidence-hub.com/study/8552-prognostic-significance-of-metformin-treatment-in-endometrial-cancer2026-10-08 https://evidence-hub.com/study/8553-association-between-metformin-use-in-early-gestational-or-type-22026-10-08 https://evidence-hub.com/study/8554-metformin-use-and-incidence-cancer-risk-evidence-for-a-selective2026-10-06 https://evidence-hub.com/study/8555-efficacy-of-acarbose-and-metformin-in-newly-diagnosed-type-2-diabetes2026-10-06 https://evidence-hub.com/study/8556-the-impact-of-metformin-use-on-the-risk-of-prostate-cancer-after2026-10-06 https://evidence-hub.com/study/8557-effect-of-metformin-and-spironolactone-therapy-on-ogtt-in-patients2026-10-06 https://evidence-hub.com/study/8558-metformin-and-the-risk-of-chronic-urticaria-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/8559-decreased-sfrp5-correlated-with-excessive-metabolic-inflammation-in2026-10-06 https://evidence-hub.com/study/8560-metformin-versus-insulin-use-for-treatment-of-gestational-diabetes2026-10-06 https://evidence-hub.com/study/8561-risk-of-metformin-associated-lactic-acidosis-mala-in-patients-after2026-10-08 https://evidence-hub.com/study/8562-adherence-to-metformin-and-the-onset-of-rheumatoid-arthritis-a2026-10-08 https://evidence-hub.com/study/8563-the-effect-of-metformin-on-responses-to-chemotherapy-and-survival-in2026-10-06 https://evidence-hub.com/study/8564-effectiveness-and-long-term-safety-of-thiazolidinediones-and2026-10-06 https://evidence-hub.com/study/8565-stopping-versus-continuing-metformin-in-patients-with-advanced-ckd-a2026-10-06 https://evidence-hub.com/study/8566-progesterone-suppression-of-luteinizing-hormone-pulse-frequency-in2026-10-06 https://evidence-hub.com/study/8567-can-metformin-change-the-prognosis-of-pancreatic-cancer-retrospective2026-10-06 https://evidence-hub.com/study/8568-limitations-of-metformin-use-in-patients-with-kidney-disease-are-they2026-10-06 https://evidence-hub.com/study/8569-efficacy-and-safety-of-metformin-for-treatment-of-type-2-diabetes-in2026-10-06 https://evidence-hub.com/study/8570-treatment-of-type-2-diabetes-mellitus-in-children-and-adolescents2026-10-06 https://evidence-hub.com/study/8571-metformin-use-and-clinical-outcomes-in-very-elderly-patients-with2026-10-06 https://evidence-hub.com/study/8572-metformin-does-not-improve-survival-in-patients-with-hepatocellular2026-10-08 https://evidence-hub.com/study/8573-metformin-use-in-diabetes-prior-to-hospitalization-effects-on2026-10-06 https://evidence-hub.com/study/8574-enhanced-release-of-glucose-into-the-intraluminal-space-of-the2026-10-06 https://evidence-hub.com/study/8575-metformin-use-in-kidney-transplant-recipients-in-the-united-states-an2026-10-06 https://evidence-hub.com/study/8576-postpartum-use-of-weight-loss-and-metformin-for-the-prevention-of2026-10-06 https://evidence-hub.com/study/8577-no-effect-of-metformin-on-ovarian-cancer-survival-a-systematic-review2026-10-06 https://evidence-hub.com/study/8578-risk-of-pre-eclampsia-in-women-taking-metformin-a-systematic-review2026-10-08 https://evidence-hub.com/study/8579-mental-state-and-health-related-quality-of-life-in-patients-with2026-10-06 https://evidence-hub.com/study/8580-organic-cation-transporter-1-variants-and-gastrointestinal-side2026-10-06 https://evidence-hub.com/study/8581-pharmaceutical-clinical-and-immunohistochemical-studies-of-metformin2026-10-06 https://evidence-hub.com/study/8582-a-follow-up-of-a-randomised-study-of-metformin-and-insulin-in2026-10-06 https://evidence-hub.com/study/8583-effect-of-metformin-on-survival-outcomes-in-diabetic-patients-with2026-10-06 https://evidence-hub.com/study/8584-associations-of-metformin-use-history-with-delirium-and-mortality-in2026-10-06 https://evidence-hub.com/study/8585-the-impact-of-metformin-on-plasma-prolactin-levels-in-antipsychotics2026-10-06 https://evidence-hub.com/study/8586-metformin-use-in-patients-hospitalized-with-covid-19-lower2026-10-06 https://evidence-hub.com/study/8587-metformin-usage-and-the-risk-of-colorectal-cancer-a-national-cohort2026-10-08 https://evidence-hub.com/study/8588-metformin-monotherapy-significantly-decreases-epicardial-adipose2026-10-06 https://evidence-hub.com/study/8589-metformin-has-a-positive-therapeutic-effect-on-prostate-cancer-in2026-10-06 https://evidence-hub.com/study/8590-preadmission-metformin-use-is-associated-with-reduced-mortality-in2026-10-06 https://evidence-hub.com/study/8591-the-role-of-circulating-mirnas-in-mechanism-of-action-and-prediction2026-10-06 https://evidence-hub.com/study/8592-the-suggested-chemopreventive-association-of-metformin-with-prostate2026-10-06 https://evidence-hub.com/study/8593-metformin-use-is-associated-with-improved-survival-in-patients2026-10-06 https://evidence-hub.com/study/8594-prognostic-impact-of-metformin-in-diabetic-patients-undergoing-a2026-10-06 https://evidence-hub.com/study/8595-impact-of-metformin-therapy-on-health-related-quality-of-life2026-10-06 https://evidence-hub.com/study/8596-effects-of-metformin-exposure-on-neurodegenerative-diseases-in2026-10-08 https://evidence-hub.com/study/8597-association-of-metformin-treatment-with-changes-in-metal-dynamics-in2026-10-08 https://evidence-hub.com/study/8598-effect-of-metformin-on-outcomes-of-patients-treated-with-immune2026-10-08 https://evidence-hub.com/study/8599-lack-of-effect-of-the-slc47a1-and-slc47a2-gene-polymorphisms-on-the2026-10-06 https://evidence-hub.com/study/8600-predictors-of-metformin-failure-repurposing-electronic-health-record2026-10-06 https://evidence-hub.com/study/8601-long-term-metformin-treatment-and-risk-of-peripheral-neuropathy-in2026-10-06 https://evidence-hub.com/study/8602-metformin-in-combination-with-various-insulin-secretagogues-in-type-22026-10-06 https://evidence-hub.com/study/8603-effects-of-short-term-metformin-administration-on-androgens-in2026-10-06 https://evidence-hub.com/study/8604-outcome-of-severe-lactic-acidosis-associated-with-metformin2026-10-08 https://evidence-hub.com/study/8605-the-use-of-metformin-in-women-with-polycystic-ovary-syndrome-an2026-10-06 https://evidence-hub.com/study/8606-use-of-metformin-and-survival-of-diabetic-women-with-breast-cancer2026-10-08 https://evidence-hub.com/study/8607-the-common-antidiabetic-drug-metformin-reduces-odds-of-developing-age2026-10-08 https://evidence-hub.com/study/8608-association-between-metformin-use-and-risk-of-esophageal-squamous2026-10-08 https://evidence-hub.com/study/8609-metformin-use-and-survival-of-patients-with-pancreatic-cancer-a2026-10-08 https://evidence-hub.com/study/8610-incidence-of-bladder-cancer-in-patients-with-type-2-diabetes-treated2026-10-06 https://evidence-hub.com/study/8611-metformin-use-and-cirrhotic-decompensation-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/8612-kidney-function-decline-in-metformin-versus-sulfonylurea-initiators2026-10-06 https://evidence-hub.com/study/8613-long-term-metformin-use-may-improve-clinical-outcomes-in-diabetic2026-10-06 https://evidence-hub.com/study/8614-differential-cardiovascular-outcomes-after-dipeptidyl-peptidase-42026-10-06 https://evidence-hub.com/study/8615-the-combination-of-dpp-4-inhibitors-versus-sulfonylureas-with2026-10-06 https://evidence-hub.com/study/8616-effectiveness-of-vildagliptin-as-add-on-to-metformin-monotherapy2026-10-06 https://evidence-hub.com/study/8617-effect-of-metformin-in-diabetic-patients-after-treatment-of2026-10-06 https://evidence-hub.com/study/8618-metformin-is-associated-with-reduced-covid-19-severity-in-patients2026-10-06 https://evidence-hub.com/study/8619-metformin-use-in-elderly-population-with-diabetes-reduced-the-risk-of2026-10-06 https://evidence-hub.com/study/8620-pharmacogenetic-predictors-of-metformin-response-in-metabolic2026-10-06 https://evidence-hub.com/study/8621-comparison-of-acarbose-and-metformin-therapy-in-newly-diagnosed-type2026-10-06 https://evidence-hub.com/study/8622-the-efficacy-of-different-insulin-sensitizing-agents-on-treatment2026-10-06 https://evidence-hub.com/study/8623-the-effect-of-metformin-on-esophageal-cancer-risk-in-patients-with2026-10-08 https://evidence-hub.com/study/8624-relationship-between-type-2-diabetes-and-use-of-metformin-with-risk2026-10-06 https://evidence-hub.com/study/8625-metformin-use-and-mortality-in-asian-diabetic-patients-with-prostate2026-10-06 https://evidence-hub.com/study/8626-metformin-reduces-ovarian-cancer-risk-in-taiwanese-women-with-type-22026-10-06 https://evidence-hub.com/study/8627-metformin-and-risk-of-gingival-periodontal-diseases-in-diabetes2026-10-08 https://evidence-hub.com/study/8628-cost-effectiveness-analysis-of-polycystic-ovary-syndrome-management2026-10-06 https://evidence-hub.com/study/8629-predictors-of-hba1c-levels-in-patients-initiating-metformin2026-10-06 https://evidence-hub.com/study/8630-association-between-metformin-use-and-reduced-short-and-long-term-all2026-10-06 https://evidence-hub.com/study/8631-exploring-the-protective-effect-of-metformin-against-sarcopenia2026-10-08 https://evidence-hub.com/study/8632-impact-of-metformin-use-on-clinical-and-pathological-outcomes-in2026-10-06 https://evidence-hub.com/study/8633-safety-of-anagliptin-metformin-combination-tablets-evaluated-by-non2026-10-06 https://evidence-hub.com/study/8634-risk-of-acute-kidney-injury-and-survival-in-patients-treated-with2026-10-08 https://evidence-hub.com/study/8635-use-of-antidiabetic-agents-in-the-treatment-of-gestational-diabetes2026-10-06 https://evidence-hub.com/study/8636-glycaemic-control-and-cost-analysis-when-changing-from-gliclazide-co2026-10-06 https://evidence-hub.com/study/8637-clinical-effects-of-metformin-in-patients-with-polcystic-ovarian2026-10-06 https://evidence-hub.com/study/8638-the-impact-of-metformin-on-kidney-disease-progression-and-mortality2026-10-08 https://evidence-hub.com/study/8639-impact-of-metformin-on-cardiovascular-and-kidney-outcome-based-on2026-10-08 https://evidence-hub.com/study/8641-metformin-use-correlated-with-lower-risk-of-cardiometabolic-diseases2026-10-08 https://evidence-hub.com/study/8642-paternal-metformin-use-and-risk-of-congenital-malformations-in2026-10-08 https://evidence-hub.com/study/8643-prevalent-metformin-use-in-adults-with-diabetes-and-the-incidence-of2026-10-08 https://evidence-hub.com/study/8645-effect-of-metformin-on-hepatocellular-carcinoma-patients-with-type-ii2026-10-08 https://evidence-hub.com/study/8646-sodium-glucose-transporter-2-inhibitors-versus-metformin-on2026-10-08 https://evidence-hub.com/study/8647-incident-dementia-risk-among-patients-with-type-2-diabetes-receiving2026-10-08 https://evidence-hub.com/study/8648-metformin-s-role-in-lowering-colorectal-cancer-risk-among-individuals2026-10-08 https://evidence-hub.com/study/8649-relationship-between-metformin-use-and-mortality-in-tuberculosis2026-10-08 https://evidence-hub.com/study/8651-metformin-use-and-survival-in-people-with-ovarian-cancer-a-population2026-10-08 https://evidence-hub.com/study/8652-metformin-versus-insulin-and-risk-of-major-congenital-malformations2026-10-08 https://evidence-hub.com/study/8653-metformin-treatment-is-associated-with-reduced-risk-of-hypoglycaemia2026-10-08 https://evidence-hub.com/study/8654-low-dose-aspirin-statins-and-metformin-and-survival-in-patients-with2026-10-08 https://evidence-hub.com/study/8655-diabetes-metformin-use-and-survival-in-esophageal-cancer-a-population2026-10-08 https://evidence-hub.com/study/8656-metformin-adherence-reduces-the-risk-of-dementia-in-patients-with2026-10-08 https://evidence-hub.com/study/8657-metformin-reduces-the-risk-of-hearing-loss-a-retrospective-cohort2026-10-08 https://evidence-hub.com/study/8658-the-impact-of-metformin-on-survival-in-diabetes-patients-with2026-10-08 https://evidence-hub.com/study/8659-metformin-in-pregnancy-and-risk-of-adverse-long-term-outcomes-a2026-10-08 https://evidence-hub.com/study/8660-metformin-adherence-and-the-risk-of-cardiovascular-disease-a2026-10-08 https://evidence-hub.com/study/8661-a-multicenter-cohort-study-on-the-association-between-metformin-use2026-10-08 https://evidence-hub.com/study/8662-use-of-metformin-and-insulin-among-pregnant-women-with-gestation2026-10-08 https://evidence-hub.com/study/8663-metformin-in-pregnancy-and-risk-of-abnormal-growth-outcomes-at-birth2026-10-08 https://evidence-hub.com/study/8664-risk-of-genital-and-urinary-tract-infections-associated-with-sglt-22026-10-08 https://evidence-hub.com/study/8665-metformin-and-risk-of-age-related-macular-degeneration-in-individuals2026-10-08 https://evidence-hub.com/study/8666-sulfonylurea-is-associated-with-higher-risks-of-ventricular2026-10-08 https://evidence-hub.com/study/8668-a-prospective-cohort-study-of-metformin-as-an-adjuvant-therapy-for2026-10-08 https://evidence-hub.com/study/8669-clinical-outcomes-following-discontinuation-of-metformin-in-patients2026-10-08 https://evidence-hub.com/study/8670-metformin-use-was-associated-with-reduced-risk-of-incidental-sjogren2026-10-08 https://evidence-hub.com/study/8671-the-association-between-antipsychotics-and-weight-gain-and-the2026-10-08 https://evidence-hub.com/study/8672-metformin-use-and-the-risk-of-total-knee-replacement-among-diabetic2026-10-08 https://evidence-hub.com/study/8673-correlation-between-long-term-use-of-metformin-and-incidence-of-nafld2026-10-08 https://evidence-hub.com/study/8674-effect-of-metformin-use-on-clinical-outcomes-and-serum-urate-in-gout2026-10-08 https://evidence-hub.com/study/8675-prognostic-relevance-of-type-2-diabetes-and-metformin-treatment-in2026-10-08 https://evidence-hub.com/study/8676-the-potential-benefit-of-metformin-to-reduce-delirium-risk-and2026-10-08 https://evidence-hub.com/study/8677-metformin-use-and-associated-risk-of-total-joint-replacement-in2026-10-08 https://evidence-hub.com/study/8678-metformin-for-the-prevention-of-clozapine-induced-weight-gain-a2026-10-08 https://evidence-hub.com/study/8680-metformin-increases-survival-in-hypopharyngeal-cancer-patients-with2026-10-08 https://evidence-hub.com/study/8681-metformin-s-effects-on-varicocele-erectile-dysfunction-infertility2026-10-08 https://evidence-hub.com/study/8682-patients-with-obesity-and-a-history-of-metformin-treatment-have-lower2026-10-08 https://evidence-hub.com/study/8684-metformin-use-and-risk-of-covid-19-among-patients-with-type-ii2026-10-08 https://evidence-hub.com/study/8685-the-risk-of-multiple-myeloma-is-reduced-in-metformin-initiators-a2026-10-08 https://evidence-hub.com/study/8686-impact-of-metformin-on-survival-outcome-in-ovarian-cancer-a2026-10-08 https://evidence-hub.com/study/8688-association-of-aspirin-metformin-and-statin-use-with-gastric-cancer2026-10-08 https://evidence-hub.com/study/8689-hospitalization-for-heart-failure-among-patients-with-diabetes2026-10-08 https://evidence-hub.com/study/8691-a-safety-comparison-of-metformin-vs-sulfonylurea-initiation-in2026-10-08 https://evidence-hub.com/study/8692-association-of-metformin-with-mortality-or-ards-in-patients-with2026-10-08 https://evidence-hub.com/study/8693-association-between-metformin-use-and-disease-progression-in-obese2026-10-08 https://evidence-hub.com/study/8694-metformin-reduces-the-increased-risk-of-oral-squamous-cell-carcinoma2026-10-08 https://evidence-hub.com/study/8695-prognostic-impact-of-elevated-lactate-levels-on-mortality-in2026-10-08 https://evidence-hub.com/study/8696-metformin-treated-gdm-has-lower-risk-of-macrosomia-compared-to-diet2026-10-08 https://evidence-hub.com/study/8697-risk-of-dementia-after-initiation-of-sodium-glucose-cotransporter-22026-10-08 https://evidence-hub.com/study/8698-metformin-use-and-cardiovascular-outcomes-in-patients-with-diabetes2026-10-08 https://evidence-hub.com/study/8699-association-of-metformin-initiation-and-risk-of-asthma-exacerbation-a2026-10-08 https://evidence-hub.com/study/8700-altered-glycemic-control-associated-with-polymorphisms-in-the-slc22a12026-10-08 https://evidence-hub.com/study/8701-metformin-treatment-is-associated-with-a-decreased-risk-of2026-10-08 https://evidence-hub.com/study/8702-metformin-use-and-cardiovascular-outcomes-after-acute-myocardial2026-10-08 https://evidence-hub.com/study/8703-metformin-reduces-prostate-cancer-risk-among-men-with-benign2026-10-08 https://evidence-hub.com/study/8704-metformin-therapy-and-hip-fracture-risk-among-patients-with-type-ii2026-10-08 https://evidence-hub.com/study/8705-metformin-use-and-the-risk-of-cancer-in-patients-with-diabetes-a2026-10-08 https://evidence-hub.com/study/8706-metformin-use-and-risk-of-gastric-adenocarcinoma-in-a-swedish2026-10-08 https://evidence-hub.com/study/8707-safety-of-metformin-in-psoriasis-patients-with-diabetes-mellitus-a-172026-10-08 https://evidence-hub.com/study/8708-effect-of-metformin-monotherapy-on-serum-lipid-profile-in-statin2026-10-08 https://evidence-hub.com/study/8709-association-of-metformin-use-with-risk-of-lactic-acidosis-across-the2026-10-08 https://evidence-hub.com/study/8710-metformin-reduces-12-month-change-in-body-weight-among-people-newly2026-10-08 https://evidence-hub.com/study/8711-metformin-induced-weight-loss-in-patients-with-or-without-type-22026-10-08 https://evidence-hub.com/study/8712-metformin-use-and-risk-of-cancer-in-patients-with-type-2-diabetes-a2026-10-08 https://evidence-hub.com/study/8713-impact-of-metformin-on-disease-control-and-survival-in-patients-with2026-10-08 https://evidence-hub.com/study/8714-outcomes-after-surgery-in-patients-with-diabetes-who-used-metformin-a2026-10-08 https://evidence-hub.com/study/8715-a-cohort-study-of-metformin-and-colorectal-cancer-risk-among-patients2026-10-08 https://evidence-hub.com/study/8716-the-impact-of-metformin-on-survival-in-patients-with-melanoma2026-10-08 https://evidence-hub.com/study/8718-postdiagnostic-metformin-use-and-survival-of-patients-with-colorectal2026-10-08 https://evidence-hub.com/study/8719-metformin-adherence-and-discontinuation-among-patients-with-type-22026-10-08 https://evidence-hub.com/study/8721-metformin-use-is-associated-with-a-low-risk-of-tuberculosis-among2026-10-08 https://evidence-hub.com/study/8722-dipeptidyl-peptidase-4-inhibitor-compared-with-sulfonylurea-in2026-10-08 https://evidence-hub.com/study/8723-association-between-metformin-use-on-admission-and-outcomes-in2026-10-08 https://evidence-hub.com/study/8724-metformin-increases-cancer-specific-survival-in-colorectal-cancer2026-10-08 https://evidence-hub.com/study/8725-metformin-attenuates-osteoporosis-in-diabetic-patients-with-carcinoma2026-10-08 https://evidence-hub.com/study/8728-combination-cox-2-inhibitor-and-metformin-attenuate-rate-of-joint2026-10-06 https://evidence-hub.com/study/8729-impact-of-metformin-use-on-the-cardiovascular-effects-of-dipeptidyl2026-10-06 https://evidence-hub.com/study/8730-the-use-of-metformin-and-the-incidence-of-lung-cancer-in-patients2026-10-06 https://evidence-hub.com/study/8731-database-evaluation-of-the-effects-of-long-term-rosiglitazone2026-10-06 https://evidence-hub.com/study/8732-effects-of-diabetes-mellitus-and-metformin-administration-on-prostate2026-10-08 https://evidence-hub.com/study/8733-metformin-for-non-small-cell-lung-cancer-patients-opportunities-and2026-10-06 https://evidence-hub.com/study/8734-the-use-of-metformin-in-patients-with-prostate-cancer-and-the-risk-of2026-10-06 https://evidence-hub.com/study/8735-the-anti-atherogenic-aspect-of-metformin-treatment-in-insulin2026-10-06 https://evidence-hub.com/study/8736-glycemic-control-with-metformin-or-insulin-therapy-in-adolescents2026-10-06 https://evidence-hub.com/study/8737-effect-of-continuous-use-of-metformin-on-kidney-function-in-diabetes2026-10-06 https://evidence-hub.com/study/8738-association-between-metformin-initiation-and-incident-dementia-among2026-10-06 https://evidence-hub.com/study/8739-impact-of-the-mhra-safety-update-on-vitamin-b12-testing-and-coding-in2026-10-06 https://evidence-hub.com/study/8740-metformin-use-and-prostate-cancer-risk2026-10-06 https://evidence-hub.com/study/8741-gout-incidence-in-metformin-versus-sodium-glucose-co-transporter-22026-10-06 https://evidence-hub.com/study/8742-metformin-decreases-bone-turnover-markers-in-polycystic-ovary2026-10-06 https://evidence-hub.com/study/8743-phase-i-ii-trial-of-metformin-as-a-chemo-radiosensitizer-in-a-head2026-10-06 https://evidence-hub.com/study/8744-epidemiology-of-lactic-acidosis-in-type-2-diabetes-patients-with2026-10-06 https://evidence-hub.com/study/8745-no-reduced-risk-of-overall-colorectal-lung-breast-and-prostate-cancer2026-10-06 https://evidence-hub.com/study/8746-metformin-and-the-risk-of-endometrial-cancer-a-population-based2026-10-06 https://evidence-hub.com/study/8747-relationship-between-metformin-and-frailty-syndrome-in-elderly-people2026-10-06 https://evidence-hub.com/study/8748-patient-compliance-and-persistence-with-anti-hyperglycemic-therapy2026-10-06 https://evidence-hub.com/study/8749-metformin-is-associated-with-decreased-skin-cancer-risk-in-taiwanese2026-10-06 https://evidence-hub.com/study/8750-effectiveness-of-metformin-pretreatment-for-stroke-severity-a2026-10-06 https://evidence-hub.com/study/8751-efficacy-and-safety-of-replacing-sitagliptin-with-canagliflozin-in2026-10-06 https://evidence-hub.com/study/8752-secondary-failure-of-glycemic-control-for-patients-adding2026-10-06 https://evidence-hub.com/study/8753-association-of-metformin-use-and-survival-in-patients-with-cutaneous2026-10-06 https://evidence-hub.com/study/8754-stacked-classifiers-for-individualized-prediction-of-glycemic-control2026-10-06 https://evidence-hub.com/study/8755-metformin-influences-progression-in-diabetic-glioblastoma-patients2026-10-08 https://evidence-hub.com/study/8756-evaluation-approach-can-significantly-influence-oral-glucose-lowering2026-10-06 https://evidence-hub.com/study/8757-chronic-pretreatment-of-metformin-is-associated-with-the-reduction-of2026-10-06 https://evidence-hub.com/study/8758-risk-of-mortality-and-adverse-cardiovascular-outcomes-in-type-22026-10-01 https://evidence-hub.com/study/8759-metformin-intake-and-risk-of-metabolic-acidosis-after-radical2026-10-06 https://evidence-hub.com/study/8760-renal-protective-effect-of-metformin-in-type-2-diabetes-patients2026-10-06 https://evidence-hub.com/study/8761-positive-effect-of-metformin-treatment-in-colorectal-cancer-patients2026-10-06 https://evidence-hub.com/study/8762-use-of-oral-antidiabetic-agents-and-risk-of-community-acquired2026-10-08 https://evidence-hub.com/study/8763-statin-and-metformin-use-prolongs-survival-in-patients-with2026-10-06 https://evidence-hub.com/study/8764-use-of-metformin-and-vildagliptin-for-treatment-of-type-2-diabetes-in2026-10-06 https://evidence-hub.com/study/8765-metformin-induced-thyrotropin-suppression-is-not-associated-with2026-10-06 https://evidence-hub.com/study/8766-the-length-of-hospital-stay-in-covid-19-patients-using-pre-hospital2026-10-06 https://evidence-hub.com/study/8767-metformin-use-is-associated-with-a-decrease-in-the-risk-of2026-10-06 https://evidence-hub.com/study/8768-safety-of-add-on-sulfonylurea-therapy-in-patients-with-type-22026-10-08 https://evidence-hub.com/study/8769-effects-of-pioglitazone-add-on-to-gliclazide-and-metformin-on2026-10-06 https://evidence-hub.com/study/8770-impact-of-metformin-use-on-survival-outcomes-in-non-small-cell-lung2026-10-06 https://evidence-hub.com/study/8771-incident-infection-risks-depending-on-oral-antidiabetic-exposure-in2026-10-06 https://evidence-hub.com/study/8772-contraindications-to-metformin-therapy-in-patients-with-niddm2026-10-08 https://evidence-hub.com/study/8773-effect-of-metformin-therapy-on-vitamin-d-and-vitamin-b12-levels-in2026-10-06 https://evidence-hub.com/study/8774-metformin-treatment-is-associated-with-an-increase-in-bone-mineral2026-10-06 https://evidence-hub.com/study/8775-effects-of-metformin-on-clinical-outcome-in-diabetic-patients-with2026-10-06 https://evidence-hub.com/study/8776-evaluation-of-metformin-for-epilepsy-prevention-or-seizure-control-in2026-10-08 https://evidence-hub.com/study/8777-a-randomized-phase-2-study-of-bicalutamide-with-or-without-metformin2026-10-06 https://evidence-hub.com/study/8778-the-long-term-effects-of-metformin-on-patients-with-type-2-diabetic2026-10-08 https://evidence-hub.com/study/8779-metformin-relieves-h-r-induced-cardiomyocyte-injury-through-mir-19a2026-10-06 https://evidence-hub.com/study/8780-metformin-use-reverses-the-increased-mortality-associated-with2026-10-06 https://evidence-hub.com/study/8781-effect-of-metformin-by-employing-2-hour-postload-insulin-for2026-10-06 https://evidence-hub.com/study/8782-results-of-the-adequacy-of-glycemic-control-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/8783-comparative-safety-of-sulfonylurea-and-metformin-monotherapy-on-the2026-10-06 https://evidence-hub.com/study/8784-clinical-impact-of-metformin-therapy-on-gestational-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/8785-association-of-metformin-with-the-growth-of-vestibular-schwannomas2026-10-08 https://evidence-hub.com/study/8786-diabetes-mellitus-and-metformin-are-not-associated-with-breast-cancer2026-10-06 https://evidence-hub.com/study/8787-metformin-is-not-associated-with-lactic-acidosis-in-patients-with2026-10-08 https://evidence-hub.com/study/8788-metformin-is-associated-with-a-lower-risk-of-colorectal-cancer-in2026-10-06 https://evidence-hub.com/study/8789-metformin-and-endometrial-cancer-risk-in-chinese-women-with-type-22026-10-06 https://evidence-hub.com/study/8790-the-effects-of-metformin-on-cisplatin-induced-ototoxicity-in-diabetic2026-10-06 https://evidence-hub.com/study/8791-kidney-outcomes-with-sglt2is-for-type-2-diabetes-patients-does2026-10-06 https://evidence-hub.com/study/8792-metformin-and-cervical-cancer-risk-in-patients-with-newly-diagnosed2026-10-06 https://evidence-hub.com/study/8793-is-there-an-association-between-metformin-use-and-clinical-outcomes2026-10-06 https://evidence-hub.com/study/8794-gdf-15-as-a-weight-watcher-for-diabetic-and-non-diabetic-people2026-10-06 https://evidence-hub.com/study/8795-protective-effect-of-metformin-against-tuberculosis-infections-in2026-10-06 https://evidence-hub.com/study/8796-metformin-and-risk-of-alzheimer-s-disease-among-community-dwelling2026-10-08 https://evidence-hub.com/study/8797-managing-glycaemia-in-older-people-with-type-2-diabetes-a2026-10-06 https://evidence-hub.com/study/8798-risk-of-death-and-heart-failure-among-patients-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/8799-recent-metformin-adherence-and-the-risk-of-hypoglycaemia-in-the-year2026-10-06 https://evidence-hub.com/study/8800-effect-of-metformin-on-the-expression-of-tumor-necrosis-factor-toll2026-10-06 https://evidence-hub.com/study/8801-clinical-retrospective-analysis-of-metformin-on-tsh-levels-and-nodule2026-10-06 https://evidence-hub.com/study/8802-effects-of-slc22a2-rs201919874-and-slc47a2-rs138244461-genetic2026-10-06 https://evidence-hub.com/study/8803-metformin-use-associated-with-lower-rate-of-hospitalization-for2026-10-06 https://evidence-hub.com/study/8804-effect-of-metformin-in-the-prognosis-of-patients-with-smallcell-lung2026-10-06 https://evidence-hub.com/study/8805-metformin-use-and-risk-of-non-melanoma-skin-cancer-a-propensity2026-10-08 https://evidence-hub.com/study/8806-metformin-use-and-risk-of-myeloproliferative-neoplasms-a-danish2026-10-08 https://evidence-hub.com/study/8807-metformin-reduces-new-onset-atrial-fibrillation-risk-rather-than2026-10-08 https://evidence-hub.com/study/8808-association-of-metformin-and-other-diabetes-medication-use-and-the2026-10-08 https://evidence-hub.com/study/8809-the-use-of-metformin-in-overactive-bladder-a-retrospective-nested2026-10-08 https://evidence-hub.com/study/8810-association-of-metformin-use-with-age-related-macular-degeneration-a2026-10-08 https://evidence-hub.com/study/8811-association-of-metformin-use-with-alzheimer-s-disease-in-patients2026-10-08 https://evidence-hub.com/study/8812-the-effect-of-metformin-treatment-on-leukocyte-telomere-length-in2026-10-08 https://evidence-hub.com/study/8813-metformin-as-a-potential-agent-for-modulating-the-faulty2026-10-08 https://evidence-hub.com/study/8814-metformin-is-associated-with-decreased-risk-of-basal-cell-carcinoma-a2026-10-08 https://evidence-hub.com/study/8815-metformin-and-risk-of-alzheimer-s-disease-among-community-dwelling2026-10-08 https://evidence-hub.com/study/8816-metformin-exposure-in-first-trimester-of-pregnancy-and-risk-of-all-or2026-10-08 https://evidence-hub.com/study/8817-acupuncture-or-metformin-to-improve-insulin-resistance-in-women-with2026-10-08 https://evidence-hub.com/study/8818-risk-of-lactic-acidosis-in-type-2-diabetes-patients-using-metformin-a2026-10-08 https://evidence-hub.com/study/8819-metformin-is-the-key-factor-in-elevated-plasma-growth-differentiation2026-10-08 https://evidence-hub.com/study/8820-lactic-acidosis-associated-with-metformin-in-patients-with-moderate2026-10-08 https://evidence-hub.com/study/8822-metformin-other-antidiabetic-drugs-and-endometrial-cancer-risk-a2026-10-08 https://evidence-hub.com/study/8823-outcomes-for-women-with-gestational-diabetes-treated-with-metformin-a2026-10-08 https://evidence-hub.com/study/8826-the-role-of-metformin-in-tuberculosis-control-among-tb-and-diabetes2026-10-08 https://evidence-hub.com/study/8828-association-between-stroke-risk-and-metformin-use-in-hemodialysis2026-10-08 https://evidence-hub.com/study/8829-the-effects-of-exenatide-and-metformin-on-endothelial-function-in2026-10-08 https://evidence-hub.com/study/8830-metformin-is-associated-with-increase-in-lactate-level-in-elderly2026-10-08 https://evidence-hub.com/study/8832-lactic-acidosis-in-diabetic-population-is-metformin-implicated2026-10-08 https://evidence-hub.com/study/8833-metformin-sustained-release-and-vildagliptin-fixed-dose-combination2026-10-08 https://evidence-hub.com/study/8834-no-evidence-for-a-decreased-risk-of-thyroid-cancer-in-association2026-10-08 https://evidence-hub.com/study/8836-case-control-study-of-second-line-therapies-for-type-2-diabetes-in2026-10-08 https://evidence-hub.com/study/8837-diabetes-antidiabetic-medications-and-risk-of-depression-a-population2026-10-08 https://evidence-hub.com/study/8840-metformin-for-primary-colorectal-cancer-prevention-in-diabetic2026-10-08 https://evidence-hub.com/study/8841-long-term-use-of-metformin-and-colorectal-cancer-risk-in-type-ii2026-10-08 https://evidence-hub.com/study/8842-clinical-outcomes-following-a-change-in-gestational-diabetes-mellitus2026-10-08 https://evidence-hub.com/study/8843-metformin-monotherapy-alters-the-human-plasma-lipidome-independent-of2026-10-08 https://evidence-hub.com/study/8844-metformin-use-among-type-2-diabetics-and-risk-of-pancreatic-cancer-in2026-10-08 https://evidence-hub.com/study/8845-influence-of-metformin-dose-and-treatment-adherence-on-glycemic2026-10-08 https://evidence-hub.com/study/8847-combination-therapies-with-thiazolidinediones-are-associated-with-a2026-10-08 https://evidence-hub.com/study/8849-prevalence-of-vitamin-b12-deficiency-in-patients-of-type-2-diabetes2026-10-08 https://evidence-hub.com/study/8851-metformin-toxicity-a-meta-summary-of-case-reports2026-10-08 https://evidence-hub.com/study/8852-antidiabetic-medication-and-risk-of-dementia-in-patients-with-type-22026-10-08 https://evidence-hub.com/study/8853-case-report-late-onset-mitochondrial-disease-uncovered-by-metformin2026-10-08 https://evidence-hub.com/study/8855-metformin-and-the-incidence-of-cancer-in-patients-with-diabetes-a2026-10-08 https://evidence-hub.com/study/8856-hypoglycemia-induced-basal-ganglia-infarct-a-rare-case-of-metformin2026-10-08 https://evidence-hub.com/study/8859-an-unusual-association-between-metformin-and-nightmares-a-case-report2026-10-08 https://evidence-hub.com/study/8861-optimized-in-silico-modeling-of-drug-absorption-after-gastric-bypass2026-10-08 https://evidence-hub.com/study/8862-plasma-adiponectin-levels-in-women-with-polycystic-ovary-syndrome2026-10-08 https://evidence-hub.com/study/8864-impact-of-thioctic-acid-on-glycemic-indices-and-associated2026-10-08 https://evidence-hub.com/study/8865-antidiabetic-treatment-level-of-glycemic-control-and-risk-of-fracture2026-10-08 https://evidence-hub.com/study/8866-role-of-pck1-gene-on-oil-tea-induced-glucose-homeostasis-and-type-22026-10-08 https://evidence-hub.com/study/8869-association-of-type-2-diabetes-mellitus-and-antidiabetic-medication2026-10-08 https://evidence-hub.com/study/8870-increased-f-18-fdg-intestinal-uptake-in-diabetic-patients-on2026-10-08 https://evidence-hub.com/study/8873-metformin-use-and-prostate-cancer-in-caucasian-men-results-from-a2026-10-08 https://evidence-hub.com/study/8874-oral-diabetes-medications-other-than-dipeptidyl-peptidase-42026-10-08 https://evidence-hub.com/study/8875-inverse-association-between-glucose-lowering-medications-and-severe2026-10-08 https://evidence-hub.com/study/8880-differences-in-risk-factors-of-malignancy-between-men-and-women-with2026-10-08 https://evidence-hub.com/study/8881-high-circulating-plasma-dipeptidyl-peptidase-4-levels-in-non-obese2026-10-08 https://evidence-hub.com/study/8882-association-between-use-of-oral-antidiabetic-drugs-and-the-risk-of2026-10-08 https://evidence-hub.com/study/8883-safe-use-of-metformin-in-mitochondrial-diabetes-in-mitochondrial2026-10-08 https://evidence-hub.com/study/8884-the-association-between-metformin-use-and-new-onset-icd-coding-of2026-10-08 https://evidence-hub.com/study/8886-remission-of-bulimia-nervosa-observed-during-administration-of2026-10-08 https://evidence-hub.com/study/8887-metformin-use-is-associated-with-reduced-mortality-risk-in-diabetic2026-10-08 https://evidence-hub.com/study/8888-metformin-modifies-plasma-microbial-derived-extracellular-vesicles-in2026-10-08 https://evidence-hub.com/study/8890-metformin-in-elderly-type-2-diabetes-mellitus-dose-dependent-dementia2026-10-08 https://evidence-hub.com/study/8891-association-between-use-of-oral-anti-diabetic-drugs-and-the-risk-of2026-10-08 https://evidence-hub.com/study/8892-metformin-use-and-age-related-macular-degeneration-in-patients2026-10-08 https://evidence-hub.com/study/8893-the-relationship-between-metformin-consumption-and-cancer-risk-an2026-10-08 https://evidence-hub.com/study/8894-metformin-treatment-of-hidradenitis-suppurativa-effect-on-metabolic2026-10-06 https://evidence-hub.com/study/8895-analysis-of-english-general-practice-level-data-linking-medication2026-10-06 https://evidence-hub.com/study/8896-factors-associated-with-early-onset-androgenetic-alopecia-a-scoping2026-10-08 https://evidence-hub.com/study/8897-type-2-diabetes-mellitus-accelerates-brain-aging-and-cognitive2026-10-08 https://evidence-hub.com/study/8898-assessment-of-knowledge-regarding-prediabetes-among-a-sample-of2026-10-08 https://evidence-hub.com/study/8899-increases-in-circulating-and-fecal-butyrate-are-associated-with2026-10-06 https://evidence-hub.com/study/8900-prescription-pattern-glycemic-control-status-and-predictors-of-poor2026-10-06 https://evidence-hub.com/study/8901-the-association-of-diabetes-mellitus-and-insulin-treatment-with2026-10-06 https://evidence-hub.com/study/8902-metabolic-health-in-people-living-with-type-1-diabetes-in-belgium-a2026-10-06 https://evidence-hub.com/study/8903-evaluation-of-orthostatic-hypotension-frequency-and-associated2026-10-08 https://evidence-hub.com/study/8904-patterns-of-prescribing-sodium-glucose-cotransporter-2-inhibitors-for2026-10-08 https://evidence-hub.com/study/8905-serum-homocysteine-level-and-severity-of-coronavirus-disease-20192026-10-08 https://evidence-hub.com/study/8906-ogtt-glucose-response-curves-insulin-sensitivity-and-cell-function-in2026-10-06 https://evidence-hub.com/study/8907-screening-for-insulin-resistance-in-polycystic-ovary-syndrome-views2026-10-08 https://evidence-hub.com/study/8908-risk-factors-for-sarcopenia-in-the-elderly-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/8909-effect-of-metformin-and-metformin-linagliptin-on-gut-microbiota-in2026-10-08 https://evidence-hub.com/study/8910-the-metabolic-syndrome-and-schizophrenia2026-10-08 https://evidence-hub.com/study/8911-use-of-diabetes-medications-in-traditional-medicare-and-medicare2026-10-08 https://evidence-hub.com/study/8912-glycaemic-control-in-native-kuwaiti-arab-patients-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/8913-resistance-training-modulates-the-humoral-inflammatory-but-not-the2026-10-06 https://evidence-hub.com/study/8914-potentially-inappropriately-prescribed-medications-among-medicare2026-10-08 https://evidence-hub.com/study/8915-gestational-diabetes-mellitus-prevalence-screening-and-treatment2026-10-08 https://evidence-hub.com/study/8916-cost-effectiveness-analysis-of-intensive-blood-glucose-control-with2026-10-06 https://evidence-hub.com/study/8917-the-impact-of-glycosylated-hemoglobin-target-value-in-treatment2026-10-08 https://evidence-hub.com/study/8918-associations-between-antidiabetic-medications-and-cerebrospinal-fluid2026-10-06 https://evidence-hub.com/study/8919-tb-infection-in-adults-with-diabetes-mellitus-in-uganda2026-10-06 https://evidence-hub.com/study/8920-analysis-of-antidiabetic-therapy-for-type-2-diabetes-in-primary2026-10-06 https://evidence-hub.com/study/8921-metformin-treatment-and-gastrointestinal-symptoms-in-youth-findings2026-10-08 https://evidence-hub.com/study/8922-diagnosis-rates-therapeutic-characteristics-lifestyle-and-cancer2026-10-06 https://evidence-hub.com/study/8923-prescription-of-oral-antidiabetics-in-mexico-a-cross-sectional-study2026-10-08 https://evidence-hub.com/study/8924-polycystic-ovary-syndrome-and-obesity-a-cross-sectional-survey-of2026-10-08 https://evidence-hub.com/study/8925-china-type-2-diabetes-treatment-status-survey-of-treatment-pattern-of2026-10-08 https://evidence-hub.com/study/8926-severe-hypoglycemia-is-associated-with-antidiabetic-oral-treatment2026-10-06 https://evidence-hub.com/study/8927-coronary-artery-calcium-and-cognitive-decline-in-the-diabetes2026-10-08 https://evidence-hub.com/study/8928-profiling-of-circulating-micrornas-reveals-common-micrornas-linked-to2026-10-08 https://evidence-hub.com/study/8929-repurposing-sglt2-and-dpp-4-inhibitors-for-mild-cognitive-impairment2026-10-06 https://evidence-hub.com/study/8930-metformin-use-and-respiratory-outcomes-in-asthma-copd-overlap2026-10-08 https://evidence-hub.com/study/8931-prevalence-of-insulin-resistance-in-adults-living-with-hiv2026-10-06 https://evidence-hub.com/study/8932-latent-tuberculosis-in-patients-with-diabetes-mellitus-prevalence2026-10-06 https://evidence-hub.com/study/8933-risk-factors-associated-with-diabetic-neuropathy-in-mexican-patients2026-10-06 https://evidence-hub.com/study/8934-independent-and-joint-cross-sectional-associations-of-statin-and2026-10-06 https://evidence-hub.com/study/8935-correlation-of-serum-thyrotropin-and-thyroid-hormone-levels-with2026-10-08 https://evidence-hub.com/study/8936-differences-in-national-diabetes-treatment-patterns-and-trends2026-10-06 https://evidence-hub.com/study/8937-trends-in-self-reported-prediabetes-and-metformin-use-in-the-usa2026-10-08 https://evidence-hub.com/study/8938-relationship-between-ethnicity-and-glycemic-control-lipid-profiles2026-10-06 https://evidence-hub.com/study/8939-assessment-of-knowledge-attitude-and-practice-of-obstetricians-and2026-10-08 https://evidence-hub.com/study/8940-study-of-diversity-of-metformin-related-gastrointestinal-side-effects2026-10-06 https://evidence-hub.com/study/8941-drug-utilization-pattern-among-type-ii-diabetic-patients-in-palestine2026-10-08 https://evidence-hub.com/study/8942-clinical-pharmacology-profile-of-care-in-hepatology-clinic2026-10-08 https://evidence-hub.com/study/8943-clinical-characteristics-and-risk-of-diabetic-complications-in-data2026-10-06 https://evidence-hub.com/study/8944-effectiveness-and-clinical-inertia-in-patients-with-antidiabetic2026-10-08 https://evidence-hub.com/study/8945-the-gut-microbiome-and-type-2-diabetes-status-in-the-multiethnic2026-10-08 https://evidence-hub.com/study/8946-factors-associated-with-severe-lower-extremity-artery-disease-in-type2026-10-06 https://evidence-hub.com/study/8947-a-retrospective-cross-sectional-study-of-type-2-diabetes2026-10-06 https://evidence-hub.com/study/8948-reduced-mortality-from-lower-respiratory-tract-disease-in-adult2026-10-08 https://evidence-hub.com/study/8949-the-association-between-bullous-pemphigoid-and-comorbidities-a-case2026-10-06 https://evidence-hub.com/study/8950-effect-of-in-utero-metformin-exposure-in-gestational-diabetes2026-10-06 https://evidence-hub.com/study/8951-an-examination-of-whether-diabetes-control-and-treatments-are2026-10-06 https://evidence-hub.com/study/8952-annual-decline-in-cell-function-in-patients-with-type-2-diabetes-in2026-10-08 https://evidence-hub.com/study/8953-medicine-prices-and-availability-in-the-brazilian-popular-pharmacy2026-10-06 https://evidence-hub.com/study/8954-the-relationship-between-hemoglobin-levels-and-endothelial-functions2026-10-06 https://evidence-hub.com/study/8955-the-prevalence-of-potential-alcohol-drug-interactions-in-older-adults2026-10-08 https://evidence-hub.com/study/8956-cerebral-microbleeds-and-amyloid-pathology-estimates-from-the-amyloid2026-10-06 https://evidence-hub.com/study/8957-association-between-vitamin-b12-levels-and-mortality-in-hospitalized2026-10-06 https://evidence-hub.com/study/8958-medication-prescribing-for-type-2-diabetes-in-the-us-long-term-care2026-10-06 https://evidence-hub.com/study/8959-metformin-as-add-on-to-intensive-insulin-therapy-in-type-1-diabetes2026-10-06 https://evidence-hub.com/study/8960-characteristics-of-turkish-children-with-type-2-diabetes-at-onset-a2026-10-06 https://evidence-hub.com/study/8961-use-of-sodium-glucose-cotransporter-2-inhibitors-in-france-analysis2026-10-06 https://evidence-hub.com/study/8962-influence-of-different-factors-duration-of-disease-gender-education2026-10-06 https://evidence-hub.com/study/8963-increased-circulating-resistin-is-associated-with-insulin-resistance2026-10-08 https://evidence-hub.com/study/8964-clinical-trends-in-catalonia-s-primary-care-setting-2018-2023-in2026-10-06 https://evidence-hub.com/study/8965-prevalence-of-vitamin-b12-deficiency-in-type-2-diabetic-patients2026-10-08 https://evidence-hub.com/study/8966-current-understanding-of-treatment-and-management-protocol-for-adult2026-10-06 https://evidence-hub.com/study/8967-use-of-potentially-nephrotoxic-medications-by-u-s-adults-with-chronic2026-10-06 https://evidence-hub.com/study/8968-older-adults-with-type-2-diabetes-treated-with-metformin-ame-met2026-10-06 https://evidence-hub.com/study/8969-prevalence-of-diabetes-and-pre-diabetes-in-greece-results-of-the2026-10-06 https://evidence-hub.com/study/8970-vertebral-fractures-in-males-with-type-2-diabetes-treated-with2026-10-06 https://evidence-hub.com/study/8971-combined-intake-of-glucose-and-lipid-lowering-medications-further2026-10-06 https://evidence-hub.com/study/8972-twelve-year-trends-in-pharmacologic-treatment-of-type-2-diabetes2026-10-06 https://evidence-hub.com/study/8973-ethnic-and-socioeconomic-disparities-in-initiation-of-second-line2026-10-06 https://evidence-hub.com/study/8974-new-prescription-of-antihyperglycemic-agents-among-patients-with2026-10-06 https://evidence-hub.com/study/8975-patterns-and-preferences-of-antidiabetic-drug-use-in-turkish-patients2026-10-06 https://evidence-hub.com/study/8976-construct-and-concurrent-validity-of-a-patient-reported-adverse-drug2026-10-06 https://evidence-hub.com/study/8977-impact-of-hypoglycemia-on-health-related-quality-of-life-among-type-22026-10-06 https://evidence-hub.com/study/8978-prescribing-of-diabetes-medications-to-people-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/8979-influence-of-glycemic-control-in-sleep-status-in-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/8980-vitamin-b-12-in-type-2-diabetic-patients-treated-with-metformin2026-10-06 https://evidence-hub.com/study/8981-use-of-glucose-lowering-drugs-in-a-primary-care-setting-in-malaga2026-10-06 https://evidence-hub.com/study/8982-investigation-of-inflammatory-markers-in-patients-with-polycystic2026-10-06 https://evidence-hub.com/study/8983-leukocyte-telomere-length-correlates-with-glucose-control-in-adults2026-10-06 https://evidence-hub.com/study/8984-the-association-between-type-2-diabetes-and-bone-microarchitecture2026-10-06 https://evidence-hub.com/study/8985-hypoglycaemic-symptoms-treatment-satisfaction-adherence-and-their2026-10-06 https://evidence-hub.com/study/8986-associations-among-diabetes-medication-use-serum-magnesium-and2026-10-06 https://evidence-hub.com/study/8987-the-correlation-between-urinary-8-iso-prostaglandin-f2-and-hydrogen2026-10-06 https://evidence-hub.com/study/8988-evaluation-of-metformin-use-in-non-critically-hospitalized-patients2026-10-08 https://evidence-hub.com/study/8989-sglt-2-inhibitors-may-be-targeting-higher-risk-patients-with-diabetes2026-10-08 https://evidence-hub.com/study/8990-investigating-attitudes-towards-medication-and-barriers-to-self2026-10-08 https://evidence-hub.com/study/8991-process-evaluation-of-the-diabetes-mellitus-management-program-at2026-10-06 https://evidence-hub.com/study/8992-hipoglicemiantes-orais-para-diabetes-mellitus-tipo-2-comparacao-de2026-10-06 https://evidence-hub.com/study/8993-association-between-vitamin-b12-deficiency-and-metformin-use-in-type2026-10-08 https://evidence-hub.com/study/8994-metformin-induced-vitamin-b12-deficiency-a-cross-sectional-study2026-10-08 https://evidence-hub.com/study/8995-association-of-metformin-administration-with-the-serum-levels-of-zinc2026-10-08 https://evidence-hub.com/study/8996-past-use-of-metformin-is-associated-with-increased-risk-of2026-10-08 https://evidence-hub.com/study/8997-the-effect-of-metformin-on-the-absorption-of-vitamin-b12-folic-acid2026-10-08 https://evidence-hub.com/study/8998-vitamin-b12-levels-in-patients-with-type-2-diabetes-mellitus2026-10-08 https://evidence-hub.com/study/8999-quality-of-life-in-people-with-type-2-diabetes-on-metformin2026-10-08 https://evidence-hub.com/study/9000-risk-of-hyperlactatemia-in-patients-with-obstructive-sleep-apnea2026-10-08 https://evidence-hub.com/study/9001-risk-factors-for-sarcopenia-in-women-with-type-2-diabetes-and-the2026-10-08 https://evidence-hub.com/study/9002-vitamin-b12-deficiency-in-diabetic-patients-treated-with-metformin-a2026-10-08 https://evidence-hub.com/study/9003-frailty-medication-adherence-and-glycemic-control-in-patients-with2026-10-08 https://evidence-hub.com/study/9004-neonatal-outcomes-of-gestational-diabetes-mellitus-gdm-mothers-a2026-10-08 https://evidence-hub.com/study/9005-prevalence-of-gastroparesis-and-the-impact-of-metformin-in-diabetic2026-10-08 https://evidence-hub.com/study/9006-prevalence-of-vitamin-b12-deficiency-in-patients-with-type-2-diabetes2026-10-08 https://evidence-hub.com/study/9007-factors-potentiating-risk-of-higher-lactate-level-associated-with2026-10-08 https://evidence-hub.com/study/9008-prevalence-of-vitamin-b12-deficiency-in-type-2-diabetic-patients2026-10-08 https://evidence-hub.com/study/9009-effect-of-choline-inositol-and-metformin-combination-versus-metformin2026-10-08 https://evidence-hub.com/study/9010-influence-of-slc22a1-rs628031-and-slc47a1-rs2289669-genetic2026-10-08 https://evidence-hub.com/study/9011-neuropsychiatric-and-neurocognitive-outcomes-of-metformin-versus2026-10-08 https://evidence-hub.com/study/9012-pharmacometabolomic-approach-to-investigate-the-response-to-metformin2026-10-08 https://evidence-hub.com/study/9013-knowledge-and-practice-pattern-of-physicians-regarding-vitamin-b122026-10-08 https://evidence-hub.com/study/9014-microbiome-differences-related-to-metformin-intolerance-among-black2026-10-08 https://evidence-hub.com/study/9015-oral-health-indices-in-patients-with-type-2-diabetes-receiving2026-10-08 https://evidence-hub.com/study/9016-assessment-of-cognitive-impairment-and-depressive-signs-in-patients2026-10-08 https://evidence-hub.com/study/9017-the-effects-of-daily-dose-and-treatment-duration-of-metformin-on-the2026-10-08 https://evidence-hub.com/study/9018-prediction-model-for-metformin-intolerance-in-chinese-elderly2026-10-08 https://evidence-hub.com/study/9020-high-prevalence-of-metformin-associated-vitamin-b12-deficiency-among2026-10-08 https://evidence-hub.com/study/9021-evaluation-of-the-effects-of-metformin-on-antioxidant-biomarkers-and2026-10-08 https://evidence-hub.com/study/9022-insights-into-metformin-xr-pharmacotherapy-knowledge-among-community2026-10-08 https://evidence-hub.com/study/9023-clinical-application-of-metformin-use-in-anhui-province-china-a-cross2026-10-08 https://evidence-hub.com/study/9024-the-association-of-metformin-and-aspirin-intake-with-mammographic2026-10-08 https://evidence-hub.com/study/9025-does-metformin-in-different-doses-cause-vitamin-b12-deficiency-a2026-10-08 https://evidence-hub.com/study/9026-prospective-cross-sectional-study-on-adverse-effects-of-metformin2026-10-08 https://evidence-hub.com/study/9027-possible-protective-role-of-metformin-therapy-on-colonic-polyps-in2026-10-08 https://evidence-hub.com/study/9028-overweight-management-a-cross-sectional-study-with-special-insight-on2026-10-08 https://evidence-hub.com/study/9030-estimation-of-serum-creatinine-aspartate-aminotransferase-alanine2026-10-08 https://evidence-hub.com/study/9031-serum-vitamin-b12-status-of-patients-with-type-2-diabetes-mellitus-on2026-10-08 https://evidence-hub.com/study/9032-assessment-of-serum-vitamin-b12-and-folate-levels-and-macrocytosis-in2026-10-08 https://evidence-hub.com/study/9033-a-cross-sectional-study-to-estimate-the-prevalence-of-vitamin-b122026-10-08 https://evidence-hub.com/study/9034-a-cross-sectional-study-on-prevalence-of-vitamin-b12-deficiency-and2026-10-08 https://evidence-hub.com/study/9035-preventive-metformin-monotherapy-medication-prescription-redemption2026-10-08 https://evidence-hub.com/study/9036-association-between-use-of-metformin-and-insulin-with-hematological2026-10-08 https://evidence-hub.com/study/9039-the-effect-of-the-anti-diabetic-drug-metformin-on-musculoskeletal2026-10-08 https://evidence-hub.com/study/9040-vitamin-b12-deficiency-and-diabetic-neuropathy-in-patients-taking2026-10-08 https://evidence-hub.com/study/9041-neuropathy-and-neuropathic-pain-in-patients-with-type-2-diabetes2026-10-08 https://evidence-hub.com/study/9042-slc22a1-rs622342-polymorphism-predicts-insulin-resistance-improvement2026-10-08 https://evidence-hub.com/study/9043-vitamin-b12-deficiency-in-type-2-diabetic-patients-on-metformin-a2026-10-08 https://evidence-hub.com/study/9044-734-p-prevalence-of-low-and-borderline-levels-of-vitamin-b12-in-type2026-10-08 https://evidence-hub.com/study/9046-vitamin-b12-deficiency-in-metformin-treated-community-dwelling-older2026-10-08 https://evidence-hub.com/study/9047-sun-588-association-between-vitamin-b-12-deficiency-and-metformin-use2026-10-08 https://evidence-hub.com/study/9048-vitamin-b12-deficiency-in-diabetic-subjects-taking-metformin-a-cross2026-10-08 https://evidence-hub.com/study/9049-characterization-of-treatment-intensified-add-on-to-metformin-adults2026-10-08 https://evidence-hub.com/study/9050-analysis-of-patient-education-guides-generated-by-chatgpt-and-gemini2026-10-08 https://evidence-hub.com/study/9051-metformin-increases-3-hydroxy-medium-chain-fatty-acids-in-patients2026-10-08 https://evidence-hub.com/study/9052-prevalence-and-determinants-of-erectile-dysfunction-among-male-type-22026-10-08 https://evidence-hub.com/study/9054-effect-of-metformin-on-peripheral-nerve-morphology-in-type-2-diabetes2026-10-08 https://evidence-hub.com/study/9055-medication-age-and-abstinence-days-associated-with-low-semen-quality2026-10-08 https://evidence-hub.com/study/9056-magnesium-level-and-related-factors-in-type-2-diabetes-mellitus-a2026-10-08 https://evidence-hub.com/study/9057-factors-determining-blood-and-urine-concentrations-of-metformin-among2026-10-08 https://evidence-hub.com/study/9058-association-of-type-2-diabetes-mellitus-with-histopathological2026-10-08 https://evidence-hub.com/study/9059-comment-on-prevalence-and-determinants-of-poor-sleep-quality-among2026-10-08 https://evidence-hub.com/study/9061-serum-vitamin-b12-levels-in-type-2-diabetes-patients-on-metformin2026-10-08 https://evidence-hub.com/study/9062-therapeutic-competitions-and-frailty-among-older-adults-in-sao-paulo2026-10-08 https://evidence-hub.com/study/9063-impact-of-metformin-use-on-liver-function-tests-in-diabetic-patients2026-10-08 https://evidence-hub.com/study/9064-vitamin-b12-deficiency-in-metformin-treated-type-2-diabetic-patients2026-10-08 https://evidence-hub.com/study/9065-renal-drug-dosage-adjustments-and-adverse-drug-events-in-patients2026-10-08 https://evidence-hub.com/study/9066-prevalence-and-determinants-of-poor-sleep-quality-among-patients-of2026-10-08 https://evidence-hub.com/study/9067-real-time-use-of-sglt2i-verified-in-pre-dialysis-the-rsvp-cross2026-10-08 https://evidence-hub.com/study/9068-socioeconomic-disparity-in-stage-at-cancer-diagnosis-among-patients2026-10-08 https://evidence-hub.com/study/9070-7265-characterization-of-treatment-intensified-add-on-to-metformin2026-10-08 https://evidence-hub.com/study/9071-noninsulin-antidiabetic-prescription-patterns-in-colombia-a-cross2026-10-08 https://evidence-hub.com/study/9072-cobalamin-status-in-patients-with-type-2-diabetes-mellitus-at-primary2026-10-08 https://evidence-hub.com/study/9073-clinical-management-of-type-ii-dm-in-patients-showing-progressive2026-10-08 https://evidence-hub.com/study/9074-factors-affecting-mother-infant-bonding-in-women-with-gestational2026-10-08 https://evidence-hub.com/study/9077-new-insights-into-the-role-of-metformin-effects-on-serum-omentin-12026-10-08 https://evidence-hub.com/study/9081-clomiphene-citrate-alone-versus-combined-metformin-and-clomiphene2026-10-08 https://evidence-hub.com/study/9084-associations-of-cardiovascular-agents-and-metformin-with-depression2026-10-08 https://evidence-hub.com/study/9085-comparison-of-teneligliptin-and-other-gliptin-based-regimens-in2026-10-08 https://evidence-hub.com/study/9086-hedgehog-interacting-protein-as-a-circulating-biomarker-in-women-with2026-10-08 https://evidence-hub.com/study/9087-the-modifier-effect-of-physical-activity-body-mass-index-and-age-on2026-10-08 https://evidence-hub.com/study/9088-antidiabetic-medication-and-asthma-attacks2026-10-08 https://evidence-hub.com/study/9089-low-dose-metformin-and-profibrotic-signature-in-central-centrifugal2026-10-08 https://evidence-hub.com/study/9090-medication-induced-hyperlactatemia-and-lactic-acidosis-a-systematic2026-10-08 https://evidence-hub.com/study/9091-polycystic-ovary-syndrome-and-recurrent-pregnancy-loss-a-review-of2026-10-08 https://evidence-hub.com/study/9092-beyond-antivirals-alternative-therapies-for-long-covid2026-10-08 https://evidence-hub.com/study/9093-pravastatin-proton-pump-inhibitors-metformin-micronutrients-and2026-10-08 https://evidence-hub.com/study/9094-metformin-associated-lactic-acidosis-in-chinese-patients-with-type-ii2026-10-08 https://evidence-hub.com/study/9095-proposed-treatment-strategy-for-reactive-hypoglycaemia2026-10-08 https://evidence-hub.com/study/9096-berardinelli-seip-congenital-generalised-lipodystrophy2026-10-08 https://evidence-hub.com/study/9097-metformin-for-the-treatment-of-recurrent-respiratory-papillomatosis2026-10-08 https://evidence-hub.com/study/9098-laboratory-confirmed-metformin-associated-lactic-acidosis2026-10-08 https://evidence-hub.com/study/9099-adulteration-of-herbal-antidiabetic-products-with-undeclared2026-10-08 https://evidence-hub.com/study/9100-metformin-toxicity-in-the-intensive-care-unit-a-case-series-and2026-10-08 https://evidence-hub.com/study/9101-hyperlactataemia-and-clinical-severity-of-acute-metformin-overdose2026-10-08 https://evidence-hub.com/study/9102-acne-vulgaris-associated-with-metabolic-syndrome-a-three-case-series2026-10-08 https://evidence-hub.com/study/9103-hyperglycemia-management-in-patients-with-posttransplantation-diabetes2026-10-08 https://evidence-hub.com/study/9104-new-treatments-for-adult-female-acne2026-10-08 https://evidence-hub.com/study/9105-sulfonylureas-and-metformin-were-not-associated-with-an-increased2026-10-08 https://evidence-hub.com/study/9106-metformin-induced-lactic-acidosis-a-case-series2026-10-08 https://evidence-hub.com/study/9107-covid-19-and-diabetic-ketoacidosis-a-case-series-at-an-urban-district2026-10-08 https://evidence-hub.com/study/9108-combined-metformin-associated-lactic-acidosis-and-euglycemic2026-10-08 https://evidence-hub.com/study/9109-angiotensin-converting-enzyme-inhibitors-used-concomitantly-with2026-10-08 https://evidence-hub.com/study/9110-acute-diabetic-neuropathy-following-improved-glycaemic-control-a-case2026-10-08 https://evidence-hub.com/study/9111-metformin-use-and-young-age-lung-cancer-a-case-series-report2026-10-08 https://evidence-hub.com/study/9112-metformin-associated-lactic-acidosis-a-case-series-of-28-patients2026-10-08 https://evidence-hub.com/study/9113-metformin-in-the-treatment-of-clomiphene-citrate-resistant-women-with2026-10-08 https://evidence-hub.com/study/9114-spurious-hba1c-results-in-patients-with-diabetes-treated-with-dapsone2026-10-08 https://evidence-hub.com/study/9115-a-case-report-on-metformin-associated-lactic-acidosis-and-transient2026-10-08 https://evidence-hub.com/study/9116-the-role-of-continuous-renal-replacement-therapy-in-the-treatment-of2026-10-08 https://evidence-hub.com/study/9117-cardiovascular-benefits-of-sglt2-inhibitors-in-type-2-diabetes2026-10-08 https://evidence-hub.com/study/9118-metformin-treatment-in-young-children-with-fragile-x-syndrome2026-10-08 https://evidence-hub.com/study/9119-metformin-use-in-patients-with-type-2-diabetes-mellitus-and-chronic2026-10-08 https://evidence-hub.com/study/9120-treatment-strategies-for-dopamine-agonist-resistant-and-aggressive2026-10-08 https://evidence-hub.com/study/9121-clinical-and-laboratory-characteristics-of-mody-cases-genetic2026-10-08 https://evidence-hub.com/study/9122-continuous-extracorporeal-clearance-in-metformin-associated-lactic2026-10-08 https://evidence-hub.com/study/9123-serious-hypoglycemia-and-use-of-warfarin-in-combination-with2026-10-08 https://evidence-hub.com/study/9124-obstetrical-and-medical-outcomes-following-glp-1-receptor-agonist2026-10-08 https://evidence-hub.com/study/9125-multicenter-case-series-of-pediatric-metformin-ingestion2026-10-08 https://evidence-hub.com/study/9126-inpatient-case-characteristics-of-sglt2-inhibitor-associated-diabetic2026-10-08 https://evidence-hub.com/study/9128-topical-steroid-withdrawal-is-a-targetable-excess-of-mitochondrial-nad2026-10-08 https://evidence-hub.com/study/9129-metformin-associated-lactic-acidosis-requiring-hospitalization-a2026-10-08 https://evidence-hub.com/study/9130-calcium-citrate-anticoagulation-during-continuous-renal-replacement2026-10-08 https://evidence-hub.com/study/9131-evaluation-of-the-concurrent-use-of-dolutegravir-and-metformin-in2026-10-08 https://evidence-hub.com/study/9132-metformin-associated-lactic-acidosis-in-clinical-practice-a-case2026-10-08 https://evidence-hub.com/study/9133-guideline-no-390-classification-and-management-of-endometrial2026-10-08 https://evidence-hub.com/study/9134-the-extrapyramidal-syndromes-of-chronic-kidney-disease-and-dialysis2026-10-08 https://evidence-hub.com/study/9135-pregnancies-following-use-of-metformin-for-ovulation-induction-in2026-10-08 https://evidence-hub.com/study/9136-hot-flashes-and-fatigue-relieved-by-metformin2026-10-08 https://evidence-hub.com/study/9137-is-there-a-role-for-antiandrogen-therapy-for-hidradenitis-suppurativa2026-10-08 https://evidence-hub.com/study/9138-non-insulin-anti-diabetic-agents-in-patients-with-type-2-diabetes-and2026-10-08 https://evidence-hub.com/study/9139-metformin-prevents-the-progression-of-dysplastic-mucosa-of-the-head2026-10-08 https://evidence-hub.com/study/9140-can-acute-overdose-of-metformin-lead-to-lactic-acidosis2026-10-08 https://evidence-hub.com/study/9141-describing-the-natural-history-of-clinical-biochemical-and2026-10-08 https://evidence-hub.com/study/9142-metformin-associated-lactic-acidosis-mala-is-it-an-underestimated2026-10-08 https://evidence-hub.com/study/9143-case-report-latent-autoimmune-diabetes-in-two-young-female-patients2026-10-08 https://evidence-hub.com/study/9144-metformin-overdose-with-a-resultant-serum-ph-of-6-59-survival-without2026-10-08 https://evidence-hub.com/study/9145-risks-of-metformin-in-type-2-diabetes-and-chronic-kidney-disease2026-10-08 https://evidence-hub.com/study/9146-a-case-series-of-bardet-biedl-syndrome-in-a-large-turkish-family-and2026-10-08 https://evidence-hub.com/study/9147-maintenance-therapy-containing-metformin-and-or-zyflamend-for2026-10-08 https://evidence-hub.com/study/9148-progestin-intrauterine-devices-and-metformin-endometrial-hyperplasia2026-10-08 https://evidence-hub.com/study/9149-semaglutide-for-the-treatment-of-antipsychotic-associated-weight-gain2026-10-08 https://evidence-hub.com/study/9150-management-of-hyperglycemia-in-the-noncritical-care-setting-a-real2026-10-08 https://evidence-hub.com/study/9151-dementia-and-multimorbidity-trends-in-al-baha-saudi-arabia-an2026-10-06 https://evidence-hub.com/study/9152-metformin-poisoning-treated-with-high-dose-insulin-dextrose-therapy-a2026-10-08 https://evidence-hub.com/study/9153-is-the-use-of-metformin-in-patients-undergoing-dialysis-hazardous-for2026-10-08 https://evidence-hub.com/study/9154-amniotic-stem-cell-transplantation-therapy-for-type-2-diabetes-32026-10-08 https://evidence-hub.com/study/9155-dipeptidyl-peptidase-4-dpp-iv-inhibitor-was-associated-with-mortality2026-10-08 https://evidence-hub.com/study/9156-do-patients-die-with-or-from-metformin-associated-lactic-acidosis2026-10-08 https://evidence-hub.com/study/9157-anti-obesity-medication-use-in-children-and-adolescents-with-prader2026-10-08 https://evidence-hub.com/study/9158-treating-alpelisib-induced-hyperglycemia-with-very-low-carbohydrate2026-10-08 https://evidence-hub.com/study/9159-efficacy-of-medical-treatments-for-pediatric-hidradenitis-suppurativa2026-10-08 https://evidence-hub.com/study/9160-addressing-metabolic-comorbidity-in-individuals-with-intellectual-and2026-10-08 https://evidence-hub.com/study/9161-case-series-of-rosiglitazone-used-during-the-first-trimester-of2026-10-08 https://evidence-hub.com/study/9162-liraglutide-and-obesity-in-elderly-efficacy-in-fat-loss-and-safety-in2026-10-08 https://evidence-hub.com/study/9163-the-role-of-metformin-in-metformin-associated-lactic-acidosis-mala2026-10-08 https://evidence-hub.com/study/9164-achieving-high-dialysis-dose-via-continuous-renal-replacement-therapy2026-10-08 https://evidence-hub.com/study/9165-systematic-review-of-current-guidelines-and-their-evidence-base-on2026-10-08 https://evidence-hub.com/study/9166-use-of-pasireotide-in-acromegaly-clinical-experiences-from-a-series2026-10-08 https://evidence-hub.com/study/9167-effects-of-caloric-restriction-and-low-glycemic-index-diets2026-10-08 https://evidence-hub.com/study/9168-the-usefulness-of-measuring-the-anion-gap-in-diagnosing-metformin2026-10-08 https://evidence-hub.com/study/9169-metformin-and-carbohydrate-modified-diet-a-novel-obesity-treatment2026-10-08 https://evidence-hub.com/study/9170-metformin-accumulation-lactic-acidosis-and-high-plasmatic-metformin2026-10-08 https://evidence-hub.com/study/9171-sweet-and-simple-as-syrup-a-review-and-guidance-for-use-of-novel2026-10-08 https://evidence-hub.com/study/9172-the-role-of-metformin-in-dysplastic-mucosa-of-the-larynx-a-follow-up2026-10-08 https://evidence-hub.com/study/9173-biomedical-informatics-approaches-to-identifying-drug-drug2026-10-08 https://evidence-hub.com/study/9174-surgical-safety-and-personal-costs-in-morbidly-obese-multimorbid2026-10-08 https://evidence-hub.com/study/9175-fournier-gangrene-associated-with-sodium-glucose-cotransporter-22026-10-08 https://evidence-hub.com/study/9176-thiazolidinediones-in-type-2-diabetes-a-cardiology-perspective2026-10-08 https://evidence-hub.com/study/9177-type-2-diabetes-mellitus-in-the-northern-tree-shrew-tupaia-belangeri2026-10-08 https://evidence-hub.com/study/9178-bariatric-surgery-in-individuals-with-human-immunodeficiency-virus2026-10-08 https://evidence-hub.com/study/9179-metformin-associated-lactic-acidosis-during-flood-related-healthcare2026-10-08 https://evidence-hub.com/study/9180-adjunctive-metformin-therapy-in-type-1-diabetes-in-pregnancy-insights2026-10-08 https://evidence-hub.com/study/9181-continuous-glucose-monitoring-guided-management-of-capivasertib2026-10-08 https://evidence-hub.com/study/9182-clinical-efficacy-of-tirzepatide-for-weight-regain-and-suboptimal2026-10-08 https://evidence-hub.com/study/9183-is-there-a-better-day-of-the-week-to-administer-semaglutide-or2026-10-08 https://evidence-hub.com/study/9184-challenges-in-managing-pregnancy-in-patients-with-fructose-1-62026-10-08 https://evidence-hub.com/study/9185-management-and-outcomes-of-fertility-preservation-in-rare-cowden2026-10-08 https://evidence-hub.com/study/9186-managing-capivasertib-induced-hyperglycemia-a-report-of-3-cases2026-10-08 https://evidence-hub.com/study/9187-effects-of-glp-1-receptor-agonists-on-psoriasis-an-agent-specific2026-10-08 https://evidence-hub.com/study/9188-efficacy-and-safety-of-semaglutide-in-patients-with-polycystic-ovary2026-10-08 https://evidence-hub.com/study/9189-rfx6-maturity-onset-diabetes-of-the-young-clinical-considerations-and2026-10-08 https://evidence-hub.com/study/9190-familial-partial-lipodystrophy-type-2-associated-with-a-novel-lmna2026-10-08 https://evidence-hub.com/study/9191-mechanism-driven-evolution-of-fertility-sparing-treatment-and2026-10-08 https://evidence-hub.com/study/9192-tirzepatide-and-metformin-effects-on-hunger-and-bmi-in-an-adolescent2026-10-08 https://evidence-hub.com/study/9193-personalized-combination-of-a-ketogenic-diet-and-low-dose-semaglutide2026-10-08 https://evidence-hub.com/study/9194-eradicating-hyperandrogenism-hormonal-changes-following-helicobacter2026-10-08 https://evidence-hub.com/study/9195-safety-and-clinical-considerations-of-alopecia-therapies-during2026-10-08 https://evidence-hub.com/study/9196-semaglutide-and-neovascular-age-related-macular-degeneration-among2026-10-08 https://evidence-hub.com/study/9197-time-restricted-eating-in-adults-with-type-2-diabetes-mellitus-on2026-10-08 https://evidence-hub.com/study/9198-the-development-of-a-framework-to-classify-medication-deprescribing2026-10-08 https://evidence-hub.com/study/9199-dupilumab-for-drug-induced-bullous-pemphigoid-a-case-series-and2026-10-08 https://evidence-hub.com/study/9200-effectiveness-and-safety-of-antidiabetic-medications-in-hidradenitis2026-10-08 https://evidence-hub.com/study/9201-concurrent-metformin-associated-lactic-acidosis-and-euglycemic2026-10-08 https://evidence-hub.com/study/9202-progressive-loss-of-glycemic-control-during-chronic-dpp-4-inhibitor2026-10-08 https://evidence-hub.com/study/9203-biomarker-based-prediction-of-oatp1b1-activity-in-clinical-routine2026-10-08 https://evidence-hub.com/study/9204-venoarterial-extracorporeal-membrane-oxygenation-as-bridge-support2026-10-08 https://evidence-hub.com/study/9205-case-report-tirzepatide-improves-glycemic-control-in-rabson2026-10-08 https://evidence-hub.com/study/9206-systemic-treatment-of-advanced-chordoma-with-molecular-targeted2026-10-08 https://evidence-hub.com/study/9207-semaglutide-for-refractory-reactive-hypoglycaemia-a-case-report2026-10-08 https://evidence-hub.com/study/9208-metformin-induced-lactic-acidosis-following-intentional-overdose-a2026-10-08 https://evidence-hub.com/study/9209-when-metabolism-recovers-but-the-brain-does-not-a-case-report-of2026-10-08 https://evidence-hub.com/study/9210-beyond-weight-loss-a-comprehensive-review-of-integrated2026-10-08 https://evidence-hub.com/study/9211-vitamin-b12-deficiency-in-long-term-metformin-use-and-clinician2026-10-08 https://evidence-hub.com/study/9212-use-of-testosterone-lowering-medication-in-patients-with-intellectual2026-10-08 https://evidence-hub.com/study/9213-werner-syndrome-masquerading-as-type-2-diabetes-a-diagnostic-odyssey2026-10-08 https://evidence-hub.com/study/9214-pharmacological-management-of-obesity-in-pregnancy-a-review-of2026-10-08 https://evidence-hub.com/study/9215-clinical-and-biochemical-recovery-from-immune-checkpoint-inhibitor2026-10-08 https://evidence-hub.com/study/9216-photodynamic-therapy-in-head-and-neck-squamous-cell-carcinoma2026-10-12 https://evidence-hub.com/study/9217-psychosis-in-a-47-xxx-adolescent-clinical-management-and2026-10-08 https://evidence-hub.com/study/9218-management-of-a-patient-with-severe-insulin-resistance2026-10-08 https://evidence-hub.com/study/9219-actinomyces-neuii-in-chronic-hidradenitis-suppurativa-a-case-series2026-10-08 https://evidence-hub.com/study/9220-targeting-novel-pathways-in-pulmonary-arterial-hypertension-a2026-10-10 https://evidence-hub.com/study/9221-prevalence-and-treatment-of-mitochondrial-diabetes-in-southwest2026-10-08 https://evidence-hub.com/study/9222-pregnancy-outcomes-in-three-distinct-uterine-anomalies-a-case-series2026-10-08 https://evidence-hub.com/study/9223-glucagon-like-peptide-1-receptor-agonists-their-therapeutic-potential2026-10-08 https://evidence-hub.com/study/9224-sodium-glucose-like-co-transporter-2-inhibitor-sglt2i-use-in-adults2026-10-08 https://evidence-hub.com/study/9225-integrating-bioenergetic-therapy-model-with2026-10-08 https://evidence-hub.com/study/9226-euglycemic-diabetic-ketoacidosis-associated-with-sodium-glucose2026-10-08 https://evidence-hub.com/study/9227-candidate-treatments-for-long-covid-a-narrative-review-of-expert-and2026-10-08 https://evidence-hub.com/study/9228-mc4r-related-monogenic-obesity-in-children-insights-from-2-cases2026-10-08 https://evidence-hub.com/study/9229-topical-piperine-for-the-management-of-burning-mouth-syndrome-a-case2026-10-08 https://evidence-hub.com/study/9230-elevated-fecal-calprotectin-values-appear-more-common-following2026-10-08 https://evidence-hub.com/study/9231-a-case-and-literature-review-of-hypokalemic-periodic-paralysis2026-10-08 https://evidence-hub.com/study/9232-semaglutide-plus-low-dose-metformin-combination-therapy-for-the2026-10-08 https://evidence-hub.com/study/9233-levonorgestrel-releasing-intrauterine-system-treatment-for2026-10-08 https://evidence-hub.com/study/9234-insulin-autoimmune-hypoglycemia-unmasking-monoclonal-gammopathy-in2026-10-08 https://evidence-hub.com/study/9235-benefits-of-incretin-therapy-on-ovarian-function-a-scientific2026-10-08 https://evidence-hub.com/study/9236-approach-to-the-patient-with-acquired-hypothalamic-syndrome2026-10-08 https://evidence-hub.com/study/9237-ethanol-as-a-modifier-of-drug-toxicity-in-humans-pathways-of-toxicity2026-10-08 https://evidence-hub.com/study/9238-management-of-advanced-hr-positive-breast-cancer-using-metabolically2026-10-08 https://evidence-hub.com/study/9239-glp-1-receptor-agonists-and-preconception-planning-bridging-the-gap2026-10-08 https://evidence-hub.com/study/9240-identification-of-maturity-onset-diabetes-of-the-young-through2026-10-08 https://evidence-hub.com/study/9241-phenotypic-discordance-in-semilobar-holoprosencephaly-a-case-report2026-10-08 https://evidence-hub.com/study/9242-melkersson-rosenthal-syndrome-mrs-a-case-report2026-10-08 https://evidence-hub.com/study/9243-cognitive-impairment-associated-with-chemotherapy-neuroimmunological2026-10-08 https://evidence-hub.com/study/9244-hypertensive-urgency-and-pulmonary-infiltrates-a-report-of-three-cases2026-10-08 https://evidence-hub.com/study/9245-glp-1-receptor-agonists-fertility-restoration-and-reproductive-safety2026-10-08 https://evidence-hub.com/study/9246-drug-induced-normoglycemic-candidal-balanoposthitis-a-case-series2026-10-06 https://evidence-hub.com/study/9247-rare-implantation-sites-of-ectopic-pregnancy-a-case-series-of-ovarian2026-10-06 https://evidence-hub.com/study/9248-clinical-and-mechanistic-effects-of-glp-1-receptor-agonists-in2026-10-08 https://evidence-hub.com/study/9249-a-narrative-review-of-emerging-chemoprotective-agents-for2026-10-08 https://evidence-hub.com/study/9250-a-case-series-of-vildagliptin-associated-bullous-pemphigoid-rare-side2026-10-06 https://evidence-hub.com/study/9251-lactic-acidosis-associated-with-metformin-a-case-series-from-the2026-10-08 https://evidence-hub.com/study/9258-gastric-emptying-delay-with-pre-meal-administration-of-metformin-and2026-10-08 https://evidence-hub.com/study/9259-a-novel-supplement-regimen-for-healthy-aging-a-case-series2026-10-08 https://evidence-hub.com/study/9260-7944-elevated-serum-alkaline-phosphatase-without-other-abnormalities2026-10-08 https://evidence-hub.com/study/9261-utility-of-individualised-homoeopathic-medicine-in-treatment-of2026-10-08 https://evidence-hub.com/study/9262-12585-metabolic-profile-in-familial-partial-lipodystrophy-type-3-case2026-10-08 https://evidence-hub.com/study/9264-sat110-euglycemic-diabetes-ketoacidosis-associated-with-sodium2026-10-08 https://evidence-hub.com/study/9265-a-case-series-of-cbt-inspired-behavioral-and-medical-interventions2026-10-08 https://evidence-hub.com/study/9266-ep816-ece-2033-the-clinical-value-of-routine-c-peptide-measurement-in2026-10-08 https://evidence-hub.com/study/9267-ep699-ece-2343-mature-onset-of-diabetes-of-young-in-paediatric2026-10-08 https://evidence-hub.com/study/9269-severe-metformin-associated-lactic-acidosis-a-case-series-of-an2026-10-08 https://evidence-hub.com/study/9270-stevia-and-uncaria-extract-glucomedix-reduces-glucose-levels-and-the2026-10-08 https://evidence-hub.com/study/9272-metformin-combined-with-endoscopic-therapy-in-patients-with-familial2026-10-08 https://evidence-hub.com/study/9273-improvement-in-polymyalgia-rheumatica-associated-with-improved2026-10-08 https://evidence-hub.com/study/9274-canagliflozin-in-type-1-diabetes-a-case-series-of-patient-outcomes-in2026-10-08 https://evidence-hub.com/study/9277-safety-and-efficacy-of-meglitinides-in-combination-with-glp-12026-10-08 https://evidence-hub.com/study/9278-hemophagocytic-lymphohistiocytosis-as-the-presenting-symptom-of2026-10-08 https://evidence-hub.com/study/9282-frequency-of-pre-eclampsia-in-obese-pregnant-females-taking-metformin2026-10-08 https://evidence-hub.com/study/9286-extracorporeal-treatment-for-metformin-poisoning-systematic-review2026-10-08 https://evidence-hub.com/study/9287-impact-metformin-and-insulin-therapy-on-parathyroid-hormone-and-25-oh2026-10-08 https://evidence-hub.com/study/9288-p0600long-term-prognosis-of-patients-with-metformin-associated-lactic2026-10-08 https://evidence-hub.com/study/9289-editorial-it-is-not-a-wide-open-field-for-incretins-collateral2026-10-08 https://evidence-hub.com/study/9290-liver-enzyme-trends-in-patients-taking-uninterrupted-metformin-before2026-10-08 https://evidence-hub.com/study/9293-acute-pancreatitis-frequency-in-diabetic-patients-taking-combination2026-10-08 https://evidence-hub.com/study/9294-insulin-resistant-diabetes-mellitus-in-short-syndrome-case-report-and2026-10-06 https://evidence-hub.com/study/9295-nut-midline-carcinoma-morphoproteomic-characterization-with-genomic2026-10-06 https://evidence-hub.com/study/9296-optimizing-outcomes-for-glp-1-agonists2026-10-06 https://evidence-hub.com/study/9297-felodipine-influenced-gingival-enlargement-in-an-uncontrolled-type-22026-10-06 https://evidence-hub.com/study/9298-effects-of-octreotide-on-serum-and-urine-electrolytes-in-a-patient2026-10-06 https://evidence-hub.com/study/9299-approach-to-the-treatment-of-the-older-unfit-patient-with-myeloma2026-10-06 https://evidence-hub.com/study/9300-diabetes-mellitus-with-laron-syndrome-case-report2026-10-06 https://evidence-hub.com/study/9301-sensitivity-to-sulphonylureas-in-patients-with-hepatocyte-nuclear2026-10-06 https://evidence-hub.com/study/9302-lactic-acidosis-and-multisystem-organ-failure-following-ibuprofen2026-10-06 https://evidence-hub.com/study/9303-erectile-dysfunction-as-a-possible-important-side-effect-of-metformin2026-10-08 https://evidence-hub.com/study/9304-metformin-induced-acute-hepatitis2026-10-06 https://evidence-hub.com/study/9305-euglycemic-ketoacidosis-and-lactic-acidosis-associated-with-metformin2026-10-06 https://evidence-hub.com/study/9306-metformin-induced-mixed-hepatocellular-and-cholestatic-hepatic-injury2026-10-08 https://evidence-hub.com/study/9307-acute-myocardial-injury-in-association-with-metformin-toxicity2026-10-06 https://evidence-hub.com/study/9308-metformin-abuse-and-weight-loss-a-case-report2026-10-06 https://evidence-hub.com/study/9309-metformin-associated-encephalopathy-as-a-rare-but-serious-adverse2026-10-08 https://evidence-hub.com/study/9310-focal-brain-lactate-accumulation-in-metformin-induced-encephalopathy2026-10-08 https://evidence-hub.com/study/9311-extreme-lactic-acidosis-type-b-associated-with-metformin-treatment2026-10-06 https://evidence-hub.com/study/9312-metformin-toxicity-masquerading-as-acute-abdomen-a-clinical-reminder2026-10-06 https://evidence-hub.com/study/9313-metformin-induced-eosinophilic-interstitial-lung-disease2026-10-06 https://evidence-hub.com/study/9314-a-novel-case-of-metformin-induced-pancreatitis-in-an-individual-with2026-10-06 https://evidence-hub.com/study/9315-combination-of-olanzapine-pamoate-with-melatonin-and-metformin2026-10-06 https://evidence-hub.com/study/9316-metformin-toxicity-leading-to-severe-refractory-hyperkalemia-and2026-10-08 https://evidence-hub.com/study/9317-a-rare-case-of-metformin-induced-lactic-acidosis-and-concomitant2026-10-06 https://evidence-hub.com/study/9318-a-rare-case-of-metformin-intoxication-with-mortal-course2026-10-06 https://evidence-hub.com/study/9319-methylene-blue-as-treatment-for-vasoplegic-shock-in-severe-metformin2026-10-08 https://evidence-hub.com/study/9320-lentiform-fork-sign-secondary-to-metformin-induced-encephalopathy2026-10-06 https://evidence-hub.com/study/9321-potential-ketoacidosis-linked-to-imeglimin-and-metformin-co2026-10-06 https://evidence-hub.com/study/9322-successful-use-of-methylene-blue-for-catecholamine-refractory2026-10-06 https://evidence-hub.com/study/9323-combination-therapy-with-a-dipeptidyl-peptidase-4-inhibitor2026-10-06 https://evidence-hub.com/study/9324-a-case-of-metformin-associated-lactic-acidosis2026-10-06 https://evidence-hub.com/study/9325-dancing-with-death-at-ph-6-8-and-lactate-of-29-mmol-l-extreme2026-10-06 https://evidence-hub.com/study/9326-confirmation-of-metformin-induced-acute-generalized-exanthematous2026-10-06 https://evidence-hub.com/study/9327-a-concealed-history-behind-the-disaster-extremely-rare-presentations2026-10-06 https://evidence-hub.com/study/9328-reactive-hypoglycemia-from-metformin-immediate-release-monotherapy2026-10-06 https://evidence-hub.com/study/9329-pseudo-ischemic-ecg-changes-in-a-patient-with-profound-mixed2026-10-08 https://evidence-hub.com/study/9330-treatment-of-recurrent-granulosa-cell-tumor-with-metformin-and2026-10-06 https://evidence-hub.com/study/9331-suspected-metformin-induced-cobalamin-deficiency-mimicking-thrombotic2026-10-06 https://evidence-hub.com/study/9332-metformin-induced-hemolysis-in-a-glucose-6-phosphate-dehydrogenase2026-10-06 https://evidence-hub.com/study/9333-atypical-presentation-of-metformin-associated-lactic-acidosis-a-case2026-10-08 https://evidence-hub.com/study/9334-metformin-associated-lactic-acidosis-successfully-treated-with2026-10-06 https://evidence-hub.com/study/9335-metformin-associated-vitamin-b12-deficiency-an-underrecognized2026-10-06 https://evidence-hub.com/study/9336-life-threatening-acidosis-with-metformin-and-dapagliflozin2026-10-06 https://evidence-hub.com/study/9337-transient-blindness-in-metformin-associated-lactic-acidosis2026-10-06 https://evidence-hub.com/study/9338-metformin-associated-lactic-acidosis-precipitated-by-liraglutide-use2026-10-06 https://evidence-hub.com/study/9339-exercise-precision-medicine-for-type-2-diabetes-targeted-benefit-or2026-10-06 https://evidence-hub.com/study/9340-lactic-acidosis-lactic-acidosis-associated-with-metformin-use-in2026-10-06 https://evidence-hub.com/study/9341-continuous-veno-venous-hemodiafiltration-in-metformin-associated2026-10-06 https://evidence-hub.com/study/9342-the-role-of-serum-lactate-in-the-acute-care-setting2026-10-06 https://evidence-hub.com/study/9343-acute-kidney-injury-and-long-term-renal-effects-of-alectinib-in2026-10-08 https://evidence-hub.com/study/9344-a-case-of-metformin-associated-lactic-acidosis-complicated-by-acute2026-10-06 https://evidence-hub.com/study/9345-bilateral-ureteral-obstruction-causing-acute-kidney-injury-and2026-10-06 https://evidence-hub.com/study/9346-morel-lavallee-lesion-in-a-patient-with-metformin-induced-b122026-10-06 https://evidence-hub.com/study/9347-severe-metabolic-acidosis-due-to-massive-metformin-overdose-in-a-man2026-10-08 https://evidence-hub.com/study/9348-metformin-associated-lactic-acidosis-in-an-elderly-diabetic-patient2026-10-08 https://evidence-hub.com/study/9349-effect-of-metformin-on-breast-density-in-overweight-obese2026-10-06 https://evidence-hub.com/study/9350-metformin-associated-lactic-acidosis-in-the-intensive-care-unit-a2026-10-06 https://evidence-hub.com/study/9351-profound-metabolic-acidosis-due-to-metformin-intoxication-requiring2026-10-06 https://evidence-hub.com/study/9352-metformin-associated-lactic-acidosis-in-an-older-adult-a-case-report2026-10-08 https://evidence-hub.com/study/9353-severe-metabolic-acidosis-related-to-simultaneous-use-of-metformin2026-10-06 https://evidence-hub.com/study/9354-metformin-induced-lactic-acidosis-a-question-of-time2026-10-06 https://evidence-hub.com/study/9355-an-unexpected-evolution-of-symptomatic-mild-middle-cerebral-artery2026-10-06 https://evidence-hub.com/study/9356-a-case-report-of-metformin-associated-lactic-acidosis2026-10-08 https://evidence-hub.com/study/9357-two-cases-of-metformin-associated-lactic-acidosis-in-post-operative2026-10-06 https://evidence-hub.com/study/9358-successful-treatment-of-metformin-and-rodenticide-intoxication-with2026-10-06 https://evidence-hub.com/study/9359-an-unexpected-complication-due-to-metformin-use-after-femur-fracture2026-10-06 https://evidence-hub.com/study/9360-transient-blindness-in-a-patient-with-severe-metformin-associated2026-10-06 https://evidence-hub.com/study/9361-metnet-a-phase-ii-trial-of-metformin-in-patients-with-well2026-10-06 https://evidence-hub.com/study/9362-sudden-onset-hypoglycemia-following-fluid-replacement-in-a-patient2026-10-06 https://evidence-hub.com/study/9363-durable-response-to-nivolumab-combined-with-metformin-in-advanced2026-10-06 https://evidence-hub.com/study/9364-metformin-treatment-a-potential-cause-of-megaloblastic-anemia-in2026-10-06 https://evidence-hub.com/study/9365-survival-and-vision-restoration-following-severe-metformin-associated2026-10-06 https://evidence-hub.com/study/9366-metformin-may-alter-the-course-of-leber-s-hereditary-optic-neuropathy2026-10-06 https://evidence-hub.com/study/9367-glycemic-impact-of-gabapentin-and-nucleo-c-m-p-in-metformin2026-10-08 https://evidence-hub.com/study/9368-where-is-the-lactate-coming-from-an-unusual-presentation-of2026-10-08 https://evidence-hub.com/study/9369-severe-metformin-associated-lactic-acidosis-managed-without-dialysis2026-10-06 https://evidence-hub.com/study/9370-sensory-ataxia-mimicking-diabetic-neuropathy-in-a-long-term-metformin2026-10-08 https://evidence-hub.com/study/9371-emergent-hemodialysis-followed-by-continuous-renal-replacement2026-10-06 https://evidence-hub.com/study/9372-4-polycystic-ovary-syndrome2026-10-06 https://evidence-hub.com/study/9373-a-disease-modifying-approach-for-advanced-hidradenitis-suppurativa2026-10-08 https://evidence-hub.com/study/9374-efficacy-of-pioglitazone-in-familial-partial-lipodystrophy-of-the2026-10-06 https://evidence-hub.com/study/9375-successful-rescue-of-a-rare-case-of-refractory-shock-due-to-multidrug2026-10-06 https://evidence-hub.com/study/9376-reversal-of-type-2-diabetes-in-a-patient-with-hashimoto-s-thyroiditis2026-10-06 https://evidence-hub.com/study/9377-metformin-and-gliclazide-based-diabetes-treatment-experience-in-a2026-10-06 https://evidence-hub.com/study/9378-hyperglycemia-after-dolutegravir-based-antiretroviral-therapy2026-10-06 https://evidence-hub.com/study/9379-novel-approach-for-treating-diabetes-in-a-patient-with-the2026-10-06 https://evidence-hub.com/study/9380-roux-en-y-gastric-bypass-in-the-treatment-of-non-classic-congenital2026-10-06 https://evidence-hub.com/study/9381-metformin-associated-hepatotoxicity2026-10-08 https://evidence-hub.com/study/9382-insulin-and-type-2-diabetes-last-resort-or-rational-management2026-10-06 https://evidence-hub.com/study/9383-hyperglycaemic-hyperosmolar-state-in-an-obese-prepubertal-girl-with2026-10-06 https://evidence-hub.com/study/9384-presence-of-ghost-capsules-in-stool-mimicking-parasites-due-to2026-10-06 https://evidence-hub.com/study/9385-multiple-limb-compartment-syndrome-as-a-manifestation-of-capillary2026-10-06 https://evidence-hub.com/study/9386-metformin-induced-hemolytic-anemia2026-10-08 https://evidence-hub.com/study/9387-metformin-induced-nightmares-an-uncommon-event2026-10-08 https://evidence-hub.com/study/9388-primary-care-recognition-of-rabson-mendenhall-syndrome-despite2026-10-08 https://evidence-hub.com/study/9389-case-report-early-onset-euglycemic-diabetic-ketoacidosis-following2026-10-08 https://evidence-hub.com/study/9390-a-rare-case-of-possible-iron-overload-and-b12-deficiency-in2026-10-08 https://evidence-hub.com/study/9391-a-case-of-metformin-associated-encephalopathy-in-a-patient-undergoing2026-10-08 https://evidence-hub.com/study/9392-brain-neuromodulation-via-endoscopic-gastric-implant-improves2026-10-08 https://evidence-hub.com/study/9393-case-report-tirzepatide-responsive-refractory-diabetes-mellitus-in-an2026-10-08 https://evidence-hub.com/study/9394-early-onset-type-1-diabetes-mellitus-in-a-child-with-a-pathogenic2026-10-08 https://evidence-hub.com/study/9395-case-report-efficacy-and-safety-of-sglt2-inhibitors-in-patients-with2026-10-08 https://evidence-hub.com/study/9396-coexistence-of-metabolic-neuropathy-and-cervical-myelopathy2026-10-08 https://evidence-hub.com/study/9397-metformin-induced-xerostomia-and-chapped-lips-in-a-56-year-old2026-10-08 https://evidence-hub.com/study/9398-diagnosing-metformin-intoxication-with-high-resolution-platelet2026-10-08 https://evidence-hub.com/study/9399-tirzepatide-based-therapy-for-multidomain-metabolic-improvement-in-an2026-10-08 https://evidence-hub.com/study/9400-a-case-report-of-young-onset-type-2-diabetes-patient-with-severe2026-10-08 https://evidence-hub.com/study/9401-semaglutide-induced-sarcopenia-via-glp-1r-mtor-satellite-cells-axis2026-10-08 https://evidence-hub.com/study/9402-ulcerative-bullosis-diabeticorum-in-a-man-with-chronic-uncontrolled2026-10-10 https://evidence-hub.com/study/9403-a-67-year-old-woman-with-intractable-cough-and-dyspnea-after-catheter2026-10-08 https://evidence-hub.com/study/9404-probable-metformin-associated-erythema-multiforme-a-case-report-and2026-10-08 https://evidence-hub.com/study/9405-recognizing-euglycemic-diabetic-ketoacidosis-in-the-era-of-sglt22026-10-08 https://evidence-hub.com/study/9406-sequential-liraglutide-and-setmelanotide-therapy-in-bardet-biedl2026-10-08 https://evidence-hub.com/study/9407-fatal-metformin-associated-lactic-acidosis-in-a-healthy-woman-after2026-10-08 https://evidence-hub.com/study/9408-early-hemodialysis-in-pediatric-metformin-overdose-with-severe-lactic2026-10-08 https://evidence-hub.com/study/9409-metformin-associated-functional-vitamin-b12-deficiency-presenting-as2026-10-08 https://evidence-hub.com/study/9410-probable-vildagliptin-associated-acute-pancreatitis-in-a-patient-with2026-10-08 https://evidence-hub.com/study/9411-atypical-hypoglycemia-induced-stroke-mimic-a-case-report-and2026-10-08 https://evidence-hub.com/study/9412-a-parental-request-for-an-unproven-treatment-for-a-rare-pediatric2026-10-08 https://evidence-hub.com/study/9413-multi-factorial-hyperlactatemia-due-to-linezolid-and-metformin2026-10-08 https://evidence-hub.com/study/9414-long-term-survival-in-three-cases-with-pulmonary-metastases-from2026-10-08 https://evidence-hub.com/study/9415-severe-macrocytic-anemia-uncovering-pernicious-anemia-and-early-stage2026-10-08 https://evidence-hub.com/study/9416-late-onset-autoimmune-diabetes-in-2-octogenarians-diagnostic2026-10-08 https://evidence-hub.com/study/9417-metformin-induced-encephalopathy-in-a-peritoneal-dialysis-patient-the2026-10-08 https://evidence-hub.com/study/9418-antenatal-management-of-hnf4a-mody-and-insr-mutations-in-pregnancy2026-10-08 https://evidence-hub.com/study/9419-durable-insulin-free-remission-in-a-ketosis-prone-diabetes-with-sglt22026-10-08 https://evidence-hub.com/study/9420-successful-pregnancy-after-in-vitro-fertilization-embryo-transfer-in2026-10-08 https://evidence-hub.com/study/9421-double-autoimmune-endocrinopathies-concurrent-presentation-of-latent2026-10-08 https://evidence-hub.com/study/9422-first-diagnosis-of-familial-partial-lipodystrophy-syndrome-type-32026-10-08 https://evidence-hub.com/study/9423-treatment-approaches-for-obesity-in-children-with-heterozygous-mc4r2026-10-08 https://evidence-hub.com/study/9424-impact-of-yoga-and-naturopathy-in-a-patient-with-chronic-idiopathic2026-10-08 https://evidence-hub.com/study/9425-quadruple-non-insulin-therapy-for-advanced-type-2-diabetes-mellitus2026-10-08 https://evidence-hub.com/study/9426-case-report-rapid-progressive-puberty-in-siblings-with-mc4r-p2026-10-08 https://evidence-hub.com/study/9427-fatal-pediatric-metformin-associated-lactic-acidosis-when-severity2026-10-08 https://evidence-hub.com/study/9428-identification-and-functional-characterization-of-a-novel-mutation-in2026-10-08 https://evidence-hub.com/study/9429-acromegaly-discovered-after-head-trauma-multivessel-coronary-disease2026-10-08 https://evidence-hub.com/study/9430-multiple-endocrine-dysfunctions-in-twins-with-wilson-s-disease-two2026-10-08 https://evidence-hub.com/study/9431-a-case-report-of-postoperative-poor-drainage-of-perianal-abscess-in2026-10-08 https://evidence-hub.com/study/9432-bupropion-toxicity-presenting-as-alcohol-withdrawal-syndrome-a-case2026-10-08 https://evidence-hub.com/study/9433-a-case-report-treatment-follow-up-and-literature-review-of-type-a2026-10-08 https://evidence-hub.com/study/9434-the-influence-of-falsely-low-hba1c-levels-in-diabetes-patients-with2026-10-08 https://evidence-hub.com/study/9435-fulminant-emphysematous-hepatitis-with-pneumoperitoneum-a-case-report2026-10-08 https://evidence-hub.com/study/9436-type-b-insulin-resistance-with-glycemic-extremes-a-case-report-and2026-10-08 https://evidence-hub.com/study/9437-lipodystrophy-an-uncommon-cause-of-insulin-resistance-and-young-onset2026-10-08 https://evidence-hub.com/study/9438-severe-multifactorial-lactic-acidosis-with-pulmonary-edema-and2026-10-08 https://evidence-hub.com/study/9439-reversing-20-years-of-diabetes-using-the-carnivore-diet-in-india-a2026-10-08 https://evidence-hub.com/study/9440-type-2-diabetes-mellitus-complicated-by-acquired-reactive-perforating2026-10-08 https://evidence-hub.com/study/9441-hnf1b-mody-mody-5-a-rare-form-of-diabetes-with-multisystemic-features2026-10-08 https://evidence-hub.com/study/9442-tirzepatide-associated-interstitial-kidney-injury2026-10-08 https://evidence-hub.com/study/9443-severe-hyperglycemia-after-initiation-of-long-acting-cabotegravir-in2026-10-08 https://evidence-hub.com/study/9444-sternoclavicular-joint-infection-caused-by-staphylococcus-capitis2026-10-08 https://evidence-hub.com/study/9445-implant-rehabilitation-following-loss-of-tooth-restorability2026-10-08 https://evidence-hub.com/study/9446-decreasing-hemoglobin-a1c-progress-or-pathology2026-10-08 https://evidence-hub.com/study/9447-polypharmacy-s-paradox-accelerated-decline-in-a-rare-case-of-lafora2026-10-08 https://evidence-hub.com/study/9448-spironolactone-induced-bilateral-gynecomastia-in-a-patient-with2026-10-08 https://evidence-hub.com/study/9449-linagliptan-associated-delirium-in-an-older-patient2026-10-08 https://evidence-hub.com/study/9450-unmasking-ketosis-prone-diabetes-in-a-young-adult2026-10-08 https://evidence-hub.com/study/9451-type-b-insulin-resistance-syndrome-coexisting-with-aplastic-anemia2026-10-08 https://evidence-hub.com/study/9452-type-1-diabetes-mellitus-in-a-child-with-genetically-confirmed2026-10-08 https://evidence-hub.com/study/9453-metformin-related-fatalities-the-importance-of-combining-forensic2026-10-08 https://evidence-hub.com/study/9454-acute-phosphate-nephropathy-following-oral-sodium-phosphate-bowel2026-10-08 https://evidence-hub.com/study/9455-delayed-rupture-of-the-extensor-pollicis-longus-tendon-following2026-10-06 https://evidence-hub.com/study/9456-severe-hypertriglyceridemia-managed-in-a-pregnant-patient-using2026-10-06 https://evidence-hub.com/study/9458-late-onset-chronic-severe-painless-diarrhea-secondary-to-metformin2026-10-08 https://evidence-hub.com/study/9460-life-threatening-metformin-induced-lactic-acidosis-associated-with2026-10-08 https://evidence-hub.com/study/9461-chronic-radiation-proctitis-refractory-to-steroid-enema-was2026-10-08 https://evidence-hub.com/study/9463-treatment-of-severe-metformin-associated-lactic-acidosis-with-renal2026-10-08 https://evidence-hub.com/study/9464-reversible-acute-blindness-in-suspected-metformin-associated-lactic2026-10-08 https://evidence-hub.com/study/9465-a-case-report-of-metformin-related-lactic-acidosis2026-10-08 https://evidence-hub.com/study/9466-fatal-metformin-poisoning-adolescent-case-report2026-10-08 https://evidence-hub.com/study/9467-simultaneous-dual-continuous-veno-venous-haemofiltration-for2026-10-08 https://evidence-hub.com/study/9468-ventilator-management-in-metformin-associated-lactic-acidosis-a-case2026-10-08 https://evidence-hub.com/study/9469-metformin-associated-lactic-acidosis-a-case-report2026-10-08 https://evidence-hub.com/study/9470-metformin-associated-lactic-acidosis-in-individuals-without-chronic2026-10-08 https://evidence-hub.com/study/9471-extrapyramidal-syndromes-of-chronic-kidney-disease-and-dialysis2026-10-08 https://evidence-hub.com/study/9472-daily-dose-of-metformin-caused-acute-kidney-injury-with-lactic2026-10-08 https://evidence-hub.com/study/9473-metformin-induced-generalized-bullous-fixed-drug-eruption-with-a2026-10-08 https://evidence-hub.com/study/9474-metformin-induced-bullous-pemphigoid-a-rare-case-report2026-10-08 https://evidence-hub.com/study/9475-a-patient-with-severe-metformin-associated-lactic-acidosis2026-10-08 https://evidence-hub.com/study/9476-metformin-associated-lactic-acidosis-a-case-report-and-review2026-10-08 https://evidence-hub.com/study/9477-a-rare-case-report-of-combined-metformin-associated-lactic-acidosis2026-10-08 https://evidence-hub.com/study/9478-case-report-off-label-utilization-of-topiramate-and-metformin-in2026-10-08 https://evidence-hub.com/study/9480-melas-syndrome-and-midd-unmasked-by-metformin-use-a-case-report2026-10-08 https://evidence-hub.com/study/9481-lactic-acidosis-a-potential-toxicity-from-drug-drug-interaction2026-10-08 https://evidence-hub.com/study/9482-metformin-associated-lactic-acidosis-treated-successfully-by2026-10-08 https://evidence-hub.com/study/9483-a-patient-with-metformin-associated-lactic-acidosis-successfully2026-10-08 https://evidence-hub.com/study/9484-a-case-report-on-metformin-associated-lactic-acidosis2026-10-08 https://evidence-hub.com/study/9485-donohue-syndrome-with-a-homozygous-insr-exon-14-deletion-a-case-report2026-10-06 https://evidence-hub.com/study/9486-bilateral-primary-nonrefluxing-unobstructed-megaureter-in-an-adult-a2026-10-08 https://evidence-hub.com/study/9487-case-report-hemolysis-in-a-g6pd-deficient-patient-a-dose-dependent2026-10-08 https://evidence-hub.com/study/9488-case-report-a-case-of-encephalopathy-presenting-the-lentiform-fork2026-10-08 https://evidence-hub.com/study/9489-hypersensitivity-reaction-with-metformin-a-case-report2026-10-08 https://evidence-hub.com/study/9490-recurrent-hypoglycemia-secondary-to-metformin-toxicity-in-the-absence2026-10-08 https://evidence-hub.com/study/9491-metformin-associated-lactic-acidosis-a-case-report2026-10-08 https://evidence-hub.com/study/9492-a-case-report-of-systemic-allergic-reaction-to-the-dual-glucose2026-10-08 https://evidence-hub.com/study/9493-severe-hypomagnesemia-and-hypocalcemia-linked-to-semaglutide-in-type2026-10-08 https://evidence-hub.com/study/9494-metformin-associated-lactic-acidosis-a-case-report2026-10-08 https://evidence-hub.com/study/9495-effect-of-high-flow-high-volume-intermittent-hemodiafiltration-on2026-10-08 https://evidence-hub.com/study/9496-case-report-a-case-of-rabson-mendenhall-syndrome-long-term-follow-up2026-10-08 https://evidence-hub.com/study/9497-iatrogenic-chronic-abdominal-pain-in-a-geriatric-patient-a-case-report2026-10-08 https://evidence-hub.com/study/9498-when-a-harmless-procedure-causes-a-life-threatening-problem-a-case2026-10-08 https://evidence-hub.com/study/9499-efficacy-of-metformin-for-advanced-stage-endometrial-cancer-a-case2026-10-08 https://evidence-hub.com/study/9500-metabolic-acidosis-in-postsurgical-patient-on-canagliflozin-and2026-10-08 https://evidence-hub.com/study/9501-case-report-glycaemic-management-and-pregnancy-outcomes-in-a-woman2026-10-08 https://evidence-hub.com/study/9502-metformin-associated-inflammation-levels-regulation-in-type-22026-10-08 https://evidence-hub.com/study/9505-metformin-related-lactic-acidosis-case-report2026-10-08 https://evidence-hub.com/study/9507-metformin-as-a-rare-cause-of-drug-induced-liver-injury-a-case-report2026-10-08 https://evidence-hub.com/study/9509-metformin-for-lithium-induced-weight-gain-a-case-report2026-10-08 https://evidence-hub.com/study/9510-hyperglycemia-after-metformin-overdose-a-case-report2026-10-08 https://evidence-hub.com/study/9511-acute-esophageal-necrosis-as-a-rare-complication-of-metabolic2026-10-08 https://evidence-hub.com/study/9512-liraglutide-and-liver-injury-rare-case-report-with-literature-review2026-10-08 https://evidence-hub.com/study/9513-recreational-nitrous-oxide-induced-subacute-combined-degeneration-of2026-10-08 https://evidence-hub.com/study/9514-lifestyle-medicine-approach-in-managing-pemphigus-vulgaris-a-case2026-10-08 https://evidence-hub.com/study/9515-metformin-a-modulator-of-bevacizumab-activity-in-cancer-a-case-report2026-10-08 https://evidence-hub.com/study/9517-euglycemic-diabetic-ketoacidosis-induced-by-sodium-glucose2026-10-08 https://evidence-hub.com/study/9518-metformin-associated-lactic-acidosis-presenting-as-an-ischemic-gut-in2026-10-08 https://evidence-hub.com/study/9519-sglt-2-inhibitor-associated-euglycemic-diabetic-ketoacidosis-a-case2026-10-08 https://evidence-hub.com/study/9520-combination-therapy-with-semaglutide-and-dapagliflozin-as-an2026-10-08 https://evidence-hub.com/study/9522-metformin-associated-lactic-acidosis-and-temporary-ileostomy-a-case2026-10-08 https://evidence-hub.com/study/9523-expanding-the-phenotype-of-trmt10a-mutations-case-report-and-a-review2026-10-08 https://evidence-hub.com/study/9525-sglt2-inhibitors-as-potentially-helpful-drugs-in-pi3k-inhibitor2026-10-08 https://evidence-hub.com/study/9526-unusual-case-of-metformin-associated-lactic-acidosis-in-patient-with2026-10-08 https://evidence-hub.com/study/9529-fournier-gangrene-in-a-patient-with-type-2-diabetes-mellitus-treated2026-10-08 https://evidence-hub.com/study/9530-novel-pik3r1-mutation-of-short-syndrome-a-case-report-with-a-6-month2026-10-08 https://evidence-hub.com/study/9531-insulin-insulin-everywhere-a-rare-case-report-of-rabson-mendenhall2026-10-08 https://evidence-hub.com/study/9532-novel-insights-into-monogenic-obesity-syndrome-due-to-inpp5e-gene2026-10-08 https://evidence-hub.com/study/9533-case-report-metreleptin-and-sglt2-inhibitor-combination-therapy-is2026-10-08 https://evidence-hub.com/study/9534-megaloblastic-anemia-related-iron-overload-and-erythroid-regulators-a2026-10-08 https://evidence-hub.com/study/9535-recurrent-generalized-seizures-with-postictal-todd-s-paralysis-caused2026-10-08 https://evidence-hub.com/study/9536-improvement-in-glycaemic-parameters-using-sglt-2-inhibitor-and-glp-12026-10-08 https://evidence-hub.com/study/9537-euglycemic-diabetic-ketoacidosis-caused-by-canagliflozin-a-case-report2026-10-08 https://evidence-hub.com/study/9538-ketogenic-diet-as-a-trigger-for-diabetic-ketoacidosis-in-a2026-10-08 https://evidence-hub.com/study/9539-early-signs-of-thiamine-deficiency-a-case-report2026-10-08 https://evidence-hub.com/study/9540-mapping-the-extended-pain-pathway-human-genetic-and-multi-omic2026-10-01 https://evidence-hub.com/study/9541-diagnosis-and-treatment-of-polycystic-ovary-syndrome-an-endocrine2026-10-08 https://evidence-hub.com/study/9542-american-association-of-clinical-endocrinologists-american-college-of2026-10-08 https://evidence-hub.com/study/9543-preexisting-diabetes-and-pregnancy-an-endocrine-society-and-european2026-10-13 https://evidence-hub.com/study/9544-newer-pharmacologic-treatments-in-adults-with-type-2-diabetes-a2026-10-08 https://evidence-hub.com/study/9545-recommendations-of-the-spanish-society-of-endocrinology-and-nutrition2026-10-08 https://evidence-hub.com/study/9546-international-society-for-pediatric-and-adolescent-diabetes-clinical2026-10-08 https://evidence-hub.com/study/9547-canadian-association-of-radiologists-consensus-guidelines-for-the2026-10-08 https://evidence-hub.com/study/9548-prescribing-a-sglt2-inhibitor-for-treating-heart-failure-without2026-10-08 https://evidence-hub.com/study/9549-managing-hyperglycaemia-during-antenatal-steroid-administration2026-10-08 https://evidence-hub.com/study/9550-perioperative-management-of-adult-diabetic-patients-preoperative2026-10-08 https://evidence-hub.com/study/9551-executive-summary-of-the-2020-kdigo-diabetes-management-in-ckd2026-10-08 https://evidence-hub.com/study/9552-joint-tos-oma-oac-expert-guidance-statement-on-the-pharmacological2026-10-08 https://evidence-hub.com/study/9553-recommendations-on-the-effect-of-antidiabetic-drugs-in-bone2026-10-08 https://evidence-hub.com/study/9554-ovulation-induction-in-polycystic-ovary-syndrome-no-242-may-20102026-10-08 https://evidence-hub.com/study/9555-consensus-statement-on-prevention-and-detection-of-ovarian2026-10-08 https://evidence-hub.com/study/9556-ovulation-induction-in-polycystic-ovary-syndrome2026-10-08 https://evidence-hub.com/study/9557-a-european-evidence-based-guideline-for-the-prevention-of-type-22026-10-08 https://evidence-hub.com/study/9558-statement-of-the-spanish-interdisciplinary-vascular-prevention2026-10-08 https://evidence-hub.com/study/9559-management-guideline-for-werner-syndrome-2020-3-diabetes-associated2026-10-08 https://evidence-hub.com/study/9560-british-fertility-society-policy-and-practice-committee-adjuvants-in2026-10-08 https://evidence-hub.com/study/9561-treatment-of-type-1-diabetes-synopsis-of-the-2017-american-diabetes2026-10-08 https://evidence-hub.com/study/9562-metformin-and-intervention-in-polycystic-ovary-syndrome-endocrine2026-10-08 https://evidence-hub.com/study/9563-european-society-of-urogenital-radiology-guidelines-on-administering2026-10-08 https://evidence-hub.com/study/9564-medicines-for-treatment-intensification-in-type-2-diabetes-and-type2026-10-08 https://evidence-hub.com/study/9565-how-i-manage-a-patient-with-type-2-diabetes-not-well-controlled-with2026-10-08 https://evidence-hub.com/study/9566-diabetic-kidney-disease-new-clinical-and-therapeutic-issues-joint2026-10-08 https://evidence-hub.com/study/9567-pharmacologic-approaches-to-glycemic-treatment-of-type-2-diabetes2026-10-08 https://evidence-hub.com/study/9568-aga-clinical-practice-update-on-chemoprevention-for-colorectal2026-10-08 https://evidence-hub.com/study/9569-metformin-in-the-management-of-antipsychotic-induced-weight-gain-in2026-10-08 https://evidence-hub.com/study/9570-bap-guidelines-on-the-management-of-weight-gain-metabolic2026-10-08 https://evidence-hub.com/study/9571-pharmacologic-therapy-for-type-2-diabetes-synopsis-of-the-20172026-10-08 https://evidence-hub.com/study/9572-oral-pharmacologic-treatment-of-type-2-diabetes-mellitus-a-clinical2026-10-08 https://evidence-hub.com/study/9573-canadian-association-of-radiologists-consensus-guidelines-for-the2026-10-08 https://evidence-hub.com/study/9574-consensus-on-the-detection-and-management-of-prediabetes-consensus2026-10-08 https://evidence-hub.com/study/9575-the-canadian-network-for-mood-and-anxiety-treatments-canmat-task2026-10-08 https://evidence-hub.com/study/9576-consensus-on-infertility-treatment-related-to-polycystic-ovary2026-10-08 https://evidence-hub.com/study/9577-summary-of-the-practice-guideline-diabetes-mellitus-type-2-second2026-10-08 https://evidence-hub.com/study/9578-intervening-early-in-the-cardiovascular-kidney-metabolic-syndrome2026-10-08 https://evidence-hub.com/study/9579-guidelines-for-good-practice-in-the-diagnosis-and-treatment-of-non2026-10-08 https://evidence-hub.com/study/9580-summary-of-the-practice-guideline-diabetes-mellitus-type-2-first2026-10-08 https://evidence-hub.com/study/9581-contrast-media-and-metformin-guidelines-to-diminish-the-risk-of2026-10-08 https://evidence-hub.com/study/9582-a-new-blood-glucose-management-algorithm-for-type-2-diabetes-a2026-10-08 https://evidence-hub.com/study/9583-management-of-newly-diagnosed-type-2-diabetes-mellitus-t2dm-in2026-10-08 https://evidence-hub.com/study/9584-preexisting-diabetes-expert-consensus-from-the-college-of-french2026-10-08 https://evidence-hub.com/study/9585-diabetes-management-in-people-undergoing-metabolic-bariatric-surgery2026-10-08 https://evidence-hub.com/study/9586-sglt-2-inhibitors-or-glp-1-receptor-agonists-for-adults-with-type-22026-10-08 https://evidence-hub.com/study/9587-which-place-for-metformin-in-the-management-of-type-2-diabetes2026-10-08 https://evidence-hub.com/study/9588-triple-oral-therapy-with-metformin-dpp-4-inhibitor-and-sglt22026-10-08 https://evidence-hub.com/study/9589-executive-summary-of-the-kdigo-2022-clinical-practice-guideline-for2026-10-08 https://evidence-hub.com/study/9590-oral-pharmacologic-treatment-of-type-2-diabetes-mellitus-a-clinical2026-10-08 https://evidence-hub.com/study/9591-american-association-of-clinical-endocrinologists-american-college-of2026-10-08 https://evidence-hub.com/study/9592-clinical-practice-guideline-for-long-covid-prevention-and-treatment2026-10-08 https://evidence-hub.com/study/9593-clinical-practice-guideline-on-the-pharmacological-management-of2026-10-08 https://evidence-hub.com/study/9594-hospital-diabetes-management-update-20262026-10-08 https://evidence-hub.com/study/9595-2026-aha-acc-ada-asn-guideline-for-the-prevention-detection2026-10-08 https://evidence-hub.com/study/9596-prevention-surveillance-and-early-detection-of-hepatocellular2026-10-08 https://evidence-hub.com/study/9597-australian-and-new-zealand-journal-of-psychiatry-grading-of2026-10-08 https://evidence-hub.com/study/9598-diabetic-kidney-disease-update-2026-guidelines-in-a-collaboration-of2026-10-08 https://evidence-hub.com/study/9599-australasian-periprocedural-guideline-for-children-and-adolescents2026-10-08 https://evidence-hub.com/study/9600-clinical-practice-guideline-on-the-choice-of-first-antipsychotic2026-10-08 https://evidence-hub.com/study/9601-eshre-guideline-ovarian-stimulation-for-ivf-icsi-an-update-in-20252026-10-10 https://evidence-hub.com/study/9602-diagnosis-and-management-of-infertility-in-patients-with-polycystic2026-10-08 https://evidence-hub.com/study/9603-use-of-continuous-glucose-monitoring-in-non-intensively-managed-type2026-10-08 https://evidence-hub.com/study/9604-recommendations-from-the-who-guideline-for-the-prevention-diagnosis2026-10-08 https://evidence-hub.com/study/9605-saudi-clinical-practice-guidelines-for-management-of-diabetic-kidney2026-10-08 https://evidence-hub.com/study/9606-clinical-guidelines-on-physical-activity-and-exercise-therapy-for2026-10-08 https://evidence-hub.com/study/9607-10-cardiovascular-disease-and-risk-management-standards-of-care-in2026-10-08 https://evidence-hub.com/study/9608-cardiovascular-prevention-in-children-adolescents-and-young-adults-a2026-10-08 https://evidence-hub.com/study/9609-icardio-alliance-global-implementation-guidelines-for-the-management2026-10-08 https://evidence-hub.com/study/9610-ispad-clinical-practice-consensus-guidelines-2024-type-2-diabetes-in2026-10-08 https://evidence-hub.com/study/9611-national-heart-center-saudi-heart-association-2025-guidelines-for2026-10-08 https://evidence-hub.com/study/9613-individualizing-antihypertensive-therapy-in-diabetes-mellitus2026-10-08 https://evidence-hub.com/study/9614-cardiovascular-kidney-related-and-weight-loss-effects-of-therapeutics2026-10-08 https://evidence-hub.com/study/9615-major-revision-version-13-0-of-the-european-aids-clinical-society2026-10-08 https://evidence-hub.com/study/9616-eta-guidelines-for-the-use-of-levothyroxine-sodium-preparations-in2026-10-08 https://evidence-hub.com/study/9617-prevention-of-obesity-among-adults-evidence-and-consensus-based2026-10-08 https://evidence-hub.com/study/9618-pharmacological-nephroprotection-in-chronic-kidney-disease-patients2026-10-08 https://evidence-hub.com/study/9619-british-society-of-gastroenterology-practice-guidance-on-the2026-10-08 https://evidence-hub.com/study/9620-current-management-of-chronic-kidney-disease-in-type-2-diabetes-a2026-10-08 https://evidence-hub.com/study/9621-esr-essentials-imaging-of-lymphoma-practice-recommendations-by-the2026-10-08 https://evidence-hub.com/study/9622-european-s2k-guidelines-for-hidradenitis-suppurativa-acne-inversa2026-10-08 https://evidence-hub.com/study/9623-european-s2k-guideline-on-chronic-pruritus2026-10-08 https://evidence-hub.com/study/9624-easl-easd-easo-clinical-practice-guidelines-on-the-management-of2026-10-08 https://evidence-hub.com/study/9625-recommendations-for-the-diagnosis-and-treatment-of-chronic-kidney2026-10-08 https://evidence-hub.com/study/9626-pharmacological-and-somatic-treatments-for-first-episode-psychosis2026-10-08 https://evidence-hub.com/study/9627-easl-easd-easo-clinical-practice-guidelines-on-the-management-of2026-10-08 https://evidence-hub.com/study/9628-cardiometabolic-risk-in-children-and-adolescents-with-obesity-a2026-10-08 https://evidence-hub.com/study/9629-acg-clinical-guideline-diagnosis-and-management-of-gastric2026-10-08 https://evidence-hub.com/study/9630-antiretroviral-postexposure-prophylaxis-after-sexual-injection-drug2026-10-08 https://evidence-hub.com/study/9631-eanm-snmmi-guideline-procedure-standard-for-18f-fdg-hybrid-pet-use-in2026-10-08 https://evidence-hub.com/study/9632-clinical-practice-guideline-shared-decision-making-diagnostic2026-10-08 https://evidence-hub.com/study/9633-european-guidelines-for-the-diagnosis-and-treatment-of-pancreatic2026-10-13 https://evidence-hub.com/study/9634-british-society-of-gastroenterology-guidelines-for-the-management-of2026-10-08 https://evidence-hub.com/study/9635-managing-obesity-in-children-a-clinical-practice-guideline2026-10-08 https://evidence-hub.com/study/9636-the-management-of-chronic-kidney-disease-not-requiring-renal2026-10-08 https://evidence-hub.com/study/9637-chinese-stroke-association-guidelines-for-clinical-management-of2026-10-08 https://evidence-hub.com/study/9638-extracorporeal-treatment-in-poisoning2026-10-08 https://evidence-hub.com/study/9639-australasian-recurrent-pregnancy-loss-clinical-management-guideline2026-10-08 https://evidence-hub.com/study/9640-new-guideline-on-diabetes-management-in-chronic-kidney-disease2026-10-08 https://evidence-hub.com/study/9641-elective-peri-operative-management-of-adults-taking-glucagon-like2026-10-08 https://evidence-hub.com/study/9642-latin-american-guidelines-of-recommendations-at-discharge-from-an2026-10-08 https://evidence-hub.com/study/9643-american-association-of-clinical-endocrinology-clinical-practice2026-10-08 https://evidence-hub.com/study/9644-cardiovascular-preventive-recommendations-papps-2024-thematic-updates2026-10-08 https://evidence-hub.com/study/9645-uk-kidney-association-clinical-practice-guideline-sodium-glucose-co2026-10-08 https://evidence-hub.com/study/9646-2023-clinical-practice-guidelines-for-diabetes-mellitus-of-the-korean2026-10-08 https://evidence-hub.com/study/9647-dunnigan-lipodystrophy-syndrome-french-national-diagnosis-and-care2026-10-08 https://evidence-hub.com/study/9648-the-egyptian-clinical-practice-guidelines-for-the-diagnosis-and2026-10-08 https://evidence-hub.com/study/9649-the-italian-guideline-on-diagnosis-and-treatment-of-dementia-and-mild2026-10-08 https://evidence-hub.com/study/9650-clozapine-optimization-a-delphi-consensus-guideline-from-the2026-10-08 https://evidence-hub.com/study/9651-new-classification-and-diagnostic-criteria-for-insulin-resistance2026-10-08 https://evidence-hub.com/study/9652-diagnosis-and-management-of-patients-with-diabetes-and-co-existing2026-10-08 https://evidence-hub.com/study/9653-tackling-potentially-inappropriate-prescriptions-in-older-adults2026-10-08 https://evidence-hub.com/study/9654-adult-and-late-onset-male-hypogonadism-the-clinical-practice2026-10-08 https://evidence-hub.com/study/9655-guidance-for-canadian-breast-cancer-practice-national-consensus2026-10-08 https://evidence-hub.com/study/9656-non-alcoholic-fatty-liver-disease-in-adults-2021-a-clinical-practice2026-10-08 https://evidence-hub.com/study/9657-metabolic-surgery-in-treatment-of-obese-japanese-patients-with-type-22026-10-08 https://evidence-hub.com/study/9658-structural-patterns-in-chronic-disease-clinical-practice-guidelines2026-10-08 https://evidence-hub.com/study/9659-management-of-hyperglycemia-in-hospitalized-adult-patients-in-non2026-10-13 https://evidence-hub.com/study/9660-2022-klca-ncc-korea-practice-guidelines-for-the-management-of2026-10-08 https://evidence-hub.com/study/9661-individualising-antihypertensive-therapy-in-patients-with-diabetes-a2026-10-08 https://evidence-hub.com/study/9662-2021-clinical-practice-guidelines-for-diabetes-mellitus-of-the-korean2026-10-08 https://evidence-hub.com/study/9663-wilderness-medical-society-clinical-practice-guidelines-for-diabetes2026-10-08 https://evidence-hub.com/study/9664-integrated-care-protocol-prevention-diagnosis-and-treatment-of2026-10-08 https://evidence-hub.com/study/9665-assessment-and-management-of-vitamin-status-in-children-with-ckd2026-10-06 https://evidence-hub.com/study/9666-2019-clinical-practice-guidelines-for-type-2-diabetes-mellitus-in2026-10-06 https://evidence-hub.com/study/9667-metformin-for-the-prevention-of-antipsychotic-induced-weight-gain2026-10-08 https://evidence-hub.com/study/9668-metformin-in-the-treatment-of-hyperglycemia-during-pregnancy-and2026-10-08 https://evidence-hub.com/study/9673-anti-obesity-pharmacological-agents-for-polycystic-ovary-syndrome-a2026-10-08 https://evidence-hub.com/study/9674-erbp-guideline-on-management-of-patients-with-diabetes-and-chronic2026-10-08 https://evidence-hub.com/study/9675-reduced-metformin-concentrations-in-obese-women-with-human2026-10-08 https://evidence-hub.com/study/9676-stability-indicating-hplc-for-remogliflozin-vildagliptin-and2026-10-08 https://evidence-hub.com/study/9677-deciphering-mortality-risk-of-diabetes-medications-in-heart-failure2026-10-08 https://evidence-hub.com/study/9678-are-guideline-concordant-processes-of-care-consistent-across-the2026-10-08 https://evidence-hub.com/study/9679-abstract-wp5-outcomes-of-pre-stroke-use-of-metformin-in-acute2026-10-08 https://evidence-hub.com/study/9680-uhplc-apci-tq-ms-analytical-method-capable-of-quantifying-eight2026-10-08 https://evidence-hub.com/study/9681-development-and-validation-of-a-high-performance-liquid2026-10-08 https://evidence-hub.com/study/9682-simultaneous-estimation-of-sitagliptin-metformin-hydrochloride2026-10-08 https://evidence-hub.com/study/9683-l26-p-720-optimizing-metformin-use-in-polycystic-ovary-syndrome-met2026-10-08 https://evidence-hub.com/study/9685-a-simple-precise-and-sensitive-rp-hplc-method-for-quantification-of2026-10-08 https://evidence-hub.com/study/9687-association-of-metformin-treatment-with-risk-for-death-in-diabetic2026-10-08 https://evidence-hub.com/study/9688-dissolution-testing-and-content-uniformity-analysis-for-metformin2026-10-08 https://evidence-hub.com/study/9689-the-efficacy-of-vitamin-b12-supplementation-for-treating-vitamin-b122026-10-08 https://evidence-hub.com/study/9690-association-of-metformin-monotherapy-or-combined-therapy-with2026-10-08 https://evidence-hub.com/study/9691-simultaneous-uv-spectrophotometric-method-for-estimation-of2026-10-08 https://evidence-hub.com/study/9692-uhplc-apci-tq-ms-analytical-method-to-quantify-nitrosamine-impurities2026-10-08 https://evidence-hub.com/study/9693-the-use-of-metformin-for-type-2-diabetes-prevention-observational2026-10-08 https://evidence-hub.com/study/9697-sodium-glucose-cotransporter-2-inhibitor-versus-metformin-as-first2026-10-08 https://evidence-hub.com/study/9698-glucagon-like-peptide-1-agonists-for-treatment-of-patients-with-type2026-10-08 https://evidence-hub.com/study/9699-changing-patterns-in-medication-prescription-for-gestational-diabetes2026-10-08 https://evidence-hub.com/study/9701-a-stability-indicating-rp-hplc-method-validation-for-simultaneous2026-10-08 https://evidence-hub.com/study/9702-non-alcoholic-steatohepatitis-diagnosis-and-treatment-medical-and2026-10-08 https://evidence-hub.com/study/9704-a-stability-indicating-rp-hplc-method-validation-for-simultaneous2026-10-08 https://evidence-hub.com/study/9705-physicochemical-quality-of-metformin-hydrochloride-tablet-brands2026-10-08 https://evidence-hub.com/study/9706-reverse-phase-chromatographic-method-of-analysis-for-assay-and2026-10-08 https://evidence-hub.com/study/9707-sitagliptin-add-on-to-metformin-plus-sulphonylurea-combination2026-10-08 https://evidence-hub.com/study/9708-the-saudi-clinical-practice-guideline-for-the-management-of2026-10-08 https://evidence-hub.com/study/9709-metformin-in-heart-failure-patients2026-10-08 https://evidence-hub.com/study/9710-metformin-use-in-gestational-diabetes-awareness-attitude-and-practice2026-10-08 https://evidence-hub.com/study/9711-determinants-of-treatment-modification-before-and-after2026-10-08 https://evidence-hub.com/study/9712-development-and-stability-of-forced-degradation-studies-indicating2026-10-08 https://evidence-hub.com/study/9715-headspace-gas-chromatography-for-the-determination-of-residual2026-10-08 https://evidence-hub.com/study/9717-evaluation-of-vitamin-b12-monitoring-in-veterans-with-type-2-diabetes2026-10-08 https://evidence-hub.com/study/9721-development-and-validation-of-rp-hplc-method-for-simultaneous2026-10-08 https://evidence-hub.com/study/9722-metformin-hydrochloride-extended-release-tablets2026-10-08 https://evidence-hub.com/study/9724-keeping-up-with-guideline-recommendations-does-patient-volume-matter2026-10-08 https://evidence-hub.com/study/9726-development-and-validation-of-a-high-performance-liquid2026-10-08 https://evidence-hub.com/study/9727-metformin-glimepiride-and-metformin-glibenclamide-which-is-better-a2026-10-08 https://evidence-hub.com/study/9731-microwave-assisted-acrylamide-grafting-on-a-natural-gum-cassia-tora2026-10-08 https://evidence-hub.com/study/9732-association-between-guideline-recommended-drugs-and-death-in-older2026-10-08 https://evidence-hub.com/study/9733-assessment-of-quality-control-parameters-and-in-vitro-bioequivalence2026-10-08 https://evidence-hub.com/study/9736-incurred-sample-stability-of-metformin-hydrochloride-in-plasma-of-six2026-10-08 https://evidence-hub.com/study/9746-sex-prescribing-practices-and-guideline-recommended-blood-pressure2026-10-08 https://evidence-hub.com/study/9747-maternal-to-infant-transfer-of-medications-for-type-2-diabetes2026-10-08 https://evidence-hub.com/study/9748-should-prediabetes-be-classified-as-a-treatable-disease2026-10-08 https://evidence-hub.com/study/9749-glycemic-effectiveness-of-metformin-based-dual-combination-therapies2026-10-08 https://evidence-hub.com/study/9750-quantitative-planner-chromatographic-method-development-for2026-10-08 https://evidence-hub.com/study/9751-potential-benefits-of-glp-1-receptor-agonist-in-dialysis-patients2026-10-08 https://evidence-hub.com/study/9753-management-of-adolescent-polycystic-ovary-syndrome2026-10-06 https://evidence-hub.com/study/9754-the-effect-of-functional-electrical-stimulation-of-the-legs-on2026-10-20 https://evidence-hub.com/study/9755-how-to-perform-a-meta-analysis-with-r-a-practical-tutorial2026-10-20 https://evidence-hub.com/study/9756-synthesis-without-meta-analysis-swim-in-systematic-reviews-reporting2026-10-20 https://evidence-hub.com/study/9757-systematic-review-and-meta-analysis2026-10-20 https://evidence-hub.com/study/9759-blockers-after-myocardial-infarction-with-mildly-reduced-ejection2026-10-20 https://evidence-hub.com/study/9760-global-prevalence-of-depressive-and-anxiety-symptoms-in-children-and2026-10-20 https://evidence-hub.com/study/9761-preferred-reporting-items-for-systematic-review-and-meta-analysis2026-10-20 https://evidence-hub.com/study/9762-prevalence-of-stress-anxiety-depression-among-the-general-population2026-10-20 https://evidence-hub.com/study/9763-physical-distancing-face-masks-and-eye-protection-to-prevent-person2026-10-20 https://evidence-hub.com/study/9764-preferred-reporting-items-for-systematic-review-and-meta-analysis2026-10-20 https://evidence-hub.com/study/9766-circulating-micrornas-as-a-novel-class-of-diagnostic-biomarkers-in2026-10-20 https://evidence-hub.com/study/9768-prevalence-of-depression-anxiety-and-insomnia-among-healthcare2026-10-20 https://evidence-hub.com/study/9769-global-prevalence-of-chronic-kidney-disease-a-systematic-review-and2026-10-20 https://evidence-hub.com/study/9771-prevalence-of-comorbidities-and-its-effects-in-patients-infected-with2026-10-20 https://evidence-hub.com/study/9775-cardiovascular-mortality-and-kidney-outcomes-with-glp-1-receptor2026-10-20 https://evidence-hub.com/study/9777-global-prevalence-of-sarcopenia-and-severe-sarcopenia-a-systematic2026-10-20 https://evidence-hub.com/study/9780-meta-analysis-of-74-046-individuals-identifies-11-new-susceptibility2026-10-20 https://evidence-hub.com/study/9782-reevaluating-aminosalicylates-role-in-maintaining-remission-in2026-10-20 https://evidence-hub.com/study/9783-swallowed-topical-steroid-maintenance-therapy-for-eosinophilic2026-10-20 https://evidence-hub.com/study/9785-sglt2-inhibitors-for-primary-and-secondary-prevention-of2026-10-20 https://evidence-hub.com/study/9786-fatigue-and-cognitive-impairment-in-post-covid-19-syndrome-a2026-10-20 https://evidence-hub.com/study/9787-genetic-meta-analysis-of-diagnosed-alzheimer-s-disease-identifies-new2026-10-20 https://evidence-hub.com/study/9789-association-between-administration-of-systemic-corticosteroids-and2026-10-20 https://evidence-hub.com/study/9790-the-global-prevalence-of-osteoporosis-in-the-world-a-comprehensive2026-10-20 https://evidence-hub.com/study/9792-diabetes-distress-the-mediator-of-the-poor-glycemic-control-and2026-10-20 https://evidence-hub.com/study/9794-the-association-between-the-big-five-personality-traits-and-driving2026-10-20 https://evidence-hub.com/study/9795-metal-fast-and-efficient-meta-analysis-of-genomewide-association-scans2026-10-20 https://evidence-hub.com/study/9796-the-relationship-between-aggressive-driving-and-driver-performance-a2026-10-20 https://evidence-hub.com/study/9797-genome-wide-meta-analysis-of-depression-identifies-102-independent2026-10-20 https://evidence-hub.com/study/9798-exploring-influences-and-risk-of-bias-of-studies-on-return-to-sport2026-10-20 https://evidence-hub.com/study/9799-practical-methods-for-incorporating-summary-time-to-event-data-into2026-10-20 https://evidence-hub.com/study/9800-genome-wide-meta-analysis-identifies-new-loci-and-functional-pathways2026-10-20 https://evidence-hub.com/study/9801-cinema-an-approach-for-assessing-confidence-in-the-results-of-a2026-10-20 https://evidence-hub.com/study/9802-meta-analysis-of-prevalence-i2-statistic-and-how-to-deal-with2026-10-20 https://evidence-hub.com/study/9804-fixed-effect-vs-random-effects-models-for-meta-analysis-3-points-to2026-10-19 https://evidence-hub.com/study/9806-body-mass-index-and-incidence-of-cancer-a-systematic-review-and-meta2026-10-20 https://evidence-hub.com/study/9808-conducting-proportional-meta-analysis-in-different-types-of2026-10-20 https://evidence-hub.com/study/9810-networkanalyst-3-0-a-visual-analytics-platform-for-comprehensive-gene2026-10-20 https://evidence-hub.com/study/9815-meta-analysis-of-genome-wide-association-studies-for-height-and-body2026-10-20 https://evidence-hub.com/study/9817-psychological-correlates-of-university-students-academic-performance2026-10-20 https://evidence-hub.com/study/9818-editorial-review-articles-systematic-reviews-meta-analysis-and-the2026-10-20 https://evidence-hub.com/study/9823-thrombocytopenia-is-associated-with-severe-coronavirus-disease-20192026-10-20 https://evidence-hub.com/study/9825-cardiovascular-mortality-and-kidney-outcomes-with-glp-1-receptor2026-10-20 https://evidence-hub.com/study/9828-graphical-tools-for-network-meta-analysis-in-stata2026-10-19 https://evidence-hub.com/study/9829-the-power-of-feedback-revisited-a-meta-analysis-of-educational2026-10-17 https://evidence-hub.com/study/9830-carbapenems-vs-alternative-antibiotics-for-the-treatment-of2026-10-20 https://evidence-hub.com/study/9832-meta-analysis-of-fecal-metagenomes-reveals-global-microbial2026-10-20 https://evidence-hub.com/study/9833-comparative-efficacy-and-tolerability-of-32-oral-antipsychotics-for2026-10-20 https://evidence-hub.com/study/9835-endoscopic-vs-radiologic-gastrostomy-for-enteral-feeding-a-systematic2026-10-20 https://evidence-hub.com/study/9838-meta-analysis-with-robust-variance-estimation-expanding-the-range-of2026-10-20 https://evidence-hub.com/study/9840-drug-treatments-for-covid-19-living-systematic-review-and-network2026-10-19 https://evidence-hub.com/study/9841-the-prevalence-of-depression-anxiety-and-sleep-disturbances-in-covid2026-10-19 https://evidence-hub.com/study/9843-global-prevalence-of-gaming-disorder-a-systematic-review-and-meta2026-10-20 https://evidence-hub.com/study/9845-meta-analysis-in-clinical-trials-revisited2026-10-19 https://evidence-hub.com/study/9846-fruit-and-vegetable-intake-and-the-risk-of-cardiovascular-disease2026-10-20 https://evidence-hub.com/study/9847-preferred-reporting-items-for-systematic-review-and-meta-analysis-of2026-10-20 https://evidence-hub.com/study/9849-plea-for-routinely-presenting-prediction-intervals-in-meta-analysis2026-10-20 https://evidence-hub.com/study/9850-vitamin-d-supplementation-to-prevent-acute-respiratory-tract2026-10-20 https://evidence-hub.com/study/9854-suzetrigine-a-nonopioid-na-v-1-8-inhibitor-for-treatment-of-moderate2026-10-01 https://evidence-hub.com/study/9855-pharmacology-and-mechanism-of-action-of-suzetrigine-a-potent-and2026-10-01 https://evidence-hub.com/study/9856-suzetrigine-a-non-opioid-nav1-8-inhibitor-with-broad-applicability2026-10-01 https://evidence-hub.com/study/9857-vx-548-in-the-treatment-of-acute-pain2026-10-01 https://evidence-hub.com/study/9858-beyond-opioids-a-review-of-suzetrigine-for-acute-pain-management2026-10-01 https://evidence-hub.com/study/9859-suzetrigine-a-non-opioid-small-molecule-analgesic-mechanism-of-action2026-10-01 https://evidence-hub.com/study/9860-state-dependent-inhibition-of-nav1-8-sodium-channels-by-vx-150-and-vx2026-10-01 https://evidence-hub.com/study/9861-suzetrigine-a-novel-non-opioid-analgesic-for-acute-pain-management-a2026-10-01 https://evidence-hub.com/study/9862-pharmacology-update-suzetrigine-a-novel-nav1-8-sodium-channel2026-09-27 https://evidence-hub.com/study/9863-suzetrigine-as-a-novel-non-opioid-analgesic-drug-in-pain-management-a2026-10-01 https://evidence-hub.com/study/9864-differential-state-dependent-nav1-8-inhibition-by-suzetrigine-ltgo-332026-10-01 https://evidence-hub.com/study/9865-human-pain-neuroscience-and-the-next-generation-of-pain-therapeutics2026-10-01 https://evidence-hub.com/study/9866-suzetrigine-a-selective-nav1-8-inhibitor-in-acute-and-chronic-pain2026-09-27 https://evidence-hub.com/study/9867-suzetrigine-the-first-nav1-8-inhibitor-approved-for-the-treatment-of2026-10-01 https://evidence-hub.com/study/9868-sensory-neuron-sodium-channels-as-pain-targets-from-cocaine-to2026-10-01 https://evidence-hub.com/study/9869-sodium-channel-inhibitors-in-clinical-development-for-pain-management2026-10-01 https://evidence-hub.com/study/9870-suzetrigine-a-nav1-8-inhibitor-versus-placebo-for-acute-postoperative2026-10-01 https://evidence-hub.com/study/9871-efficacy-and-safety-of-suzetrigine-for-acute-postoperative-pain-a2026-09-27 https://evidence-hub.com/study/9872-budget-impact-of-suzetrigine-for-the-treatment-of-moderate-to-severe2026-09-27 https://evidence-hub.com/study/9873-modulation-of-human-dorsal-root-ganglion-neuron-firing-by-the-nav1-82026-10-01 https://evidence-hub.com/study/9874-the-clinical-application-of-suzetrigine2026-09-27 https://evidence-hub.com/study/9875-targeting-nav1-8-with-the-nonopioid-antagonist-suzetrigine-for2026-10-01 https://evidence-hub.com/study/9876-pharmacological-inhibition-of-nav1-8-by-suzetrigine-reveals-potent2026-10-01 https://evidence-hub.com/study/9877-clinical-efficacy-and-safety-profile-of-suzetrigine-a-novel-non2026-10-01 https://evidence-hub.com/study/9878-emerging-adverse-event-signals-of-new-analgesic-suzetrigine-a2026-10-06 https://evidence-hub.com/study/9879-patient-reported-paresthesia-after-administration-of-suzetrigine-a2026-09-27 https://evidence-hub.com/study/9880-what-is-the-potential-role-of-the-nonopioid-suzetrigine-in-pain2026-09-27 https://evidence-hub.com/study/9881-toward-brain-nav1-8-imaging-with-11c-suzetrigine2026-10-01 https://evidence-hub.com/study/9882-suzetrigine-in-equestrian-sports-optimized-extraction-and-lc-hrms2026-09-27 https://evidence-hub.com/study/9883-transforming-pain-management-suzetrigine-a-novel-non-opioid-analgesic2026-10-01 https://evidence-hub.com/study/9884-suzetrigine-a-novel-selective-sodium-channel-inhibitor-for-pain2026-09-27 https://evidence-hub.com/study/9885-suzetrigine-a-novel-nonopioid-analgesic-for-acute-pain2026-09-27 https://evidence-hub.com/study/9886-suzetrigine-as-a-novel-treatment-for-headache-disorders-a-case-series2026-10-04 https://evidence-hub.com/study/9887-not-just-neurons-pain-is-orchestrated-in-partnership-with-many-non2026-10-01 https://evidence-hub.com/study/9888-suzetrigine-a-novel-fda-approved-analgesic-opportunities-challenges2026-10-01 https://evidence-hub.com/study/9889-safety-and-efficacy-of-suzetrigine-vx-548-for-acute-moderate-to2026-09-27 https://evidence-hub.com/study/9890-suzetrigine-as-part-of-multimodal-therapy-enables-opioid-free2026-10-01 https://evidence-hub.com/study/9891-the-excelsatoxin-a-receptor-tmem233-modulates-nav1-82026-10-01 https://evidence-hub.com/study/9892-suzetrigine-and-the-emergence-of-selective-nav1-8-inhibition-in-acute2026-10-06 https://evidence-hub.com/study/9893-suzetrigine-a-promising-analgesic-targeting-voltage-gated-sodium2026-10-06 https://evidence-hub.com/study/9894-suzetrigine-a-new-and-novel-analgesic-for-acute-pain2026-10-05 https://evidence-hub.com/study/9895-selective-nav1-8-inhibition-for-pain-management-current-evidence-and2026-10-01 https://evidence-hub.com/study/9896-suzetrigine-for-acute-pain-in-the-emergency-department-a-first-in2026-10-01 https://evidence-hub.com/study/9897-suzetrigine-a-potential-alternative-for-palliative-pain-management-in2026-10-01 https://evidence-hub.com/study/9898-suzetrigine-for-moderate-to-severe-acute-pain2026-10-01 https://evidence-hub.com/study/9899-drugs-in-development-to-manage-acute-pain2026-10-01 https://evidence-hub.com/study/9900-from-ion-channel-biology-to-clinical-practice-suzetrigine-as-a2026-10-01 https://evidence-hub.com/study/9901-suzetrigine-vx-548-exhibits-activity-dependent-effects-on-human2026-10-01 https://evidence-hub.com/study/9902-selective-targeting-of-voltage-gated-sodium-channels-to-achieve2026-09-27 https://evidence-hub.com/study/9903-suzetrigine-for-pain-management-an-observational-study-of-early2026-10-01 https://evidence-hub.com/study/9904-suzetrigine-is-not-expected-to-have-clinically-relevant-ddis-with2026-10-01 https://evidence-hub.com/study/9905-suzetrigine-a-nav1-8-inhibitor-as-a-novel-approach-for-pain-therapy-a2026-10-01 https://evidence-hub.com/study/9906-suzetrigine-for-cancer-related-bone-pain-a-three-patient-case-series2026-10-01 https://evidence-hub.com/study/9907-review-of-physiology-pathology-and-pharmacology-of-voltage-gated2026-10-01 https://evidence-hub.com/study/9908-modulation-of-human-dorsal-root-ganglion-neuron-excitability-by-nav12026-10-01 https://evidence-hub.com/study/9909-selective-nav1-8-inhibition-by-suzetrigine-a-novel-nonopioid2026-10-01 https://evidence-hub.com/study/9910-suzetrigine-a-newly-fda-approved-non-opioid-treatment-option-for2026-10-06 https://evidence-hub.com/study/9911-the-real-world-safety-evaluation-of-the-selective-nav1-8-inhibitor2026-10-06 https://evidence-hub.com/study/9912-suzetrigine-for-postoperative-pain-in-head-and-neck-free-flap-or2026-10-01 https://evidence-hub.com/study/9913-functional-role-of-nav1-8-channels-in-action-potentials-of-mouse-cgrp2026-10-06 https://evidence-hub.com/study/9914-advances-in-the-discovery-of-selective-nav1-8-inhibitors-for-pain2026-09-27 https://evidence-hub.com/study/9915-use-of-suzetrigine-for-treatment-of-refractory-trigeminal-neuralgia2026-09-27 https://evidence-hub.com/study/9916-suzetrigine-vx-548-bidding-goodbye-to-opioids-the-latest-oral-non2026-10-01 https://evidence-hub.com/study/9917-shaping-the-action-potential-in-dorsal-root-and-trigeminal-ganglia2026-10-06 https://evidence-hub.com/study/9918-myotonic-muscle-activity-drives-a-persistent-pain-state-responsive-to2026-10-01 https://evidence-hub.com/study/9919-suzetrigine-what-should-plastic-surgeons-know2026-10-01 https://evidence-hub.com/study/9920-suzetrigine-for-pain-relief-key-considerations-for-nurses2026-09-27 https://evidence-hub.com/study/9921-an-update-on-the-role-of-multimodal-analgesia-in-perioperative-pain2026-10-06 https://evidence-hub.com/study/9922-spared-but-not-silent-ion-channel-plasticity-in-uninjured-sensory2026-10-06 https://evidence-hub.com/study/9923-targeting-nav-channels-for-pain-relief-structural-insights-and2026-10-01 https://evidence-hub.com/study/9924-chasing-the-wrong-door-for-30-years-is-suzetrigine-the-key-to2026-10-06 https://evidence-hub.com/study/9925-suzetrigine-journavx-for-acute-dental-pain-first-clinical-case-series2026-09-27 https://evidence-hub.com/study/9926-analysis-of-suzetrigine-a-novel-nonopioid-pain-medication-in-whole2026-10-06 https://evidence-hub.com/study/9927-the-drug-update-recent-drug-approvals-winter-2026-edition2026-10-06 https://evidence-hub.com/study/9928-nav1-8-and-chronic-pain-from-laboratory-animals-to-clinical-patients2026-10-06 https://evidence-hub.com/study/9929-paresthesia-after-suzetrigine-a-second-report-and-case-comparison2026-09-27 https://evidence-hub.com/study/9930-mapping-the-metabolic-fate-of-suzetrigine-in-equine-and-camel-models2026-09-27 https://evidence-hub.com/study/9931-protocol-for-a-prospective-single-arm-feasibility-study-of2026-10-06 https://evidence-hub.com/study/9932-analgesia-in-tactical-combat-casualty-care-tccc-tccc-guideline-change2026-10-06 https://evidence-hub.com/study/9933-emerging-nonopioid-analgesic-strategies-in-total-joint-arthroplasty2026-09-27 https://evidence-hub.com/study/9934-suzetrigine-approval-breaks-a-25-year-silence-a-new-era-in-non-opioid2026-10-01 https://evidence-hub.com/study/9935-therapeutic-effect-of-suzetrigine-in-the-management-of-notalgia2026-10-06 https://evidence-hub.com/study/9936-novel-drugs-approved-by-the-ema-the-fda-and-the-mhra-in-2025-a-year2026-10-06 https://evidence-hub.com/study/9937-suzetrigine-for-vaso-occlusive-pain-in-sickle-cell-disease-a-three2026-10-01 https://evidence-hub.com/study/9938-the-elusive-management-of-an-individual-patient-with-scn9a-sodium2026-10-06 https://evidence-hub.com/study/9939-aqbd-guided-chiral-hplc-for-enantiomeric-impurity-analysis-of2026-10-01 https://evidence-hub.com/study/9940-nav1-8-mediates-peripheral-to-central-nociceptive-transmission2026-10-01 https://evidence-hub.com/study/9941-managing-erythromelalgia-associated-pain-with-suzetrigine-a-case2026-10-06 https://evidence-hub.com/study/9942-suzetrigine-a-new-non-opioid-analgesic-option-with-potential2026-09-27 https://evidence-hub.com/study/9943-dorsal-root-ganglion-as-a-hub-for-peripheral-sensitization-a2026-10-08 https://evidence-hub.com/study/9944-use-of-suzetrigine-a-selective-sodium-channel-blocker-in2026-09-27 https://evidence-hub.com/study/9945-pharmacological-management-of-diabetic-neuropathy-current-evidence2026-10-06 https://evidence-hub.com/study/9946-suzetrigine-as-part-of-multimodal-therapy-enables-opioid-free2026-10-01 https://evidence-hub.com/study/9947-association-of-suzetrigine-with-postoperative-outcomes-versus-opioid2026-10-01 https://evidence-hub.com/study/9948-unlocking-pain-therapeutics-how-to-find-the-right-target-and2026-09-27 https://evidence-hub.com/study/9949-pain-management-strategies-in-reverse-total-shoulder-arthroplasty2026-10-06 https://evidence-hub.com/study/9950-a-phase-i-study-to-evaluate-the-safety-tolerability-and2026-10-06 https://evidence-hub.com/study/9951-sustained-relief-of-chronic-pain-via-a-nav1-7-targeting-aso-sirna2026-10-06 https://evidence-hub.com/study/9952-a-comprehensive-review-of-small-molecule-drugs-approved-by-the-fda-in2026-10-06 https://evidence-hub.com/study/9953-first-in-human-phase-i-trial-of-hrs-2129-a-selective-nav1-8-inhibitor2026-10-01 https://evidence-hub.com/study/9954-isoform-specific-nav-modulation-in-painful-chemotherapy-induced2026-10-06 https://evidence-hub.com/study/9955-suzetrigine-vx-548-exhibits-activity-dependent-effects-on-human2026-10-01 https://evidence-hub.com/study/9956-functional-and-molecular-diversity-of-human-c-fibers-in-pain2026-10-06 https://evidence-hub.com/study/9957-regional-multimodal-and-opioid-sparing-strategies-after-trauma-a2026-10-06 https://evidence-hub.com/study/9958-suzetrigine-first-approval2026-10-01 https://evidence-hub.com/study/9961-fluorine-containing-fda-approved-small-molecule-drugs-in-20252026-10-01 https://evidence-hub.com/study/9962-sex-specific-mechanisms-of-central-sensitization-a-narrative-review2026-10-01 https://evidence-hub.com/study/9963-nitrogen-containing-fda-approved-drugs-in-2025-synthesis-significance2026-10-06 https://evidence-hub.com/study/9964-halogen-containing-drugs-in-2025-a-record-year-for-the-therapeutic2026-10-06 https://evidence-hub.com/study/9965-between-promise-and-peril-role-of-suzetrigine-as-a-non-opioid2026-10-01 https://evidence-hub.com/study/9967-suzetrigine-journavx-a-sodium-channel-blocker-for-acute-pain2026-09-27 https://evidence-hub.com/study/9971-suzetrigine-is-this-what-we-have-been-waiting-for-or-just-the2026-10-01 https://evidence-hub.com/study/9972-suzetrigine-and-the-future-of-non-addictive-pain-management-in-the2026-10-01 https://evidence-hub.com/study/9979-beyond-opioids-fda-approved-suzetrigine-offers-hope-for-acute-pain2026-10-01 https://evidence-hub.com/study/9980-mechanisms-efficacy-and-safety-of-suzetrigine-compared-with-other2026-10-06 https://evidence-hub.com/study/9981-breaking-the-pain-barrier-how-suzetrigine-and-selective-sodium2026-10-01 https://evidence-hub.com/study/9985-suzetrigine-fda-approval-a-transformative-milestone-in-pain-management2026-10-01 https://evidence-hub.com/study/9987-innovation-versus-consolidation-critical-reflections-on-suzetrigine2026-09-27 https://evidence-hub.com/study/9990-fda-approves-journavx-suzetrigine-as-the-first-non-opioid-treatment2026-10-01 https://evidence-hub.com/study/9993-suzetrigine-an-analgesic-of-the-future-a-clinical-review2026-10-01 https://evidence-hub.com/study/9996-journavx-suzetrigine-a-safer-alternative-for-pain-relief2026-10-01 https://evidence-hub.com/study/9997-fda-approves-vertex-s-suzetrigine2026-09-27